{\rtf1\adeflang1025\ansi\ansicpg10000\uc1\adeff0\deff0\stshfdbch0\stshfloch0\stshfhich0\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \fnil\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f1\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}{\f2\fbidi \fnil\fcharset0\fprq2{\*\panose 02070309020205020404}Courier New{\*\falt Courier};}{\f3\fbidi \fnil\fcharset2\fprq2{\*\panose 00000000000000000000}Symbol;}{\f4\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Times;}{\f5\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Helvetica;}{\f6\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Courier;}{\f7\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503030404040204}Geneva;}{\f8\fbidi \froman\fcharset77\fprq2{\*\panose 00000000000000000000}Tms Rmn;}{\f9\fbidi \fswiss\fcharset77\fprq2{\*\panose 00000000000000000000}Helv;}{\f10\fbidi \froman\fcharset77\fprq2{\*\panose 00000000000000000000}MS Serif;}{\f11\fbidi \fswiss\fcharset77\fprq2{\*\panose 00000000000000000000}MS Sans Serif;}{\f12\fbidi \froman\fcharset77\fprq2{\*\panose 00000000000000000000}New York;}{\f13\fbidi \fswiss\fcharset77\fprq2{\*\panose 00000000000000000000}System;}{\f14\fbidi \fnil\fcharset2\fprq2{\*\panose 05000000000000000000}Wingdings;}{\f15\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9;}{\f16\fbidi \fnil\fcharset79\fprq2 \'b9\'d9\'c5\'c1;}{\f17\fbidi \fnil\fcharset80\fprq2 \'cb\'ce\'cc\'e5;}{\f18\fbidi \fnil\fcharset81\fprq2 \'b7\'73\'b2\'d3\'a9\'fa\'c5\'e9;}{\f19\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e;}{\f20\fbidi \fnil\fcharset0\fprq2{\*\panose 02040604050505020304}Century;}{\f21\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604030504040204}Verdana;}{\f22\fbidi \froman\fcharset222\fprq2{\*\panose 00000000000000000000}Angsana New;}{\f23\fbidi \froman\fcharset222\fprq2{\*\panose 00000000000000000000}Cordia New;}{\f24\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Mangal;}{\f25\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Latha;}{\f26\fbidi \froman\fcharset77\fprq2{\*\panose 00000000000000000000}Sylfaen;}{\f27\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Vrinda;}{\f28\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Raavi;}{\f29\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Shruti;}{\f30\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Sendnya;}{\f31\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Gautami;}{\f32\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Tunga;}{\f33\fbidi \froman\fcharset1\fprq2{\*\panose 00000000000000000000}Estrangelo Edessa;}{\f34\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}{\f35\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\f36\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria;}{\f37\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0a06030101010103}Abadi MT Condensed Extra Bold;}{\f38\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0306030101010103}Abadi MT Condensed Light;}{\f39\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Academy Engraved LET;}{\f40\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201020203}Adobe Arabic;}{\f41\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060201020203}Adobe Arabic Bold;}{\f42\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060201090203}Adobe Arabic Bold Italic;}{\f43\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201090203}Adobe Arabic Italic;}{\f44\fbidi \fnil\fcharset0\fprq2{\*\panose 0205050205050a020403}Adobe Caslon Pro;}{\f45\fbidi \fnil\fcharset0\fprq2{\*\panose 0205070206050a020403}Adobe Caslon Pro Bold;}{\f46\fbidi \fnil\fcharset0\fprq2{\*\panose 0205070206050b090a03}Adobe Caslon Pro Bold Italic;}{\f47\fbidi \fnil\fcharset0\fprq2{\*\panose 0205050205050b090a03}Adobe Caslon Pro Italic;}{\f48\fbidi \fnil\fcharset0\fprq2{\*\panose 0205060205050a020403}Adobe Caslon Pro SmBd;}{\f49\fbidi \fnil\fcharset0\fprq2{\*\panose 0205060205050b090a03}Adobe Caslon Pro SmBd Italic;}{\f50\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201020203}Adobe Devanagari;}{\f51\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060201020203}Adobe Devanagari Bold;}{\f52\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060201090203}Adobe Devanagari Bold Italic;}{\f53\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201090203}Adobe Devanagari Italic;}{\f54\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060506020403}Adobe Garamond Pro;}{\f55\fbidi \fnil\fcharset0\fprq2{\*\panose 02020702060506020403}Adobe Garamond Pro Bold;}{\f56\fbidi \fnil\fcharset0\fprq2{\*\panose 02020702060506090403}Adobe Garamond Pro Bold Italic;}{\f57\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502050506090403}Adobe Garamond Pro Italic;}{\f58\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201020203}Adobe Hebrew;}{\f59\fbidi \fnil\fcharset0\fprq2{\*\panose 02040603060201020203}Adobe Hebrew Bold;}{\f60\fbidi \fnil\fcharset0\fprq2{\*\panose 02040603060201090203}Adobe Hebrew Bold Italic;}{\f61\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050201090203}Adobe Hebrew Italic;}{\f62\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Adobe Naskh Medium;}{\f63\fbidi \fnil\fcharset0\fprq2{\*\panose 02090604020004020304}American Typewriter;}{\f64\fbidi \fnil\fcharset0\fprq2{\*\panose 02090606020004020304}American Typewriter Condensed;}{\f65\fbidi \fnil\fcharset0\fprq2{\*\panose 02090304020004020304}American Typewriter Light;}{\f66\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0509000000000004}Andale Mono;}{\f67\fbidi \fnil\fcharset0\fprq2{\*\panose 03020702040506060504}Apple Chancery;}{\f68\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Apple Symbols;}{\f69\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0a04020102020204}Arial Black;}{\f70\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0704020202020204}Arial Bold;}{\f71\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0704020202090204}Arial Bold Italic;}{\f72\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202090204}Arial Italic;}{\f73\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506020202030204}Arial Narrow;}{\f74\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706020202030204}Arial Narrow Bold;}{\f75\fbidi \fnil\fcharset0\fprq2{\*\panose 020b07060202020a0204}Arial Narrow Bold Italic;}{\f76\fbidi \fnil\fcharset0\fprq2{\*\panose 020b06060202020a0204}Arial Narrow Italic;}{\f77\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0704030504030204}Arial Rounded MT Bold;}{\f78\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial Unicode MS;}{\f79\fbidi \fnil\fcharset0\fprq2{\*\panose 02000803070000020003}Athelas Bold;}{\f80\fbidi \fnil\fcharset0\fprq2{\*\panose 02000803000000090003}Athelas Bold Italic;}{\f81\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503000000090003}Athelas Italic;}{\f82\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503000000020003}Athelas Regular;}{\f83\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803020203020204}Avenir Black;}{\f84\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803020203090204}Avenir Black Oblique;}{\f85\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503020000020003}Avenir Book;}{\f86\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503020000020003}Avenir Book Oblique;}{\f87\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020203020204}Avenir Heavy;}{\f88\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020203090204}Avenir Heavy Oblique;}{\f89\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0402020203020204}Avenir Light;}{\f90\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0402020203090204}Avenir Light Oblique;}{\f91\fbidi \fnil\fcharset0\fprq2{\*\panose 02000603020000020003}Avenir Medium;}{\f92\fbidi \fnil\fcharset0\fprq2{\*\panose 02000603020000020003}Avenir Medium Oblique;}{\f93\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803020202020204}Avenir Next Bold;}{\f94\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803020202090204}Avenir Next Bold Italic;}{\f95\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0806020202020204}Avenir Next Condensed Bold;}{\f96\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706020202020204}Avenir Next Condensed Demi Bold;}{\f97\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0906020202020204}Avenir Next Condensed Heavy;}{\f98\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506020202090204}Avenir Next Condensed Italic;}{\f99\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0606020202020204}Avenir Next Condensed Medium;}{\f100\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506020202020204}Avenir Next Condensed Regular;}{\f101\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020202020204}Avenir Next Demi Bold;}{\f102\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020202090204}Avenir Next Demi Bold Italic;}{\f103\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0903020202020204}Avenir Next Heavy;}{\f104\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0903020202090204}Avenir Next Heavy Italic;}{\f105\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020202090204}Avenir Next Italic;}{\f106\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020202020204}Avenir Next Medium;}{\f107\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020202090204}Avenir Next Medium Italic;}{\f108\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020202020204}Avenir Next Regular;}{\f109\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0203020202020204}Avenir Next Ultra Light;}{\f110\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0203020202090204}Avenir Next Ultra Light Italic;}{\f111\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020203090204}Avenir Oblique;}{\f112\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020203020204}Avenir Roman;}{\f113\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Ayuthaya;}{\f114\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500020000000000}Bangla MN;}{\f115\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500020000000000}Bangla MN Bold;}{\f116\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Bangla Sangam MN;}{\f117\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Bangla Sangam MN Bold;}{\f118\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bank Gothic;}{\f119\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Baoli SC Regular;}{\f120\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502070401020303}Baskerville;}{\f121\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802070401020303}Baskerville Bold;}{\f122\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802070401090303}Baskerville Bold Italic;}{\f123\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502070401020303}Baskerville Italic;}{\f124\fbidi \fnil\fcharset0\fprq2{\*\panose 02020602080505020303}Baskerville Old Face;}{\f125\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802070401020303}Baskerville SemiBold;}{\f126\fbidi \fnil\fcharset0\fprq2{\*\panose 02020702070400090203}Baskerville SemiBold Italic;}{\f127\fbidi \fnil\fcharset0\fprq2{\*\panose 04030905020b02020c02}Bauhaus 93;}{\f128\fbidi \fnil\fcharset0\fprq2{\*\panose 00000600000000000000}Beirut;}{\f129\fbidi \fnil\fcharset0\fprq2{\*\panose 02020503060305020303}Bell MT;}{\f130\fbidi \fnil\fcharset0\fprq2{\*\panose 02050806060905020404}Bernard MT Condensed;}{\f131\fbidi \fnil\fcharset0\fprq2{\*\panose 02000603090000020003}Big Caslon;}{\f132\fbidi \fnil\fcharset0\fprq2{\*\panose 03060502040705060204}Birch Std;}{\f133\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Blackmoor LET;}{\f134\fbidi \fnil\fcharset0\fprq2{\*\panose 04050907060602020202}Blackoak Std;}{\f135\fbidi \fnil\fcharset0\fprq2{\*\panose 00000500000000000000}BlairMdITC TT-Medium;}{\f136\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Bodoni Ornaments ITC TT;}{\f137\fbidi \fnil\fcharset0\fprq2{\*\panose 00000700000000000000}Bodoni SvtyTwo ITC TT-Bold;}{\f138\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bodoni SvtyTwo ITC TT-Book;}{\f139\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bodoni SvtyTwo ITC TT-BookIta;}{\f140\fbidi \fnil\fcharset0\fprq2{\*\panose 00000700000000000000}Bodoni SvtyTwo OS ITC TT-Bold;}{\f141\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bodoni SvtyTwo OS ITC TT-Book;}{\f142\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bodoni SvtyTwo OS ITC TT-BookIt;}{\f143\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Bodoni SvtyTwo SC ITC TT-Book;}{\f144\fbidi \fnil\fcharset0\fprq2{\*\panose 02040602050305030304}Book Antiqua;}{\f145\fbidi \fnil\fcharset0\fprq2{\*\panose 02050604050505020204}Bookman Old Style;}{\f146\fbidi \fnil\fcharset0\fprq2{\*\panose 05010101010101010101}Bookshelf Symbol 7;}{\f147\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Bordeaux Roman Bold LET;}{\f148\fbidi \fnil\fcharset0\fprq2{\*\panose 00000700000000000000}Bradley Hand ITC TT-Bold;}{\f149\fbidi \fnil\fcharset0\fprq2{\*\panose 04030b070d0b02020403}Braggadocio;}{\f150\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0903060703020204}Britannic Bold;}{\f151\fbidi \fnil\fcharset0\fprq2{\*\panose 03060802040406070304}Brush Script MT Italic;}{\f152\fbidi \fnil\fcharset0\fprq2{\*\panose 03060802040607070404}Brush Script Std;}{\f153\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0702030404030204}Calibri Bold;}{\f154\fbidi \fnil\fcharset0\fprq2{\*\panose 020f07020304040a0204}Calibri Bold Italic;}{\f155\fbidi \fnil\fcharset0\fprq2{\*\panose 020f05020202040a0204}Calibri Italic;}{\f156\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}{\f157\fbidi \fnil\fcharset0\fprq2{\*\panose 02040603050505030304}Calisto MT;}{\f158\fbidi \fnil\fcharset0\fprq2{\*\panose 02040803050406030204}Cambria Bold;}{\f159\fbidi \fnil\fcharset0\fprq2{\*\panose 020408030504060a0204}Cambria Bold Italic;}{\f160\fbidi \fnil\fcharset0\fprq2{\*\panose 020405030504060a0204}Cambria Italic;}{\f161\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0502030303020204}Candara;}{\f162\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0702030303020204}Candara Bold;}{\f163\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0702030303090204}Candara Bold Italic;}{\f164\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0502030303090204}Candara Italic;}{\f165\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Capitals;}{\f166\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0502020202020204}Century Gothic;}{\f167\fbidi \fnil\fcharset0\fprq2{\*\panose 02040604050505020304}Century Schoolbook;}{\f168\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkboard;}{\f169\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkboard Bold;}{\f170\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkboard SE Bold;}{\f171\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkboard SE Light;}{\f172\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkboard SE Regular;}{\f173\fbidi \fnil\fcharset0\fprq2{\*\panose 03050602040202020205}Chalkduster;}{\f174\fbidi \fnil\fcharset0\fprq2{\*\panose 02060503040505020203}Chaparral Pro;}{\f175\fbidi \fnil\fcharset0\fprq2{\*\panose 02060503040505020203}Chaparral Pro Bold;}{\f176\fbidi \fnil\fcharset0\fprq2{\*\panose 02060803050505090203}Chaparral Pro Bold Ital;}{\f177\fbidi \fnil\fcharset0\fprq2{\*\panose 02060503040505090203}Chaparral Pro Ital;}{\f178\fbidi \fnil\fcharset0\fprq2{\*\panose 02060403030505090203}Chaparral Pro Light Ital;}{\f179\fbidi \fnil\fcharset0\fprq2{\*\panose 04020705060702020204}Charlemagne Std Bold;}{\f180\fbidi \fnil\fcharset0\fprq2{\*\panose 02040803050506020203}Charter Black;}{\f181\fbidi \fnil\fcharset0\fprq2{\*\panose 02040803050506090203}Charter Black Italic;}{\f182\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703050506020203}Charter Bold;}{\f183\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703050506090203}Charter Bold Italic;}{\f184\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050506090203}Charter Italic;}{\f185\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050506020203}Charter Roman;}{\f186\fbidi \fnil\fcharset0\fprq2{\*\panose 02000603020000020003}Cochin;}{\f187\fbidi \fnil\fcharset0\fprq2{\*\panose 04020805060202030203}Colonna MT;}{\f188\fbidi \fnil\fcharset0\fprq2{\*\panose 030f0702030302020204}Comic Sans MS;}{\f189\fbidi \fnil\fcharset0\fprq2{\*\panose 030f0902030302020204}Comic Sans MS Bold;}{\f190\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0609020204030204}Consolas;}{\f191\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0709020204030204}Consolas Bold;}{\f192\fbidi \fnil\fcharset0\fprq2{\*\panose 020b07090202040a0204}Consolas Bold Italic;}{\f193\fbidi \fnil\fcharset0\fprq2{\*\panose 020b06090202040a0204}Consolas Italic;}{\f194\fbidi \fnil\fcharset0\fprq2{\*\panose 02030602050306030303}Constantia;}{\f195\fbidi \fnil\fcharset0\fprq2{\*\panose 02030702060306030303}Constantia Bold;}{\f196\fbidi \fnil\fcharset0\fprq2{\*\panose 020307020603060a0303}Constantia Bold Italic;}{\f197\fbidi \fnil\fcharset0\fprq2{\*\panose 020306020503060a0303}Constantia Italic;}{\f198\fbidi \fnil\fcharset0\fprq2{\*\panose 0208090404030b020404}Cooper Black;}{\f199\fbidi \fnil\fcharset0\fprq2{\*\panose 0208090305030b090404}Cooper Black Std Italic;}{\f200\fbidi \fnil\fcharset0\fprq2{\*\panose 0208090304030b020404}Cooper Std Black;}{\f201\fbidi \fnil\fcharset0\fprq2{\*\panose 02000504000000020004}Copperplate;}{\f202\fbidi \fnil\fcharset0\fprq2{\*\panose 02000904050000020004}Copperplate Bold;}{\f203\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0705020206020404}Copperplate Gothic Bold;}{\f204\fbidi \fnil\fcharset0\fprq2{\*\panose 020e0507020206020404}Copperplate Gothic Light;}{\f205\fbidi \fnil\fcharset0\fprq2{\*\panose 02000604030000020004}Copperplate Light;}{\f206\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020204020204}Corbel;}{\f207\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020204020204}Corbel Bold;}{\f208\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020204090204}Corbel Bold Italic;}{\f209\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020204090204}Corbel Italic;}{\f210\fbidi \fnil\fcharset0\fprq2{\*\panose 02070609020205020404}Courier New Bold;}{\f211\fbidi \fnil\fcharset0\fprq2{\*\panose 02070609020205090404}Courier New Bold Italic;}{\f212\fbidi \fnil\fcharset0\fprq2{\*\panose 02070409020205090404}Courier New Italic;}{\f213\fbidi \fnil\fcharset0\fprq2{\*\panose 04040404050702020202}Curlz MT;}{\f214\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Damascus;}{\f215\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Damascus Bold;}{\f216\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Damascus Medium;}{\f217\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Damascus Semi Bold;}{\f218\fbidi \fnil\fcharset0\fprq2{\*\panose 04020505020e03040504}Desdemona;}{\f219\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Devanagari Sangam MN;}{\f220\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Devanagari Sangam MN Bold;}{\f221\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0500000000000000}DIN Alternate Bold;}{\f222\fbidi \fnil\fcharset0\fprq2{\*\panose 00000500000000000000}DIN Condensed Bold;}{\f223\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503000000020003}Didot;}{\f224\fbidi \fnil\fcharset0\fprq2{\*\panose 030303020407070d0804}Edwardian Script ITC;}{\f225\fbidi \fnil\fcharset0\fprq2{\*\panose 02090707080505020304}Engravers MT;}{\f226\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040102020104}Euphemia UCAS;}{\f227\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803040102020104}Euphemia UCAS Bold;}{\f228\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040102020104}Euphemia UCAS Italic;}{\f229\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0504020202050204}Eurostile;}{\f230\fbidi \fnil\fcharset0\fprq2{\*\panose 0204060206030a020304}Footlight MT Light;}{\f231\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020102020204}Franklin Gothic Book;}{\f232\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020102090204}Franklin Gothic Book Italic;}{\f233\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020102020204}Franklin Gothic Medium;}{\f234\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020102090204}Franklin Gothic Medium Italic;}{\f235\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602020204020303}Futura;}{\f236\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506020204030204}Futura Condensed;}{\f237\fbidi \fnil\fcharset0\fprq2{\*\panose 04040605051002020d02}Gabriola;}{\f238\fbidi \fnil\fcharset0\fprq2{\*\panose 02020404030301010803}Garamond;}{\f239\fbidi \fnil\fcharset0\fprq2{\*\panose 02040502050405020303}Georgia;}{\f240\fbidi \fnil\fcharset0\fprq2{\*\panose 02040802050405020203}Georgia Bold;}{\f241\fbidi \fnil\fcharset0\fprq2{\*\panose 02040802050405090203}Georgia Bold Italic;}{\f242\fbidi \fnil\fcharset0\fprq2{\*\panose 02040502050405090303}Georgia Italic;}{\f243\fbidi \fnil\fcharset0\fprq2{\*\panose 03050402040302040404}Giddyup Std;}{\f244\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0502020104020203}Gill Sans;}{\f245\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0302020104020203}Gill Sans Light;}{\f246\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0502020104020203}Gill Sans MT;}{\f247\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0802020104020203}Gill Sans MT Bold;}{\f248\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0802020104090203}Gill Sans MT Bold Italic;}{\f249\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0502020104090203}Gill Sans MT Italic;}{\f250\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0702020104020203}Gill Sans SemiBold;}{\f251\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0702020104090203}Gill Sans SemiBold Italic;}{\f252\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0b04020104020203}Gill Sans UltraBold;}{\f253\fbidi \fnil\fcharset0\fprq2{\*\panose 02030808020601010101}Gloucester MT Extra Condensed;}{\f254\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502050305020303}Goudy Old Style;}{\f255\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Gujarati Sangam MN;}{\f256\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Gujarati Sangam MN Bold;}{\f257\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Gurmukhi MN;}{\f258\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Gurmukhi MN Bold;}{\f259\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Gurmukhi Sangam MN;}{\f260\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Gurmukhi Sangam MN Bold;}{\f261\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706040902060204}Haettenschweiler;}{\f262\fbidi \fnil\fcharset0\fprq2{\*\panose 04040505050a02020702}Harrington;}{\f263\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0403020202020204}Helvetica Light;}{\f264\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503000000020004}Helvetica Neue;}{\f265\fbidi \fnil\fcharset0\fprq2{\*\panose 02000a06000000020004}Helvetica Neue Black Condensed;}{\f266\fbidi \fnil\fcharset0\fprq2{\*\panose 02000806000000020004}Helvetica Neue Bold Condensed;}{\f267\fbidi \fnil\fcharset0\fprq2{\*\panose 02000403000000020004}Helvetica Neue Light;}{\f268\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202020204}Helvetica Neue Medium;}{\f269\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0403020202020204}Helvetica Neue Thin;}{\f270\fbidi \fnil\fcharset0\fprq2{\*\panose 02000206000000020004}Helvetica Neue UltraLight;}{\f271\fbidi \fnil\fcharset0\fprq2{\*\panose 02000505000000020004}Herculanum;}{\f272\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803040709020204}Hobo Std;}{\f273\fbidi \fnil\fcharset0\fprq2{\*\panose 02030602050506020203}Hoefler Text;}{\f274\fbidi \fnil\fcharset2\fprq2{\*\panose 00000000000000000000}Hoefler Text Ornaments;}{\f275\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0806030902050204}Impact;}{\f276\fbidi \fnil\fcharset0\fprq2{\*\panose 04020605060303030202}Imprint MT Shadow;}{\f277\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}InaiMathi;}{\f278\fbidi \fnil\fcharset0\fprq2{\*\panose 02040805050506020204}Iowan Old Style Black;}{\f279\fbidi \fnil\fcharset0\fprq2{\*\panose 02040805050506090204}Iowan Old Style Black Italic;}{\f280\fbidi \fnil\fcharset0\fprq2{\*\panose 02040702050506020204}Iowan Old Style Bold;}{\f281\fbidi \fnil\fcharset0\fprq2{\*\panose 02040702050506090204}Iowan Old Style Bold Italic;}{\f282\fbidi \fnil\fcharset0\fprq2{\*\panose 02040602040506090204}Iowan Old Style Italic;}{\f283\fbidi \fnil\fcharset0\fprq2{\*\panose 02040602040506020204}Iowan Old Style Roman;}{\f284\fbidi \fnil\fcharset0\fprq2{\*\panose 02040602040506020204}Iowan Old Style Titling;}{\f285\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Jazz LET;}{\f286\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Kaiti SC Black;}{\f287\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Kannada MN;}{\f288\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Kannada MN Bold;}{\f289\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Kannada Sangam MN;}{\f290\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Kannada Sangam MN Bold;}{\f291\fbidi \fnil\fcharset0\fprq2{\*\panose 02000506000000020004}Kefa;}{\f292\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Khmer MN;}{\f293\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Khmer MN Bold;}{\f294\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Khmer Sangam MN;}{\f295\fbidi \fnil\fcharset0\fprq2{\*\panose 040307050d0c02020703}Kino MT;}{\f296\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Krungthep;}{\f297\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}KufiStandardGK;}{\f298\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Lantinghei SC Demibold;}{\f299\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Lantinghei SC Extralight;}{\f300\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Lantinghei SC Heavy;}{\f301\fbidi \fnil\fcharset0\fprq2{\*\panose 03000509000000000000}Lantinghei TC Demibold;}{\f302\fbidi \fnil\fcharset0\fprq2{\*\panose 03000509000000000000}Lantinghei TC Extralight;}{\f303\fbidi \fnil\fcharset0\fprq2{\*\panose 03000509000000000000}Lantinghei TC Heavy;}{\f304\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Lao MN;}{\f305\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Lao MN Bold;}{\f306\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Lao Sangam MN;}{\f307\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0409020202030304}Letter Gothic Std;}{\f308\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0509020202030304}Letter Gothic Std Bold;}{\f309\fbidi \fnil\fcharset0\fprq2{\*\panose 020b05090202020a0304}Letter Gothic Std Bold Slanted;}{\f310\fbidi \fnil\fcharset0\fprq2{\*\panose 020b04090202020a0304}Letter Gothic Std Slanted;}{\f311\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Libian SC Regular;}{\f312\fbidi \fnil\fcharset0\fprq2{\*\panose 04020905040e02020a04}Lithos Pro Black;}{\f313\fbidi \fnil\fcharset0\fprq2{\*\panose 04020505030e02020a04}Lithos Pro Regular;}{\f314\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Lucida Blackletter;}{\f315\fbidi \fnil\fcharset0\fprq2{\*\panose 02040602050505020304}Lucida Bright;}{\f316\fbidi \fnil\fcharset0\fprq2{\*\panose 03010101010101010101}Lucida Calligraphy;}{\f317\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0609040504020204}Lucida Console;}{\f318\fbidi \fnil\fcharset0\fprq2{\*\panose 02060602050505020204}Lucida Fax;}{\f319\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0600040502020204}Lucida Grande;}{\f320\fbidi \fnil\fcharset0\fprq2{\*\panose 03010101010101010101}Lucida Handwriting;}{\f321\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602030504020204}Lucida Sans;}{\f322\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0509030504030204}Lucida Sans Typewriter;}{\f323\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602030504020204}Lucida Sans Unicode;}{\f324\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Malayalam MN;}{\f325\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Malayalam MN Bold;}{\f326\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Malayalam Sangam MN;}{\f327\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Malayalam Sangam MN Bold;}{\f328\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802060400020003}Marion Bold;}{\f329\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060400020003}Marion Italic;}{\f330\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060400020003}Marion Regular;}{\f331\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Marker Felt;}{\f332\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Marlett;}{\f333\fbidi \fnil\fcharset0\fprq2{\*\panose 03020802060602070202}Matura MT Script Capitals;}{\f334\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0709030604020204}Menlo Bold;}{\f335\fbidi \fnil\fcharset0\fprq2{\*\panose 020b07090303040b0204}Menlo Bold Italic;}{\f336\fbidi \fnil\fcharset0\fprq2{\*\panose 020b06090303040b0204}Menlo Italic;}{\f337\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0609030804020204}Menlo Regular;}{\f338\fbidi \fnil\fcharset0\fprq2{\*\panose 04090703060e02020a04}Mesquite Std;}{\f339\fbidi \fnil\fcharset0\fprq2{\*\panose 01010100010101010101}Microsoft Himalaya;}{\f340\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202020204}Microsoft Sans Serif;}{\f341\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0502040204020203}Microsoft Tai Le;}{\f342\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0802040204020203}Microsoft Tai Le Bold;}{\f343\fbidi \fnil\fcharset0\fprq2{\*\panose 03000500000000000000}Microsoft Yi Baiti;}{\f344\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}MingLiU-ExtB;}{\f345\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}@MingLiU-ExtB;}{\f346\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}MingLiU_HKSCS-ExtB;}{\f347\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}@MingLiU_HKSCS-ExtB;}{\f348\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050306020203}Minion Pro;}{\f349\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060306020203}Minion Pro Bold;}{\f350\fbidi \fnil\fcharset0\fprq2{\*\panose 02040706060306020203}Minion Pro Bold Cond;}{\f351\fbidi \fnil\fcharset0\fprq2{\*\panose 02040706060306090203}Minion Pro Bold Cond Ital;}{\f352\fbidi \fnil\fcharset0\fprq2{\*\panose 02040703060306090203}Minion Pro Bold Ital;}{\f353\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050306090203}Minion Pro Ital;}{\f354\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050306020203}Minion Pro Med;}{\f355\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050306090203}Minion Pro Med Ital;}{\f356\fbidi \fnil\fcharset0\fprq2{\*\panose 02040603060306020203}Minion Pro SmBd;}{\f357\fbidi \fnil\fcharset0\fprq2{\*\panose 02040603060306090203}Minion Pro SmBd Ital;}{\f358\fbidi \fnil\fcharset0\fprq2{\*\panose 03090702030407020403}Mistral;}{\f359\fbidi \fnil\fcharset0\fprq2{\*\panose 02070704070505020303}Modern No. 20;}{\f360\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Mona Lisa Solid ITC TT;}{\f361\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Monaco;}{\f362\fbidi \fnil\fcharset0\fprq2{\*\panose 03000500000000000000}Mongolian Baiti;}{\f363\fbidi \fnil\fcharset0\fprq2{\*\panose 03010101010201010101}Monotype Corsiva;}{\f364\fbidi \fnil\fcharset2\fprq2{\*\panose 01010601010101010101}Monotype Sorts;}{\f365\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604030504040204}MS Reference Sans Serif;}{\f366\fbidi \fnil\fcharset0\fprq2{\*\panose 05000500000000000000}MS Reference Specialty;}{\f367\fbidi \fnil\fcharset2\fprq2{\*\panose 05050102010205020202}MT Extra;}{\f368\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Myanmar MN;}{\f369\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Myanmar MN Bold;}{\f370\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Myanmar Sangam MN;}{\f371\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Arabic;}{\f372\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Arabic Bold;}{\f373\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Arabic Bold Italic;}{\f374\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Arabic Italic;}{\f375\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Hebrew Bold;}{\f376\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Hebrew Bold Italic;}{\f377\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Hebrew Italic;}{\f378\fbidi \fnil\fcharset0\fprq2{\*\panose 01010101010101010101}Myriad Hebrew Regular;}{\f379\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503030403020204}Myriad Pro;}{\f380\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703030403020204}Myriad Pro Bold;}{\f381\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706030403020204}Myriad Pro Bold Cond;}{\f382\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706030403090204}Myriad Pro Bold Cond It;}{\f383\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703030403090204}Myriad Pro Bold It;}{\f384\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506030403020204}Myriad Pro Cond;}{\f385\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506030403090204}Myriad Pro Cond It;}{\f386\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503030403090204}Myriad Pro It;}{\f387\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603030403020204}Myriad Pro Semibold;}{\f388\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603030403090204}Myriad Pro Semibold It;}{\f389\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0504020203020204}News Gothic MT;}{\f390\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Noteworthy Bold;}{\f391\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Noteworthy Light;}{\f392\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803070504020203}Nueva Std Bold;}{\f393\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0806070504020203}Nueva Std Bold Cond;}{\f394\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0806070504090203}Nueva Std Bold Cond Italic;}{\f395\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506070504020203}Nueva Std Cond;}{\f396\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506070504090203}Nueva Std Cond Italic;}{\f397\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503070504090203}Nueva Std Italic;}{\f398\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0609000104060307}OCR A Std;}{\f399\fbidi \fnil\fcharset0\fprq2{\*\panose 04050602080702020203}Onyx;}{\f400\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503060000020004}Optima;}{\f401\fbidi \fnil\fcharset0\fprq2{\*\panose 02000b03000000020004}Optima ExtraBlack;}{\f402\fbidi \fnil\fcharset0\fprq2{\*\panose 020d0509020203030204}Orator Std;}{\f403\fbidi \fnil\fcharset0\fprq2{\*\panose 020d05090202030a0204}Orator Std Slanted;}{\f404\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Oriya MN;}{\f405\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Oriya MN Bold;}{\f406\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Oriya Sangam MN;}{\f407\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Oriya Sangam MN Bold;}{\f408\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Palatino;}{\f409\fbidi \fnil\fcharset0\fprq2{\*\panose 02000800000000000000}Palatino Bold;}{\f410\fbidi \fnil\fcharset0\fprq2{\*\panose 02000800000000000000}Palatino Bold Italic;}{\f411\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Palatino Italic;}{\f412\fbidi \fnil\fcharset0\fprq2{\*\panose 02040502050505030304}Palatino Linotype;}{\f413\fbidi \fnil\fcharset0\fprq2{\*\panose 020407020603050a0204}Palatino Linotype Bold;}{\f414\fbidi \fnil\fcharset0\fprq2{\*\panose 020407020603050a0204}Palatino Linotype Bold Italic;}{\f415\fbidi \fnil\fcharset0\fprq2{\*\panose 020405020503050a0304}Palatino Linotype Italic;}{\f416\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602040200020303}Papyrus;}{\f417\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602040200020303}Papyrus Condensed;}{\f418\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Party LET;}{\f419\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060401020303}Perpetua;}{\f420\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802060401020303}Perpetua Bold;}{\f421\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802060401090303}Perpetua Bold Italic;}{\f422\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060401090303}Perpetua Italic;}{\f423\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502060505020804}Perpetua Titling MT;}{\f424\fbidi \fnil\fcharset0\fprq2{\*\panose 02020000000000000000}Plantagenet Cherokee;}{\f425\fbidi \fnil\fcharset0\fprq2{\*\panose 040506030a0602020202}Playbill;}{\f426\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}PMingLiU-ExtB;}{\f427\fbidi \fnil\fcharset81\fprq2{\*\panose 02020500000000000000}@PMingLiU-ExtB;}{\f428\fbidi \fnil\fcharset0\fprq2{\*\panose 04020903030b02020202}Poplar Std;}{\f429\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}PortagoITC TT;}{\f430\fbidi \fnil\fcharset0\fprq2{\*\panose 02060509020206020304}Prestige Elite Std Bold;}{\f431\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Princetown LET;}{\f432\fbidi \fnil\fcharset0\fprq2{\*\panose 02060509020205020204}PT Mono;}{\f433\fbidi \fnil\fcharset0\fprq2{\*\panose 02060709020205020204}PT Mono Bold;}{\f434\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020203020204}PT Sans;}{\f435\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020203020204}PT Sans Bold;}{\f436\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020203090204}PT Sans Bold Italic;}{\f437\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020203020204}PT Sans Caption;}{\f438\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020203020204}PT Sans Caption Bold;}{\f439\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503020203090204}PT Sans Italic;}{\f440\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0506020203020204}PT Sans Narrow;}{\f441\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0706020203020204}PT Sans Narrow Bold;}{\f442\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0603040505020204}PT Serif;}{\f443\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0703040505020204}PT Serif Bold;}{\f444\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0703040505090204}PT Serif Bold Italic;}{\f445\fbidi \fnil\fcharset0\fprq2{\*\panose 02060603050505020204}PT Serif Caption;}{\f446\fbidi \fnil\fcharset0\fprq2{\*\panose 02060603050505090204}PT Serif Caption Italic;}{\f447\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0603040505090204}PT Serif Italic;}{\f448\fbidi \fnil\fcharset0\fprq2{\*\panose 02060603020205020403}Rockwell;}{\f449\fbidi \fnil\fcharset0\fprq2{\*\panose 02060903040505020403}Rockwell Extra Bold;}{\f450\fbidi \fnil\fcharset0\fprq2{\*\panose 04090804040204020202}Rosewood Std Regular;}{\f451\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0802070306020202}Sabon Next LT Pro Bold;}{\f452\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0802070306090202}Sabon Next LT Pro Bold Italic;}{\f453\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0702070306020202}Sabon Next LT Pro Demi;}{\f454\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0702070306090202}Sabon Next LT Pro Demi Italic;}{\f455\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0902070306020202}Sabon Next LT Pro Extra Bold;}{\f456\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0902070306090202}Sabon Next LT Pro Extra Bold It;}{\f457\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0502070306090202}Sabon Next LT Pro Italic;}{\f458\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0502070306020202}Sabon Next LT Pro Regular;}{\f459\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Santa Fe LET;}{\f460\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Sathu;}{\f461\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Savoye LET;}{\f462\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}Savoye LET Plain CC.:1.0;}{\f463\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}SchoolHouse Cursive B;}{\f464\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}SchoolHouse Printed A;}{\f465\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040000020004}Seravek;}{\f466\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803050000020004}Seravek Bold;}{\f467\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0803050000090004}Seravek Bold Italic;}{\f468\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040000020004}Seravek ExtraLight;}{\f469\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040000090004}Seravek ExtraLight Italic;}{\f470\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503050000090004}Seravek Italic;}{\f471\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040000020004}Seravek Light;}{\f472\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0503040000090004}Seravek Light Italic;}{\f473\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703050000020004}Seravek Medium;}{\f474\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703050000090004}Seravek Medium Italic;}{\f475\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Silom;}{\f476\fbidi \fnil\fcharset81\fprq2{\*\panose 02010609060101010101}SimSun-ExtB;}{\f477\fbidi \fnil\fcharset81\fprq2{\*\panose 02010609060101010101}@SimSun-ExtB;}{\f478\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503080000020003}Sinhala MN;}{\f479\fbidi \fnil\fcharset0\fprq2{\*\panose 02000503080000020003}Sinhala MN Bold;}{\f480\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Sinhala Sangam MN;}{\f481\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Sinhala Sangam MN Bold;}{\f482\fbidi \fnil\fcharset0\fprq2{\*\panose 020d0502020204020204}Skia;}{\f483\fbidi \fnil\fcharset0\fprq2{\*\panose 02000603080000090004}Snell Roundhand;}{\f484\fbidi \fnil\fcharset0\fprq2{\*\panose 02000a04090000090004}Snell Roundhand Black;}{\f485\fbidi \fnil\fcharset0\fprq2{\*\panose 02000803090000090004}Snell Roundhand Bold;}{\f486\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Songti SC Black;}{\f487\fbidi \fnil\fcharset0\fprq2{\*\panose 00000800000000000000}STIXGeneral-Bold;}{\f488\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXGeneral-BoldItalic;}{\f489\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXGeneral-Italic;}{\f490\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXGeneral-Regular;}{\f491\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsD-Bold;}{\f492\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsD-Regular;}{\f493\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsSm-Bold;}{\f494\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsSm-Regular;}{\f495\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUp-Bold;}{\f496\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUp-Regular;}{\f497\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUpD-Bold;}{\f498\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUpD-Regular;}{\f499\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUpSm-Bold;}{\f500\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXIntegralsUpSm-Regular;}{\f501\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXNonUnicode-Bold;}{\f502\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXNonUnicode-BoldItalic;}{\f503\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXNonUnicode-Italic;}{\f504\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXNonUnicode-Regular;}{\f505\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeFiveSym-Regular;}{\f506\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeFourSym-Bold;}{\f507\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeFourSym-Regular;}{\f508\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeOneSym-Bold;}{\f509\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeOneSym-Regular;}{\f510\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeThreeSym-Bold;}{\f511\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeThreeSym-Regular;}{\f512\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeTwoSym-Bold;}{\f513\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXSizeTwoSym-Regular;}{\f514\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXVariants-Bold;}{\f515\fbidi \fnil\fcharset0\fprq2{\*\panose 00000000000000000000}STIXVariants-Regular;}{\f516\fbidi \fnil\fcharset0\fprq2{\*\panose 040409050d0802020404}Stencil;}{\f517\fbidi \fnil\fcharset0\fprq2{\*\panose 04020904080802020404}Stencil Std;}{\f518\fbidi \fnil\fcharset0\fprq2{\*\panose 00000700000000000000}Stone Sans ITC TT-Bold;}{\f519\fbidi \fnil\fcharset0\fprq2{\*\panose 00000600000000000000}Stone Sans ITC TT-Semi;}{\f520\fbidi \fnil\fcharset0\fprq2{\*\panose 00000600000000000000}Stone Sans ITC TT-SemiIta;}{\f521\fbidi \fnil\fcharset0\fprq2{\*\panose 02060a05060000020003}Superclarendon Black;}{\f522\fbidi \fnil\fcharset0\fprq2{\*\panose 02060a05060000020003}Superclarendon Black Italic;}{\f523\fbidi \fnil\fcharset0\fprq2{\*\panose 02060805060000020003}Superclarendon Bold;}{\f524\fbidi \fnil\fcharset0\fprq2{\*\panose 02060805060000020003}Superclarendon Bold Italic;}{\f525\fbidi \fnil\fcharset0\fprq2{\*\panose 02060605060000020003}Superclarendon Italic;}{\f526\fbidi \fnil\fcharset0\fprq2{\*\panose 02060305060000020003}Superclarendon Light;}{\f527\fbidi \fnil\fcharset0\fprq2{\*\panose 02060305060000020003}Superclarendon Light Italic;}{\f528\fbidi \fnil\fcharset0\fprq2{\*\panose 02060605060000020003}Superclarendon Regular;}{\f529\fbidi \fnil\fcharset0\fprq2{\*\panose 00000400000000000000}Synchro LET;}{\f530\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604030504040204}Tahoma;}{\f531\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0804030504040204}Tahoma Bold;}{\f532\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Tamil MN;}{\f533\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Tamil MN Bold;}{\f534\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Tamil Sangam MN;}{\f535\fbidi \fnil\fcharset0\fprq2{\*\panose 02000400000000000000}Tamil Sangam MN Bold;}{\f536\fbidi \fnil\fcharset0\fprq2{\*\panose 050b0102010101010101}TeamViewer8;}{\f537\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0603020208020904}Tekton Pro Bold;}{\f538\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0606020208020904}Tekton Pro BoldCond;}{\f539\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0605020208020904}Tekton Pro BoldExt;}{\f540\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0603020208090904}Tekton Pro BoldObl;}{\f541\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Telugu MN;}{\f542\fbidi \fnil\fcharset0\fprq2{\*\panose 02020600050405020304}Telugu MN Bold;}{\f543\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Telugu Sangam MN;}{\f544\fbidi \fnil\fcharset0\fprq2{\*\panose 02000000000000000000}Telugu Sangam MN Bold;}{\f545\fbidi \fnil\fcharset0\fprq2{\*\panose 00000300000000000000}Thonburi Light;}{\f546\fbidi \fnil\fcharset0\fprq2{\*\panose 02020803070505020304}Times New Roman Bold;}{\f547\fbidi \fnil\fcharset0\fprq2{\*\panose 02020703060505090304}Times New Roman Bold Italic;}{\f548\fbidi \fnil\fcharset0\fprq2{\*\panose 02020503050405090304}Times New Roman Italic;}{\f549\fbidi \fnil\fcharset0\fprq2{\*\panose 02020502050506020301}Trajan Pro;}{\f550\fbidi \fnil\fcharset0\fprq2{\*\panose 02020802050506020301}Trajan Pro Bold;}{\f551\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020202020204}Trebuchet MS;}{\f552\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020202020204}Trebuchet MS Bold;}{\f553\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0703020202090204}Trebuchet MS Bold Italic;}{\f554\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0603020202090204}Trebuchet MS Italic;}{\f555\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602020104020603}Tw Cen MT;}{\f556\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0802020104020603}Tw Cen MT Bold;}{\f557\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0802020104090603}Tw Cen MT Bold Italic;}{\f558\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0602020104090603}Tw Cen MT Italic;}{\f559\fbidi \fnil\fcharset0\fprq2{\*\panose 02000500000000000000}Type Embellishments One LET;}{\f560\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0804030504040204}Verdana Bold;}{\f561\fbidi \fnil\fcharset0\fprq2{\*\panose 020b08040305040b0204}Verdana Bold Italic;}{\f562\fbidi \fnil\fcharset0\fprq2{\*\panose 020b06040305040b0204}Verdana Italic;}{\f563\fbidi \fnil\fcharset0\fprq2{\*\panose 040b0500000000000000}Wawati SC Regular;}{\f564\fbidi \fnil\fcharset0\fprq2{\*\panose 040b0500000000000000}Wawati TC Regular;}{\f565\fbidi \fnil\fcharset2\fprq2{\*\panose 05030102010509060703}Webdings;}{\f566\fbidi \fnil\fcharset0\fprq2{\*\panose 020a0a07050505020404}Wide Latin;}{\f567\fbidi \fnil\fcharset2\fprq2{\*\panose 05020102010507070707}Wingdings 2;}{\f568\fbidi \fnil\fcharset2\fprq2{\*\panose 05040102010807070707}Wingdings 3;}{\f569\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Xingkai SC Bold;}{\f570\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Xingkai SC Light;}{\f571\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Yuanti SC Bold;}{\f572\fbidi \fnil\fcharset0\fprq2{\*\panose 02010800040101010101}Yuanti SC Regular;}{\f573\fbidi \fnil\fcharset2\fprq2{\*\panose 05020102010704020609}Zapf Dingbats;}{\f574\fbidi \fnil\fcharset0\fprq2{\*\panose 03030300040707070c03}Zapfino;}{\f575\fbidi \fnil\fcharset88\fprq2{\*\panose 020b0600040502020204}Lucida Grande CE;}{\f576\fbidi \fnil\fcharset89\fprq2{\*\panose 00000400000000000000}Charcoal CY;}{\f577\fbidi \fnil\fcharset89\fprq2{\*\panose 00000400000000000000}Geneva CY;}{\f578\fbidi \fnil\fcharset89\fprq2{\*\panose 00000400000000000000}Helvetica CY;}{\f579\fbidi \fnil\fcharset89\fprq2{\*\panose 020b0600040502020204}Lucida Grande CY;}{\f580\fbidi \fnil\fcharset89\fprq2{\*\panose 00000400000000000000}Thonburi;}{\f581\fbidi \fnil\fcharset89\fprq2{\*\panose 00000400000000000000}Thonburi Bold;}{\f582\fbidi \fnil\fcharset81\fprq2 Adobe \'a9\'fa\'c5\'e9 Std L;}{\f583\fbidi \fnil\fcharset81\fprq2 @Adobe \'a9\'fa\'c5\'e9 Std L;}{\f584\fbidi \fnil\fcharset81\fprq2 Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B;}{\f585\fbidi \fnil\fcharset81\fprq2 @Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B;}{\f586\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}Apple LiGothic Medium;}{\f587\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}@Apple LiGothic Medium;}{\f588\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}Apple LiSung Light;}{\f589\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}@Apple LiSung Light;}{\f590\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}BiauKai;}{\f591\fbidi \fnil\fcharset81\fprq2{\*\panose 02000500000000000000}@BiauKai;}{\f592\fbidi \fnil\fcharset81\fprq2{\*\panose 03000700000000000000}Hannotate TC Bold;}{\f593\fbidi \fnil\fcharset81\fprq2{\*\panose 03000700000000000000}@Hannotate TC Bold;}{\f594\fbidi \fnil\fcharset81\fprq2{\*\panose 03000500000000000000}Hannotate TC Regular;}{\f595\fbidi \fnil\fcharset81\fprq2{\*\panose 03000500000000000000}@Hannotate TC Regular;}{\f596\fbidi \fnil\fcharset81\fprq2{\*\panose 03000500000000000000}HanziPen TC Bold;}{\f597\fbidi \fnil\fcharset81\fprq2{\*\panose 03000500000000000000}@HanziPen TC Bold;}{\f598\fbidi \fnil\fcharset81\fprq2{\*\panose 03000300000000000000}HanziPen TC Regular;}{\f599\fbidi \fnil\fcharset81\fprq2{\*\panose 03000300000000000000}@HanziPen TC Regular;}{\f600\fbidi \fnil\fcharset81\fprq2{\*\panose 02000000000000000000}Heiti TC Light;}{\f601\fbidi \fnil\fcharset81\fprq2{\*\panose 02000000000000000000}@Heiti TC Light;}{\f602\fbidi \fnil\fcharset81\fprq2{\*\panose 00000000000000000000}Heiti TC Medium;}{\f603\fbidi \fnil\fcharset81\fprq2{\*\panose 00000000000000000000}@Heiti TC Medium;}{\f604\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}Kaiti TC Bold;}{\f605\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}@Kaiti TC Bold;}{\f606\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}Kaiti TC Regular;}{\f607\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}@Kaiti TC Regular;}{\f608\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}Songti TC Bold;}{\f609\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}@Songti TC Bold;}{\f610\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}Songti TC Light;}{\f611\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}@Songti TC Light;}{\f612\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}Songti TC Regular;}{\f613\fbidi \fnil\fcharset81\fprq2{\*\panose 02010600040101010101}@Songti TC Regular;}{\f614\fbidi \fnil\fcharset81\fprq2{\*\panose 03000800000000000000}Weibei TC Bold;}{\f615\fbidi \fnil\fcharset81\fprq2{\*\panose 03000800000000000000}@Weibei TC Bold;}{\f616\fbidi \fnil\fcharset81\fprq2{\*\panose 00000600000000000000}Yuppy TC Regular;}{\f617\fbidi \fnil\fcharset81\fprq2{\*\panose 00000600000000000000}@Yuppy TC Regular;}{\f618\fbidi \fnil\fcharset81\fprq2 \'b2\'d3\'a9\'fa\'c5\'e9;}{\f619\fbidi \fnil\fcharset81\fprq2 @\'b2\'d3\'a9\'fa\'c5\'e9;}{\f620\fbidi \fnil\fcharset81\fprq2 \'b2\'d3\'a9\'fa\'c5\'e9_HKSCS;}{\f621\fbidi \fnil\fcharset81\fprq2 @\'b2\'d3\'a9\'fa\'c5\'e9_HKSCS;}{\f622\fbidi \fnil\fcharset81\fprq2 @\'b7\'73\'b2\'d3\'a9\'fa\'c5\'e9;}{\f623\fbidi \fnil\fcharset81\fprq2 \'c4\'d7\'a7\'ba Pro;}{\f624\fbidi \fnil\fcharset81\fprq2 @\'c4\'d7\'a7\'ba Pro;}{\f625\fbidi \fnil\fcharset81\fprq2 \'c4\'d7\'b6\'c2 Pro;}{\f626\fbidi \fnil\fcharset81\fprq2 @\'c4\'d7\'b6\'c2 Pro;}{\f627\fbidi \fnil\fcharset80\fprq2 Adobe \'b7\'c2\'cb\'ce Std R;}{\f628\fbidi \fnil\fcharset80\fprq2 @Adobe \'b7\'c2\'cb\'ce Std R;}{\f629\fbidi \fnil\fcharset80\fprq2 Adobe \'ba\'da\'cc\'e5 Std R;}{\f630\fbidi \fnil\fcharset80\fprq2 @Adobe \'ba\'da\'cc\'e5 Std R;}{\f631\fbidi \fnil\fcharset80\fprq2 Adobe \'bf\'ac\'cc\'e5 Std R;}{\f632\fbidi \fnil\fcharset80\fprq2 @Adobe \'bf\'ac\'cc\'e5 Std R;}{\f633\fbidi \fnil\fcharset80\fprq2 Adobe \'cb\'ce\'cc\'e5 Std L;}{\f634\fbidi \fnil\fcharset80\fprq2 @Adobe \'cb\'ce\'cc\'e5 Std L;}{\f635\fbidi \fnil\fcharset80\fprq2 GB18030 Bitmap;}{\f636\fbidi \fnil\fcharset80\fprq2 @GB18030 Bitmap;}{\f637\fbidi \fnil\fcharset80\fprq2{\*\panose 03000700000000000000}Hannotate SC Bold;}{\f638\fbidi \fnil\fcharset80\fprq2{\*\panose 03000700000000000000}@Hannotate SC Bold;}{\f639\fbidi \fnil\fcharset80\fprq2{\*\panose 03000500000000000000}Hannotate SC Regular;}{\f640\fbidi \fnil\fcharset80\fprq2{\*\panose 03000500000000000000}@Hannotate SC Regular;}{\f641\fbidi \fnil\fcharset80\fprq2{\*\panose 03000500000000000000}HanziPen SC Bold;}{\f642\fbidi \fnil\fcharset80\fprq2{\*\panose 03000500000000000000}@HanziPen SC Bold;}{\f643\fbidi \fnil\fcharset80\fprq2{\*\panose 03000300000000000000}HanziPen SC Regular;}{\f644\fbidi \fnil\fcharset80\fprq2{\*\panose 03000300000000000000}@HanziPen SC Regular;}{\f645\fbidi \fnil\fcharset80\fprq2{\*\panose 02000500000000000000}Hei;}{\f646\fbidi \fnil\fcharset80\fprq2{\*\panose 02000500000000000000}@Hei;}{\f647\fbidi \fnil\fcharset80\fprq2{\*\panose 02000000000000000000}Heiti SC Light;}{\f648\fbidi \fnil\fcharset80\fprq2{\*\panose 02000000000000000000}@Heiti SC Light;}{\f649\fbidi \fnil\fcharset80\fprq2{\*\panose 00000000000000000000}Heiti SC Medium;}{\f650\fbidi \fnil\fcharset80\fprq2{\*\panose 00000000000000000000}@Heiti SC Medium;}{\f651\fbidi \fnil\fcharset80\fprq2{\*\panose 020b0300000000000000}Hiragino Sans GB W3;}{\f652\fbidi \fnil\fcharset80\fprq2{\*\panose 020b0300000000000000}@Hiragino Sans GB W3;}{\f653\fbidi \fnil\fcharset80\fprq2{\*\panose 020b0600000000000000}Hiragino Sans GB W6;}{\f654\fbidi \fnil\fcharset80\fprq2{\*\panose 020b0600000000000000}@Hiragino Sans GB W6;}{\f655\fbidi \fnil\fcharset80\fprq2{\*\panose 02000500000000000000}Kai;}{\f656\fbidi \fnil\fcharset80\fprq2{\*\panose 02000500000000000000}@Kai;}{\f657\fbidi \fnil\fcharset80\fprq2{\*\panose 02010800040101010101}Kaiti SC Bold;}{\f658\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Kaiti SC Bold;}{\f659\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}Kaiti SC Regular;}{\f660\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Kaiti SC Regular;}{\f661\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}Songti SC Bold;}{\f662\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Songti SC Bold;}{\f663\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}Songti SC Light;}{\f664\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Songti SC Light;}{\f665\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}Songti SC Regular;}{\f666\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Songti SC Regular;}{\f667\fbidi \fnil\fcharset80\fprq2{\*\panose 03000800000000000000}Weibei SC Bold;}{\f668\fbidi \fnil\fcharset80\fprq2{\*\panose 03000800000000000000}@Weibei SC Bold;}{\f669\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}Yuanti SC Light;}{\f670\fbidi \fnil\fcharset80\fprq2{\*\panose 02010600040101010101}@Yuanti SC Light;}{\f671\fbidi \fnil\fcharset80\fprq2{\*\panose 00000500000000000000}Yuppy SC Regular;}{\f672\fbidi \fnil\fcharset80\fprq2{\*\panose 00000500000000000000}@Yuppy SC Regular;}{\f673\fbidi \fnil\fcharset80\fprq2 \'ba\'da\'cc\'e5;}{\f674\fbidi \fnil\fcharset80\fprq2 @\'ba\'da\'cc\'e5;}{\f675\fbidi \fnil\fcharset80\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce;}{\f676\fbidi \fnil\fcharset80\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce;}{\f677\fbidi \fnil\fcharset80\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5;}{\f678\fbidi \fnil\fcharset80\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5;}{\f679\fbidi \fnil\fcharset80\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5;}{\f680\fbidi \fnil\fcharset80\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5;}{\f681\fbidi \fnil\fcharset80\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5;}{\f682\fbidi \fnil\fcharset80\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5;}{\f683\fbidi \fnil\fcharset80\fprq2 \'bb\'aa\'ce\'c4\'cf\'b8\'ba\'da;}{\f684\fbidi \fnil\fcharset80\fprq2 @\'bb\'aa\'ce\'c4\'cf\'b8\'ba\'da;}{\f685\fbidi \fnil\fcharset80\fprq2 @\'cb\'ce\'cc\'e5;}{\f686\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e;}{\f687\fbidi \fnil\fcharset78\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e;}{\f688\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9;}{\f689\fbidi \fnil\fcharset78\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9;}{\f690\fbidi \fnil\fcharset78\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e;}{\f691\fbidi \fnil\fcharset78\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9;}{\f692\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0600000000000000}Osaka;}{\f693\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0600000000000000}@Osaka;}{\f694\fbidi \fnil\fcharset78\fprq2 Osaka\'81\'7c\'93\'99\'95\'9d;}{\f695\fbidi \fnil\fcharset78\fprq2 @Osaka\'81\'7c\'93\'99\'95\'9d;}{\f696\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0700000000000000}YuGothic Bold;}{\f697\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0700000000000000}@YuGothic Bold;}{\f698\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0500000000000000}YuGothic Medium;}{\f699\fbidi \fnil\fcharset78\fprq2{\*\panose 020b0500000000000000}@YuGothic Medium;}{\f700\fbidi \fnil\fcharset78\fprq2{\*\panose 02020600000000000000}YuMincho Demibold;}{\f701\fbidi \fnil\fcharset78\fprq2{\*\panose 02020600000000000000}@YuMincho Demibold;}{\f702\fbidi \fnil\fcharset78\fprq2{\*\panose 02020500000000000000}YuMincho Medium;}{\f703\fbidi \fnil\fcharset78\fprq2{\*\panose 02020500000000000000}@YuMincho Medium;}{\f704\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3;}{\f705\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3;}{\f706\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6;}{\f707\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6;}{\f708\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3;}{\f709\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3;}{\f710\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6;}{\f711\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6;}{\f712\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8;}{\f713\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8;}{\f714\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8;}{\f715\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8;}{\f716\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4;}{\f717\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4;}{\f718\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4;}{\f719\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4;}{\f720\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3;}{\f721\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3;}{\f722\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6;}{\f723\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6;}{\f724\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3;}{\f725\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3;}{\f726\fbidi \fnil\fcharset78\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6;}{\f727\fbidi \fnil\fcharset78\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6;}{\f728\fbidi \fnil\fcharset78\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49;}{\f729\fbidi \fnil\fcharset78\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49;}{\f730\fbidi \fnil\fcharset78\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e;}{\f731\fbidi \fnil\fcharset78\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e;}{\f732\fbidi \fnil\fcharset78\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68;}{\f733\fbidi \fnil\fcharset78\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68;}{\f734\fbidi \fnil\fcharset78\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e;}{\f735\fbidi \fnil\fcharset78\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e;}{\f736\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B;}{\f737\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B;}{\f738\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL;}{\f739\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL;}{\f740\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H;}{\f741\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H;}{\f742\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L;}{\f743\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L;}{\f744\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M;}{\f745\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M;}{\f746\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R;}{\f747\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R;}{\f748\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B;}{\f749\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B;}{\f750\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL;}{\f751\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL;}{\f752\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H;}{\f753\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H;}{\f754\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L;}{\f755\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L;}{\f756\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M;}{\f757\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M;}{\f758\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R;}{\f759\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R;}{\f760\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B;}{\f761\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B;}{\f762\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL;}{\f763\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL;}{\f764\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H;}{\f765\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H;}{\f766\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L;}{\f767\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L;}{\f768\fbidi \fnil\fcharset0\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M;}{\f769\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R;}{\f770\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R;}{\f771\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B;}{\f772\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B;}{\f773\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL;}{\f774\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL;}{\f775\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H;}{\f776\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H;}{\f777\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L;}{\f778\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L;}{\f779\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M;}{\f780\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M;}{\f781\fbidi \fnil\fcharset78\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R;}{\f782\fbidi \fnil\fcharset78\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R;}{\f783\fbidi \fnil\fcharset79\fprq2 Adobe \'b0\'ed\'b5\'f1 Std B;}{\f784\fbidi \fnil\fcharset79\fprq2 @Adobe \'b0\'ed\'b5\'f1 Std B;}{\f785\fbidi \fnil\fcharset79\fprq2 Adobe \'b8\'ed\'c1\'b6 Std M;}{\f786\fbidi \fnil\fcharset79\fprq2 @Adobe \'b8\'ed\'c1\'b6 Std M;}{\f787\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee;}{\f788\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee;}{\f789\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc;}{\f790\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc;}{\f791\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc;}{\f792\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc;}{\f793\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc;}{\f794\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc;}{\f795\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc;}{\f796\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc;}{\f797\fbidi \fnil\fcharset79\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc;}{\f798\fbidi \fnil\fcharset79\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc;}{\f799\fbidi \fnil\fcharset79\fprq2{\*\panose 02000500000000000000}AppleGothic;}{\f800\fbidi \fnil\fcharset79\fprq2{\*\panose 02000500000000000000}@AppleGothic;}{\f801\fbidi \fnil\fcharset79\fprq2{\*\panose 02000500000000000000}AppleMyungjo;}{\f802\fbidi \fnil\fcharset79\fprq2{\*\panose 02000500000000000000}@AppleMyungjo;}{\f803\fbidi \fnil\fcharset79\fprq2 PC\'b8\'ed\'c1\'b6;}{\f804\fbidi \fnil\fcharset79\fprq2 @PC\'b8\'ed\'c1\'b6;}{\f805\fbidi \fnil\fcharset79\fprq2 \'b1\'bc\'b8\'b2;}{\f806\fbidi \fnil\fcharset79\fprq2 @\'b1\'bc\'b8\'b2;}{\f807\fbidi \fnil\fcharset79\fprq2 \'b1\'c3\'bc\'ad\'c3\'bc;}{\f808\fbidi \fnil\fcharset79\fprq2 @\'b1\'c3\'bc\'ad\'c3\'bc;}{\f809\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1;}{\f810\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1;}{\f811\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Bold;}{\f812\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Bold;}{\f813\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 ExtraBold;}{\f814\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 ExtraBold;}{\f815\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6;}{\f816\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6;}{\f817\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Bold;}{\f818\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Bold;}{\f819\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 ExtraBold;}{\f820\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 ExtraBold;}{\f821\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'ba\'d7;}{\f822\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'ba\'d7;}{\f823\fbidi \fnil\fcharset79\fprq2 \'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'c6\'e6;}{\f824\fbidi \fnil\fcharset79\fprq2 @\'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'c6\'e6;}{\f825\fbidi \fnil\fcharset79\fprq2 @\'b9\'d9\'c5\'c1;}{\f826\fbidi \fnil\fcharset79\fprq2 \'c7\'ca\'b1\'e2\'c3\'bc;}{\f827\fbidi \fnil\fcharset79\fprq2 @\'c7\'ca\'b1\'e2\'c3\'bc;}{\f828\fbidi \fnil\fcharset79\fprq2 \'c7\'ec\'b5\'e5\'b6\'f3\'c0\'ceA;}{\f829\fbidi \fnil\fcharset79\fprq2 @\'c7\'ec\'b5\'e5\'b6\'f3\'c0\'ceA;}{\f830\fbidi \froman\fcharset77\fprq0{\*\panose 00000000000000000000}Ming(for ISO10646) {\*\falt &#39636,MingLiU_HKSCS};}{\flomajor\f31500\fbidi \fnil\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}{\fdbmajor\f31501\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e;}{\fhimajor\f31502\fbidi \fnil\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}{\fbimajor\f31503\fbidi \fnil\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\flominor\f31504\fbidi \fnil\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fdbminor\f31505\fbidi \fnil\fcharset78\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9;}{\fhiminor\f31506\fbidi \fnil\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria;}{\fbiminor\f31507\fbidi \fnil\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f831\fbidi \fnil\fcharset238\fprq2 Times New Roman CE;}{\f832\fbidi \fnil\fcharset204\fprq2 Times New Roman Cyr;}{\f834\fbidi \fnil\fcharset161\fprq2 Times New Roman Greek;}{\f835\fbidi \fnil\fcharset162\fprq2 Times New Roman Tur;}{\f836\fbidi \fnil\fcharset177\fprq2 Times New Roman (Hebrew);}{\f837\fbidi \fnil\fcharset178\fprq2 Times New Roman (Arabid);}{\f838\fbidi \fnil\fcharset186\fprq2 Times New Roman Baltic;}{\f839\fbidi \fnil\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f841\fbidi \fnil\fcharset238\fprq2 Arial CE;}{\f842\fbidi \fnil\fcharset204\fprq2 Arial Cyr;}{\f844\fbidi \fnil\fcharset161\fprq2 Arial Greek;}{\f845\fbidi \fnil\fcharset162\fprq2 Arial Tur;}{\f846\fbidi \fnil\fcharset177\fprq2 Arial (Hebrew);}{\f847\fbidi \fnil\fcharset178\fprq2 Arial (Arabid);}{\f848\fbidi \fnil\fcharset186\fprq2 Arial Baltic;}{\f849\fbidi \fnil\fcharset163\fprq2 Arial (Vietnamese);}{\f851\fbidi \fnil\fcharset238\fprq2 Courier CE{\*\falt Courier};}{\f852\fbidi \fnil\fcharset204\fprq2 Courier Cyr{\*\falt Courier};}{\f854\fbidi \fnil\fcharset161\fprq2 Courier Greek{\*\falt Courier};}{\f855\fbidi \fnil\fcharset162\fprq2 Courier Tur{\*\falt Courier};}{\f856\fbidi \fnil\fcharset177\fprq2 Courier (Hebrew){\*\falt Courier};}{\f857\fbidi \fnil\fcharset178\fprq2 Courier (Arabid){\*\falt Courier};}{\f858\fbidi \fnil\fcharset186\fprq2 Courier Baltic{\*\falt Courier};}{\f859\fbidi \fnil\fcharset163\fprq2 Courier (Vietnamese){\*\falt Courier};}{\f881\fbidi \fnil\fcharset238\fprq2 Helvetica CE;}{\f882\fbidi \fnil\fcharset204\fprq2 Helvetica Cyr;}{\f884\fbidi \fnil\fcharset161\fprq2 Helvetica Greek;}{\f885\fbidi \fnil\fcharset162\fprq2 Helvetica Tur;}{\f888\fbidi \fnil\fcharset186\fprq2 Helvetica Baltic;}{\f889\fbidi \fnil\fcharset163\fprq2 Helvetica (Vietnamese);}{\f901\fbidi \fnil\fcharset238\fprq2 Geneva CE;}{\f905\fbidi \fnil\fcharset162\fprq2 Geneva Tur;}{\f908\fbidi \fnil\fcharset186\fprq2 Geneva Baltic;}{\f983\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Western;}{\f981\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 CE;}{\f982\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Cyr;}{\f984\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Greek;}{\f985\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Tur;}{\f988\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Baltic;}{\f993\fbidi \fnil\fcharset0\fprq2 \'b9\'d9\'c5\'c1 Western;}{\f991\fbidi \fnil\fcharset238\fprq2 \'b9\'d9\'c5\'c1 CE;}{\f992\fbidi \fnil\fcharset204\fprq2 \'b9\'d9\'c5\'c1 Cyr;}{\f994\fbidi \fnil\fcharset161\fprq2 \'b9\'d9\'c5\'c1 Greek;}{\f995\fbidi \fnil\fcharset162\fprq2 \'b9\'d9\'c5\'c1 Tur;}{\f998\fbidi \fnil\fcharset186\fprq2 \'b9\'d9\'c5\'c1 Baltic;}{\f1003\fbidi \fnil\fcharset0\fprq2 \'cb\'ce\'cc\'e5 Western;}{\f1013\fbidi \fnil\fcharset0\fprq2 \'b7\'73\'b2\'d3\'a9\'fa\'c5\'e9 Western;}{\f1023\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Western;}{\f1021\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e CE;}{\f1022\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Cyr;}{\f1024\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Greek;}{\f1025\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Tur;}{\f1028\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Baltic;}{\f1031\fbidi \fnil\fcharset238\fprq2 Century CE;}{\f1032\fbidi \fnil\fcharset204\fprq2 Century Cyr;}{\f1034\fbidi \fnil\fcharset161\fprq2 Century Greek;}{\f1035\fbidi \fnil\fcharset162\fprq2 Century Tur;}{\f1038\fbidi \fnil\fcharset186\fprq2 Century Baltic;}{\f1041\fbidi \fnil\fcharset238\fprq2 Verdana CE;}{\f1042\fbidi \fnil\fcharset204\fprq2 Verdana Cyr;}{\f1044\fbidi \fnil\fcharset161\fprq2 Verdana Greek;}{\f1045\fbidi \fnil\fcharset162\fprq2 Verdana Tur;}{\f1048\fbidi \fnil\fcharset186\fprq2 Verdana Baltic;}{\f1049\fbidi \fnil\fcharset163\fprq2 Verdana (Vietnamese);}{\f1092\fbidi \froman\fcharset204\fprq2 Sylfaen Cyr;}{\f1094\fbidi \froman\fcharset161\fprq2 Sylfaen Greek;}{\f1171\fbidi \fnil\fcharset238\fprq2 Cambria Math CE;}{\f1172\fbidi \fnil\fcharset204\fprq2 Cambria Math Cyr;}{\f1174\fbidi \fnil\fcharset161\fprq2 Cambria Math Greek;}{\f1175\fbidi \fnil\fcharset162\fprq2 Cambria Math Tur;}{\f1178\fbidi \fnil\fcharset186\fprq2 Cambria Math Baltic;}{\f1179\fbidi \fnil\fcharset163\fprq2 Cambria Math (Vietnamese);}{\f1181\fbidi \fnil\fcharset238\fprq2 Calibri CE;}{\f1182\fbidi \fnil\fcharset204\fprq2 Calibri Cyr;}{\f1184\fbidi \fnil\fcharset161\fprq2 Calibri Greek;}{\f1185\fbidi \fnil\fcharset162\fprq2 Calibri Tur;}{\f1188\fbidi \fnil\fcharset186\fprq2 Calibri Baltic;}{\f1189\fbidi \fnil\fcharset163\fprq2 Calibri (Vietnamese);}{\f1191\fbidi \fnil\fcharset238\fprq2 Cambria CE;}{\f1192\fbidi \fnil\fcharset204\fprq2 Cambria Cyr;}{\f1194\fbidi \fnil\fcharset161\fprq2 Cambria Greek;}{\f1195\fbidi \fnil\fcharset162\fprq2 Cambria Tur;}{\f1198\fbidi \fnil\fcharset186\fprq2 Cambria Baltic;}{\f1199\fbidi \fnil\fcharset163\fprq2 Cambria (Vietnamese);}{\f1237\fbidi \fnil\fcharset178\fprq2 Adobe Arabic (Arabid);}{\f1247\fbidi \fnil\fcharset178\fprq2 Adobe Arabic Bold (Arabid);}{\f1257\fbidi \fnil\fcharset178\fprq2 Adobe Arabic Bold Italic (Arabid);}{\f1267\fbidi \fnil\fcharset178\fprq2 Adobe Arabic Italic (Arabid);}{\f1271\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro CE;}{\f1275\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro Tur;}{\f1278\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro Baltic;}{\f1281\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro Bold CE;}{\f1285\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro Bold Tur;}{\f1288\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro Bold Baltic;}{\f1291\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro Bold Italic CE;}{\f1295\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro Bold Italic Tur;}{\f1298\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro Bold Italic Baltic;}{\f1301\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro Italic CE;}{\f1305\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro Italic Tur;}{\f1308\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro Italic Baltic;}{\f1311\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro SmBd CE;}{\f1315\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro SmBd Tur;}{\f1318\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro SmBd Baltic;}{\f1321\fbidi \fnil\fcharset238\fprq2 Adobe Caslon Pro SmBd Italic CE;}{\f1325\fbidi \fnil\fcharset162\fprq2 Adobe Caslon Pro SmBd Italic Tur;}{\f1328\fbidi \fnil\fcharset186\fprq2 Adobe Caslon Pro SmBd Italic Baltic;}{\f1371\fbidi \fnil\fcharset238\fprq2 Adobe Garamond Pro CE;}{\f1375\fbidi \fnil\fcharset162\fprq2 Adobe Garamond Pro Tur;}{\f1378\fbidi \fnil\fcharset186\fprq2 Adobe Garamond Pro Baltic;}{\f1381\fbidi \fnil\fcharset238\fprq2 Adobe Garamond Pro Bold CE;}{\f1385\fbidi \fnil\fcharset162\fprq2 Adobe Garamond Pro Bold Tur;}{\f1388\fbidi \fnil\fcharset186\fprq2 Adobe Garamond Pro Bold Baltic;}{\f1391\fbidi \fnil\fcharset238\fprq2 Adobe Garamond Pro Bold Italic CE;}{\f1395\fbidi \fnil\fcharset162\fprq2 Adobe Garamond Pro Bold Italic Tur;}{\f1398\fbidi \fnil\fcharset186\fprq2 Adobe Garamond Pro Bold Italic Baltic;}{\f1401\fbidi \fnil\fcharset238\fprq2 Adobe Garamond Pro Italic CE;}{\f1405\fbidi \fnil\fcharset162\fprq2 Adobe Garamond Pro Italic Tur;}{\f1408\fbidi \fnil\fcharset186\fprq2 Adobe Garamond Pro Italic Baltic;}{\f1416\fbidi \fnil\fcharset177\fprq2 Adobe Hebrew (Hebrew);}{\f1426\fbidi \fnil\fcharset177\fprq2 Adobe Hebrew Bold (Hebrew);}{\f1436\fbidi \fnil\fcharset177\fprq2 Adobe Hebrew Bold Italic (Hebrew);}{\f1446\fbidi \fnil\fcharset177\fprq2 Adobe Hebrew Italic (Hebrew);}{\f1457\fbidi \fnil\fcharset178\fprq2 Adobe Naskh Medium (Arabid);}{\f1465\fbidi \fnil\fcharset162\fprq2 American Typewriter Tur;}{\f1469\fbidi \fnil\fcharset163\fprq2 American Typewriter (Vietnamese);}{\f1475\fbidi \fnil\fcharset162\fprq2 American Typewriter Condensed Tur;}{\f1479\fbidi \fnil\fcharset163\fprq2 American Typewriter Condensed (Vietnamese);}{\f1485\fbidi \fnil\fcharset162\fprq2 American Typewriter Light Tur;}{\f1489\fbidi \fnil\fcharset163\fprq2 American Typewriter Light (Vietnamese);}{\f1491\fbidi \fnil\fcharset238\fprq2 Andale Mono CE;}{\f1492\fbidi \fnil\fcharset204\fprq2 Andale Mono Cyr;}{\f1494\fbidi \fnil\fcharset161\fprq2 Andale Mono Greek;}{\f1495\fbidi \fnil\fcharset162\fprq2 Andale Mono Tur;}{\f1498\fbidi \fnil\fcharset186\fprq2 Andale Mono Baltic;}{\f1501\fbidi \fnil\fcharset238\fprq2 Apple Chancery CE;}{\f1505\fbidi \fnil\fcharset162\fprq2 Apple Chancery Tur;}{\f1506\fbidi \fnil\fcharset177\fprq2 Apple Chancery (Hebrew);}{\f1507\fbidi \fnil\fcharset178\fprq2 Apple Chancery (Arabid);}{\f1508\fbidi \fnil\fcharset186\fprq2 Apple Chancery Baltic;}{\f1509\fbidi \fnil\fcharset163\fprq2 Apple Chancery (Vietnamese);}{\f1511\fbidi \fnil\fcharset238\fprq2 Apple Symbols CE;}{\f1514\fbidi \fnil\fcharset161\fprq2 Apple Symbols Greek;}{\f1515\fbidi \fnil\fcharset162\fprq2 Apple Symbols Tur;}{\f1516\fbidi \fnil\fcharset177\fprq2 Apple Symbols (Hebrew);}{\f1517\fbidi \fnil\fcharset178\fprq2 Apple Symbols (Arabid);}{\f1518\fbidi \fnil\fcharset186\fprq2 Apple Symbols Baltic;}{\f1519\fbidi \fnil\fcharset163\fprq2 Apple Symbols (Vietnamese);}{\f1521\fbidi \fnil\fcharset238\fprq2 Arial Black CE;}{\f1522\fbidi \fnil\fcharset204\fprq2 Arial Black Cyr;}{\f1524\fbidi \fnil\fcharset161\fprq2 Arial Black Greek;}{\f1525\fbidi \fnil\fcharset162\fprq2 Arial Black Tur;}{\f1528\fbidi \fnil\fcharset186\fprq2 Arial Black Baltic;}{\f1531\fbidi \fnil\fcharset238\fprq2 Arial Bold CE;}{\f1532\fbidi \fnil\fcharset204\fprq2 Arial Bold Cyr;}{\f1534\fbidi \fnil\fcharset161\fprq2 Arial Bold Greek;}{\f1535\fbidi \fnil\fcharset162\fprq2 Arial Bold Tur;}{\f1536\fbidi \fnil\fcharset177\fprq2 Arial Bold (Hebrew);}{\f1537\fbidi \fnil\fcharset178\fprq2 Arial Bold (Arabid);}{\f1538\fbidi \fnil\fcharset186\fprq2 Arial Bold Baltic;}{\f1539\fbidi \fnil\fcharset163\fprq2 Arial Bold (Vietnamese);}{\f1541\fbidi \fnil\fcharset238\fprq2 Arial Bold Italic CE;}{\f1542\fbidi \fnil\fcharset204\fprq2 Arial Bold Italic Cyr;}{\f1544\fbidi \fnil\fcharset161\fprq2 Arial Bold Italic Greek;}{\f1545\fbidi \fnil\fcharset162\fprq2 Arial Bold Italic Tur;}{\f1546\fbidi \fnil\fcharset177\fprq2 Arial Bold Italic (Hebrew);}{\f1548\fbidi \fnil\fcharset186\fprq2 Arial Bold Italic Baltic;}{\f1549\fbidi \fnil\fcharset163\fprq2 Arial Bold Italic (Vietnamese);}{\f1551\fbidi \fnil\fcharset238\fprq2 Arial Italic CE;}{\f1552\fbidi \fnil\fcharset204\fprq2 Arial Italic Cyr;}{\f1554\fbidi \fnil\fcharset161\fprq2 Arial Italic Greek;}{\f1555\fbidi \fnil\fcharset162\fprq2 Arial Italic Tur;}{\f1556\fbidi \fnil\fcharset177\fprq2 Arial Italic (Hebrew);}{\f1558\fbidi \fnil\fcharset186\fprq2 Arial Italic Baltic;}{\f1559\fbidi \fnil\fcharset163\fprq2 Arial Italic (Vietnamese);}{\f1561\fbidi \fnil\fcharset238\fprq2 Arial Narrow CE;}{\f1562\fbidi \fnil\fcharset204\fprq2 Arial Narrow Cyr;}{\f1564\fbidi \fnil\fcharset161\fprq2 Arial Narrow Greek;}{\f1565\fbidi \fnil\fcharset162\fprq2 Arial Narrow Tur;}{\f1568\fbidi \fnil\fcharset186\fprq2 Arial Narrow Baltic;}{\f1571\fbidi \fnil\fcharset238\fprq2 Arial Narrow Bold CE;}{\f1572\fbidi \fnil\fcharset204\fprq2 Arial Narrow Bold Cyr;}{\f1574\fbidi \fnil\fcharset161\fprq2 Arial Narrow Bold Greek;}{\f1575\fbidi \fnil\fcharset162\fprq2 Arial Narrow Bold Tur;}{\f1578\fbidi \fnil\fcharset186\fprq2 Arial Narrow Bold Baltic;}{\f1581\fbidi \fnil\fcharset238\fprq2 Arial Narrow Bold Italic CE;}{\f1582\fbidi \fnil\fcharset204\fprq2 Arial Narrow Bold Italic Cyr;}{\f1584\fbidi \fnil\fcharset161\fprq2 Arial Narrow Bold Italic Greek;}{\f1585\fbidi \fnil\fcharset162\fprq2 Arial Narrow Bold Italic Tur;}{\f1588\fbidi \fnil\fcharset186\fprq2 Arial Narrow Bold Italic Baltic;}{\f1591\fbidi \fnil\fcharset238\fprq2 Arial Narrow Italic CE;}{\f1592\fbidi \fnil\fcharset204\fprq2 Arial Narrow Italic Cyr;}{\f1594\fbidi \fnil\fcharset161\fprq2 Arial Narrow Italic Greek;}{\f1595\fbidi \fnil\fcharset162\fprq2 Arial Narrow Italic Tur;}{\f1598\fbidi \fnil\fcharset186\fprq2 Arial Narrow Italic Baltic;}{\f1611\fbidi \fnil\fcharset238\fprq2 Arial Unicode MS CE;}{\f1612\fbidi \fnil\fcharset204\fprq2 Arial Unicode MS Cyr;}{\f1614\fbidi \fnil\fcharset161\fprq2 Arial Unicode MS Greek;}{\f1615\fbidi \fnil\fcharset162\fprq2 Arial Unicode MS Tur;}{\f1616\fbidi \fnil\fcharset177\fprq2 Arial Unicode MS (Hebrew);}{\f1617\fbidi \fnil\fcharset178\fprq2 Arial Unicode MS (Arabid);}{\f1618\fbidi \fnil\fcharset186\fprq2 Arial Unicode MS Baltic;}{\f1619\fbidi \fnil\fcharset163\fprq2 Arial Unicode MS (Vietnamese);}{\f1620\fbidi \fnil\fcharset222\fprq2 Arial Unicode MS (That);}{\f1621\fbidi \fnil\fcharset238\fprq2 Athelas Bold CE;}{\f1625\fbidi \fnil\fcharset162\fprq2 Athelas Bold Tur;}{\f1628\fbidi \fnil\fcharset186\fprq2 Athelas Bold Baltic;}{\f1631\fbidi \fnil\fcharset238\fprq2 Athelas Bold Italic CE;}{\f1634\fbidi \fnil\fcharset161\fprq2 Athelas Bold Italic Greek;}{\f1635\fbidi \fnil\fcharset162\fprq2 Athelas Bold Italic Tur;}{\f1638\fbidi \fnil\fcharset186\fprq2 Athelas Bold Italic Baltic;}{\f1641\fbidi \fnil\fcharset238\fprq2 Athelas Italic CE;}{\f1644\fbidi \fnil\fcharset161\fprq2 Athelas Italic Greek;}{\f1645\fbidi \fnil\fcharset162\fprq2 Athelas Italic Tur;}{\f1648\fbidi \fnil\fcharset186\fprq2 Athelas Italic Baltic;}{\f1651\fbidi \fnil\fcharset238\fprq2 Athelas Regular CE;}{\f1654\fbidi \fnil\fcharset161\fprq2 Athelas Regular Greek;}{\f1655\fbidi \fnil\fcharset162\fprq2 Athelas Regular Tur;}{\f1658\fbidi \fnil\fcharset186\fprq2 Athelas Regular Baltic;}{\f1661\fbidi \fnil\fcharset238\fprq2 Avenir Black CE;}{\f1664\fbidi \fnil\fcharset161\fprq2 Avenir Black Greek;}{\f1665\fbidi \fnil\fcharset162\fprq2 Avenir Black Tur;}{\f1668\fbidi \fnil\fcharset186\fprq2 Avenir Black Baltic;}{\f1671\fbidi \fnil\fcharset238\fprq2 Avenir Black Oblique CE;}{\f1674\fbidi \fnil\fcharset161\fprq2 Avenir Black Oblique Greek;}{\f1675\fbidi \fnil\fcharset162\fprq2 Avenir Black Oblique Tur;}{\f1678\fbidi \fnil\fcharset186\fprq2 Avenir Black Oblique Baltic;}{\f1681\fbidi \fnil\fcharset238\fprq2 Avenir Book CE;}{\f1684\fbidi \fnil\fcharset161\fprq2 Avenir Book Greek;}{\f1685\fbidi \fnil\fcharset162\fprq2 Avenir Book Tur;}{\f1688\fbidi \fnil\fcharset186\fprq2 Avenir Book Baltic;}{\f1691\fbidi \fnil\fcharset238\fprq2 Avenir Book Oblique CE;}{\f1694\fbidi \fnil\fcharset161\fprq2 Avenir Book Oblique Greek;}{\f1695\fbidi \fnil\fcharset162\fprq2 Avenir Book Oblique Tur;}{\f1698\fbidi \fnil\fcharset186\fprq2 Avenir Book Oblique Baltic;}{\f1701\fbidi \fnil\fcharset238\fprq2 Avenir Heavy CE;}{\f1704\fbidi \fnil\fcharset161\fprq2 Avenir Heavy Greek;}{\f1705\fbidi \fnil\fcharset162\fprq2 Avenir Heavy Tur;}{\f1708\fbidi \fnil\fcharset186\fprq2 Avenir Heavy Baltic;}{\f1711\fbidi \fnil\fcharset238\fprq2 Avenir Heavy Oblique CE;}{\f1714\fbidi \fnil\fcharset161\fprq2 Avenir Heavy Oblique Greek;}{\f1715\fbidi \fnil\fcharset162\fprq2 Avenir Heavy Oblique Tur;}{\f1718\fbidi \fnil\fcharset186\fprq2 Avenir Heavy Oblique Baltic;}{\f1721\fbidi \fnil\fcharset238\fprq2 Avenir Light CE;}{\f1724\fbidi \fnil\fcharset161\fprq2 Avenir Light Greek;}{\f1725\fbidi \fnil\fcharset162\fprq2 Avenir Light Tur;}{\f1728\fbidi \fnil\fcharset186\fprq2 Avenir Light Baltic;}{\f1731\fbidi \fnil\fcharset238\fprq2 Avenir Light Oblique CE;}{\f1734\fbidi \fnil\fcharset161\fprq2 Avenir Light Oblique Greek;}{\f1735\fbidi \fnil\fcharset162\fprq2 Avenir Light Oblique Tur;}{\f1738\fbidi \fnil\fcharset186\fprq2 Avenir Light Oblique Baltic;}{\f1741\fbidi \fnil\fcharset238\fprq2 Avenir Medium CE;}{\f1744\fbidi \fnil\fcharset161\fprq2 Avenir Medium Greek;}{\f1745\fbidi \fnil\fcharset162\fprq2 Avenir Medium Tur;}{\f1748\fbidi \fnil\fcharset186\fprq2 Avenir Medium Baltic;}{\f1751\fbidi \fnil\fcharset238\fprq2 Avenir Medium Oblique CE;}{\f1754\fbidi \fnil\fcharset161\fprq2 Avenir Medium Oblique Greek;}{\f1755\fbidi \fnil\fcharset162\fprq2 Avenir Medium Oblique Tur;}{\f1758\fbidi \fnil\fcharset186\fprq2 Avenir Medium Oblique Baltic;}{\f1761\fbidi \fnil\fcharset238\fprq2 Avenir Next Bold CE;}{\f1764\fbidi \fnil\fcharset161\fprq2 Avenir Next Bold Greek;}{\f1765\fbidi \fnil\fcharset162\fprq2 Avenir Next Bold Tur;}{\f1768\fbidi \fnil\fcharset186\fprq2 Avenir Next Bold Baltic;}{\f1771\fbidi \fnil\fcharset238\fprq2 Avenir Next Bold Italic CE;}{\f1774\fbidi \fnil\fcharset161\fprq2 Avenir Next Bold Italic Greek;}{\f1775\fbidi \fnil\fcharset162\fprq2 Avenir Next Bold Italic Tur;}{\f1778\fbidi \fnil\fcharset186\fprq2 Avenir Next Bold Italic Baltic;}{\f1781\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Bold CE;}{\f1784\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Bold Greek;}{\f1785\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Bold Tur;}{\f1788\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Bold Baltic;}{\f1791\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Demi Bold CE;}{\f1794\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Demi Bold Greek;}{\f1795\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Demi Bold Tur;}{\f1798\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Demi Bold Baltic;}{\f1801\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Heavy CE;}{\f1804\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Heavy Greek;}{\f1805\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Heavy Tur;}{\f1808\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Heavy Baltic;}{\f1811\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Italic CE;}{\f1814\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Italic Greek;}{\f1815\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Italic Tur;}{\f1818\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Italic Baltic;}{\f1821\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Medium CE;}{\f1824\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Medium Greek;}{\f1825\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Medium Tur;}{\f1828\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Medium Baltic;}{\f1831\fbidi \fnil\fcharset238\fprq2 Avenir Next Condensed Regular CE;}{\f1834\fbidi \fnil\fcharset161\fprq2 Avenir Next Condensed Regular Greek;}{\f1835\fbidi \fnil\fcharset162\fprq2 Avenir Next Condensed Regular Tur;}{\f1838\fbidi \fnil\fcharset186\fprq2 Avenir Next Condensed Regular Baltic;}{\f1841\fbidi \fnil\fcharset238\fprq2 Avenir Next Demi Bold CE;}{\f1844\fbidi \fnil\fcharset161\fprq2 Avenir Next Demi Bold Greek;}{\f1845\fbidi \fnil\fcharset162\fprq2 Avenir Next Demi Bold Tur;}{\f1848\fbidi \fnil\fcharset186\fprq2 Avenir Next Demi Bold Baltic;}{\f1851\fbidi \fnil\fcharset238\fprq2 Avenir Next Demi Bold Italic CE;}{\f1854\fbidi \fnil\fcharset161\fprq2 Avenir Next Demi Bold Italic Greek;}{\f1855\fbidi \fnil\fcharset162\fprq2 Avenir Next Demi Bold Italic Tur;}{\f1858\fbidi \fnil\fcharset186\fprq2 Avenir Next Demi Bold Italic Baltic;}{\f1861\fbidi \fnil\fcharset238\fprq2 Avenir Next Heavy CE;}{\f1864\fbidi \fnil\fcharset161\fprq2 Avenir Next Heavy Greek;}{\f1865\fbidi \fnil\fcharset162\fprq2 Avenir Next Heavy Tur;}{\f1868\fbidi \fnil\fcharset186\fprq2 Avenir Next Heavy Baltic;}{\f1871\fbidi \fnil\fcharset238\fprq2 Avenir Next Heavy Italic CE;}{\f1874\fbidi \fnil\fcharset161\fprq2 Avenir Next Heavy Italic Greek;}{\f1875\fbidi \fnil\fcharset162\fprq2 Avenir Next Heavy Italic Tur;}{\f1878\fbidi \fnil\fcharset186\fprq2 Avenir Next Heavy Italic Baltic;}{\f1881\fbidi \fnil\fcharset238\fprq2 Avenir Next Italic CE;}{\f1884\fbidi \fnil\fcharset161\fprq2 Avenir Next Italic Greek;}{\f1885\fbidi \fnil\fcharset162\fprq2 Avenir Next Italic Tur;}{\f1888\fbidi \fnil\fcharset186\fprq2 Avenir Next Italic Baltic;}{\f1891\fbidi \fnil\fcharset238\fprq2 Avenir Next Medium CE;}{\f1894\fbidi \fnil\fcharset161\fprq2 Avenir Next Medium Greek;}{\f1895\fbidi \fnil\fcharset162\fprq2 Avenir Next Medium Tur;}{\f1898\fbidi \fnil\fcharset186\fprq2 Avenir Next Medium Baltic;}{\f1901\fbidi \fnil\fcharset238\fprq2 Avenir Next Medium Italic CE;}{\f1904\fbidi \fnil\fcharset161\fprq2 Avenir Next Medium Italic Greek;}{\f1905\fbidi \fnil\fcharset162\fprq2 Avenir Next Medium Italic Tur;}{\f1908\fbidi \fnil\fcharset186\fprq2 Avenir Next Medium Italic Baltic;}{\f1911\fbidi \fnil\fcharset238\fprq2 Avenir Next Regular CE;}{\f1914\fbidi \fnil\fcharset161\fprq2 Avenir Next Regular Greek;}{\f1915\fbidi \fnil\fcharset162\fprq2 Avenir Next Regular Tur;}{\f1918\fbidi \fnil\fcharset186\fprq2 Avenir Next Regular Baltic;}{\f1921\fbidi \fnil\fcharset238\fprq2 Avenir Next Ultra Light CE;}{\f1924\fbidi \fnil\fcharset161\fprq2 Avenir Next Ultra Light Greek;}{\f1925\fbidi \fnil\fcharset162\fprq2 Avenir Next Ultra Light Tur;}{\f1928\fbidi \fnil\fcharset186\fprq2 Avenir Next Ultra Light Baltic;}{\f1931\fbidi \fnil\fcharset238\fprq2 Avenir Next Ultra Light Italic CE;}{\f1934\fbidi \fnil\fcharset161\fprq2 Avenir Next Ultra Light Italic Greek;}{\f1935\fbidi \fnil\fcharset162\fprq2 Avenir Next Ultra Light Italic Tur;}{\f1938\fbidi \fnil\fcharset186\fprq2 Avenir Next Ultra Light Italic Baltic;}{\f1941\fbidi \fnil\fcharset238\fprq2 Avenir Oblique CE;}{\f1944\fbidi \fnil\fcharset161\fprq2 Avenir Oblique Greek;}{\f1945\fbidi \fnil\fcharset162\fprq2 Avenir Oblique Tur;}{\f1948\fbidi \fnil\fcharset186\fprq2 Avenir Oblique Baltic;}{\f1951\fbidi \fnil\fcharset238\fprq2 Avenir Roman CE;}{\f1954\fbidi \fnil\fcharset161\fprq2 Avenir Roman Greek;}{\f1955\fbidi \fnil\fcharset162\fprq2 Avenir Roman Tur;}{\f1958\fbidi \fnil\fcharset186\fprq2 Avenir Roman Baltic;}{\f1961\fbidi \fnil\fcharset238\fprq2 Ayuthaya CE;}{\f1962\fbidi \fnil\fcharset204\fprq2 Ayuthaya Cyr;}{\f1964\fbidi \fnil\fcharset161\fprq2 Ayuthaya Greek;}{\f1965\fbidi \fnil\fcharset162\fprq2 Ayuthaya Tur;}{\f1966\fbidi \fnil\fcharset177\fprq2 Ayuthaya (Hebrew);}{\f1967\fbidi \fnil\fcharset178\fprq2 Ayuthaya (Arabid);}{\f1968\fbidi \fnil\fcharset186\fprq2 Ayuthaya Baltic;}{\f1969\fbidi \fnil\fcharset163\fprq2 Ayuthaya (Vietnamese);}{\f1970\fbidi \fnil\fcharset222\fprq2 Ayuthaya (That);}{\f2011\fbidi \fnil\fcharset238\fprq2 Bank Gothic CE;}{\f2015\fbidi \fnil\fcharset162\fprq2 Bank Gothic Tur;}{\f2018\fbidi \fnil\fcharset186\fprq2 Bank Gothic Baltic;}{\f2019\fbidi \fnil\fcharset163\fprq2 Bank Gothic (Vietnamese);}{\f2031\fbidi \fnil\fcharset238\fprq2 Baskerville CE;}{\f2032\fbidi \fnil\fcharset204\fprq2 Baskerville Cyr;}{\f2034\fbidi \fnil\fcharset161\fprq2 Baskerville Greek;}{\f2035\fbidi \fnil\fcharset162\fprq2 Baskerville Tur;}{\f2038\fbidi \fnil\fcharset186\fprq2 Baskerville Baltic;}{\f2039\fbidi \fnil\fcharset163\fprq2 Baskerville (Vietnamese);}{\f2041\fbidi \fnil\fcharset238\fprq2 Baskerville Bold CE;}{\f2042\fbidi \fnil\fcharset204\fprq2 Baskerville Bold Cyr;}{\f2044\fbidi \fnil\fcharset161\fprq2 Baskerville Bold Greek;}{\f2045\fbidi \fnil\fcharset162\fprq2 Baskerville Bold Tur;}{\f2048\fbidi \fnil\fcharset186\fprq2 Baskerville Bold Baltic;}{\f2049\fbidi \fnil\fcharset163\fprq2 Baskerville Bold (Vietnamese);}{\f2051\fbidi \fnil\fcharset238\fprq2 Baskerville Bold Italic CE;}{\f2052\fbidi \fnil\fcharset204\fprq2 Baskerville Bold Italic Cyr;}{\f2054\fbidi \fnil\fcharset161\fprq2 Baskerville Bold Italic Greek;}{\f2055\fbidi \fnil\fcharset162\fprq2 Baskerville Bold Italic Tur;}{\f2058\fbidi \fnil\fcharset186\fprq2 Baskerville Bold Italic Baltic;}{\f2059\fbidi \fnil\fcharset163\fprq2 Baskerville Bold Italic (Vietnamese);}{\f2061\fbidi \fnil\fcharset238\fprq2 Baskerville Italic CE;}{\f2062\fbidi \fnil\fcharset204\fprq2 Baskerville Italic Cyr;}{\f2064\fbidi \fnil\fcharset161\fprq2 Baskerville Italic Greek;}{\f2065\fbidi \fnil\fcharset162\fprq2 Baskerville Italic Tur;}{\f2068\fbidi \fnil\fcharset186\fprq2 Baskerville Italic Baltic;}{\f2069\fbidi \fnil\fcharset163\fprq2 Baskerville Italic (Vietnamese);}{\f2081\fbidi \fnil\fcharset238\fprq2 Baskerville SemiBold CE;}{\f2082\fbidi \fnil\fcharset204\fprq2 Baskerville SemiBold Cyr;}{\f2084\fbidi \fnil\fcharset161\fprq2 Baskerville SemiBold Greek;}{\f2085\fbidi \fnil\fcharset162\fprq2 Baskerville SemiBold Tur;}{\f2088\fbidi \fnil\fcharset186\fprq2 Baskerville SemiBold Baltic;}{\f2089\fbidi \fnil\fcharset163\fprq2 Baskerville SemiBold (Vietnamese);}{\f2091\fbidi \fnil\fcharset238\fprq2 Baskerville SemiBold Italic CE;}{\f2092\fbidi \fnil\fcharset204\fprq2 Baskerville SemiBold Italic Cyr;}{\f2094\fbidi \fnil\fcharset161\fprq2 Baskerville SemiBold Italic Greek;}{\f2095\fbidi \fnil\fcharset162\fprq2 Baskerville SemiBold Italic Tur;}{\f2098\fbidi \fnil\fcharset186\fprq2 Baskerville SemiBold Italic Baltic;}{\f2099\fbidi \fnil\fcharset163\fprq2 Baskerville SemiBold Italic (Vietnamese);}{\f2141\fbidi \fnil\fcharset238\fprq2 Big Caslon CE;}{\f2144\fbidi \fnil\fcharset161\fprq2 Big Caslon Greek;}{\f2145\fbidi \fnil\fcharset162\fprq2 Big Caslon Tur;}{\f2146\fbidi \fnil\fcharset177\fprq2 Big Caslon (Hebrew);}{\f2147\fbidi \fnil\fcharset178\fprq2 Big Caslon (Arabid);}{\f2148\fbidi \fnil\fcharset186\fprq2 Big Caslon Baltic;}{\f2149\fbidi \fnil\fcharset163\fprq2 Big Caslon (Vietnamese);}{\f2315\fbidi \fnil\fcharset162\fprq2 Bradley Hand ITC TT-Bold Tur;}{\f2319\fbidi \fnil\fcharset163\fprq2 Bradley Hand ITC TT-Bold (Vietnamese);}{\f2341\fbidi \fnil\fcharset238\fprq2 Brush Script MT Italic CE;}{\f2344\fbidi \fnil\fcharset161\fprq2 Brush Script MT Italic Greek;}{\f2345\fbidi \fnil\fcharset162\fprq2 Brush Script MT Italic Tur;}{\f2346\fbidi \fnil\fcharset177\fprq2 Brush Script MT Italic (Hebrew);}{\f2350\fbidi \fnil\fcharset222\fprq2 Brush Script MT Italic (That);}{\f2361\fbidi \fnil\fcharset238\fprq2 Calibri Bold CE;}{\f2362\fbidi \fnil\fcharset204\fprq2 Calibri Bold Cyr;}{\f2364\fbidi \fnil\fcharset161\fprq2 Calibri Bold Greek;}{\f2365\fbidi \fnil\fcharset162\fprq2 Calibri Bold Tur;}{\f2368\fbidi \fnil\fcharset186\fprq2 Calibri Bold Baltic;}{\f2369\fbidi \fnil\fcharset163\fprq2 Calibri Bold (Vietnamese);}{\f2371\fbidi \fnil\fcharset238\fprq2 Calibri Bold Italic CE;}{\f2372\fbidi \fnil\fcharset204\fprq2 Calibri Bold Italic Cyr;}{\f2374\fbidi \fnil\fcharset161\fprq2 Calibri Bold Italic Greek;}{\f2375\fbidi \fnil\fcharset162\fprq2 Calibri Bold Italic Tur;}{\f2378\fbidi \fnil\fcharset186\fprq2 Calibri Bold Italic Baltic;}{\f2379\fbidi \fnil\fcharset163\fprq2 Calibri Bold Italic (Vietnamese);}{\f2381\fbidi \fnil\fcharset238\fprq2 Calibri Italic CE;}{\f2382\fbidi \fnil\fcharset204\fprq2 Calibri Italic Cyr;}{\f2384\fbidi \fnil\fcharset161\fprq2 Calibri Italic Greek;}{\f2385\fbidi \fnil\fcharset162\fprq2 Calibri Italic Tur;}{\f2388\fbidi \fnil\fcharset186\fprq2 Calibri Italic Baltic;}{\f2389\fbidi \fnil\fcharset163\fprq2 Calibri Italic (Vietnamese);}{\f2391\fbidi \fnil\fcharset238\fprq2 Calibri Light CE;}{\f2392\fbidi \fnil\fcharset204\fprq2 Calibri Light Cyr;}{\f2394\fbidi \fnil\fcharset161\fprq2 Calibri Light Greek;}{\f2395\fbidi \fnil\fcharset162\fprq2 Calibri Light Tur;}{\f2398\fbidi \fnil\fcharset186\fprq2 Calibri Light Baltic;}{\f2411\fbidi \fnil\fcharset238\fprq2 Cambria Bold CE;}{\f2412\fbidi \fnil\fcharset204\fprq2 Cambria Bold Cyr;}{\f2414\fbidi \fnil\fcharset161\fprq2 Cambria Bold Greek;}{\f2415\fbidi \fnil\fcharset162\fprq2 Cambria Bold Tur;}{\f2418\fbidi \fnil\fcharset186\fprq2 Cambria Bold Baltic;}{\f2419\fbidi \fnil\fcharset163\fprq2 Cambria Bold (Vietnamese);}{\f2421\fbidi \fnil\fcharset238\fprq2 Cambria Bold Italic CE;}{\f2422\fbidi \fnil\fcharset204\fprq2 Cambria Bold Italic Cyr;}{\f2424\fbidi \fnil\fcharset161\fprq2 Cambria Bold Italic Greek;}{\f2425\fbidi \fnil\fcharset162\fprq2 Cambria Bold Italic Tur;}{\f2428\fbidi \fnil\fcharset186\fprq2 Cambria Bold Italic Baltic;}{\f2429\fbidi \fnil\fcharset163\fprq2 Cambria Bold Italic (Vietnamese);}{\f2431\fbidi \fnil\fcharset238\fprq2 Cambria Italic CE;}{\f2432\fbidi \fnil\fcharset204\fprq2 Cambria Italic Cyr;}{\f2434\fbidi \fnil\fcharset161\fprq2 Cambria Italic Greek;}{\f2435\fbidi \fnil\fcharset162\fprq2 Cambria Italic Tur;}{\f2438\fbidi \fnil\fcharset186\fprq2 Cambria Italic Baltic;}{\f2439\fbidi \fnil\fcharset163\fprq2 Cambria Italic (Vietnamese);}{\f2441\fbidi \fnil\fcharset238\fprq2 Candara CE;}{\f2442\fbidi \fnil\fcharset204\fprq2 Candara Cyr;}{\f2444\fbidi \fnil\fcharset161\fprq2 Candara Greek;}{\f2445\fbidi \fnil\fcharset162\fprq2 Candara Tur;}{\f2448\fbidi \fnil\fcharset186\fprq2 Candara Baltic;}{\f2449\fbidi \fnil\fcharset163\fprq2 Candara (Vietnamese);}{\f2451\fbidi \fnil\fcharset238\fprq2 Candara Bold CE;}{\f2452\fbidi \fnil\fcharset204\fprq2 Candara Bold Cyr;}{\f2454\fbidi \fnil\fcharset161\fprq2 Candara Bold Greek;}{\f2455\fbidi \fnil\fcharset162\fprq2 Candara Bold Tur;}{\f2458\fbidi \fnil\fcharset186\fprq2 Candara Bold Baltic;}{\f2459\fbidi \fnil\fcharset163\fprq2 Candara Bold (Vietnamese);}{\f2461\fbidi \fnil\fcharset238\fprq2 Candara Bold Italic CE;}{\f2462\fbidi \fnil\fcharset204\fprq2 Candara Bold Italic Cyr;}{\f2464\fbidi \fnil\fcharset161\fprq2 Candara Bold Italic Greek;}{\f2465\fbidi \fnil\fcharset162\fprq2 Candara Bold Italic Tur;}{\f2468\fbidi \fnil\fcharset186\fprq2 Candara Bold Italic Baltic;}{\f2469\fbidi \fnil\fcharset163\fprq2 Candara Bold Italic (Vietnamese);}{\f2471\fbidi \fnil\fcharset238\fprq2 Candara Italic CE;}{\f2472\fbidi \fnil\fcharset204\fprq2 Candara Italic Cyr;}{\f2474\fbidi \fnil\fcharset161\fprq2 Candara Italic Greek;}{\f2475\fbidi \fnil\fcharset162\fprq2 Candara Italic Tur;}{\f2478\fbidi \fnil\fcharset186\fprq2 Candara Italic Baltic;}{\f2479\fbidi \fnil\fcharset163\fprq2 Candara Italic (Vietnamese);}{\f2571\fbidi \fnil\fcharset238\fprq2 Chaparral Pro CE;}{\f2575\fbidi \fnil\fcharset162\fprq2 Chaparral Pro Tur;}{\f2578\fbidi \fnil\fcharset186\fprq2 Chaparral Pro Baltic;}{\f2581\fbidi \fnil\fcharset238\fprq2 Chaparral Pro Bold CE;}{\f2585\fbidi \fnil\fcharset162\fprq2 Chaparral Pro Bold Tur;}{\f2588\fbidi \fnil\fcharset186\fprq2 Chaparral Pro Bold Baltic;}{\f2591\fbidi \fnil\fcharset238\fprq2 Chaparral Pro Bold Ital CE;}{\f2595\fbidi \fnil\fcharset162\fprq2 Chaparral Pro Bold Ital Tur;}{\f2598\fbidi \fnil\fcharset186\fprq2 Chaparral Pro Bold Ital Baltic;}{\f2601\fbidi \fnil\fcharset238\fprq2 Chaparral Pro Ital CE;}{\f2605\fbidi \fnil\fcharset162\fprq2 Chaparral Pro Ital Tur;}{\f2608\fbidi \fnil\fcharset186\fprq2 Chaparral Pro Ital Baltic;}{\f2611\fbidi \fnil\fcharset238\fprq2 Chaparral Pro Light Ital CE;}{\f2615\fbidi \fnil\fcharset162\fprq2 Chaparral Pro Light Ital Tur;}{\f2618\fbidi \fnil\fcharset186\fprq2 Chaparral Pro Light Ital Baltic;}{\f2635\fbidi \fnil\fcharset162\fprq2 Charter Black Tur;}{\f2645\fbidi \fnil\fcharset162\fprq2 Charter Black Italic Tur;}{\f2655\fbidi \fnil\fcharset162\fprq2 Charter Bold Tur;}{\f2665\fbidi \fnil\fcharset162\fprq2 Charter Bold Italic Tur;}{\f2675\fbidi \fnil\fcharset162\fprq2 Charter Italic Tur;}{\f2685\fbidi \fnil\fcharset162\fprq2 Charter Roman Tur;}{\f2691\fbidi \fnil\fcharset238\fprq2 Cochin CE;}{\f2692\fbidi \fnil\fcharset204\fprq2 Cochin Cyr;}{\f2711\fbidi \fnil\fcharset238\fprq2 Comic Sans MS CE;}{\f2712\fbidi \fnil\fcharset204\fprq2 Comic Sans MS Cyr;}{\f2714\fbidi \fnil\fcharset161\fprq2 Comic Sans MS Greek;}{\f2715\fbidi \fnil\fcharset162\fprq2 Comic Sans MS Tur;}{\f2718\fbidi \fnil\fcharset186\fprq2 Comic Sans MS Baltic;}{\f2721\fbidi \fnil\fcharset238\fprq2 Comic Sans MS Bold CE;}{\f2722\fbidi \fnil\fcharset204\fprq2 Comic Sans MS Bold Cyr;}{\f2724\fbidi \fnil\fcharset161\fprq2 Comic Sans MS Bold Greek;}{\f2725\fbidi \fnil\fcharset162\fprq2 Comic Sans MS Bold Tur;}{\f2728\fbidi \fnil\fcharset186\fprq2 Comic Sans MS Bold Baltic;}{\f2731\fbidi \fnil\fcharset238\fprq2 Consolas CE;}{\f2732\fbidi \fnil\fcharset204\fprq2 Consolas Cyr;}{\f2734\fbidi \fnil\fcharset161\fprq2 Consolas Greek;}{\f2735\fbidi \fnil\fcharset162\fprq2 Consolas Tur;}{\f2738\fbidi \fnil\fcharset186\fprq2 Consolas Baltic;}{\f2739\fbidi \fnil\fcharset163\fprq2 Consolas (Vietnamese);}{\f2741\fbidi \fnil\fcharset238\fprq2 Consolas Bold CE;}{\f2742\fbidi \fnil\fcharset204\fprq2 Consolas Bold Cyr;}{\f2744\fbidi \fnil\fcharset161\fprq2 Consolas Bold Greek;}{\f2745\fbidi \fnil\fcharset162\fprq2 Consolas Bold Tur;}{\f2748\fbidi \fnil\fcharset186\fprq2 Consolas Bold Baltic;}{\f2749\fbidi \fnil\fcharset163\fprq2 Consolas Bold (Vietnamese);}{\f2751\fbidi \fnil\fcharset238\fprq2 Consolas Bold Italic CE;}{\f2752\fbidi \fnil\fcharset204\fprq2 Consolas Bold Italic Cyr;}{\f2754\fbidi \fnil\fcharset161\fprq2 Consolas Bold Italic Greek;}{\f2755\fbidi \fnil\fcharset162\fprq2 Consolas Bold Italic Tur;}{\f2758\fbidi \fnil\fcharset186\fprq2 Consolas Bold Italic Baltic;}{\f2759\fbidi \fnil\fcharset163\fprq2 Consolas Bold Italic (Vietnamese);}{\f2761\fbidi \fnil\fcharset238\fprq2 Consolas Italic CE;}{\f2762\fbidi \fnil\fcharset204\fprq2 Consolas Italic Cyr;}{\f2764\fbidi \fnil\fcharset161\fprq2 Consolas Italic Greek;}{\f2765\fbidi \fnil\fcharset162\fprq2 Consolas Italic Tur;}{\f2768\fbidi \fnil\fcharset186\fprq2 Consolas Italic Baltic;}{\f2769\fbidi \fnil\fcharset163\fprq2 Consolas Italic (Vietnamese);}{\f2771\fbidi \fnil\fcharset238\fprq2 Constantia CE;}{\f2772\fbidi \fnil\fcharset204\fprq2 Constantia Cyr;}{\f2774\fbidi \fnil\fcharset161\fprq2 Constantia Greek;}{\f2775\fbidi \fnil\fcharset162\fprq2 Constantia Tur;}{\f2778\fbidi \fnil\fcharset186\fprq2 Constantia Baltic;}{\f2779\fbidi \fnil\fcharset163\fprq2 Constantia (Vietnamese);}{\f2781\fbidi \fnil\fcharset238\fprq2 Constantia Bold CE;}{\f2782\fbidi \fnil\fcharset204\fprq2 Constantia Bold Cyr;}{\f2784\fbidi \fnil\fcharset161\fprq2 Constantia Bold Greek;}{\f2785\fbidi \fnil\fcharset162\fprq2 Constantia Bold Tur;}{\f2788\fbidi \fnil\fcharset186\fprq2 Constantia Bold Baltic;}{\f2789\fbidi \fnil\fcharset163\fprq2 Constantia Bold (Vietnamese);}{\f2791\fbidi \fnil\fcharset238\fprq2 Constantia Bold Italic CE;}{\f2792\fbidi \fnil\fcharset204\fprq2 Constantia Bold Italic Cyr;}{\f2794\fbidi \fnil\fcharset161\fprq2 Constantia Bold Italic Greek;}{\f2795\fbidi \fnil\fcharset162\fprq2 Constantia Bold Italic Tur;}{\f2798\fbidi \fnil\fcharset186\fprq2 Constantia Bold Italic Baltic;}{\f2799\fbidi \fnil\fcharset163\fprq2 Constantia Bold Italic (Vietnamese);}{\f2801\fbidi \fnil\fcharset238\fprq2 Constantia Italic CE;}{\f2802\fbidi \fnil\fcharset204\fprq2 Constantia Italic Cyr;}{\f2804\fbidi \fnil\fcharset161\fprq2 Constantia Italic Greek;}{\f2805\fbidi \fnil\fcharset162\fprq2 Constantia Italic Tur;}{\f2808\fbidi \fnil\fcharset186\fprq2 Constantia Italic Baltic;}{\f2809\fbidi \fnil\fcharset163\fprq2 Constantia Italic (Vietnamese);}{\f2845\fbidi \fnil\fcharset162\fprq2 Copperplate Tur;}{\f2849\fbidi \fnil\fcharset163\fprq2 Copperplate (Vietnamese);}{\f2855\fbidi \fnil\fcharset162\fprq2 Copperplate Bold Tur;}{\f2859\fbidi \fnil\fcharset163\fprq2 Copperplate Bold (Vietnamese);}{\f2885\fbidi \fnil\fcharset162\fprq2 Copperplate Light Tur;}{\f2889\fbidi \fnil\fcharset163\fprq2 Copperplate Light (Vietnamese);}{\f2891\fbidi \fnil\fcharset238\fprq2 Corbel CE;}{\f2892\fbidi \fnil\fcharset204\fprq2 Corbel Cyr;}{\f2894\fbidi \fnil\fcharset161\fprq2 Corbel Greek;}{\f2895\fbidi \fnil\fcharset162\fprq2 Corbel Tur;}{\f2898\fbidi \fnil\fcharset186\fprq2 Corbel Baltic;}{\f2899\fbidi \fnil\fcharset163\fprq2 Corbel (Vietnamese);}{\f2901\fbidi \fnil\fcharset238\fprq2 Corbel Bold CE;}{\f2902\fbidi \fnil\fcharset204\fprq2 Corbel Bold Cyr;}{\f2904\fbidi \fnil\fcharset161\fprq2 Corbel Bold Greek;}{\f2905\fbidi \fnil\fcharset162\fprq2 Corbel Bold Tur;}{\f2908\fbidi \fnil\fcharset186\fprq2 Corbel Bold Baltic;}{\f2909\fbidi \fnil\fcharset163\fprq2 Corbel Bold (Vietnamese);}{\f2911\fbidi \fnil\fcharset238\fprq2 Corbel Bold Italic CE;}{\f2912\fbidi \fnil\fcharset204\fprq2 Corbel Bold Italic Cyr;}{\f2914\fbidi \fnil\fcharset161\fprq2 Corbel Bold Italic Greek;}{\f2915\fbidi \fnil\fcharset162\fprq2 Corbel Bold Italic Tur;}{\f2918\fbidi \fnil\fcharset186\fprq2 Corbel Bold Italic Baltic;}{\f2919\fbidi \fnil\fcharset163\fprq2 Corbel Bold Italic (Vietnamese);}{\f2921\fbidi \fnil\fcharset238\fprq2 Corbel Italic CE;}{\f2922\fbidi \fnil\fcharset204\fprq2 Corbel Italic Cyr;}{\f2924\fbidi \fnil\fcharset161\fprq2 Corbel Italic Greek;}{\f2925\fbidi \fnil\fcharset162\fprq2 Corbel Italic Tur;}{\f2928\fbidi \fnil\fcharset186\fprq2 Corbel Italic Baltic;}{\f2929\fbidi \fnil\fcharset163\fprq2 Corbel Italic (Vietnamese);}{\f2931\fbidi \fnil\fcharset238\fprq2 Courier New Bold CE;}{\f2932\fbidi \fnil\fcharset204\fprq2 Courier New Bold Cyr;}{\f2934\fbidi \fnil\fcharset161\fprq2 Courier New Bold Greek;}{\f2935\fbidi \fnil\fcharset162\fprq2 Courier New Bold Tur;}{\f2936\fbidi \fnil\fcharset177\fprq2 Courier New Bold (Hebrew);}{\f2937\fbidi \fnil\fcharset178\fprq2 Courier New Bold (Arabid);}{\f2938\fbidi \fnil\fcharset186\fprq2 Courier New Bold Baltic;}{\f2939\fbidi \fnil\fcharset163\fprq2 Courier New Bold (Vietnamese);}{\f2941\fbidi \fnil\fcharset238\fprq2 Courier New Bold Italic CE;}{\f2942\fbidi \fnil\fcharset204\fprq2 Courier New Bold Italic Cyr;}{\f2944\fbidi \fnil\fcharset161\fprq2 Courier New Bold Italic Greek;}{\f2945\fbidi \fnil\fcharset162\fprq2 Courier New Bold Italic Tur;}{\f2946\fbidi \fnil\fcharset177\fprq2 Courier New Bold Italic (Hebrew);}{\f2948\fbidi \fnil\fcharset186\fprq2 Courier New Bold Italic Baltic;}{\f2949\fbidi \fnil\fcharset163\fprq2 Courier New Bold Italic (Vietnamese);}{\f2951\fbidi \fnil\fcharset238\fprq2 Courier New Italic CE;}{\f2952\fbidi \fnil\fcharset204\fprq2 Courier New Italic Cyr;}{\f2954\fbidi \fnil\fcharset161\fprq2 Courier New Italic Greek;}{\f2955\fbidi \fnil\fcharset162\fprq2 Courier New Italic Tur;}{\f2956\fbidi \fnil\fcharset177\fprq2 Courier New Italic (Hebrew);}{\f2958\fbidi \fnil\fcharset186\fprq2 Courier New Italic Baltic;}{\f2959\fbidi \fnil\fcharset163\fprq2 Courier New Italic (Vietnamese);}{\f2987\fbidi \fnil\fcharset178\fprq2 Damascus Bold (Arabid);}{\f3045\fbidi \fnil\fcharset162\fprq2 DIN Alternate Bold Tur;}{\f3049\fbidi \fnil\fcharset163\fprq2 DIN Alternate Bold (Vietnamese);}{\f3061\fbidi \fnil\fcharset238\fprq2 Didot CE;}{\f3064\fbidi \fnil\fcharset161\fprq2 Didot Greek;}{\f3065\fbidi \fnil\fcharset162\fprq2 Didot Tur;}{\f3066\fbidi \fnil\fcharset177\fprq2 Didot (Hebrew);}{\f3067\fbidi \fnil\fcharset178\fprq2 Didot (Arabid);}{\f3068\fbidi \fnil\fcharset186\fprq2 Didot Baltic;}{\f3069\fbidi \fnil\fcharset163\fprq2 Didot (Vietnamese);}{\f3091\fbidi \fnil\fcharset238\fprq2 Euphemia UCAS CE;}{\f3095\fbidi \fnil\fcharset162\fprq2 Euphemia UCAS Tur;}{\f3096\fbidi \fnil\fcharset177\fprq2 Euphemia UCAS (Hebrew);}{\f3097\fbidi \fnil\fcharset178\fprq2 Euphemia UCAS (Arabid);}{\f3098\fbidi \fnil\fcharset186\fprq2 Euphemia UCAS Baltic;}{\f3099\fbidi \fnil\fcharset163\fprq2 Euphemia UCAS (Vietnamese);}{\f3101\fbidi \fnil\fcharset238\fprq2 Euphemia UCAS Bold CE;}{\f3105\fbidi \fnil\fcharset162\fprq2 Euphemia UCAS Bold Tur;}{\f3106\fbidi \fnil\fcharset177\fprq2 Euphemia UCAS Bold (Hebrew);}{\f3107\fbidi \fnil\fcharset178\fprq2 Euphemia UCAS Bold (Arabid);}{\f3108\fbidi \fnil\fcharset186\fprq2 Euphemia UCAS Bold Baltic;}{\f3109\fbidi \fnil\fcharset163\fprq2 Euphemia UCAS Bold (Vietnamese);}{\f3111\fbidi \fnil\fcharset238\fprq2 Euphemia UCAS Italic CE;}{\f3115\fbidi \fnil\fcharset162\fprq2 Euphemia UCAS Italic Tur;}{\f3116\fbidi \fnil\fcharset177\fprq2 Euphemia UCAS Italic (Hebrew);}{\f3117\fbidi \fnil\fcharset178\fprq2 Euphemia UCAS Italic (Arabid);}{\f3118\fbidi \fnil\fcharset186\fprq2 Euphemia UCAS Italic Baltic;}{\f3119\fbidi \fnil\fcharset163\fprq2 Euphemia UCAS Italic (Vietnamese);}{\f3141\fbidi \fnil\fcharset238\fprq2 Franklin Gothic Book CE;}{\f3142\fbidi \fnil\fcharset204\fprq2 Franklin Gothic Book Cyr;}{\f3144\fbidi \fnil\fcharset161\fprq2 Franklin Gothic Book Greek;}{\f3145\fbidi \fnil\fcharset162\fprq2 Franklin Gothic Book Tur;}{\f3148\fbidi \fnil\fcharset186\fprq2 Franklin Gothic Book Baltic;}{\f3151\fbidi \fnil\fcharset238\fprq2 Franklin Gothic Book Italic CE;}{\f3152\fbidi \fnil\fcharset204\fprq2 Franklin Gothic Book Italic Cyr;}{\f3154\fbidi \fnil\fcharset161\fprq2 Franklin Gothic Book Italic Greek;}{\f3155\fbidi \fnil\fcharset162\fprq2 Franklin Gothic Book Italic Tur;}{\f3158\fbidi \fnil\fcharset186\fprq2 Franklin Gothic Book Italic Baltic;}{\f3161\fbidi \fnil\fcharset238\fprq2 Franklin Gothic Medium CE;}{\f3162\fbidi \fnil\fcharset204\fprq2 Franklin Gothic Medium Cyr;}{\f3164\fbidi \fnil\fcharset161\fprq2 Franklin Gothic Medium Greek;}{\f3165\fbidi \fnil\fcharset162\fprq2 Franklin Gothic Medium Tur;}{\f3168\fbidi \fnil\fcharset186\fprq2 Franklin Gothic Medium Baltic;}{\f3171\fbidi \fnil\fcharset238\fprq2 Franklin Gothic Medium Italic CE;}{\f3172\fbidi \fnil\fcharset204\fprq2 Franklin Gothic Medium Italic Cyr;}{\f3174\fbidi \fnil\fcharset161\fprq2 Franklin Gothic Medium Italic Greek;}{\f3175\fbidi \fnil\fcharset162\fprq2 Franklin Gothic Medium Italic Tur;}{\f3178\fbidi \fnil\fcharset186\fprq2 Franklin Gothic Medium Italic Baltic;}{\f3181\fbidi \fnil\fcharset238\fprq2 Futura CE;}{\f3184\fbidi \fnil\fcharset161\fprq2 Futura Greek;}{\f3185\fbidi \fnil\fcharset162\fprq2 Futura Tur;}{\f3186\fbidi \fnil\fcharset177\fprq2 Futura (Hebrew);}{\f3187\fbidi \fnil\fcharset178\fprq2 Futura (Arabid);}{\f3188\fbidi \fnil\fcharset186\fprq2 Futura Baltic;}{\f3189\fbidi \fnil\fcharset163\fprq2 Futura (Vietnamese);}{\f3191\fbidi \fnil\fcharset238\fprq2 Futura Condensed CE;}{\f3194\fbidi \fnil\fcharset161\fprq2 Futura Condensed Greek;}{\f3195\fbidi \fnil\fcharset162\fprq2 Futura Condensed Tur;}{\f3196\fbidi \fnil\fcharset177\fprq2 Futura Condensed (Hebrew);}{\f3197\fbidi \fnil\fcharset178\fprq2 Futura Condensed (Arabid);}{\f3198\fbidi \fnil\fcharset186\fprq2 Futura Condensed Baltic;}{\f3199\fbidi \fnil\fcharset163\fprq2 Futura Condensed (Vietnamese);}{\f3201\fbidi \fnil\fcharset238\fprq2 Gabriola CE;}{\f3202\fbidi \fnil\fcharset204\fprq2 Gabriola Cyr;}{\f3204\fbidi \fnil\fcharset161\fprq2 Gabriola Greek;}{\f3205\fbidi \fnil\fcharset162\fprq2 Gabriola Tur;}{\f3208\fbidi \fnil\fcharset186\fprq2 Gabriola Baltic;}{\f3221\fbidi \fnil\fcharset238\fprq2 Georgia CE;}{\f3222\fbidi \fnil\fcharset204\fprq2 Georgia Cyr;}{\f3224\fbidi \fnil\fcharset161\fprq2 Georgia Greek;}{\f3225\fbidi \fnil\fcharset162\fprq2 Georgia Tur;}{\f3228\fbidi \fnil\fcharset186\fprq2 Georgia Baltic;}{\f3231\fbidi \fnil\fcharset238\fprq2 Georgia Bold CE;}{\f3232\fbidi \fnil\fcharset204\fprq2 Georgia Bold Cyr;}{\f3234\fbidi \fnil\fcharset161\fprq2 Georgia Bold Greek;}{\f3235\fbidi \fnil\fcharset162\fprq2 Georgia Bold Tur;}{\f3238\fbidi \fnil\fcharset186\fprq2 Georgia Bold Baltic;}{\f3241\fbidi \fnil\fcharset238\fprq2 Georgia Bold Italic CE;}{\f3242\fbidi \fnil\fcharset204\fprq2 Georgia Bold Italic Cyr;}{\f3244\fbidi \fnil\fcharset161\fprq2 Georgia Bold Italic Greek;}{\f3245\fbidi \fnil\fcharset162\fprq2 Georgia Bold Italic Tur;}{\f3248\fbidi \fnil\fcharset186\fprq2 Georgia Bold Italic Baltic;}{\f3251\fbidi \fnil\fcharset238\fprq2 Georgia Italic CE;}{\f3252\fbidi \fnil\fcharset204\fprq2 Georgia Italic Cyr;}{\f3254\fbidi \fnil\fcharset161\fprq2 Georgia Italic Greek;}{\f3255\fbidi \fnil\fcharset162\fprq2 Georgia Italic Tur;}{\f3258\fbidi \fnil\fcharset186\fprq2 Georgia Italic Baltic;}{\f3271\fbidi \fnil\fcharset238\fprq2 Gill Sans CE;}{\f3272\fbidi \fnil\fcharset204\fprq2 Gill Sans Cyr;}{\f3275\fbidi \fnil\fcharset162\fprq2 Gill Sans Tur;}{\f3276\fbidi \fnil\fcharset177\fprq2 Gill Sans (Hebrew);}{\f3277\fbidi \fnil\fcharset178\fprq2 Gill Sans (Arabid);}{\f3278\fbidi \fnil\fcharset186\fprq2 Gill Sans Baltic;}{\f3279\fbidi \fnil\fcharset163\fprq2 Gill Sans (Vietnamese);}{\f3281\fbidi \fnil\fcharset238\fprq2 Gill Sans Light CE;}{\f3282\fbidi \fnil\fcharset204\fprq2 Gill Sans Light Cyr;}{\f3285\fbidi \fnil\fcharset162\fprq2 Gill Sans Light Tur;}{\f3286\fbidi \fnil\fcharset177\fprq2 Gill Sans Light (Hebrew);}{\f3287\fbidi \fnil\fcharset178\fprq2 Gill Sans Light (Arabid);}{\f3288\fbidi \fnil\fcharset186\fprq2 Gill Sans Light Baltic;}{\f3289\fbidi \fnil\fcharset163\fprq2 Gill Sans Light (Vietnamese);}{\f3291\fbidi \fnil\fcharset238\fprq2 Gill Sans MT CE;}{\f3301\fbidi \fnil\fcharset238\fprq2 Gill Sans MT Bold CE;}{\f3311\fbidi \fnil\fcharset238\fprq2 Gill Sans MT Bold Italic CE;}{\f3321\fbidi \fnil\fcharset238\fprq2 Gill Sans MT Italic CE;}{\f3332\fbidi \fnil\fcharset204\fprq2 Gill Sans SemiBold Cyr;}{\f3342\fbidi \fnil\fcharset204\fprq2 Gill Sans SemiBold Italic Cyr;}{\f3351\fbidi \fnil\fcharset238\fprq2 Gill Sans UltraBold CE;}{\f3352\fbidi \fnil\fcharset204\fprq2 Gill Sans UltraBold Cyr;}{\f3354\fbidi \fnil\fcharset161\fprq2 Gill Sans UltraBold Greek;}{\f3355\fbidi \fnil\fcharset162\fprq2 Gill Sans UltraBold Tur;}{\f3358\fbidi \fnil\fcharset186\fprq2 Gill Sans UltraBold Baltic;}{\f3359\fbidi \fnil\fcharset163\fprq2 Gill Sans UltraBold (Vietnamese);}{\f3501\fbidi \fnil\fcharset238\fprq2 Helvetica Neue Light CE;}{\f3502\fbidi \fnil\fcharset204\fprq2 Helvetica Neue Light Cyr;}{\f3511\fbidi \fnil\fcharset238\fprq2 Helvetica Neue Medium CE;}{\f3514\fbidi \fnil\fcharset161\fprq2 Helvetica Neue Medium Greek;}{\f3515\fbidi \fnil\fcharset162\fprq2 Helvetica Neue Medium Tur;}{\f3518\fbidi \fnil\fcharset186\fprq2 Helvetica Neue Medium Baltic;}{\f3521\fbidi \fnil\fcharset238\fprq2 Helvetica Neue Thin CE;}{\f3522\fbidi \fnil\fcharset204\fprq2 Helvetica Neue Thin Cyr;}{\f3524\fbidi \fnil\fcharset161\fprq2 Helvetica Neue Thin Greek;}{\f3525\fbidi \fnil\fcharset162\fprq2 Helvetica Neue Thin Tur;}{\f3528\fbidi \fnil\fcharset186\fprq2 Helvetica Neue Thin Baltic;}{\f3561\fbidi \fnil\fcharset238\fprq2 Hoefler Text CE;}{\f3562\fbidi \fnil\fcharset204\fprq2 Hoefler Text Cyr;}{\f3565\fbidi \fnil\fcharset162\fprq2 Hoefler Text Tur;}{\f3568\fbidi \fnil\fcharset186\fprq2 Hoefler Text Baltic;}{\f3569\fbidi \fnil\fcharset163\fprq2 Hoefler Text (Vietnamese);}{\f3573\fbidi \fnil\fcharset0\fprq2 Hoefler Text Ornaments;}{\f3576\fbidi \fnil\fcharset177\fprq2 Hoefler Text Ornaments (Hebrew);}{\f3577\fbidi \fnil\fcharset178\fprq2 Hoefler Text Ornaments (Arabid);}{\f3580\fbidi \fnil\fcharset222\fprq2 Hoefler Text Ornaments (That);}{\f3581\fbidi \fnil\fcharset238\fprq2 Impact CE;}{\f3582\fbidi \fnil\fcharset204\fprq2 Impact Cyr;}{\f3584\fbidi \fnil\fcharset161\fprq2 Impact Greek;}{\f3585\fbidi \fnil\fcharset162\fprq2 Impact Tur;}{\f3588\fbidi \fnil\fcharset186\fprq2 Impact Baltic;}{\f3611\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Black CE;}{\f3615\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Black Tur;}{\f3618\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Black Baltic;}{\f3621\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Black Italic CE;}{\f3625\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Black Italic Tur;}{\f3628\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Black Italic Baltic;}{\f3631\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Bold CE;}{\f3635\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Bold Tur;}{\f3638\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Bold Baltic;}{\f3641\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Bold Italic CE;}{\f3645\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Bold Italic Tur;}{\f3648\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Bold Italic Baltic;}{\f3651\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Italic CE;}{\f3655\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Italic Tur;}{\f3658\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Italic Baltic;}{\f3661\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Roman CE;}{\f3665\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Roman Tur;}{\f3668\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Roman Baltic;}{\f3671\fbidi \fnil\fcharset238\fprq2 Iowan Old Style Titling CE;}{\f3675\fbidi \fnil\fcharset162\fprq2 Iowan Old Style Titling Tur;}{\f3678\fbidi \fnil\fcharset186\fprq2 Iowan Old Style Titling Baltic;}{\f3791\fbidi \fnil\fcharset238\fprq2 Krungthep CE;}{\f3795\fbidi \fnil\fcharset162\fprq2 Krungthep Tur;}{\f3798\fbidi \fnil\fcharset186\fprq2 Krungthep Baltic;}{\f3799\fbidi \fnil\fcharset163\fprq2 Krungthep (Vietnamese);}{\f3951\fbidi \fnil\fcharset238\fprq2 Lithos Pro Black CE;}{\f3954\fbidi \fnil\fcharset161\fprq2 Lithos Pro Black Greek;}{\f3955\fbidi \fnil\fcharset162\fprq2 Lithos Pro Black Tur;}{\f3958\fbidi \fnil\fcharset186\fprq2 Lithos Pro Black Baltic;}{\f3961\fbidi \fnil\fcharset238\fprq2 Lithos Pro Regular CE;}{\f3964\fbidi \fnil\fcharset161\fprq2 Lithos Pro Regular Greek;}{\f3965\fbidi \fnil\fcharset162\fprq2 Lithos Pro Regular Tur;}{\f3968\fbidi \fnil\fcharset186\fprq2 Lithos Pro Regular Baltic;}{\f4001\fbidi \fnil\fcharset238\fprq2 Lucida Console CE;}{\f4002\fbidi \fnil\fcharset204\fprq2 Lucida Console Cyr;}{\f4004\fbidi \fnil\fcharset161\fprq2 Lucida Console Greek;}{\f4005\fbidi \fnil\fcharset162\fprq2 Lucida Console Tur;}{\f4021\fbidi \fnil\fcharset238\fprq2 Lucida Grande CE;}{\f4022\fbidi \fnil\fcharset204\fprq2 Lucida Grande Cyr;}{\f4024\fbidi \fnil\fcharset161\fprq2 Lucida Grande Greek;}{\f4025\fbidi \fnil\fcharset162\fprq2 Lucida Grande Tur;}{\f4026\fbidi \fnil\fcharset177\fprq2 Lucida Grande (Hebrew);}{\f4028\fbidi \fnil\fcharset186\fprq2 Lucida Grande Baltic;}{\f4029\fbidi \fnil\fcharset163\fprq2 Lucida Grande (Vietnamese);}{\f4061\fbidi \fnil\fcharset238\fprq2 Lucida Sans Unicode CE;}{\f4062\fbidi \fnil\fcharset204\fprq2 Lucida Sans Unicode Cyr;}{\f4064\fbidi \fnil\fcharset161\fprq2 Lucida Sans Unicode Greek;}{\f4065\fbidi \fnil\fcharset162\fprq2 Lucida Sans Unicode Tur;}{\f4066\fbidi \fnil\fcharset177\fprq2 Lucida Sans Unicode (Hebrew);}{\f4068\fbidi \fnil\fcharset186\fprq2 Lucida Sans Unicode Baltic;}{\f4111\fbidi \fnil\fcharset238\fprq2 Marion Bold CE;}{\f4118\fbidi \fnil\fcharset186\fprq2 Marion Bold Baltic;}{\f4119\fbidi \fnil\fcharset163\fprq2 Marion Bold (Vietnamese);}{\f4121\fbidi \fnil\fcharset238\fprq2 Marion Italic CE;}{\f4128\fbidi \fnil\fcharset186\fprq2 Marion Italic Baltic;}{\f4129\fbidi \fnil\fcharset163\fprq2 Marion Italic (Vietnamese);}{\f4131\fbidi \fnil\fcharset238\fprq2 Marion Regular CE;}{\f4138\fbidi \fnil\fcharset186\fprq2 Marion Regular Baltic;}{\f4139\fbidi \fnil\fcharset163\fprq2 Marion Regular (Vietnamese);}{\f4145\fbidi \fnil\fcharset162\fprq2 Marker Felt Tur;}{\f4149\fbidi \fnil\fcharset163\fprq2 Marker Felt (Vietnamese);}{\f4171\fbidi \fnil\fcharset238\fprq2 Menlo Bold CE;}{\f4172\fbidi \fnil\fcharset204\fprq2 Menlo Bold Cyr;}{\f4174\fbidi \fnil\fcharset161\fprq2 Menlo Bold Greek;}{\f4175\fbidi \fnil\fcharset162\fprq2 Menlo Bold Tur;}{\f4177\fbidi \fnil\fcharset178\fprq2 Menlo Bold (Arabid);}{\f4178\fbidi \fnil\fcharset186\fprq2 Menlo Bold Baltic;}{\f4179\fbidi \fnil\fcharset163\fprq2 Menlo Bold (Vietnamese);}{\f4181\fbidi \fnil\fcharset238\fprq2 Menlo Bold Italic CE;}{\f4182\fbidi \fnil\fcharset204\fprq2 Menlo Bold Italic Cyr;}{\f4184\fbidi \fnil\fcharset161\fprq2 Menlo Bold Italic Greek;}{\f4185\fbidi \fnil\fcharset162\fprq2 Menlo Bold Italic Tur;}{\f4188\fbidi \fnil\fcharset186\fprq2 Menlo Bold Italic Baltic;}{\f4189\fbidi \fnil\fcharset163\fprq2 Menlo Bold Italic (Vietnamese);}{\f4191\fbidi \fnil\fcharset238\fprq2 Menlo Italic CE;}{\f4192\fbidi \fnil\fcharset204\fprq2 Menlo Italic Cyr;}{\f4194\fbidi \fnil\fcharset161\fprq2 Menlo Italic Greek;}{\f4195\fbidi \fnil\fcharset162\fprq2 Menlo Italic Tur;}{\f4198\fbidi \fnil\fcharset186\fprq2 Menlo Italic Baltic;}{\f4199\fbidi \fnil\fcharset163\fprq2 Menlo Italic (Vietnamese);}{\f4201\fbidi \fnil\fcharset238\fprq2 Menlo Regular CE;}{\f4202\fbidi \fnil\fcharset204\fprq2 Menlo Regular Cyr;}{\f4204\fbidi \fnil\fcharset161\fprq2 Menlo Regular Greek;}{\f4205\fbidi \fnil\fcharset162\fprq2 Menlo Regular Tur;}{\f4207\fbidi \fnil\fcharset178\fprq2 Menlo Regular (Arabid);}{\f4208\fbidi \fnil\fcharset186\fprq2 Menlo Regular Baltic;}{\f4209\fbidi \fnil\fcharset163\fprq2 Menlo Regular (Vietnamese);}{\f4231\fbidi \fnil\fcharset238\fprq2 Microsoft Sans Serif CE;}{\f4232\fbidi \fnil\fcharset204\fprq2 Microsoft Sans Serif Cyr;}{\f4234\fbidi \fnil\fcharset161\fprq2 Microsoft Sans Serif Greek;}{\f4235\fbidi \fnil\fcharset162\fprq2 Microsoft Sans Serif Tur;}{\f4236\fbidi \fnil\fcharset177\fprq2 Microsoft Sans Serif (Hebrew);}{\f4237\fbidi \fnil\fcharset178\fprq2 Microsoft Sans Serif (Arabid);}{\f4238\fbidi \fnil\fcharset186\fprq2 Microsoft Sans Serif Baltic;}{\f4239\fbidi \fnil\fcharset163\fprq2 Microsoft Sans Serif (Vietnamese);}{\f4240\fbidi \fnil\fcharset222\fprq2 Microsoft Sans Serif (That);}{\f4273\fbidi \fnil\fcharset0\fprq2 MingLiU-ExtB Western;}{\f4283\fbidi \fnil\fcharset0\fprq2 @MingLiU-ExtB Western;}{\f4293\fbidi \fnil\fcharset0\fprq2 MingLiU_HKSCS-ExtB Western;}{\f4303\fbidi \fnil\fcharset0\fprq2 @MingLiU_HKSCS-ExtB Western;}{\f4311\fbidi \fnil\fcharset238\fprq2 Minion Pro CE;}{\f4312\fbidi \fnil\fcharset204\fprq2 Minion Pro Cyr;}{\f4314\fbidi \fnil\fcharset161\fprq2 Minion Pro Greek;}{\f4315\fbidi \fnil\fcharset162\fprq2 Minion Pro Tur;}{\f4318\fbidi \fnil\fcharset186\fprq2 Minion Pro Baltic;}{\f4319\fbidi \fnil\fcharset163\fprq2 Minion Pro (Vietnamese);}{\f4321\fbidi \fnil\fcharset238\fprq2 Minion Pro Bold CE;}{\f4322\fbidi \fnil\fcharset204\fprq2 Minion Pro Bold Cyr;}{\f4324\fbidi \fnil\fcharset161\fprq2 Minion Pro Bold Greek;}{\f4325\fbidi \fnil\fcharset162\fprq2 Minion Pro Bold Tur;}{\f4328\fbidi \fnil\fcharset186\fprq2 Minion Pro Bold Baltic;}{\f4329\fbidi \fnil\fcharset163\fprq2 Minion Pro Bold (Vietnamese);}{\f4331\fbidi \fnil\fcharset238\fprq2 Minion Pro Bold Cond CE;}{\f4332\fbidi \fnil\fcharset204\fprq2 Minion Pro Bold Cond Cyr;}{\f4334\fbidi \fnil\fcharset161\fprq2 Minion Pro Bold Cond Greek;}{\f4335\fbidi \fnil\fcharset162\fprq2 Minion Pro Bold Cond Tur;}{\f4338\fbidi \fnil\fcharset186\fprq2 Minion Pro Bold Cond Baltic;}{\f4339\fbidi \fnil\fcharset163\fprq2 Minion Pro Bold Cond (Vietnamese);}{\f4341\fbidi \fnil\fcharset238\fprq2 Minion Pro Bold Cond Ital CE;}{\f4342\fbidi \fnil\fcharset204\fprq2 Minion Pro Bold Cond Ital Cyr;}{\f4344\fbidi \fnil\fcharset161\fprq2 Minion Pro Bold Cond Ital Greek;}{\f4345\fbidi \fnil\fcharset162\fprq2 Minion Pro Bold Cond Ital Tur;}{\f4348\fbidi \fnil\fcharset186\fprq2 Minion Pro Bold Cond Ital Baltic;}{\f4349\fbidi \fnil\fcharset163\fprq2 Minion Pro Bold Cond Ital (Vietnamese);}{\f4351\fbidi \fnil\fcharset238\fprq2 Minion Pro Bold Ital CE;}{\f4352\fbidi \fnil\fcharset204\fprq2 Minion Pro Bold Ital Cyr;}{\f4354\fbidi \fnil\fcharset161\fprq2 Minion Pro Bold Ital Greek;}{\f4355\fbidi \fnil\fcharset162\fprq2 Minion Pro Bold Ital Tur;}{\f4358\fbidi \fnil\fcharset186\fprq2 Minion Pro Bold Ital Baltic;}{\f4359\fbidi \fnil\fcharset163\fprq2 Minion Pro Bold Ital (Vietnamese);}{\f4361\fbidi \fnil\fcharset238\fprq2 Minion Pro Ital CE;}{\f4362\fbidi \fnil\fcharset204\fprq2 Minion Pro Ital Cyr;}{\f4364\fbidi \fnil\fcharset161\fprq2 Minion Pro Ital Greek;}{\f4365\fbidi \fnil\fcharset162\fprq2 Minion Pro Ital Tur;}{\f4368\fbidi \fnil\fcharset186\fprq2 Minion Pro Ital Baltic;}{\f4369\fbidi \fnil\fcharset163\fprq2 Minion Pro Ital (Vietnamese);}{\f4371\fbidi \fnil\fcharset238\fprq2 Minion Pro Med CE;}{\f4372\fbidi \fnil\fcharset204\fprq2 Minion Pro Med Cyr;}{\f4374\fbidi \fnil\fcharset161\fprq2 Minion Pro Med Greek;}{\f4375\fbidi \fnil\fcharset162\fprq2 Minion Pro Med Tur;}{\f4378\fbidi \fnil\fcharset186\fprq2 Minion Pro Med Baltic;}{\f4379\fbidi \fnil\fcharset163\fprq2 Minion Pro Med (Vietnamese);}{\f4381\fbidi \fnil\fcharset238\fprq2 Minion Pro Med Ital CE;}{\f4382\fbidi \fnil\fcharset204\fprq2 Minion Pro Med Ital Cyr;}{\f4384\fbidi \fnil\fcharset161\fprq2 Minion Pro Med Ital Greek;}{\f4385\fbidi \fnil\fcharset162\fprq2 Minion Pro Med Ital Tur;}{\f4388\fbidi \fnil\fcharset186\fprq2 Minion Pro Med Ital Baltic;}{\f4389\fbidi \fnil\fcharset163\fprq2 Minion Pro Med Ital (Vietnamese);}{\f4391\fbidi \fnil\fcharset238\fprq2 Minion Pro SmBd CE;}{\f4392\fbidi \fnil\fcharset204\fprq2 Minion Pro SmBd Cyr;}{\f4394\fbidi \fnil\fcharset161\fprq2 Minion Pro SmBd Greek;}{\f4395\fbidi \fnil\fcharset162\fprq2 Minion Pro SmBd Tur;}{\f4398\fbidi \fnil\fcharset186\fprq2 Minion Pro SmBd Baltic;}{\f4399\fbidi \fnil\fcharset163\fprq2 Minion Pro SmBd (Vietnamese);}{\f4401\fbidi \fnil\fcharset238\fprq2 Minion Pro SmBd Ital CE;}{\f4402\fbidi \fnil\fcharset204\fprq2 Minion Pro SmBd Ital Cyr;}{\f4404\fbidi \fnil\fcharset161\fprq2 Minion Pro SmBd Ital Greek;}{\f4405\fbidi \fnil\fcharset162\fprq2 Minion Pro SmBd Ital Tur;}{\f4408\fbidi \fnil\fcharset186\fprq2 Minion Pro SmBd Ital Baltic;}{\f4409\fbidi \fnil\fcharset163\fprq2 Minion Pro SmBd Ital (Vietnamese);}{\f4435\fbidi \fnil\fcharset162\fprq2 Mona Lisa Solid ITC TT Tur;}{\f4439\fbidi \fnil\fcharset163\fprq2 Mona Lisa Solid ITC TT (Vietnamese);}{\f4481\fbidi \fnil\fcharset238\fprq2 MS Reference Sans Serif CE;}{\f4482\fbidi \fnil\fcharset204\fprq2 MS Reference Sans Serif Cyr;}{\f4484\fbidi \fnil\fcharset161\fprq2 MS Reference Sans Serif Greek;}{\f4485\fbidi \fnil\fcharset162\fprq2 MS Reference Sans Serif Tur;}{\f4488\fbidi \fnil\fcharset186\fprq2 MS Reference Sans Serif Baltic;}{\f4489\fbidi \fnil\fcharset163\fprq2 MS Reference Sans Serif (Vietnamese);}{\f4503\fbidi \fnil\fcharset0\fprq2 MT Extra;}{\f4541\fbidi \fnil\fcharset238\fprq2 Myriad Arabic CE;}{\f4547\fbidi \fnil\fcharset178\fprq2 Myriad Arabic (Arabid);}{\f4551\fbidi \fnil\fcharset238\fprq2 Myriad Arabic Bold CE;}{\f4557\fbidi \fnil\fcharset178\fprq2 Myriad Arabic Bold (Arabid);}{\f4561\fbidi \fnil\fcharset238\fprq2 Myriad Arabic Bold Italic CE;}{\f4567\fbidi \fnil\fcharset178\fprq2 Myriad Arabic Bold Italic (Arabid);}{\f4571\fbidi \fnil\fcharset238\fprq2 Myriad Arabic Italic CE;}{\f4577\fbidi \fnil\fcharset178\fprq2 Myriad Arabic Italic (Arabid);}{\f4581\fbidi \fnil\fcharset238\fprq2 Myriad Hebrew Bold CE;}{\f4586\fbidi \fnil\fcharset177\fprq2 Myriad Hebrew Bold (Hebrew);}{\f4591\fbidi \fnil\fcharset238\fprq2 Myriad Hebrew Bold Italic CE;}{\f4596\fbidi \fnil\fcharset177\fprq2 Myriad Hebrew Bold Italic (Hebrew);}{\f4601\fbidi \fnil\fcharset238\fprq2 Myriad Hebrew Italic CE;}{\f4606\fbidi \fnil\fcharset177\fprq2 Myriad Hebrew Italic (Hebrew);}{\f4611\fbidi \fnil\fcharset238\fprq2 Myriad Hebrew Regular CE;}{\f4616\fbidi \fnil\fcharset177\fprq2 Myriad Hebrew Regular (Hebrew);}{\f4621\fbidi \fnil\fcharset238\fprq2 Myriad Pro CE;}{\f4622\fbidi \fnil\fcharset204\fprq2 Myriad Pro Cyr;}{\f4624\fbidi \fnil\fcharset161\fprq2 Myriad Pro Greek;}{\f4625\fbidi \fnil\fcharset162\fprq2 Myriad Pro Tur;}{\f4628\fbidi \fnil\fcharset186\fprq2 Myriad Pro Baltic;}{\f4629\fbidi \fnil\fcharset163\fprq2 Myriad Pro (Vietnamese);}{\f4631\fbidi \fnil\fcharset238\fprq2 Myriad Pro Bold CE;}{\f4632\fbidi \fnil\fcharset204\fprq2 Myriad Pro Bold Cyr;}{\f4634\fbidi \fnil\fcharset161\fprq2 Myriad Pro Bold Greek;}{\f4635\fbidi \fnil\fcharset162\fprq2 Myriad Pro Bold Tur;}{\f4638\fbidi \fnil\fcharset186\fprq2 Myriad Pro Bold Baltic;}{\f4639\fbidi \fnil\fcharset163\fprq2 Myriad Pro Bold (Vietnamese);}{\f4641\fbidi \fnil\fcharset238\fprq2 Myriad Pro Bold Cond CE;}{\f4642\fbidi \fnil\fcharset204\fprq2 Myriad Pro Bold Cond Cyr;}{\f4644\fbidi \fnil\fcharset161\fprq2 Myriad Pro Bold Cond Greek;}{\f4645\fbidi \fnil\fcharset162\fprq2 Myriad Pro Bold Cond Tur;}{\f4648\fbidi \fnil\fcharset186\fprq2 Myriad Pro Bold Cond Baltic;}{\f4649\fbidi \fnil\fcharset163\fprq2 Myriad Pro Bold Cond (Vietnamese);}{\f4651\fbidi \fnil\fcharset238\fprq2 Myriad Pro Bold Cond It CE;}{\f4652\fbidi \fnil\fcharset204\fprq2 Myriad Pro Bold Cond It Cyr;}{\f4654\fbidi \fnil\fcharset161\fprq2 Myriad Pro Bold Cond It Greek;}{\f4655\fbidi \fnil\fcharset162\fprq2 Myriad Pro Bold Cond It Tur;}{\f4658\fbidi \fnil\fcharset186\fprq2 Myriad Pro Bold Cond It Baltic;}{\f4659\fbidi \fnil\fcharset163\fprq2 Myriad Pro Bold Cond It (Vietnamese);}{\f4661\fbidi \fnil\fcharset238\fprq2 Myriad Pro Bold It CE;}{\f4662\fbidi \fnil\fcharset204\fprq2 Myriad Pro Bold It Cyr;}{\f4664\fbidi \fnil\fcharset161\fprq2 Myriad Pro Bold It Greek;}{\f4665\fbidi \fnil\fcharset162\fprq2 Myriad Pro Bold It Tur;}{\f4668\fbidi \fnil\fcharset186\fprq2 Myriad Pro Bold It Baltic;}{\f4669\fbidi \fnil\fcharset163\fprq2 Myriad Pro Bold It (Vietnamese);}{\f4671\fbidi \fnil\fcharset238\fprq2 Myriad Pro Cond CE;}{\f4672\fbidi \fnil\fcharset204\fprq2 Myriad Pro Cond Cyr;}{\f4674\fbidi \fnil\fcharset161\fprq2 Myriad Pro Cond Greek;}{\f4675\fbidi \fnil\fcharset162\fprq2 Myriad Pro Cond Tur;}{\f4678\fbidi \fnil\fcharset186\fprq2 Myriad Pro Cond Baltic;}{\f4679\fbidi \fnil\fcharset163\fprq2 Myriad Pro Cond (Vietnamese);}{\f4681\fbidi \fnil\fcharset238\fprq2 Myriad Pro Cond It CE;}{\f4682\fbidi \fnil\fcharset204\fprq2 Myriad Pro Cond It Cyr;}{\f4684\fbidi \fnil\fcharset161\fprq2 Myriad Pro Cond It Greek;}{\f4685\fbidi \fnil\fcharset162\fprq2 Myriad Pro Cond It Tur;}{\f4688\fbidi \fnil\fcharset186\fprq2 Myriad Pro Cond It Baltic;}{\f4689\fbidi \fnil\fcharset163\fprq2 Myriad Pro Cond It (Vietnamese);}{\f4691\fbidi \fnil\fcharset238\fprq2 Myriad Pro It CE;}{\f4692\fbidi \fnil\fcharset204\fprq2 Myriad Pro It Cyr;}{\f4694\fbidi \fnil\fcharset161\fprq2 Myriad Pro It Greek;}{\f4695\fbidi \fnil\fcharset162\fprq2 Myriad Pro It Tur;}{\f4698\fbidi \fnil\fcharset186\fprq2 Myriad Pro It Baltic;}{\f4699\fbidi \fnil\fcharset163\fprq2 Myriad Pro It (Vietnamese);}{\f4701\fbidi \fnil\fcharset238\fprq2 Myriad Pro Semibold CE;}{\f4702\fbidi \fnil\fcharset204\fprq2 Myriad Pro Semibold Cyr;}{\f4704\fbidi \fnil\fcharset161\fprq2 Myriad Pro Semibold Greek;}{\f4705\fbidi \fnil\fcharset162\fprq2 Myriad Pro Semibold Tur;}{\f4708\fbidi \fnil\fcharset186\fprq2 Myriad Pro Semibold Baltic;}{\f4709\fbidi \fnil\fcharset163\fprq2 Myriad Pro Semibold (Vietnamese);}{\f4711\fbidi \fnil\fcharset238\fprq2 Myriad Pro Semibold It CE;}{\f4712\fbidi \fnil\fcharset204\fprq2 Myriad Pro Semibold It Cyr;}{\f4714\fbidi \fnil\fcharset161\fprq2 Myriad Pro Semibold It Greek;}{\f4715\fbidi \fnil\fcharset162\fprq2 Myriad Pro Semibold It Tur;}{\f4718\fbidi \fnil\fcharset186\fprq2 Myriad Pro Semibold It Baltic;}{\f4719\fbidi \fnil\fcharset163\fprq2 Myriad Pro Semibold It (Vietnamese);}{\f4735\fbidi \fnil\fcharset162\fprq2 Noteworthy Bold Tur;}{\f4739\fbidi \fnil\fcharset163\fprq2 Noteworthy Bold (Vietnamese);}{\f4745\fbidi \fnil\fcharset162\fprq2 Noteworthy Light Tur;}{\f4749\fbidi \fnil\fcharset163\fprq2 Noteworthy Light (Vietnamese);}{\f4846\fbidi \fnil\fcharset177\fprq2 Optima ExtraBlack (Hebrew);}{\f4847\fbidi \fnil\fcharset178\fprq2 Optima ExtraBlack (Arabid);}{\f4850\fbidi \fnil\fcharset222\fprq2 Optima ExtraBlack (That);}{\f4911\fbidi \fnil\fcharset238\fprq2 Palatino CE;}{\f4915\fbidi \fnil\fcharset162\fprq2 Palatino Tur;}{\f4918\fbidi \fnil\fcharset186\fprq2 Palatino Baltic;}{\f4919\fbidi \fnil\fcharset163\fprq2 Palatino (Vietnamese);}{\f4921\fbidi \fnil\fcharset238\fprq2 Palatino Bold CE;}{\f4925\fbidi \fnil\fcharset162\fprq2 Palatino Bold Tur;}{\f4928\fbidi \fnil\fcharset186\fprq2 Palatino Bold Baltic;}{\f4929\fbidi \fnil\fcharset163\fprq2 Palatino Bold (Vietnamese);}{\f4931\fbidi \fnil\fcharset238\fprq2 Palatino Bold Italic CE;}{\f4935\fbidi \fnil\fcharset162\fprq2 Palatino Bold Italic Tur;}{\f4938\fbidi \fnil\fcharset186\fprq2 Palatino Bold Italic Baltic;}{\f4939\fbidi \fnil\fcharset163\fprq2 Palatino Bold Italic (Vietnamese);}{\f4941\fbidi \fnil\fcharset238\fprq2 Palatino Italic CE;}{\f4945\fbidi \fnil\fcharset162\fprq2 Palatino Italic Tur;}{\f4948\fbidi \fnil\fcharset186\fprq2 Palatino Italic Baltic;}{\f4949\fbidi \fnil\fcharset163\fprq2 Palatino Italic (Vietnamese);}{\f4951\fbidi \fnil\fcharset238\fprq2 Palatino Linotype CE;}{\f4952\fbidi \fnil\fcharset204\fprq2 Palatino Linotype Cyr;}{\f4954\fbidi \fnil\fcharset161\fprq2 Palatino Linotype Greek;}{\f4955\fbidi \fnil\fcharset162\fprq2 Palatino Linotype Tur;}{\f4958\fbidi \fnil\fcharset186\fprq2 Palatino Linotype Baltic;}{\f4959\fbidi \fnil\fcharset163\fprq2 Palatino Linotype (Vietnamese);}{\f4961\fbidi \fnil\fcharset238\fprq2 Palatino Linotype Bold CE;}{\f4962\fbidi \fnil\fcharset204\fprq2 Palatino Linotype Bold Cyr;}{\f4964\fbidi \fnil\fcharset161\fprq2 Palatino Linotype Bold Greek;}{\f4965\fbidi \fnil\fcharset162\fprq2 Palatino Linotype Bold Tur;}{\f4968\fbidi \fnil\fcharset186\fprq2 Palatino Linotype Bold Baltic;}{\f4969\fbidi \fnil\fcharset163\fprq2 Palatino Linotype Bold (Vietnamese);}{\f4971\fbidi \fnil\fcharset238\fprq2 Palatino Linotype Bold Italic CE;}{\f4972\fbidi \fnil\fcharset204\fprq2 Palatino Linotype Bold Italic Cyr;}{\f4974\fbidi \fnil\fcharset161\fprq2 Palatino Linotype Bold Italic Greek;}{\f4975\fbidi \fnil\fcharset162\fprq2 Palatino Linotype Bold Italic Tur;}{\f4978\fbidi \fnil\fcharset186\fprq2 Palatino Linotype Bold Italic Baltic;}{\f4979\fbidi \fnil\fcharset163\fprq2 Palatino Linotype Bold Italic (Vietnamese);}{\f4981\fbidi \fnil\fcharset238\fprq2 Palatino Linotype Italic CE;}{\f4982\fbidi \fnil\fcharset204\fprq2 Palatino Linotype Italic Cyr;}{\f4984\fbidi \fnil\fcharset161\fprq2 Palatino Linotype Italic Greek;}{\f4985\fbidi \fnil\fcharset162\fprq2 Palatino Linotype Italic Tur;}{\f4988\fbidi \fnil\fcharset186\fprq2 Palatino Linotype Italic Baltic;}{\f4989\fbidi \fnil\fcharset163\fprq2 Palatino Linotype Italic (Vietnamese);}{\f4996\fbidi \fnil\fcharset177\fprq2 Papyrus (Hebrew);}{\f4997\fbidi \fnil\fcharset178\fprq2 Papyrus (Arabid);}{\f5006\fbidi \fnil\fcharset177\fprq2 Papyrus Condensed (Hebrew);}{\f5007\fbidi \fnil\fcharset178\fprq2 Papyrus Condensed (Arabid);}{\f5071\fbidi \fnil\fcharset238\fprq2 Plantagenet Cherokee CE;}{\f5075\fbidi \fnil\fcharset162\fprq2 Plantagenet Cherokee Tur;}{\f5076\fbidi \fnil\fcharset177\fprq2 Plantagenet Cherokee (Hebrew);}{\f5077\fbidi \fnil\fcharset178\fprq2 Plantagenet Cherokee (Arabid);}{\f5078\fbidi \fnil\fcharset186\fprq2 Plantagenet Cherokee Baltic;}{\f5079\fbidi \fnil\fcharset163\fprq2 Plantagenet Cherokee (Vietnamese);}{\f5093\fbidi \fnil\fcharset0\fprq2 PMingLiU-ExtB Western;}{\f5103\fbidi \fnil\fcharset0\fprq2 @PMingLiU-ExtB Western;}{\f5151\fbidi \fnil\fcharset238\fprq2 PT Mono CE;}{\f5152\fbidi \fnil\fcharset204\fprq2 PT Mono Cyr;}{\f5155\fbidi \fnil\fcharset162\fprq2 PT Mono Tur;}{\f5158\fbidi \fnil\fcharset186\fprq2 PT Mono Baltic;}{\f5161\fbidi \fnil\fcharset238\fprq2 PT Mono Bold CE;}{\f5162\fbidi \fnil\fcharset204\fprq2 PT Mono Bold Cyr;}{\f5165\fbidi \fnil\fcharset162\fprq2 PT Mono Bold Tur;}{\f5168\fbidi \fnil\fcharset186\fprq2 PT Mono Bold Baltic;}{\f5171\fbidi \fnil\fcharset238\fprq2 PT Sans CE;}{\f5172\fbidi \fnil\fcharset204\fprq2 PT Sans Cyr;}{\f5175\fbidi \fnil\fcharset162\fprq2 PT Sans Tur;}{\f5178\fbidi \fnil\fcharset186\fprq2 PT Sans Baltic;}{\f5181\fbidi \fnil\fcharset238\fprq2 PT Sans Bold CE;}{\f5182\fbidi \fnil\fcharset204\fprq2 PT Sans Bold Cyr;}{\f5185\fbidi \fnil\fcharset162\fprq2 PT Sans Bold Tur;}{\f5188\fbidi \fnil\fcharset186\fprq2 PT Sans Bold Baltic;}{\f5191\fbidi \fnil\fcharset238\fprq2 PT Sans Bold Italic CE;}{\f5192\fbidi \fnil\fcharset204\fprq2 PT Sans Bold Italic Cyr;}{\f5195\fbidi \fnil\fcharset162\fprq2 PT Sans Bold Italic Tur;}{\f5198\fbidi \fnil\fcharset186\fprq2 PT Sans Bold Italic Baltic;}{\f5201\fbidi \fnil\fcharset238\fprq2 PT Sans Caption CE;}{\f5202\fbidi \fnil\fcharset204\fprq2 PT Sans Caption Cyr;}{\f5205\fbidi \fnil\fcharset162\fprq2 PT Sans Caption Tur;}{\f5208\fbidi \fnil\fcharset186\fprq2 PT Sans Caption Baltic;}{\f5211\fbidi \fnil\fcharset238\fprq2 PT Sans Caption Bold CE;}{\f5212\fbidi \fnil\fcharset204\fprq2 PT Sans Caption Bold Cyr;}{\f5215\fbidi \fnil\fcharset162\fprq2 PT Sans Caption Bold Tur;}{\f5218\fbidi \fnil\fcharset186\fprq2 PT Sans Caption Bold Baltic;}{\f5221\fbidi \fnil\fcharset238\fprq2 PT Sans Italic CE;}{\f5222\fbidi \fnil\fcharset204\fprq2 PT Sans Italic Cyr;}{\f5225\fbidi \fnil\fcharset162\fprq2 PT Sans Italic Tur;}{\f5228\fbidi \fnil\fcharset186\fprq2 PT Sans Italic Baltic;}{\f5231\fbidi \fnil\fcharset238\fprq2 PT Sans Narrow CE;}{\f5232\fbidi \fnil\fcharset204\fprq2 PT Sans Narrow Cyr;}{\f5235\fbidi \fnil\fcharset162\fprq2 PT Sans Narrow Tur;}{\f5238\fbidi \fnil\fcharset186\fprq2 PT Sans Narrow Baltic;}{\f5241\fbidi \fnil\fcharset238\fprq2 PT Sans Narrow Bold CE;}{\f5242\fbidi \fnil\fcharset204\fprq2 PT Sans Narrow Bold Cyr;}{\f5245\fbidi \fnil\fcharset162\fprq2 PT Sans Narrow Bold Tur;}{\f5248\fbidi \fnil\fcharset186\fprq2 PT Sans Narrow Bold Baltic;}{\f5251\fbidi \fnil\fcharset238\fprq2 PT Serif CE;}{\f5252\fbidi \fnil\fcharset204\fprq2 PT Serif Cyr;}{\f5255\fbidi \fnil\fcharset162\fprq2 PT Serif Tur;}{\f5258\fbidi \fnil\fcharset186\fprq2 PT Serif Baltic;}{\f5261\fbidi \fnil\fcharset238\fprq2 PT Serif Bold CE;}{\f5262\fbidi \fnil\fcharset204\fprq2 PT Serif Bold Cyr;}{\f5265\fbidi \fnil\fcharset162\fprq2 PT Serif Bold Tur;}{\f5268\fbidi \fnil\fcharset186\fprq2 PT Serif Bold Baltic;}{\f5271\fbidi \fnil\fcharset238\fprq2 PT Serif Bold Italic CE;}{\f5272\fbidi \fnil\fcharset204\fprq2 PT Serif Bold Italic Cyr;}{\f5275\fbidi \fnil\fcharset162\fprq2 PT Serif Bold Italic Tur;}{\f5278\fbidi \fnil\fcharset186\fprq2 PT Serif Bold Italic Baltic;}{\f5281\fbidi \fnil\fcharset238\fprq2 PT Serif Caption CE;}{\f5282\fbidi \fnil\fcharset204\fprq2 PT Serif Caption Cyr;}{\f5285\fbidi \fnil\fcharset162\fprq2 PT Serif Caption Tur;}{\f5288\fbidi \fnil\fcharset186\fprq2 PT Serif Caption Baltic;}{\f5291\fbidi \fnil\fcharset238\fprq2 PT Serif Caption Italic CE;}{\f5292\fbidi \fnil\fcharset204\fprq2 PT Serif Caption Italic Cyr;}{\f5295\fbidi \fnil\fcharset162\fprq2 PT Serif Caption Italic Tur;}{\f5298\fbidi \fnil\fcharset186\fprq2 PT Serif Caption Italic Baltic;}{\f5301\fbidi \fnil\fcharset238\fprq2 PT Serif Italic CE;}{\f5302\fbidi \fnil\fcharset204\fprq2 PT Serif Italic Cyr;}{\f5305\fbidi \fnil\fcharset162\fprq2 PT Serif Italic Tur;}{\f5308\fbidi \fnil\fcharset186\fprq2 PT Serif Italic Baltic;}{\f5341\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Bold CE;}{\f5344\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Bold Greek;}{\f5345\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Bold Tur;}{\f5348\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Bold Baltic;}{\f5351\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Bold Italic CE;}{\f5354\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Bold Italic Greek;}{\f5355\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Bold Italic Tur;}{\f5358\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Bold Italic Baltic;}{\f5361\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Demi CE;}{\f5364\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Demi Greek;}{\f5365\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Demi Tur;}{\f5368\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Demi Baltic;}{\f5371\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Demi Italic CE;}{\f5374\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Demi Italic Greek;}{\f5375\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Demi Italic Tur;}{\f5378\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Demi Italic Baltic;}{\f5381\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Extra Bold CE;}{\f5384\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Extra Bold Greek;}{\f5385\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Extra Bold Tur;}{\f5388\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Extra Bold Baltic;}{\f5391\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Extra Bold It CE;}{\f5394\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Extra Bold It Greek;}{\f5395\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Extra Bold It Tur;}{\f5398\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Extra Bold It Baltic;}{\f5401\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Italic CE;}{\f5404\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Italic Greek;}{\f5405\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Italic Tur;}{\f5408\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Italic Baltic;}{\f5411\fbidi \fnil\fcharset238\fprq2 Sabon Next LT Pro Regular CE;}{\f5414\fbidi \fnil\fcharset161\fprq2 Sabon Next LT Pro Regular Greek;}{\f5415\fbidi \fnil\fcharset162\fprq2 Sabon Next LT Pro Regular Tur;}{\f5418\fbidi \fnil\fcharset186\fprq2 Sabon Next LT Pro Regular Baltic;}{\f5431\fbidi \fnil\fcharset238\fprq2 Sathu CE;}{\f5432\fbidi \fnil\fcharset204\fprq2 Sathu Cyr;}{\f5435\fbidi \fnil\fcharset162\fprq2 Sathu Tur;}{\f5438\fbidi \fnil\fcharset186\fprq2 Sathu Baltic;}{\f5439\fbidi \fnil\fcharset163\fprq2 Sathu (Vietnamese);}{\f5451\fbidi \fnil\fcharset238\fprq2 Savoye LET Plain CC.:1.0 CE;}{\f5452\fbidi \fnil\fcharset204\fprq2 Savoye LET Plain CC.:1.0 Cyr;}{\f5454\fbidi \fnil\fcharset161\fprq2 Savoye LET Plain CC.:1.0 Greek;}{\f5455\fbidi \fnil\fcharset162\fprq2 Savoye LET Plain CC.:1.0 Tur;}{\f5458\fbidi \fnil\fcharset186\fprq2 Savoye LET Plain CC.:1.0 Baltic;}{\f5459\fbidi \fnil\fcharset163\fprq2 Savoye LET Plain CC.:1.0 (Vietnamese);}{\f5481\fbidi \fnil\fcharset238\fprq2 Seravek CE;}{\f5482\fbidi \fnil\fcharset204\fprq2 Seravek Cyr;}{\f5484\fbidi \fnil\fcharset161\fprq2 Seravek Greek;}{\f5485\fbidi \fnil\fcharset162\fprq2 Seravek Tur;}{\f5488\fbidi \fnil\fcharset186\fprq2 Seravek Baltic;}{\f5491\fbidi \fnil\fcharset238\fprq2 Seravek Bold CE;}{\f5492\fbidi \fnil\fcharset204\fprq2 Seravek Bold Cyr;}{\f5494\fbidi \fnil\fcharset161\fprq2 Seravek Bold Greek;}{\f5495\fbidi \fnil\fcharset162\fprq2 Seravek Bold Tur;}{\f5498\fbidi \fnil\fcharset186\fprq2 Seravek Bold Baltic;}{\f5501\fbidi \fnil\fcharset238\fprq2 Seravek Bold Italic CE;}{\f5502\fbidi \fnil\fcharset204\fprq2 Seravek Bold Italic Cyr;}{\f5504\fbidi \fnil\fcharset161\fprq2 Seravek Bold Italic Greek;}{\f5505\fbidi \fnil\fcharset162\fprq2 Seravek Bold Italic Tur;}{\f5508\fbidi \fnil\fcharset186\fprq2 Seravek Bold Italic Baltic;}{\f5511\fbidi \fnil\fcharset238\fprq2 Seravek ExtraLight CE;}{\f5512\fbidi \fnil\fcharset204\fprq2 Seravek ExtraLight Cyr;}{\f5514\fbidi \fnil\fcharset161\fprq2 Seravek ExtraLight Greek;}{\f5515\fbidi \fnil\fcharset162\fprq2 Seravek ExtraLight Tur;}{\f5518\fbidi \fnil\fcharset186\fprq2 Seravek ExtraLight Baltic;}{\f5521\fbidi \fnil\fcharset238\fprq2 Seravek ExtraLight Italic CE;}{\f5522\fbidi \fnil\fcharset204\fprq2 Seravek ExtraLight Italic Cyr;}{\f5524\fbidi \fnil\fcharset161\fprq2 Seravek ExtraLight Italic Greek;}{\f5525\fbidi \fnil\fcharset162\fprq2 Seravek ExtraLight Italic Tur;}{\f5528\fbidi \fnil\fcharset186\fprq2 Seravek ExtraLight Italic Baltic;}{\f5531\fbidi \fnil\fcharset238\fprq2 Seravek Italic CE;}{\f5532\fbidi \fnil\fcharset204\fprq2 Seravek Italic Cyr;}{\f5534\fbidi \fnil\fcharset161\fprq2 Seravek Italic Greek;}{\f5535\fbidi \fnil\fcharset162\fprq2 Seravek Italic Tur;}{\f5538\fbidi \fnil\fcharset186\fprq2 Seravek Italic Baltic;}{\f5541\fbidi \fnil\fcharset238\fprq2 Seravek Light CE;}{\f5542\fbidi \fnil\fcharset204\fprq2 Seravek Light Cyr;}{\f5544\fbidi \fnil\fcharset161\fprq2 Seravek Light Greek;}{\f5545\fbidi \fnil\fcharset162\fprq2 Seravek Light Tur;}{\f5548\fbidi \fnil\fcharset186\fprq2 Seravek Light Baltic;}{\f5551\fbidi \fnil\fcharset238\fprq2 Seravek Light Italic CE;}{\f5552\fbidi \fnil\fcharset204\fprq2 Seravek Light Italic Cyr;}{\f5554\fbidi \fnil\fcharset161\fprq2 Seravek Light Italic Greek;}{\f5555\fbidi \fnil\fcharset162\fprq2 Seravek Light Italic Tur;}{\f5558\fbidi \fnil\fcharset186\fprq2 Seravek Light Italic Baltic;}{\f5561\fbidi \fnil\fcharset238\fprq2 Seravek Medium CE;}{\f5562\fbidi \fnil\fcharset204\fprq2 Seravek Medium Cyr;}{\f5564\fbidi \fnil\fcharset161\fprq2 Seravek Medium Greek;}{\f5565\fbidi \fnil\fcharset162\fprq2 Seravek Medium Tur;}{\f5568\fbidi \fnil\fcharset186\fprq2 Seravek Medium Baltic;}{\f5571\fbidi \fnil\fcharset238\fprq2 Seravek Medium Italic CE;}{\f5572\fbidi \fnil\fcharset204\fprq2 Seravek Medium Italic Cyr;}{\f5574\fbidi \fnil\fcharset161\fprq2 Seravek Medium Italic Greek;}{\f5575\fbidi \fnil\fcharset162\fprq2 Seravek Medium Italic Tur;}{\f5578\fbidi \fnil\fcharset186\fprq2 Seravek Medium Italic Baltic;}{\f5581\fbidi \fnil\fcharset238\fprq2 Silom CE;}{\f5585\fbidi \fnil\fcharset162\fprq2 Silom Tur;}{\f5588\fbidi \fnil\fcharset186\fprq2 Silom Baltic;}{\f5589\fbidi \fnil\fcharset163\fprq2 Silom (Vietnamese);}{\f5593\fbidi \fnil\fcharset0\fprq2 SimSun-ExtB Western;}{\f5603\fbidi \fnil\fcharset0\fprq2 @SimSun-ExtB Western;}{\f5665\fbidi \fnil\fcharset162\fprq2 Snell Roundhand Tur;}{\f5669\fbidi \fnil\fcharset163\fprq2 Snell Roundhand (Vietnamese);}{\f5675\fbidi \fnil\fcharset162\fprq2 Snell Roundhand Black Tur;}{\f5679\fbidi \fnil\fcharset163\fprq2 Snell Roundhand Black (Vietnamese);}{\f5685\fbidi \fnil\fcharset162\fprq2 Snell Roundhand Bold Tur;}{\f5689\fbidi \fnil\fcharset163\fprq2 Snell Roundhand Bold (Vietnamese);}{\f5701\fbidi \fnil\fcharset238\fprq2 STIXGeneral-Bold CE;}{\f5702\fbidi \fnil\fcharset204\fprq2 STIXGeneral-Bold Cyr;}{\f5704\fbidi \fnil\fcharset161\fprq2 STIXGeneral-Bold Greek;}{\f5705\fbidi \fnil\fcharset162\fprq2 STIXGeneral-Bold Tur;}{\f5706\fbidi \fnil\fcharset177\fprq2 STIXGeneral-Bold (Hebrew);}{\f5707\fbidi \fnil\fcharset178\fprq2 STIXGeneral-Bold (Arabid);}{\f5708\fbidi \fnil\fcharset186\fprq2 STIXGeneral-Bold Baltic;}{\f5709\fbidi \fnil\fcharset163\fprq2 STIXGeneral-Bold (Vietnamese);}{\f5711\fbidi \fnil\fcharset238\fprq2 STIXGeneral-BoldItalic CE;}{\f5712\fbidi \fnil\fcharset204\fprq2 STIXGeneral-BoldItalic Cyr;}{\f5714\fbidi \fnil\fcharset161\fprq2 STIXGeneral-BoldItalic Greek;}{\f5715\fbidi \fnil\fcharset162\fprq2 STIXGeneral-BoldItalic Tur;}{\f5716\fbidi \fnil\fcharset177\fprq2 STIXGeneral-BoldItalic (Hebrew);}{\f5717\fbidi \fnil\fcharset178\fprq2 STIXGeneral-BoldItalic (Arabid);}{\f5718\fbidi \fnil\fcharset186\fprq2 STIXGeneral-BoldItalic Baltic;}{\f5719\fbidi \fnil\fcharset163\fprq2 STIXGeneral-BoldItalic (Vietnamese);}{\f5721\fbidi \fnil\fcharset238\fprq2 STIXGeneral-Italic CE;}{\f5722\fbidi \fnil\fcharset204\fprq2 STIXGeneral-Italic Cyr;}{\f5724\fbidi \fnil\fcharset161\fprq2 STIXGeneral-Italic Greek;}{\f5725\fbidi \fnil\fcharset162\fprq2 STIXGeneral-Italic Tur;}{\f5726\fbidi \fnil\fcharset177\fprq2 STIXGeneral-Italic (Hebrew);}{\f5727\fbidi \fnil\fcharset178\fprq2 STIXGeneral-Italic (Arabid);}{\f5728\fbidi \fnil\fcharset186\fprq2 STIXGeneral-Italic Baltic;}{\f5729\fbidi \fnil\fcharset163\fprq2 STIXGeneral-Italic (Vietnamese);}{\f5731\fbidi \fnil\fcharset238\fprq2 STIXGeneral-Regular CE;}{\f5732\fbidi \fnil\fcharset204\fprq2 STIXGeneral-Regular Cyr;}{\f5734\fbidi \fnil\fcharset161\fprq2 STIXGeneral-Regular Greek;}{\f5735\fbidi \fnil\fcharset162\fprq2 STIXGeneral-Regular Tur;}{\f5736\fbidi \fnil\fcharset177\fprq2 STIXGeneral-Regular (Hebrew);}{\f5737\fbidi \fnil\fcharset178\fprq2 STIXGeneral-Regular (Arabid);}{\f5738\fbidi \fnil\fcharset186\fprq2 STIXGeneral-Regular Baltic;}{\f5739\fbidi \fnil\fcharset163\fprq2 STIXGeneral-Regular (Vietnamese);}{\f5889\fbidi \fnil\fcharset163\fprq2 STIXSizeFiveSym-Regular (Vietnamese);}{\f5909\fbidi \fnil\fcharset163\fprq2 STIXSizeFourSym-Regular (Vietnamese);}{\f5929\fbidi \fnil\fcharset163\fprq2 STIXSizeOneSym-Regular (Vietnamese);}{\f5949\fbidi \fnil\fcharset163\fprq2 STIXSizeThreeSym-Regular (Vietnamese);}{\f5969\fbidi \fnil\fcharset163\fprq2 STIXSizeTwoSym-Regular (Vietnamese);}{\f6041\fbidi \fnil\fcharset238\fprq2 Superclarendon Black CE;}{\f6048\fbidi \fnil\fcharset186\fprq2 Superclarendon Black Baltic;}{\f6049\fbidi \fnil\fcharset163\fprq2 Superclarendon Black (Vietnamese);}{\f6051\fbidi \fnil\fcharset238\fprq2 Superclarendon Black Italic CE;}{\f6058\fbidi \fnil\fcharset186\fprq2 Superclarendon Black Italic Baltic;}{\f6059\fbidi \fnil\fcharset163\fprq2 Superclarendon Black Italic (Vietnamese);}{\f6061\fbidi \fnil\fcharset238\fprq2 Superclarendon Bold CE;}{\f6068\fbidi \fnil\fcharset186\fprq2 Superclarendon Bold Baltic;}{\f6069\fbidi \fnil\fcharset163\fprq2 Superclarendon Bold (Vietnamese);}{\f6071\fbidi \fnil\fcharset238\fprq2 Superclarendon Bold Italic CE;}{\f6078\fbidi \fnil\fcharset186\fprq2 Superclarendon Bold Italic Baltic;}{\f6079\fbidi \fnil\fcharset163\fprq2 Superclarendon Bold Italic (Vietnamese);}{\f6081\fbidi \fnil\fcharset238\fprq2 Superclarendon Italic CE;}{\f6088\fbidi \fnil\fcharset186\fprq2 Superclarendon Italic Baltic;}{\f6089\fbidi \fnil\fcharset163\fprq2 Superclarendon Italic (Vietnamese);}{\f6091\fbidi \fnil\fcharset238\fprq2 Superclarendon Light CE;}{\f6098\fbidi \fnil\fcharset186\fprq2 Superclarendon Light Baltic;}{\f6099\fbidi \fnil\fcharset163\fprq2 Superclarendon Light (Vietnamese);}{\f6101\fbidi \fnil\fcharset238\fprq2 Superclarendon Light Italic CE;}{\f6108\fbidi \fnil\fcharset186\fprq2 Superclarendon Light Italic Baltic;}{\f6109\fbidi \fnil\fcharset163\fprq2 Superclarendon Light Italic (Vietnamese);}{\f6111\fbidi \fnil\fcharset238\fprq2 Superclarendon Regular CE;}{\f6118\fbidi \fnil\fcharset186\fprq2 Superclarendon Regular Baltic;}{\f6119\fbidi \fnil\fcharset163\fprq2 Superclarendon Regular (Vietnamese);}{\f6131\fbidi \fnil\fcharset238\fprq2 Tahoma CE;}{\f6132\fbidi \fnil\fcharset204\fprq2 Tahoma Cyr;}{\f6134\fbidi \fnil\fcharset161\fprq2 Tahoma Greek;}{\f6135\fbidi \fnil\fcharset162\fprq2 Tahoma Tur;}{\f6136\fbidi \fnil\fcharset177\fprq2 Tahoma (Hebrew);}{\f6137\fbidi \fnil\fcharset178\fprq2 Tahoma (Arabid);}{\f6138\fbidi \fnil\fcharset186\fprq2 Tahoma Baltic;}{\f6139\fbidi \fnil\fcharset163\fprq2 Tahoma (Vietnamese);}{\f6140\fbidi \fnil\fcharset222\fprq2 Tahoma (That);}{\f6141\fbidi \fnil\fcharset238\fprq2 Tahoma Bold CE;}{\f6142\fbidi \fnil\fcharset204\fprq2 Tahoma Bold Cyr;}{\f6144\fbidi \fnil\fcharset161\fprq2 Tahoma Bold Greek;}{\f6145\fbidi \fnil\fcharset162\fprq2 Tahoma Bold Tur;}{\f6146\fbidi \fnil\fcharset177\fprq2 Tahoma Bold (Hebrew);}{\f6147\fbidi \fnil\fcharset178\fprq2 Tahoma Bold (Arabid);}{\f6148\fbidi \fnil\fcharset186\fprq2 Tahoma Bold Baltic;}{\f6149\fbidi \fnil\fcharset163\fprq2 Tahoma Bold (Vietnamese);}{\f6150\fbidi \fnil\fcharset222\fprq2 Tahoma Bold (That);}{\f6201\fbidi \fnil\fcharset238\fprq2 Tekton Pro Bold CE;}{\f6205\fbidi \fnil\fcharset162\fprq2 Tekton Pro Bold Tur;}{\f6208\fbidi \fnil\fcharset186\fprq2 Tekton Pro Bold Baltic;}{\f6211\fbidi \fnil\fcharset238\fprq2 Tekton Pro BoldCond CE;}{\f6215\fbidi \fnil\fcharset162\fprq2 Tekton Pro BoldCond Tur;}{\f6218\fbidi \fnil\fcharset186\fprq2 Tekton Pro BoldCond Baltic;}{\f6221\fbidi \fnil\fcharset238\fprq2 Tekton Pro BoldExt CE;}{\f6225\fbidi \fnil\fcharset162\fprq2 Tekton Pro BoldExt Tur;}{\f6228\fbidi \fnil\fcharset186\fprq2 Tekton Pro BoldExt Baltic;}{\f6231\fbidi \fnil\fcharset238\fprq2 Tekton Pro BoldObl CE;}{\f6235\fbidi \fnil\fcharset162\fprq2 Tekton Pro BoldObl Tur;}{\f6238\fbidi \fnil\fcharset186\fprq2 Tekton Pro BoldObl Baltic;}{\f6281\fbidi \fnil\fcharset238\fprq2 Thonburi Light CE;}{\f6285\fbidi \fnil\fcharset162\fprq2 Thonburi Light Tur;}{\f6288\fbidi \fnil\fcharset186\fprq2 Thonburi Light Baltic;}{\f6289\fbidi \fnil\fcharset163\fprq2 Thonburi Light (Vietnamese);}{\f6291\fbidi \fnil\fcharset238\fprq2 Times New Roman Bold CE;}{\f6292\fbidi \fnil\fcharset204\fprq2 Times New Roman Bold Cyr;}{\f6294\fbidi \fnil\fcharset161\fprq2 Times New Roman Bold Greek;}{\f6295\fbidi \fnil\fcharset162\fprq2 Times New Roman Bold Tur;}{\f6296\fbidi \fnil\fcharset177\fprq2 Times New Roman Bold (Hebrew);}{\f6297\fbidi \fnil\fcharset178\fprq2 Times New Roman Bold (Arabid);}{\f6298\fbidi \fnil\fcharset186\fprq2 Times New Roman Bold Baltic;}{\f6299\fbidi \fnil\fcharset163\fprq2 Times New Roman Bold (Vietnamese);}{\f6301\fbidi \fnil\fcharset238\fprq2 Times New Roman Bold Italic CE;}{\f6302\fbidi \fnil\fcharset204\fprq2 Times New Roman Bold Italic Cyr;}{\f6304\fbidi \fnil\fcharset161\fprq2 Times New Roman Bold Italic Greek;}{\f6305\fbidi \fnil\fcharset162\fprq2 Times New Roman Bold Italic Tur;}{\f6306\fbidi \fnil\fcharset177\fprq2 Times New Roman Bold Italic (Hebrew);}{\f6308\fbidi \fnil\fcharset186\fprq2 Times New Roman Bold Italic Baltic;}{\f6309\fbidi \fnil\fcharset163\fprq2 Times New Roman Bold Italic (Vietnamese);}{\f6311\fbidi \fnil\fcharset238\fprq2 Times New Roman Italic CE;}{\f6312\fbidi \fnil\fcharset204\fprq2 Times New Roman Italic Cyr;}{\f6314\fbidi \fnil\fcharset161\fprq2 Times New Roman Italic Greek;}{\f6315\fbidi \fnil\fcharset162\fprq2 Times New Roman Italic Tur;}{\f6316\fbidi \fnil\fcharset177\fprq2 Times New Roman Italic (Hebrew);}{\f6318\fbidi \fnil\fcharset186\fprq2 Times New Roman Italic Baltic;}{\f6319\fbidi \fnil\fcharset163\fprq2 Times New Roman Italic (Vietnamese);}{\f6321\fbidi \fnil\fcharset238\fprq2 Trajan Pro CE;}{\f6325\fbidi \fnil\fcharset162\fprq2 Trajan Pro Tur;}{\f6328\fbidi \fnil\fcharset186\fprq2 Trajan Pro Baltic;}{\f6331\fbidi \fnil\fcharset238\fprq2 Trajan Pro Bold CE;}{\f6335\fbidi \fnil\fcharset162\fprq2 Trajan Pro Bold Tur;}{\f6338\fbidi \fnil\fcharset186\fprq2 Trajan Pro Bold Baltic;}{\f6341\fbidi \fnil\fcharset238\fprq2 Trebuchet MS CE;}{\f6342\fbidi \fnil\fcharset204\fprq2 Trebuchet MS Cyr;}{\f6344\fbidi \fnil\fcharset161\fprq2 Trebuchet MS Greek;}{\f6345\fbidi \fnil\fcharset162\fprq2 Trebuchet MS Tur;}{\f6348\fbidi \fnil\fcharset186\fprq2 Trebuchet MS Baltic;}{\f6351\fbidi \fnil\fcharset238\fprq2 Trebuchet MS Bold CE;}{\f6352\fbidi \fnil\fcharset204\fprq2 Trebuchet MS Bold Cyr;}{\f6354\fbidi \fnil\fcharset161\fprq2 Trebuchet MS Bold Greek;}{\f6355\fbidi \fnil\fcharset162\fprq2 Trebuchet MS Bold Tur;}{\f6358\fbidi \fnil\fcharset186\fprq2 Trebuchet MS Bold Baltic;}{\f6361\fbidi \fnil\fcharset238\fprq2 Trebuchet MS Bold Italic CE;}{\f6362\fbidi \fnil\fcharset204\fprq2 Trebuchet MS Bold Italic Cyr;}{\f6364\fbidi \fnil\fcharset161\fprq2 Trebuchet MS Bold Italic Greek;}{\f6365\fbidi \fnil\fcharset162\fprq2 Trebuchet MS Bold Italic Tur;}{\f6368\fbidi \fnil\fcharset186\fprq2 Trebuchet MS Bold Italic Baltic;}{\f6371\fbidi \fnil\fcharset238\fprq2 Trebuchet MS Italic CE;}{\f6372\fbidi \fnil\fcharset204\fprq2 Trebuchet MS Italic Cyr;}{\f6374\fbidi \fnil\fcharset161\fprq2 Trebuchet MS Italic Greek;}{\f6375\fbidi \fnil\fcharset162\fprq2 Trebuchet MS Italic Tur;}{\f6378\fbidi \fnil\fcharset186\fprq2 Trebuchet MS Italic Baltic;}{\f6381\fbidi \fnil\fcharset238\fprq2 Tw Cen MT CE;}{\f6391\fbidi \fnil\fcharset238\fprq2 Tw Cen MT Bold CE;}{\f6401\fbidi \fnil\fcharset238\fprq2 Tw Cen MT Bold Italic CE;}{\f6411\fbidi \fnil\fcharset238\fprq2 Tw Cen MT Italic CE;}{\f6431\fbidi \fnil\fcharset238\fprq2 Verdana Bold CE;}{\f6432\fbidi \fnil\fcharset204\fprq2 Verdana Bold Cyr;}{\f6434\fbidi \fnil\fcharset161\fprq2 Verdana Bold Greek;}{\f6435\fbidi \fnil\fcharset162\fprq2 Verdana Bold Tur;}{\f6438\fbidi \fnil\fcharset186\fprq2 Verdana Bold Baltic;}{\f6439\fbidi \fnil\fcharset163\fprq2 Verdana Bold (Vietnamese);}{\f6441\fbidi \fnil\fcharset238\fprq2 Verdana Bold Italic CE;}{\f6442\fbidi \fnil\fcharset204\fprq2 Verdana Bold Italic Cyr;}{\f6444\fbidi \fnil\fcharset161\fprq2 Verdana Bold Italic Greek;}{\f6445\fbidi \fnil\fcharset162\fprq2 Verdana Bold Italic Tur;}{\f6448\fbidi \fnil\fcharset186\fprq2 Verdana Bold Italic Baltic;}{\f6449\fbidi \fnil\fcharset163\fprq2 Verdana Bold Italic (Vietnamese);}{\f6451\fbidi \fnil\fcharset238\fprq2 Verdana Italic CE;}{\f6452\fbidi \fnil\fcharset204\fprq2 Verdana Italic Cyr;}{\f6454\fbidi \fnil\fcharset161\fprq2 Verdana Italic Greek;}{\f6455\fbidi \fnil\fcharset162\fprq2 Verdana Italic Tur;}{\f6458\fbidi \fnil\fcharset186\fprq2 Verdana Italic Baltic;}{\f6459\fbidi \fnil\fcharset163\fprq2 Verdana Italic (Vietnamese);}{\f6461\fbidi \fnil\fcharset238\fprq2 Wawati SC Regular CE;}{\f6471\fbidi \fnil\fcharset238\fprq2 Wawati TC Regular CE;}{\f6571\fbidi \fnil\fcharset238\fprq2 Zapfino CE;}{\f6575\fbidi \fnil\fcharset162\fprq2 Zapfino Tur;}{\f6578\fbidi \fnil\fcharset186\fprq2 Zapfino Baltic;}{\f6583\fbidi \fnil\fcharset0\fprq2 Lucida Grande CE;}{\f6582\fbidi \fnil\fcharset204\fprq2 Lucida Grande CE Cyr;}{\f6584\fbidi \fnil\fcharset161\fprq2 Lucida Grande CE Greek;}{\f6585\fbidi \fnil\fcharset162\fprq2 Lucida Grande CE Tur;}{\f6586\fbidi \fnil\fcharset177\fprq2 Lucida Grande CE (Hebrew);}{\f6588\fbidi \fnil\fcharset186\fprq2 Lucida Grande CE Baltic;}{\f6589\fbidi \fnil\fcharset163\fprq2 Lucida Grande CE (Vietnamese);}{\f6591\fbidi \fnil\fcharset238\fprq2 Charcoal CY CE;}{\f6597\fbidi \fnil\fcharset178\fprq2 Charcoal CY (Arabid);}{\f6598\fbidi \fnil\fcharset186\fprq2 Charcoal CY Baltic;}{\f6599\fbidi \fnil\fcharset163\fprq2 Charcoal CY (Vietnamese);}{\f6601\fbidi \fnil\fcharset238\fprq2 Geneva CY CE;}{\f6607\fbidi \fnil\fcharset178\fprq2 Geneva CY (Arabid);}{\f6608\fbidi \fnil\fcharset186\fprq2 Geneva CY Baltic;}{\f6609\fbidi \fnil\fcharset163\fprq2 Geneva CY (Vietnamese);}{\f6611\fbidi \fnil\fcharset238\fprq2 Helvetica CY CE;}{\f6617\fbidi \fnil\fcharset178\fprq2 Helvetica CY (Arabid);}{\f6618\fbidi \fnil\fcharset186\fprq2 Helvetica CY Baltic;}{\f6619\fbidi \fnil\fcharset163\fprq2 Helvetica CY (Vietnamese);}{\f6623\fbidi \fnil\fcharset0\fprq2 Lucida Grande CY;}{\f6621\fbidi \fnil\fcharset238\fprq2 Lucida Grande CY CE;}{\f6624\fbidi \fnil\fcharset161\fprq2 Lucida Grande CY Greek;}{\f6625\fbidi \fnil\fcharset162\fprq2 Lucida Grande CY Tur;}{\f6626\fbidi \fnil\fcharset177\fprq2 Lucida Grande CY (Hebrew);}{\f6628\fbidi \fnil\fcharset186\fprq2 Lucida Grande CY Baltic;}{\f6629\fbidi \fnil\fcharset163\fprq2 Lucida Grande CY (Vietnamese);}{\f6633\fbidi \fnil\fcharset0\fprq2 Thonburi;}{\f6631\fbidi \fnil\fcharset238\fprq2 Thonburi CE;}{\f6635\fbidi \fnil\fcharset162\fprq2 Thonburi Tur;}{\f6638\fbidi \fnil\fcharset186\fprq2 Thonburi Baltic;}{\f6639\fbidi \fnil\fcharset163\fprq2 Thonburi (Vietnamese);}{\f6643\fbidi \fnil\fcharset0\fprq2 Thonburi Bold;}{\f6641\fbidi \fnil\fcharset238\fprq2 Thonburi Bold CE;}{\f6645\fbidi \fnil\fcharset162\fprq2 Thonburi Bold Tur;}{\f6648\fbidi \fnil\fcharset186\fprq2 Thonburi Bold Baltic;}{\f6649\fbidi \fnil\fcharset163\fprq2 Thonburi Bold (Vietnamese);}{\f6653\fbidi \fnil\fcharset0\fprq2 Adobe \'a9\'fa\'c5\'e9 Std L Western;}{\f6652\fbidi \fnil\fcharset204\fprq2 Adobe \'a9\'fa\'c5\'e9 Std L Cyr;}{\f6663\fbidi \fnil\fcharset0\fprq2 @Adobe \'a9\'fa\'c5\'e9 Std L Western;}{\f6662\fbidi \fnil\fcharset204\fprq2 @Adobe \'a9\'fa\'c5\'e9 Std L Cyr;}{\f6673\fbidi \fnil\fcharset0\fprq2 Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B Western;}{\f6672\fbidi \fnil\fcharset204\fprq2 Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B Cyr;}{\f6683\fbidi \fnil\fcharset0\fprq2 @Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B Western;}{\f6682\fbidi \fnil\fcharset204\fprq2 @Adobe \'c1\'63\'b6\'c2\'c5\'e9 Std B Cyr;}{\f6753\fbidi \fnil\fcharset0\fprq2 Hannotate TC Bold Western;}{\f6763\fbidi \fnil\fcharset0\fprq2 @Hannotate TC Bold Western;}{\f6773\fbidi \fnil\fcharset0\fprq2 Hannotate TC Regular Western;}{\f6783\fbidi \fnil\fcharset0\fprq2 @Hannotate TC Regular Western;}{\f6793\fbidi \fnil\fcharset0\fprq2 HanziPen TC Bold Western;}{\f6803\fbidi \fnil\fcharset0\fprq2 @HanziPen TC Bold Western;}{\f6813\fbidi \fnil\fcharset0\fprq2 HanziPen TC Regular Western;}{\f6823\fbidi \fnil\fcharset0\fprq2 @HanziPen TC Regular Western;}{\f6873\fbidi \fnil\fcharset0\fprq2 Kaiti TC Bold Western;}{\f6871\fbidi \fnil\fcharset238\fprq2 Kaiti TC Bold CE;}{\f6872\fbidi \fnil\fcharset204\fprq2 Kaiti TC Bold Cyr;}{\f6874\fbidi \fnil\fcharset161\fprq2 Kaiti TC Bold Greek;}{\f6875\fbidi \fnil\fcharset162\fprq2 Kaiti TC Bold Tur;}{\f6883\fbidi \fnil\fcharset0\fprq2 @Kaiti TC Bold Western;}{\f6881\fbidi \fnil\fcharset238\fprq2 @Kaiti TC Bold CE;}{\f6882\fbidi \fnil\fcharset204\fprq2 @Kaiti TC Bold Cyr;}{\f6884\fbidi \fnil\fcharset161\fprq2 @Kaiti TC Bold Greek;}{\f6885\fbidi \fnil\fcharset162\fprq2 @Kaiti TC Bold Tur;}{\f6893\fbidi \fnil\fcharset0\fprq2 Kaiti TC Regular Western;}{\f6891\fbidi \fnil\fcharset238\fprq2 Kaiti TC Regular CE;}{\f6892\fbidi \fnil\fcharset204\fprq2 Kaiti TC Regular Cyr;}{\f6894\fbidi \fnil\fcharset161\fprq2 Kaiti TC Regular Greek;}{\f6895\fbidi \fnil\fcharset162\fprq2 Kaiti TC Regular Tur;}{\f6903\fbidi \fnil\fcharset0\fprq2 @Kaiti TC Regular Western;}{\f6901\fbidi \fnil\fcharset238\fprq2 @Kaiti TC Regular CE;}{\f6902\fbidi \fnil\fcharset204\fprq2 @Kaiti TC Regular Cyr;}{\f6904\fbidi \fnil\fcharset161\fprq2 @Kaiti TC Regular Greek;}{\f6905\fbidi \fnil\fcharset162\fprq2 @Kaiti TC Regular Tur;}{\f6913\fbidi \fnil\fcharset0\fprq2 Songti TC Bold Western;}{\f6911\fbidi \fnil\fcharset238\fprq2 Songti TC Bold CE;}{\f6912\fbidi \fnil\fcharset204\fprq2 Songti TC Bold Cyr;}{\f6914\fbidi \fnil\fcharset161\fprq2 Songti TC Bold Greek;}{\f6915\fbidi \fnil\fcharset162\fprq2 Songti TC Bold Tur;}{\f6918\fbidi \fnil\fcharset186\fprq2 Songti TC Bold Baltic;}{\f6923\fbidi \fnil\fcharset0\fprq2 @Songti TC Bold Western;}{\f6921\fbidi \fnil\fcharset238\fprq2 @Songti TC Bold CE;}{\f6922\fbidi \fnil\fcharset204\fprq2 @Songti TC Bold Cyr;}{\f6924\fbidi \fnil\fcharset161\fprq2 @Songti TC Bold Greek;}{\f6925\fbidi \fnil\fcharset162\fprq2 @Songti TC Bold Tur;}{\f6928\fbidi \fnil\fcharset186\fprq2 @Songti TC Bold Baltic;}{\f6933\fbidi \fnil\fcharset0\fprq2 Songti TC Light Western;}{\f6931\fbidi \fnil\fcharset238\fprq2 Songti TC Light CE;}{\f6932\fbidi \fnil\fcharset204\fprq2 Songti TC Light Cyr;}{\f6934\fbidi \fnil\fcharset161\fprq2 Songti TC Light Greek;}{\f6935\fbidi \fnil\fcharset162\fprq2 Songti TC Light Tur;}{\f6943\fbidi \fnil\fcharset0\fprq2 @Songti TC Light Western;}{\f6941\fbidi \fnil\fcharset238\fprq2 @Songti TC Light CE;}{\f6942\fbidi \fnil\fcharset204\fprq2 @Songti TC Light Cyr;}{\f6944\fbidi \fnil\fcharset161\fprq2 @Songti TC Light Greek;}{\f6945\fbidi \fnil\fcharset162\fprq2 @Songti TC Light Tur;}{\f6953\fbidi \fnil\fcharset0\fprq2 Songti TC Regular Western;}{\f6951\fbidi \fnil\fcharset238\fprq2 Songti TC Regular CE;}{\f6952\fbidi \fnil\fcharset204\fprq2 Songti TC Regular Cyr;}{\f6954\fbidi \fnil\fcharset161\fprq2 Songti TC Regular Greek;}{\f6955\fbidi \fnil\fcharset162\fprq2 Songti TC Regular Tur;}{\f6958\fbidi \fnil\fcharset186\fprq2 Songti TC Regular Baltic;}{\f6963\fbidi \fnil\fcharset0\fprq2 @Songti TC Regular Western;}{\f6961\fbidi \fnil\fcharset238\fprq2 @Songti TC Regular CE;}{\f6962\fbidi \fnil\fcharset204\fprq2 @Songti TC Regular Cyr;}{\f6964\fbidi \fnil\fcharset161\fprq2 @Songti TC Regular Greek;}{\f6965\fbidi \fnil\fcharset162\fprq2 @Songti TC Regular Tur;}{\f6968\fbidi \fnil\fcharset186\fprq2 @Songti TC Regular Baltic;}{\f6973\fbidi \fnil\fcharset0\fprq2 Weibei TC Bold Western;}{\f6971\fbidi \fnil\fcharset238\fprq2 Weibei TC Bold CE;}{\f6972\fbidi \fnil\fcharset204\fprq2 Weibei TC Bold Cyr;}{\f6978\fbidi \fnil\fcharset186\fprq2 Weibei TC Bold Baltic;}{\f6979\fbidi \fnil\fcharset163\fprq2 Weibei TC Bold (Vietnamese);}{\f6983\fbidi \fnil\fcharset0\fprq2 @Weibei TC Bold Western;}{\f6981\fbidi \fnil\fcharset238\fprq2 @Weibei TC Bold CE;}{\f6982\fbidi \fnil\fcharset204\fprq2 @Weibei TC Bold Cyr;}{\f6988\fbidi \fnil\fcharset186\fprq2 @Weibei TC Bold Baltic;}{\f6989\fbidi \fnil\fcharset163\fprq2 @Weibei TC Bold (Vietnamese);}{\f6993\fbidi \fnil\fcharset0\fprq2 Yuppy TC Regular Western;}{\f6992\fbidi \fnil\fcharset204\fprq2 Yuppy TC Regular Cyr;}{\f7003\fbidi \fnil\fcharset0\fprq2 @Yuppy TC Regular Western;}{\f7002\fbidi \fnil\fcharset204\fprq2 @Yuppy TC Regular Cyr;}{\f7013\fbidi \fnil\fcharset0\fprq2 \'b2\'d3\'a9\'fa\'c5\'e9 Western;}{\f7023\fbidi \fnil\fcharset0\fprq2 @\'b2\'d3\'a9\'fa\'c5\'e9 Western;}{\f7033\fbidi \fnil\fcharset0\fprq2 \'b2\'d3\'a9\'fa\'c5\'e9_HKSCS Western;}{\f7043\fbidi \fnil\fcharset0\fprq2 @\'b2\'d3\'a9\'fa\'c5\'e9_HKSCS Western;}{\f7053\fbidi \fnil\fcharset0\fprq2 @\'b7\'73\'b2\'d3\'a9\'fa\'c5\'e9 Western;}{\f7103\fbidi \fnil\fcharset0\fprq2 Adobe \'b7\'c2\'cb\'ce Std R Western;}{\f7101\fbidi \fnil\fcharset238\fprq2 Adobe \'b7\'c2\'cb\'ce Std R CE;}{\f7102\fbidi \fnil\fcharset204\fprq2 Adobe \'b7\'c2\'cb\'ce Std R Cyr;}{\f7113\fbidi \fnil\fcharset0\fprq2 @Adobe \'b7\'c2\'cb\'ce Std R Western;}{\f7111\fbidi \fnil\fcharset238\fprq2 @Adobe \'b7\'c2\'cb\'ce Std R CE;}{\f7112\fbidi \fnil\fcharset204\fprq2 @Adobe \'b7\'c2\'cb\'ce Std R Cyr;}{\f7123\fbidi \fnil\fcharset0\fprq2 Adobe \'ba\'da\'cc\'e5 Std R Western;}{\f7121\fbidi \fnil\fcharset238\fprq2 Adobe \'ba\'da\'cc\'e5 Std R CE;}{\f7122\fbidi \fnil\fcharset204\fprq2 Adobe \'ba\'da\'cc\'e5 Std R Cyr;}{\f7133\fbidi \fnil\fcharset0\fprq2 @Adobe \'ba\'da\'cc\'e5 Std R Western;}{\f7131\fbidi \fnil\fcharset238\fprq2 @Adobe \'ba\'da\'cc\'e5 Std R CE;}{\f7132\fbidi \fnil\fcharset204\fprq2 @Adobe \'ba\'da\'cc\'e5 Std R Cyr;}{\f7143\fbidi \fnil\fcharset0\fprq2 Adobe \'bf\'ac\'cc\'e5 Std R Western;}{\f7141\fbidi \fnil\fcharset238\fprq2 Adobe \'bf\'ac\'cc\'e5 Std R CE;}{\f7142\fbidi \fnil\fcharset204\fprq2 Adobe \'bf\'ac\'cc\'e5 Std R Cyr;}{\f7153\fbidi \fnil\fcharset0\fprq2 @Adobe \'bf\'ac\'cc\'e5 Std R Western;}{\f7151\fbidi \fnil\fcharset238\fprq2 @Adobe \'bf\'ac\'cc\'e5 Std R CE;}{\f7152\fbidi \fnil\fcharset204\fprq2 @Adobe \'bf\'ac\'cc\'e5 Std R Cyr;}{\f7163\fbidi \fnil\fcharset0\fprq2 Adobe \'cb\'ce\'cc\'e5 Std L Western;}{\f7161\fbidi \fnil\fcharset238\fprq2 Adobe \'cb\'ce\'cc\'e5 Std L CE;}{\f7162\fbidi \fnil\fcharset204\fprq2 Adobe \'cb\'ce\'cc\'e5 Std L Cyr;}{\f7173\fbidi \fnil\fcharset0\fprq2 @Adobe \'cb\'ce\'cc\'e5 Std L Western;}{\f7171\fbidi \fnil\fcharset238\fprq2 @Adobe \'cb\'ce\'cc\'e5 Std L CE;}{\f7172\fbidi \fnil\fcharset204\fprq2 @Adobe \'cb\'ce\'cc\'e5 Std L Cyr;}{\f7183\fbidi \fnil\fcharset0\fprq2 GB18030 Bitmap Western;}{\f7181\fbidi \fnil\fcharset238\fprq2 GB18030 Bitmap CE;}{\f7182\fbidi \fnil\fcharset204\fprq2 GB18030 Bitmap Cyr;}{\f7184\fbidi \fnil\fcharset161\fprq2 GB18030 Bitmap Greek;}{\f7185\fbidi \fnil\fcharset162\fprq2 GB18030 Bitmap Tur;}{\f7188\fbidi \fnil\fcharset186\fprq2 GB18030 Bitmap Baltic;}{\f7193\fbidi \fnil\fcharset0\fprq2 @GB18030 Bitmap Western;}{\f7191\fbidi \fnil\fcharset238\fprq2 @GB18030 Bitmap CE;}{\f7192\fbidi \fnil\fcharset204\fprq2 @GB18030 Bitmap Cyr;}{\f7194\fbidi \fnil\fcharset161\fprq2 @GB18030 Bitmap Greek;}{\f7195\fbidi \fnil\fcharset162\fprq2 @GB18030 Bitmap Tur;}{\f7198\fbidi \fnil\fcharset186\fprq2 @GB18030 Bitmap Baltic;}{\f7203\fbidi \fnil\fcharset0\fprq2 Hannotate SC Bold Western;}{\f7213\fbidi \fnil\fcharset0\fprq2 @Hannotate SC Bold Western;}{\f7223\fbidi \fnil\fcharset0\fprq2 Hannotate SC Regular Western;}{\f7233\fbidi \fnil\fcharset0\fprq2 @Hannotate SC Regular Western;}{\f7243\fbidi \fnil\fcharset0\fprq2 HanziPen SC Bold Western;}{\f7253\fbidi \fnil\fcharset0\fprq2 @HanziPen SC Bold Western;}{\f7263\fbidi \fnil\fcharset0\fprq2 HanziPen SC Regular Western;}{\f7273\fbidi \fnil\fcharset0\fprq2 @HanziPen SC Regular Western;}{\f7343\fbidi \fnil\fcharset0\fprq2 Hiragino Sans GB W3 Western;}{\f7341\fbidi \fnil\fcharset238\fprq2 Hiragino Sans GB W3 CE;}{\f7342\fbidi \fnil\fcharset204\fprq2 Hiragino Sans GB W3 Cyr;}{\f7353\fbidi \fnil\fcharset0\fprq2 @Hiragino Sans GB W3 Western;}{\f7351\fbidi \fnil\fcharset238\fprq2 @Hiragino Sans GB W3 CE;}{\f7352\fbidi \fnil\fcharset204\fprq2 @Hiragino Sans GB W3 Cyr;}{\f7363\fbidi \fnil\fcharset0\fprq2 Hiragino Sans GB W6 Western;}{\f7361\fbidi \fnil\fcharset238\fprq2 Hiragino Sans GB W6 CE;}{\f7362\fbidi \fnil\fcharset204\fprq2 Hiragino Sans GB W6 Cyr;}{\f7373\fbidi \fnil\fcharset0\fprq2 @Hiragino Sans GB W6 Western;}{\f7371\fbidi \fnil\fcharset238\fprq2 @Hiragino Sans GB W6 CE;}{\f7372\fbidi \fnil\fcharset204\fprq2 @Hiragino Sans GB W6 Cyr;}{\f7403\fbidi \fnil\fcharset0\fprq2 Kaiti SC Bold Western;}{\f7401\fbidi \fnil\fcharset238\fprq2 Kaiti SC Bold CE;}{\f7402\fbidi \fnil\fcharset204\fprq2 Kaiti SC Bold Cyr;}{\f7404\fbidi \fnil\fcharset161\fprq2 Kaiti SC Bold Greek;}{\f7405\fbidi \fnil\fcharset162\fprq2 Kaiti SC Bold Tur;}{\f7413\fbidi \fnil\fcharset0\fprq2 @Kaiti SC Bold Western;}{\f7411\fbidi \fnil\fcharset238\fprq2 @Kaiti SC Bold CE;}{\f7412\fbidi \fnil\fcharset204\fprq2 @Kaiti SC Bold Cyr;}{\f7414\fbidi \fnil\fcharset161\fprq2 @Kaiti SC Bold Greek;}{\f7415\fbidi \fnil\fcharset162\fprq2 @Kaiti SC Bold Tur;}{\f7423\fbidi \fnil\fcharset0\fprq2 Kaiti SC Regular Western;}{\f7421\fbidi \fnil\fcharset238\fprq2 Kaiti SC Regular CE;}{\f7422\fbidi \fnil\fcharset204\fprq2 Kaiti SC Regular Cyr;}{\f7424\fbidi \fnil\fcharset161\fprq2 Kaiti SC Regular Greek;}{\f7425\fbidi \fnil\fcharset162\fprq2 Kaiti SC Regular Tur;}{\f7433\fbidi \fnil\fcharset0\fprq2 @Kaiti SC Regular Western;}{\f7431\fbidi \fnil\fcharset238\fprq2 @Kaiti SC Regular CE;}{\f7432\fbidi \fnil\fcharset204\fprq2 @Kaiti SC Regular Cyr;}{\f7434\fbidi \fnil\fcharset161\fprq2 @Kaiti SC Regular Greek;}{\f7435\fbidi \fnil\fcharset162\fprq2 @Kaiti SC Regular Tur;}{\f7443\fbidi \fnil\fcharset0\fprq2 Songti SC Bold Western;}{\f7441\fbidi \fnil\fcharset238\fprq2 Songti SC Bold CE;}{\f7442\fbidi \fnil\fcharset204\fprq2 Songti SC Bold Cyr;}{\f7444\fbidi \fnil\fcharset161\fprq2 Songti SC Bold Greek;}{\f7445\fbidi \fnil\fcharset162\fprq2 Songti SC Bold Tur;}{\f7448\fbidi \fnil\fcharset186\fprq2 Songti SC Bold Baltic;}{\f7453\fbidi \fnil\fcharset0\fprq2 @Songti SC Bold Western;}{\f7451\fbidi \fnil\fcharset238\fprq2 @Songti SC Bold CE;}{\f7452\fbidi \fnil\fcharset204\fprq2 @Songti SC Bold Cyr;}{\f7454\fbidi \fnil\fcharset161\fprq2 @Songti SC Bold Greek;}{\f7455\fbidi \fnil\fcharset162\fprq2 @Songti SC Bold Tur;}{\f7458\fbidi \fnil\fcharset186\fprq2 @Songti SC Bold Baltic;}{\f7463\fbidi \fnil\fcharset0\fprq2 Songti SC Light Western;}{\f7461\fbidi \fnil\fcharset238\fprq2 Songti SC Light CE;}{\f7462\fbidi \fnil\fcharset204\fprq2 Songti SC Light Cyr;}{\f7464\fbidi \fnil\fcharset161\fprq2 Songti SC Light Greek;}{\f7465\fbidi \fnil\fcharset162\fprq2 Songti SC Light Tur;}{\f7473\fbidi \fnil\fcharset0\fprq2 @Songti SC Light Western;}{\f7471\fbidi \fnil\fcharset238\fprq2 @Songti SC Light CE;}{\f7472\fbidi \fnil\fcharset204\fprq2 @Songti SC Light Cyr;}{\f7474\fbidi \fnil\fcharset161\fprq2 @Songti SC Light Greek;}{\f7475\fbidi \fnil\fcharset162\fprq2 @Songti SC Light Tur;}{\f7483\fbidi \fnil\fcharset0\fprq2 Songti SC Regular Western;}{\f7481\fbidi \fnil\fcharset238\fprq2 Songti SC Regular CE;}{\f7482\fbidi \fnil\fcharset204\fprq2 Songti SC Regular Cyr;}{\f7484\fbidi \fnil\fcharset161\fprq2 Songti SC Regular Greek;}{\f7485\fbidi \fnil\fcharset162\fprq2 Songti SC Regular Tur;}{\f7488\fbidi \fnil\fcharset186\fprq2 Songti SC Regular Baltic;}{\f7493\fbidi \fnil\fcharset0\fprq2 @Songti SC Regular Western;}{\f7491\fbidi \fnil\fcharset238\fprq2 @Songti SC Regular CE;}{\f7492\fbidi \fnil\fcharset204\fprq2 @Songti SC Regular Cyr;}{\f7494\fbidi \fnil\fcharset161\fprq2 @Songti SC Regular Greek;}{\f7495\fbidi \fnil\fcharset162\fprq2 @Songti SC Regular Tur;}{\f7498\fbidi \fnil\fcharset186\fprq2 @Songti SC Regular Baltic;}{\f7503\fbidi \fnil\fcharset0\fprq2 Weibei SC Bold Western;}{\f7501\fbidi \fnil\fcharset238\fprq2 Weibei SC Bold CE;}{\f7502\fbidi \fnil\fcharset204\fprq2 Weibei SC Bold Cyr;}{\f7508\fbidi \fnil\fcharset186\fprq2 Weibei SC Bold Baltic;}{\f7509\fbidi \fnil\fcharset163\fprq2 Weibei SC Bold (Vietnamese);}{\f7513\fbidi \fnil\fcharset0\fprq2 @Weibei SC Bold Western;}{\f7511\fbidi \fnil\fcharset238\fprq2 @Weibei SC Bold CE;}{\f7512\fbidi \fnil\fcharset204\fprq2 @Weibei SC Bold Cyr;}{\f7518\fbidi \fnil\fcharset186\fprq2 @Weibei SC Bold Baltic;}{\f7519\fbidi \fnil\fcharset163\fprq2 @Weibei SC Bold (Vietnamese);}{\f7523\fbidi \fnil\fcharset0\fprq2 Yuanti SC Light Western;}{\f7521\fbidi \fnil\fcharset238\fprq2 Yuanti SC Light CE;}{\f7522\fbidi \fnil\fcharset204\fprq2 Yuanti SC Light Cyr;}{\f7524\fbidi \fnil\fcharset161\fprq2 Yuanti SC Light Greek;}{\f7525\fbidi \fnil\fcharset162\fprq2 Yuanti SC Light Tur;}{\f7528\fbidi \fnil\fcharset186\fprq2 Yuanti SC Light Baltic;}{\f7533\fbidi \fnil\fcharset0\fprq2 @Yuanti SC Light Western;}{\f7531\fbidi \fnil\fcharset238\fprq2 @Yuanti SC Light CE;}{\f7532\fbidi \fnil\fcharset204\fprq2 @Yuanti SC Light Cyr;}{\f7534\fbidi \fnil\fcharset161\fprq2 @Yuanti SC Light Greek;}{\f7535\fbidi \fnil\fcharset162\fprq2 @Yuanti SC Light Tur;}{\f7538\fbidi \fnil\fcharset186\fprq2 @Yuanti SC Light Baltic;}{\f7543\fbidi \fnil\fcharset0\fprq2 Yuppy SC Regular Western;}{\f7541\fbidi \fnil\fcharset238\fprq2 Yuppy SC Regular CE;}{\f7542\fbidi \fnil\fcharset204\fprq2 Yuppy SC Regular Cyr;}{\f7553\fbidi \fnil\fcharset0\fprq2 @Yuppy SC Regular Western;}{\f7551\fbidi \fnil\fcharset238\fprq2 @Yuppy SC Regular CE;}{\f7552\fbidi \fnil\fcharset204\fprq2 @Yuppy SC Regular Cyr;}{\f7563\fbidi \fnil\fcharset0\fprq2 \'ba\'da\'cc\'e5 Western;}{\f7573\fbidi \fnil\fcharset0\fprq2 @\'ba\'da\'cc\'e5 Western;}{\f7583\fbidi \fnil\fcharset0\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Western;}{\f7581\fbidi \fnil\fcharset238\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce CE;}{\f7582\fbidi \fnil\fcharset204\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Cyr;}{\f7584\fbidi \fnil\fcharset161\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Greek;}{\f7585\fbidi \fnil\fcharset162\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Tur;}{\f7588\fbidi \fnil\fcharset186\fprq2 \'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Baltic;}{\f7593\fbidi \fnil\fcharset0\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Western;}{\f7591\fbidi \fnil\fcharset238\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce CE;}{\f7592\fbidi \fnil\fcharset204\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Cyr;}{\f7594\fbidi \fnil\fcharset161\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Greek;}{\f7595\fbidi \fnil\fcharset162\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Tur;}{\f7598\fbidi \fnil\fcharset186\fprq2 @\'bb\'aa\'ce\'c4\'b7\'c2\'cb\'ce Baltic;}{\f7603\fbidi \fnil\fcharset0\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Western;}{\f7601\fbidi \fnil\fcharset238\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 CE;}{\f7602\fbidi \fnil\fcharset204\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Cyr;}{\f7604\fbidi \fnil\fcharset161\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Greek;}{\f7605\fbidi \fnil\fcharset162\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Tur;}{\f7608\fbidi \fnil\fcharset186\fprq2 \'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Baltic;}{\f7613\fbidi \fnil\fcharset0\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Western;}{\f7611\fbidi \fnil\fcharset238\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 CE;}{\f7612\fbidi \fnil\fcharset204\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Cyr;}{\f7614\fbidi \fnil\fcharset161\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Greek;}{\f7615\fbidi \fnil\fcharset162\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Tur;}{\f7618\fbidi \fnil\fcharset186\fprq2 @\'bb\'aa\'ce\'c4\'ba\'da\'cc\'e5 Baltic;}{\f7623\fbidi \fnil\fcharset0\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Western;}{\f7621\fbidi \fnil\fcharset238\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 CE;}{\f7622\fbidi \fnil\fcharset204\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Cyr;}{\f7624\fbidi \fnil\fcharset161\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Greek;}{\f7625\fbidi \fnil\fcharset162\fprq2 \'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Tur;}{\f7633\fbidi \fnil\fcharset0\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Western;}{\f7631\fbidi \fnil\fcharset238\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 CE;}{\f7632\fbidi \fnil\fcharset204\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Cyr;}{\f7634\fbidi \fnil\fcharset161\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Greek;}{\f7635\fbidi \fnil\fcharset162\fprq2 @\'bb\'aa\'ce\'c4\'bf\'ac\'cc\'e5 Tur;}{\f7643\fbidi \fnil\fcharset0\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Western;}{\f7641\fbidi \fnil\fcharset238\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 CE;}{\f7642\fbidi \fnil\fcharset204\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Cyr;}{\f7644\fbidi \fnil\fcharset161\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Greek;}{\f7645\fbidi \fnil\fcharset162\fprq2 \'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Tur;}{\f7653\fbidi \fnil\fcharset0\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Western;}{\f7651\fbidi \fnil\fcharset238\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 CE;}{\f7652\fbidi \fnil\fcharset204\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Cyr;}{\f7654\fbidi \fnil\fcharset161\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Greek;}{\f7655\fbidi \fnil\fcharset162\fprq2 @\'bb\'aa\'ce\'c4\'cb\'ce\'cc\'e5 Tur;}{\f7663\fbidi \fnil\fcharset0\fprq2 \'bb\'aa\'ce\'c4\'cf\'b8\'ba\'da Western;}{\f7673\fbidi \fnil\fcharset0\fprq2 @\'bb\'aa\'ce\'c4\'cf\'b8\'ba\'da Western;}{\f7683\fbidi \fnil\fcharset0\fprq2 @\'cb\'ce\'cc\'e5 Western;}{\f7693\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Western;}{\f7691\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e CE;}{\f7692\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Cyr;}{\f7694\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Greek;}{\f7695\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Tur;}{\f7698\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Baltic;}{\f7703\fbidi \fnil\fcharset0\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Western;}{\f7701\fbidi \fnil\fcharset238\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e CE;}{\f7702\fbidi \fnil\fcharset204\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Cyr;}{\f7704\fbidi \fnil\fcharset161\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Greek;}{\f7705\fbidi \fnil\fcharset162\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Tur;}{\f7708\fbidi \fnil\fcharset186\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'83\'53\'83\'56\'83\'62\'83\'4e Baltic;}{\f7713\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Western;}{\f7711\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 CE;}{\f7712\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Cyr;}{\f7714\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Greek;}{\f7715\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Tur;}{\f7718\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Baltic;}{\f7723\fbidi \fnil\fcharset0\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Western;}{\f7721\fbidi \fnil\fcharset238\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 CE;}{\f7722\fbidi \fnil\fcharset204\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Cyr;}{\f7724\fbidi \fnil\fcharset161\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Greek;}{\f7725\fbidi \fnil\fcharset162\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Tur;}{\f7728\fbidi \fnil\fcharset186\fprq2 @\'82\'6c\'82\'72 \'82\'6f\'96\'be\'92\'a9 Baltic;}{\f7733\fbidi \fnil\fcharset0\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Western;}{\f7731\fbidi \fnil\fcharset238\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e CE;}{\f7732\fbidi \fnil\fcharset204\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Cyr;}{\f7734\fbidi \fnil\fcharset161\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Greek;}{\f7735\fbidi \fnil\fcharset162\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Tur;}{\f7738\fbidi \fnil\fcharset186\fprq2 @\'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Baltic;}{\f7743\fbidi \fnil\fcharset0\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 Western;}{\f7741\fbidi \fnil\fcharset238\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 CE;}{\f7742\fbidi \fnil\fcharset204\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 Cyr;}{\f7744\fbidi \fnil\fcharset161\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 Greek;}{\f7745\fbidi \fnil\fcharset162\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 Tur;}{\f7748\fbidi \fnil\fcharset186\fprq2 @\'82\'6c\'82\'72 \'96\'be\'92\'a9 Baltic;}{\f7753\fbidi \fnil\fcharset0\fprq2 Osaka Western;}{\f7751\fbidi \fnil\fcharset238\fprq2 Osaka CE;}{\f7755\fbidi \fnil\fcharset162\fprq2 Osaka Tur;}{\f7758\fbidi \fnil\fcharset186\fprq2 Osaka Baltic;}{\f7763\fbidi \fnil\fcharset0\fprq2 @Osaka Western;}{\f7761\fbidi \fnil\fcharset238\fprq2 @Osaka CE;}{\f7765\fbidi \fnil\fcharset162\fprq2 @Osaka Tur;}{\f7768\fbidi \fnil\fcharset186\fprq2 @Osaka Baltic;}{\f7773\fbidi \fnil\fcharset0\fprq2 Osaka\'81\'7c\'93\'99\'95\'9d Western;}{\f7771\fbidi \fnil\fcharset238\fprq2 Osaka\'81\'7c\'93\'99\'95\'9d CE;}{\f7775\fbidi \fnil\fcharset162\fprq2 Osaka\'81\'7c\'93\'99\'95\'9d Tur;}{\f7778\fbidi \fnil\fcharset186\fprq2 Osaka\'81\'7c\'93\'99\'95\'9d Baltic;}{\f7783\fbidi \fnil\fcharset0\fprq2 @Osaka\'81\'7c\'93\'99\'95\'9d Western;}{\f7781\fbidi \fnil\fcharset238\fprq2 @Osaka\'81\'7c\'93\'99\'95\'9d CE;}{\f7785\fbidi \fnil\fcharset162\fprq2 @Osaka\'81\'7c\'93\'99\'95\'9d Tur;}{\f7788\fbidi \fnil\fcharset186\fprq2 @Osaka\'81\'7c\'93\'99\'95\'9d Baltic;}{\f7793\fbidi \fnil\fcharset0\fprq2 YuGothic Bold Western;}{\f7791\fbidi \fnil\fcharset238\fprq2 YuGothic Bold CE;}{\f7792\fbidi \fnil\fcharset204\fprq2 YuGothic Bold Cyr;}{\f7794\fbidi \fnil\fcharset161\fprq2 YuGothic Bold Greek;}{\f7795\fbidi \fnil\fcharset162\fprq2 YuGothic Bold Tur;}{\f7798\fbidi \fnil\fcharset186\fprq2 YuGothic Bold Baltic;}{\f7803\fbidi \fnil\fcharset0\fprq2 @YuGothic Bold Western;}{\f7801\fbidi \fnil\fcharset238\fprq2 @YuGothic Bold CE;}{\f7802\fbidi \fnil\fcharset204\fprq2 @YuGothic Bold Cyr;}{\f7804\fbidi \fnil\fcharset161\fprq2 @YuGothic Bold Greek;}{\f7805\fbidi \fnil\fcharset162\fprq2 @YuGothic Bold Tur;}{\f7808\fbidi \fnil\fcharset186\fprq2 @YuGothic Bold Baltic;}{\f7813\fbidi \fnil\fcharset0\fprq2 YuGothic Medium Western;}{\f7811\fbidi \fnil\fcharset238\fprq2 YuGothic Medium CE;}{\f7812\fbidi \fnil\fcharset204\fprq2 YuGothic Medium Cyr;}{\f7814\fbidi \fnil\fcharset161\fprq2 YuGothic Medium Greek;}{\f7815\fbidi \fnil\fcharset162\fprq2 YuGothic Medium Tur;}{\f7818\fbidi \fnil\fcharset186\fprq2 YuGothic Medium Baltic;}{\f7823\fbidi \fnil\fcharset0\fprq2 @YuGothic Medium Western;}{\f7821\fbidi \fnil\fcharset238\fprq2 @YuGothic Medium CE;}{\f7822\fbidi \fnil\fcharset204\fprq2 @YuGothic Medium Cyr;}{\f7824\fbidi \fnil\fcharset161\fprq2 @YuGothic Medium Greek;}{\f7825\fbidi \fnil\fcharset162\fprq2 @YuGothic Medium Tur;}{\f7828\fbidi \fnil\fcharset186\fprq2 @YuGothic Medium Baltic;}{\f7833\fbidi \fnil\fcharset0\fprq2 YuMincho Demibold Western;}{\f7831\fbidi \fnil\fcharset238\fprq2 YuMincho Demibold CE;}{\f7832\fbidi \fnil\fcharset204\fprq2 YuMincho Demibold Cyr;}{\f7834\fbidi \fnil\fcharset161\fprq2 YuMincho Demibold Greek;}{\f7835\fbidi \fnil\fcharset162\fprq2 YuMincho Demibold Tur;}{\f7838\fbidi \fnil\fcharset186\fprq2 YuMincho Demibold Baltic;}{\f7843\fbidi \fnil\fcharset0\fprq2 @YuMincho Demibold Western;}{\f7841\fbidi \fnil\fcharset238\fprq2 @YuMincho Demibold CE;}{\f7842\fbidi \fnil\fcharset204\fprq2 @YuMincho Demibold Cyr;}{\f7844\fbidi \fnil\fcharset161\fprq2 @YuMincho Demibold Greek;}{\f7845\fbidi \fnil\fcharset162\fprq2 @YuMincho Demibold Tur;}{\f7848\fbidi \fnil\fcharset186\fprq2 @YuMincho Demibold Baltic;}{\f7853\fbidi \fnil\fcharset0\fprq2 YuMincho Medium Western;}{\f7851\fbidi \fnil\fcharset238\fprq2 YuMincho Medium CE;}{\f7852\fbidi \fnil\fcharset204\fprq2 YuMincho Medium Cyr;}{\f7854\fbidi \fnil\fcharset161\fprq2 YuMincho Medium Greek;}{\f7855\fbidi \fnil\fcharset162\fprq2 YuMincho Medium Tur;}{\f7858\fbidi \fnil\fcharset186\fprq2 YuMincho Medium Baltic;}{\f7863\fbidi \fnil\fcharset0\fprq2 @YuMincho Medium Western;}{\f7861\fbidi \fnil\fcharset238\fprq2 @YuMincho Medium CE;}{\f7862\fbidi \fnil\fcharset204\fprq2 @YuMincho Medium Cyr;}{\f7864\fbidi \fnil\fcharset161\fprq2 @YuMincho Medium Greek;}{\f7865\fbidi \fnil\fcharset162\fprq2 @YuMincho Medium Tur;}{\f7868\fbidi \fnil\fcharset186\fprq2 @YuMincho Medium Baltic;}{\f7873\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Western;}{\f7872\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Cyr;}{\f7874\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Greek;}{\f7883\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Western;}{\f7882\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Cyr;}{\f7884\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W3 Greek;}{\f7893\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Western;}{\f7892\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Cyr;}{\f7894\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Greek;}{\f7903\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Western;}{\f7902\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Cyr;}{\f7904\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Pro W6 Greek;}{\f7913\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Western;}{\f7912\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Cyr;}{\f7914\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Greek;}{\f7923\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Western;}{\f7922\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Cyr;}{\f7924\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W3 Greek;}{\f7933\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Western;}{\f7932\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Cyr;}{\f7934\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Greek;}{\f7943\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Western;}{\f7942\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Cyr;}{\f7944\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 ProN W6 Greek;}{\f7953\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Western;}{\f7952\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Cyr;}{\f7954\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Greek;}{\f7963\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Western;}{\f7962\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Cyr;}{\f7964\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 Std W8 Greek;}{\f7973\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Western;}{\f7972\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Cyr;}{\f7974\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Greek;}{\f7983\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Western;}{\f7982\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Cyr;}{\f7984\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'70\'83\'53 StdN W8 Greek;}{\f7993\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Western;}{\f7992\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Cyr;}{\f7994\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Greek;}{\f8003\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Western;}{\f8002\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Cyr;}{\f8004\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 Pro W4 Greek;}{\f8013\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Western;}{\f8012\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Cyr;}{\f8014\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Greek;}{\f8023\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Western;}{\f8022\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Cyr;}{\f8024\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'8a\'db\'83\'53 ProN W4 Greek;}{\f8033\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Western;}{\f8032\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Cyr;}{\f8034\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Greek;}{\f8043\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Western;}{\f8042\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Cyr;}{\f8044\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W3 Greek;}{\f8053\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Western;}{\f8052\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Cyr;}{\f8054\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Greek;}{\f8063\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Western;}{\f8062\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Cyr;}{\f8064\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 Pro W6 Greek;}{\f8073\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Western;}{\f8072\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Cyr;}{\f8074\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Greek;}{\f8083\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Western;}{\f8082\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Cyr;}{\f8084\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W3 Greek;}{\f8093\fbidi \fnil\fcharset0\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Western;}{\f8092\fbidi \fnil\fcharset204\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Cyr;}{\f8094\fbidi \fnil\fcharset161\fprq2 \'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Greek;}{\f8103\fbidi \fnil\fcharset0\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Western;}{\f8102\fbidi \fnil\fcharset204\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Cyr;}{\f8104\fbidi \fnil\fcharset161\fprq2 @\'83\'71\'83\'89\'83\'4d\'83\'6d\'96\'be\'92\'a9 ProN W6 Greek;}{\f8113\fbidi \fnil\fcharset0\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 Western;}{\f8111\fbidi \fnil\fcharset238\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 CE;}{\f8112\fbidi \fnil\fcharset204\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 Cyr;}{\f8114\fbidi \fnil\fcharset161\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 Greek;}{\f8115\fbidi \fnil\fcharset162\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 Tur;}{\f8118\fbidi \fnil\fcharset186\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 Baltic;}{\f8123\fbidi \fnil\fcharset0\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 Western;}{\f8121\fbidi \fnil\fcharset238\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 CE;}{\f8122\fbidi \fnil\fcharset204\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 Cyr;}{\f8124\fbidi \fnil\fcharset161\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 Greek;}{\f8125\fbidi \fnil\fcharset162\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 Tur;}{\f8128\fbidi \fnil\fcharset186\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 Baltic;}{\f8133\fbidi \fnil\fcharset0\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Western;}{\f8131\fbidi \fnil\fcharset238\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e CE;}{\f8132\fbidi \fnil\fcharset204\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Cyr;}{\f8134\fbidi \fnil\fcharset161\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Greek;}{\f8135\fbidi \fnil\fcharset162\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Tur;}{\f8138\fbidi \fnil\fcharset186\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Baltic;}{\f8143\fbidi \fnil\fcharset0\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Western;}{\f8141\fbidi \fnil\fcharset238\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e CE;}{\f8142\fbidi \fnil\fcharset204\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Cyr;}{\f8144\fbidi \fnil\fcharset161\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Greek;}{\f8145\fbidi \fnil\fcharset162\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Tur;}{\f8148\fbidi \fnil\fcharset186\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Baltic;}{\f8153\fbidi \fnil\fcharset0\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Western;}{\f8151\fbidi \fnil\fcharset238\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 CE;}{\f8152\fbidi \fnil\fcharset204\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Cyr;}{\f8154\fbidi \fnil\fcharset161\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Greek;}{\f8155\fbidi \fnil\fcharset162\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Tur;}{\f8158\fbidi \fnil\fcharset186\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Baltic;}{\f8163\fbidi \fnil\fcharset0\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Western;}{\f8161\fbidi \fnil\fcharset238\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 CE;}{\f8162\fbidi \fnil\fcharset204\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Cyr;}{\f8164\fbidi \fnil\fcharset161\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Greek;}{\f8165\fbidi \fnil\fcharset162\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Tur;}{\f8168\fbidi \fnil\fcharset186\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 Baltic;}{\f8173\fbidi \fnil\fcharset0\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Western;}{\f8171\fbidi \fnil\fcharset238\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e CE;}{\f8172\fbidi \fnil\fcharset204\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Cyr;}{\f8174\fbidi \fnil\fcharset161\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Greek;}{\f8175\fbidi \fnil\fcharset162\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Tur;}{\f8178\fbidi \fnil\fcharset186\fprq2 \'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Baltic;}{\f8183\fbidi \fnil\fcharset0\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Western;}{\f8181\fbidi \fnil\fcharset238\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e CE;}{\f8182\fbidi \fnil\fcharset204\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Cyr;}{\f8184\fbidi \fnil\fcharset161\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Greek;}{\f8185\fbidi \fnil\fcharset162\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Tur;}{\f8188\fbidi \fnil\fcharset186\fprq2 @\'83\'81\'83\'43\'83\'8a\'83\'49 \'83\'7b\'81\'5b\'83\'8b\'83\'68 \'83\'43\'83\'5e\'83\'8a\'83\'62\'83\'4e Baltic;}{\f8193\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Western;}{\f8191\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B CE;}{\f8192\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Cyr;}{\f8194\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Greek;}{\f8195\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Tur;}{\f8198\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Baltic;}{\f8203\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Western;}{\f8201\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B CE;}{\f8202\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Cyr;}{\f8204\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Greek;}{\f8205\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Tur;}{\f8208\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N B Baltic;}{\f8213\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Western;}{\f8211\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL CE;}{\f8212\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Cyr;}{\f8214\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Greek;}{\f8215\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Tur;}{\f8218\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Baltic;}{\f8223\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Western;}{\f8221\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL CE;}{\f8222\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Cyr;}{\f8224\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Greek;}{\f8225\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Tur;}{\f8228\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N EL Baltic;}{\f8233\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Western;}{\f8231\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H CE;}{\f8232\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Cyr;}{\f8234\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Greek;}{\f8235\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Tur;}{\f8238\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Baltic;}{\f8243\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Western;}{\f8241\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H CE;}{\f8242\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Cyr;}{\f8244\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Greek;}{\f8245\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Tur;}{\f8248\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N H Baltic;}{\f8253\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Western;}{\f8251\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L CE;}{\f8252\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Cyr;}{\f8254\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Greek;}{\f8255\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Tur;}{\f8258\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Baltic;}{\f8263\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Western;}{\f8261\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L CE;}{\f8262\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Cyr;}{\f8264\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Greek;}{\f8265\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Tur;}{\f8268\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N L Baltic;}{\f8273\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Western;}{\f8271\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M CE;}{\f8272\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Cyr;}{\f8274\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Greek;}{\f8275\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Tur;}{\f8278\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Baltic;}{\f8283\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Western;}{\f8281\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M CE;}{\f8282\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Cyr;}{\f8284\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Greek;}{\f8285\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Tur;}{\f8288\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N M Baltic;}{\f8293\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Western;}{\f8291\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R CE;}{\f8292\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Cyr;}{\f8294\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Greek;}{\f8295\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Tur;}{\f8298\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Baltic;}{\f8303\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Western;}{\f8301\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R CE;}{\f8302\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Cyr;}{\f8304\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Greek;}{\f8305\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Tur;}{\f8308\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pr6N R Baltic;}{\f8313\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B Western;}{\f8312\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B Cyr;}{\f8323\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B Western;}{\f8322\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro B Cyr;}{\f8333\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL Western;}{\f8332\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL Cyr;}{\f8343\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL Western;}{\f8342\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro EL Cyr;}{\f8353\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H Western;}{\f8352\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H Cyr;}{\f8363\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H Western;}{\f8362\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro H Cyr;}{\f8373\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L Western;}{\f8372\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L Cyr;}{\f8383\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L Western;}{\f8382\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro L Cyr;}{\f8393\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M Western;}{\f8392\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M Cyr;}{\f8403\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M Western;}{\f8402\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro M Cyr;}{\f8413\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R Western;}{\f8412\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R Cyr;}{\f8423\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R Western;}{\f8422\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'83\'53\'83\'56\'83\'62\'83\'4e Pro R Cyr;}{\f8433\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Western;}{\f8431\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B CE;}{\f8432\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Cyr;}{\f8434\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Greek;}{\f8435\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Tur;}{\f8438\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Baltic;}{\f8443\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Western;}{\f8441\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B CE;}{\f8442\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Cyr;}{\f8444\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Greek;}{\f8445\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Tur;}{\f8448\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N B Baltic;}{\f8453\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Western;}{\f8451\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL CE;}{\f8452\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Cyr;}{\f8454\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Greek;}{\f8455\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Tur;}{\f8458\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Baltic;}{\f8463\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Western;}{\f8461\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL CE;}{\f8462\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Cyr;}{\f8464\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Greek;}{\f8465\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Tur;}{\f8468\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N EL Baltic;}{\f8473\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Western;}{\f8471\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H CE;}{\f8472\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Cyr;}{\f8474\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Greek;}{\f8475\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Tur;}{\f8478\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Baltic;}{\f8483\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Western;}{\f8481\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H CE;}{\f8482\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Cyr;}{\f8484\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Greek;}{\f8485\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Tur;}{\f8488\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N H Baltic;}{\f8493\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Western;}{\f8491\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L CE;}{\f8492\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Cyr;}{\f8494\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Greek;}{\f8495\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Tur;}{\f8498\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Baltic;}{\f8503\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Western;}{\f8501\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L CE;}{\f8502\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Cyr;}{\f8504\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Greek;}{\f8505\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Tur;}{\f8508\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N L Baltic;}{\f8511\fbidi \fnil\fcharset238\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M CE;}{\f8512\fbidi \fnil\fcharset204\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M Cyr;}{\f8514\fbidi \fnil\fcharset161\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M Greek;}{\f8515\fbidi \fnil\fcharset162\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M Tur;}{\f8518\fbidi \fnil\fcharset186\fprq2 \'e8\'a8\'ed\'c0\'f1\'e6\'ed\'a9 Pr6N M Baltic;}{\f8523\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Western;}{\f8521\fbidi \fnil\fcharset238\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R CE;}{\f8522\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Cyr;}{\f8524\fbidi \fnil\fcharset161\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Greek;}{\f8525\fbidi \fnil\fcharset162\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Tur;}{\f8528\fbidi \fnil\fcharset186\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Baltic;}{\f8533\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Western;}{\f8531\fbidi \fnil\fcharset238\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R CE;}{\f8532\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Cyr;}{\f8534\fbidi \fnil\fcharset161\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Greek;}{\f8535\fbidi \fnil\fcharset162\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Tur;}{\f8538\fbidi \fnil\fcharset186\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pr6N R Baltic;}{\f8543\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B Western;}{\f8542\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B Cyr;}{\f8553\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B Western;}{\f8552\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro B Cyr;}{\f8563\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL Western;}{\f8562\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL Cyr;}{\f8573\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL Western;}{\f8572\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro EL Cyr;}{\f8583\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H Western;}{\f8582\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H Cyr;}{\f8593\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H Western;}{\f8592\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro H Cyr;}{\f8603\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L Western;}{\f8602\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L Cyr;}{\f8613\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L Western;}{\f8612\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro L Cyr;}{\f8623\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M Western;}{\f8622\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M Cyr;}{\f8633\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M Western;}{\f8632\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro M Cyr;}{\f8643\fbidi \fnil\fcharset0\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R Western;}{\f8642\fbidi \fnil\fcharset204\fprq2 \'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R Cyr;}{\f8653\fbidi \fnil\fcharset0\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R Western;}{\f8652\fbidi \fnil\fcharset204\fprq2 @\'8f\'ac\'92\'cb\'96\'be\'92\'a9 Pro R Cyr;}{\f8663\fbidi \fnil\fcharset0\fprq2 Adobe \'b0\'ed\'b5\'f1 Std B Western;}{\f8662\fbidi \fnil\fcharset204\fprq2 Adobe \'b0\'ed\'b5\'f1 Std B Cyr;}{\f8673\fbidi \fnil\fcharset0\fprq2 @Adobe \'b0\'ed\'b5\'f1 Std B Western;}{\f8672\fbidi \fnil\fcharset204\fprq2 @Adobe \'b0\'ed\'b5\'f1 Std B Cyr;}{\f8683\fbidi \fnil\fcharset0\fprq2 Adobe \'b8\'ed\'c1\'b6 Std M Western;}{\f8682\fbidi \fnil\fcharset204\fprq2 Adobe \'b8\'ed\'c1\'b6 Std M Cyr;}{\f8693\fbidi \fnil\fcharset0\fprq2 @Adobe \'b8\'ed\'c1\'b6 Std M Western;}{\f8692\fbidi \fnil\fcharset204\fprq2 @Adobe \'b8\'ed\'c1\'b6 Std M Cyr;}{\f8703\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee Western;}{\f8702\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee Cyr;}{\f8713\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee Western;}{\f8712\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'b9\'ab\'b0\'c5\'bf\'ee Cyr;}{\f8723\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc Western;}{\f8722\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc Cyr;}{\f8733\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc Western;}{\f8732\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'ba\'bc\'b5\'e5\'c3\'bc Cyr;}{\f8743\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc Western;}{\f8742\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc Cyr;}{\f8753\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc Western;}{\f8752\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'be\'e3\'c0\'ba\'c3\'bc Cyr;}{\f8763\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc Western;}{\f8762\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc Cyr;}{\f8773\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc Western;}{\f8772\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'bf\'b6\'c0\'ba\'c3\'bc Cyr;}{\f8783\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc Western;}{\f8782\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc Cyr;}{\f8793\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc Western;}{\f8792\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c0\'cf\'b9\'dd\'c3\'bc Cyr;}{\f8803\fbidi \fnil\fcharset0\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc Western;}{\f8802\fbidi \fnil\fcharset204\fprq2 Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc Cyr;}{\f8813\fbidi \fnil\fcharset0\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc Western;}{\f8812\fbidi \fnil\fcharset204\fprq2 @Apple SD \'bb\'ea\'b5\'b9\'b0\'ed\'b5\'f1 Neo \'c1\'df\'b0\'a3\'c3\'bc Cyr;}{\f8883\fbidi \fnil\fcharset0\fprq2 \'b1\'bc\'b8\'b2 Western;}{\f8881\fbidi \fnil\fcharset238\fprq2 \'b1\'bc\'b8\'b2 CE;}{\f8882\fbidi \fnil\fcharset204\fprq2 \'b1\'bc\'b8\'b2 Cyr;}{\f8884\fbidi \fnil\fcharset161\fprq2 \'b1\'bc\'b8\'b2 Greek;}{\f8885\fbidi \fnil\fcharset162\fprq2 \'b1\'bc\'b8\'b2 Tur;}{\f8888\fbidi \fnil\fcharset186\fprq2 \'b1\'bc\'b8\'b2 Baltic;}{\f8893\fbidi \fnil\fcharset0\fprq2 @\'b1\'bc\'b8\'b2 Western;}{\f8891\fbidi \fnil\fcharset238\fprq2 @\'b1\'bc\'b8\'b2 CE;}{\f8892\fbidi \fnil\fcharset204\fprq2 @\'b1\'bc\'b8\'b2 Cyr;}{\f8894\fbidi \fnil\fcharset161\fprq2 @\'b1\'bc\'b8\'b2 Greek;}{\f8895\fbidi \fnil\fcharset162\fprq2 @\'b1\'bc\'b8\'b2 Tur;}{\f8898\fbidi \fnil\fcharset186\fprq2 @\'b1\'bc\'b8\'b2 Baltic;}{\f8923\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Western;}{\f8933\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Western;}{\f8943\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Bold Western;}{\f8953\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 Bold Western;}{\f8963\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 ExtraBold Western;}{\f8973\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b0\'ed\'b5\'f1 ExtraBold Western;}{\f8983\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Western;}{\f8993\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Western;}{\f9003\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Bold Western;}{\f9013\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 Bold Western;}{\f9023\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 ExtraBold Western;}{\f9033\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'b8\'ed\'c1\'b6 ExtraBold Western;}{\f9043\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'ba\'d7 Western;}{\f9053\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'ba\'d7 Western;}{\f9063\fbidi \fnil\fcharset0\fprq2 \'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'c6\'e6 Western;}{\f9073\fbidi \fnil\fcharset0\fprq2 @\'b3\'aa\'b4\'ae\'bc\'d5\'b1\'db\'be\'be \'c6\'e6 Western;}{\f9083\fbidi \fnil\fcharset0\fprq2 @\'b9\'d9\'c5\'c1 Western;}{\f9081\fbidi \fnil\fcharset238\fprq2 @\'b9\'d9\'c5\'c1 CE;}{\f9082\fbidi \fnil\fcharset204\fprq2 @\'b9\'d9\'c5\'c1 Cyr;}{\f9084\fbidi \fnil\fcharset161\fprq2 @\'b9\'d9\'c5\'c1 Greek;}{\f9085\fbidi \fnil\fcharset162\fprq2 @\'b9\'d9\'c5\'c1 Tur;}{\f9088\fbidi \fnil\fcharset186\fprq2 @\'b9\'d9\'c5\'c1 Baltic;}{\flomajor\f31508\fbidi \fnil\fcharset238\fprq2 Arial CE;}{\flomajor\f31509\fbidi \fnil\fcharset204\fprq2 Arial Cyr;}{\flomajor\f31511\fbidi \fnil\fcharset161\fprq2 Arial Greek;}{\flomajor\f31512\fbidi \fnil\fcharset162\fprq2 Arial Tur;}{\flomajor\f31513\fbidi \fnil\fcharset177\fprq2 Arial (Hebrew);}{\flomajor\f31514\fbidi \fnil\fcharset178\fprq2 Arial (Arabid);}{\flomajor\f31515\fbidi \fnil\fcharset186\fprq2 Arial Baltic;}{\flomajor\f31516\fbidi \fnil\fcharset163\fprq2 Arial (Vietnamese);}{\fdbmajor\f31520\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Western;}{\fdbmajor\f31518\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e CE;}{\fdbmajor\f31519\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Cyr;}{\fdbmajor\f31521\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Greek;}{\fdbmajor\f31522\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Tur;}{\fdbmajor\f31525\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'83\'53\'83\'56\'83\'62\'83\'4e Baltic;}{\fhimajor\f31528\fbidi \fnil\fcharset238\fprq2 Calibri CE;}{\fhimajor\f31529\fbidi \fnil\fcharset204\fprq2 Calibri Cyr;}{\fhimajor\f31531\fbidi \fnil\fcharset161\fprq2 Calibri Greek;}{\fhimajor\f31532\fbidi \fnil\fcharset162\fprq2 Calibri Tur;}{\fhimajor\f31535\fbidi \fnil\fcharset186\fprq2 Calibri Baltic;}{\fhimajor\f31536\fbidi \fnil\fcharset163\fprq2 Calibri (Vietnamese);}{\fbimajor\f31538\fbidi \fnil\fcharset238\fprq2 Times New Roman CE;}{\fbimajor\f31539\fbidi \fnil\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \fnil\fcharset161\fprq2 Times New Roman Greek;}{\fbimajor\f31542\fbidi \fnil\fcharset162\fprq2 Times New Roman Tur;}{\fbimajor\f31543\fbidi \fnil\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \fnil\fcharset178\fprq2 Times New Roman (Arabid);}{\fbimajor\f31545\fbidi \fnil\fcharset186\fprq2 Times New Roman Baltic;}{\fbimajor\f31546\fbidi \fnil\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \fnil\fcharset238\fprq2 Times New Roman CE;}{\flominor\f31549\fbidi \fnil\fcharset204\fprq2 Times New Roman Cyr;}{\flominor\f31551\fbidi \fnil\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \fnil\fcharset162\fprq2 Times New Roman Tur;}{\flominor\f31553\fbidi \fnil\fcharset177\fprq2 Times New Roman (Hebrew);}{\flominor\f31554\fbidi \fnil\fcharset178\fprq2 Times New Roman (Arabid);}{\flominor\f31555\fbidi \fnil\fcharset186\fprq2 Times New Roman Baltic;}{\flominor\f31556\fbidi \fnil\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbminor\f31560\fbidi \fnil\fcharset0\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Western;}{\fdbminor\f31558\fbidi \fnil\fcharset238\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 CE;}{\fdbminor\f31559\fbidi \fnil\fcharset204\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Cyr;}{\fdbminor\f31561\fbidi \fnil\fcharset161\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Greek;}{\fdbminor\f31562\fbidi \fnil\fcharset162\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Tur;}{\fdbminor\f31565\fbidi \fnil\fcharset186\fprq2 \'82\'6c\'82\'72 \'96\'be\'92\'a9 Baltic;}{\fhiminor\f31568\fbidi \fnil\fcharset238\fprq2 Cambria CE;}{\fhiminor\f31569\fbidi \fnil\fcharset204\fprq2 Cambria Cyr;}{\fhiminor\f31571\fbidi \fnil\fcharset161\fprq2 Cambria Greek;}{\fhiminor\f31572\fbidi \fnil\fcharset162\fprq2 Cambria Tur;}{\fhiminor\f31575\fbidi \fnil\fcharset186\fprq2 Cambria Baltic;}{\fhiminor\f31576\fbidi \fnil\fcharset163\fprq2 Cambria (Vietnamese);}{\fbiminor\f31578\fbidi \fnil\fcharset238\fprq2 Times New Roman CE;}{\fbiminor\f31579\fbidi \fnil\fcharset204\fprq2 Times New Roman Cyr;}{\fbiminor\f31581\fbidi \fnil\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \fnil\fcharset162\fprq2 Times New Roman Tur;}{\fbiminor\f31583\fbidi \fnil\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbiminor\f31584\fbidi \fnil\fcharset178\fprq2 Times New Roman (Arabid);}{\fbiminor\f31585\fbidi \fnil\fcharset186\fprq2 Times New Roman Baltic;}{\fbiminor\f31586\fbidi \fnil\fcharset163\fprq2 Times New Roman (Vietnamese);}}{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red235\green235\blue216;\red204\green0\blue51;}{\*\defchp }{\*\defpap \ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \sunhideused \spriority1 Default Paragraph Font;}{\*\ts11\tsrowd\trftsWidthB3\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv \ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \sunhideused Normal Table;}}{\*\revtbl {Unknown;}}{\*\rsidtbl \rsid2900964\rsid9710937}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapIndent1440\mintLim0\mnaryLim1}{\info{\operator Duco Wiertsema}{\creatim\yr2013\mo11\dy26\hr20\min44}{\revtim\yr2013\mo11\dy26\hr20\min44}{\version2}{\edmins1}{\nofpages409}{\nofwords164885}{\nofchars939846}{\nofcharsws1102526}{\vern49555}{\*\saveprevpict}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}\paperw12240\paperh15840\margl1296\margr1296\margt1728\margb1296\gutter0\ltrsect \ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml0\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors0\hyphauto1\horzdoc\dghspace120\dgvspace120\dghorigin1701\dgvorigin1984\dghshow0\dgvshow3\jcompress\viewkind1\viewscale140\rsidroot9710937\outdisponlyhtml \fet0{\*\wgrffmtfilter 2450}\ilfomacatclnup0{\*\ftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2900964 \chftnsep \par }}{\*\ftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2900964 \chftnsepc \par }}{\*\aftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2900964 \chftnsep \par }}{\*\aftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\nowidctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2900964 \chftnsepc \par }}\ltrpar \sectd \ltrsect\linex0\sectdefaultcl\sftnbj {\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 {\*\shppict{\pict{\*\picprop\shplid1025{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLine}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw2787\pich847\picwgoal1580\pichgoal480\pngblip\bliptag833577996 89504e470d0a1a0a0000000d494844520000004f0000001808030000008c6150fb00000300504c5445ffffff231f205a5758c8c7c7918f8f312d2ef1f1f14c494ad6d5d5767374acabab3f3b3ce3e3e3848182bab9b96865669e9d9d0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000009b312fed0000000174524e530040e6d8660000023c4944415478daad54898edd200cb4b921e7ff7f65aba6ab94cdb1c6405ef2b24fea766b450a8719b0676c400b679328e02f4c6a0c9fef20fa7fc053f8c28f56e7005f3603605fbd0fd17df97d1046f3028e5f1f0fbc0d37f886d16b022c08ffcb086f5510fd3720a47b0a38500ac75bfe7a2f84f03d0fc9a192e610bbe4862ae7d1260244da3583108e13d8d192bce2b98684a4ba066dba9d1c749b89b5ec50f13c364186265d015e0d83cd8488c3bfe0399d81e8b84e44daaa378fd63cf064de357c5848e17df652c4c9fb4900665d00671ac45d2d0bfdb5823d018cf3490b002dac6916e594ee34ed9f2de3c5c4897cf86d0bb839ef10105d3e1161ab03f713fc7c4afe2fd0fce7b515d0628e170e4e72bc94bcbe1c190b5794c2a66d0a0b355e81b7322e789513c633343607e1a5c029851a07b8e00d89dbfe5aff65100947862876dc01d287d9f40aebce4cecdb66ded722db1d04d511a669d48d89273dd796f1c449b1778a930713f1bd3dedcf2cbc65fadddde2658de0c0f15234f70a4cdb87d80f3d831b450a43ddf19813918eb4a7fc1d12b248ea7ee2a3a886526b3fc1634ef809fac16fb58136dc5147173cd2f303e512992878fed67e3bae046acb5c104f7874cedef8289ce4eb49c5e10834a56202491c52635bceada82d13ffc0b9669e922e6a2a4b0369909773036a752d5cfe75dc0848f3a5fa6f7804946f0a74500fca37a8fb949f2ae4beca9ef18888a653d4338e2aa1e5e50a086ff925b8a501ba2542ff06a22a769ca0fd01ed0c7bd272bfc70861e37ec0f6019a0662fb16f1f5ff0000000049454e44ae426082}}{\nonshppict{\pict\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw79\pich24\picwgoal1580\pichgoal480\macpict\bliptag833577996 00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000018004f001102ff0c00fffe00000048000000480000000000000018004f00000000001e0001000a000000000018004f820000001e3a00000001000000000000000000000000000000010000000000000000000000000000400000000000000000000000000000000000000000000018004f000003000000000000000056726177200000000000000000000000006170706c0000040000000400004f0018004800000048000000001da0000100000000000000000000000000000000000000000000000000000000000000000020ffffff231f20ff4c494a00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff312d2eff231f20ffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff918f8fff231f20ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ff231f20ffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffacababff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ff231f20ff231f20ffd6d5d500ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffacababff9e9d9dfff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ff231f20ff231f20ff312d2efff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ff3f3b3cff231f20ff231f20ff4c494a00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f20ffd6d5d5ff312d2eff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ffd6d5d500ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffffffacababff231f20ff231f20ff231f20ff9e9d9d00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffbab9b9ff767374ff5a5758ff5a5758ff5a5758ff767374ffbab9b900ffffff00ffffff00ffffff00ffffffffbab9b9ff231f20ff231f20ff231f20ffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff231f20ff231f20ff84818200ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffffffacababff4c494aff231f20ff231f20ff231f20ff231f20ff5a5758ffacabab00ffffff00ffffff00fffffffff1f1f1ff686566ff5a5758ff5a5758ffd6d5d5ff231f20ff231f2000ffffff00ffffffff848182ff231f20ff231f20ff231f20ffc8c7c700ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff3f3b3cff231f20ff231f20ff767374ff918f8fff848182ff3f3b3cff231f20ff4c494affd6d5d500ffffff00ffffff00ffffffff848182ff231f20ff231f20ff312d2effe3e3e300ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff4c494aff231f20ff5a575800ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffffff767374ff231f20ff3f3b3cffacababffc8c7c7ffacababff3f3b3cff231f20ff84818200ffffff00ffffff00ffffffff767374ff918f8fff686566ff686566ff4c494aff231f20ff231f2000ffffff00ffffff00ffffffff5a5758ff231f20ff231f20ff312d2effe3e3e300ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffff00ffffffffd6d5d5ff312d2eff231f20ff4c494affd6d5d500ffffff00ffffff00fffffffff1f1f1ff4c494aff231f20ff312d2efff1f1f100ffffff00ffffff00ffffffff4c494aff231f20ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffffff767374ff231f20ff4c494afff1f1f100ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffffc8c7c7ff231f20ff312d2efff1f1f100ffffff00ffffff00fffffffff1f1f1ff312d2effe3e3e300ffffff00ffffff00ffffffff5a5758ffc8c7c7ff5a5758ff767374ff767374ff231f20ff231f2000ffffff00ffffff00fffffffff1f1f1ff3f3b3cff231f20ff231f20ff4c494afff1f1f100ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00fffffffff1f1f1ff312d2eff231f20ff231f20ffd6d5d500ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff312d2eff231f20ff5a575800ffffff00ffffff00ffffffffe3e3e3ff312d2eff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff9e9d9dff231f20ff312d2effd6d5d500ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff686566ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d500ffffff00ffffff00ffffff00ffffffff767374ff767374ffbab9b9ff5a5758ff4c494aff231f20ff231f2000ffffff00ffffff00ffffff00ffffffffd6d5d5ff312d2eff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffffff918f8fff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff767374ff231f20ff231f20ffe3e3e300ffffff00ffffff00ffffffffbab9b9ff231f20ff231f20ff231f20ffd6d5d500ffffffffd6d5d5ff231f20ff231f20ffbab9b900ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff5a5758ff231f20ff4c494a00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff767374ff686566ff767374ffd6d5d5ff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffffffacababff231f20ff231f20ff231f20ff9e9d9d00ffffff00ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffff00ffffffff3f3b3cff231f20ff231f20ffbab9b900ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff9e9d9dff231f20ff231f20ff9e9d9d00ffffff00ffffff00ffffff00ffffffff848182ff231f20ff231f20ff3f3b3cffe3e3e3ff3f3b3cff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff5a5758ff231f20ff231f20ffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff848182ff231f20ff231f20ff231f20ffc8c7c700ffffff00ffffffffc8c7c7ff231f20ff5a575800ffffff00fffffffff1f1f1ff231f20ff231f20ff231f20fff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffffff4c494aff231f20ff231f20ff312d2eff231f20ff68656600ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff686566ff231f20ff231f20ff231f20ff5a5758ffbab9b900ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff5a5758ff231f20ff231f20ff312d2effe3e3e300ffffffffc8c7c7ff231f20ff5a575800ffffff00ffffffffc8c7c7ff231f20ff231f20ff231f20ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff4c494aff231f20ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffffffe3e3e3ff312d2eff231f20ff231f20ff4c494afff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffffd6d5d5ff231f20ff231f20ff231f20ff231f20ff231f20ff312d2eff848182ffe3e3e300ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff3f3b3cff231f20ff231f20ff4c494afff1f1f1ffc8c7c7ff231f20ff5a575800ffffff00ffffffffc8c7c7ff231f20ff231f20ff231f20ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff5a5758ff84818200ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff848182ff231f20ff231f20ff312d2effe3e3e300ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffffffc8c7c7ff3f3b3cff231f20ff231f20ff231f20ff231f20ff231f20ff231f20ff84818200ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff312d2eff231f20ff231f20ff686566ffc8c7c7ff231f20ff5a575800ffffff00ffffffffc8c7c7ff231f20ff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff312d2eff231f20ff231f20ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff9e9d9dff5a5758ff231f20ff231f20ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffacababff231f20ff231f20ff231f20ff5a5758ff231f20ff5a575800ffffff00ffffffffe3e3e3ff231f20ff231f20ff231f20fff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff4c494aff231f20ff848182ff3f3b3cff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffe3e3e3ff4c494aff231f20ff231f20ff4c494a00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff848182ff231f20ff231f20ff231f20ff231f20ff5a575800ffffff00ffffff00ffffffff312d2eff231f20ff231f20ffbab9b900ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff686566ff231f20ff5a575800ffffffffd6d5d5ff231f20ff231f20ff231f20ffc8c7c700ffffff00ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff312d2eff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff5a5758ff231f20ff231f20ff231f20ff5a575800ffffff00ffffff00ffffffff767374ff231f20ff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff848182ff231f20ff312d2efff1f1f100ffffff00ffffffff918f8fff231f20ff231f20ff312d2efff1f1f100ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff5a5758ff231f20ff4c494a00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff3f3b3cff231f20ff231f20ff5a575800ffffff00ffffff00ffffffffe3e3e3ff312d2eff231f20ff231f20ffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00fffffffff1f1f1ff4c494a00ffffff00ffffff00ffffffffacababff231f20ff231f20ffd6d5d500ffffff00ffffff00ffffff00ffffffff5a5758ff231f20ff231f20ff68656600ffffff00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffffe3e3e3ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff3f3b3cff231f20ff76737400ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffd6d5d5ff312d2eff231f20ff5a575800ffffff00ffffff00ffffff00ffffffffacababff231f20ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffff00ffffff00ffffffffacababff3f3b3cff231f2000ffffff00ffffffffd6d5d5ff312d2eff231f20ff9e9d9d00ffffff00ffffff00ffffff00ffffff00ffffffffe3e3e3ff312d2eff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff848182ff231f20ff84818200ffffff00ffffff00ffffff00ffffffff9e9d9dff231f20ff312d2effe3e3e300ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff231f20ff231f2000ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffacababff231f20ff5a575800ffffff00ffffff00ffffff00ffffff00ffffffffacababff312d2eff231f20ff231f20ff312d2eff686566ff918f8fff767374ff3f3b3cff231f20ff312d2effbab9b900fffffffff1f1f1ff312d2eff231f20ff68656600ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffbab9b9ff231f20ff231f20ff231f20ffc8c7c700ffffff00ffffffffc8c7c7ff231f20ff231f20ff918f8f00ffffff00ffffff00ffffffff4c494aff231f20ff231f20ff3f3b3cff848182ff918f8fff4c494aff231f20ff312d2effacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff918f8fff918f8f00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffacababffacabab00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffffe3e3e3ff848182ff3f3b3cff231f20ff231f20ff231f20ff231f20ff5a5758ffacababfff1f1f100ffffff00ffffffffbab9b9ff918f8fff918f8ffff1f1f100ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffffff9e9d9dff918f8fff918f8fff9e9d9d00ffffff00ffffffffe3e3e3ff918f8fff918f8fffc8c7c700ffffff00ffffff00ffffff00ffffffffbab9b9ff848182ff4c494aff231f20ff231f20ff3f3b3cff767374ffe3e3e300ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff00ffffff000700ae00700007000100010003000300040000000d000c0010004f004f00ba00ba00280007001110517569636b54696d65aa20616e642061000028000c00140d206465636f6d70726573736f720028001100001f617265206e656564656420746f20736565207468697320706963747572652e000000a100e007ac00000000000007a86170706c022000006d6e74725247422058595a2007d900020019000b001a000b616373704150504c000000006170706c000000000000000000000000000000000000f6d6000100000000d32d6170706c00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000b64657363000001080000006f6473636d000001780000056c63707274000006e400000038777470740000071c000000147258595a00000730000000146758595a00000744000000146258595a0000075800000014725452430000076c0000000e636861640000077c0000002c625452430000076c0000000e675452430000076c0000000e64657363000000000000001447656e65726963205247422050726f66696c6500000000000000000000001447656e65726963205247422050726f66696c6500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000006d6c7563000000000000001e0000000c736b534b00000028000001786872485200000028000001a06361455300000024000001c87074425200000026000001ec756b55410000002a0000021266724655000000280000023c7a685457000000160000026469744954000000280000027a6e624e4f00000026000002a26b6f4b5200000016000002c86373435a00000022000002de6865494c0000001e00000300646544450000002c0000031e68754855000000280000034a7376534500000026000002a27a68434e00000016000003726a614a500000001a00000388726f524f00000024000003a2656c475200000022000003c67074504f00000026000003e86e6c4e4c000000280000040e6573455300000026000003e874685448000000240000043674725452000000220000045a66694649000000280000047c706c504c0000002c000004a47275525500000022000004d06172454700000026000004f2656e555300000026000005186461444b0000002e0000053e005601610065006f006200650063006e00fd0020005200470042002000700072006f00660069006c00470065006e006500720069010d006b00690020005200470042002000700072006f00660069006c00500065007200660069006c0020005200470042002000670065006e00e800720069006300500065007200660069006c0020005200470042002000470065006e00e9007200690063006f0417043004330430043b044c043d043804390020043f0440043e044404300439043b002000520047004200500072006f00660069006c0020006700e9006e00e9007200690071007500650020005200560042901a75280020005200470042002082725f6963cf8ff000500072006f00660069006c006f0020005200470042002000670065006e0065007200690063006f00470065006e0065007200690073006b0020005200470042002d00700072006f00660069006cc77cbc1800200052004700420020d504b85cd30cc77c004f006200650063006e00fd0020005200470042002000700072006f00660069006c05e405e805d505e405d905dc0020005200470042002005db05dc05dc05d90041006c006c00670065006d00650069006e006500730020005200470042002d00500072006f00660069006c00c1006c00740061006c00e1006e006f00730020005200470042002000700072006f00660069006c666e901a0020005200470042002063cf8ff065874ef64e00822c0020005200470042002030d730ed30d530a130a430eb00500072006f00660069006c0020005200470042002000670065006e0065007200690063039303b503bd03b903ba03cc002003c003c103bf03c603af03bb002000520047004200500065007200660069006c0020005200470042002000670065006e00e9007200690063006f0041006c00670065006d00650065006e0020005200470042002d00700072006f006600690065006c0e420e1b0e230e440e1f0e250e4c002000520047004200200e170e310e480e270e440e1b00470065006e0065006c0020005200470042002000500072006f00660069006c00690059006c00650069006e0065006e0020005200470042002d00700072006f006600690069006c00690055006e006900770065007200730061006c006e0079002000700072006f00660069006c0020005200470042041e04310449043804390020043f0440043e04440438043b044c00200052004700420645064406410020062a06390631064a0641002000520047004200200627064406390627064500470065006e00650072006900630020005200470042002000500072006f00660069006c006500470065006e006500720065006c0020005200470042002d006200650073006b0072006900760065006c007300657465787400000000436f707972696768742032303037204170706c6520496e632e2c20616c6c207269676874732072657365727665642e0058595a20000000000000f35200010000000116cf58595a20000000000000744d00003dee000003d058595a200000000000005a750000ac730000173458595a20000000000000281a0000159f0000b83663757276000000000000000101cd0000736633320000000000010c42000005defffff326000007920000fd91fffffba2fffffda3000003dc0000c06c00a100e000040000000200ff}}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par \par \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 Download Request: Selected Items: 151-288\par Time Of Request: Tuesday, November 26, 2013  20:37:56\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 Send To:\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 UNIVERSITEIT VAN AMSTERDAM\par POSTBUS 19185\par AMSTERDAM, NLD 1000 GD\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 Terms: ((Cipla AND Patent) and Date(geq(01/01/2003) and leq(01/01/2013)))\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 Source: Major World Publications (English)\par Project ID: \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af2 \ltrch\fcs0 \f2\insrsid2900964 \par \sect }\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\ltrrow\trowd \irow0\irowband0\ltrrow\ts11\trgaph60\trleft-60\trhdr\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \clcfpat17\clcbpat17\clshdng10000\cltxlrtb\clftsWidth3\clwWidth540\clcbpatraw17\clcfpatraw17\clshdngraw10000 \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \clcfpat17\clcbpat17\clshdng10000\cltxlrtb\clftsWidth3\clwWidth9180\clcbpatraw17\clcfpatraw17\clshdngraw10000 \cellx9660\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_1_0}{\*\bkmkstart cite_id_1}{\*\bkmkend DOC_ID_1_0}{\*\bkmkend cite_id_1} \cell Results\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\ltrrow\ts11\trgaph60\trleft-60\trhdr\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \clcfpat17\clcbpat17\clshdng10000\cltxlrtb\clftsWidth3\clwWidth540\clcbpatraw17\clcfpatraw17\clshdngraw10000 \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \clcfpat17\clcbpat17\clshdng10000\cltxlrtb\clftsWidth3\clwWidth9180\clcbpatraw17\clcfpatraw17\clshdngraw10000 \cellx9660\row \ltrrow}\trowd \irow1\irowband1\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 1.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_1"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda;  New Law Will Hinder ARV Supply}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Africa News, July 25, 2006 Tuesday, 486 words, New Vision\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow1\irowband1\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_2_0}{\*\bkmkstart cite_id_2}{\*\bkmkend DOC_ID_2_0}{\*\bkmkend cite_id_2}2.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_2"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Need to know}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Times (London), July 22, 2006, Saturday, BUSINESS; Pg. 58, 1412 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_3_0}{\*\bkmkstart cite_id_3}{\*\bkmkend DOC_ID_3_0}{\*\bkmkend cite_id_3}3.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_3"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Need to know}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Times (London), July 22, 2006, Saturday, BUSINESS; Pg. 58, 1412 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_4_0}{\*\bkmkstart cite_id_4}{\*\bkmkend DOC_ID_4_0}{\*\bkmkend cite_id_4}4.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_4"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Cipla Medpro. GROWING COMPANY AN OBVIOUS TARGET}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Financial Mail (South Africa), June 09, 2006, ECONOMY, BUSINESS & FINANCE; Pg. 12, 1071  words, Jacqui Wilmot\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_5_0}{\*\bkmkstart cite_id_5}{\*\bkmkend DOC_ID_5_0}{\*\bkmkend cite_id_5}5.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_5"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Cipla Medpro pipeline. BANKING ON ARVs FOR GROWTH}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Financial Mail (South Africa), June 09, 2006, ECONOMY, BUSINESS & FINANCE; Pg. 12, 464  words, Jacqui Wilmot\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_6_0}{\*\bkmkstart cite_id_6}{\*\bkmkend DOC_ID_6_0}{\*\bkmkend cite_id_6}6.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_6"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India overtakes South Africa for HIV/AIDS}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Pharma Marketletter, June 2, 2006 Friday, 160 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_7_0}{\*\bkmkstart cite_id_7}{\*\bkmkend DOC_ID_7_0}{\*\bkmkend cite_id_7}7.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_7"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian pharma firms go shopping abroad;  They are acquiring Western companies to overcome the restrictions of a new patent regime}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Business Times Singapore, May 25, 2006 Thursday, VIEWS AND OPINIONS; BT Comment Others, 1125  words, Yogi Aggarwal\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_8_0}{\*\bkmkstart cite_id_8}{\*\bkmkend DOC_ID_8_0}{\*\bkmkend cite_id_8}8.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_8"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS Groups In India Sue To Halt Patent For U.S. Drug}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, May 12, 2006 Friday, Section A; Column 6; Foreign Desk; Pg. 4, 493 words, By AMELIA GENTLEMAN and HARI KUMAR\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_9_0}{\*\bkmkstart cite_id_9}{\*\bkmkend DOC_ID_9_0}{\*\bkmkend cite_id_9}9.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_9"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000900000064006f0063005f00690064005f0039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS drug provokes legal fight in India;  Rights group sayspatent would imperil thousands of lives}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, May 11, 2006 Thursday, NEWS; Pg. 1, 1002 words, Amelia Gentleman and Hari Kumar\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_10_0}{\*\bkmkstart cite_id_10}{\*\bkmkend DOC_ID_10_0}{\*\bkmkend cite_id_10}10.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_10"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS drug provokes patent battle in India;  Approval could cost lives, critics say}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, May 11, 2006 Thursday, NEWS; Pg. 7, 1188 words, Amelia Gentleman and Hari Kumar\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_11_0}{\*\bkmkstart cite_id_11}{\*\bkmkend DOC_ID_11_0}{\*\bkmkend cite_id_11}11.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_11"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 U.S. pushes to limit generic drug rights;  Agreements seek to extend monopolies in exchange for improvements in trade}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, April 19, 2006 Wednesday, NEWS; Pg. 1, 1610 words, Anand Giridharadas\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_12_0}{\*\bkmkstart cite_id_12}{\*\bkmkend DOC_ID_12_0}{\*\bkmkend cite_id_12}12.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_12"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 U.S. pushes to limit generic-drug rights in trade pacts}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, April 19, 2006 Wednesday, FINANCE; Pg. 13, 1381 words, Anand Giridharadas\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_13_0}{\*\bkmkstart cite_id_13}{\*\bkmkend DOC_ID_13_0}{\*\bkmkend cite_id_13}13.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_13"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 The pink of health for drug companies;  AROUND ASIA'S MARKETS;  BUSINESS ASIA by Bloomberg}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, March 13, 2006 Monday, FINANCE; Pg. 12, 581 words, Darren Boey\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_14_0}{\*\bkmkstart cite_id_14}{\*\bkmkend DOC_ID_14_0}{\*\bkmkend cite_id_14}14.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_14"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Times (London), March 6, 2006, Monday, BUSINESS; Pg. 51, 1041 words, Michael Binyon\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_15_0}{\*\bkmkstart cite_id_15}{\*\bkmkend DOC_ID_15_0}{\*\bkmkend cite_id_15}15.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_15"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Times (London), March 6, 2006, Monday, BUSINESS; Pg. 51, 1041 words, Michael Binyon\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_16_0}{\*\bkmkstart cite_id_16}{\*\bkmkend DOC_ID_16_0}{\*\bkmkend cite_id_16}16.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_16"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian company vows to make bird flu drugs available}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   BBC Monitoring South Asia - Political Supplied by BBC Worldwide Monitoring, February 20, 2006 Monday, 498 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_17_0}{\*\bkmkstart cite_id_17}{\*\bkmkend DOC_ID_17_0}{\*\bkmkend cite_id_17}17.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_17"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Fine Chemicals; Indian Firms Tear Into Overseas API Markets}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Chemical Week, February 15, 2006, COVER STORY; Pg. 27, 3495 words, ALEX SCOTT\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_18_0}{\*\bkmkstart cite_id_18}{\*\bkmkend DOC_ID_18_0}{\*\bkmkend cite_id_18}18.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_18"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Despite Viagra's cost, India beckons Pfizer;  BUSINESS ASIA by Bloomberg}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, December 22, 2005 Thursday, FINANCE; Pg. 20, 615 words, Mrinalini Datta and Paresh Jatakia\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_19_0}{\*\bkmkstart cite_id_19}{\*\bkmkend DOC_ID_19_0}{\*\bkmkend cite_id_19}19.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_19"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00310039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Counting on the Viagra brand in India;  Pfizer set to introduce drug next week despite a crowd of copies}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, December 22, 2005 Thursday, FINANCE; Pg. 16, 633 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_20_0}{\*\bkmkstart cite_id_20}{\*\bkmkend DOC_ID_20_0}{\*\bkmkend cite_id_20}20.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_20"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda;  Uganda Enters HIV/Aids Drug Deal With India}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Africa News, December 13, 2005 Tuesday, 417 words, The East African\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_21_0}{\*\bkmkstart cite_id_21}{\*\bkmkend DOC_ID_21_0}{\*\bkmkend cite_id_21}21.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_21"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche picks Chinese partner for Tamiflu}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, December 13, 2005 Tuesday, FINANCE; Pg. 16, 841 words, Tom Wright\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_22_0}{\*\bkmkstart cite_id_22}{\*\bkmkend DOC_ID_22_0}{\*\bkmkend cite_id_22}22.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_22"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche Tells Indonesia That It Can Produce Tamiflu Without a License }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, November 26, 2005 Saturday, Section C; Column 4; Business/Financial Desk; Pg. 3, 404 words, By Bloomberg News\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_23_0}{\*\bkmkstart cite_id_23}{\*\bkmkend DOC_ID_23_0}{\*\bkmkend cite_id_23}23.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_23"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 G2: What Grace did next: Three years ago the Guardian published an award-winning supplement featuring the story of Grace Mathanga, an ordinary African woman with HIV. To launch this year's Christmas appeal, which focuses on Aids in Africa, Sarah Boseley returns to Malawi to find out how Grace is doing now, and what her life can tell us about the future of the continent}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London) - Final Edition, November 24, 2005, Guardian Features Pages, Pg. 8, 4076 words, Sarah Boseley\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_24_0}{\*\bkmkstart cite_id_24}{\*\bkmkend DOC_ID_24_0}{\*\bkmkend cite_id_24}24.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_24"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Don't wait for Tamiflu - make our own}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Australian Financial Review, November 15, 2005 Tuesday, NEWS; Opinion; Pg. 71, 603 words, Peter Drahos and Buddhima Lokuge Peter Drahos is professor of law in the Research School of Social Sciences at the Australian National University. Buddhima Lokuge is director of the International Trade, Innovation and Population Health program.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_25_0}{\*\bkmkstart cite_id_25}{\*\bkmkend DOC_ID_25_0}{\*\bkmkend cite_id_25}25.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_25"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 When MNC profits matter more than global health}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, November 11, 2005 Friday, VIEWS AND OPINIONS; The Bottomline, 795 words, Harish Mehta\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_26_0}{\*\bkmkstart cite_id_26}{\*\bkmkend DOC_ID_26_0}{\*\bkmkend cite_id_26}26.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_26"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche bends to pressure on flu drug demand}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, November 11, 2005 Friday, FINANCE; Pg. 17, 894 words, Tom Wright\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_27_0}{\*\bkmkstart cite_id_27}{\*\bkmkend DOC_ID_27_0}{\*\bkmkend cite_id_27}27.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_27"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche bows to pressure on flu drug demand}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, November 10, 2005 Thursday, FINANCE; Pg. 13, 883 words, Tom Wright\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_28_0}{\*\bkmkstart cite_id_28}{\*\bkmkend DOC_ID_28_0}{\*\bkmkend cite_id_28}28.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_28"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche Plans Big Increase In Tamiflu Production}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, November 10, 2005 Thursday, Section C; Column 6; Business/Financial Desk; Pg. 6, 658 words, By TOM WRIGHT; International Herald Tribune\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_29_0}{\*\bkmkstart cite_id_29}{\*\bkmkend DOC_ID_29_0}{\*\bkmkend cite_id_29}29.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_29"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00320039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Steps and missteps in bird flu fight;  Old Chinese cooking spice could hold key to making Tamiflu}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The International Herald Tribune, November 8, 2005 Tuesday, FINANCE; Pg. 13, 955 words, Andrew Pollack\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_30_0}{\*\bkmkstart cite_id_30}{\*\bkmkend DOC_ID_30_0}{\*\bkmkend cite_id_30}30.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_30"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Debating How Difficult It Is to Make Tamiflu }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, November 5, 2005 Saturday, Section C; Column 3; Business/Financial Desk; Is Bird Flu Drug Really So Vexing?; Pg. 1, 1751 words, By ANDREW POLLACK; Keith Bradsher contributed reporting for this article.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_31_0}{\*\bkmkstart cite_id_31}{\*\bkmkend DOC_ID_31_0}{\*\bkmkend cite_id_31}31.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_31"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964  Let others make life-saving drug, company told}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Times (London), November 5, 2005, Saturday, Home news; 6, 584 words, Richard Irving and Mark Henderson\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_32_0}{\*\bkmkstart cite_id_32}{\*\bkmkend DOC_ID_32_0}{\*\bkmkend cite_id_32}32.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_32"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 BIRD FLU PATENTS RAISE THE REPUTATION STAKES}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   PR Week, November 4, 2005, OPINION; Pg. 18, 418  words, By Kate Nicholas, kate.nicholas@haynet.com\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_33_0}{\*\bkmkstart cite_id_33}{\*\bkmkend DOC_ID_33_0}{\*\bkmkend cite_id_33}33.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_33"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Bird Flu Threat Boosts Pharma Outsourcing}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Chemical Week, October 26, 2005, PHARMACEUTICALS & FINE CHEMICALS; Manufacture; Pg. 34, 473 words, ALEX SCOTT\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_34_0}{\*\bkmkstart cite_id_34}{\*\bkmkend DOC_ID_34_0}{\*\bkmkend cite_id_34}34.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_34"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Fighting to break the Tamiflu monopoly}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Toronto Star, October 25, 2005 Tuesday, NEWS; Pg. A02, 396 words, Andrew Mills, Toronto Star\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_35_0}{\*\bkmkstart cite_id_35}{\*\bkmkend DOC_ID_35_0}{\*\bkmkend cite_id_35}35.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_35"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Comment: Profit and the price of life: Pharmaceutical companies can save millions of lives but who will pick up the bill for the poor?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Observer, October 23, 2005, Observer News Pages, Pg. 26, 1131 words, Mary Riddell\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_36_0}{\*\bkmkstart cite_id_36}{\*\bkmkend DOC_ID_36_0}{\*\bkmkend cite_id_36}36.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_36"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Call to break patents on flu treatment}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   Australian Financial Review, October 20, 2005 Thursday, NEWS; Pg. 3, 348 words, Annabel Stafford\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_37_0}{\*\bkmkstart cite_id_37}{\*\bkmkend DOC_ID_37_0}{\*\bkmkend cite_id_37}37.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_37"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GSK PREPARES TO CASH IN ON BIRD FLU FEARS}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Independent (London), October 19, 2005, Wednesday, First Edition; BUSINESS; Pg. 60, 474 words, BY STEPHEN FOLEY\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_38_0}{\*\bkmkstart cite_id_38}{\*\bkmkend DOC_ID_38_0}{\*\bkmkend cite_id_38}38.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_38"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Pressure on Roche to increase production of antiviral drug}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Irish Times, October 19, 2005, Ireland; Other Stories; Pg. 11, 410 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_39_0}{\*\bkmkstart cite_id_39}{\*\bkmkend DOC_ID_39_0}{\*\bkmkend cite_id_39}39.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_39"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00330039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche Offers To Negotiate On Flu Drug}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, October 19, 2005 Wednesday, Section C; Column 5; Business/Financial Desk; Pg. 1, 776 words, By JAMES KANTER; International Herald Tribune\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_40_0}{\*\bkmkstart cite_id_40}{\*\bkmkend DOC_ID_40_0}{\*\bkmkend cite_id_40}40.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_40"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 SHORTAGE OF VACCINES LEAVES EU UNPREPARED FOR BIRD FLU ATTACK}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Scotsman, October 19, 2005, Wednesday, Pg. 6, 850 words, Louise Gray\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_41_0}{\*\bkmkstart cite_id_41}{\*\bkmkend DOC_ID_41_0}{\*\bkmkend cite_id_41}41.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_41"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Prostate surgery not too risky in healthy 70s}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  St. Petersburg Times (Florida), October 19, 2005 Wednesday 0 South Pinellas Edition, NATIONAL; Pg. 6A, 433 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_42_0}{\*\bkmkstart cite_id_42}{\*\bkmkend DOC_ID_42_0}{\*\bkmkend cite_id_42}42.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_42"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Swiss Firm May Cede Bird Flu Drug Rights}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Washington Post, October 19, 2005 Wednesday, A Section; A13, 692 words, Marc Kaufman, Washington Post Staff Writer\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_43_0}{\*\bkmkstart cite_id_43}{\*\bkmkend DOC_ID_43_0}{\*\bkmkend cite_id_43}43.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_43"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Roche pressed to let others make Tamiflu}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  USA TODAY, October 18, 2005, Tuesday,, 349 words, Julie Schmit\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_44_0}{\*\bkmkstart cite_id_44}{\*\bkmkend DOC_ID_44_0}{\*\bkmkend cite_id_44}44.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_44"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Fear of a pandemic can be more dangerous than the virus}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  THE DAILY TELEGRAPH(LONDON), October 17, 2005, Monday, 70 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_45_0}{\*\bkmkstart cite_id_45}{\*\bkmkend DOC_ID_45_0}{\*\bkmkend cite_id_45}45.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_45"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Bird Flu: Access to treatment: Avian flu found to be resistant to stockpiled drug, experts warn}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London) - Final Edition, October 15, 2005, Guardian Home Pages, Pg. 7, 466 words, Sarah Boseley\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_46_0}{\*\bkmkstart cite_id_46}{\*\bkmkend DOC_ID_46_0}{\*\bkmkend cite_id_46}46.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_46"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian Company to Make Generic Version of Flu Drug Tamiflu}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, October 14, 2005 Friday, Section A; Column 1; Foreign Desk; Pg. 3, 616 words, By DONALD G. McNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_47_0}{\*\bkmkstart cite_id_47}{\*\bkmkend DOC_ID_47_0}{\*\bkmkend cite_id_47}47.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_47"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Malawi; Local Manufacture of Anti-Aids Drugs Considered}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 13, 2005 Wednesday, 143 words, UN Integrated Regional Information Networks\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_48_0}{\*\bkmkstart cite_id_48}{\*\bkmkend DOC_ID_48_0}{\*\bkmkend cite_id_48}48.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_48"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 HIV-Aids and STDs; Global Aids Treatment Drive Takes Off}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, April 28, 2005 Thursday, 3207 words, Africa Renewal\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_49_0}{\*\bkmkstart cite_id_49}{\*\bkmkend DOC_ID_49_0}{\*\bkmkend cite_id_49}49.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_49"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00340039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Is it the end of cheap drugs from India?; Medicine prices may soar in a few years as the country can no longer make generic drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, April 12, 2005 Tuesday, VIEWS AND OPINIONS; BT Comment Others, 1347 words, Yogi Aggarwal\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_50_0}{\*\bkmkstart cite_id_50}{\*\bkmkend DOC_ID_50_0}{\*\bkmkend cite_id_50}50.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_50"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; New Law in India Drives Up Africa's Cost of Halting Aids}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, March 29, 2005 Tuesday, 752 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_51_0}{\*\bkmkstart cite_id_51}{\*\bkmkend DOC_ID_51_0}{\*\bkmkend cite_id_51}51.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_51"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Drugs Sector Needs Dose of Courage}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, March 29, 2005 Tuesday, 802 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_52_0}{\*\bkmkstart cite_id_52}{\*\bkmkend DOC_ID_52_0}{\*\bkmkend cite_id_52}52.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_52"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Zambia; India's Cheap Medicines}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, March 29, 2005 Tuesday, 776 words, The Post\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_53_0}{\*\bkmkstart cite_id_53}{\*\bkmkend DOC_ID_53_0}{\*\bkmkend cite_id_53}53.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_53"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Trade; Indian Move to Hurt Uganda Aids Patients}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, March 28, 2005 Monday, 282 words, The East African\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_54_0}{\*\bkmkstart cite_id_54}{\*\bkmkend DOC_ID_54_0}{\*\bkmkend cite_id_54}54.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_54"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Generic drug frenzy}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   BRW, March 24, 2005 Thursday, Pg. 40-43, 92 words, Beth Quinlivan\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_55_0}{\*\bkmkstart cite_id_55}{\*\bkmkend DOC_ID_55_0}{\*\bkmkend cite_id_55}55.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_55"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 INDIA ALTERS LAW ON DRUG PATENTS}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, March 24, 2005 Thursday, Section A; Column 3; Foreign Desk; Pg. 1, 1166 words, By DONALD G. McNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_56_0}{\*\bkmkstart cite_id_56}{\*\bkmkend DOC_ID_56_0}{\*\bkmkend cite_id_56}56.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_56"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India Adopts Patent Law Covering Pharmaceuticals}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, March 24, 2005 Thursday, Section C; Column 5; Business/Financial Desk; INTERNATIONAL BUSINESS; Pg. 6, 859 words, By SARITHA RAI; Anand Giridharadas from The International Herald Tribune contributed reporting from Mumbai for this article.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_57_0}{\*\bkmkstart cite_id_57}{\*\bkmkend DOC_ID_57_0}{\*\bkmkend cite_id_57}57.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_57"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Cheap Aids drugs under threat: Body blow to developing states' fight against disease as Indian MPs ban copying of patented products}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London) - Final Edition, March 23, 2005, Guardian Home Pages, Pg. 2, 579 words, Randeep Ramesh in New Delhi\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_58_0}{\*\bkmkstart cite_id_58}{\*\bkmkend DOC_ID_58_0}{\*\bkmkend cite_id_58}58.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_58"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Microsoft and Pfizer Suing 2 Web Sites That Sell Pills}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, February 11, 2005 Friday, Section C; Column 5; Business/Financial Desk; Pg. 6, 650 words, By SAUL HANSELL\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_59_0}{\*\bkmkstart cite_id_59}{\*\bkmkend DOC_ID_59_0}{\*\bkmkend cite_id_59}59.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_59"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00350039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Nigeria; How Safe Are Anti-Retroviral Drugs?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, February 8, 2005 Tuesday, 1044 words, This Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_60_0}{\*\bkmkstart cite_id_60}{\*\bkmkend DOC_ID_60_0}{\*\bkmkend cite_id_60}60.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_60"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Aspen Aids Drugs Receive U.S. Regulatory Approval}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, January 26, 2005 Wednesday, 509 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_61_0}{\*\bkmkstart cite_id_61}{\*\bkmkend DOC_ID_61_0}{\*\bkmkend cite_id_61}61.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_61"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Kenya; Are Days of Cheap ARVs Over?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, January 6, 2005 Thursday, 1042 words, The Nation\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_62_0}{\*\bkmkstart cite_id_62}{\*\bkmkend DOC_ID_62_0}{\*\bkmkend cite_id_62}62.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_62"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India courts investors with drug patents}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  THE DAILY TELEGRAPH(LONDON), December 31, 2004, Friday, 414 words, By Rosie Murray-West City Correspondent\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_63_0}{\*\bkmkstart cite_id_63}{\*\bkmkend DOC_ID_63_0}{\*\bkmkend cite_id_63}63.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_63"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964  Whether document is privileged}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Times (London), December 2, 2004, Thursday, Features; 79, 395 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_64_0}{\*\bkmkstart cite_id_64}{\*\bkmkend DOC_ID_64_0}{\*\bkmkend cite_id_64}64.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_64"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; Goodbye to Cheap Indian Aids Drugs?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, November 26, 2004 Friday, 1225 words, Inter Press Service\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_65_0}{\*\bkmkstart cite_id_65}{\*\bkmkend DOC_ID_65_0}{\*\bkmkend cite_id_65}65.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_65"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Generic drug doubts cause HIV alarm}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Canberra Times (Australia), November 24, 2004 Wednesday, 884 words, Brendan Grabau\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_66_0}{\*\bkmkstart cite_id_66}{\*\bkmkend DOC_ID_66_0}{\*\bkmkend cite_id_66}66.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_66"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India Kicks the Habit}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Newsweek, November 22, 2004 Atlantic Edition, PHARMACEUTICALS; Pg. 56, 969 words, By Seema Singh\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_67_0}{\*\bkmkstart cite_id_67}{\*\bkmkend DOC_ID_67_0}{\*\bkmkend cite_id_67}67.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_67"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS policy in shambles}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Washington Times, November 17, 2004 Wednesday, COMMENTARY; Pg. A16, 768 words, By James K. Glassman, SPECIAL TO THE WASHINGTON TIMES\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_68_0}{\*\bkmkstart cite_id_68}{\*\bkmkend DOC_ID_68_0}{\*\bkmkend cite_id_68}68.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_68"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Tests lead to recall of cheap Aids drugs: Move by generics manufacturer hits the WHO's targets for Africa}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London) - Final Edition, November 11, 2004, Guardian Foreign Pages, Pg. 18, 667 words, Sarah Boseley, Health editor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_69_0}{\*\bkmkstart cite_id_69}{\*\bkmkend DOC_ID_69_0}{\*\bkmkend cite_id_69}69.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_69"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00360039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India's pharma ache; The upcoming amendment to the Indian Patent Act may lead to increased competition from MNCs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, November 4, 2004 Thursday, mviews, 1251 words, YOGI AGGARWAL\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_70_0}{\*\bkmkstart cite_id_70}{\*\bkmkend DOC_ID_70_0}{\*\bkmkend cite_id_70}70.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_70"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 HIV-Aids and STDs; Vaccine, Treatment and PEPFAR Developments}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 20, 2004 Wednesday, 1668 words, Kaisernetwork.org\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_71_0}{\*\bkmkstart cite_id_71}{\*\bkmkend DOC_ID_71_0}{\*\bkmkend cite_id_71}71.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_71"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 George W. Bush: AIDS warrior: Attacking the U.S. administration for indifference to AIDS is like attacking it for inadequate defence spending: The fact is the United States is far and away the leader in the global AIDS fight}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Gazette (Montreal, Quebec), July 22, 2004 Thursday Final Edition, Editorial / Op-ed; Pg. A23, 868 words, SEBASTIAN MALLABY\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_72_0}{\*\bkmkstart cite_id_72}{\*\bkmkend DOC_ID_72_0}{\*\bkmkend cite_id_72}72.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_72"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS Activists Misfiring}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Washington Post, July 19, 2004 Monday, Editorial; A17, 919 words, Sebastian Mallaby\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_73_0}{\*\bkmkstart cite_id_73}{\*\bkmkend DOC_ID_73_0}{\*\bkmkend cite_id_73}73.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_73"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS; Daily HIV/Aids Report}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 15, 2004 Thursday, 6123 words, Kaisernetwork.org\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_74_0}{\*\bkmkstart cite_id_74}{\*\bkmkend DOC_ID_74_0}{\*\bkmkend cite_id_74}74.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_74"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS; Daily HIV/Aids Report}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 14, 2004 Wednesday, 9442 words, Kaisernetwork.org\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_75_0}{\*\bkmkstart cite_id_75}{\*\bkmkend DOC_ID_75_0}{\*\bkmkend cite_id_75}75.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_75"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Early Tests for U.S. in Its Global Fight on AIDS}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, July 14, 2004 Wednesday, Section A; Column 2; Foreign Desk; Pg. 1, 3655 words, This article was reported by Deborah Sontag, Sharon LaFraniere and Michael Wines, and was written by Ms. Sontag.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_76_0}{\*\bkmkstart cite_id_76}{\*\bkmkend DOC_ID_76_0}{\*\bkmkend cite_id_76}76.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_76"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; Cipla Patents Generic Drug}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 13, 2004 Tuesday, 382 words, The East African Standard\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_77_0}{\*\bkmkstart cite_id_77}{\*\bkmkend DOC_ID_77_0}{\*\bkmkend cite_id_77}77.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_77"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; Daily HIV/Aids Report}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 13, 2004 Tuesday, 11362 words, Kaisernetwork.org\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_78_0}{\*\bkmkstart cite_id_78}{\*\bkmkend DOC_ID_78_0}{\*\bkmkend cite_id_78}78.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_78"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GENERIC AIDS PILL GETS PATENT IN AFRICA}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  WALL STREET JOURNAL ABSTRACTS, July 13, 2004, Tuesday, Section D; Page 3, Column 1, 40 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_79_0}{\*\bkmkstart cite_id_79}{\*\bkmkend DOC_ID_79_0}{\*\bkmkend cite_id_79}79.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_79"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00370039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GENERIC AIDS PILL GETS PATENT IN AFRICA}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  WALL STREET JOURNAL ABSTRACTS, July 13, 2004, Tuesday, Section D; Page 3, Column 1, 40 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_80_0}{\*\bkmkstart cite_id_80}{\*\bkmkend DOC_ID_80_0}{\*\bkmkend cite_id_80}80.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_80"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda; Drugs Worry Aids Patients}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 7, 2004 Wednesday, 183 words, The Monitor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_81_0}{\*\bkmkstart cite_id_81}{\*\bkmkend DOC_ID_81_0}{\*\bkmkend cite_id_81}81.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_81"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS; Daily HIV/Aids Report}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 7, 2004 Wednesday, 4531 words, Kaisernetwork.org\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_82_0}{\*\bkmkstart cite_id_82}{\*\bkmkend DOC_ID_82_0}{\*\bkmkend cite_id_82}82.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_82"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda; Patients Worried of Aids Drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, July 5, 2004 Monday, 277 words, The Monitor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_83_0}{\*\bkmkstart cite_id_83}{\*\bkmkend DOC_ID_83_0}{\*\bkmkend cite_id_83}83.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_83"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Study Finds Generic AIDS Drug Effective}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, July 2, 2004 Friday, Section A; Column 1; Foreign Desk; Pg. 5, 859 words, By DONALD G. McNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_84_0}{\*\bkmkstart cite_id_84}{\*\bkmkend DOC_ID_84_0}{\*\bkmkend cite_id_84}84.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_84"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; World Health Body Scraps Two Generic Antiretrovirals}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, June 18, 2004 Friday, 263 words, Cape Argus\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_85_0}{\*\bkmkstart cite_id_85}{\*\bkmkend DOC_ID_85_0}{\*\bkmkend cite_id_85}85.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_85"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 U.N. Agency Drops 2 Drugs For AIDS Care Worldwide}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, June 16, 2004 Wednesday, Section A; Column 1; Foreign Desk; Pg. 6, 541 words, By LAWRENCE K. ALTMAN and DONALD G. MCNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_86_0}{\*\bkmkstart cite_id_86}{\*\bkmkend DOC_ID_86_0}{\*\bkmkend cite_id_86}86.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_86"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Indian drug firms stand to gain much from WTO talks; Potential to carve out slice of US$15b US generics market}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, June 7, 2004 Monday, THE NEWS; South Asia, 632 words, Yogi Aggarwal in Bombay\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_87_0}{\*\bkmkstart cite_id_87}{\*\bkmkend DOC_ID_87_0}{\*\bkmkend cite_id_87}87.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_87"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 The lab pirates teaching the West how to fill the world's prescriptions India's pharmaceutical expertise is fast making it a global player, writes Rosie Murray-West}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  THE DAILY TELEGRAPH(LONDON), June 01, 2004, Tuesday, 1207 words, By Rosie Murray-West\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_88_0}{\*\bkmkstart cite_id_88}{\*\bkmkend DOC_ID_88_0}{\*\bkmkend cite_id_88}88.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_88"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Drugs for the Poor Collect Dust As Council Drags Its Feet}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, April 18, 2004 Sunday, 559 words, Sunday Times\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_89_0}{\*\bkmkstart cite_id_89}{\*\bkmkend DOC_ID_89_0}{\*\bkmkend cite_id_89}89.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_89"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00380039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Activists against Africa; HIV/AIDS fight takes wrong turn}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Washington Times, April 8, 2004, Thursday, Final Edition, OPED; Pg. A19, 857 words, By Robert Goldberg, SPECIAL TO THE WASHINGTON TIMES\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_90_0}{\*\bkmkstart cite_id_90}{\*\bkmkend DOC_ID_90_0}{\*\bkmkend cite_id_90}90.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_90"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Deal reached for cheaper AIDS drugs;  UN, World Bank and other groups join up to send generic medicine to poor countries}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Globe and Mail (Canada), April 6, 2004 Tuesday, INTERNATIONAL NEWS; Pg. A14, 551 words, MAGGIE FOX, Reuters News Agency\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_91_0}{\*\bkmkstart cite_id_91}{\*\bkmkend DOC_ID_91_0}{\*\bkmkend cite_id_91}91.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_91"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Plan to Bring Generic AIDS Drugs to Poor Nations}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, April 6, 2004 Tuesday, Section F; Column 3; Health & Fitness; Pg. 6, 1033 words, By DONALD G. McNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_92_0}{\*\bkmkstart cite_id_92}{\*\bkmkend DOC_ID_92_0}{\*\bkmkend cite_id_92}92.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_92"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Coalition Expands AIDS Drug Plan;  Over 100 Nations May Get Discounts}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Washington Post, April 6, 2004 Tuesday, A Section; A01, 822 words, Shankar Vedantam, Washington Post Staff Writer\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_93_0}{\*\bkmkstart cite_id_93}{\*\bkmkend DOC_ID_93_0}{\*\bkmkend cite_id_93}93.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_93"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PLAN TO BATTLE AIDS WORLDWIDE IS FALLING SHORT}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The New York Times, March 28, 2004 Sunday  Correction Appended, Section 1; Column 6; Foreign Desk; Pg. 1, 1393 words, By DONALD G. McNEIL Jr.\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_94_0}{\*\bkmkstart cite_id_94}{\*\bkmkend DOC_ID_94_0}{\*\bkmkend cite_id_94}94.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_94"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GSK loses third court case in as many weeks}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Chemist & Druggist, March 27, 2004, Pg. 8, 285 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_95_0}{\*\bkmkstart cite_id_95}{\*\bkmkend DOC_ID_95_0}{\*\bkmkend cite_id_95}95.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_95"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 WHITE HOUSE GETS PRESSURE ON AIDS PLAN}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  WALL STREET JOURNAL ABSTRACTS, March 25, 2004, Thursday, Section A; Page 4, Column 1, 44 words, BY SARAH LUECK\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_96_0}{\*\bkmkstart cite_id_96}{\*\bkmkend DOC_ID_96_0}{\*\bkmkend cite_id_96}96.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_96"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 International}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Globe and Mail (Canada), March 22, 2004 Monday, REPORT ON BUSINESS: THE WALL STREET JOURNAL; What's News; Pg. B6, 80 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_97_0}{\*\bkmkstart cite_id_97}{\*\bkmkend DOC_ID_97_0}{\*\bkmkend cite_id_97}97.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_97"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GSK loses generic battle}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London) - Final Edition, March 20, 2004, Guardian City Pages, Pg. 28, 349 words, Heather Stewart\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_98_0}{\*\bkmkstart cite_id_98}{\*\bkmkend DOC_ID_98_0}{\*\bkmkend cite_id_98}98.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_98"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 GSK LOSES PATENT CASE ON TOP ASTHMA DRUG}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Independent (London), March 20, 2004, Saturday, First Edition; BUSINESS; Pg. 55, 299 words, OUR CITY STAFF\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_99_0}{\*\bkmkstart cite_id_99}{\*\bkmkend DOC_ID_99_0}{\*\bkmkend cite_id_99}99.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_99"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000064006f0063005f00690064005f00390039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Glaxo loses patent case on asthma drug}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Irish Times, March 20, 2004, CITY EDITION; BUSINESS AND FINANCE; IN SHORT; Pg. 16, 88 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_100_0}{\*\bkmkstart cite_id_100}{\*\bkmkend DOC_ID_100_0}{\*\bkmkend cite_id_100}100.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_100"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Dose of turf war: Indian generic drugmakers are waging ferocious battle with global conglomerates bent on protecting their patents}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Gazette (Montreal, Quebec), December 27, 2003 Saturday Final Edition, Business; Pg. B4, 902 words, SARITHA RAI\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_101_0}{\*\bkmkstart cite_id_101}{\*\bkmkend DOC_ID_101_0}{\*\bkmkend cite_id_101}101.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_101"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 INTERNATIONAL BUSINESS;  Generic Drugs From India Prompting Turf Battles}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964    The New York Times, December 26, 2003 Friday, Section C; Column 2; Business/Financial Desk; Pg. 1, 1699 words,  By SARITHA RAI \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_102_0}{\*\bkmkstart cite_id_102}{\*\bkmkend DOC_ID_102_0}{\*\bkmkend cite_id_102}102.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_102"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Pioneering spirit of a drugmaker}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  New Straits Times (Malaysia), December 9, 2003, Tuesday, Health; Pg. 7, 885 words, By Koh Lay Chin\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_103_0}{\*\bkmkstart cite_id_103}{\*\bkmkend DOC_ID_103_0}{\*\bkmkend cite_id_103}103.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_103"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; World Health Organisation Announces Approval of Generic Antiretrovirals}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, December 2, 2003 Tuesday, 538 words, UN Integrated Regional Information Networks\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_104_0}{\*\bkmkstart cite_id_104}{\*\bkmkend DOC_ID_104_0}{\*\bkmkend cite_id_104}104.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_104"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Welcome news for Aids patients}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Sunday Times (South Africa), November 30, 2003, Economy, Business & Finance; Pg. 22, 261 words, Nicholas Neveling\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_105_0}{\*\bkmkstart cite_id_105}{\*\bkmkend DOC_ID_105_0}{\*\bkmkend cite_id_105}105.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_105"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa Gears Up for AIDS Fight }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964    The New York Times, November 21, 2003 Friday, Section W; Column 4; Business/Financial Desk; Pg. 1, 1120 words,  By NICOLE ITANO\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_106_0}{\*\bkmkstart cite_id_106}{\*\bkmkend DOC_ID_106_0}{\*\bkmkend cite_id_106}106.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_106"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 India's drug makers gain clout}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Globe and Mail (Canada), November 13, 2003 Thursday, REPORT ON BUSINESS: THE WALL STREET JOURNAL; Pg. B10, 595 words, JOANNA SLATER\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_107_0}{\*\bkmkstart cite_id_107}{\*\bkmkend DOC_ID_107_0}{\*\bkmkend cite_id_107}107.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_107"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Will US Opt for Copies Or Generics?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 30, 2003 Thursday, 806 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_108_0}{\*\bkmkstart cite_id_108}{\*\bkmkend DOC_ID_108_0}{\*\bkmkend cite_id_108}108.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_108"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS Plan Would Cut Drug Costs For Poor;  WHO Would Provide 3-in-1 Pill to Nations}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Washington Post, October 25, 2003 Saturday, A Section; A01, 1133 words, Shankar Vedantam, Washington Post Staff Writer\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_109_0}{\*\bkmkstart cite_id_109}{\*\bkmkend DOC_ID_109_0}{\*\bkmkend cite_id_109}109.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_109"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100300039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; The Bottom Line}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 24, 2003 Friday, 926 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_110_0}{\*\bkmkstart cite_id_110}{\*\bkmkend DOC_ID_110_0}{\*\bkmkend cite_id_110}110.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_110"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; Clinton, Aspen to Cut Price of Aids Drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 24, 2003 Friday, 471 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_111_0}{\*\bkmkstart cite_id_111}{\*\bkmkend DOC_ID_111_0}{\*\bkmkend cite_id_111}111.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_111"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Aids-Drugs Price War is Far From Over}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 20, 2003 Monday, 603 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_112_0}{\*\bkmkstart cite_id_112}{\*\bkmkend DOC_ID_112_0}{\*\bkmkend cite_id_112}112.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_112"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Foreign Firms Block Generic Aids Drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, October 17, 2003 Friday, 551 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_113_0}{\*\bkmkstart cite_id_113}{\*\bkmkend DOC_ID_113_0}{\*\bkmkend cite_id_113}113.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_113"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Pharmaceutical companies charging unfair prices for essential Aids medicines, says South African commission: Ruling opens the door for cut-price HIV drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian - Final Edition, October 17, 2003, Guardian Foreign Pages, Pg. 17, 796 words, Sarah Boseley Health editor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_114_0}{\*\bkmkstart cite_id_114}{\*\bkmkend DOC_ID_114_0}{\*\bkmkend cite_id_114}114.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_114"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 AIDS; Are Generic Drugs As Cheap As They Are Priced?}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, September 15, 2003 Monday, 1043 words, African Church Information Service\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_115_0}{\*\bkmkstart cite_id_115}{\*\bkmkend DOC_ID_115_0}{\*\bkmkend cite_id_115}115.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_115"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda; Ugandans Outdo Americans in Aids Drugs Compliance}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, September 5, 2003 Friday, 663 words, The Monitor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_116_0}{\*\bkmkstart cite_id_116}{\*\bkmkend DOC_ID_116_0}{\*\bkmkend cite_id_116}116.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_116"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Africans Outdo U.S. Patients In Following AIDS Therapy }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964    The New York Times, September 3, 2003 Wednesday  Correction Appended, Section A; Column 1; Foreign Desk; Pg. 1, 1465 words,   By DONALD G. McNEIL Jr. \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_117_0}{\*\bkmkstart cite_id_117}{\*\bkmkend DOC_ID_117_0}{\*\bkmkend cite_id_117}117.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_117"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 WTO drug deal to spark competition}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, September 2, 2003 Tuesday, THE NEWS; World, 610 words, By RAVI KANTH IN GENEVA\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_118_0}{\*\bkmkstart cite_id_118}{\*\bkmkend DOC_ID_118_0}{\*\bkmkend cite_id_118}118.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_118"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Cheap drug plan founders}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Globe and Mail (Canada), August 30, 2003 Saturday, REPORT ON BUSINESS: INTERNATIONAL; Pg. B6, 544 words, WARREN GILES, Bloomberg News\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_119_0}{\*\bkmkstart cite_id_119}{\*\bkmkend DOC_ID_119_0}{\*\bkmkend cite_id_119}119.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_119"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100310039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Proposed WTO deal set to bring hope to poorer nations; It calls for relaxing patent provisions, issuing of licences to producers in poorer nations}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Business Times Singapore, August 29, 2003 Friday, THE NEWS; World, 416 words, Ravi Kanth\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_120_0}{\*\bkmkstart cite_id_120}{\*\bkmkend DOC_ID_120_0}{\*\bkmkend cite_id_120}120.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_120"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Mixed View of a Pact for Generic Drugs }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964    The New York Times, August 29, 2003 Friday, Section C; Column 3; Business/Financial Desk; Pg. 3, 990 words,  By TONY SMITH; Saritha Rai and Nicole Itano contributed to this article. \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_121_0}{\*\bkmkstart cite_id_121}{\*\bkmkend DOC_ID_121_0}{\*\bkmkend cite_id_121}121.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_121"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Last-minute deal on cheap drugs: Late deal on cheap drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), August 28, 2003, Guardian Home Pages, Pg. 1, 757 words, Charlotte Denny and Sarah Boseley\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_122_0}{\*\bkmkstart cite_id_122}{\*\bkmkend DOC_ID_122_0}{\*\bkmkend cite_id_122}122.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_122"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Americans seeking pledges on drug rules}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Toronto Star, August 26, 2003 Tuesday, 238 words, Warren Giles, Bloomberg News\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_123_0}{\*\bkmkstart cite_id_123}{\*\bkmkend DOC_ID_123_0}{\*\bkmkend cite_id_123}123.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_123"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964  Future looks healthy for India's copycat drugs industry}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Times (London), August 16, 2003, Saturday, Business; 46, 1308 words, Carl Mortished\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_124_0}{\*\bkmkstart cite_id_124}{\*\bkmkend DOC_ID_124_0}{\*\bkmkend cite_id_124}124.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_124"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Bush in Africa: The diplomacy: SPECIAL REPORT by Jo Revill in Gaborone: How the Aids battle can be won: In Botswana, where a third of the population has the condition, one pioneering clinic has shown it is not too late for a ravaged continent to fight back and survive the epidemic}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Observer, July 6, 2003, Observer News Pages, Pg. 21, 1244 words, Jo Revill\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_125_0}{\*\bkmkstart cite_id_125}{\*\bkmkend DOC_ID_125_0}{\*\bkmkend cite_id_125}125.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_125"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 South Africa; Generic Medicines Market May Double}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, June 25, 2003 Wednesday, 328 words, Business Day\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_126_0}{\*\bkmkstart cite_id_126}{\*\bkmkend DOC_ID_126_0}{\*\bkmkend cite_id_126}126.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_126"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Drug Maker's Vow to Donate Cancer Medicine Falls Short }}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964    The New York Times, June 5, 2003 Thursday  Correction Appended, Section A; Column 1; Business/Financial Desk; Pg. 1, 3007 words,   By STEPHANIE STROM and MATT FLEISCHER-BLACK; Saritha Rai in Bangalore, India, contributed to this report. \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_127_0}{\*\bkmkstart cite_id_127}{\*\bkmkend DOC_ID_127_0}{\*\bkmkend cite_id_127}127.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_127"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 TIME TO PUT DRUG GIANTS ON TRIAL}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Scotsman, May 19, 2003, Monday, Pg. 12, 1543 words, Margaret Cook\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_128_0}{\*\bkmkstart cite_id_128}{\*\bkmkend DOC_ID_128_0}{\*\bkmkend cite_id_128}128.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_128"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Uganda; 3 Firms to Supply Cheap Aids Drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, May 8, 2003 Thursday, 363 words, The Monitor\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_129_0}{\*\bkmkstart cite_id_129}{\*\bkmkend DOC_ID_129_0}{\*\bkmkend cite_id_129}129.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_129"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100320039000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 PanAfrica; Aids: Even With Discounts from Drug Firms, Generics Remain Far Cheaper}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Africa News, May 5, 2003 Monday, 1233 words, The East African\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_130_0}{\*\bkmkstart cite_id_130}{\*\bkmkend DOC_ID_130_0}{\*\bkmkend cite_id_130}130.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_130"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330030000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 LAST NIGHT'S TELEVISION: ENOUGH TO MAKE YOU FEEL SICK; DYING FOR DRUGS C4}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Independent (London), April 28, 2003, Monday, FEATURES; Pg. 21, 690 words, THOMAS SUTCLIFFE\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_131_0}{\*\bkmkstart cite_id_131}{\*\bkmkend DOC_ID_131_0}{\*\bkmkend cite_id_131}131.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_131"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330031000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Lundbeck setback to protection of Cipramil}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Chemist & Druggist, February 22, 2003, Pg. 24, 220 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_132_0}{\*\bkmkstart cite_id_132}{\*\bkmkend DOC_ID_132_0}{\*\bkmkend cite_id_132}132.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_132"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330032000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Saving grace: Yusuf Hamied Generic drugs boss: He says he could save millions from death if the western giants would waive their patent rights and more governments would buy his drugs}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), February 18, 2003, Guardian Special Supplement, Pg. 8, 1353 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_133_0}{\*\bkmkstart cite_id_133}{\*\bkmkend DOC_ID_133_0}{\*\bkmkend cite_id_133}133.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_133"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330033000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Saving grace: Harvey Bale Jnr Drug firms' federation: The 20-year monopoly on new drugs is essential in generating profits to pay for research. Aids is a government problem, he says, not an industry one}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), February 18, 2003, Guardian Special Supplement, Pg. 8, 1329 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_134_0}{\*\bkmkstart cite_id_134}{\*\bkmkend DOC_ID_134_0}{\*\bkmkend cite_id_134}134.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_134"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330034000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Saving Grace: The 12 essential Aids drugs: The World Health Organisation list}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), February 18, 2003, Guardian Special Supplement, Pg. 9, 825 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_135_0}{\*\bkmkstart cite_id_135}{\*\bkmkend DOC_ID_135_0}{\*\bkmkend cite_id_135}135.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_135"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330035000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Saving grace: Jean Pierre Garnier Head of Glaxo: He will drop the prices of his drugs to the poorest countries, as long as GSK does not make a loss. If they are still unaffordable, the UN should pay}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), February 18, 2003, Guardian Special Supplement, Pg. 10, 2546 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_136_0}{\*\bkmkstart cite_id_136}{\*\bkmkend DOC_ID_136_0}{\*\bkmkend cite_id_136}136.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_136"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330036000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Leading article: Saving Grace: Defeating Aids needs a global approach}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  The Guardian (London), February 18, 2003, Guardian Leader Pages, Pg. 19, 716 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_137_0}{\*\bkmkstart cite_id_137}{\*\bkmkend DOC_ID_137_0}{\*\bkmkend cite_id_137}137.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_137"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330037000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Glaxo hit over on-line stand, AIDS;  Ad campaign, false advertising suit land as drug maker announces 11% profit rise}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964   The Globe and Mail (Canada), February 13, 2003 Thursday, REPORT ON BUSINESS: INTERNATIONAL; Pg. B11, 620 words, LEONARD ZEHR, BIOTECHNOLOGY REPORTER, With files from Reuters\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par \ltrrow}\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\hyphpar0\faauto\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 {\*\bkmkstart DOC_ID_138_0}{\*\bkmkstart cite_id_138}{\*\bkmkend DOC_ID_138_0}{\*\bkmkend cite_id_138}138.\cell }{\field{\*\fldinst {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 HYPERLINK \\l"doc_id_138"}{\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000064006f0063005f00690064005f003100330038000000}}}{\fldrslt {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\ul\cf2\insrsid2900964 Bush in backflip with AIDS approach}}}\sectd \ltrsect\pgnrestart\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964  Hobart Mercury (Australia), January 31, 2003, Friday, WORLD; Pg. 18, 358 words\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1\afs18 \ltrch\fcs0 \f1\fs18\insrsid2900964 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph60\trleft-60\trftsWidth1\trpaddl60\trpaddr60\trpaddfl3\trpaddfr3\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth540\clshdrawnil \cellx480\clvertalt\clbrdrt\brdrs\brdrw15 \clbrdrl\brdrs\brdrw15 \clbrdrb\brdrs\brdrw15 \clbrdrr\brdrs\brdrw15 \cltxlrtb\clftsWidth3\clwWidth9180\clshdrawnil \cellx9660\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda; New Law Will Hinder ARV Supply Africa News July 25, 2006 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_139}{\*\bkmkstart DOC_ID_139_0}{\*\bkmkstart doc_id_1}{\*\bkmkend DOC_ID_139}{\*\bkmkend DOC_ID_139_0}{\*\bkmkend doc_id_1}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_1"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2006 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda; \par New Law Will Hinder ARV Supply}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 New Vision\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 486 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SCARING news for the poor living with HIV/AIDS has popped up once again. Reuters reported last week that India is planning to change its drug approval system in a way that would put the price of Anti Retroviral drugs (ARVs) out of reach of millions of poor people.\par New Delhi, under pressure from the United States and global drug giants, is considering a law that could grant a monopoly to the developer of a new drug for several years even without a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Leena Menghaney of Swiss-based Medecins Sans Frontieres, which campaigns for better access to healthcare, says this will seriously affect accessibility to essential drugs for poor people, especially in developing countries. \par Particularly threatened are people with HIV who had developed immunity to first-line anti-retroviral drugs and were waiting for second-line drugs to become affordable, Menghaney said.\par According to a Reuters report, making generic ARVs has been easy in India. Once a new drug is approved for sale, other drug companies only need to prove that the one they are copying is identical to the original. But innovating drug companies say this is unfair. That they invest millions of dollars collecting the necessary data they need for marketing approval through clinical trials yet the system makes it difficult for them to r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cover their investment capital.\par They argue that this reduces the incentive to research and develop new drugs.\par India, as a member of the World Health Organisation (WHO), is being hard pressed to concede to the d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mands of the US and the giant companies by giving them exclusive rights to reap the benefit of their inves}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment for several years under the Trade-related aspects of Intellectual Property Rights (TRIPs) treaty.\par However, other campaigners including WHO argue that facts go beyond what TRIPS require and should not be introduced at the expense of public health.\par At least 90,000 Ugandans urgently need ARVs and India remains the main manufacturer of these lifesavers.\par But Dr Elizabeth Madra, the Head of the Aids Control Programme at the Ministry of Health, says Uganda is on the verge of manufacturing ARVs. Quality Chemicals Limited, a local agent of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd, the worlds lea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing manufacturer of generic pharmaceutical drugs, is constructing the plant in Luzira Industrial Park.\par Emmanuel Katongore, the managing director of Quality Chemicals, said the $50m project is expected to start test runs this month and the project is expected to be commissioned in October.\par Dr Philip Okumu from Bugolobi Nursing Home said generic drugs have been a blessing to the poor who ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 not afford brand names. The cost of one brand name ARV dose can purchase three doses of generic drugs. Okumu said if India yields to the US pressure, over 25 million people in sub-Saharan Africa would be affec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed. "Very few people can afford branded ARVs. This would mean that over 80% of the people in poor cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries would be affected," he said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); AIDS & HIV (91%); CLINICAL TRIALS (90%); DRUG & MEDICAL DEVICES APPROVAL (90%); ANTIVIRALS (89%); PRESCRIPTION DRUGS (89%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (89%); GENERIC DRUGS (89%); PUBLIC HEALTH ADMINISTRATION (87%); BRANDING (87%); MANUFACTURING OUTPUT (78%); HEALTH DEPARTMENTS (78%); DRUG DESIGN & DISCOVERY (78%); AIDS & HIV TREATMENT (78%); DEVELOPING COUNTRIES (78%); INTELLE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUAL PROPERTY (78%); APPROVALS (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (76%); INDUSTRIAL PROPERTY (76%); PHARMACEUTICALS PRODUCT DEVELOPMENT (76%); DRUG PRICES (73%); GENERIC PRODUCTS (72%); LEGAL MONOPOLIZATION (71%); RELIEF ORGANIZATIONS (70%); MEDICAL CHARITIES (70%); HEALTH CARE ACCESS (70%); LONG TERM HEALTH CARE (70%); LICENSING AGREEMENTS (66%); PLANT CONSTRUCTION (61%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (71%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (84%); SIC2834 PHARMACEUTICAL PREPARATIONS (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (90%) INDIA (95%); UNITED STATES (94%); UGANDA (94%); AFR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CA (79%); SUB SAHARAN AFRICA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 26, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newsletter\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Need to know The Times (London) July 22, 2006, Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_140}{\*\bkmkstart DOC_ID_140_0}{\*\bkmkstart doc_id_2}{\*\bkmkend DOC_ID_140}{\*\bkmkend DOC_ID_140_0}{\*\bkmkend doc_id_2}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_2"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 2 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2006, Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Need to know}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSINESS; Pg. 58\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1412 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMICS\par UK output grew by 0.8 per cent in the second quarter of 2006, making overall growth more than 1.5 per cent for the first half of the year, according to first estimates from the Office for National Statistics. Year on year, GDP rose by 2.6 per cent. Page 60\par World Cup fever hit France even more than Britain, causing a 1.7 per cent surge in consumer spending in June, as families stocked up on new television systems. \par BANKING & FINANCE\par DOWN 1.22%\par John Mack, one of the most powerful figures on Wall Street, is to be interviewed by the US Securities and Exchange Commission over allegations linking him to insider trading. Page 56\par Huw van Steenis, the Morgan Stanley banking analyst, is quitting research to lead a new division at the i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vestment bank focusing on advising asset and wealth management firms.\par HSBC has agreed the $1.7 billion (\u163\'a3 960 million) takeover of the biggest bank in Central America in a deal that will propel Europe's biggest lender into five new markets in the fast-growing region. Page 62\par An American judge has thrown out claims against Barclays in a multibillion dollar class-action lawsuit brought by Enron shareholders. Page 62\par Christian Siva-Jothy, the former Goldman Sachs trader, has delivered disappointing returns at his new hedge fund. Page 65\par CONSTRUCTION & PROPERTY\par DOWN 0.71%\par London's Hippodrome in Leicester Square has been granted consent for a casino.\par Simon Thomas, Jon Shipley and Peter NcNally, the entrepreneurs, want to transform the Grade II-listed building into a casino and cabaret club.\par CONSUMER GOODS\par UP 0.75%\par Sara Lee, the US conglomerate, will be paid $2.4 billion (\u163\'a3 1.3 billion) by Hanesbrands, its apparel unit which is being spun off into a standalone listed entity.\par Nigel Stapleton, the long-serving chairman of Uniq, is standing down at the end of the year, to be replaced by Ross Warburton.\par ENGINEERING\par DOWN 1.56%\par Volvo, the Swedish carmaker, is negotiating a tie-up with a construction machinery maker in East China, b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 coming the latest foreign giant to tap the country's booming construction equipment sector.\par BMW, the carmaker, is recalling 22,000 1-Series and 3-Series cars to check possible faults with a screw that holds the generator in place.\par HEALTH\par UP 0.03%\par Strong US demand for leading drugs, boosted by recent Medicare reforms, should allow AstraZeneca to d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 liver another quarter of strong earnings growth next week, according to industry analysts.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India's most valuable drug maker, said on Friday that its quarterly net profit rose 52.6 per cent, beating estimates, because of higher sales of off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  generics, anti-asthma inhalers and lower factory tax.\par Transgene, the French biotechnology company, said it has appointed Michel Dubois as its chairman to su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceed Christophe Merieux, who died last week.\par Eli Lilly, of the US, reported second-quarter profits fuelled by strong revenue growth for newer drugs, inclu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing almost doubled sales of its Cymbalta depression treatment.\par INDUSTRIALS\par DOWN 2.03%\par SeverStal, the Russian steel maker, said it was paid Euro 140 million (\u163\'a3 95.5 million) in compensation by Arcelor after the European steel giant abandoned a proposed merger of the two companies in favour of a takeover by Mittal Steel.\par LEISURE\par DOWN 0.38%\par Mitchells & Butlers, the public house operator, said that it still planned to return \u163\'a3 500 million to shareholders by the end of the year, despite confirmation that it is buying 239 pub-restaurants from Whitbread for \u163\'a3 497 million.\par London Clubs International, which is engaged in merger talks with Stanley Leisure, reported a full-year loss of \u163\'a3 3.6 million, compared with \u163\'a3 5 million previously.\par MEDIA\par DOWN 0.69%\par Metal Bulletin, the publisher of data and information on metal and financial markets, has spurned a "derisory" \u163\'a3 188 million takeover approach from Euromoney. Page 63\par Rupert Murdoch, chief executive of News Corporation, hinted that he would be interested in a US satellite merger between DirecTV and rival Echostar. Page 63\par Financial News is in talks sell its weekly newspaper to an unnamed "US-based financial publisher" for \u163\'a3 25 million.\par PagesJaunes, the French Yellow Pages business, forecast that its 2006 revenue and gross operating margin growth would be at the bottom end of targets as it posted a 9.5 per cent rise in first-half net profit.\par NATURAL RESOURCES\par DOWN 2.51%\par Oxus Gold, the embattled AIM-listed miner, said it would pursue "all legal remedies available" to reclaim its licence to develop the massive Jerooy goldfield in Kyrgyzstan.\par Inco has dropped a poison pill plan that was designed to deter any predatory takeover activity, after strong opposition from Teck Cominco, which has launched a hostile bid for the Canadian nickel miner.\par RETAILING\par UP 0.33%\par Retailers have criticised the imposition of anti-dumping tariffs on the import of plastic bags from China and Thailand.\par John Lewis said sales at its department stores were up 16.2 per cent in the week to July 15 compared with the same week a year before. Sales at Waitrose, the group's supermarket, were up 8.5 per cent.\par SUPPORT SERVICES\par DOWN 1.44%\par Regus has continued its UK spending spree, buying Managed Office Solutions, the London-based serviced office company.\par Alpha Airports, the airline caterer and airports retailer, has paid Kevin Abbott, its former chief executive, \u163\'a3 264,630 and Heather McRae, its former finance director, \u163\'a3 118,957 in compensation after forcing their resi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nation in May.\par Vedior, the world's third-largest temping agency, said it completed a private debt placement of $215 million (\u163\'a3 116 million) with US institutional investors. It said the placement was oversubscribed.\par Cognos, a business consulting firm, said the Securities and Exchange Commission had no objections to the company's financial reporting methods after completing a review.\par TECHNOLOGY\par DOWN 2.20%\par NSB Retail Systems, the software group, predicted a 40 per cent rise in first-half operating profits excluding one-off items to $9 million (\u163\'a3 4.8 million), ahead of expectations.\par Ericsson, the telecoms equipment maker, reported continued losses at the former business of Marconi du}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the second quarter, knocking shares in the Swedish group. However, the group gave an upbeat report on progress at Sony Ericsson, the joint venture mobile-phone maker.\par Shares in Dell plummeted to their lowest level in almost five years as the world's largest computer maker gave warning that second-quarter profits would fall short of Wall Street expectations by a third. Page 63\par Infineon, the German chip maker, missed expectations for its third quarter as strong results at Qimonda, its soon-to-be divested memory subsidiary, failed to compensate for the rest of the business.\par Telent, the rump of the Marconi telecoms equipment business, yesterday postponed a shareholder vote on a \u163\'a3 346 million takeover in an attempt to stop a secretive American hedge fund manager from blocking the deal. Page 63\par TELECOMS\par UP 0.22%\par Eutelsat, the European telecoms group, reported forecast-beating full-year sales, helped by demand for its video broadcasting services in emerging markets.\par Arun Sarin, the chief executive of Vodafone, will face a fight to save his job next week after Morley Fund Management announced that it would vote against his reappointment to the board. Page 56\par KDDI, Japan's second-largest telecoms operator, reported a 39 per cent jump in operating profits to 121.9 billion yen (\u163\'a3 564 million) in the April to June quarter, on the back of strong demand for its mobile-phone se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices.\par Lee Hsien Yang, chief executive of Singapore Telecommunications and son of Lee Kuan Yew, the city-state's founding father, has stepped down from his post at South-East Asia's largest telecoms group.\par Cable & Wireless shareholders have agreed to plans to hand executives payouts of as much as \u163\'a3 220 mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lion. Page 63\par TRANSPORT\par 0.74%\par Singapore Airlines became the world's first airline to order the new Airbus A350 XWB and pledged to buy more of the delayed A380 superjumbo in a deal potentially worth $7.5 billion (\u163\'a3 4 billion). Page 60\par UTILITIES\par 0.09%\par Four of the 22 water companies in England and Wales failed to hit their leakage targets last year. They co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lectively lost 76 million litres of water per day in excess of the limits set by Ofwat.\par sectors@thetimes.co.uk = sector index percentage change\par This newspaper adheres to the system of self-regulation overseen by the Press Complaints Commission. The PCC takes complaints about the editorial content of publications under the Editors' Code of Practice, a copy of which can be found at www.pcc.org.uk\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMIC NEWS (90%); BANKING & FINANCE (90%); AUTOMOBILE MFG (89%); COMP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NY EARNINGS (89%); PHARMACEUTICALS INDUSTRY (89%); AUTOMOTIVE MFG (88%); AUTOMA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 K}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERS (85%); GROSS DOMESTIC PRODUCT (79%); CONSUMER SPENDING (78%); CONSUMER SPEN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING & CREDIT (78%); BANKING & FINANCE SECTOR PERFORMANCE (78%); COMPANY PROFITS (78%); STATISTICS (78%); INDUSTRY ANALYSTS (77%); ENGINEERING (75%); INVESTMENT BAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 K}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (75%); LITIGATION (74%); FOOD INDUSTRY (73%); TAKEOVERS (73%); SUITS & CLAIMS (72%); APPOINTMENTS (71%); GENERIC PRODUCTS (71%); SPORTS & RECREATION (71%); CONSTRU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (70%); SHAREHOLDERS (69%); INSIDER TRADING (69%); CLASS ACTIONS (69%); AUTOMOTIVE RECALLS (69%); BIOTECHNOLOGY & GENETIC SCIENCE (69%); ENTREPRENEURSHIP (68%); WEALTH MANAGEMENT (68%); JUDGES (66%); MEDICARE (66%); PHARMACEUTICAL PREPARATION MFG (65%); CONSTRUCTION EQUIPMENT MFG (65%); MACHINERY & EQUIPMENT MFG (65%); DRUG DELIVERY SYSTEMS (63%); AEROSOL DRUGS (60%); CONSTRUCTION EQUIPMENT (60%); BI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TECHNOLOGY INDUSTRY (60%); ASTHMA (50%); PRODUCT RECALLS (50%); HEDGE FUNDS (50%) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GOLDMAN SACHS GROUP INC (90%); MORGAN STANLEY (57%); ENRON CREDITORS RECOVERY CORP (55%); HANESBRANDS INC (53%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (51%); ASTRAZENECA PLC (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SECURITIES & EXCHANGE COMMISSION (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GS (NYSE) (90%); MS (NYSE) (57%); HBI (NYSE) (53%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (51%); AZN (STO) (51%); AZN (NYSE) (51%); AZN (LSE) (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS523930 INVESTMENT ADVICE (90%); NAICS523920 PORTFOLIO MANAGEMENT (90%); NAICS523110 INVESTMENT BANKING & SECURITIES DEALING (90%); SIC6289 SERVICES A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LIED WITH THE EXCHANGE OF SECURITIES OR COMMODITIES, NEC (90%); SIC6282 INVESTMENT ADVICE (90%); SIC6211 SECURITY BROKERS, DEALERS, & FLOTATION COMPANIES (90%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS523120 SECURITIES BROKERAGE (57%); SIC4911 ELECTRIC SERVICES (55%); NAICS315990 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAREL ACCESSORIES & OTHER APPAREL MANUFACTURING (53%); NAICS315240 WOMEN'S, GIRLS' & INFANTS' CUT & SEW APPAREL MANUFACTURING (53%); NAICS315220 MEN'S & BOYS' CUT & SEW APPAREL MANUFACTURING (53%); SIC2389 APPAREL & ACCESSORIES, NEC (53%); SIC2341 WOMEN'S, MISSES', CHILDREN'S, & INFANTS' UNDERWEAR & NIGHTWEAR (53%); SIC2322 MEN'S & BOYS' UNDERWEAR & NIGHTWEAR (53%); NAICS325412 PHARMACEUTICAL PREPARATION MAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FACTURING (51%); SIC2834 PHARMACEUTICAL PREPARATIONS (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (58%) UNITED STATES (93%); FRANCE (92%); UNITED KINGDOM (91%); INDIA (79%); CHINA (79%); EUROPE (79%); CENTRAL AMERICA (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 22, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Times Newspapers Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Need to know The Times (London) July 22, 2006, Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_141}{\*\bkmkstart DOC_ID_141_0}{\*\bkmkstart doc_id_3}{\*\bkmkend DOC_ID_141}{\*\bkmkend DOC_ID_141_0}{\*\bkmkend doc_id_3}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_3"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 3 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2006, Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Need to know}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSINESS; Pg. 58\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1412 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMICS\par UK output grew by 0.8 per cent in the second quarter of 2006, making overall growth more than 1.5 per cent for the first half of the year, according to first estimates from the Office for National Statistics. Year on year, GDP rose by 2.6 per cent. Page 60\par World Cup fever hit France even more than Britain, causing a 1.7 per cent surge in consumer spending in June, as families stocked up on new television systems. \par BANKING & FINANCE\par DOWN 1.22%\par John Mack, one of the most powerful figures on Wall Street, is to be interviewed by the US Securities and Exchange Commission over allegations linking him to insider trading. Page 56\par Huw van Steenis, the Morgan Stanley banking analyst, is quitting research to lead a new division at the i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vestment bank focusing on advising asset and wealth management firms.\par HSBC has agreed the $1.7 billion (\u163\'a3 960 million) takeover of the biggest bank in Central America in a deal that will propel Europe's biggest lender into five new markets in the fast-growing region. Page 62\par An American judge has thrown out claims against Barclays in a multibillion dollar class-action lawsuit brought by Enron shareholders. Page 62\par Christian Siva-Jothy, the former Goldman Sachs trader, has delivered disappointing returns at his new hedge fund. Page 65\par CONSTRUCTION & PROPERTY\par DOWN 0.71%\par London's Hippodrome in Leicester Square has been granted consent for a casino.\par Simon Thomas, Jon Shipley and Peter NcNally, the entrepreneurs, want to transform the Grade II-listed building into a casino and cabaret club.\par CONSUMER GOODS\par UP 0.75%\par Sara Lee, the US conglomerate, will be paid $2.4 billion (\u163\'a3 1.3 billion) by Hanesbrands, its apparel unit which is being spun off into a standalone listed entity.\par Nigel Stapleton, the long-serving chairman of Uniq, is standing down at the end of the year, to be replaced by Ross Warburton.\par ENGINEERING\par DOWN 1.56%\par Volvo, the Swedish carmaker, is negotiating a tie-up with a construction machinery maker in East China, b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 coming the latest foreign giant to tap the country's booming construction equipment sector.\par BMW, the carmaker, is recalling 22,000 1-Series and 3-Series cars to check possible faults with a screw that holds the generator in place.\par HEALTH\par UP 0.03%\par Strong US demand for leading drugs, boosted by recent Medicare reforms, should allow AstraZeneca to d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 liver another quarter of strong earnings growth next week, according to industry analysts.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India's most valuable drug maker, said on Friday that its quarterly net profit rose 52.6 per cent, beating estimates, because of higher sales of off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  generics, anti-asthma inhalers and lower factory tax.\par Transgene, the French biotechnology company, said it has appointed Michel Dubois as its chairman to su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceed Christophe Merieux, who died last week.\par Eli Lilly, of the US, reported second-quarter profits fuelled by strong revenue growth for newer drugs, inclu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing almost doubled sales of its Cymbalta depression treatment.\par INDUSTRIALS\par DOWN 2.03%\par SeverStal, the Russian steel maker, said it was paid Euro 140 million (\u163\'a3 95.5 million) in compensation by Arcelor after the European steel giant abandoned a proposed merger of the two companies in favour of a takeover by Mittal Steel.\par LEISURE\par DOWN 0.38%\par Mitchells & Butlers, the public house operator, said that it still planned to return \u163\'a3 500 million to shareholders by the end of the year, despite confirmation that it is buying 239 pub-restaurants from Whitbread for \u163\'a3 497 million.\par London Clubs International, which is engaged in merger talks with Stanley Leisure, reported a full-year loss of \u163\'a3 3.6 million, compared with \u163\'a3 5 million previously.\par MEDIA\par DOWN 0.69%\par Metal Bulletin, the publisher of data and information on metal and financial markets, has spurned a "derisory" \u163\'a3 188 million takeover approach from Euromoney. Page 63\par Rupert Murdoch, chief executive of News Corporation, hinted that he would be interested in a US satellite merger between DirecTV and rival Echostar. Page 63\par Financial News is in talks sell its weekly newspaper to an unnamed "US-based financial publisher" for \u163\'a3 25 million.\par PagesJaunes, the French Yellow Pages business, forecast that its 2006 revenue and gross operating margin growth would be at the bottom end of targets as it posted a 9.5 per cent rise in first-half net profit.\par NATURAL RESOURCES\par DOWN 2.51%\par Oxus Gold, the embattled AIM-listed miner, said it would pursue "all legal remedies available" to reclaim its licence to develop the massive Jerooy goldfield in Kyrgyzstan.\par Inco has dropped a poison pill plan that was designed to deter any predatory takeover activity, after strong opposition from Teck Cominco, which has launched a hostile bid for the Canadian nickel miner.\par RETAILING\par UP 0.33%\par Retailers have criticised the imposition of anti-dumping tariffs on the import of plastic bags from China and Thailand.\par John Lewis said sales at its department stores were up 16.2 per cent in the week to July 15 compared with the same week a year before. Sales at Waitrose, the group's supermarket, were up 8.5 per cent.\par SUPPORT SERVICES\par DOWN 1.44%\par Regus has continued its UK spending spree, buying Managed Office Solutions, the London-based serviced office company.\par Alpha Airports, the airline caterer and airports retailer, has paid Kevin Abbott, its former chief executive, \u163\'a3 264,630 and Heather McRae, its former finance director, \u163\'a3 118,957 in compensation after forcing their resi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nation in May.\par Vedior, the world's third-largest temping agency, said it completed a private debt placement of $215 million (\u163\'a3 116 million) with US institutional investors. It said the placement was oversubscribed.\par Cognos, a business consulting firm, said the Securities and Exchange Commission had no objections to the company's financial reporting methods after completing a review.\par TECHNOLOGY\par DOWN 2.20%\par NSB Retail Systems, the software group, predicted a 40 per cent rise in first-half operating profits excluding one-off items to $9 million (\u163\'a3 4.8 million), ahead of expectations.\par Ericsson, the telecoms equipment maker, reported continued losses at the former business of Marconi du}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the second quarter, knocking shares in the Swedish group. However, the group gave an upbeat report on progress at Sony Ericsson, the joint venture mobile-phone maker.\par Shares in Dell plummeted to their lowest level in almost five years as the world's largest computer maker gave warning that second-quarter profits would fall short of Wall Street expectations by a third. Page 63\par Infineon, the German chip maker, missed expectations for its third quarter as strong results at Qimonda, its soon-to-be divested memory subsidiary, failed to compensate for the rest of the business.\par Telent, the rump of the Marconi telecoms equipment business, yesterday postponed a shareholder vote on a \u163\'a3 346 million takeover in an attempt to stop a secretive American hedge fund manager from blocking the deal. Page 63\par TELECOMS\par UP 0.22%\par Eutelsat, the European telecoms group, reported forecast-beating full-year sales, helped by demand for its video broadcasting services in emerging markets.\par Arun Sarin, the chief executive of Vodafone, will face a fight to save his job next week after Morley Fund Management announced that it would vote against his reappointment to the board. Page 56\par KDDI, Japan's second-largest telecoms operator, reported a 39 per cent jump in operating profits to 121.9 billion yen (\u163\'a3 564 million) in the April to June quarter, on the back of strong demand for its mobile-phone se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices.\par Lee Hsien Yang, chief executive of Singapore Telecommunications and son of Lee Kuan Yew, the city-state's founding father, has stepped down from his post at South-East Asia's largest telecoms group.\par Cable & Wireless shareholders have agreed to plans to hand executives payouts of as much as \u163\'a3 220 mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lion. Page 63\par TRANSPORT\par 0.74%\par Singapore Airlines became the world's first airline to order the new Airbus A350 XWB and pledged to buy more of the delayed A380 superjumbo in a deal potentially worth $7.5 billion (\u163\'a3 4 billion). Page 60\par UTILITIES\par 0.09%\par Four of the 22 water companies in England and Wales failed to hit their leakage targets last year. They co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lectively lost 76 million litres of water per day in excess of the limits set by Ofwat.\par sectors@thetimes.co.uk = sector index percentage change\par This newspaper adheres to the system of self-regulation overseen by the Press Complaints Commission. The PCC takes complaints about the editorial content of publications under the Editors' Code of Practice, a copy of which can be found at www.pcc.org.uk\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMIC NEWS (90%); BANKING & FINANCE (90%); AUTOMOBILE MFG (89%); COMP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NY EARNINGS (89%); PHARMACEUTICALS INDUSTRY (89%); AUTOMOTIVE MFG (88%); AUTOMA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 K}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERS (85%); GROSS DOMESTIC PRODUCT (79%); CONSUMER SPENDING (78%); CONSUMER SPEN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING & CREDIT (78%); BANKING & FINANCE SECTOR PERFORMANCE (78%); COMPANY PROFITS (78%); STATISTICS (78%); INDUSTRY ANALYSTS (77%); ENGINEERING (75%); INVESTMENT BAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 K}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (75%); LITIGATION (74%); FOOD INDUSTRY (73%); TAKEOVERS (73%); SUITS & CLAIMS (72%); APPOINTMENTS (71%); GENERIC PRODUCTS (71%); SPORTS & RECREATION (71%); CONSTRU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (70%); SHAREHOLDERS (69%); INSIDER TRADING (69%); CLASS ACTIONS (69%); AUTOMOTIVE RECALLS (69%); BIOTECHNOLOGY & GENETIC SCIENCE (69%); ENTREPRENEURSHIP (68%); WEALTH MANAGEMENT (68%); JUDGES (66%); MEDICARE (66%); PHARMACEUTICAL PREPARATION MFG (65%); CONSTRUCTION EQUIPMENT MFG (65%); MACHINERY & EQUIPMENT MFG (65%); DRUG DELIVERY SYSTEMS (63%); AEROSOL DRUGS (60%); CONSTRUCTION EQUIPMENT (60%); BI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TECHNOLOGY INDUSTRY (60%); ASTHMA (50%); PRODUCT RECALLS (50%); HEDGE FUNDS (50%) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GOLDMAN SACHS GROUP INC (90%); MORGAN STANLEY (57%); ENRON CREDITORS RECOVERY CORP (55%); HANESBRANDS INC (53%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (51%); ASTRAZENECA PLC (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SECURITIES & EXCHANGE COMMISSION (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GS (NYSE) (90%); MS (NYSE) (57%); HBI (NYSE) (53%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (51%); AZN (STO) (51%); AZN (NYSE) (51%); AZN (LSE) (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS523930 INVESTMENT ADVICE (90%); NAICS523920 PORTFOLIO MANAGEMENT (90%); NAICS523110 INVESTMENT BANKING & SECURITIES DEALING (90%); SIC6289 SERVICES A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LIED WITH THE EXCHANGE OF SECURITIES OR COMMODITIES, NEC (90%); SIC6282 INVESTMENT ADVICE (90%); SIC6211 SECURITY BROKERS, DEALERS, & FLOTATION COMPANIES (90%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS523120 SECURITIES BROKERAGE (57%); SIC4911 ELECTRIC SERVICES (55%); NAICS315990 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAREL ACCESSORIES & OTHER APPAREL MANUFACTURING (53%); NAICS315240 WOMEN'S, GIRLS' & INFANTS' CUT & SEW APPAREL MANUFACTURING (53%); NAICS315220 MEN'S & BOYS' CUT & SEW APPAREL MANUFACTURING (53%); SIC2389 APPAREL & ACCESSORIES, NEC (53%); SIC2341 WOMEN'S, MISSES', CHILDREN'S, & INFANTS' UNDERWEAR & NIGHTWEAR (53%); SIC2322 MEN'S & BOYS' UNDERWEAR & NIGHTWEAR (53%); NAICS325412 PHARMACEUTICAL PREPARATION MAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FACTURING (51%); SIC2834 PHARMACEUTICAL PREPARATIONS (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (58%) UNITED STATES (93%); FRANCE (92%); UNITED KINGDOM (91%); INDIA (79%); CHINA (79%); EUROPE (79%); CENTRAL AMERICA (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 22, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Times Newspapers Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Cipla Medpro. GROWING COMPANY AN OBVIOUS TARGET Financial Mail (South Africa) June 09, 2006 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_142}{\*\bkmkstart DOC_ID_142_0}{\*\bkmkstart doc_id_4}{\*\bkmkend DOC_ID_142}{\*\bkmkend DOC_ID_142_0}{\*\bkmkend doc_id_4}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_4"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 4 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Financial Mail (South Africa)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  09, 2006  \par Surveys Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Medpro. GROWING COMPANY AN OBVIOUS TARGET}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Jacqui Wilmot\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMY, BUSINESS & FINANCE; Pg. 12\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1071  words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro\par GROWING COMPANY AN OBVIOUS TARGET\par As the third-largest generics supplier in the SA private market and one of the fastest-growing pharmaceutical companies in SA, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro was always going to be an acquisition target. Its strong balance sheet and solid growth prospects made it attractive. Understanding the competition in the market, Enaleni knew it had to secure the transaction quickly.\par It took just three months for the deal to be completed.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro has a 13% share of the generics market in SA and a 2% share of the total private market.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  medpro has a much larger share by volume and is a market leader in respiratory, cardio and other s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lected major therapeutic categories, such as psychiatry.\par Nedcor Securities believes that the SA pharmaceutical market will grow by 9% in 2006, with growth in gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ics at the expense of the originating sector.\par It estimates that SA's generic market is likely to increase to R5,5bn in 2005, showing growth of about 30% in the next year.\par The generics penetration in the market is currently only about 20% in value and 40% in volume terms, sho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing that there is scope for generic companies to continue growing.\par "Enaleni was a good strategic fit because there were no competition board issues and because of the group's BEE credentials," says }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro CEO Jerome Smith.\par "It came along at the right time for us, just as we were looking to expand our tender business."\par The purchase was one of the largest acquisitions accomplished within the pharmaceutical industry.\par Armed with a business degree from Rhodes University and experience in a number of multinational pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceutical companies, Smith founded Medpro in 1992.\par "A short while after setting up Medpro, we realised we had to put up a manufacturing facility and research & development lab to grow," says Smith. "We really needed technical information and dossiers to take us fu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ther."\par But Smith and his team then asked: why reinvent the wheel?\par "We decided it was time to get a big brother," he says.\par Though the obvious place to look for a partner was the US or Europe, where the multinationals had set up huge facilities and research capabilities, Smith set off for India, against the recommendations of almost ev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ryone in the business.\par Among other challenges, India and SA had a tumultuous relationship prior to 1994.\par However, Smith wanted to access low-cost manufacturing and because India did not enforce }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  it was the only country where companies were developing drugs that had not yet been launched even by multin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tionals.\par Smith met with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  MD Amar Lulla and owners Yusuf and Muku Hamied and was surprised when they agreed that Medpro would distribute }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  products in SA.\par "I was a bit concerned that they would ask for Medpro's financials, as they probably wouldn't have been that impressive to a huge company the size of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , but they basically said that they did business with people that they liked and trusted," says Smith.\par The outcome of the visit to India was that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India agreed to supply }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro with its entire pipeline of drugs and that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro would own the dossiers, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and trademarks of these products.\par The relationship between the companies has proved successful. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro has become the fifth-largest supplier of pharmaceuticals in SA by volume and achieved 40% annual growth in sales over the past three years.\par Revenues have increased from R4,8m in 1993 to R283m in 2005. Forecast revenues for the next financial year are close to R500m.\par Most of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro's growth has been from selling to the private sector - private hospitals, pharmaceutical wholesalers, retail pharmacies and dispensing doctors. Now the company is focused on winning far more state tenders by leveraging Enaleni's empowerment credentials.\par Drug spend by the public sector accounted for just R3bn of total spend on drugs and is growing at only 5%. But as government focuses on providing better access to health care for more people - currently about 23m people do not have access to medicines - there are significant growth opportunities for lower-priced generic medicines.\par State tender business comprises about 16% of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro's current revenue. Overall, the company co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mands a small share of the state tender market.\par Though state tender business does attract lower margins, volumes are significant and are expected to co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tinue growing exponentially, especially with the increased use of antiretrovirals as government implements its Aids treatment plan.\par "The potential amount we could tender for - just in the areas in which we have registered products - is about R1bn over two years, excluding ARVs," says Smith.\par In the private sector, mandatory substitution as well as pressure applied by medical schemes on members to switch to generics has continued to boost growth. \par An area that has shown significant growth is the sale of generic products through private hospitals' retail pharmacies.\par According to Nedcor Securities, at Medicross pharmacies (owned by Netcare), generic sales now comprise 50% of all pharmaceutical products sold.\par "Once there is more clarity on the single exit price, and the dispensing fee is agreed upon, there will be a larger shift to generics by retail pharmacies too," says Smith.\par Though private hospitals in SA are one of the largest buyers of pharmaceutical products, the use of generics is still low, at about 10% of total usage.\par "Once alternative reimbursement models are introduced, there will be greater incentives for private hospitals to reduce input costs and opt for generics," says Smith. "But we have a lot of work to do convincing doctors that generics are the way to go."\par Still, there are likely to be other factors driving the growth of generics. The introduction of a list of conditions for which medical schemes must also provide cover, including HIV/Aids and 25 chronic conditions, has spurred schemes into introducing formularies promoting the use of generics.\par "We are well represented in the supply of chronic medication, which generates a regular income stream," says Smith.\par Coverage for chronic medication in open schemes increased from 87% to 100% in 2004. About 57% of these schemes also provided for the non-statutory chronic conditions.\par There is significant scope for strong volume growth, with estimates that annual turnover of the SA generic market will increase to R14,3bn by 2009. The market share of generics in the value pie is expected to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 crease to 30%.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); GENERIC PRODUCTS (92%); COMPANY LISTS & RANKINGS (90%); PHARMACEUTICAL PREPARATION MFG (89%); DRUG DESIGN & DISCOVERY (78%); RESEARCH & DEVELOPMENT (77%); BUSINESS EDUCATION (69%); PLANT CONSTRUCTION (62%); MANUFACTURING FACILITIES (62%) Corporate Report; Surveys; ENALENI : 4577 : 7110; ENAL}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NI PHARMACEUTICALS LTD\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  MEDPRO SOUTH AFRICA LTD (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CMP (JSE) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (79%); EUROPE (71%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 10, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Magazine\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 BDFM Publishers PTY Ltd.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Cipla Medpro pipeline. BANKING ON ARVs FOR GROWTH Financial Mail (South Africa) June 09, 2006 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_143}{\*\bkmkstart DOC_ID_143_0}{\*\bkmkstart doc_id_5}{\*\bkmkend DOC_ID_143}{\*\bkmkend DOC_ID_143_0}{\*\bkmkend doc_id_5}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_5"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 5 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Financial Mail (South Africa)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  09, 2006  \par Surveys Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Medpro pipeline. BANKING ON ARVs FOR GROWTH}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Jacqui Wilmot\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECONOMY, BUSINESS & FINANCE; Pg. 12\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 464  words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro pipeline\par BANKING ON ARVs FOR GROWTH\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro has a robust pipeline of drugs - a good indication of future revenue streams. With access to all new drugs developed by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India, the leading pharmaceutical company in that country, the local company has 140 new product dossiers in development likely to be launched over the next four years. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India has a pipeline of 1200 products.\par In 2004, 27 of the new drugs }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro launched were first to market and 8 of these are still the only available generic in the market. About 10% of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro's revenue for 2005 will from new products.\par "Though the product is manufactured by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India, in one of its 32 state-of-the art manufacturing facilities, the pipeline for new products is managed in SA," says }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro CEO Jerome Smith. "We look at all the markets, assess the potential and decide which product we want to launch. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , in different centres of the world, then compiles the science, including biostudies and clinical studies, for submission in SA."\par The dossier then goes through the necessary channels at the Medicines Control Council (MCC) to receive registration.\par These dossiers are then the sole property of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro and may not be revoked by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India in favour of any other parties.\par For the financial year 2006, the group is targeting about 30 new products. This does, however, hinge on the speed with which the dossier is registered by the MCC. The average time is about 18-21 months.\par "MCC approval times are getting better and better," says Smith. "Our approval times of 18-21 months are better than most other companies, basicaly due to, firstly, the quality of the data submitted and, secondly, due to a comprehensive review and evaluation prior to submission to ensure minimal delays in the registr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion procoss."\par Smith says it's important to understand that once a product comes off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , numerous manufacturers pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce a generic equivalent.\par "Generics can very quickly become a commodity," says Smith. "Being first to market has a significant a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vantage in terms of the ability to generate high margins during the window period, when it has at least some exclusivity."\par He says }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro always attempts to identify products coming off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that are not easily replicable and are unlikely to attract the attention of other generics producers. \par "This can help to maintain high turnover and margins for longer," says Smith.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro's growth is also likely to come from antiretrovirals, the drugs used to treat Aids.\par The company has 11 ARVs in the market, a further nine are in the process of approval at the MCC. This year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro announced the successful registration of Triomune, the first-ever three-in-one combination\par of a first-line recommended anti-HIV/Aids treatment regimen.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); NEW PRODUCTS (90%); PHARMACEUTICALS PRODUCT DEVELOPMENT (90%); DRUG DESIGN & DISCOVERY (90%); AIDS & HIV TREATMENT (89%); GENERIC PRODUCTS (89%); AIDS & HIV (78%); GENERIC DRUGS (78%); DELAYS & POS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PONEMENTS (78%); PHARMACEUTICAL PREPARATION MFG (77%); ANTIVIRALS (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (69%); MANUFACTURING FACILITIES (69%) Corporate Report; Surveys; ENALENI : 4577 : 7110; ENAL}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NI PHARMACEUTICALS LTD\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 10, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Magazine\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 BDFM Publishers PTY Ltd.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India overtakes South Africa for HIV/AIDS Pharma Marketletter June 2, 2006 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_144}{\*\bkmkstart DOC_ID_144_0}{\*\bkmkstart doc_id_6}{\*\bkmkend DOC_ID_144}{\*\bkmkend DOC_ID_144_0}{\*\bkmkend doc_id_6}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_6"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 6 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pharma Marketletter\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  2, 2006 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India overtakes South Africa for HIV/AIDS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 160 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The world's second largest country in terms of population has become the world's largest in terms of HIV/AIDS cases. The United Nations' AIDS agency (UNAIDS) has published figures showing that whereas there are an estimated 5.5 million people with HIV/AIDS in South Africa, the number in India is now believed to be as high as 5.7 million. Because of the difference in overall population size, the visibility of the problem in India is low, about 0.9% of the population (compared with 0.6% for the USA). \par Last month, hundreds of HIV/AIDS sufferers protested in New Dehli against the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application for Viread (tenofovir), an antiretroviral drug developed by US drugmaker Gilead Sciences. A court case was underway which would determine the effectiveness of new intellectual property legislation passed in India in 2005 (Marketletters passim). Local generic firms, including }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are reported to offer unbranded versions of the drug at a significant discount.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); POPULATION SIZE (88%); AIDS & HIV TREATMENT (88%); UNITED N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS INSTITUTIONS (88%); POPULATION & DEMOGRAPHICS (88%); INTELLECTUAL PROPERTY (85%); PHARMACEUTICALS INDUSTRY (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (67%); DRUG DESIGN & DISCOVERY (67%); ANTIVIRALS (67%); LEGISLATION (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (84%); UNITED NATIONS (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (94%); INDIA (94%); UNITED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 2, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newsletter\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Marketletter Publications Ltd.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian pharma firms go shopping abroad; They are acquiring Western companies to overcome the restrictions of a new patent regime The Business Times Singapore May 25, 2006 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_145}{\*\bkmkstart DOC_ID_145_0}{\*\bkmkstart doc_id_7}{\*\bkmkend DOC_ID_145}{\*\bkmkend DOC_ID_145_0}{\*\bkmkend doc_id_7}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_7"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 7 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2006 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian pharma firms go shopping abroad; \par They are acquiring Western companies to overcome the restrictions of a new }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  regime}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Yogi Aggarwal\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VIEWS AND OPINIONS; BT Comment Others\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1125  words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WHEN the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime was changed at the end of 2004 as part of India's WTO commitments, there were many fears that Indian companies, used to reverse engineering of patented medicines, would not be able to survive in the new environment. This has not happened.\par The new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime has accelerated the pace of globalisation of Indian industry, which has responded to the new situation by developing strategies that have taken them to the heart of the developed markets. \par A central part of the new strategy is to buy out existing manufacturers of generic medicines in Europe and the US. 'Indian companies had started thinking of ways to meet the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenge some time before the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules began to apply,' says Timmie Kandhari, executive director at the Indian office of Price W}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 terhouseCoopers (PWC), the international consultancy.\par Takeovers of international pharmas by Indian firms increased from $139US million in 2004 to $341US million last year. During the first four months of 2006, takeovers skyrocketed further to $904US million. Takeovers of companies serve to expand the market for Indian companies.\par Other strategies include contract manufacturing or outsourcing the manufacture of pharmaceuticals for fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eign companies by Indian partners, joint ventures to develop and produce drugs, in-licensing deals where the foreign firms market drugs made by Indian firms under license, and R&D work that includes clinical trials done by Indian companies for their foreign partners.\par While such deals have expanded options for Indian companies after 2004, it is the takeover of foreign co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies that is the major step. Until last year the deals were generally small ones, varying from $5US million to $59US million. The biggest deal in 2005 was the $263US million buyout of the Belgian company Docpharma by Matrix labs.\par In the first three months of 2006, two major deals have been struck - the buyout for $572US million of the German generic manufacturer Betapharma by Dr Reddy's from India, and the takeover of the Romanian g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nerics drug company Terapia for $324US million by Ranbaxy, India's largest pharma. Besides these deals, Ranbaxy has bought out Allen SpA of Italy and Ethimed of Belgium for undisclosed sums. And this is just the beginning. Indian pharmas are planning to raise over $2US.5 billion in the international market through co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vertible bonds.\par Ranbaxy has already raised $400US million and is planning on raising another $1US.1 billion, Wockhardt has got shareholder approval to raise $800US million. Other companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Sun Pharma, Nicolas Piramal and Torrent are also sitting on tidy piles of cash, waiting for the right acquisition opportunity.\par One reason for the aggressive buying is the lack of substantial success and high cost in legally opposing big pharma's extension of their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on drugs going off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  'Big pharma will fight you every inch of the way,' says Mr Kandhari. So while companies like Ranbaxy also pursue this strategy, it is no longer enough.\par The route of filing abbreviated new drug applications (Anda) is cumbersome and expensive. It takes two to three years to file Anda in the US and Europe and each application could cost a couple of million dollars. D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spite this, Ranbaxy has over 70 products registered in the US while Dr Raddy's has over a dozen, says D G Shah, secretary general of the Indian Pharmaceutical Alliance (IPA), which represents big pharma comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies.\par Foreign acquisitions were another route. They mean that the Indian company takes over an established E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ropean company which already has approval to sell several generic drug brands and an established custo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er base. They also allow the drug to be made at lower cost in India and packaged and sold in the European market.\par Bigger sales base\par 'Whether this translates to a sales increase by a factor of two, three or four is subject to the company cap}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bilities,' maintains Jayashri Kulkarni, director of healthcare practise at Frost & Sullivan India in an emailed response to questions.\par 'With three of the top five markets in Europe, it is imperative for a company in the pharmaceutical industry to focus on strategies that help it evolve in the region. Acquisitions are a quick boost to Indian companies by providing ready access to a new and growing market.\par 'Secondly, directly selling in the country will allow for growth of the bottom line as well given our cost a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vantage,' maintains Ms Kulkarni.\par Another reason why European generic companies are preferred is that they are generally smaller than US companies and more affordable. Of course, the deals can really be big as in the $7US.4 billion acquisition last July by the Israeli generics company Teva of Ivax Corporation in Europe.\par An acquisition of a European pharma company also means that it is easier to sell in the other countries of the EU. The total pharma market for the top seven countries in EU is estimated at $162US billion. Of the five biggest pharma markets, three (Germany, France and the UK) are in Europe. While generics only form around one-tenth of the total pharma market in Europe, in these countries it's between 20 per cent and 25 per cent.\par And the generics market is growing more rapidly than any other. Estimates put together by PWC show that the European generics market is growing at a 22 per cent CAGR. It was at $29US.8 billion in 2003, estima}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed at $54US.2 billion in 2006 and at $80US.7 billion in 2009.\par 'By 2010 we can get 20 per cent of the world generics market,' maintains Mr Shah of IPA. 'Now that India is trying to grow into a global pharma giant,' says Mr Kandhari, 'it makes sense to concentrate on Europe since we are buying into a safe space.' For the Mumbai-based Wockhardt, with 2005 sales of 14.1 billion rupees ($488S million), Europe is already the biggest market, larger than even the domestic Indian market. It has made three acquisitions in Europe so far, Wallis Laboratory and CP Pharmaceuticals in UK, and Esparma GmbH in Germany.\par They are now scouting for acquisitions in the US. 'We look for a strong front-end organisation that will give us market access, we also look for technical capabilities that will compliment ours,' says Habil Khorakiwala, chairman of Wockhardt. 'We should be able to drive faster growth of the acquired asset through our ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 agement.' Mr Khorakiwala is also quite relaxed about the changes in the industry after the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gime. \par 'Many people were led to believe that Indian companies would be at a disadvantage with the introduction of product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . But now outsourcing into India has gathered momentum and Indian companies are adap}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing themselves to integrate their businesses into the global economy. Companies are discovering their strengths and weaknesses with the rest of the world.'\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); EDITORIALS & OPINIONS (91%); PHARMACEUTICALS INDUSTRY (91%); TAKEOVERS (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC DRUGS (90%); RESEARCH & DEVELOPMENT (90%); GENERIC PRODUCTS (89%); ALLIANCES & PARTNERSHIPS (90%); INTERN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL TRADE (78%); GLOBALIZATION (78%); OUTSOURCING (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (78%); DRUG DESIGN & DISCOVERY (77%); PHARMACEUTICAL PREPARATION MFG (77%); ENTERPRISE GLOBA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IZATION (73%); LICENSING AGREEMENTS (73%); PHARMACEUTICALS PRODUCT DEVELOPMENT (71%); MANUFACTURING OUTPUT (70%); SHAREHOLDERS (68%); JOINT VENTURES (66%); BONDS (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PRICEWATERHOUSECOOPERS (70%); RANBAXY LABORATORIES LTD (52%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); RANBAXY (NSE) (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS541211 OFFICES OF CERTIFIED PUBLIC ACCOUNTANTS (70%); SIC8721 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COUNTING, AUDITING, & BOOKKEEPING SERVICES (70%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOSEPH C PAPA (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); UNITED STATES (79%); GERMANY (77%); BELGIUM (72%); EUROPE (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 24, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Singapore Press Holdings Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS Groups In India Sue To Halt Patent For U.S. Drug The New York Times May 12, 2006 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_146}{\*\bkmkstart DOC_ID_146_0}{\*\bkmkstart doc_id_8}{\*\bkmkend DOC_ID_146}{\*\bkmkend DOC_ID_146_0}{\*\bkmkend doc_id_8}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_8"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 8 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  12, 2006 Friday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS Groups In India Sue To Halt }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  For U.S. Drug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By AMELIA GENTLEMAN and HARI KUMAR\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 6; Foreign Desk; Pg. 4\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 493 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, May 11 \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS groups this week brought an important test of India's new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law, which restricts the ability of Ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an companies to produce low-cost generic drugs.\par   Two patients-rights groups asked Indian authorities to stop Gilead Sciences, a California biopharmaceutical company, from patenting the antiretroviral drug Viread -- its brand-name version of tenofovir, which is avail}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble here as a generic drug. If it is patented, the groups contend, making the cheaper versions will become illegal, and the drug will become too costly for patients here and in other developing countries. \par ''These generic drugs are not only consumed in India,'' said Leena Menghaney of Doctors Without Borders in New Delhi, which is working with the Indian groups on the issue. ''People in Africa and the Caribbean are relying on India to produce these drugs,'' she said, later adding, ''The quality matches that of U.S.-manufactured drugs, but the prices are affordable.''\par   The lawyers for the two groups -- the Delhi Network of Positive People and the Indian Network for People Living with H.I.V./AIDS -- presented arguments on Tuesday, contending that tenofovir is not a new drug, but a modified version of an earlier drug, and therefore not eligible for a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  under India's new law. \par   Those backing the legal challenge are hoping to gain a legal precedent for use in other }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  applications. They say the recent rejection of a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application by Novartis for a cancer drug, Gleevac, on the grounds of similar legal arguments, gave some cause for optimism.\par   The World Health Organization recently recommended tenofovir for patients who are just starting treatment for AIDS and for those who have been receiving antiretroviral treatment therapy but who have become r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sistant to other treatments. \par   In developed countries, Gilead's tenofovir costs $5,718 per patient per year. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , one of the largest gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic companies in India, is marketing a version called Tenvir, at a cost of $700 per person per year in India. Yusuf Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , said the drug would eventually be made available in Africa for about half that price.\par   But Tenvir would have to be withdrawn if Gilead were given a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , which would be in effect for 12 years.\par   Gilead Sciences said Thursday in an e-mail message, referring to its brand name for the drug: ''We dis}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gree with statements that Viread should not be patented; we believe that Viread represents innovation and is patentable under Indian law. We will use this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  responsibly, and will not block access to our medication in India or in other resource-limited countries where the H.I.V. epidemic has hit the hardest.''\par   The company, the message said, is ''pursuing a broad policy of nonexclusive voluntary licensing under this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to generic manufacturers in India for the local Indian market as well as provision for manufacturers to export product to the 97 developing-world countries included in Gilead's access program.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTELLECTUAL PROPERTY LAW (92%); PHARMACEUTICALS INDUSTRY (91%); AIDS & HIV (91%); GENERIC DRUGS (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); AIDS & HIV TREATMENT (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); GENERIC PRODUCTS (89%); BIOTECHNOLOGY }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); ANTIVIRALS (89%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICALS & MEDICINES MFG (77%); DISEASES & DISORDERS (77%); LAWYERS (74%); PHYS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CIANS & SURGEONS (73%); BIOTECHNOLOGY INDUSTRY (73%); DEVELOPING COUNTRIES (73%); ILLEGAL DRUGS (72%); MEDICAL CHARITIES (72%); HEALTH DEPARTMENTS (72%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICAL PREPARATION MFG (72%); CANCER DRUGS (72%); CANCER (72%); RELIEF ORGANIZATIONS (69%); PUBLIC HEALTH ADMINISTRATION (65%); UNITED NATIONS INSTITUTIONS (50%) Acquired Immune Deficiency Syndrome; Drugs (Pharmaceuticals); Generic and Brand Name Products; Law and Le}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 islation; Viread (Drug); Tenofovir (Drug)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); NOVARTIS AG (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DOCTORS WITHOUT BORDERS (56%) Gilead Sciences Inc\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); NVS (NYSE) (58%); NOVN (SWX) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS339115 OPHTHALMIC GOODS MANUFACTURING (58%); SIC3851 OPHTHALMIC GOODS (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Amelia Gentleman; Hari Kumar\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (73%); DELHI, INDIA (58%) CALIFORNIA, USA (92%) INDIA (96%); UNITED STATES (92%); AFRICA (92%); CARIBBEAN ISLANDS (79%) India\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 12, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS drug provokes legal fight in India; Rights group sayspatent would imperil thousands of lives The International Herald Tribune May 11, 2006 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_147}{\*\bkmkstart DOC_ID_147_0}{\*\bkmkstart doc_id_9}{\*\bkmkend DOC_ID_147}{\*\bkmkend DOC_ID_147_0}{\*\bkmkend doc_id_9}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_9"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000a00000063006900740065005f00690064005f0039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 9 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2006 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS drug provokes legal fight in India; \par Rights group sayspatent would imperil thousands of lives}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Amelia Gentleman and Hari Kumar\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1002 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A legal challenge to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application in India on a crucial AIDS drug was filed this week in Delhi by two patients' rights groups, who claim that thousands of lives could be put at risk if the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is approved.\par If the drug, tenofovir, is granted a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the manufacture of cheaper versions in India will become illegal, making the drug too expensive for patients in developing countries.\par The suit is one of the first major challenges to Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation, introduced last year, designed to control the country's large pharmaceutical industry, which makes cheaper copies of Western manufactured medicines.\par The Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  office is processing about 9,000 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  applications, most of them filed by international pharmaceutical companies. Patient advocates warn that the supply of a wide range of vital drugs to people in the developing world may be jeopardized. Hundreds of thousands of AIDS patients in the developing world are treated with generic Indian drugs. \par Supported by Medecins Sans Frontieres or Doctors Without Borders The Delhi Network of Positive People and the Indian Network for People Living with HIV/AIDS registered a formal opposition Tuesday to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application in India by the U.S.-based Gilead Sciences for the drug tenofovir disoproxil fumarate, commonly known just as tenofovir.\par The World Health Organization recently recommended the drug for patients who are just starting treatment for AIDS and for those who have been receiving anti-retroviral treatment therapy for some time, but who have become resistant to other treatments. The drug has relatively few known side effects and is in wide use in the United States and Europe, although less so in the rest of the world.\par ''These generic drugs are not only consumed in India,'' said Leena Menghaney, who is working on the issue for Medecins Sans Frontieres in Delhi. ''People in Africa and the Caribbean are relying on India to produce these drugs.\par ''The quality matches that of U.S.-manufactured drugs, but the prices are affordable. These drugs are very important, which is why we are opposing this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application.\par ''People who suffer extreme side effects from other drugs, and people who have developed resistance to other drugs, have been waiting for an effective substitute such as tenovir. If they don't get it, then probably their lives will be at risk, and certainly their quality of life will be worse.''\par Eric Goermaere, of Medecins Sans Frontieres in South Africa, said in a written statement: ''We have all been waiting impatiently to get tenofovir as a generic from India. It's clear that the world desperately needs more sources of tenofovir. If Gilead is granted the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , our patients will face a potentially deadly delay.''\par In developed countries, Gilead's tenofovir costs $5,718 per patient per year. According to company's Web site, it has been offering the drug at cost to treatment programs in eligible developing countries.\par But officials with Medecins Sans Frontieres said the company has not yet made the drug available in many low-income regions.\par A spokeswoman for Gilead, Erin Edgley, said in an e-mail message that the company declined to comment.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , one of the largest generics companies in India, is already marketing a generic version of tenovir, called tenvir, at a cost of $700 per person per year in India.\par Yusuf Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , said the drug would in time be made available in Africa for about half the price in India. Tenvir will have to be withdrawn if the Gilead }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , which would last for 12 years, were granted.\par About 150 protesters, many of them HIV-positive, demonstrated outside the Indian Parliament on Wedne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day in support of the legal action, carrying banners declaring ''Patients before }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents'}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ' and ''Lives before profit.''\par A number of campaigners were detained when they crossed the police barriers.\par Among the protesters was Loon Gangte, president of the Delhi Network of Positive People, who like more than 5.1 million other people in India is HIV-positive.\par ''If this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is granted, it will chop off a lifeline for me,'' he said, adding that he has been taking anti-retroviral treatment for the past 3 1/2 years. ''Any time now I am going to become resistant to the first line treatment and I will need new drugs. For many of us living with HIV/AIDS, newer drugs like tenofovir offer new hope of continuing treatment.\par ''If the government grants the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  the price of these drugs will go up, and I won't be able to afford them. It is a life-and-death issue for me and many more people like me around the world. We do not want to die when our lives can be easily saved,'' he said.\par The Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law, introduced last March, was designed to regulate the copying of Western medicines by the Indian pharmaceutical industry and to bring the country into line with World Trade Organization rules.\par International aid organizations warned that the legislation marked the beginning of the end of affordable g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nerics.\par Supporters of the legislation counter that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  ensures that pharmaceutical companies have the security to invest in further research allowing them to develop vital drugs. They argue the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law also creates benefits for the Indian pharmaceutical industry as it begins to develop world-class drugs. Those innovators will want protection from generic copies.\par Earlier this year, a cancer patients' pressure group was successful in blocking an attempt by Novartis to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  its anti-cancer drug, Gleevac.\par The AIDS patients rights' groups issued the formal opposition to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on a scientific technicality, arg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing that tenofovir is not a new drug, but just a modified version of an earlier drug.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  plans to start a parallel legal opposition to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application.\par ''We have never been against intellectual property and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ,'' Hamied said by telephone from Mumbai. ''We are against monopoly. I believe that life-saving, essential drugs should be freely available and the inn}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vator should be paid a suitable royalty payment for his invention.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (95%); AIDS & HIV TREATMENT (94%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (93%); ANTIVIRALS (92%); INTELLECTUAL PROPERTY LAW (91%); PHARMACEUTICALS INDUSTRY (90%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (90%); MEDICAL CHARITIES (89%); RELIEF ORGANIZATIONS (89%); INTERNATIONAL ASSI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TANCE (88%); PRESCRIPTION DRUGS (78%); APPROVALS (78%); GENERIC DRUGS (78%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICAL PREPARATION MFG (77%); HEALTH DEPARTMENTS (73%); PHYSICIANS & SURGEONS (73%); AIDS & HIV REPORTING (73%); PUBLIC HEALTH ADMINISTRATION (67%); LEGISLATION (56%); UNITED NATIONS INSTITUTIONS (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DOCTORS WITHOUT BORDERS (55%); WORLD HEALTH ORGANIZATION (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DELHI, INDIA (90%); NEW DELHI, INDIA (58%) INDIA (96%); UNITED STATES (92%); SOUTH AFRICA (79%); EUROPE (79%); AFRICA (79%); CARIBBEAN ISLANDS (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 17, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS drug provokes patent battle in India; Approval could cost lives, critics say The International Herald Tribune May 11, 2006 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_148}{\*\bkmkstart DOC_ID_148_0}{\*\bkmkstart doc_id_10}{\*\bkmkend DOC_ID_148}{\*\bkmkend DOC_ID_148_0}{\*\bkmkend doc_id_10}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_10"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 10 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2006 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS drug provokes }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  battle in India; \par Approval could cost lives, critics say}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Amelia Gentleman and Hari Kumar\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Pg. 7\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1188 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A legal challenge to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application in India on a crucial AIDS drug was filed this week in Delhi by two patients' rights groups, who claim that thousands of lives could be put at risk if the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is approved.\par If the drug, tenofovir, is granted a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the manufacture of cheaper versions in India will become illegal, making the drug too expensive for patients in developing countries.\par The suit is one of the first major challenges to an Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation introduced last year that was d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 signed to control the country's large pharmaceutical industry, which for decades has specialized in making cheaper copies of Western manufactured medicines.\par The Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  office is processing about 9,000 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  applications, most of them filed by international pharmaceutical companies. Patient advocates warn that the supply of a wide range of vital drugs to people in the developing world may be jeopardized. Hundreds of thousands of AIDS patients in developing countries are treated with generic Indian drugs. \par Those backing the legal challenge are hopeful that this case, if successful, could help set a legal precedent, thereby making it easier to block other pending }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  applications. They say the recent rejection of a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application by Novartis for a cancer drug, on the grounds of similar legal arguments, gives some cause for optimism.\par The Delhi Network of Positive People and the Indian Network for People Living with HIV/AIDS registered a formal opposition Tuesday to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application by the U.S.-based Gilead Sciences for the drug tenofovir disoproxil fumarate, commonly known just as tenofovir.\par Their lawyers make the case on a scientific technicality, arguing that tenofovir is not a new drug, but just a modified version of an earlier drug, and therefore not eligible for a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  under India's act.\par The successful challenge to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for the cancer drug, Gleevac, was also made on this basis that the a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plication claims ''a new form of a known substance.''\par The World Health Organization recently recommended the drug for patients who are just starting treatment for AIDS and for those who have been receiving anti-retroviral treatment therapy for some time, but who have become resistant to other treatments. The drug has relatively few known side effects and is in wide use in the United States and Europe, although less so in the rest of the world.\par ''These generic drugs are not only consumed in India,'' said Leena Menghaney of Medecins Sans Frontieres, or Doctors Without Borders, in Delhi, which is working with the Indian groups on the issue. ''People in Africa and the Caribbean are relying on India to produce these drugs.\par ''The quality matches that of U.S.-manufactured drugs, but the prices are affordable. These drugs are very important, which is why we are opposing this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application.\par ''People who suffer extreme side effects from other drugs, and people who have developed resistance to other drugs, have been waiting for an effective substitute such as tenofovir. If they don't get it, then probably their lives will be at risk, and certainly their quality of life will be worse.''\par Eric Goermaere, of Medecins Sans Frontieres in South Africa, said in a written statement: ''We have all been waiting impatiently to get tenofovir as a generic from India. It's clear that the world desperately needs more sources of tenofovir. If Gilead is granted the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , our patients will face a potentially deadly delay.''\par In developed countries, Gilead's tenofovir costs $5,718 per patient per year. According to company's Web site, it has been offering the drug at cost to treatment programs in eligible developing countries. But officials with Medecins Sans Frontieres said the company has not yet made the drug available in many low-income regions. A spokeswoman for Gilead, Erin Edgley, said in an e-mail message that the company declined to comment.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , one of the largest generics companies in India, is already marketing a generic version of tenofovir, called tenvir, at a cost of $700 per person per year in India.\par Yusuf Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , said the drug would in time be made available in Africa for about half the price in India. Tenvir will have to be withdrawn if the Gilead }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , which would last for 12 years, were granted.\par About 150 protesters, many of them HIV-positive, demonstrated outside the Indian Parliament on Wedne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day in support of the legal action, carrying banners declaring ''Patients before }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents'}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ' and ''Lives before profit.'' A number of campaigners were detained when they crossed the police barriers.\par Among the protesters was Loon Gangte, president of the Delhi Network of Positive People, who like more than 5.1 million people in India is HIV-positive.\par ''If this }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is granted, it will chop off a lifeline for me,'' he said, adding that he has been taking anti-retroviral treatment for the past 3 1/2 years. ''Any time now I am going to become resistant to the first line treatment and I will need new drugs. For many of us living with HIV/AIDS, newer drugs like tenofovir offer new hope of continuing treatment.\par ''If the government grants the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  the price of these drugs will go up, and I won't be able to afford them. It is a life-and-death issue for me and many more people like me around the world. We do not want to die when our lives can be easily saved.''\par The Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law, introduced last March, was designed to regulate the copying of Western medicines by the Indian pharmaceutical industry and to bring the country into line with World Trade Organization rules.\par International aid organizations warned that the legislation could mark the beginning of the end of affordable generic drugs.\par Supporters of the legislation counter that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  ensures that pharmaceutical companies have the security to invest in further research allowing them to develop vital drugs. They argue the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law also creates benefits for the Indian pharmaceutical industry as it begins to develop world-class drugs. Those innovators will want protection from generic copies.\par The AIDS patients rights' groups issued the formal opposition to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on a scientific technicality, arg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing that tenofovir is not a new drug, but just a modified version of an earlier drug.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  plans to start a parallel legal opposition to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  application.\par ''We have never been against intellectual property and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ,'' Hamied said by telephone from Mumbai. ''We are against monopoly. I believe that life-saving, essential drugs should be freely available and the inn}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vator should be paid a suitable royalty payment for his invention.''\par He said he believed that a large number of the 9,000 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  currently pending will ultimately prove to have no basis in law and will be rejected. Most of them were filed speculatively before the Indian legislation was passed in 2005 and before the precise details of the new legislation were announced.\par Hamied called on those multinational corporations with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are pending which do not comply with the current Indian law, ''to withdraw them voluntarily, instead of entering into litigation after litigation after litig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (95%); AIDS & HIV (93%); AIDS & HIV TREATMENT (92%); INTELLECTUAL PROPERTY LAW (91%); PHARMACEUTICALS INDUSTRY (91%); ANTIVIRALS (90%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL PREPARATION MFG (90%); DEVELOPING COUNTRIES (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (89%); MEDICAL CHARITIES (78%); PRESCRIPTION DRUGS (78%); CANCER (78%); APPROVALS (78%); CANCER DRUGS (78%); GENERIC DRUGS (78%); LEGISLATION (75%); LAWYERS (75%); INTERNATIONAL A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SISTANCE (74%); HEALTH DEPARTMENTS (73%); PHYSICIANS & SURGEONS (73%); AIDS & HIV R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PORTING (73%); RELIEF ORGANIZATIONS (66%); UNITED NATIONS INSTITUTIONS (50%); PUBLIC HEALTH ADMINISTRATION (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOVARTIS AG (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NVS (NYSE) (57%); NOVN (SWX) (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS339115 OPHTHALMIC GOODS MANUFACTURING (57%); NAICS325412 PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MANUFACTURING (57%); SIC3851 OPHTHALMIC GOODS (57%); SIC2834 PHARMACEUTICAL PREPARATIONS (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DELHI, INDIA (90%); NEW DELHI, INDIA (58%) INDIA (96%); UNITED STATES (92%); EUROPE (79%); AFRICA (79%); CARIBBEAN ISLANDS (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 17, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 U.S. pushes to limit generic drug rights; Agreements seek to extend monopolies in exchange for improvements in trade The International Herald Tribune April 19, 2006 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_149}{\*\bkmkstart DOC_ID_149_0}{\*\bkmkstart doc_id_11}{\*\bkmkend DOC_ID_149}{\*\bkmkend DOC_ID_149_0}{\*\bkmkend doc_id_11}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_11"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 11 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2006 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 U.S. pushes to limit generic drug rights; \par Agreements seek to extend monopolies in exchange for improvements in trade}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Anand Giridharadas\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1610 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Brian Knowlton in Washington contributed reporting to this article.\par *\par Under global trading rules, the inventors of medicines ordinarily enjoy the right to a 20-year monopoly on their inventions. But five years ago, the United States joined 141 other countries to sign the Doha Declar}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, confirming the right of poor countries to break drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and produce cheap generic drugs in the event of contagions like HIV.\par At the time, Thailand was heartened. It had been trying everything in its fight against AIDS. It coined a jingle to promote safe sex. It placed condoms in massage parlors. Most important, it curbed deaths among the poor by giving them generic versions of medicines invented by multinational drug makers. \par So it came as a jolt in January when the United States asked Thailand to sign a free trade agreement that would, on paper, dilute its right to break }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and use generics.\par Washington said the agreement would save lives by spurring innovation and by making multinationals more confident in selling drugs in the country. But Thai officials saw the proposal as a morbid bargain: either r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fuse the U.S. offer, and thereby scuttle a trade deal with the United States worth billions of dollars, or accept it and lift the price of AIDS drugs beyond the reach of the poor.\par ''Those who require the essential drugs but cannot afford it, they will have to die,'' said Dr. Suwit Wibu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 polprasert, the Thai official who is coordinating the Public Health Ministry's response to the U.S. proposal.\par Thailand is not alone. It is merely the latest target of a quiet worldwide campaign by the administration of President George W. Bush to coax developing nations to barter away their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking rights in e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 change for lucrative trade benefits, according to public-health experts and government officials from Thailand to Brazil.\par Specifically, Washington is pushing bilateral and regional trade agreements in which countries enact ''supe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 patents'' that prolong U.S. drug makers' monopolies and limit the conditions under which their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  can be broken. These new rules, once they are adopted by developing countries, roll back the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking rights that were confirmed by the 2001 declaration at World Trade Organization talks in Doha, Qatar.\par In effect, Washington is stitching together its own parallel global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system. The trade deals, negotiated in secret, attract little notice. But they have already been signed with developing countries battling AIDS, i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cluding six in Central America. And negotiations are beginning with several nations pivotal to the fight against the virus, from Thailand to five southern African countries, including South Africa and Botswana.\par Because of these agreements, India's generics industry, the world's largest, is reining in plans to supply poor countries and refocusing on richer ones, said Dilip Shah, head of the Indian Pharmaceutical Alliance, which represents generic makers.\par "For the Indian pharma industry," he said, "it's not doomed; it will find a way out. But for the patients in the third world, it's bad."\par Public health officials warn of catastrophic consequences if the bilateral deals are applied to AIDS drugs.\par ''If you prevent countries from using generic drugs,'' said Pedro Chequer, the head of Brazil's national AIDS program, ''you are creating a concrete obstacle to providing access to drugs. You are promoting genocide, because you're killing people.''\par First-generation AIDS drugs reached the world's poorest people only when the use of generics cut their cost to $140 a year from more than $10,000. As new drugs emerge to treat patients resistant to first-line med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines, the trade agreements make a similar drop ''extremely difficult to ensure,'' according to Medecins Sans Frontieres, or Doctors Without Borders.\par Washington maintains that the trade deals are directed toward diseases other than AIDS.\par And Richard Feachem, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, based in Geneva, acknowledged that it was too early to tell whether the bilateral agreements would be used to block access to AIDS drugs.\par ''If we do see this in practice,'' he said, ''we should condemn it. But it really is in the interpretation of these agreements in very particular circumstances.''\par Yet, in defending the bilateral agreements, Bush administration officials often cite the AIDS example to make their case. Stronger }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  save lives, the argument goes, by keeping companies confident enough in profit to keep discovering new drugs.\par Dr. Mark Dybul, the second-ranking official in the White House program to fight AIDS, said that because AIDS patients constantly grow resistant to medicines, it is disastrous to widen access today and have no drugs tomorrow.\par ''As an individual physician sitting in front of an individual patient, you will do whatever you need to for that patient now,'' said Dybul, a physician by training. ''When you're a public-health physician, you're not a phys}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cian for one person but for millions of people. And you need to be thinking about whether the action in that single setting, repeated hundreds of thousands of times, will cause a problem for the millions.''\par Spreading the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system are U.S. trade negotiators, who some experts believe are assuming the influence that public health experts once had over the Bush administration's AIDS policy.\par Victoria Espinel, an assistant U.S. trade representative, strongly defended the use of trade agreements to promote }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that ''have more in place'' than the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  agreed upon at the WTO talks in Doha, which she described as merely ''harmonizing minimum standards.''\par ''It is crucial to public health,'' she said, ''to promote the innovation of drugs and to make sure that research and development of drugs continues.''\par As for exempting AIDS drugs from the new accords on }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking, she said, ''I want to emphasize that there is enough flexibility in our free-trade agreements to allow our partners to do what they need to do.''\par An explicit promise to exempt AIDS drugs, however, is not in the agreements, said Wibulpolprasert, the Thai official. And that, experts say, is at the heart of the problem: Nations must take Washington's word for it.\par An examination by the International Herald Tribune of several free-trade accords reveals provisions that a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pear, on paper, to limit the freedom to use generics.\par Several agreements, for example, prolong a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  monopoly beyond 20 years if the developing country's regulators show ''unreasonable delays'' in approving a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . This provision, absent from World Trade O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganization rules, sustains higher prices.\par Many agreements also serve to prolong }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  by requiring generics to be retested as if they were new inventions. Retesting a drug biologically equivalent to one already approved takes time and may be uneth}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal, since infected patients must be given placebos. The WTO rejected this five-year ban on the use by g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric makers of the safety data submitted for the original branded drug.\par And while the WTO lets countries decide when to break }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the new U.S. agreements limit this action to special cases to enforce antitrust law, for example, or during emergencies. Experts say the most important use of generics is excluded: to reduce costs by making branded products compete with generics.\par The generics question has also opened a rift in the United States, between Bush and former President Bill Clinton. On a recent visit to New Delhi, Clinton said he had confronted Bush about generics while flying to Rome for the papal funeral last April.\par ''The American position is untenable,'' Clinton recalled saying.\par In an interview, Clinton said Washington was succumbing to the influence of the drug lobby in undermining the Agreement on Trade-Related Aspects of Intellectual Property Rights, or TRIPS, the WTO framework on which the Doha Declaration built.\par ''The TRIPS system essentially said there was an exception for life-saving medicine,'' Clinton said. ''And b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sically, the American drug companies and the American government really put the hammer on the bill not to use the TRIPS system.''\par Referring to generic producers, he added: ''If a company develops a new advance in AIDS, TB, malaria, you need large numbers right away and all the people who need it are in poor places. If you don't have }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ranbaxy, Hetero, Aspen in South Africa and other people to step into the breach, how are we going to do that?''\par Last year, when Brazil was faced with upgrading tens of thousands from $140-a-year generics to Kaletra, a patented drug costing more than $3,000 a year, it threatened to break the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  unless given a discount by the U.S. company Abbott Laboratories, Kaletra's inventor. Members of Congress in the United States threa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ened import tariffs in retaliation. Although the Bush administration says it was not involved, Espinel, the a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sistant U.S. trade representative, hinted at how Washington's tacit desires can be enough to make countries fall into line.\par ''Do I think that that would be the best way for a country to go about promoting itself as an innovation player and a destination for foreign investment?'' Espinel said. ''Probably not.''\par Clinton came to Brazil's rescue. His foundation tapped overseas contacts to find a generic drug for about $900 a year a price Brazil used to negotiate with Abbott, which spent $1.8 billion on research in 2005 and reported a profit of $3.4 billion\par Finally, Brazil backed down from its threat to break the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , and Abbott gave it a discount of about 50 percent.\par Abbott is ''gratified to get support'' from ''people in and outside of government,'' said a company spokesman, Brian Kyhos.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (91%); TRADE TREATIES & AGREEMENTS (90%); AIDS & HIV (90%); TREATIES & AGREEMENTS (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC PRODUCTS (90%); INTERNATIONAL TRADE LAW (89%); TRADE DEVELOPMENT (89%); PHARMACEUTICAL PREPARATION MFG (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); INTERNATIONAL TRADE (89%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); AGENCY RULEMAKING (78%); AIDS & HIV TREATMENT (78%); ANTIVIRALS (78%); HEALTH DEPARTMENTS (78%); MULTINATIONAL CORPOR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (78%); EMERGING MARKETS (78%); INTERGOVERNMENTAL TALKS (77%); FREE TRADE TREATIES & AGREEMENTS (77%); DRUG PRICES (73%); US PRESIDENTS (72%); PUBLIC HEALTH ADMINISTRATION (66%); MASSAGE SERVICES (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (79%) UNITED STATES (99%); THAILAND (93%); INDIA (92%); Q}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TAR (92%); BOTSWANA (79%); AFRICA (79%); CENTRAL AMERICA (79%); SOUTHERN AFRICA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 19, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 U.S. pushes to limit generic-drug rights in trade pacts The International Herald Tribune April 19, 2006 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_150}{\*\bkmkstart DOC_ID_150_0}{\*\bkmkstart doc_id_12}{\*\bkmkend DOC_ID_150}{\*\bkmkend DOC_ID_150_0}{\*\bkmkend doc_id_12}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_12"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 12 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2006 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 U.S. pushes to limit generic-drug rights in trade pacts}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Anand Giridharadas\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 13\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1381 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Brian Knowlton in Washington contributed reporting to this article.\par *\par Under global trading rules, the inventors of medicines ordinarily have the right to a 20-year monopoly on their inventions. But five years ago, the United States joined 141 other countries in signing the Doha Declaration, confirming the right of poor countries to break drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and produce cheap generic drugs in the event of contagions like HIV.\par At the time, Thailand was heartened. It had been trying everything in its fight against AIDS. It coined a jingle to promote safe sex. It placed condoms in massage parlors. Most important, it curbed deaths among the poor by giving them generic versions of medicines invented by multinational drug makers. \par So it came as a jolt in January when the United States asked Thailand to sign a free trade agreement that would, on paper, dilute its right to break }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and use generics.\par Washington said the agreement would save lives by spurring innovation and by making multinationals more confident to sell drugs in the country. But Thai officials saw the proposal as a morbid bargain: either refuse the U.S. offer and scuttle a trade deal with the United States worth billions of dollars, or accept it and lift the price of AIDS drugs beyond the reach of the poor.\par ''Those who require the essential drugs but cannot afford it, they will have to die,'' said Dr. Suwit Wibu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 polprasert, the Thai official who is coordinating the Public Health Ministry's response to the U.S. proposal.\par Thailand is not alone. It is merely the latest target of a quiet worldwide campaign by the administration of President George W. Bush to coax developing nations to barter away their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking rights in e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 change for lucrative trade benefits, according to public health experts and government officials from Thailand to Brazil.\par Specifically, Washington is pushing bilateral and regional trade agreements in which countries enact ''supe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 patents'' that prolong U.S. drug makers' monopolies and limit the conditions under which their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  can be broken.\par These new rules, once they are adopted by developing countries, roll back the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking rights that were confirmed by the 2001 declaration at World Trade Organization talks in Doha, Qatar.\par In effect, Washington is stitching together a parallel global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system.\par The trade deals, negotiated in secret, attract little notice. But they have already been signed with developing countries battling AIDS, including six in Central America. And negotiations are beginning with several nations pivotal to the fight against the virus, from Thailand to five southern African countries, including South Africa and Botswana.\par Because of these agreements, India's generics industry, the world's largest, is reining in plans to supply poor countries and refocusing on richer ones, said Dilip Shah, head of the Indian Pharmaceutical Alliance, which represents generic makers.\par ''For the Indian pharma industry,'' he said, ''it's not doomed; it will find a way out. But for the patients in the Third World, it's bad.''\par Public health officials warn of catastrophic consequences if the bilateral deals are applied to AIDS drugs.\par ''If you prevent countries from using generic drugs,'' said Pedro Chequer, the head of Brazil's national AIDS program, ''you are creating a concrete obstacle to providing access to drugs. You are promoting genocide, because you're killing people.''\par First-generation AIDS drugs reached the world's poorest people only when the use of generics cut their cost to $140 a year from more than $10,000. As new drugs emerge to treat patients resistant to first-line med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines, the trade agreements make a similar drop ''extremely difficult to ensure,'' according to Medecins Sans Frontieres, or Doctors Without Borders.\par Washington maintains that the trade deals are directed toward diseases other than AIDS.\par And Richard Feachem, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria, based in Geneva, acknowledged that it was too early to tell whether the bilateral agreements would be used to block access to AIDS drugs.\par ''If we do see this in practice,'' he said, ''we should condemn it. But it really is in the interpretation of these agreements in very particular circumstances.''\par Yet, in defending the bilateral agreements, Bush administration officials often cite the AIDS example to make their case. Stronger }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  save lives, the argument goes, by keeping companies confident enough in profit to keep discovering new drugs.\par Dr. Mark Dybul, the second-ranking official in the White House program to fight AIDS, said that because AIDS patients constantly grow resistant to medicines, it is disastrous to widen access today and have no drugs tomorrow.\par ''As an individual physician sitting in front of an individual patient, you will do whatever you need to for that patient now,'' said Dybul, a physician. ''When you're a public health physician, you're not a physician for one person but for millions of people. And you need to be thinking about whether the action in that single setting, repeated hundreds of thousands of times, will cause a problem for the millions.''\par Spreading the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system are U.S. trade negotiators, who some experts believe are assuming the influence that public health experts once had over the Bush administration's AIDS policy.\par Victoria Espinel, an assistant U.S. trade representative, strongly defended the use of trade agreements to promote }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that ''have more in place'' than the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  agreed upon at the WTO talks in Doha, a step she described as merely ''harmonizing minimum standards.''\par ''It is crucial to public health,'' she said, ''to promote the innovation of drugs and to make sure that research and development of drugs continues.''\par As for exempting AIDS drugs from the new accords on }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -breaking, she said, ''I want to emphasize that there is enough flexibility in our free trade agreements to allow our partners to do what they need to do.''\par An explicit promise to exempt AIDS drugs, however, is not in the agreements, said Wibulpolprasert, the Thai official. And that, experts say, is at the heart of the problem: Nations must take Washington's word for it.\par An examination by the International Herald Tribune of several free trade agreements reveals provisions that appear, on paper, to limit the freedom to use generics.\par Several agreements, for example, prolong a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  monopoly beyond 20 years if the developing country's regulators show ''unreasonable delays'' in approving a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . This provision, absent from WTO rules, su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tains higher prices.\par Many agreements also serve to prolong }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  by requiring generics to be retested as if they were new inventions. Retesting a drug biologically equivalent to one already approved takes time and may be uneth}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal, since infected patients must be given placebos.\par The WTO rejected this requirement, a five-year ban on the use by generics makers of the safety data submi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ted for the original branded drug.\par And while the WTO lets countries decide when to break }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the new U.S. agreements limit this action to special cases to enforce antitrust law, for example, or during emergencies.\par Experts say the most important use of generics is excluded: to reduce costs by making branded products compete with generics.\par The generics question has also opened a rift in the United States, between Bush and former President Bill Clinton. On a recent visit to New Delhi, Clinton said he had confronted Bush about generics while flying to Rome for the papal funeral last April.\par ''The American position is untenable,'' Clinton recalled saying.\par In an interview, Clinton said Washington was succumbing to the influence of the drug lobby in undermining the Agreement on Trade-Related Aspects of Intellectual Property Rights, or Trips, the WTO framework on which the Doha declaration built.\par ''If a company develops a new advance in AIDS, TB, malaria, you need large numbers right away and all the people who need it are in poor places,'' Clinton said, referring to generics producers.\par ''If you don't have }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ranbaxy, Hetero, Aspen in South Africa and other people to step into the breach, how are we going to do that? I don't understand the apparent obsession with some of the big pharma inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ests in trying to block them off.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (91%); TRADE TREATIES & AGREEMENTS (90%); AIDS & HIV (90%); TREATIES & AGREEMENTS (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC PRODUCTS (90%); INTERNATIONAL TRADE LAW (89%); TRADE DEVELOPMENT (89%); PHARMACEUTICAL PREPARATION MFG (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); INTERNATIONAL TRADE (89%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); AGENCY RULEMAKING (78%); AIDS & HIV TREATMENT (78%); ANTIVIRALS (78%); HEALTH DEPARTMENTS (78%); MULTINATIONAL CORPOR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (78%); EMERGING MARKETS (78%); INTERGOVERNMENTAL TALKS (77%); FREE TRADE TREATIES & AGREEMENTS (77%); DRUG PRICES (73%); US PRESIDENTS (72%); PUBLIC HEALTH ADMINISTRATION (66%); MASSAGE SERVICES (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (79%) UNITED STATES (99%); THAILAND (93%); INDIA (92%); Q}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TAR (92%); BOTSWANA (79%); AFRICA (79%); CENTRAL AMERICA (79%); SOUTHERN AFRICA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 19, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The pink of health for drug companies; AROUND ASIA'S MARKETS; BUSINESS ASIA by Bloomberg The International Herald Tribune March 13, 2006 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_151}{\*\bkmkstart DOC_ID_151_0}{\*\bkmkstart doc_id_13}{\*\bkmkend DOC_ID_151}{\*\bkmkend DOC_ID_151_0}{\*\bkmkend doc_id_13}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_13"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 13 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2006 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 The pink of health for drug companies; \par AROUND ASIA'S MARKETS; \par BUSINESS ASIA by Bloomberg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Darren Boey\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 12\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 581 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Asian health care stocks are beating U.S. and European counterparts this year and rank among the region's best performers. New products and the threat of a bird-flu epidemic may help them keep their lead.\par ''Health care shares are picking up because demand for drugs is picking up,'' said Renault Kam, an asset manager at Atlantis Investment Management in Hong Kong, which holds shares of Southeast Asian pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceutical firms. \par ''We could expect these stocks to have another run if the bird-flu situation gets out of control,'' Kam said.\par Expectations of takeovers in the industry may also strengthen shares of drug makers. Tanabe Seiyaku has gained 16 percent this year amid speculation that the Japanese company may become a target.\par Kalbe Farma of Indonesia has jumped 39 percent, after merging with its parent and a subsidiary. That is the biggest gain among drug stocks in Morgan Stanley Capital International's Asia-Pacific index.\par A gauge of the index's health care stocks has risen 5.4 percent, the third-biggest gain among 10 industry groups. The group rose last week as the MSCI Asia-Pacific dropped, cutting its advance for the year to 1.7 percent.\par The Standard & Poor's 500 Health Care index has added just 2 percent for the year, the third-worst perfo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mance among the 10 broadest groups in the S&P 500. In Europe, the Stoxx 600 Health Care index has risen 3.7 percent, trailing a 6.5 percent gain for the Stoxx 600. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges and increasing sales of generic medicines have weighed on the sector.\par Asian drug makers are relatively expensive by the region's standards. The industry's MSCI Asia-Pacific index is valued at 29.7 times earnings, the second-highest ratio behind makers of consumer staples including food and beverages. The overall index is at 19.6 times earnings.\par Pharmaceutical companies have a growth premium built into them, based on expectations that profit will rise as they develop and sell new drugs, said Franki Chung, an investor at CIBC Global Asset Management (Asia).\par Chung owns shares of CSL, which makes blood plasma products. The Australian company is adding pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts like a cervical cancer vaccine and it plans to sell influenza vaccines in the United States next year. CSL last month raised its full-year profit forecast.\par Kalbe Farma, Indonesia's biggest drug maker, is also seeking to develop new drugs to increase sales, Vidjongtius Bernadetta Ruth, a director, said in a March 7 interview. He did not say what drugs it was wor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing on.\par ''These companies have capabilities in making products that are used to treat these sorts of ailments,'' said Paras Adenwala, chief investment officer at ING Investment Management in Mumbai. ''There's a possibility those stocks could move up higher.''\par Adenwala holds shares of Ranbaxy Laboratories, India's biggest drug maker. The stock has gained 16 pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cent in 2006.\par The Indian government has asked two of the nation's drug companies, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Hetero Drugs, to bid on supplying versions of Roche Holding's Tamiflu in order to help combat the H5N1 avian influenza virus.\par GlaxoSmithKline Pharmaceuticals, the Indian unit of GlaxoSmithKline, expects regulatory approval by April to sell the company's Relenza bird-flu medication in the country.\par Bird flu has spread from Asia to Europe, the Middle East and Africa, killing at least 97 of the 176 people i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fected since late 2003, according to the World Health Organization in Geneva. The risk of a pandemic is the highest in more than 35 years, according to the organization.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STOCK INDEXES (92%); PHARMACEUTICALS INDUSTRY (92%); AVIAN INFLUENZA (90%); HEALTH CARE SECTOR PERFORMANCE (90%); DISEASES & DISORDERS (89%); COMPANY EAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INGS (89%); INVESTMENT MANAGEMENT (89%); PHARMACEUTICAL PREPARATION MFG (89%); E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IDEMICS (89%); INFLUENZA (89%); ANNUAL FINANCIAL RESULTS (78%); TAKEOVERS (78%); GENE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IC DRUGS (77%); DRUG DESIGN & DISCOVERY (77%); EXECUTIVES (76%); EARNINGS PREA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOUNCEMENTS (75%); BUSINESS & PROFESSIONAL ASSOCIATIONS (74%); GENERIC PRODUCTS (73%); WOMEN'S HEALTH (73%); ANTIVIRALS (72%); CANCER (72%); CANCER DRUGS (72%); FINA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CIAL RESULTS (71%); COMPANY PROFITS (70%); INTERVIEWS (67%); VACCINES (63%); BLOOD D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RIVATIVES (50%); CERVICAL CANCER (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING GROEP NV (57%); MITSUBISHI TANABE PHARMA CORP (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INGA (BIT) (57%); INGA (AMS) (57%); ING (NYSE) (57%); 4508 (TSE) (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS525910 OPEN-END INVESTMENT FUNDS (57%); NAICS524113 DIRECT LIFE I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SURANCE CARRIERS (57%); NAICS523920 PORTFOLIO MANAGEMENT (57%); NAICS522110 CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MERCIAL BANKING (57%); SIC6311 LIFE INSURANCE (57%); SIC6282 INVESTMENT ADVICE (57%); SIC6081 BRANCHES & AGENCIES OF FOREIGN BANKS (57%); NAICS424210 DRUGS & DRUGGISTS' SUNDRIES MERCHANT WHOLESALERS (56%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (56%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (56%); SIC2834 PHARMACEUTICAL PREPARATIONS (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (79%) ASIA (96%); EUROPE (93%); HONG KONG (92%); INDONESIA (92%); SOUTH-EASTERN ASIA (90%); AUSTRALIA (79%); SOUTHERN ASIA (79%); INDIA (79%); UNI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 17, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions The Times (London) March 6, 2006, Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_152}{\*\bkmkstart DOC_ID_152_0}{\*\bkmkstart doc_id_14}{\*\bkmkend DOC_ID_152}{\*\bkmkend DOC_ID_152_0}{\*\bkmkend doc_id_14}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_14"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 14 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2006, Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Michael Binyon\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSINESS; Pg. 51\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1041 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 He took on Big Pharma over Aids. Now Yusuf Hamied wants to help poor countries beat the latest killer, writes Michael Binyon.\par HIS name is a red rag to Big Pharma, but his noisy challenge to the global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system has made him a hero to thousands fighting for better health in the developing world.\par Yusuf Hamied, head of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , India's huge generic drugs company, has stirred global controversy by promi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to supply Aids drugs for less than $1 a day. Now he has announced that he is ready to take on bird flu. \par At issue, again, is the whole question of generic versus proprietary drugs - an issue that has pitted Western capitalism against Third World campaigners and, perhaps more than any other dispute, cast moral opprobr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 um on multinationals attempting to protect the fruits of their expensive research.\par India has just granted }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a licence to distribute Anti-Flu, the generic version of Tamiflu, the drug sought across the world in the fight to contain bird flu.\par From his company's 30 manufacturing centres in India, Dr Hamied promises that he can distribute 500,000 capsules immediately to any Asian country in need. It is a pledge that has gained him fresh support in his long fight to break the global monopoly of multinational drug companies.\par Officially, that fight is over. For years India was able to produce cheap drugs by ignoring global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and allowing powerful companies, such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , to produce reverseengineered copies that were more afford}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble. But India has now joined the World Trade Organisation and, since the beginning of last year, has co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mitted itself to enforcing the protection of international property. Now no manufacturer can produce drugs that infringe }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or depend wholly on the research of Western pharmaceutical giants.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  days are far from over, however, and Dr Hamied, the indefatigable chairman and managing director, is as combative as ever in defying attempts to limit his products. Indian law allows manufacturers that began production before January 1 last year to continue, whatever the dispute over }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . The same applies to any company that had already invested substantial research and development (R&D) funds in its product.\par Dr Hamied argues that oseltamavir, the generic anti-flu drug, was being researched by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  before Roche marketed Tamiflu. The Swiss giant's application for a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India - which }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  opposes - has not yet been granted. He therefore intends to sell his drug not only to a subcontinent fearful that avian flu - which, if it mutates into a form transmissible between human beings, will sweep through poor villages - he is also ready to export the product to countries where }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection is not enforced and to the 49 countries designated as the least developed, where the world is willing to allow cheap generic replicas.\par Already }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  says that it has received four export orders. The clients' identities are secret, but the first 50,000 doses have gone to a country where Roche does not have a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par In many ways, this is a replay of the confrontation over Aids. The promise by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  - among other generic manufacturers - to deliver a year's supply of Aids drugs to African victims at a cost of $300 a year, at a time when Western multinationals were charging $15,000, brought the issue to a head.\par There was uproar over\par what campaigners saw as exploitation by Big Pharma.\par An international conference, called by the United Nations, put enormous pressure on the multinationals to change tack. Bill Gates and President Clinton threw their weight behind the campaign and the multinationals were forced to cut prices charged for Aids drugs in Africa by up to 90 per cent.\par For Dr Hamied, who at 25 became one of the youngest Indians to receive a doctorate at Cambridge, it is a moral issue. "I'm not against intellectual property, I'm against monopoly," he says.\par Most Indians are still poor, and the choice for villagers is generic drugs or nothing. In the days of the Cold War and non-alignment, when India kept the West at arm's length, it disregarded }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and made a fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tune selling generic medicine to the Soviet Union and other countries unable to pay hard currency for Wes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ern drugs. However, the Indian pharmaceutical market is now approaching $5 billion and India has since b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 come central to the global economy; it has had to ditch its cheap drugs policy as part of its adherence to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ternational agreements on intellectual property at the very time when many, even in the West, believe that Dr Hamied's approach is fully justified.\par Bill Clinton was in India last month and accompanied Dr Hamied around the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  plant in Goa, applauding his commitment to giving the maximum number of Aids victims treatment through low-cost medicine. Neve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 theless, he said, only 1.5 million of the 6.2 million people desperately in need were getting the medicines.\par The multinationals have fought back hard against the generic companies, which they see as parasites.\par Dr Hamied, whose father started }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in a Bombay bungalow in 1935, is now a rich man, but he points to the market failures of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection in India and other developing countries. Before 1970, many drugs available in the developed world could not be found in India. And, almost alone among India's pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal producers, Dr Hamied would like a regime under which the innovator receives royalties from imitators, not an exclusive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par Others argue that India is no longer poor. There are plenty of people who can afford Western drugs. They say that the country cannot afford to alienate the multinationals at a time when India is trying to market itself in the West as an alternative health supplier for elective surgery - for which, of course, Western patients would expect the latest Western drugs.\par In many ways Dr Hamied, 70, has won his long fight: Big Pharma is making many products available cheaply in poor countries; the United Nations has taken up the issue; and some Indian drug makers are themselves now able to pioneer new medicines for which they want full global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection. Without his challenge, however, the world's poor might have had far less access than they do to cheap drugs to combat the big kil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers: TB, malaria, heart disease. It is a legacy of which he is proud.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); AVIAN INFLUENZA (91%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (90%); INFLUENZA (90%); GENERIC DRUGS (90%); RESEARCH & DEVELOPMENT (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); GENERIC PRODUCTS (89%); MULTINATIONAL CORPORATIONS (89%); EXPORT TRADE (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PRESCRIPTION DRUGS (78%); INTERNATIONAL TRADE (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (77%); REVERSE ENGINEERING (77%); EMERGING MARKETS (77%); AGRICULTURAL TRADE (73%); PHARMACEUTICAL PREPARATION MFG (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRING}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (72%); AIDS & HIV TREATMENT (71%); TRADE DEVELOPMENT (69%) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (96%); ASIA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 6, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Times Newspapers Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions The Times (London) March 6, 2006, Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_153}{\*\bkmkstart DOC_ID_153_0}{\*\bkmkstart doc_id_15}{\*\bkmkend DOC_ID_153}{\*\bkmkend DOC_ID_153_0}{\*\bkmkend doc_id_15}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_15"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 15 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2006, Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian hero's new mission: to bring cheap drug for bird flu to millions}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Michael Binyon\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSINESS; Pg. 51\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1041 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 He took on Big Pharma over Aids. Now Yusuf Hamied wants to help poor countries beat the latest killer, writes Michael Binyon.\par HIS name is a red rag to Big Pharma, but his noisy challenge to the global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system has made him a hero to thousands fighting for better health in the developing world.\par Yusuf Hamied, head of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , India's huge generic drugs company, has stirred global controversy by promi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to supply Aids drugs for less than $1 a day. Now he has announced that he is ready to take on bird flu. \par At issue, again, is the whole question of generic versus proprietary drugs - an issue that has pitted Western capitalism against Third World campaigners and, perhaps more than any other dispute, cast moral opprobr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 um on multinationals attempting to protect the fruits of their expensive research.\par India has just granted }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a licence to distribute Anti-Flu, the generic version of Tamiflu, the drug sought across the world in the fight to contain bird flu.\par From his company's 30 manufacturing centres in India, Dr Hamied promises that he can distribute 500,000 capsules immediately to any Asian country in need. It is a pledge that has gained him fresh support in his long fight to break the global monopoly of multinational drug companies.\par Officially, that fight is over. For years India was able to produce cheap drugs by ignoring global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and allowing powerful companies, such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , to produce reverseengineered copies that were more afford}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble. But India has now joined the World Trade Organisation and, since the beginning of last year, has co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mitted itself to enforcing the protection of international property. Now no manufacturer can produce drugs that infringe }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or depend wholly on the research of Western pharmaceutical giants.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  days are far from over, however, and Dr Hamied, the indefatigable chairman and managing director, is as combative as ever in defying attempts to limit his products. Indian law allows manufacturers that began production before January 1 last year to continue, whatever the dispute over }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . The same applies to any company that had already invested substantial research and development (R&D) funds in its product.\par Dr Hamied argues that oseltamavir, the generic anti-flu drug, was being researched by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  before Roche marketed Tamiflu. The Swiss giant's application for a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India - which }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  opposes - has not yet been granted. He therefore intends to sell his drug not only to a subcontinent fearful that avian flu - which, if it mutates into a form transmissible between human beings, will sweep through poor villages - he is also ready to export the product to countries where }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection is not enforced and to the 49 countries designated as the least developed, where the world is willing to allow cheap generic replicas.\par Already }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  says that it has received four export orders. The clients' identities are secret, but the first 50,000 doses have gone to a country where Roche does not have a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par In many ways, this is a replay of the confrontation over Aids. The promise by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  - among other generic manufacturers - to deliver a year's supply of Aids drugs to African victims at a cost of $300 a year, at a time when Western multinationals were charging $15,000, brought the issue to a head.\par There was uproar over\par what campaigners saw as exploitation by Big Pharma.\par An international conference, called by the United Nations, put enormous pressure on the multinationals to change tack. Bill Gates and President Clinton threw their weight behind the campaign and the multinationals were forced to cut prices charged for Aids drugs in Africa by up to 90 per cent.\par For Dr Hamied, who at 25 became one of the youngest Indians to receive a doctorate at Cambridge, it is a moral issue. "I'm not against intellectual property, I'm against monopoly," he says.\par Most Indians are still poor, and the choice for villagers is generic drugs or nothing. In the days of the Cold War and non-alignment, when India kept the West at arm's length, it disregarded }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and made a fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tune selling generic medicine to the Soviet Union and other countries unable to pay hard currency for Wes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ern drugs. However, the Indian pharmaceutical market is now approaching $5 billion and India has since b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 come central to the global economy; it has had to ditch its cheap drugs policy as part of its adherence to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ternational agreements on intellectual property at the very time when many, even in the West, believe that Dr Hamied's approach is fully justified.\par Bill Clinton was in India last month and accompanied Dr Hamied around the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  plant in Goa, applauding his commitment to giving the maximum number of Aids victims treatment through low-cost medicine. Neve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 theless, he said, only 1.5 million of the 6.2 million people desperately in need were getting the medicines.\par The multinationals have fought back hard against the generic companies, which they see as parasites.\par Dr Hamied, whose father started }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in a Bombay bungalow in 1935, is now a rich man, but he points to the market failures of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection in India and other developing countries. Before 1970, many drugs available in the developed world could not be found in India. And, almost alone among India's pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal producers, Dr Hamied would like a regime under which the innovator receives royalties from imitators, not an exclusive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par Others argue that India is no longer poor. There are plenty of people who can afford Western drugs. They say that the country cannot afford to alienate the multinationals at a time when India is trying to market itself in the West as an alternative health supplier for elective surgery - for which, of course, Western patients would expect the latest Western drugs.\par In many ways Dr Hamied, 70, has won his long fight: Big Pharma is making many products available cheaply in poor countries; the United Nations has taken up the issue; and some Indian drug makers are themselves now able to pioneer new medicines for which they want full global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection. Without his challenge, however, the world's poor might have had far less access than they do to cheap drugs to combat the big kil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers: TB, malaria, heart disease. It is a legacy of which he is proud.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); AVIAN INFLUENZA (91%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (90%); INFLUENZA (90%); GENERIC DRUGS (90%); RESEARCH & DEVELOPMENT (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); GENERIC PRODUCTS (89%); MULTINATIONAL CORPORATIONS (89%); EXPORT TRADE (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PRESCRIPTION DRUGS (78%); INTERNATIONAL TRADE (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (77%); REVERSE ENGINEERING (77%); EMERGING MARKETS (77%); AGRICULTURAL TRADE (73%); PHARMACEUTICAL PREPARATION MFG (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRING}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (72%); AIDS & HIV TREATMENT (71%); TRADE DEVELOPMENT (69%) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (96%); ASIA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 6, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Times Newspapers Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian company vows to make bird flu drugs available BBC Monitoring South Asia - PoliticalSupplied by BBC Worldwide Monitoring February 20, 2006 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_154}{\*\bkmkstart DOC_ID_154_0}{\*\bkmkstart doc_id_16}{\*\bkmkend DOC_ID_154}{\*\bkmkend DOC_ID_154_0}{\*\bkmkend doc_id_16}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_16"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 16 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BBC Monitoring South Asia - Political\par Supplied by BBC Worldwide Monitoring\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2006 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian company vows to make bird flu drugs available}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 498 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Text of report by Olga Tellis, published by Indian newspaper The Asian Age website on 20 February\par Mumbai, 19 February: Dr Yusuf Hamied, chairman and managing director of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , said the drug they have produced, called anti-flu (oselta mivir, the generic name), will be put on the market by mid-week. Dr Hamied said: "My product will be in the market as anti-flu by Wednesday [ 22 February]. It will match the competition price wise. It took us two months to get regulatory approval." \par Dr Hamied said, "There is a second drug for anti flu, the generic name is zanamivir and that is given by inh}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lation. We are also going to make that and it will be ready in two months." Dr Hamied said: "Now that there is a possibility of an epidemic of bird flu, the government of India should take a firm stand and permit Indian firms to produce the anti-flu drug. The originator of the product is a company called Gilead in the US and they then licensed it to Roche that marketed it under a monopoly. We have been against this monopoly. Roche have filed for a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India and the priority date of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is February 1995, which is very close to the date of 1 January 1995, when India signed the International Property Rights."\par Dr Hamied said that a study has been made of all the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and there are no grounds for monopoly and for India issuing them a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . The Indian government should make a full announcement to that effect at the earliest." [single quotation mark as published] He said: "I believe that Roche should not be granted the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  because it was known prior to 1995. There are errors in the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  as well. A }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is a grant of a favour by a government on the innovator. If the government does not want to grant the favour, they need not. In case of national emergency, the government should take a firm action, examine the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and not grant it as it is not valid."\par Dr Hamied said that the government should have made an announcement that bird flu is serious and "we will give permission to any company to manufacture the drugs." Dr Hamied said that the government has d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 layed in giving this permission, but }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has on its own gone ahead and done it. In fact, he had told the New York Times that right or wrong he is going ahead and he is in the right. This drug, he insists, was known way before 1995, so there is no issue about international property rights. He said. "There is an issue with oselta mivir and the government should take a stand firmly and soon in the national interest."\par Dr Hamied's factory in Goa can produce up to one lakh [100,000] doses per week. He said that at subsidized rates for wholesale purchase, it will cost  650 rupees [about 14.5 dollars] for a dose of 10 capsules and 1,000 rupees [about 22 dollars] for 10 in retail. It's a five-day treatment and should be taken at the first signs of flu. Dr Hamied said: "We anticipated this and told the government about the threat many months ago."\par Source: The Asian Age website, Delhi, in English 20 Feb 06\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (93%); AVIAN INFLUENZA (90%); ANTIVIRALS (90%); PUBLISHING (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (87%); APPROVALS (75%); MANUFACTURING FACILITIES (60%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (92%); ROCHE HOLDING AG (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%); ROG (SWX) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UFACTURING (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (73%) GOA, INDIA (58%) INDIA (94%); UNITED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 20, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Transcript\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 British Broadcasting Corporation\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Fine Chemicals;Indian Firms Tear Into Overseas API Markets Chemical Week February 15, 2006 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_155}{\*\bkmkstart DOC_ID_155_0}{\*\bkmkstart doc_id_17}{\*\bkmkend DOC_ID_155}{\*\bkmkend DOC_ID_155_0}{\*\bkmkend doc_id_17}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_17"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 17 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Chemical Week\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  15, 2006\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Fine Chemicals;\par Indian Firms Tear Into Overseas API Markets}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ALEX SCOTT\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COVER STORY; Pg. 27\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 3495 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian custom fine chemical contract manufacturing organizations (CMO) are no longer satisfied with i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 creasing their share of the pharmaceutical intermediates market and have started to target the high-value, high-tech active pharma ingredient (API) sector, which until now was served only by European and North American competitors including BASF, Cambrex, and Degussa.  Indian firms such as Dr Reddys Laborat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ries (DRL; Hyderabad), Nicholas Piramal India Ltd. (NPIL; Mumbai), and Shasun Chemicals and Drugs (Chennai) have in recent months made what they consider to be key API acquisitions overseas.  They e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pect these acquisitions to be a springboard to building an overseas presence in high-tech API manufacturing sectors such as high-potency APIs (HPAPI).  Leading European and North American API manufacturers say their competitive position in APIs is based on unique technologies and service capabilities.  But more acqu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sitions by Indian firms are expected, and the core custom API market in Europe and North America is coming under threat.  Rhodia's recently announced sale of its Rhodia Pharma Services (RPS) custom pharma inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mediates business to Shasun will not be the last deal of its kind, industry experts say. \par India's contact manufacturing sector will increase its sales from $ 100 million in 2005, to $ 1 billion in 2010, says investment broker Motilal Oswal Securities (Mumbai) in a recent report.  All of the leading low-cost Asian CMOs "are going for the API business in the West," says Girish Malhotra, president of pharma consul}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing firm EPCOT International (Pepper Pike, OH).  "They are making significant inroads into the U.S. API market," Malhotra says.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOW-COST BASE.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Companies such as NPIL are approaching the international API market from a relatively low cost base, and in many cases firms from a number of Asian countries are practicing more efficient che}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istry and manufacturing processes than their European and American counterparts, Malhotra says.\par Roche's production process for the antiviral drug Tamiflu, used to treat human flu and possibly bird flu, is an example, he says.  Roche says that production of the drug is highly complex and that it has taken about a year to commercialize.  However, generic drugs firm }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (Mumbai) says that over the last few months it has developed a new process for Tamiflu that it expects will squeeze commercialization time to three months, and that it hopes to gain FDA approval for the process within weeks.  "In the West, in one unnamed case, a pharma company has been using a process with a 14% product yield," Malhotra says.  "Even 50% yield processes today should be unacceptable, but are in use in the West.  Indian companies are beating them hands down."\par FDA is striving to develop a more efficient approach to chemistry, and will increasingly favor Indian CMOs, Malhotra says.  "Improving the foundation of manufacturing science in our current manufacturing practices should be the primary basis for moving away from the corrective-action 'crisis' to continuous improvement," FDA says in a recent report.\par Indian CMOs' strategy to increase their share of overseas API markets will likely be underpinned by major pharma companies such as Pfizer and Merck & Co., which are striving to reduce manufacturing costs by bi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lions of dollars, some experts say.  Major pharma companies will look at outsourcing to low-cost Asian CMOs rather than to European and North America suppliers as a way of reducing their own costs further, says P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ter Young, president of life sciences and chemicals investment banking firm Young and Partners (Y&P; New York).  More major pharma companies will announce substantial cost-reduction programs in the year ahead, and that will increase price pressure further on fine chemical suppliers, Young says.\par Wages and salaries for chemists in India are 20% of those in the U.S. and Europe, according to API man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facturer Divi's Laboratories (Hyderabad).  Indian firms also have a cost advantage in chemical and pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceutical manufacturing, says Hari Pujar, chemical engineer and research fellow at Merck Research Laborat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ries (West Point, PA), a Merck & Co. subsidiary.\par Leading U.S.-based CMOs say that even taking into account the cost difference, they can offer a string of benefits to customers that their Indian competitors cannot match.  Benefits include proximity to the major U.S. pharma companies and ownership of sophisticated technologies.  Recently, however, and particularly during the past year, Asian firms say they have started to close the gap on all of these assumed advantages, primarily by acquiring established and sometimes poorly performing U.S. custom manufacturers.\par Jubilant has acquired a number of pharma research and manufacturing businesses in the past few years, including CRO Target Research Associates (Berkeley Heights, NJ) for $ 33.5 million and generics group Trinity Laboratories (Salisbury, MD) for $ 12.5 million }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, July 13, 2005, p. 36).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Jubilant says that its strat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gy is bearing fruit with the agreement of manufacturing contracts with multinational life-science companies in 2006 worth a combined $ 40 million.  The company also has agreed on contract research deals with multin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional companies for 2007 worth a combined $ 28 million.  About 48% of Jubilant's 2005 sales were to Eur}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pean markets, and 25% to the U.S. Jubilant increased profits 41%, to Rs1.1 billion ($ 26 million) in the fiscal year ended March 31, 2005, on sales up 30%, to Rs11.1 billion.\par Jubilant's strengthening of its R&D and manufacturing base matches the increased outsourcing demands of multinational companies, the company says.  Jubilant has long-standing relationships with more than 150 multinationals, including 15 of the top-20 pharma companies, and seven of the top-10 agchem companies, Shyam S. Bhartia, chairman and managing director of Jubilant, tells }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 CW.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Expansion into U.S. and European markets has occurred through organic growth and acquisitions, Bhartia says.  Jubilant also is involved in drug discovery, and believes its business "has the potential to ramp up significantly over the next few years" in the U.S., he says.  The company says it is developing leading-edge custom manufacturing technologies, and that it has unique technologies of its own.  "But if there are good opportunities for acquiring new techno}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ogies, we would consider such proposals," particularly in the key markets of Europe and the U.S., he adds.\par Other Indian CMOs are looking to emulate Jubilant's success through acquisition of custom research and manufacturing companies in Europe and North America.  Shasun plans to close the purchase of money-losing RPS by the end of next month }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Jan. 18, p. 25).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The acquisition includes all of RPS's development and custom manufacturing services catering to pharma companies in Asia, Europe, and the U.S., as well as manufacturing sites at Dudley and Annan, U.K. RPS's technologies such as hydrolytic kinetic resolution (HKR), aromatic bond formation (ABF), and Radical Trifluoromethylation, together with their respective }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tents,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are also included, as are products and building blocks related to the technologies.\par Shasun generated 60% of its $ 73-million sales from Europe and the U.S. in 2004.  Buying RPS fits with Shasun's strategy to strengthen its global presence further in API custom synthesis, says CEO Narayanan Govindarajan.  "Shasun will be in a better position to serve pharmaceutical industry clients throughout the drug life cycle by offering services for pre-launch, launch, and post-launch supply, as well as for late life c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cle," Govindarajan says.  The deal will also expand Shasun's customer base across innovator and emerging pharma companies, he says.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 NOVEL TECHNOLOGIES.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  NPIL announced last October that it had agreed to acquire Avecia's pharma business for \u163\'a3 9.5 million ($ 17 million), in part to secure access to novel technologies in sectors including chiral synthesis, fermentation, biotransformation, and HPAPI production }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Nov. 2, 2005, p. 5).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Avecia's pharma business unit includes API manufacturing activities at Grangemouth and Huddersfield, U.K., and A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rora, ON, and generates sales of \u163\'a3 36.1 million/year.  The business features "a deep pipeline of products backed by strong customer relationships and a mix of unique technologies," NPIL says.  All 350 staff at Avecia Pharmaceuticals will transfer to NPIL.  The acquisition provides NPIL with a manufacturing presence in Europe and the U.S., and entry into the HPAPI sector, the company says.  NPIL says it had been seeking a suitable acquisition for about one year.\par NPIL opted also to acquire Avecia's 25% stake in fine chemical catalyst spin-out Reaxa (Manchester, U.K.), which owns catalyst technologies for fine chemical processing.  The Avecia acquisition follows NPIL's pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 chase of Rhodia's inhalation anaesthetics business in December 2004.\par The Avecia business adds novel technologies to NPIL's low cost base in India.  "Avecia Pharmaceuticals has a long tradition of technology-driven, high-end service to the global pharma industry, driven by highly comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tent specialists," NPIL says.  "Additionally, the Avecia business brings a distinct group of new customers from both the big pharma and biotechnology fields." Merging Avecia Pharmaceuticals with NPIL's custom man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facturing group "will go a long way to making the combined entity a truly global custom manufacturing pla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er," says Aja Piramal, chairman of NPIL.\par NPIL says it anticipates that Asian companies will make further acquisitions in Europe and North America.  The Avecia Pharmaceuticals deal "will trigger a new wave of restructuring within the global custom manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turing industry," the company says.  "The winning custom manufacturers of the future will have a strong manufacturing base in India with technology and early phase beachheads in North America and Europe," it says.  NPIL predicts 2005 after-tax profits of R1.7 billion, on sales of Rs12.3 billion, and says it is a top-four player in the Indian pharma market.\par NPIL and several other custom manufacturers in India, say they have each established production deals with overseas pharma companies.  NPIL has about $ 500 million worth of contracts covering the next eight years for a number of leading pharma companies, including Novartis.\par DRL announced last November that it had agreed to purchase Roche's API manufacturing business at Cue}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 navaca, Mexico for $ 59 million, including the cost of working capital }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Nov. 23, 2005, p. 25).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The deal includes all existing business supply contracts, including ongoing supplies to Roche.  All 340 of the bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ness's staff will be transferred to DRL.\par The former Roche business makes about 18 products including "mature APIs," and a range of intermediates and steroid-based HPAPIs.  DRL says the acquisition will enable it to deliver a wider range of pharma se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices.  "Dr Reddys will emerge as a leading player in custom pharmaceutical services, with strategic offe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ings spanning the entire value chain," says GV Prasad, DRL CEO. DRL is targeting sales of finished pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts to the U.S., and last year raised $ 56 million from ICICI Venture (Bangalore) to fund the launch of gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic drugs there.  DRL reported a 72% increase in net profits, to Rs890 million, for its fiscal quarter ended Se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tember 30, 2005, on sales up 7%, to Rs5.8 billion.\par Indian API manufacturer Matrix Laboratories (Secunderabad) has also been acquisitive.  In 2005 the comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ny acquired a 43% stake in API and intermediates manufacturer Explora Laboratories (Mendrisio, Switze}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 land), and a 60% stake in Mchem Group (Xiamen, China), a producer of APIs, basic chemicals, finished-dose products, and intermediates }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Oct. 12, 2005, p. 33).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Matrix also purchased a 22% stake in generics firm Docpharma (Interleuvenlaan, Belgium) in July 2005 for (euro) 217 million ($ 259 million).\par Indian pharma companies are also seeking to acquire small European and U.S. pharma firms.  Biocon (Ba}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 galore) has made an approach to acquire the intellectual property of drug developer Nobex (Research Tria}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gle Park, NC) following Nobex's filing under Chapter 11 bankruptcy protection.  Pharma and API manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turer Sun Pharmaceutical Industries (Mumbai) has made a move to acquire generics firm Able Laboratories (Cranbury, NJ) for $ 23 million.  Able Laboratories has also filed for chapter 11 due to manufacturing quality issues.\par Indian companies are seeking to reduce their own costs by securing deals to source pharma intermediates from Chinese suppliers.  Hikal recently announced plans to take a minority stake in a Sinochem fine chem}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal subsidiary.  The move "will help Hikal improve its cost base, as we see many sourcing opportunities of raw materials and intermediates for our APIs," says Jai Hiremath, vice chairman and managing director.  "The association with Sinochem will open up new avenues for marketing and sourcing of products in different markets."\par Indian generics and API manufacturers are also climbing the technology ladder by licensing in novel pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cesses.  Indian companies are among the early adopters of biocatalytic technologies, says Alan Shaw, pre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ident and CEO of biocatalysis technology firm Codexis (Redwood City, CA).  Codexis says it has agreed on deals to license its proprietary enzyme technology to four Indian firms, including Arch Pharmalabs (Mumbai), Matrix Laboratories, and Shasun, to develop biocatalytic processes using enzymes engineered via Codexis's directed evolution technology.\par "Our processes are often as much as 40%-60% cheaper than the nearest chemistry equivalent," Shaw says.  Essentially, "you've got a 60% cheaper product than the rest of the market," he says.  No additional capital is required as biocatalysts operate in simple, stirred vessels at room temperature, he adds.\par Relatively few Europe- or U.S.-based fine chemical firms have entered into agreements with Codexis.  "A lot of people in the Western fine chemical industry think they have what they need to be competitive," Shaw says.  "The reality is that they haven't.  The European and U.S. fine chemical industry has got some real problems here because the only differentiator it has left is technology," he adds.\par Codexis, in addition to licensing its enzyme technology to third parties, plans to use the technology to pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce certain generic APIs, and, using its network of Indian affiliates, to manufacture the products in India.  "We are going straight from California to manufacture in India and will be sidestepping production in Europe completely," Shaw says.  "This will give a real competitive edge."\par Most European and North American API manufacturers have been striving to differentiate themselves from low-cost Asian competitors by developing novel technologies.  Firms including Clariant, Lonza, and RPS have also built a manufacturing presence in countries with low labor costs.  RPS, has shifted paracetamol capacity from plants in the U.S. and France to Wuxi, China as part of a long-term strategy to reduce costs.  The company also has a cGMP manufacturing facility at Bangpoo, Thailand.  RPS's asset base is in "good shape" partly as a result of its low-cost strategy, Nick Green, president of RPS, told CW recently.  Some pharma companies remain "nervous" about their intellectual property when projects are shifted to Asia, ho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ever, Green says.  RPS, even prior to its planned purchase by Shasun, provided customers with a choice of production in Asia, North America, or Western Europe, he adds }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Nov. 16, 2005, p. 23).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Clariant says it is growing its manufacturing base in Asia, and completed construction last year of a Rs80-million ($ 1.8 million) intermediates factory at Roha, India that forms part of the company's previously a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nounced plans to shift a significant proportion of its intermediates for agchems and the pharma sector from Europe to countries with low labor costs }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Jan. 19, 2005, p. 23).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The facility provides Clariant with pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts of international quality at Indian costs, the company says.\par Lonza CEO Stefan Bogas announced recently that Lonza is building an R&D center for pharma intermed}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ates and API-related activities at Nansha, China }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Sept. 21, 2005, p. 42).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The center will house about 60 research staff and include research laboratories, process development facilities, and an analytical chemistry facility.  It is due to begin operations by the end of this quarter.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ASIAN PARTNERING.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Pfizer CentreSource (PCS; Kalamazoo, MI), a Pfizer subsidiary, is taking a different approach.  The company tells }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 CW}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that to cut manufacturing costs it plans to partner with Asian contract manufacturers on latter-stage processing of steroid intermediates }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Feb. 11, p. 22).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  PCS's technology is based on a single biocatalytic step, which replaces several synthetic chemical steps used during standard manufacture.  "As steroid manufacturing has grown in China and elsewhere throughout Asia, we've felt the competitive pressure," says Doris Scheffel Symonds, v.p./global marketing and fine chemicals at PCS.  The company says that shifting its technology to Chinese partners in the coming years will give it a competitive edge over any low-cost producer.\par CMOs have also been implementing lengthy cost-reduction programs in Europe and the U.S. to ensure they are better able to compete.  BASF announced last fall that it would reduce production of caffeine and the cold remedy ingredient pseudoephedrine to reduce costs and improve efficiency at its Minden, Germany o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erations, in the face of falling demand.  DSM has gone a step further, announcing recently a major cost-reduction program that involves closing the company's pharma intermediates complex at South Haven, MI in the second quarter of 2007, and mothballing biologic drugs facilities at Montreal }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, Jan. 4/11, p. 31).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  DSM's actions are expected to generate annualized savings of (euro) 20 million from mid-2007, the company says.  DSM cites the commoditization of early stage pharma intermediate and generic API markets that are increasingly served by producers in countries with low labor costs, and by Indian and Chinese companies in particular.\par Indian custom manufacturers are also becoming attractive targets for cash-rich pharma companies in other countries.  Recent deals include generics firm Watson Pharmaceuticals' (Corona, CA) acquisition of a pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ma formulation facility at Verna, India from DRL.  Financial details were not disclosed.  Watson, meanwhile, is consolidating its domestic manufacturing base, and within two years says it will close a solid-dose man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facturing facility at Humacao, Puerto Rico.\par Generic pharma manufacturer Teva Pharmaceutical Industries (Petach Tikva, Israel) is in talks to acquire bulk drugs, formulations, and oral suspensions producer Aurobindo Pharma (Ameerpet, India), reports say.  Both companies declined to comment on the reports.\par Foreign API manufacturers may be at a disadvantage when establishing a presence in countries with low labor costs, however, executives say.  Many Asian producers flout regulations to avoid costs, unlike Europ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an and North American companies that generally adhere to recognized manufacturing-quality standards and waste legislation, they say.  And there may be other downsides.  "Locating production in a newly developed country opens up liability concerns, not necessarily as a result of an individual plant being out of compliance or of pollution issues, but because of proximity to chemical companies that have lower standards," says Guy Villax, CEO of Hovione.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 QUALITY CONCERNS.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Villax was closely involved in the recent formation of the European Fine Chemicals Group (EFCG; Brussels), a Cefic lobby group that pressures the European Commission to ensure that drugs imported by Europe from less expensive Asian manufacturers are produced in approved manufacturing plants and under procedures that ensure drug quality.  EFCG says sub-quality APIs are entering Europe from plants that have not been inspected by FDA or Europe's equivalent body, the European Medicines Evaluation Agency (EMEA).\par The European Union introduced legislation last fall to ensure that sub-standard pharmaceutical imports are not permitted in Europe.  Senior European fine chemical industry executives are concerned, however, that insufficient funds will be made available to police the legislation }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 (CW, July 27, 2004, p. 31).}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  EFCG has pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lished guidelines for European and North American API manufacturers to help strengthen their position.  Recommendations include that: API audit reports be no more than three years old; that each producer write and sign a declaration certifying that each API the company supplies is made under GMP requirements as described in Drug Master Files; and that any process changes be notified to the relevant authorities prior to implementation.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MANUFACTURING OUTPUT (91%); PHARMACEUTICALS INDUSTRY (90%); MEDICINALS & BOTANICALS MFG (90%); CHEMICALS (90%); CHEMICALS MFG (90%); MARKET SHARE (90%); CHE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ISTRY (89%); SPECIALTY CHEMICALS MFG (78%); PHARMACEUTICAL PREPARATION MFG (78%); GENERIC DRUGS (78%); DRUG & MEDICAL DEVICES APPROVAL (73%); INDUSTRY ANALYSTS (73%); ANTIVIRALS (70%); APPROVALS (68%); INFLUENZA (66%); AVIAN INFLUENZA (66%); CONSULTING SERVICES (66%); US FDA APPROVALS (63%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); SHASUNPHAR (NSE) (57%); RDY (NYSE) (57%); DRREDDY (NSE) (57%); MOTILALOFS (NSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (72%); SIC2834 PHARMACEUTICAL PREPARATIONS (72%); NAICS325199 ALL OTHER BASIC ORGANIC CHEMICAL MANUFACTURING (58%); SIC2869 INDUSTRIAL ORGANIC CHEMICALS, NEC (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (57%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (57%); SIC2835 IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (57%); NAICS325510 PAINT & COATING MANUFACTURING (55%); NAICS325211 PLASTICS MATERIAL & RESIN MANUFA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TURING (55%); NAICS523120 SECURITIES BROKERAGE (54%); NAICS523110 INVESTMENT BANKING & SECURITIES DEALING (54%); SIC6211 SECURITY BROKERS, DEALERS, & FLOTATION COMPANIES (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GIRISH MALHOTRA (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NORTH AMERICA (94%); INDIA (93%); UNITED STATES (92%); ASIA (91%); EUROPE (79%); CARIBBEAN ISLANDS (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TAMIL NADU, INDIA (74%); ANDHRA PRADESH, INDIA (74%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (89%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NICHOLAS PIRAMAL INDIA LTD (72%); EVONIK DEGUSSA GMBH (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); SHASUN PHARMACEUTICALS LTD (57%); DR REDDY'S LABORATORIES LTD (57%); RHODIA SA (55%); MOTILAL OSWAL FINANCIAL SERVICES LTD (54%);   FOOD & DRUG ADMINISTRATION (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 21, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Picture 1, no caption; Picture 2, Shaw: Western firms need to be high tech.; Picture 3, Hiremath: A global player.; Picture 4, Bhartia: Establishing a Western presence.; Picture 5, Borgas: Growing R&D base in Asia.\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2006 Chemical Week Associates\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Despite Viagra's cost, India beckons Pfizer; BUSINESS ASIA by Bloomberg The International Herald Tribune December 22, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_156}{\*\bkmkstart DOC_ID_156_0}{\*\bkmkstart doc_id_18}{\*\bkmkend DOC_ID_156}{\*\bkmkend DOC_ID_156_0}{\*\bkmkend doc_id_18}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_18"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 18 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Despite Viagra's cost, India beckons Pfizer; \par BUSINESS ASIA by Bloomberg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Mrinalini Datta and Paresh Jatakia\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 20\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 615 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pfizer will introduce the impotence-treating drug Viagra in India next week, having held the drug back for seven years until India introduced firmer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws this year.\par Keeping the drug off Indian pharmaceutical shelves has not stopped a trade in as many as 40 local versions of the drug, with brand names like Penegra and Caverta.\par Viagra, which Pfizer began selling in the United States in 1998, will cost about 20 times the price of its imit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tors when it goes on sale in 30 cities on Dec. 26, Kewal Handa, managing director of Pfizer's Indian unit, told reporters in Mumbai on Tuesday.\par The company is pricing a single 50 milligram pill at 463 rupees, or $10.20, while Ranbaxy Laboratories, I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia's biggest drug maker, sells its copy at 95 rupees for four tablets of the same dosage at Nath Brothers pharmacy in New Delhi. \par Pfizer is betting on demand for the original product from people who can afford it in India, where as many as 390 million people earn less than $1 a day, according to the World Bank.\par The company expects to grab a chunk of the Indian market with Viagra, whose worldwide revenue declined 11 percent to $1.68 billion last year, which amounts to 3.2 percent of Pfizer's total revenue of $52.52 billion\par Pfizer expects there will be enough people who will demand the product once they are educated about its benefits, said K.G. Ananthakrishnan, senior director at Pfizer's Indian unit. It is seeking to expand the size of the market for impotence drugs, which has been ''stagnant,'' by creating awareness, which includes distri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 uting leaflets to doctors and experts.\par ''We are launching Viagra in India for the benefit of those customers who trust the quality of the original brand,'' Handa said. ''We strongly believe that there is an unmet need of the doctors. Patients are actually seeking introduction of the original Viagra.''\par The company expects to gain a 15 percent share of the estimated 700 million-rupee market for impotence-treating drugs in the country, within a year of sales, Handa said. One tablet of Viagra is sold every six s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 conds worldwide, the company said in a statement.\par Viagra ''is a very expensive product and will be a niche market for Pfizer,'' said Shahina Mukadam, an an}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lyst with IDBI Capital Market Services in Mumbai. ''They will be able to make some headway with upper-end consumers who are willing to pay more.''\par Pfizer had been investigating the cardiovascular effects of sildenafil citrate when it stumbled upon its side effect as an impotence drug. The company got U.S. Food & Drug Administration approval in March 1998 to sell the drug as a treatment for erectile dysfunction.\par Since then, Viagra's dominance has been eroded by drugs like Eli Lilly's Cialis, the active ingredient of which is tadalafil. Bayer and GlaxoSmithKline sell yet another impotence drug, vardenafil, under the brand names Levitra and Vivanza.\par Copies of Viagra are made by some of India's biggest drug makers, including Ranbaxy, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , Sun Pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceutical Industries and Cadila Healthcare.\par Ranbaxy's product is sold as Caverta. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  version is sold as Silagra, costing 75 rupees for four 50-milligram tablets; Sun's as Edegra at 75 rupees; and Cadila's as Penegra at 85 rupees at Nath Brothers.\par Since Jan. 1 this year, India has started recognizing product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to honor a World Trade Organization agreement signed a decade ago. That will bar Indian companies from copying drugs patented after 1995.\par The new laws will not affect Viagra copies in India, as the main compound for the drug was patented in 1992, said S. Ramkrishna, senior director of corporate affairs at Pfizer in Mumbai.\par ''It was patented pre-1995 and does not qualify for a product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India,'' he said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTELLECTUAL PROPERTY LAW (90%); PHARMACEUTICALS INDUSTRY (90%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MFG (90%); UROGENITAL DISORDERS & INJURIES (89%); SEXUAL DY}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FUNCTION (89%); PRESCRIPTION DRUGS (78%); DRUG & MEDICAL DEVICES APPROVAL (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (73%); MARKET SIZE (71%); APPROVALS (66%); INDUSTRY ANALYSTS (63%); INTERNATIONAL ECONOMIC ORGANIZATIONS (52%); US FDA APPROVALS (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (92%); RANBAXY LABORATORIES LTD (91%); ELI LILLY & CO (58%); INDU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIAL DEVELOPMENT BANK OF ISRAEL LTD (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (92%); PFEB (BRU) (92%); PFE (NYSE) (92%); RANBAXY (NSE) (91%); LLY (SWX) (58%); LLY (NYSE) (58%); LEL (LSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (92%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (92%); SIC2836 BIOLOGICAL PRODUCTS, E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEPT DIAGNOSTIC SUBSTANCES (92%); SIC6021 NATIONAL COMMERCIAL BANKS (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (91%); MUMBAI, INDIA (88%) INDIA (99%); UNITED STATES (92%); ASIA (90%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Counting on the Viagra brand in India; Pfizer set to introduce drug next week despite a crowd of copies The International Herald Tribune December 22, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_157}{\*\bkmkstart DOC_ID_157_0}{\*\bkmkstart doc_id_19}{\*\bkmkend DOC_ID_157}{\*\bkmkend DOC_ID_157_0}{\*\bkmkend doc_id_19}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_19"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00310039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 19 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Counting on the Viagra brand in India; \par Pfizer set to introduce drug next week despite a crowd of copies}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 16\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 633 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pfizer will introduce its impotence drug, Viagra, in India next week after holding it back for seven years until the country passed stronger }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws.\par Keeping the drug off Indian pharmaceutical shelves has already given as many as 40 local versions, with brand names like Penegra, an edge. Furthering Pfizer's disadvantage, Viagra will cost about 20 times as much as its imitators when it goes on sale Monday in 30 Indian cities.\par But Pfizer is betting on demand for the original product from people who can afford it in the world's second-most-populous country after China. ''We are launching Viagra in India for the benefit of those customers who trust the quality of the original brand,'' Kewal Handa, managing director of Pfizer's Indian unit, said at a news conference Tuesday. \par Analysts have tempered expectations in India for a drug that has been a driver of profit for Pfizer elsewhere.\par Viagra ''is a very expensive product and will be a niche market for Pfizer'' in India, said Shahina Mukadam, an analyst with IDBI Capital Market Services in Mumbai. ''They will be able to make some headway with u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 per-end consumers who are willing to pay more.''\par The company is pricing a single blue, diamond-shaped 50-milligram pill at 463 rupees, or $10.20. At the Nath Brothers pharmacy in New Delhi, Ranbaxy Laboratories, the biggest Indian drug maker, sells its copy, Ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erta, at 95 rupees for four tablets of the same dosage.\par Still, Pfizer expects to grab a 15 percent share of the estimated 700 million-rupee market for impotence drugs within a year, Handa said. Viagra's worldwide revenue fell 11 percent to $1.68 billion last year, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 counting for 3.2 percent of Pfizer's total revenue.\par ''We strongly believe that there is an unmet need of the doctors,'' Handa said. ''Patients are actually seeking introduction of the original Viagra.''\par That may not persuade doctors seeking cheaper drugs for patients. ''I don't think doctors will prescribe'' Via}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ra, said Dr. B.K. Roy, an endocrinologist and hormone specialist at the Sex and Hormone Center in New Delhi. ''When we have economical options available, why prescribe the costly one?''\par Roy said the number of patients coming to his clinic with impotence complaints had increased to more than 200 a month from about 15 a month five years ago, because of awareness that there are treatments.\par One tablet of Viagra, or sildenafil citrate, is sold every six seconds worldwide, according to Pfizer. But Via}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ra's dominance has since been eroded by drugs like Eli Lilly's Cialis, the active ingredient of which is tadal}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fil. Bayer and GlaxoSmithKline sell yet another impotence drug, vardenafil, under the brand names Levitra and Vivanza.\par Copies of Viagra are made by some of the biggest drug makers in India, including Ranbaxy, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , Sun Pharmaceutical Industries and Cadila Healthcare. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  drug is sold as Silagra for 75 rupees for four 50-milligram tablets, Sun's as Edegra at 75 rupees, and Cadila's as Penegra at 85 rupees at Nath Brothers in New Delhi. The profusion of copies stems from three decades of lenient }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws, which did not reco}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nize }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the product, only on the process by which it was made, allowing companies to copy the ori}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 inal by altering the manufacturing method.\par ''There are more than 40 companies making copies of Viagra,'' said Rippon Nath, owner of Nath Brothers.\par Ranbaxy is also among more than 10 Indian drug makers selling copies of Cialis. Eli Lilly has not yet intr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duced the drug in India and is seeking a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for it in the country, said Rajiv Gulati, managing director of Eli Lilly's Indian unit.\par Since Jan. 1, India has tightened its laws and started recognizing product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to honor a World Trade Organization agreement signed a decade ago. That will stop Indian companies from copying drugs patented after 1995.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTELLECTUAL PROPERTY LAW (90%); PHARMACEUTICALS INDUSTRY (90%); UROGE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ITAL DISORDERS & INJURIES (89%); PHARMACEUTICAL PREPARATION MFG (89%); SEXUAL DY}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FUNCTION (89%); INDUSTRY ANALYSTS (78%); PRESCRIPTION DRUGS (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (73%); COMPANY REVENUES (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (73%); FINANCIAL RESULTS (73%); ENDOCRINOLOGY (65%); PHYSICIANS & SURGEONS (63%); PRESS CONFERENCES (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (92%); RANBAXY LABORATORIES LTD (66%); ELI LILLY & CO (58%); GLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OSMITHKLINE PLC (58%); INDUSTRIAL DEVELOPMENT BANK OF ISRAEL LTD (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (92%); PFEB (BRU) (92%); PFE (NYSE) (92%); RANBAXY (NSE) (66%); LLY (SWX) (58%); LLY (NYSE) (58%); LEL (LSE) (58%); GSK (NYSE) (58%); GSK (LSE) (58%); BIOC (EGX) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (92%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (92%); SIC2836 BIOLOGICAL PRODUCTS, E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEPT DIAGNOSTIC SUBSTANCES (92%); SIC6021 NATIONAL COMMERCIAL BANKS (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (73%); MUMBAI, INDIA (73%) INDIA (94%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda; Uganda Enters HIV/Aids Drug Deal With India Africa News December 13, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_158}{\*\bkmkstart DOC_ID_158_0}{\*\bkmkstart doc_id_20}{\*\bkmkend DOC_ID_158}{\*\bkmkend DOC_ID_158_0}{\*\bkmkend doc_id_20}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_20"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 20 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda; \par Uganda Enters HIV/Aids Drug Deal With India}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The East African\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 417 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda has signed a deal with a leading Indian drug manufacturer, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd, to produce HIV/Aids drugs locally.\par The $15 million deal is expected to take off mid next year. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  came into the limelight when it started pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ducing generics of HIV/Aids drugs whose }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  were held by powerful Western pharmaceutical comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies. \par Although the company's move was in contravention of international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws, it managed to lower the cost of Aids treatment and to enable people in poor countries to access the medicines.\par However, India is scheduled to stop its companies from producing drugs still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , following its a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cession to the Trade Related aspects of Intellectual Property Services (Trips) treaty earlier this year - which has set off alarm bells throughout the developing world. In Uganda, the fear is that from 2006, badly needed first-line medicines will no longer be available.\par Should this happen, tens of thousands of people currently on antiretroviral treatment may no longer be able to afford the treatment. It is out of this concern that the Uganda government negotiated the deal with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to transfer part of its generics production capacity into the country. Uganda has a further seven and half years to accede to Trips.\par Our position is that as the Min-istry of Health of Uganda, we are going to do everything to keep our people alive," State Minister of Health for General Duties Mike Mukula said.\par Mr Mukula said work was scheduled to begin on a factory in Luzira, a suburb of Kampala.\par Among the drugs to be produced are new HIV/Aids brand drugs and anti-malaria drugs, the new and most effective, coatem, included.\par India is by far the biggest producer of generic drugs, making HIV/Aids drugs available cheaply to hundreds of thousands of patients. As illustration, before Uganda started importing generic drugs in 2001, the monthly cost of treating Aids was over $600. Today, it is $20 a month.\par The Indian accession and the Trips agreement means that the cost of Aids treatment will shoot up once more. However, experts say that more has to be done to ensure the availability of drugs to Aids patients. Under the Trips agreement, all drugs developed after 1996 will be subject to copyright rules. This means that older, reliable drugs will still continue to be cheaply available. But in the treatment of highly infectious disea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es like malaria, tuberculosis and HIV/Aids, it spells doom as the most effective first line drugs available for the three diseases were only developed recently.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); ANTIVIRALS (92%); AIDS & HIV TREATMENT (91%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS INDUSTRY (90%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); MALARIA (89%); DISEASES & DISORDERS (89%); INFECTIOUS DISEASE (89%); ANTI-INFECTIVES (78%); CONTROLLED SUBSTANCES CRIME (78%); PLANT CAPACITY (78%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); INTELLECTUAL PROPERTY LAW (77%); GENERIC PRODUCTS (77%); COPYRIGHT LAW (76%); HEALTH DEPARTMENTS (73%); TUBERCULOSIS (73%); INTELLECTUAL PROPERTY (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (72%); COPYRIGHT (72%); MANUFACTURING OUTPUT (71%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (96%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (96%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (96%); SIC2834 PHARMACEUTICAL PREPARATIONS (96%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KAMPALA, UGANDA (79%) UGANDA (94%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 13, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newsletter\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche picks Chinese partner for Tamiflu The International Herald Tribune December 13, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_159}{\*\bkmkstart DOC_ID_159_0}{\*\bkmkstart doc_id_21}{\*\bkmkend DOC_ID_159}{\*\bkmkend DOC_ID_159_0}{\*\bkmkend doc_id_21}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_21"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 21 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche picks Chinese partner for Tamiflu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Tom Wright\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 16\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 841 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche, the Swiss drug maker, said Monday that it had reached a sublicensing agreement with China's state-owned Shanghai Pharmaceutical Group to manufacture the influenza drug Tamiflu and was in talks with 12 other companies, including the generic producers Teva Pharmaceuticals and Mylan Laboratories, to let them take part in the production process.\par The agreement with Shanghai Pharmaceutical is the first full sublicense that Roche has awarded for Tamiflu, the drug that countries are stockpiling amid growing fears of a bird flu pandemic in humans, and comes amid reports of increasing numbers of human cases in China. Roche said it was also in talks for a sublicense with producers in India.\par It remained unclear when Shanghai Pharmaceutical, which already has a joint venture with Roche in China, would be able to start producing Tamiflu. Attempts to reach company executives for comment were not su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cessful. \par Chinese news media last month quoted the vice president of Shanghai Pharmaceutical, Huang Yanzheng, as saying it would take six months to gear up production.\par Daniel Piller, a Roche spokesman, said Shanghai Pharmaceutical would pay Roche a license fee to have full control over production and pricing of Tamiflu, which many Asian officials complain is expensive. The terms, he said, allow Shanghai Pharmaceutical to produce drugs for stockpiling against a pandemic, not for sale commercially during the regular flu season.\par Roche said it had begun detailed commercial and technical discussions with 12 companies from about 200 that had submitted requests to take part. These companies, Piller said, would have no control over produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion levels or pricing.\par Roche confirmed that Teva of Israel and Mylan of the United States were among the companies in discu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sions, after the names were released last week by Senator Charles Schumer, Democrat of New York. Roche declined to name the others, saying only that they included large pharmaceutical corporations, generic pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ducers and specialist chemical firms.\par The head of the pharmaceutical division at Roche, William Burns, said in a statement: ''As yet we have not identified anyone who could significantly speed up the agreed delivery timelines for the first half of 2006. But we have been able to identify partners to ensure against breakdowns in supply and partners to broaden ge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 graphic coverage.''\par Roche has been under pressure to allow third parties to produce Tamiflu after orders outstripped supply this year.\par The company, which is based in Basel, plans to increase its production to 300 million treatments annually by the end of next year, which it says will be enough to cover current demand.\par The antiviral drug has shown in clinical trials to work against the symptoms of the H5N1 strain of bird flu, leading to an increase in demand from governments.\par So far, 70 people in five Asian countries have died of the disease, but health experts warn that a mutation of the virus, which has killed millions of wild birds and poultry, could sharply increase human infections.\par The agreement with Shanghai Pharmaceutical comes after some Asian governments, including China's, said they would allow local companies to produce a generic version of the drug \u8249\'dc without Roche's permission, if necessary. By signing licenses, Roche is hoping to avoid governments' seizing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and making the drugs on their own.\par Until now, Roche has held out against offering full licenses, arguing that the production process is complex and involves the use of potentially explosive chemicals. Instead, Roche has concentrated on finding comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies that can take part in production, while it maintains overall control.\par A spokesman, Patrick Fitzgerald, speaking before Monday's announcement, said Mylan was in advanced discussions with Roche and was prepared to make significant quantities of Tamiflu. A Teva spokesman, also contacted last week, had no comment.\par Roche gave no further details on the discussions over a full sublicense with India, where its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu is still pending. Last month, the Indian government said it was considering allowing Ranbaxy Labor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tories and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , two large generic drug companies, to produce Tamiflu. This year, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said it had su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cessfully produced Tamiflu, but only in small quantities.\par Roche recently agreed to increase supply to meet orders from Taiwan after its government said it was co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sidering allowing local companies to produce Tamiflu.\par Roche is not in discussions with Taiwan's government for a sublicense, Piller said.\par Tamiflu is not protected by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in Thailand, the Philippines and Indonesia, meaning local companies there are free to produce the drug.\par Whether governments in Southeast Asia can quickly increase production is another thing. In Vietnam, Roche has agreed to allow local companies to put the finished ingredients of Tamiflu into capsules.\par But the bottleneck in production appears to be with the pharmaceutical ingredients, not the late stages of production. The process starts with star anise, a raw material from a Chinese tree that is in short supply.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); INFLUENZA (90%); AVIAN INFLUENZA (89%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIVIRALS (89%); LIVESTOCK DISEASE (89%); PHARMACEUTICAL PREPARATION MFG (79%); DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASES & DISORDERS (78%); EPIDEMICS (77%); INFECTIOUS DISEASE (76%); ALLIANCES & PAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERSHIPS (76%); CLINICAL TRIALS (73%); CHEMICALS MFG (73%); CHEMICALS (73%); JOINT VE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TURES (73%); POULTRY (70%); US DEMOCRATIC PARTY (69%); EXECUTIVES (68%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); SHANGHAI PHARMACEUTICALS HOLDING CO LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); 2607 (HKSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (58%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CHARLES SCHUMER (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SHANGHAI, CHINA (94%); BASEL, SWITZERLAND (79%); GENEVA, SWITZERLAND (73%) EAST CHINA (94%) CHINA (94%); SWITZERLAND (79%); INDIA (79%); UNITED STATES (79%); ASIA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 15, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche Tells Indonesia That It Can Produce Tamiflu Without a License  The New York Times November 26, 2005 Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_160}{\*\bkmkstart DOC_ID_160_0}{\*\bkmkstart doc_id_22}{\*\bkmkend DOC_ID_160}{\*\bkmkend DOC_ID_160_0}{\*\bkmkend doc_id_22}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_22"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 22 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2005 Saturday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche Tells Indonesia That It Can Produce Tamiflu Without a License }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Bloomberg News\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 4; Business/Financial Desk; Pg. 3\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 404 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche, the Swiss drug maker, said yesterday that Indonesia could make Tamiflu without its license because the medicine, which may treat avian influenza, is not protected by a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the Southeast Asian nation.  \par   ''We've informed the government they can produce it for local use,'' said Martina Rupp, a spokeswoman in Switzerland for Roche. ''Quality guidelines will have to be assured by the Indonesian government.''\par Roche also said yesterday that it would supply more of the drug to Taiwan.\par   The move will help Indonesia prepare for a possible outbreak of avian influenza among humans. The Ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nesian authorities culled more than 200 chickens in Aceh, the 23rd province in the nation to be affected by the virus. The government may ask the state-owned PT Kimia Farma or PT Indofarma to make the medicine, the nation's health minister, Siti Fadilah Supari, said.\par   ''It would be a sin for us if we are not prepared,'' the health minister said. ''We are in the process of impor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing raw materials and are looking at either China or South Korea.''\par   Roche said yesterday that it would supply Taiwan with 1.3 million more treatments of Tamiflu next year, for a total of 2.3 million. Taiwan's government had said it would issue a compulsory license to make Tamiflu l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cally in December, even without a license from Roche, if its orders were not filled on time. Roche has a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu in Taiwan.\par   ''We are confident that we will be in a position to deliver the quantities of Tamiflu requested by the Taiwa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ese government in the required timelines,'' said David Reddy, leader of Roche's pandemics unit.\par   Countries worldwide are stockpiling Tamiflu on concern the H5N1 virus, which has killed 68 people in Asia, may mutate into a form that can spread among humans. More than 150 third parties are interested in gaining licenses to make Tamiflu, Roche said this month. Roche said Nov. 10 that it was in advanced discussions to allow Vietnam to undertake the final production step locally.\par   India said last month that it would allow Ranbaxy Laboratories and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  the country's two biggest drug makers, to produce generic versions of Tamiflu. Roche does not have a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India for Tamiflu. The country has the power to revoke the right of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders to sell drugs exclusively if the government d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cides that a disease has reached epidemic proportions and that existing treatments are too expensive or are in short supply.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (92%); AVIAN INFLUENZA (91%); PHARMACEUTICALS INDUSTRY (90%); HEALTH DEPARTMENTS (90%); PHARMACEUTICAL PREPARATION MFG (90%); LICENSES & PE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MITS (90%); LIVESTOCK DISEASE (90%); PUBLIC HEALTH ADMINISTRATION (89%); DISEASES & DISORDERS (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); EPIDEMICS (89%); GENERIC DRUGS (78%); VIRUSES (75%); HOLDING COMPANIES (59%) Influenza; Tamiflu (Drug); Avian Influenza; Inventions and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ; Drugs (Pharmaceuticals)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); RANBAXY LABORATORIES LTD (63%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche Holding Ltd; PT Kimia Farma; PT Indofarma\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); RANBAXY (NSE) (63%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL MANUFACTURING (63%); SIC2834 PHARMACEUTICAL PREPARATIONS (63%); SIC2833 MEDIC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAL CHEMICALS & BOTANICAL PRODUCTS (63%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TAIWAN (95%); INDONESIA (94%); ASIA (93%); INDIA (92%); SOUTH-EASTERN ASIA (92%); SWITZERLAND (90%); CHINA (79%); CENTRAL EUROPE (73%) Indonesia; Taiwan\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 26, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: Tamiflu, which is made by Roche, is a crucial drug in the arsenal that would be used in treating any pandemic of bird flu. (Photo by Ed Wray/Associated Press)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 G2: What Grace did next: Three years ago the Guardian published an award-winning supplement featuring the story of Grace Mathanga, an ordinary African woman with HIV. To launch this year's Christmas appeal, which focuses on Aids in Africa, Sarah Boseley returns to Malawi to find out how Grace is doing now, and what her life can tell us about the future of the continent The Guardian (London) - Final Edition November 24, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_161}{\*\bkmkstart DOC_ID_161_0}{\*\bkmkstart doc_id_23}{\*\bkmkend DOC_ID_161}{\*\bkmkend DOC_ID_161_0}{\*\bkmkend doc_id_23}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_23"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 23 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London) - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 G2: What Grace did next: Three years ago the Guardian published an award-winning supplement featuring the story of Grace Mathanga, an ordinary African woman with HIV. To launch this year's Christmas a}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 peal, which focuses on Aids in Africa, Sarah Boseley returns to Malawi to find out how Grace is doing now, and what her life can tell us about the future of the continent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sarah Boseley\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Features Pages, Pg. 8\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 4076 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Grace Mathanga walks along the grass track, between scrub and shady trees, to the crumbling house that was her home until seven years ago. Black hoop earrings and handbag swing to her stride, her Sunday best remarkable against the ragged clothes of the dusty, barefoot children of the village. As she nears, Grace calls out, and a young woman launches herself through the door, falling into her arms with a shriek of laug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ter.\par  The house, its cement cladding falling off red bricks, its tin roof topped with straw, is as poor as any other here. In four small rooms live two of Grace's sisters, Precious and Chipiriro, their five children, and 12-year-old Eleni, the daughter of one of two other sisters who have died. All that stands between this family and destitution is Grace and the generosity of strangers.\par  On two small tablets a day - one when the sun rises and one when it sets - Grace, who would otherwise be dead, is alive and well. Grace is part of a small miracle that is beginning to happen in Africa. Men and wo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 en who are HIV-positive, as she is, have the chance of a reprieve from the slow and painful death by emaci}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion and infection that is Aids. Drug treatment keeps the virus levels low in their bloodstreams. Those who receive antiretroviral drugs (ARVs) stay well, and are able to work and bring up both their own and others' children. \par  Grace is one of the lucky ones because she had the courage, nearly three years ago, to talk about her infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion to the Guardian in a supplement we called Saving Grace. Her husband and her child had died of Aids. She knew she would follow them within a few years, because she had no money for ARVs, which were then available only privately and at a high price. A Dutch doctor, Hetty van Dyck, who was working as a locum in Malawi's capital, Lilongwe, read the Guardian article, tracked Grace down to the market where she sold shoes, and put her on treatment. Van Dyck went on to start a small charity to do the same for others, which she called the Saving Grace Foundation, and which the Guardian now supports.\par  When I go back to find Grace, she is still living in the house in Mwenye-Kondo - a bustling suburb of Lilon}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 we shaking to the loud boom-beat of a tavern - which she once shared with her husband and child. But she has changed. Friends and neighbours say they cannot believe the transformation since she went on ARVs. "They say I am lying when I say I am HIV- positive, because HIV people do not look like this," says Grace, laughing. "I feel happy for my life," she adds.\par  In quiet Ben Chauya village, in the hills between Lilongwe and Malawi's second city, Blantyre, Grace's si}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ters are happy too. Life for Grace means survival for them and for their children. Once a month, ever since she married and moved away seven years ago, Grace has made her way to the bus station at 4.30am for the three-hour trip to Ben Chauya. It's a further 90 minutes on foot to her old house from the main road. She stays a few hours and then makes the long return journey, arriving home at 9pm. Once she brought money that her husband had given her, but after his death, she brought money that she had earned herself, first at the market, and now as a care assistant for an organisation called the National Association of People with HIV/Aids in Malawi.\par  Grace supports all her family, but there is one child to whom she pays particular attention. Eleni and she stand apart in the shade of a tree, having a quiet conversation. When Eleni's mother, Ulemu, died, Grace was still living at home and Eleni was only five. Grace, having lost her own child, looked after Eleni like a daughter, cooking and washing for the child. Now she buys Eleni's school uniform. On a broken dresser i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 side the dark house lies a blue school exercise book, limp as a duster, filled with diagrams of circles and a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gles. Eleni does well at school, says Grace, coming in the top six for her grade.\par  Without her aunt, this thin and serious- looking girl would not be at school. At 12 Eleni would normally be working in the fields or doing chores. She might even have been sent away. In a society where most women have no status, she is vulnerable and will shortly become more vulnerable; Precious had her first baby at 14. It is not what Grace wants for Eleni. As long as she is alive, Grace will do all she can to give her a better f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ture.\par  In Malawi and all over Africa, such tiny but life-changing individual victories are being won. Because HIV/Aids is devastating the working, parenting generation - a generation that includes the continent's teac}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers, nurses and farmers - every time the disease is thwarted, every time a man or woman is started on the drugs, the lives of a whole clutch of dependents become less precarious as well.\par  But the numbers on ARVs so far are tiny compared with the need. There are an estimated 40 million - po}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sibly up to 45 million - people infected with HIV worldwide, of whom around 26 million live in sub-Saharan Africa. Of the six million people in the developing world who desperately need antiretrovirals, only a million are on the drugs so far. Unless something is done quickly, the rest will soon be dead.\par  This is a humanitarian emergency, but even though the superpowers have mobilised - George Bush has a $ 15bn Aids plan, Bill Clinton is involved, the UK and France are heavily committed - it is taking an agonisingly long time to scale up levels of treatment. The World Health Organisation wanted to have three million people in the developing world on ARVs by the end of this year. We're nowhere near.\par  Tiny Malawi, with as big a population and as grave a problem as its much larger neighbour Zambia, is doing relatively well. Nearly one million of its 12 million people are infected and 170,000 are in urgent need of treatment. Every year 85,000 young men and women die because of Aids. Life expectancy at birth has dropped to 42. But an ambitious government programme, which began last year, has pushed the numbers on treatment from 4,000 to 32,000. That is a remarkable achievement.\par  "We are saving at least 12,000 lives every year and the numbers are going up," says Erik Schouten, the Dutch HIV/Aids coordinator in Malawi's Ministry of Health. "These are young adults - the fathers and mothers of families. One of the most important determinants of child survival is having a parent alive. This is a natio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al emergency because this disease is really undermining society. The social structure is disappearing."\par  But the obstacles to scaling up any further loom like a cliff face. Schouten and Professor Tony Harris, the British technical adviser to the HIV unit, talk of walking into the unknown. The effort is heroic, but nothing of the kind has ever been attempted in Africa.\par  "From next year onwards, we really are going into uncharted territory," says Harris. "In a year's time, will we be able to cope with 70,000? I've no idea."\par  Walk into hospitals such as Lilongwe Central, where Grace's husband died, and one of the fundamental problems becomes clear. Male and female wards are a vision from hell. Every bed is full and sometimes has two occupants, head to toe. On the floor lie more patients on mattresses. Most have their eyes closed in pain or are unconscious; their wasted limbs are angular and contorted. There are no worried well in Malawi. Pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple come when they are very sick, whether from meningitis, malaria, TB or pneumonia. In more than a third of cases, HIV is responsible for their sickness. The virus strips out the immune system, making people prey to infections.\par  Such patients need the help of doctors and nurses. But those are in desperately short supply. District hosp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tals have one qualified doctor. Big central hospitals may have two nurses on a ward in the day and none at night. How is Africa going to assess patients with HIV and put them on drug treatment when people are dying in hospitals across the continent for lack of care?\par  All over Africa, clinical officers with just a couple of years' medical training are being employed to assess whether a patient with HIV is sick enough to need drugs. Malawi doesn't do the sophisticated blood tests, called CD4 counts, which tell you how depleted the body's immune response to the virus is. They haven't got the machines or the labs. Instead, they use check-lists of symptoms, infections and weight. When you have seen a fair number of people with advanced HIV infection, it's not so hard to recognise the large, listless eyes, the emaciation and the pain caused by the effort of placing one slow foot in front of another.\par  But there are far from enough clinical officers. Harris says that on paper, Malawi ought to be able to get half those who need treatment on it every year. That's 90,000. In practice, he says, "I don't think it's possible. We don't have the people."\par  Nor do they have the space. The rooms they are using for ARV clinics are too small; the pharmacies - now bursting with boxes of ARVs - are too cramped.\par  Infrastructure and human resources are cited everywhere as the main obstacles to saving more lives. But there is an even more fundamental question being asked about the drug roll-out across Africa. Will the rich donor countries continue to pay? Malawi's growing programme is mostly financed by grants from the Global Fund to fight Aids, Tuberculosis and Malaria, set up by the UN in 2001. Malawi has been granted $ 267m over five years, but the money runs out in 2008.\par  "We have got a plan to 2010," says Harris. "Will the money continue? It must surely, but I can't put my hand on my heart and say it is guaranteed. Two years of ARV drugs (for Malawi) cost $ 35m. That is the entire government health budget. If the donors should decide this is not a thing we should be doing - the fashion changes - we are really up the creek here. In 2010, we may be spending $ 40m on drugs alone. Who is g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to pay for this? The Global Fund has had trouble raising enough money."\par  In fact the Global Fund has struggled to raise anything like the $ 10bn a year that Kofi Annan called for at its launch. At a replenishment conference hosted by the UK government in September, donor countries pledged $ 3.7bn for 2006 and 2007 - half what is needed. Much depends on the United States, which is constitutio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ally unable to commit funds that far ahead, but which also prefers to put its money into programmes directly under its control.\par  Wesley Sangala, Malawi's health secretary, says his country cannot afford to treat Aids patients without help. "I don't think in the next five to 10 years Malawi will be able to take on the burden of paying for ARVs," says Dr Sangala. If the donors pull out, he says, "it is a death sentence for all those people or we would have to go to the World Bank and borrow millions that we could not go on paying."\par  So in a year or two, says Harris, Malawi will have to put in another big funding bid. "If we do a good job, the international community can't pull out, having led us this way. But what if, say, bird flu becomes a major pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lem in two years' time? It is very precarious. We're on a knife edge. Something can go wrong and we can fall off."\par  Falling off, for Grace's friends, neighbours and other women like her, would be catastrophic. West of Lilon}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 we, towards Zambia, is a peaceful, tree-shaded village called Nkhwambara. This is where 34-year-old Oliveta Janga has found refuge and the hope of a life for herself and her five children.\par  It is her mother's village. Oliveta has left her husband's house in the south of the capital city. Somehow she managed to struggle the 20 miles or so with the children, aged between eight months and 14 years. She is stick-thin and walks with the telltale slow and awkward gait of an Aids sufferer. It's as if she is treading on knives.\par  Oliveta found out that she was infected with HIV at the antenatal clinic when she was expecting her last b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 by, Ignasio. All pregnant women are offered a test. Most take it now that there is drug treatment available. But when Oliveta told her husband, he took it badly. "My husband refused to go for testing," she says. "He said I was a useless woman and he would not care for me or provide food for me."\par  Her husband stayed away all day and would return late at night. Oliveta did piecework - labouring in the fields for around 200 kwacha (the local currency) a day, less than \u163\'a31. She had to feed the family, but som}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 how managed to save up 1,000 kwacha for the journey back to her mother. When she arrived, she was very weak and could no longer see.\par  Without treatment, she would have died, and another five Aids orphans would have been added to Malawi's estimated total of half a million. But Modesta Machila, her strong and striking 55-year-old mother, gave her a house and help with the children, and Oliveta went to the nearby St Gabriel's mission hospital, where she has just started on ARVs.\par  It's a typical African story with an untypically happy ending. Oliveta will not sicken and die in a dark corner. Her children will have a chance to grow up with a parent and go to school. Education increases their chances not only of climbing out of the poverty they live in, but of avoiding HIV infection themselves. Much is riding on the continuing willingness of rich donor nations to pay for the little pills that women like Oliveta will need for the rest of their lives.\par  At the same time, Oliveta's tale says much about the deeper problem of HIV in Africa. Women are dispr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 portionately hit - they make up 57% of those infected. But they have no power to insist on safe sex or indeed no sex. Grace has given Eleni her own surname because nobody knows who her father was. Precious had a baby when she was an adolescent and now has two more, with no husband in sight.\par  The women work in the fields to earn money to feed the family; the men work in the fields to buy beer, says Modesta Machila. It's a generalisation, but it's certainly her experience. Her son-in-law turned up at the vi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lage the other day, she says. He said he had some luggage to be fetched, and demanded that his eldest son and daughter come to help him. Modesta stood in the way. "If he wanted to carry luggage, he should ask the men who have bicycles," she says. "He wanted to steal the children." He would make them work and look after him in their mother's place, Modesta says. Their life chances would shrink. Uneducated, impoverished, they too would in all likelihood contract HIV.\par  It's easy to see why behaviour change has become a favoured mantra, particularly among the moral right in the USA, as the only sure way to end the Aids pandemic. But it's one thing to advise drug injectors on clean needles and supply sex workers with condoms. It is another to give Oliveta or Precious the power to refuse to have sex with a man who is potentially violent.\par  Across Africa the abstinence message is growing: just say no. It's where the conservatism of the Bush a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ministration meets the evangelism of African churches. The President's Emergency Fund for Aids Relief (Pepfar) requires any group it funds to sign a pledge condemning prostitution, which is an embarrassment in places where the key to the HIV spread is commercial sex. To US approval, the first lady of Uganda, Janet Museveni, urges young women to abstain until marriage. Even in Malawi - not on the list of Pepfar target countries, although it is getting limited help which one official describes as "Pepfar lite" - a huge billboard in Lilongwe features President Bingu wa Mutharika proclaiming the virtues of "abstinence, abstinence, abst}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nence".\par  Mutharika is said to be a very devout Christian, as most Malawians appear to be. Gospel choruses belt out of every radio. But the churches are not about to preach the rights of women, and few women have the po}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er to say no to men.\par  Some people fear that with ARVs now visible in Africa, the world will think the job is done and retreat behind the old prevention rhetoric. Jim Yong Kim, who heads the WHO's HIV/Aids programme, says the drive to get universal access to treatment, promised by the G8 this year, must not falter because millions more are going to die before efforts to bring about social change in Africa bear any fruit. "Treatment is not rocket science," he says. "Prevention is rocket science."\par  Kim, an American whose outspoken brilliance does not win him friends in the Bush administration, is the man who set the controversial "three million by 2005" target. It won't be reached, but the progress in many countries is impressive. "I have been trying to say for years that 'three by five' is going to give pace and strength to the response," he says.\par  And once there is treatment available, you can begin to build in prevention. Lesotho, one of the worst-hit countries with around 30% of its population infected, is going to offer testing and counselling to the entire population by 2007, training five people in each and every village to help. The $ 11m scheme "could pote}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tially turn the epidemic around in this country", says Kim.\par  But testing depends on the availability to all of those ARVs, which are a three-drug combination pill. The formulae were invented by the big, research-based pharmaceutical companies in the USA and Europe, and they hold the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Africa buys cheap copies made by generics firms such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India, selling for as little as $ 130 per person per year - except where Pepfar is paying. US support for the pharmaceutical giants - "big pharma" - means the president's money is spent on more expensive brand-name drugs unless the g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric version is approved in America.\par  In August, Malawi's drug supply almost came to a halt. Floods in }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Mumbai warehouses destroyed six months' supply. It followed the removal of approval of Ranbaxy's generic drugs by WHO because of a pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lem with paperwork. The generics have since been reinstated. But seldom can a project to save so many lives have hung by such delicate threads. If patients run out of drugs, the virus in their blood will build and become resistant to the medication. Not only will they succumb, but the nightmare scenario will be upon us: the resistant virus could start to spread across Africa and beyond. "We're going to face a drug shortage," says Kim.\par  Big pharma - which is based mostly in the US, helped fund the Bush election campaign and loathes the g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric "pirates" - says it can make all the drugs that are needed. But it has been forced to drop its prices to the point where it makes a loss on every tablet. "Are they really going to scale up to meet demand for, say, 10 million people by 2010?" says Kim.\par  He thinks big pharma and its backer, the US government, need to step aside and allow the generics comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies a free hand without fear of legal action or sanctions. China, he says, has told him it can make the more expensive second-line drugs - those that will be needed when resistance inevitably sets in, as it has in E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rope and the US - for $ 100 to $ 150 per person per year.\par  In Kilolo, north-west Malawi, a tiny girl sits immobile on the floor outside a wooden hall with a doll across her outstretched legs, large eyes gazing at nothing, hands hanging loose. Her aunt is inside, singing, with hu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dreds of widows and grandmothers who struggle to care for orphans. Manneyra Esna is four, but looks two. People walking in and out pay her as little attention as if she were part of the doorframe. She doesn't notice them either. The doll slowly slips off her lap. Manneyra doesn't move.\par  She is probably HIV-positive. Her mother died from Aids last year. Here at the Consol (as in consolation) Homes orphan centre, where her aunt has come for support with the four children she now cares for - two of her own as well as Manneyra and her sister Margaret, five - it is realised that the little girl should see a do}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor. She may well need ARVs.\par  But the government programme cannot yet help. Children need to be dosed according to weight. Malawi has only adult tablets. If Manneyra is lucky, she will be seen by a paediatrician at the mission hospital who will teach the busy aunt to cut up and crush the pills twice a day and mix them with nsima, the staple maize po}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ridge. Consol Homes, a pioneering orphan support project, may pay. But most children here die. An estima}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed 660,000 children in developing countries are in urgent need of treatment, mostly in sub-Saharan Africa. Last year 570,000 died. The widespread failure across Africa to get drugs systematically to women in labour, which can prevent transmission to their baby, means that the numbers are rising inexorably.\par  If the issue of drugs for children is gaining attention, it is partly thanks to the Clinton Foundation, which is playing an interesting role in Africa's Aids pandemic, clearing logjams, cutting knots and driving through i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 novation. Ira Magaziner, Bill Clinton's former White House aide, now runs the Foundation's HIV/Aids initi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive. He is impatient with the slow, scientifically correct approach, which demands a dozen studies, presented in full colour booklets with graphics, before anything happens.\par  "Millions of people have died because we haven't been moving faster," he says. "Until we collectively have four to five million people on treatment in the developing world, I don't think we can say we're making enough progress. Every day you move faster, people live. Every day you move slower, people die."\par  The Foundation has cajoled Paul Farmer, the Harvard medic who proved drug treatment was possible in poor countries such as Haiti, into switching to Rwanda and figuring out how you treat people in remote pla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es with no doctor or nurse for miles. And they are donating enough ARV syrup to get 10,000 children on treatment, pushing aside arguments as to whether pills or syrups are better.\par  Down the road from Grace's house in Lilongwe, the reality of what this kind of decisive action - or the lack of it - means hits you in the eye. The Mac Coffin workshop, named after its owner Mac, is one of five or six such workshops in a row. Carpenters who used to fashion beds make wooden boxes: plain wood with a red ochre stain for 2,000 kwacha (\u163\'a310); formica marble lookalike with gilt handles and pillow for 150,000 kwacha (\u163\'a3750). How many coffins do they sell? Three to five a day, they say. Big ones for mothers and fathers. Small ones for children *\par  Briefing: Antiretrovirals\par  * People with HIV need a cocktail of three different types of antiretroviral drug to keep the virus levels low in the body. Generics companies (see below) made drug treatment in Africa possible by combining the three in a single cheap pill, to be taken twice a day.\par  * Combination pills are not much used in the US and Europe for two reasons: resistance and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Do}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tors in the rich world change their patients' drugs if they detect any sign that their effect may be weakening because the virus in their body is becoming resistant. They usually change just one drug of the three. But there's another reason why combination pills aren't used in the developed world: the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are held by a number of rival pharmaceutical companies, so combining them requires negotiation.\par  * Generics companies are "copycats" and sometimes, according to the pharmaceutical companies, "pirates". But it is legitimate to analyse the chemicals that make up a blockbuster drug and produce a cut-price copy once its 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expires. In many of the least developed countries, including most of Africa, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  were never taken out, which means generics companies should have free rein. But the India, China, Tha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 land and Brazil-based generics firms fear legal action by big pharma and trade sanctions from the US.\par  * Prices for the first-line combination ARVs used in Africa are down to around $ 130 per patient per year from the generics companies. But resistance will appear eventually, just as it has in Europe and the USA. Viruses are survivors: HIV mutates easily, changing its form to overcome drugs used against it, particularly if people fail to take their doses on time. Second-line drugs are much more expensive - up to $ 800 per person per year - as most have to be bought from big pharma.\par  * Children's medicines, which are not yet ordered in bulk and need to be dosed according to the child's weight, can cost up to four times as much as adult drugs.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VAN DYCK CARPETS (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MALAWI (94%); AFRICA (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MALAWI (94%); AFRICA (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (91%); DEATHS & OBITUARIES (90%); AIDS & HIV TREATMENT (90%); CHRISTMAS (78%); WOMEN (76%); ANTIVIRALS (73%); POVERTY & HOMELESSNESS (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Don't wait for Tamiflu - make our own Australian Financial Review November 15, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_162}{\*\bkmkstart DOC_ID_162_0}{\*\bkmkstart doc_id_24}{\*\bkmkend DOC_ID_162}{\*\bkmkend DOC_ID_162_0}{\*\bkmkend doc_id_24}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_24"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 24 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Australian Financial Review\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  15, 2005 Tuesday  \par First Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Don't wait for Tamiflu - make our own}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Peter Drahos and Buddhima Lokuge Peter Drahos is professor of law in the Research School of Social Sciences at the Australian National University. Buddhima Lokuge is director of the International Trade, Innovation and Population Health program.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Opinion; Pg. 71\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 603 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The government should follow the lead of others and license generic manufacturers of Tamiflu, write Peter Drahos and Buddhima Lokuge.\par Federal Health Minister Tony Abbott has called for a "cranking up [of] our production of antivirals and va}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines" to help prepare for a flu pandemic.\par There is only one sure way to overcome the shortage in Australia of Tamiflu, the influenza drug made by Roche. First, we need to understand the causes of the current shortage. This has everything to do with the politics of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  monopolies rather than actual production capacity. \par The story starts with Gilead Sciences, a biopharmaceutical company headquartered in California. It owns the key }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . In 1996 it gave Roche exclusive worldwide manufacturing rights. Starting in 2001, Gilead began to worry about what Roche was doing with Tamiflu and in June of this year it issued a notice of termination to Roche.\par Why had the deal gone bad? Gilead's allegations against Roche make frightening reading. It alleges in its notice of termination that Roche has failed to launch Tamiflu in 43 countries (including China), that there have been quality problems in manufacturing, leading to product recalls in the US and Japan, and that Roche has failed to achieve normal manufacturing efficiencies that would make Tamiflu cheaper. Gilead also claims that if Tamiflu remains in Roche's control it was likely not "to achieve its full potential in protecting the public health from the threat of influenza".\par Gilead wants to strip Roche of its rights to Tamiflu because it is very nervous about what might happen to its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . In the past few weeks governments around the world have worked out that they cannot rely on Roche to meet their demands for Tamiflu. They have threatened to override the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  using the well-established powers of a government to allow other persons to use patented inventions without penalty. India, Taiwan, Argentina, the Philippines and the US have all said they would exercise these powers if need be. When Charles Schumer raised this possibility last week in the US Senate, Roche responded by entering into talks with four US generic manufacturers. The lesson is clear. If a government wants to increase the supply of Tamiflu it has to invoke its power of compulsory licensing.\par Roche has said the process is too complex for others to make it quickly. But versions of Tamiflu have already been produced by Thai and Taiwanese manufacturers and Indian companies have said they are in a position to make it. It appears that, if governments want to, they can go to mass production of Tamiflu quite quickly.\par The Australian government could authorise the generic manufacture of Tamiflu tomorrow. It simply has to issue an authorisation in writing. If our generic industry cannot make it, we should be contracting with world-class Indian manufacturers like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or Rambaxy.\par We still need the Australian government to issue the authorisation so we can import it.\par Obviously it would be better to find local manufacturers. The threat of a pandemic will be with us for a long time. We need access to cheap drugs because any national stockpile will have a limited shelf life. The public health case for generic manufacture in the case of a pandemic is overwhelming.\par The Australian government has to use its power to allow others to manufacture Tamiflu. Gilead's allegations against Roche should be sounding alarm bells. Australia and other countries need to be able to source infl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 enza drugs from many manufacturers. Competition will ensure supply and keep prices down. Other gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments are moving on the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  issue. Why aren't we?\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (91%); HEALTH DEPARTMENTS (90%); GENERIC PRODUCTS (90%); GENERIC DRUGS (90%); EDITORIALS & OPINIONS (90%); AVIAN INFLUENZA (90%); PUBLIC HEALTH ADMI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ISTRATION (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); PHARMACEUTICALS INDUSTRY (78%); PHARMACEUTICALS & MEDICINES MFG (78%); EPIDEMICS (77%); ANTIVIRALS (77%); DISEASES & DISORDERS (77%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TELLECTUAL PROPERTY LAW (75%); LEGISLATIVE BODIES (73%); VACCINES (72%); DISASTER PLANNING (72%); INFECTIOUS DISEASE (72%); BIOTECHNOLOGY INDUSTRY (71%); PRODUCT R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALLS (52%) Health/Drugs; Industry/Pharmaceutical; Law/Copyright; Company/Hoffmann-La Roche/Roche; Company/Gilead Science; Health/Diseases/Animal related/Avian Influenza/Bird Flu\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (53%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (53%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (53%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CHARLES SCHUMER (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALIFORNIA, USA (79%) UNITED STATES (94%); AUSTRALIA (94%); TAIWAN (92%); ARGENTINA (79%); JAPAN (79%); PHILIPPINES (79%); INDIA (79%) Australia; USA; International\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 5, 2012\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Fairfax Media Publications Pty. Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore November 11, 2005 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_163}{\*\bkmkstart DOC_ID_163_0}{\*\bkmkstart doc_id_25}{\*\bkmkend DOC_ID_163}{\*\bkmkend DOC_ID_163_0}{\*\bkmkend doc_id_25}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_25"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 25 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 When MNC profits matter more than global health}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2005 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Harish Mehta\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE indigenous farmers of Asia cannot take the ownership of their traditional knowledge for granted. Their ownership of the neem tree, and basmati and jasmine rice, is not secure - as farmers in India and Thailand have found out. Now, as bird flu threatens much of the world, the focus is shifting to Chinese farmers who grow the evergreen magnolia trees that produce a vital ingredient - star anise - that goes into a lifesaving drug to cure the deadly flu.\par Native to China and Vietnam, star anise is grown almost exclusively in southern China, Indochina, Japan, and a small amount in South Asia. But only the type grown in four Chinese provinces is suitable for produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the drug Tamiflu, made by the Swiss firm Roche. \par Just as the Indians and Thais had not registered }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to protect their indigenous basmati and jasmine rice respectively, star anise is at risk of being appropriated - or misappropriated - by Western companies. The indigenous people of China who grow this lifesaving spice could lose all their rights to traditional knowledge. There are no records of star anise or magnolia tree registration with the United States }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Trademarks Office (US-PTO) for use in the production of flu medication. This means star anise has not yet been patented for use as an ingredient in flu drugs.\par However, a keyword search for 'star' and 'anise' does return 108 instances of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  granted by the US-PTO, but these are not }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for star anise per se, and instead are instances where star anise is used somewhere in the process. This star-shaped spice, used both in Chinese cooking and as Eastern medicine for treatment of colic and rheumatism, has become a topic of international medical and business diplomacy. Currently, star anise is in short supply, which means that Western drug makers are unable to produce enough Tamiflu. Roche, the holder of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Tamiflu, has refused to reveal the amount of stock it holds because it deems the information commercially sensitive. Clearly, business interests are paramount even though global health is at stake.\par Doomsday scenarios abound. A UN official says 5-150 million people could die if the bird flu becomes a pandemic. A University of Minnesota study prophesises 360 million deaths. The World Health Organization (WHO) goes along with 2-7 million deaths. The virus does not pass from person to person, but it is feared it may mutate, making such transmission possible.\par Roche acquired global rights to make and market Tamiflu from Gilead Sciences Inc. Tamiflu was launched in North America and Switzerland in 1999/2000 and in Europe in 2002/2003. Roche says 33 million people have been treated with Tamiflu in about 80 countries. It adds that its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is protected till 2016. Owing to a global shortage of Tamiflu, Roche says it is 'prepared to discuss collaborations with additional third parties to increase the manufacturing of Tamiflu'. The company says that six other companies are producing Tamiflu, and that it is mobilising a massive global effort to keep up with demand.\par But many people have doubts about Roche's claim to be able to meet global demand. There is a shortage of Tamiflu in many parts of Europe. One of the main causes of the problem is a shortage of star anise. Roche buys 90 per cent of the Chinese production, but even this is not enough. Keith Taylor, of Britain's Green Pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty, says: 'Some countries have asked the WHO to pressure Roche into relinquishing the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in order to allow a cheaper, generic version of the drug to be produced on a national level.' He adds: 'The WHO refuses, citing Roche's donation of 3 million treatment courses as evidence that Roche is being responsible. This d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cision jeopardises millions of lives in the name of profit and is anything but responsible.'\par Such concerns have prompted Indian drug maker }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to announce last month that it would begin produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of the drug. Taiwanese companies are also gearing up to produce the drug for emergencies. There is a huge gap between Roche's claims of doing enough to meet world demand and the reality. According to Klaus Stohr, director of the WHO's Global Influenza Programme, it would take US$16 billion and 10 years of production to make enough Tamiflu for 20 per cent of the world's population.\par Should Chinese drug companies take the cue from }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Taiwan, and use their national harvest to make the drug, they would have to first confront the Roche }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Tamiflu. Meanwhile, if a Western company registers a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on star anise, Chinese farmers would suffer loss of indigenous knowledge to bio-piracy. Asians could wind up being losers on both scores.\par Toronto-based Harish Mehta contributed this article to BT. He writes on environmental and IPR issues.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  SPICE FARMING (90%); PATENTS (90%); INFLUENZA (90%); INTELLECTUAL PROPERTY LAW (90%); EDITORIALS & OPINIONS (90%); INFECTIOUS DISEASE (89%); AVIAN INFLUENZA (89%); EPIDEMICS (77%); PHARMACEUTICALS INDUSTRY (76%); ANTIVIRALS (76%); PHARMACEUTICAL PREPARATION MFG (74%); HEALTH DEPARTMENTS (72%); ALTERNATIVE MEDICINE (71%); MISAPPROPRIATION (70%); TRADEMARK LAW (68%); PUBLIC HEALTH ADMINISTRATION (67%); UNITED NATIONS INST}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUTIONS (60%); \par \par  ROCHE HOLDING AG (85%); GILEAD SCIENCES INC (61%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VIEWS AND OPINIONS; The Bottomline\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 795 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 10, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche bends to pressure on flu drug demand The International Herald Tribune November 11, 2005 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_164}{\*\bkmkstart DOC_ID_164_0}{\*\bkmkstart doc_id_26}{\*\bkmkend DOC_ID_164}{\*\bkmkend DOC_ID_164_0}{\*\bkmkend doc_id_26}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_26"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 26 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2005 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche bends to pressure on flu drug demand}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Tom Wright\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 17\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 894 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, Switzerland \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 In a three-story factory on the banks of the Rhine here, a complex web of vats and pipes churns out a co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pound that until recently drew little attention. Across the street, workers in protective suits dry the product into a white, powdery substance that will later be sold as Tamiflu.\par Just how complex this process is has come under increasing scrutiny lately as countries around the world seek to stockpile antiviral drugs like Tamiflu against the possibility of global outbreak of a form of bird flu that could be spread by humans.\par Roche, the Swiss pharmaceutical company that makes the drug, opened the door to its Tamiflu factory on Wednesday to address concern that it would be unable to meet demand in the event of a bird flu pandemic. \par ''There's a shortage right now,'' said William Burns, who heads Roche's pharmaceutical division. But he said that the company planned to raise annual production to 300 million treatments by this time next year, or more than 10 times its level in 2003.\par ''This is a capacity significantly larger than the cumulative number of orders we have,'' Burns said.\par Increasing capacity by this amount, he said, is a financial risk to Roche, given the possibility that a pandemic may not occur.\par But developing countries are demanding that Roche grant them licenses to manufacture the drug in greater quantity and more cheaply. While many Western countries have stockpiled enough Tamiflu to cover a third of their populations in a pandemic, poor countries say they cannot afford to do so.\par Roche said it would supply a five-day course of treatment at \u167\'a412, or $14, to less-developed countries, as d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fined by the World Bank, compared with \u167\'a415 for developed countries.\par Bird flu has so far killed more than 60 people in Thailand, Indonesia, Vietnam and Cambodia, and infected millions of poultry and other birds.\par Infection rates in humans could soar if the virus mutates to a form that can be transmitted between people, experts warn. Tamiflu has been shown in laboratory tests to work against the H5N1 bird flu strain, sparking a rush from consumers and governments to stockpile it.\par Roche confirmed that it was in talks with Vietnam to provide the finished active ingredients for Tamiflu. Local companies could then put that into capsules ''perhaps more cheaply than we can,'' said Eugene Tierney, head of virology at Roche.\par But Roche stood by earlier statements that it was a complex process to manufacture Tamiflu, taking from 10 months to a year, including the gathering of the raw materials.\par Among the criteria to become a manufacturing partner, the company says, is the ability to quickly produce large quantities of high-quality Tamiflu, without interfering with Roche's own supply chain.\par ''Producing Tamiflu needs raw materials and fermentation capacities,'' said Pascal Franc, an analyst at Pi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tet, a private bank in Geneva.\par ''An increase of supply in this domain is not so easy,'' he added.\par Manufacturers like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian generic-drug company that wants to produce oseltamivir, the generic name for Tamiflu, will probably only be able to supply the drug on a pilot-plant scale, making little difference during a pandemic, said Tierney, the head of virology at Roche.\par Some analysts dispute this, saying that the process to make Tamiflu is no more complicated than for many other drugs.\par Gilead Sciences, the U.S. drug company that invented Tamiflu 11 years ago, blames Roche for not doing enough to manufacture and market the drug, and it is trying to regain control. The issue is in arbitration.\par Burns, the head of Roche's pharmaceutical division, said Roche had had ''good discussions'' with Gilead aimed at settling out of court. Roche bought the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu 10 years ago.\par Out of 150 requests for licenses, Roche said it had started talks with only 8 potential partners. It expects to reach a shortlist for further talks during this month.\par The company, Burns said, has sent out detailed questionnaires to help sift the ''commercial opportunists'' from those with ''serious intent.''\par Roche makes Tamiflu in 12 plants around the world, of which half are directly owned. The one in Basel, where Roche is based, is involved in the late stages of production. Another factory in Germany, owned by DSM, a Dutch company, produces the starting material for Tamiflu.\par Increasing production of that material, shikimic acid, could be problematic, analysts say.\par Until recently, Roche relied mainly on a relatively rare Chinese spice, star anise, to make shikimic acid. But that spice, which is grown in the mountains of southern China, is in increasingly short supply. The Chinese broker that supplies most of the spice, Beijing Gingko, has received requests to supply it to other, generic drug companies, but has declined, Tierney said.\par Roche says it relies on the spice for two-thirds of its shikimic acid. The rest is made in a fermentation pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess of the e-coli bacteria.\par Jan Van Koeveringe, head of global technical operations, said the company hoped to reverse that ratio, but he gave no time frame.\par The company relies on third parties for another step in the process, which it says is potentially hazardous because it involves sodium azide, the chemical that makes automobile airbags inflate. Roche says very few companies have the expertise for this work.\par ''We are not trying to scare-monger,'' Burns said. ''But it needs people with specialized skills.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (91%); AVIAN INFLUENZA (90%); INFECTIOUS DISEASE (90%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS INDUSTRY (90%); EPIDEMICS (90%); INFLUENZA (90%); LIVESTOCK DISEASE (89%); DEVE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPING COUNTRIES (89%); DEVELOPMENT BANKS (78%); PHARMACEUTICAL PREPARATION MFG (78%); DISEASES & DISORDERS (76%); INDUSTRY ANALYSTS (76%); VIROLOGY (76%); POULTRY (72%); SUPPLY CHAIN MANAGEMENT (71%); INTERNATIONAL ECONOMIC ORGANIZATIONS (67%); ALLIANCES & PARTNERSHIPS (67%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, SWITZERLAND (79%) SWITZERLAND (79%); INDONESIA (79%); THAILAND (77%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 17, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche bows to pressure on flu drug demand The International Herald Tribune November 10, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_165}{\*\bkmkstart DOC_ID_165_0}{\*\bkmkstart doc_id_27}{\*\bkmkend DOC_ID_165}{\*\bkmkend DOC_ID_165_0}{\*\bkmkend doc_id_27}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_27"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 27 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  10, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche bows to pressure on flu drug demand}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Tom Wright\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 13\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 883 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, Switzerland \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 In a three-story factory on the banks of the Rhine here, a complex web of vats and pipes churns out a co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pound that until recently drew little attention. Across the street, workers in protective suits dry the product into a white, powdery substance that will later be sold as Tamiflu.\par Just how complex this process is has come under increasing scrutiny lately, as countries around the world seek to stockpile antiviral drugs like Tamiflu against the possibility of global outbreak of a form of bird flu that could be spread by humans.\par Roche, the Swiss pharmaceutical company that makes the drug, opened the door to its Tamiflu factory on Wednesday to address concern that it would be unable to meet demand in the event of a bird flu pandemic. \par ''There's a shortage right now,'' said William Burns, head of Roche's pharmaceutical division. But he said the company planned to raise annual production to 300 million treatments by this time next year, or more than 10 times its level in 2003.\par ''This is a capacity significantly larger than the cumulative number of orders we have,'' Burns said. Increasing capacity by this amount, he said, was a financial risk to Roche, given the possibility a pandemic may not o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cur.\par But developing countries are demanding that Roche grant them licenses to manufacture the drug in greater quantity and more cheaply. While many Western countries have stockpiled enough Tamiflu to cover a third of their populations in a pandemic, poor countries say they cannot afford to do so.\par Roche said it would supply a five-day course of treatment at \u167\'a412, or $14, to less-developed countries, as d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fined by the World Bank, compared with \u167\'a415 for developed countries.\par Bird flu has so far killed more than 60 people in Thailand, Indonesia, Vietnam and Cambodia, and infected millions of poultry and other birds. Infection rates in humans could soar if the virus mutates to a form that can be transmitted between people, experts warn. Tamiflu has been shown in laboratory tests to work against the H5N1 bird flu strain, sparking a rush from consumers and governments to stockpile it.\par Roche confirmed that it was in talks with Vietnam to provide the finished active ingredients for Tamiflu. Local companies could then put that into capsules ''perhaps more cheaply than we can,'' said Eugene Tierney, head of virology at Roche.\par But Roche stood by earlier statements that it was a complex process to manufacture Tamiflu, taking from 10 months to a year, including the gathering of the raw materials. Among the criteria to become a manufacturing partner, the company says, is the ability to quickly produce large quantities of high-quality Tamiflu, without interfering with Roche's own supply chain.\par ''Producing Tamiflu needs raw materials and fermentation capacities,'' said Pascal Franc, an analyst at Pi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tet, a private bank in Geneva. ''An increase of supply in this domain is not so easy.''\par Manufacturers like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian generic-drug company that wants to produce oseltamivir, the generic name for Tamiflu, will probably only be able to supply the drug on a pilot-plant scale, making little difference during a pandemic, Tierney said. Some analysts dispute this, saying that the process to make Tamiflu is no more complicated than for many other drugs.\par Gilead Sciences, the U.S. drug company that invented Tamiflu 11 years ago, blames Roche for not doing enough to manufacture and market the drug, and it is trying to regain control. The issue is in arbitration. Burns said Roche has had ''good discussions'' with Gilead aimed at settling out of court. Roche bought the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu 10 years ago.\par Of 150 requests for licenses, Roche said it has only started talks with 8 potential partners. It expects to reach a shortlist for further talks in November. The company, Burns said, has sent out detailed questionnaires to help sift the ''commercial opportunists'' from those with ''serious intent.''\par Roche makes Tamiflu in 12 plants around the world, of which half are directly owned. The one in Basel, Switzerland, where Roche is headquartered, is involved in the late stages of production. Another factory in Germany, owned by DSM, a Dutch company, produces the starting material for Tamiflu.\par Increasing production of that material, shikimic acid, could be problematic, analysts say. Until recently, Roche relied mainly on a relatively rare Chinese spice, star anise, to make shikimic acid. But that spice, which is grown in the mountains of southern China, is in increasingly short supply. The Chinese broker that supplies most of the spice, Beijing Gingko, has received requests to supply it to other, generic drug comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies, but has declined, Tierney said.\par Roche says it currently relies on the spice for two thirds of its shikimic acid. The rest is made in a ferment}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion process of the e-coli bacteria. Jan Van Koeveringe, head of global technical operations, said the comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ny hoped to reverse that ratio, but he gave no time frame.\par The company relies on third parties for another step in the process, which it says is potentially hazardous because it involves sodium azide, the chemical that makes automobile airbags inflate. Roche says very few companies have the expertise for this work. ''We are not trying to scare-monger,'' Burns said. ''But it needs people with specialized skills.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (91%); AVIAN INFLUENZA (90%); INFECTIOUS DISEASE (90%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS INDUSTRY (90%); EPIDEMICS (90%); INFLUENZA (90%); LIVESTOCK DISEASE (89%); DEVE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPING COUNTRIES (89%); DEVELOPMENT BANKS (78%); PHARMACEUTICAL PREPARATION MFG (78%); DISEASES & DISORDERS (76%); INDUSTRY ANALYSTS (76%); VIROLOGY (76%); POULTRY (72%); SUPPLY CHAIN MANAGEMENT (71%); INTERNATIONAL ECONOMIC ORGANIZATIONS (67%); ALLIANCES & PARTNERSHIPS (67%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, SWITZERLAND (79%) SWITZERLAND (79%); INDONESIA (79%); THAILAND (77%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 13, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche Plans Big Increase In Tamiflu Production The New York Times November 10, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_166}{\*\bkmkstart DOC_ID_166_0}{\*\bkmkstart doc_id_28}{\*\bkmkend DOC_ID_166}{\*\bkmkend DOC_ID_166_0}{\*\bkmkend doc_id_28}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_28"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 28 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  10, 2005 Thursday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche Plans Big Increase In Tamiflu Production}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By TOM WRIGHT; International Herald Tribune\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 6; Business/Financial Desk; Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 658 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, Switzerland, Nov. 9 \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 In a factory here on the banks of the Rhine, three floors of linked vats and pipes churn out a compound that until recently drew only scant attention. Across the street, workers in protective suits dry that compound to make a white powder, to be packaged and sold as Tamiflu.\par   Roche, the Swiss pharmaceutical company that makes the drug, opened the doors to its Tamiflu factory Wednesday to allay fears that it might be unable to meet demand for the antiviral drug in the event of a bird flu pandemic. \par ''There's a shortage right now,'' said William M. Burns, head of Roche's pharmaceutical division. But he quickly added that the company plans to raise annual production capacity to 300 million courses of treatment by this time next year: a drastic increase from 55 million this year and more than 10 times the output capacity in 2003.\par   ''This is a capacity significantly larger than the cumulative number of orders we have,'' Mr. Burns said.\par   In response to international pressure, Roche also said Wednesday that in the less-developed countries, as defined by the World Bank, it would charge 12 euros ($14.12 at Wednesday's conversion rate) for a five-day treatment and 15 euros in the developed nations. It was the first time Roche had disclosed the price it will charge governments. For seasonal flu, the company charges 20 to 50 euros a course to the public. \par   Roche also confirmed that it was in talks with Vietnam to provide the finished active ingredients for Tamiflu. Local companies could then put them in capsules ''perhaps more cheaply than we can,'' said Eugene Tie}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ney, head of virology at Roche.\par   Of 150 requests for licenses, Roche said it has talked with eight possible partners; it expects to shorten the list this month. Roche, Mr. Burns said, has sent out questionnaires to help sift the ''commercial opportunists'' from those with ''serious intent.'' Roche is trying to find out if ''there are people out there that can help us in a serious way,'' he said.\par   Bird flu has so far killed 64 people in Thailand, Indonesia, Vietnam and Cambodia, and infected millions of poultry and other birds. Infection rates in humans could soar if the virus mutates to a form that can be tran}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mitted from person to person, experts have warned.\par   Roche stood by earlier statements that making Tamiflu was complex, taking up to a year, including gathe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the raw materials. Among the criteria to become a manufacturing partner, the company says, is the ability to produce large quantities quickly without interfering with Roche's own supply chain.\par   Companies like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian generic drug maker that wants to produce the generic version of Tamiflu, called oseltamivir, could probably supply only small amounts, making little difference in a pandemic, Mr. Tierney of Roche said.\par   Some analysts dispute this, saying it is no more complicated to make Tamiflu than many other drugs.\par   Gilead Sciences, the American drug company that invented Tamiflu 11 years ago, says Roche has not done enough to manufacture and market the drug, and is trying to regain control; the two companies are in arbitration. Mr. Burns said Roche has had ''good discussions'' with Gilead aimed at settling out of court. Roche bought control of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu 10 years ago.\par   Analysts also say that ramping up production of shikimic acid, a basic material in the making of Tamiflu, presents a potential bottleneck. Roche relies on a relatively rare Chinese spice, star anise, to make around two-thirds of the acid. The spice, grown in the mountains of southern China, is in increasingly short supply.\par   The Chinese broker that supplies most of it, Beijing Gingko, has received requests for it from generic drug companies, but has declined them, Mr. Tierney said.\par   Roche produces a third of the acid by fermenting E. coli bacteria. Jan Van Koeveringe, head of global tec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nical operations at Roche, said the company hoped to reverse that proportion, but gave no timeline.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (90%); PLANT CAPACITY (90%); AVIAN INFLUENZA (89%); ANTIVIRALS (89%); PHARMACEUTICAL PREPARATION MFG (89%); INFECTIOUS DISEASE (89%); GENERIC DRUGS (89%); LIVESTOCK DISEASE (89%); INFLUENZA (89%); DEVELOPMENT BANKS (78%); MANUFACTURING OUTPUT (78%); PRESCRIPTION DRUGS (76%); VIROLOGY (75%); EPIDE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS (75%); SUPPLY CHAIN MANAGEMENT (74%); ALLIANCES & PARTNERSHIPS (74%); EMERGING MARKETS (71%); POULTRY (71%); DEVELOPING COUNTRIES (66%); INTERNATIONAL ECONOMIC ORGANIZATIONS (65%) Terms not available from NYTimes\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, SWITZERLAND (79%) SWITZERLAND (79%); INDONESIA (79%); THAILAND (78%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 10, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Steps and missteps in bird flu fight; Old Chinese cooking spice could hold key to making Tamiflu The International Herald Tribune November 8, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_167}{\*\bkmkstart DOC_ID_167_0}{\*\bkmkstart doc_id_29}{\*\bkmkend DOC_ID_167}{\*\bkmkend DOC_ID_167_0}{\*\bkmkend doc_id_29}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_29"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00320039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 29 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The International Herald Tribune\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  8, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Steps and missteps in bird flu fight; \par Old Chinese cooking spice could hold key to making Tamiflu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Andrew Pollack\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCE; Pg. 13\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 955 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW YORK \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 If a bird flu pandemic breaks out, the world's ability to fight back may come down to an ancient Chinese cooking spice \u8249\'dc or the perseverance of people like Professor Frost.\par The Chinese spice, star anise, provides the starting material for the manufacture of the anti-influenza drug Tamiflu, which is expected to be the first line of defense when humans contract avian influenza.\par But there is probably not enough star anise in China or anywhere else to meet the rapidly growing global demand for Tamiflu.\par That could mean that Tamiflu production cannot be stepped up, even if the maker, Roche, bows to pressure to allow other companies to manufacture the drug. \par The professor is John Frost, a chemist at Michigan State University who developed a technique for making the starting material, shikimic acid, without the coveted star anise.\par Roche has used Frost's method in recent years, in fact, but he says he heard the company had cut back. Undeterred, Frost is starting a company that he says could produce huge quantities of the material.\par ''I'm just completely astonished about the gnashing of teeth and the wringing of hands about the shikimic a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 id,'' Frost said. ''The bottleneck should not be shikimic acid availability.''\par Frost is one of many entrepreneurs seeking to help increase production of Tamiflu, perhaps the most sought-after drug in the world right now. Roche says it has received licensing inquiries from more than 100 comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies. And some countries and companies say they might produce Tamiflu, whose generic name is oseltam}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vir, even without Roche's permission.\par The National Health Research Institutes of Taiwan took only 18 days to produce a small quantity of Tamiflu, with guidance from published papers and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par But producing large quantities is ''another story'' said K.S. Shia, who headed the project and acknowledged the complexities of making Tamiflu. Officials in Taiwan have not said how long it would take to achieve larger production.\par Even if companies can make the drug, they might not have enough shikimic acid. In nature, that ingredient is found in the fruit of star anise trees, which grow in southern China. Most of the star anise is now used for Roche's production, but it is also an Asian cooking spice and is used in herbal medicines and in the produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of liqueurs, including Pernod.\par Since demand for Tamiflu started growing in recent months, the price of shikimic acid from China has soared to more than $500 a kilogram, or $15 an ounce, more than 12 times its previous price.\par Because it takes years for a baby shrub to grow into one that can produce the fruit, planting new trees would not seem to be a quick remedy.\par ''We managed to corner a few tons, but it won't go very far,'' Yusuf Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , an Indian g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drug company that has announced it will produce oseltamivir. The company hopes to have produced enough by March to treat 100,000 to 200,000 people, he said.\par The government of Taiwan said last week that it had signed an agreement with an unidentified supplier for three metric tons of shikimic acid, which could help treat one million to two million people.\par But Roche says that would not be easy to do.\par It says the manufacturing process takes 10 steps over six to eight months once the raw materials are in hand. It also says some of the production steps are potentially hazardous because they involve the use of sodium azide, the chemical that makes automobile airbags inflate in an explosive rush. The company says it would take a newcomer two to three years to be able to start production.\par Part of the disagreement about the difficulty might stem from the difference between making small quantities in the laboratory, which can be done quite easily, and producing large amounts commercially.\par ''I don't think the chemistry is such a big issue,'' Hamied said. He said }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  already used sodium azide to produce two drugs.\par Ernie Prisbe, vice president for chemical development at Gilead Sciences, which invented Tamiflu, says an industry rule of thumb is that each step, even if well defined, takes a month to six weeks to put into practice. Tamiflu manufacturing, by his count, involves 12 steps.\par Roche has never said how much Tamiflu it can make by itself, only that by next year it will be making 8 to 10 times as much as it did in 2003.\par Roche would not answer questions about its manufacturing, saying it would discuss Tamiflu production at a presentation on Wednesday at its headquarters in Basel, Switzerland.\par Among those now looking at Tamiflu manufacturing is Gilead, which wants to regain control of the drug from Roche, which it accuses of not doing an adequate job of manufacturing and marketing. Roche denies that, and the dispute is in arbitration.\par Gilead initially chose quinic acid over shikimic acid as a starting material. Quinic acid, from the bark of the tropical cinchona tree, was available in much greater supply and at lower prices, even though using it r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quired more steps than using shikimic acid, Prisbe said.\par But political upheaval in Zaire, the source of its material, raised doubts about future supplies, forcing Gilead to scramble.\par ''Roche was saying if you guys don't come up with a starting material you don't have a deal with us,'' Prisbe said.\par Gilead contacted Frost and began looking at extracting shikimic acid from gingko trees and from needles of giant sequoias.\par A gingko products company based in Beijing offered to supply the material but suggested that star anise would be a better source.\par Whether for Gilead or for others, when it comes to making Tamiflu ''on a scale of 1 to 10 in difficulty, this is maybe a 7 or so,'' Prisbe said, ''There's nothing that overwhelming in this kind of synthesis, or that formid}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble, that someone couldn't do it.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (92%); AVIAN INFLUENZA (91%); COLLEGE & UNIVERSITY PROFESSORS (90%); ANTIVIRALS (89%); ENTREPRENEURSHIP (88%); EPIDEMICS (78%); CHEMISTRY (74%); DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TILLERIES (72%); ALTERNATIVE MEDICINE (72%); HERBAL MEDICINE (72%); RESEARCH INST}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUTES (69%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (64%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MICHIGAN STATE UNIVERSITY (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MICHIGAN, USA (79%); SOUTH CHINA (79%) CHINA (93%); TAIWAN (90%); UNITED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 11, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 International Herald Tribune\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Debating How Difficult It Is to Make Tamiflu  The New York Times November 5, 2005 Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_168}{\*\bkmkstart DOC_ID_168_0}{\*\bkmkstart doc_id_30}{\*\bkmkend DOC_ID_168}{\*\bkmkend DOC_ID_168_0}{\*\bkmkend doc_id_30}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_30"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 30 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2005 Saturday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Debating How Difficult It Is to Make Tamiflu }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By ANDREW POLLACK; Keith Bradsher contributed reporting for this article.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 3; Business/Financial Desk; Is Bird Flu Drug Really So Vexing?; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1751 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 If a bird flu pandemic breaks out, the world's ability to fight back may come down to an ancient Chinese cooking spice -- or the perseverance of people like Professor Frost. \par   The Chinese spice, star anise, provides the starting material for the manufacture of the anti-influenza drug Tamiflu, which is expected to be the first line of defense in a pandemic.\par But there is probably not enough star anise in China or anywhere else to meet the rapidly growing global demand for Tamiflu. That could mean that Tamiflu production cannot be ramped up, even if the maker, Roche, bows to pressure to allow other companies to manufacture the drug. \par   The professor is John W. Frost, a chemist at Michigan State University who developed a technique for ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the starting material, shikimic acid, without the coveted star anise. Roche has used Professor Frost's method in recent years, in fact, but he says he heard the company had cut back. Undeterred, Professor Frost is starting a company that he says could produce huge quantities of the material.  \par   ''I'm just completely astonished about the gnashing of teeth and the wringing of hands about the shikimic acid,'' Professor Frost said. ''The bottleneck should not be shikimic acid availability.'' \par   Professor Frost is one of many entrepreneurs seeking to help ramp up production of Tamiflu, perhaps the most sought-after drug in the world right now. Roche says it has received licensing inquiries from more than 100 companies. And some countries and companies say they might produce Tamiflu, also known as oselt}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mivir, even without Roche's permission. \par   But a debate is raging on how easy that would be to do. \par   Roche has said the manufacturing process requires 10 steps that take six to eight months once the raw materials are in hand. It also says that some steps in production are potentially hazardous because they i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 volve the use of sodium azide, the chemical that makes automobile air bags inflate in an explosive rush. The company says it would take a newcomer two to three years to be able to start production.\par   Roche has never said how much Tamiflu it can make, only that by next year it will be making 8 to 10 times the amount it did in 2003. Roche would not discuss its manufacturing for this article, saying it would do so at a presentation Wednesday at its headquarters in Basel, Switzerland. \par   But others insist that the manufacturing process, while more challenging than for some drugs, is not e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tremely difficult. \par   ''I don't think the chemistry is such a big issue,'' said Yusuf K. Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , a generic drug company in India that has announced it will produce oseltamivir, the generic name for Tamiflu. He said }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  already uses sodium azide, the air bag chemical, to produce the AIDS drug AZT and an anti-epilepsy drug. \par   Part of the disagreement about the difficulty might stem from the difference between making small quant}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ties in the laboratory, which can be done quite easily, and producing large amounts commercially. Ernie Prisbe, vice president for chemical development at Gilead Sciences, which invented Tamiflu and licensed it to Roche, said an industry rule of thumb is that each step, even if well defined, takes one month to six weeks to put into practice. Tamiflu manufacturing, by his count, involves 12 steps. \par   The National Health Research Institutes of Taiwan took only 18 days to produce a small quantity of Tamiflu, with guidance from published papers and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  But producing large quantities is ''another story'' said K. S. Shia, who headed the project. Officials in Taiwan would not say how long it would take to achieve larger production. \par   Even if companies can make the drug, they might not have enough shikimic acid. That ingredient is extrac}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed from the fruit of star anise trees, which grow in Southern China. Most of the star anise is now used for Roche's production, but it is also an Asian cooking spice and is used in herbal medicines and in the produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of the liqueur pastis. \par   Since demand for Tamiflu started growing recently, the price of shikimic acid from China has soared to more than $400 a kilogram, from $40.\par   ''We managed to corner a few tons but it won't go very far,'' said Mr. Hamied of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . The company hopes by March to have produced enough oseltamivir to treat 100,000 to 200,000 people, he said. \par   Last week, the Taiwan government said it had signed an agreement with an unidentified supplier for three metric tons of shikimic acid, which could conceivably provide enough drug to treat 2.3 million people. \par   According to a presentation at a conference last year by a Roche chemist, it takes 13 grams of star anise to make 1.3 grams of shikimic acid, which in turn can be made into 10 Tamiflu capsules -- enough to treat one person. By that reckoning, one ton of shikimic acid would be enough for 770,000 people. \par   But Mr. Hamied, a chemist, disputed that, saying one ton of shikimic acid would yield enough for only 300,000 people at most. And newcomers are not likely to have the same production efficiency as Roche, he said. \par   The alternative method of producing shikimic acid developed by Professor Frost involves fermentation u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing vats of genetically engineered bacteria. He said people he knew at Roche told him the company has cu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tailed the fermentation of shikimic acid to devote fermenting equipment to more valuable products. If so, that would increase the pressure on star anise supplies.\par   In the fiscal year that ended in June, Michigan State received $113,000 in royalties from Roche, according to Paul Hunt, the university's associate vice president for research and graduate studies. Roche pays $1.85 for each kilogram of shikimic acid it makes using the process, indicating it made about 60 metric tons in that year. \par   Roche has given conflicting statements about its use of fermentation. In an e-mail message, Daniel Piller, a spokesman for Roche, said the company got about a third of its shikimic acid from fermentation and planned to increase that over time.\par   In a conference call with securities analysts two weeks ago, William M. Burns, the head of Roche's pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 maceutical business, said fermentation was part of the company's plan for the medium term. But for now, he said, the use of star anise was the only process approved by regulators.\par   Professor Frost, some industry consultants and Gilead, though, said that government manufacturing regul}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions did not cover the production of shikimic acid. \par   In any case, Roche is apparently looking to farm out fermentation to others, according to Professor Frost. He is starting a company, Draths Industries, in hopes of supplying it to Roche and other companies. \par   Professor Frost, working with MBI International, a fermentation company in Lansing, Mich., near the unive}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sity, said he hoped to raise $1 million and had lined up a big fermentation company in Asia that would be able to produce 100 tons of shikimic acid a year. \par   Gilead initially chose quinic acid over shikimic acid as a starting material. Quinic acid, from the bark of the tropical cinchona tree, was available in much greater supply and at lower prices, even though using it r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quired more steps than using shikimic acid, Mr. Prisbe said. \par   But political upheaval in Zaire, the source of its material, raised doubts about future supplies, forcing Gilead to scramble. ''Roche was saying if you guys don't come up with a starting material you don't have a deal with us,'' Mr. Prisbe said. \par   Gilead began looking at extracting shikimic acid from gingko trees and even found a scientific paper di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cussing the extraction from needles of giant sequoias. A gingko products company in Beijing offered to su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ply the material but suggested star anise would be a better source. \par   Still, quinic acid could be a potential alternative starting material and there might be other sources of sh}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 kimic acid besides star anise. Virtually all plants produce some shikimic acid, which they use in making ce}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tain amino acids. The herbicide Roundup, in fact, works by interfering with this process.\par   To make Tamiflu, shikimic acid is turned into an intermediate called an epoxide through a series of about five steps that are not considered out of the ordinary. But then the ring-shaped epoxide molecule must be opened up and some atoms substituted for other atoms. \par   That is where the air bag chemical, sodium azide, comes in. Chemists say it is used because it can produce a sharp, clean reaction that leaves few impurities. Although the reaction used to produce Tamiflu does not involve explosions, the azides, as a class, can be explosive. But sodium azide is not dangerously so, some experts say, or it would not be used inside cars. \par   ''It's a wimpy explosive,'' said Thomas Archibald, a chemical consultant in the Virgin Islands. He and some others say that drug companies have a needless aversion to azide chemistry -- a fear that K. Barry Shar}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 less, a Nobel Prize-winning chemist at the Scripps Research Institute, has referred to as ''azidophobia.'' \par   Many drug companies, including Roche, farm out azide processing steps to companies that specialize in what the industry calls ''energetic'' chemistry. Such contractors, presumably, would be available to comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies besides Roche that want to make Tamiflu. \par   Many of the companies started doing work on explosives for the military or other uses. Aerojet Fine Chem}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cals, which did the initial azide processing for Gilead, is part of a company that builds rocket motors outside of Sacramento. \par   ''This is our version of turning swords into plowshares,'' said Joseph Carleone, Aerojet's president. ''We took our ability to handle explosives and propellants and applied it to pharmaceuticals.'' \par   Mr. Carleone would not say whether his company was doing Tamiflu work for Roche, citing customer conf}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dentiality. Roche has recently said that it has set up manufacturing in the United States at the behest of the federal government, which was worried about reliance on foreign supplies of a vital drug. \par   Among those looking at Tamiflu manufacturing is Gilead, which wants to regain control of the drug from Roche. It accuses Roche of not doing an adequate job in manufacturing and marketing. Roche denies that, and the dispute is in arbitration. \par   Whether for Gilead or for others, when it comes to making Tamiflu ''on a scale of 1 to 10 in difficulty, this is maybe a 7 or so,''' Mr. Prisbe said, ''There's nothing that overwhelming in this kind of synthesis, or that form}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dable, that someone couldn't do it.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (93%); AVIAN INFLUENZA (90%); ANTIVIRALS (90%); COLLEGE & UNIVERSITY PROFESSORS (90%); HOLDING COMPANIES (90%); EPIDEMICS (90%); PHARMACEUTICALS INDU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRY (89%); INFECTIOUS DISEASE (89%); GENERIC DRUGS (77%); AIDS & HIV TREATMENT (77%); ENTREPRENEURSHIP (74%); AIDS & HIV (73%); CENTRAL NERVOUS SYSTEM DRUGS (62%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC PRODUCTS (62%); MOTOR VEHICLE SAFETY EQUIPMENT (61%); VEHICLE AIRBAGS (61%); EPILEPSY (60%); TOXIC & HAZARDOUS SUBSTANCES (59%) Influenza; Avian Influenza  ; Tamiflu (Drug); Drugs (Pharmaceuticals); Hazardous and Toxic Substances; Sodium Azide; Production; Oseltamivir (Drug); Generic and Brand Name Products; Influenza; Shikimic Acid; Star Anise (Spice); Influenza; Influenza\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MICHIGAN STATE UNIVERSITY (91%) Roche Holding Ltd; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd; Gilead Sciences Inc; Michigan State University; Mbi Group\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Yusuf K (Dr) Hamied; Ernie Prisbe; John W Frost; Andrew Pollack\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BASEL, SWITZERLAND (79%) MICHIGAN, USA (93%) UNITED STATES (93%); CHINA (92%); INDIA (79%); SWITZERLAND (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 5, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photos: Star anise provides the starting material for the manufacture of the anti-influenza drug Tamiflu.\par  John W. Frost, a chemist at Michigan State University, developed a technique for making shikimic acid wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out star anise. With him is his wife, Karen Frost, a research assistant professor. (Photographs by Fabrizio Costantini for The New York Times)(pg. C13)Drawing (pg. 1)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Let others make life-saving drug, company told The Times (London) November 5, 2005, Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_169}{\*\bkmkstart DOC_ID_169_0}{\*\bkmkstart doc_id_31}{\*\bkmkend DOC_ID_169}{\*\bkmkend DOC_ID_169_0}{\*\bkmkend doc_id_31}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_31"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 31 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2005, Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Let others make life-saving drug, company told}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Richard Irving and Mark Henderson\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Home news; 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 584 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The company that makes the antiviral Tamiflu will come under pressure from senior health officials next week to allow other manufacturers to produce the drug.\par  The call will come on Monday at an international summit in Geneva on the threat of a flu pandemic.\par  The health officials will demand to know why Roche, which holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu, has yet to permit outside contractors to make the drug despite receiving more than 100 offers from companies and national laboratories willing to address a global shortage. \par  The World Health Organisation has urged governments to stockpile Tamiflu as a front line of defence against a potential pandemic, but analysts estimate that there are sufficient supplies for less than 2 per cent of the world's population.\par  Roche is struggling to meet a huge backlog of orders, and there is mounting concern among governments that it is dragging its feet over measures that could increase production.\par  Yesterday Thailand became the latest country to say that it would soon start making a generic version of the drug without waiting for approval from the company. Taiwan said that it would do the same by next month. Vietnam and India have also threatened to produce their versions of Tamiflu.\par  Generic production of Tamiflu will figure prominently on the agenda of the three-day Geneva summit, which brings together officials from national governments, the WHO, the World Bank and the World Organisation for Animal Health.\par  Britain is sending a large delegation led by David Harper, the chief scientist at the Department of Health.\par  The medical journal The Lancet said yesterday that the conference should draw up an international strategy for making Tamiflu and a second antiviral, GlaxoSmithKline's Relenza, more widely available.\par  The calls for generic production came as it emerged that Roche may have exaggerated the difficulty of the manufacturing process for Tamiflu. As recently as three weeks ago it gave warning that it was too complica}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed for other companies to make the drug, as the ten-stage process was highly dangerous, involving one step that could potentially cause explosions if not properly handled. Rival producers would need at least three years to develop the capability to make the drug, it said.\par  Last week the Swiss company was forced to revise those estimates after researchers at the National Health Research Institutes of Taiwan made the drug in just 18 days, not including weekends and a bank holiday, using information from publicly available documents. The Indian company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has also produced a generic version.\par  Roche has since said that it is prepared to discuss licensing deals with potential partners, but the application process is proving to be lengthy and laborious.\par  Companies interested in licensing Tamiflu must first lodge their interest in writing with Roche's head office.\par  The Swiss group will accept expressions of interest only on official notepaper.\par  Would-be contractors must then prove that they are capable of producing Tamiflu in substantial amounts before they are sent a detailed questionnaire covering their technical abilities.\par  A Roche spokeswoman told The Times: "We need to apply this strict process to ensure that patients receive a product equivalent to the quality of that produced by Roche." She added that up to 20 senior negotiators would resume talks with applicants next week. She declined to speculate on when the first licensing deal might be signed.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); GLAXOSMITHKLINE PLC (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (55%);   WORLD HEALTH ORGANIZATION  (76%); WORLD HEALTH ORGANIZATION (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (76%); WORLD HEALTH ORGANIZATION (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); GSK (NYSE) (58%); GSK (LSE) (58%); BIOC (EGX) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SWITZERLAND (92%); THAILAND (71%);   GENEVA, SWITZERLAND (57%);   GENEVA, SWITZERLAND (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SWITZERLAND (92%); THAILAND (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bird Flu  PUBLIC HEALTH ADMINISTRATION (91%); PHARMACEUTICALS INDUSTRY (90%); INFECTIOUS DISEASE (90%); INFLUENZA (90%); HEALTH DEPARTMENTS (90%); GENERIC DRUGS (89%); ANTIVIRALS (78%); AVIAN INFLUENZA (78%); CONFERENCES & CONVENTIONS (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (76%); RESEARCH INSTITUTES (76%); DEVELOPMENT BANKS (70%); INTERNATIONAL EC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOMIC ORGANIZATIONS (69%); LICENSING AGREEMENTS (62%); EPIDEMICS (58%); POPULATION SIZE (55%); HOLIDAYS & OBSERVANCES (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 5, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Times Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BIRD FLU PATENTS RAISE THE REPUTATION STAKES PR Week November 4, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_170}{\*\bkmkstart DOC_ID_170_0}{\*\bkmkstart doc_id_32}{\*\bkmkend DOC_ID_170}{\*\bkmkend DOC_ID_170_0}{\*\bkmkend doc_id_32}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_32"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 32 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PR Week\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  4, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 BIRD FLU }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  RAISE THE REPUTATION STAKES}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Kate Nicholas, kate.nicholas@haynet.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPINION; Pg. 18\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 418  words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pharmaceutical }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection probably means little to most people, despite the best efforts of pressure groups to highlight its impact on the developing world. But with bird flu winging its way to our shores and the Government frustrated at attempts to stockpile treatments, the public are beginning to question why more drugs are not available. \par And as the media turn their attention to the companies failing to supply the drugs in sufficient quantities, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection is becoming a headline issue.\par There is real potential here for pharmas to be cast as the bad guys who let a pandemic run rife rather than share the potentially gigantic profits created by a catastrophe. This, coupled with the likelihood that gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments will take the licensing decision out of their hands, is probably why GlaxoSmithKline announced its wil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ingness to sub-licence the production of its flu treatment, Relenza, to outside 'partners' last week.\par So far Relenza has played second fiddle to Roche's Tamiflu in the media, and has had to fight perceptions that, as an inhaler, it is less reliable than the Tamiflu capsule. However, with the announcement that it is boosting its own production while allowing outside licensing, GSK has - in the eyes of City analysts at least - avoided the problems dogging Roche, which is struggling to meet demand from governments. Analysts are now predicting a further pounds 800m in sales of Relenza on the back of GSK's boosted production capacity.\par The company is also busy promoting its commitment to developing a vaccine against the dreaded H5N1 strain, announcing last week that clinical trials are about to begin. GSK chief executive Jean Pierre Garnier told reporters that the company was 'pulling out all the stops to help governments have their planning in place'.\par Meanwhile, US senator Charles E Schumer has accused Roche of 'putting its own interests ahead of world health', and has threatened to 'pursue a legislative remedy' unless Roche licenses out the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu by mid-November.\par Roche claims it plans to increase production, has approval to build a new manufacturing facility in the US and is willing to discuss sub-licences.\par However, it also says the complex production process would take up to three years to master, although Ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an generic drugs company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  claims it could produce a version of Tamiflu by early 2006.\par The jury is obviously still out on who is winning the race to beat avian flu, but in terms of reputation, GSK just came up on Roche in the inside lane.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); EDITORIALS & OPINIONS (90%); INFLUENZA (90%); AVIAN INFLUENZA (90%); PHARMACEUTICALS INDUSTRY (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); DEVELOPING COUNTRIES (89%); BIOTECHNOLOGY }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); PHARMACEUTICAL DRUG & DEVICES LITIGATION (89%); PRESCRIPTION DRUGS (79%); GENERIC DRUGS (79%); DRUG DELIVERY SYSTEMS (79%); DRUG DESIGN & DISCOVERY (79%); EPIDEMICS (77%); LEGISLATIVE BODIES (77%); LICENSING AGREEMENTS (75%); PHARMACEUTICAL PREPARATION MFG (74%); B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OLOGICS MFG (74%); INFECTIOUS DISEASE (73%); VACCINES (52%); EXECUTIVES (50%); MAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FACTURING FACILITIES (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (90%); ROCHE HOLDING AG (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (59%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); BIOC (EGX) (90%); ROG (SWX) (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (59%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UFACTURING (85%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JEAN-PIERRE GARNIER (59%); CHARLES SCHUMER (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 12, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Magazine\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 JOURNAL-CODE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PRW\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Haymarket Publishing Services Ltd.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bird Flu Threat Boosts Pharma Outsourcing Chemical Week October 26, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_171}{\*\bkmkstart DOC_ID_171_0}{\*\bkmkstart doc_id_33}{\*\bkmkend DOC_ID_171}{\*\bkmkend DOC_ID_171_0}{\*\bkmkend doc_id_33}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_33"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 33 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Chemical Week\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Bird Flu Threat Boosts Pharma Outsourcing}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ALEX SCOTT\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS & FINE CHEMICALS; Manufacture; Pg. 34\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 473 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche has significantly increased its outsourced production of antiviral drug Tamiflu, and plans to build an additional Tamiflu capsule plant at an undisclosed location in the U.S., amid growing fears of a global pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 demic of avian influenza, the company tells }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 CW.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The deadly H5N1 bird flu strain has spread from Asia to Europe, and scientists are concerned that it may mutate into a form of the virus that can be passed between humans.  Tamiflu can reduce the severity of influenza once a person is infected, and it is widely regarded as the most effective antiviral drug for treating bird flu.  The drug, unlike a vaccine, does not prevent infection. \par Roche recently started outsourcing production of Tamiflu to seven sites run by undisclosed manufacturers, the company tells }{\rtlch\fcs1 \ai\af1 \ltrch\fcs0 \i\f1\insrsid2900964 CW.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Roche has six sites of its own dedicated to manufacturing Tamiflu.  The sites are split between Europe and the U.S.  The company says it has 40 suppliers involved in the manufacturing process.  It expects to increase production by mid-2006 to 8-10 times the level at the start of this year.  Roche's spen}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to outsource Tamiflu production will run to tens of millions of dollars, according to one fine chemicals an}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lyst.\par The company says it is meeting current demand for the drug, and that it has no plans to approach more cu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tom manufacturers.  However, the company is under increasing pressure from the World Health Organization (WHO; Geneva) to increase manufacturing by licensing production.  Roche announced earlier this month that it is prepared to licence production of Tamiflu to any government that approaches the company.  About 40 governments have ordered supplies of Tamiflu from Roche, the company says.\par The manufacturing process for Tamiflu is highly complex and takes about one year.  Most early production stages, including one involving potentially explosive materials, are outsourced to specialist manufacturers, Roche says.  Late stages of Tamiflu production are kept in-house.  Meanwhile, other pharmaceutical comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies are developing alternatives to Tamiflu.  Generics producer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (Mumbai, India) says that in the past few weeks it has finalized a process for manufacturing a generic version of Tamiflu, and that it is "starting manufacture" of the drug.  Roche says it fully intends to defend its Tamiflu }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par GlaxoSmithKline, meanwhile, says it recently spent $ 2 billion to expand facilities for manufacturing the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany's influenza vaccine and increase production of its Relenza antiviral drug.  Akzo Nobel's Nobilon vaccine business says it is developing a human vaccine against H5N1.  The company says it plans to begin clinical trials for its H5N1 vaccine in 2006.  Other pharma companies, including Sanofi-Aventis and Chiron, also say they are developing vaccines to counter a bird flu pandemic.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (94%); AVIAN INFLUENZA (92%); ANTIVIRALS (91%); INFECTIOUS DISEASE (91%); PHARMACEUTICALS INDUSTRY (90%); OUTSOURCING (90%); EPIDEMICS (90%); BIOLOGICS MFG (89%); DRUG DESIGN & DISCOVERY (89%); VACCINES (89%); PHARMACEUTICAL PREPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION MFG (89%); CHEMICALS (78%); CHEMICALS MFG (78%); GENERIC DRUGS (78%); HEALTH D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARTMENTS (77%); PUBLIC HEALTH ADMINISTRATION (77%); CLINICAL TRIALS (73%); UNITED N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS INSTITUTIONS (64%); GENERIC PRODUCTS (61%); SCIENCE NEWS (56%); SCIENCE & TEC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOLOGY (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (94%); SNY (NYSE) (84%); SANF (BIT) (84%); SAN (PAR) (84%); GCVRZ (NASDAQ) (84%); AKZA (AMS) (62%); GSK (NYSE) (58%); GSK (LSE) (58%); BIOC (EGX) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (94%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (94%); NAICS325411 MEDICINAL & BOTAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL MANUFACTURING (84%); NAICS325998 ALL OTHER MISCELLANEOUS CHEMICAL PRODUCT & PREPARATION MANUFACTURING (62%); NAICS325510 PAINT & COATING MANUFACTURING (62%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (71%); WORLD HEALTH ORGANIZATION (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (90%); UNITED STATES (90%); ASIA (90%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (94%); SANOFI SA (84%); AKZO NOBEL NV (62%); GLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OSMITHKLINE PLC (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (53%);   WORLD HEALTH ORGANIZATION  (71%); WORLD HEALTH ORGANIZATION (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 2, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Picture, Flat out: Bird flu threat has driven Roche to outsource.\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Chemical Week Associates\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Fighting to break the Tamiflu monopoly The Toronto Star October 25, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_172}{\*\bkmkstart DOC_ID_172_0}{\*\bkmkstart doc_id_34}{\*\bkmkend DOC_ID_172}{\*\bkmkend DOC_ID_172_0}{\*\bkmkend doc_id_34}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_34"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 34 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Toronto Star\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Fighting to break the Tamiflu monopoly}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Andrew Mills, Toronto Star\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Pg. A02\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 396 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OTTAWA World health officials gathered here began a contentious debate yesterday on how governments could break the Tamiflu }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to shore up stockpiles of the drug that might help nations fight pandemic flu. \par Switzerland's Roche is the only drug maker that can licence others to make the drug until 2016. Yet Roche itself is operating at capacity and cannot match surging demand for its Tamiflu.\par The meeting plans to discuss how nations capable of making the drug might do so if Roche does not agree to licence them.\par "It may not be resolved here. But, do you know there are countries out there (India, Taiwan) that are saying, indeed, they will defy }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  restrictions (if necessary)," said federal health minister Ujjal Dosanjh, the mee}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing chair. "We couldn't be judgmental if people are dying in countries where they don't have the anti-virals and they don't have the resources."\par Taipei has asked Roche for a licensing deal. The firm recently suggested it might licence four generic firms to make the drug.\par "Right or wrong, we're going to commercialize and make oseltamivir (Tamiflu's generic name)," Dr. Yusuf K. Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of Bombay, told the New York Times Oct. 14.\par A pandemic has not broken out, but health experts warn one is inevitable, noting the deadly H5N1 strain, that led to the deaths of 140 million birds and more than 60 people since 2003, might mutate into one passed easily among humans.\par The two-day meeting of officials from 30 countries and groups like the World Health Organization, the Food and Agriculture Organization and the World Organization for Animal Health began yesterday evening. More coordinated global response to pandemic is a goal.\par An international food expert said yesterday much public discussion has dwelled on how to protect humans through anti-viral drugs and vaccines when development of the threat depends on how quickly world leaders mobilize resources and fight the problem at its source - in birds.\par Dr. Jacques Diouf, who directs FAO, the U.N. food agency, made an urgent appeal for wealthy nations to spend $150 million to $175 million on a three-year global plan to combat bird flu.\par The plan would provide bird testing and safety equipment, veterinary expertise and vaccines. "The econ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mies of those (largely Asian) countries have suffered greatly, with losses estimated at over $10 billion (U.S.)," Diouf told the ministers.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFECTIOUS DISEASE (91%); INFLUENZA (90%); PUBLIC HEALTH ADMINISTRATION (90%); HEALTH DEPARTMENTS (90%); EPIDEMICS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); PHARMACEUTICALS I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DUSTRY (89%); ANTIVIRALS (89%); AVIAN INFLUENZA (89%); TALKS & MEETINGS (78%); INTELLE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUAL PROPERTY (78%); AGRICULTURE DEPARTMENTS (74%); PHARMACEUTICAL PREPARATION MFG (72%); LICENSING AGREEMENTS (71%); VACCINES (70%); RELIEF ORGANIZATIONS (69%); LIVESTOCK DISEASE (69%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TAIPEI, TAIWAN (79%); MUMBAI, INDIA (56%) EUROPE (91%); SWITZERLAND (91%); INDIA (79%); ASIA (79%); TAIWAN (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 25, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DOCUMENT-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COLUMN\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWSPAPER\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Toronto Star Newspapers, Ltd.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Comment: Profit and the price of life: Pharmaceutical companies can save millions of lives but who will pick up the bill for the poor? The Observer October 23, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_173}{\*\bkmkstart DOC_ID_173_0}{\*\bkmkstart doc_id_35}{\*\bkmkend DOC_ID_173}{\*\bkmkend DOC_ID_173_0}{\*\bkmkend doc_id_35}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_35"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 35 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Observer\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  23, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Comment: Profit and the price of life: Pharmaceutical companies can save millions of lives but who will pick up the bill for the poor?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Mary Riddell\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Observer News Pages, Pg. 26\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1131 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  A WOMAN'S MUDDY corpse lies in an African morgue. A man's body is found lashed to a tree. The scene is set for The Constant Gardener , John le Carre's thriller about death, poverty and the pharmaceuticals i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dustry. Fernando Meirelles's movie, which launched the London Film Festival, opens at a curious moment.\par  The world is facing a possible pandemic. A parrot dies of avian flu in British quarantine. Governments scrabble for the drugs that may save their citizens if the deadly H5N1 strain mutates into a form that humans can pass on to one another. \par  Who lives and who dies may rest, to a large extent, on the behaviour of one company. Roche, the sole maker of the anti-viral drug, Tamiflu, is a reputable Swiss firm whose products, including the breast cancer treatment Herceptin, have saved or extended countless lives.\par  Roche bears no resemblance to le Carre's malign Big Pharma. It does, however, operate under the codes and customs that have helped make the industry to which it belongs among the wealthiest on the planet. Tamiflu was once a modest earner, selling at \u163\'a316.36 for a course of 10 tablets. By last week the drugs, the best treatment for bird flu, were going for more than \u163\'a3100 on eBay.\par  The first question is whether the disease is a real threat to humans. The inverse law of public panics is this: The bigger the fuss, the smaller the risk. Sars fizzled out, and MMR was proved last week to have no link with autism. Flu is different, though. A pandemic is overdue, and Sir Liam Donaldson, the unexcitable chief medical officer, says its arrival is a question of when, not if.\par  His estimate of a possible death toll of 50,000 is not very alarming, when 32,000 people die each winter for want of proper heating, but some think his guess conservative. Up to 40 million died across the world in the Spanish Flu of 1918, and the outbreaks of 1957 and 1968 were grim. The current panic, though, is driven not by arithmetic but by proximity.\par  H5N1 swept into the British media from nowhere. Within days, the hunt for protective masks was on and tourists' luggage was being searched, in case souvenir-hunters had abandoned their taste for rough local brandy and sombrero hats in favour of moribund poultry.\par  Surrey good-lifers rearing pullets on the lawn began to rue investing in an Eggloo. Forget the terror threat. If you swung a lightly-stunned White Leghorn on the Piccadilly Line, you could clear the London tube.\par  In fact, H5N1 has been on the move since 1997. More recently, bird flu has become endemic in parts of Southeast Asia, where almost 70 people have died after catching it from infected poultry. But it took the death of an Aegean turkey to make Britons panic. Which is where Tamiflu comes in.\par  UNTIL A vaccine gets produced, six months and untold deaths after any outbreak, the anti-viral drug is the best lifesaver on offer. The trouble is that there is not enough to go round. The World Health Organisation is advising governments to lay in enough to treat 25 per cent of all populations, but even the US has Tamiflu for fewer than 1 per cent. The waiting time for orders is 15 months, and, if Roche produced it at the current rate, it would take a decade to make enough for 20 per cent of the world's population.\par  Britain, with 14.6 million doses commissioned at a cost of \u163\'a3180m, is well-positioned, like many rich cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries. Poorer ones, much more likely to be devastated by any pandemic, are in trouble. Thailand has enough to treat only 62,000 of its 62m people. Meanwhile, Roche's sales over the last three months have risen 20 per cent to \u163\'a33.88 billion, on the back of bird flu fears and the colon cancer drug, Avastin. Those results fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lowed pleas from Kofi Annan and others that the company loosen its exclusive grip on Tamiflu.\par  Governments already have the powers, in a national emergency, to issue compulsory licences allowing their own companies to make any drug vital to public health. But such discretion is rarely invoked, maybe because few choose to push mighty drugs companies around. This time, with the world growing impatient and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian manufacturer, announcing that it would produce a generic version by next year, Roche seemed to accept that its gift of three million Tamiflu courses to the WHO was not enough.\par  Last week the company said it would consider relaxing, though not waiving, its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and granting Tamiflu licences to other companies. It is not clear, though, how far Roche will go in sharing its technology and clin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal trials data. Many lives may soon hang on that decision.\par  Or they may not, if no bird flu plague is imminent. But, whatever happens next, something significant is ha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pening. Roche's change of heart, in the face of world pressure, has a lesson beyond bird flu. There has been some tacit acknowledgment that great potential power over life and death should not reside in a single boardroom.\par  A myth has died and a precedent been set. Any notion that we would be back in the days of the Black Death unless pharmaceuticals could cling to exclusive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and make the maximum amount of money possible sounds hollow now. Obviously, drugs firms are risk-takers who need to make a decent profit. But, if one can rip up the rules, others can follow.\par  NO NEED to wait for a new pandemic. There are plenty out there. Millions are dying of Aids. Tuberculosis killed 1.75m in 2003. Many sufferers cannot afford, or find, the medicines that would save their lives. The answer, as Oxfam points out, is a tiered pricing system reflecting poor countries' ability to pay, a relaxation of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules and a move away from trade deals that stop poor countries getting cheap generics. In addition, companies should concentrate on cures for the killer diseases of the developing world rather than anti-baldness pills for the rich.\par  Such issues are not just for charities and bleeding hearts. From the leader columns of the Financial Times to the US Senate, there is unease at the imbalance, illustrated by the bird flu scare, between profit and the price of life. What's new? Drugs are expensive, and life is cheap. Catch the lecture at your local Odeon.\par  But le Carre's message, in The Constant Gardener , is not ultimately bleak. His Big Pharma, as he once wrote in an essay, 'offered everything; the hopes and dreams we have of it; its vast, partly realised potential for good; and its pitch-dark underside.'\par  The way is now open for drugs companies to accommodate the hopes and dreams, whether or not bird flu becomes a mass killer. A new climate of generosity could be trialled any time on people with malaria. The sooner the better. By this day next year, assuming nothing changes, another million will have died.\par  mary.riddell@observer.co.uk\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); INFLUENZA (90%); AVIAN INFLUENZA (90%); EP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DEMICS (89%); POULTRY (89%); LIVESTOCK DISEASE (89%); WOMEN'S HEALTH (78%); ANTIVIRALS (77%); CANCER DRUGS (77%); INFECTIOUS DISEASE (77%); CANCER (77%); DISEASES & DISO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DERS (76%); PHARMACEUTICAL PREPARATION MFG (74%); POVERTY & HOMELESSNESS (72%); ARTS FESTIVALS & EXHIBITIONS (72%); FILM (72%); BREAST CANCER (70%); AUTISM (69%); O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COLOGY (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAPER\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \u169\'a9 2005 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Call to break patents on flu treatment Australian Financial Review October 20, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_174}{\*\bkmkstart DOC_ID_174_0}{\*\bkmkstart doc_id_36}{\*\bkmkend DOC_ID_174}{\*\bkmkend DOC_ID_174_0}{\*\bkmkend doc_id_36}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_36"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 36 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Australian Financial Review\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2005 Thursday  \par First Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Call to break }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patents}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  on flu treatment}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Annabel Stafford\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEWS; Pg. 3\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 348 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Drug makers, including Australian firm Biota, are under pressure to allow generic-drug makers to produce their patented antiviral treatments to help meet the threat of the H5N1 avian bird flu. \par Pharmaceutical giant Roche has caved in to pressure to allow manufacturers to copy its antiviral drug Tamiflu, according to the latest edition of New Scientist.\par Roche backflipped after Indian company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  signalled its intention to manufacture a generic version of Tamiflu. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said it could make 1 million, 10-capsule courses a month by next July, the magazine reported. However, experiments published this year showed a course of Tamiflu had saved only half of infected mice.\par GlaxoSmithKline, which holds the exclusive licence for Australian-developed antiviral drug Relenza, "would have to look at the overall circumstances" before it decided to follow Roche and allow generic copies, health-care environment director Alex Gosman said.\par In any case, the manufacturing process to make Relenza was very complex, so it would be difficult for other companies to make. GSK announced this week it was re-opening an antiviral manufacturing facility in Me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bourne.\par Simon Tucker, vice-president of research at Biota - which developed Relenza- said Biota would "certainly talk to GSK about it" if GSK wanted to allow other companies to make the drug. But he said he could not comment on whether Biota would encourage a waiving of the licence, because it was in legal proceedings against GSK for what it viewed as GSK's failure to adequately market the drug.\par Meanwhile, drug developer CSL, which began human trials of a potential vaccine this month, said its bird flu vaccine was still some way off. Even if the current trials were successful, there would need to be others to test the vaccine in older people and children.\par Federal Health Minister Tony Abbott said this week that the government was considering providing all Au}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tralians with vaccinations against pandemic flu.\par However, he admitted yesterday that "there are no guarantees" that a vaccine would be available quickly enough to prevent a pandemic.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (95%); PHARMACEUTICALS INDUSTRY (93%); PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATION MFG (93%); INFLUENZA (92%); GENERIC DRUGS (91%); AVIAN INFLUENZA (91%); VACCINES (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); LIVESTOCK DISEASE (90%); EPIDEMICS (89%); BIOLOGICS MFG (89%); DRUG DESIGN & DISCOVERY (79%); PHARMACEUTICALS PRODUCT DEVELOPMENT (79%); DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASES & DISORDERS (79%); GENERIC PRODUCTS (78%); HOLDING COMPANIES (78%); HEALTH DEPARTMENTS (77%); PUBLIC HEALTH ADMINISTRATION (75%); RODENTS (74%); MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING FACILITIES (72%) Health/Drugs; Health/Diseases/Animal related/Avian Influenza/Bird Flu; Comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ny/BIOTA HOLDINGS LTD; Company/GlaxoSmithKline; Company/Hoffmann-La Roche/Roche\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (95%); GLAXOSMITHKLINE PLC (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (95%); GSK (NYSE) (90%); GSK (LSE) (90%); BIOC (EGX) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (57%) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (95%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (95%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MELBOURNE, AUSTRALIA (73%) AUSTRALIA (93%) Australia\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 5, 2012\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Fairfax Media Publications Pty. Limited\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK PREPARES TO CASH IN ON BIRD FLU FEARS The Independent (London) October 19, 2005, Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_175}{\*\bkmkstart DOC_ID_175_0}{\*\bkmkstart doc_id_37}{\*\bkmkend DOC_ID_175}{\*\bkmkend DOC_ID_175_0}{\*\bkmkend doc_id_37}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_37"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 37 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Independent (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005, Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GSK PREPARES TO CASH IN ON BIRD FLU FEARS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BY STEPHEN FOLEY\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 First Edition; BUSINESS; Pg. 60\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 474 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  GlaxoSmithKline, the UK's biggest pharmaceuticals company, is considering a dramatic expansion of pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duction of Relenza, a flu treatment, after fears of a bird flu pandemic prompted a dramatic rise in orders.\par  The company is hoping to benefit from the contingency plans of worried governments and corporations, as Roche, its Swiss rival, struggles to keep up with demand for Tamiflu, its flu treatment and the most widely regarded means of treating any outbreak of avian flu.\par  The Swiss company is likely to say today that it has witnessed a significant upswing in orders for Tamiflu, as it reports its latest quarterly results. It received US approval yesterday for a new Tamiflu manufacturing plant but was having to bat away growing calls for the company to give up }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and allow other pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cals companies to make the pills. \par  GSK's Relenza acts in a similar way to help fight the flu virus but is regarded as less reliable because it is inhaled not swallowed. That might mean people with breathing difficulties do not get the correct dose.\par  Many governments are likely to resist calls to stockpile GSK's drug because of this drawback and because neither drug is wholly effective, only lessening the symptoms if taken early enough. The UK Government is buying 14.6 million doses of Tamiflu, enough to treat a quarter of the population.\par  GSK said it was enjoying significant interest in Relenza and was talking to several governments about co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tributing to bird flu stockpiles. One City analyst said the company might see an additional $ 1.4bn (\u163\'a3800m) in annual sales of the drug when the new capacity comes on-stream.\par  The company made 11 million doses of Relenza last year and has invested in new equipment at several manufacturing sites, including at Montrose in Scotland, that will boost capacity to 31 million doses in 2007, with more to follow.\par  Michael Leacock, a drug sector analyst at Nomura, told clients: 'A major opportunity lies in the US, where the joint National Vaccination Advisory Committee and Advisory Committee for Immunization Practices mee}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing recommended that 133 million treatments of flu drugs be stockpiled in preparation for a possible pande}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic. We understand Roche can deliver only 10 million courses of its Tamiflu in 2005 and 12 million in 2006 to the US, despite its new US plant. Relenza is seen as an important back-up product in pandemic flu planning.'\par  Shares in Roche were among the best performers on the Swiss stock exchange yesterday because of i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vestor excitement over Tamiflu, but there are increasing calls for it to give up its monopoly on the product.\par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India's second-largest drug maker, will today put in a provocative request for a licence to make Tamiflu. Several US politicians have demanded Roche allow US companies to set up manufacturing plants.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (94%); LABORATOIRE GLAXOSMITHKLINE SAS (92%); ROCHE HOLDING AG (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (94%); GSK (LSE) (94%); BIOC (EGX) (94%); ROG (SWX) (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (94%); SIC2834 PHARMACEUTICAL PREPARATIONS (94%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UFACTURING (85%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (93%); UNITED STATES (90%); SWITZERLAND (79%); INDIA (74%); SCOTLAND (73%);   LONDON, ENGLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (93%); UNITED STATES (90%); SWITZERLAND (79%); INDIA (74%); SCOTLAND (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (93%); AVIAN INFLUENZA (93%); PHARMACEUTICALS INDUSTRY (92%); PHARMACEUTICAL PREPARATION MFG (92%); ANTIVIRALS (91%); EPIDEMICS (90%); INFECTIOUS DISEASE (89%); MANUFACTURING FACILITIES (88%); SALES FIGURES (78%); DISASTER PLANNING (78%); VACCINATION & IMMUNIZATION (78%); VACCINES (77%); INTERIM FINANCIAL RESULTS (75%); VIRUSES (71%); APPROVALS (70%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (69%); INDUSTRY ANALYSTS (69%); STOCK EXCHANGES (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Independent Print Ltd\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pressure on Roche to increase production of antiviral drug The Irish Times October 19, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_176}{\*\bkmkstart DOC_ID_176_0}{\*\bkmkstart doc_id_38}{\*\bkmkend DOC_ID_176}{\*\bkmkend DOC_ID_176_0}{\*\bkmkend doc_id_38}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_38"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 38 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Irish Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Pressure on Roche to increase production of antiviral drug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Ireland; Other Stories; Pg. 11\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 410 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Swiss drugmaker Roche, under pressure to increase output of its antiviral drug Tamiflu as avian flu reaches Europe, said yesterday that it would consider granting other firms licences to make the drug.\par In a move that echoes schemes to make expensive HIV/Aids treatments available in Africa, Roche said it would consider allowing companies and governments in developing nations to produce the drug in prepar}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion for a feared bird flu pandemic.\par "If a company believes that they have the ability to do this from start to finish we would discuss that with them," said David Reddy, head of the Swiss firm's production and sales of Tamiflu, in a telephone interview. \par Mr Reddy said the firm had not received any approaches by companies, and just one approach by an Asian government.\par He added, however, that Roche would be willing to discuss production with Indian generics maker }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  which has said it wants to make a copycat version of Tamiflu.\par Thailand also said earlier it would bypass Roche to make its own version of Tamiflu by next October.\par "Every country is queuing up to buy Tamiflu from Roche and we are afraid we won't be able to get enough drug when we need it. So we have to produce it ourselves," said Thawat Suntarjarn, head of Thailand's d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 partment of disease control.\par Tamiflu, known generically as oseltamivir, is the most effective antiviral drug currently available for avian flu and is one of a class of treatments recommended by the World Health Organisation (WHO) for use in the event of a flu pandemic.\par Roche has come under pressure in recent weeks to loosen its grasp on the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that protect the trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment, with calls from the United Nations to sweep away the commercial barriers to producing the drug.\par Mike Ryan, WHO director for epidemic and pandemic alert, yesterday said that supplies were clearly insuff}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cient to face up to a potential bird flu pandemic if the steadily-spreading avian virus jumps to humans.\par "Public health must overcome all obstacles in the trade and licensing area," Mr Ryan said, echoing recent comments by UN secretary general Kofi Annan.\par Mr Reddy said companies could collaborate in the Tamiflu manufacturing process in order to help lift overall output, or Roche could discuss granting rival companies or governments a licence to produce the drug from scratch. Governments are rushing to build stocks of the treatment, with 40 nations having placed bulk orders. - (Reuters)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (56%);   WORLD HEALTH ORGANIZATION  (54%); WORLD HEALTH ORGANIZATION (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (54%); WORLD HEALTH ORGANIZATION (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (92%); AFRICA (92%); THAILAND (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (92%); AFRICA (92%); THAILAND (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (94%); AVIAN INFLUENZA (91%); AIDS & HIV TREATMENT (90%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS INDUSTRY (90%); INFECTIOUS DISEASE (90%); INFLUENZA (90%); PHARMACEUTICAL PREPARATION MFG (90%); DISEASES & DISORDERS (89%); PUBLIC HEALTH ADMINISTRATION (89%); EPIDEMICS (89%); LIVESTOCK DISEASE (89%); HEALTH DEPARTMENTS (78%); VIRUSES (78%); INTERVIEWS (74%); AIDS & HIV (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (72%); UNITED NATIONS INSTITUTIONS (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DAVID REDDY (73%); MIKE RYAN (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The Irish Times\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche Offers To Negotiate On Flu Drug The New York Times October 19, 2005 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_177}{\*\bkmkstart DOC_ID_177_0}{\*\bkmkstart doc_id_39}{\*\bkmkend DOC_ID_177}{\*\bkmkend DOC_ID_177_0}{\*\bkmkend doc_id_39}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_39"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00330039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 39 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005 Wednesday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche Offers To Negotiate On Flu Drug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By JAMES KANTER; International Herald Tribune\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 5; Business/Financial Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 776 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARIS, Oct. 18 \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Facing pressure from governments seeking to fight a possible bird flu epidemic, the Swiss drug maker Roche said Tuesday that it was willing to negotiate to allow outside companies to make its drug Tamiflu, which has been shown to fight avian influenza.\par   Roche, which made a similar overture last week, has not yet reached any agreements to license the expe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sive drug so that generic manufacturers can make it for poor countries that cannot otherwise afford it. Some Asian governments, concerned that Roche will charge a high licensing fee for any production by other co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies, are threatening to disregard the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  if the fee is too high.\par  Roche is under pressure to expand supplies of Tamiflu after a strain of avian flu spread to Turkey and R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mania. The flu has already killed 60 people in Asia, who apparently contracted it directly from infected birds. Medical investigators have not yet determined if a bird found dead of avian flu in Greece had that strain, which is seen as a possible forerunner of a deadly strain transmissible from human to human. \par   In India, a drug maker, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , is seeking talks with Roche to secure licenses to make generic versions of Tamiflu, but has threatened to go ahead even without permission.\par   ''We believe that their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India are doubtful, but that is a contentious issue,'' a joint managing dire}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , Amar Lulla, told Bloomberg News. ''If they're willing to issue sublicenses, we'd be happy to go that route.'' \par   Taiwan's health minister, Hou Sheng-mou, said Monday that he had asked Roche for permission to man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facture Tamiflu. In the United States, Senator Charles E. Schumer, Democrat of New York, called on Roche Monday to work with other companies to expand production.\par   Roche said Tuesday that it had won approval from the United States Food and Drug Administration for ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sule production of Tamiflu at a new site in the United States.\par   Roche's shares rose 4.70 Swiss francs, or 2.5 percent, to end trading Tuesday in Zurich at 192.70 Swiss francs, after the news of a new American plant and on expectations that the company will announce robust quarterly sales figures.\par   Stewart Adkins, a pharmaceuticals industry analyst at Lehman Brothers in London, said he expected Roche to move quickly to license Tamiflu to poorer countries. He said Roche could ill afford the kind of negative publicity pharmaceutical companies drew at the beginning of the decade, when they sued South Africa for threatening to override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for drugs to treat H.I.V. \par   ''Roche is almost obliged morally to cross-license or transfer any technologies necessary in order to make Tamiflu available to countries most at risk,'' Mr. Adkins said.\par   Roche has sought to avoid an attempt by poorer countries, which may not be able to afford even a low price for millions of people, to override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Tamiflu as a way to pressure Roche to let the drug be copied for little money or nothing.\par   The company and some outside experts have said that the production of Tamiflu is so complex and time-consuming that even generic makers could not quickly expand global supplies. That contradicts the views of some countries, including Taiwan, that generic versions would not be nearly as hard to produce as Roche has maintained.\par   William Burns, chief executive of Roche's pharmaceuticals division, said Tuesday that the company was prepared to discuss sublicenses to increase the Tamiflu supply, ''provided such groups can realistically pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce substantial amounts of the medicine for emergency pandemic use, in accordance with appropriate quality specifications, safety and regulatory guidelines.''\par   Roche would probably seek deals with companies and governments that prevent re-exports of low-cost Tamiflu, Mr. Adkins said. The terms of those deals, he said, could include marking drug packages with hol}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams and coloring pills made under special licenses to make re-exported drugs easily traceable. Mr. Adkins said Roche was also likely to seek time limitations in licenses.\par   In a sign of surging demand for Tamiflu, bids for a single course of treatment on the Internet auction site eBay reached $182 on Tuesday before the auction was canceled, according to Reuters. Some 28 bids were received for the drug, which was advertised as being in Birmingham, England.\par   Tamiflu prices vary widely within Europe, where drug companies negotiate individually with governments. In Switzerland, Roche charges $61.50 for a five-day course. In Britain, Roche charges the government health service $28.70 for a five-day treatment, but ''the pandemic price is significantly lower for all governments,'' a Roche spokeswoman, Susie Hackett, said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (95%); AVIAN INFLUENZA (92%); DISEASES & DISORDERS (90%); ANTIVIRALS (90%); PHARMACEUTICALS INDUSTRY (90%); PHARMACEUTICAL PREPARATION MFG (90%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); LICENSING AGREEMENTS (89%); GENERIC PRODUCTS (89%); HEALTH DEPARTMENTS (78%); DRUG & MEDICAL DEVICES APPROVAL (78%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); EPIDEMICS (78%); SALES FIGURES (77%); PUBLIC HEALTH ADMINISTR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (73%); LEGISLATIVE BODIES (73%); US DEMOCRATIC PARTY (68%); US FDA APPROVALS (68%); APPROVALS (66%); INTERIM FINANCIAL RESULTS (60%); INDUSTRY ANALYSTS (60%) Terms not available from NYTimes\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (96%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (55%); BLOOMBERG LP (54%); LEHMAN BROT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERS HOLDINGS INC (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (96%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (96%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (96%); SIC2834 PHARMACEUTICAL PREPARATIONS (55%); NAICS519130 INTERNET PUBLISHING & BROADCASTING & WEB SEARCH PORTALS (54%); NAICS519110 NEWS SYNDICATES (54%); NAICS511120 PERIODICAL PUBLISHERS (54%); NAICS523110 INVESTMENT BANKING & SECURITIES DEALING (52%); SIC6211 SECURITY BROKERS, DEALERS, & FLOTATION COMPANIES (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CHARLES SCHUMER (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (79%); ZURICH (73%) UNITED STATES (92%); ASIA (92%); INDIA (90%); TURKEY (79%); SWITZERLAND (79%); TAIWAN (79%); GREECE (71%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SHORTAGE OF VACCINES LEAVES EU UNPREPARED FOR BIRD FLU ATTACK The Scotsman October 19, 2005, Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_178}{\*\bkmkstart DOC_ID_178_0}{\*\bkmkstart doc_id_40}{\*\bkmkend DOC_ID_178}{\*\bkmkend DOC_ID_178_0}{\*\bkmkend doc_id_40}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_40"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 40 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Scotsman\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005, Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 SHORTAGE OF VACCINES LEAVES EU UNPREPARED FOR BIRD FLU ATTACK}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Louise Gray\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 850 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  EUROPEAN Union ministers yesterday conceded the region was ill-prepared for a flu pandemic after it emerged that fewer than half of its 25 member nations had the recommended level of anti-viral drugs ready.\par  The admission followed a high-level meeting in Luxembourg at which the EU declared the spread of bird flu from Asia into the EU was a "global threat" requiring international co-operation.\par  Markos Kyprianou, EU health commissioner, said: "Anti-virals are the first line of defence, and vaccines are the second. We have to step up our manufacturing capacity. We have not reached the level of preparedness we should have." \par  The news came as Macedonia became the latest country to find evidence of the disease, a day after the first suspected case in the EU was uncovered in Greece.\par  Tests are also being carried out on birds found in Croatia and Bulgaria after the deadly H5N1 virus was found in Turkey and Romania earlier this week.\par  So far the virus has only killed 60 humans, all of whom came into close contact with poultry. But if it mutates to spread between humans, it could spark a global pandemic, killing millions worldwide including, some est}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mates claim, up to 50,000 Scots.\par  The World Health Organisation has recommended that governments stockpile enough anti-viral drugs to treat 25% of their population.\par  But the 25 member states, as well as Iceland, Norway and Liechtenstein, have only 10 million doses now for an area of almost 500 million people and will have only 46 million doses by the end of 2007.\par  The UK government is urgently stockpiling the anti-viral drug Tamiflu at the rate of 800,000 courses per month. Scotland is eventually to get 1.2 million courses.\par  The increasing demand for Tamiflu has brought pressure on Swiss drugmaker Roche - which holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to the drug - to grant a licence to other firms. Indian drugs firm }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is already seeking a licence. The Swiss company is also building a new plant in the United States to boost production.\par  EU ministers underlined the seriousness of bird flu and the threat it poses to animal and public health, d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 scribing it as "a global threat".\par  Mr Kyprianou said: "We cannot protect ourselves alone. There is need for international action and intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional solidarity with countries in Asia."\par  The H5N1 virus first appeared in Asia where it led to the deaths of tens of millions of birds. The westward spread of the virus is caused by the migration of birds.\par  The first case on mainland Europe was found in Turkey but the risks to Britain have moved closer with su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pected cases in Greece, Bulgaria and Croatia, and then Macedonia yesterday.\par  Samples from a suspect chicken on a farm in southern Macedonia have been sent to a laboratory in En}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 land. The authorities have quarantined the Macedonian village and set up a square-mile exclusion zone. They now plan to cull 10,000 chickens.\par  Most of the birds migrating to Scotland at this time of the year come from the north but there is a chance individual birds may pass through infected areas on their way to Scotland.\par  Tests are being carried out on ducks, geese and swans at Caerlaverock nature reserve on the Solway Firth. Birdwatchers have been urged to be alert for signs that avian flu has reached British shores.\par  Julian Hughes, head of species conservation at the Royal Society for the Protection of Birds, told the BBC: "Birds that are likely to show evidence of avian flu are going to be wildfowl - ducks and geese in the main.\par  "When people are out bird-watching in the countryside, if they do see anything out of the ordinary - a die-off of 20, 30 or 40 birds - that's the cue that something has gone wrong, and there is a government helpline that you can ring to report the incident."\par  However, Zsuzsanna Jakab, of the European Centre for Disease Prevention and Control, said the risk to human and animal health was "minimal" at this stage.\par  And Jack Straw, the Foreign Secretary, said the EU was well equipped to cope "swiftly and efficiently" in a pandemic.\par  "We want to reassure people across Europe about this - we are working together as closely as we can," he said.\par  Customs officials across the UK were on heightened alert yesterday for imports from any of the infected countries. Dog handlers were being asked to check parcels and baggage for imported birds - dead or alive - as well as eggs and feathers.\par  Patricia Hewitt, the Health Secretary, said the UK would continue to review its preparations, "so that as far as any country can be fully prepared against the risk of pandemic flu, we in the UK will be prepared".\par  But Patrick Mercer, Conservative homeland security spokesman, said that a single minister should be a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pointed to take responsibility for dealing with the threat of avian flu.\par  He warned that if the warning signs were not heeded, Europe could see a repeat of the 1918 flu pandemic, which killed up to 50 million people worldwide.\par  Mr Mercer told the BBC: "I'm not saying that is going to happen, but there are very dangerous signs."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (52%);   EUROPEAN UNION  (91%); EUROPEAN UNION (91%); WORLD HEALTH ORGANIZATION  (55%); WORLD HEALTH ORGANIZATION (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPEAN UNION  (91%); EUROPEAN UNION (91%); WORLD HEALTH ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION  (55%); WORLD HEALTH ORGANIZATION (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (94%); MACEDONIA (94%); EUROPEAN UNION (92%); CROATIA (92%); ASIA (92%); TURKEY (92%); UNITED KINGDOM (91%); GREECE (91%); SCOTLAND (91%); LUXEMBOURG (90%); BULGARIA (79%); NORWAY (79%); ROMANIA (79%); LIECHTENSTEIN (79%); NORTH AMERICA (79%); UNITED STATES (79%); ENGLAND (78%); ICELAND (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPEAN UNION MEMBER STATES (97%); MACEDONIA, THE FORMER YUGOSLAV REPUBLIC OF (94%); ASIA (94%); EUROPE (93%); CROATIA (92%); TURKEY (92%); GREECE (91%); LUXEMBOURG (90%); SCOTLAND (79%); ICELAND (79%); ENGLAND (79%); UNITED STATES (79%); ROMANIA (79%); NORWAY (79%); LIECHTENSTEIN (79%); UNITED KINGDOM (79%); BULGARIA (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPEAN UNION (94%); INFLUENZA (93%); ANTIVIRALS (92%); AVIAN INFLUENZA (91%); INFECTIOUS DISEASE (90%); HEALTH DEPARTMENTS (90%); VACCINES (90%); EPIDEMICS (90%); INTERNATIONAL ECONOMIC ORGANIZATIONS (90%); LIVESTOCK DISEASE (90%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS INDUSTRY (89%); PUBLIC HEALTH ADMINISTRATION (89%); ANIMAL QUARANTINE (89%); VIRUSES (89%); DISEASES & DISORDERS (77%); DRUG SHORTAGES (77%); BIRDS (76%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IMALS (76%); POULTRY (76%); PLANT CAPACITY (75%); PHARMACEUTICAL PREPARATION MFG (75%); TALKS & MEETINGS (74%); MANUFACTURING OUTPUT (70%); PLANT CONSTRUCTION (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAPER\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The Scotsman Publications Ltd.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Prostate surgery not too risky in healthy 70s St. Petersburg Times (Florida) October 19, 2005 Wednesday 0 South Pinellas Edition \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_179}{\*\bkmkstart DOC_ID_179_0}{\*\bkmkstart doc_id_41}{\*\bkmkend DOC_ID_179}{\*\bkmkend DOC_ID_179_0}{\*\bkmkend doc_id_41}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_41"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 41 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 St. Petersburg Times (Florida)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005 Wednesday 0 South Pinellas Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Prostate surgery not too risky in healthy 70s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SOURCE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Compiled from Times Wires\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NATIONAL; Pg. 6A\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 433 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WASHINGTON; SAN FRANCISCO\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Age alone doesn't make surgery for prostate cancer too risky, say researchers who found the treatment a safe option for otherwise healthy men up to age 79.\par Having heart disease or other serious ailments in addition to the cancer proved a bigger predictor of surgical complications than increasing age, Canadian researchers report in today's edition of the Journal of the N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional Cancer Institute.\par About 232,000 U.S. men will be diagnosed with prostate cancer this year, and 30,000 will die, the American Cancer Society estimates. \par Surgery often is recommended for younger men. If the tumor hasn't spread beyond the prostate, removing the walnut-sized gland offers the potential of a cure. But it can be a grueling operation, and carries its own long-term risks: impotence and incontinence.\par Older patients are less likely to undergo the surgery, called a radical prostatectomy. In one U.S. study, men under age 60 were 25 times more likely to have the surgery than those 70 or older. In Canada, less than 5 percent of patients in their 70s receive a prostatectomy.\par To determine if the surgery was a safe option for older patients, scientists at Toronto's University Health Network tracked 11,000 men who received a prostatectomy during the 1990s in Ontario.\par The study didn't examine long-term complications, or whether prostatectomy is the best treatment option for men in their 70s. After all, prostate cancer usually is very slow growing.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  \par Drug company promises new U.S. Tamiflu plant\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SAN FRANCISCO - Roche AG says it will build a U.S. plant to make more of its bird flu drug Tamiflu, but that promise failed to tamp growing international pressure on the Swiss drug giant to ease its monopoly on the drug.\par European Union foreign ministers on Tuesday called bird flu a global threat after the discovery of new cases in Greece, Romania and Turkey in recent days, which led to bans on poultry from those countries.\par Meanwhile, demand for Tamiflu is far outstripping Roche's ability to make it.\par Some 40 countries are scrambling to create Tamiflu stockpiles to treat millions if a pandemic occurs, and there's growing international pressure to ignore Roche's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights and manufacturer inexpensive generic versions.\par Thailand has announced its intentions to do just that and India-based }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. said it will be ready to ship generics next year, though it said Tuesday it will seek a license from Roche.\par The World Health Organization recommends governments keep enough antiviral drugs and regular human flu vaccines to inoculate at least 25 percent of their populations.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PROSTATE DISEASE (95%); SURGERY & TRANSPLANTATION (94%); PROSTATE CANCER (93%); MEN'S HEALTH (92%); DISEASES & DISORDERS (91%); CANCER (91%); UROGENITAL DISO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DERS & INJURIES (90%); MEN (90%); ANTIVIRALS (89%); AVIAN INFLUENZA (89%); LIVESTOCK DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASE (89%); INFLUENZA (86%); HEART DISEASE (78%); RESEARCH INSTITUTES (78%); VACCINES (78%); MEDICAL RESEARCH (78%); POULTRY (78%); HEALTH DEPARTMENTS (77%); EPIDEMICS (77%); GENERIC DRUGS (72%); UNITED NATIONS INSTITUTIONS (71%); PHARMACEUTICALS INDU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRY (70%); INFECTIOUS DISEASE (69%); PUBLIC HEALTH ADMINISTRATION (69%); MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING FACILITIES (69%); EUROPEAN UNION (67%); INTERNATIONAL RELATIONS (64%); STATE D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARTMENTS & FOREIGN SERVICES (63%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (60%); GENERIC PRODUCTS (60%); INCONT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NENCE (54%);  HEALTHBRFS19\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (83%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (80%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AMERICAN CANCER SOCIETY  (57%); NATIONAL CANCER INSTITUTE  (57%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL CANCER INSTITUTE (57%); AMERICAN CANCER SOCIETY (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (83%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (80%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (83%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (83%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (80%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TORONTO, ON, CANADA (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ONTARIO, CANADA (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CANADA (94%); UNITED STATES (92%); TURKEY (79%); EUROPE (77%); ROMANIA (72%); EUROPEAN UNION MEMBER STATES (67%); GREECE (67%); INDIA (67%); THAILAND (67%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SERIES: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IN BRIEF\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Times Publishing Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Swiss Firm May Cede Bird Flu Drug Rights The Washington Post October 19, 2005 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_180}{\*\bkmkstart DOC_ID_180_0}{\*\bkmkstart doc_id_42}{\*\bkmkend DOC_ID_180}{\*\bkmkend DOC_ID_180_0}{\*\bkmkend doc_id_42}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_42"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 42 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\shppict{\pict{\*\picprop\shplid1026{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLine}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw7620\pich2540\picwgoal4320\pichgoal1440\pngblip\bliptag657880520 89504e470d0a1a0a0000000d49484452000000d8000000480803000000a398cb9c00000300504c5445ffffff000000404040bfbfbf7f7f7fccccccefefef9900331010103030309f9f9f606060cfcfcfdfdfdf2020208f8f8f505050707070afafafd47d96c04064eabfcbde9baefaeff2b0103df4dfe5e5afbecb607ebb3057c55071b6204aefcfd8000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000335c3c3e00000c254944415478daed1b8972dbb6720192004f9152e2a449dad7ffffacccbc695ed234b12d89120f106f770152b41cc94ae31ef1043316491c8b5dec89050cf0a33cf1a256df079ef22bfb87f1fe49b22b11e99394432944004f5014950588bf335ea4615516ee35470a965fec54082c288b2af40aa7ce2ec30148faa000e797ac6b78f779a2aceeea0e958c485b49fc94274551c4f4c8e82b13893aa78f13903c7e4835b3f02205c76953ff3c594a798430972443a471e409c202ea83040951297e9ca66c06a488b1e7592f9189f012ba683ec94f7972ded44fcbbf811dabf7b5857d74d2a21bc6827e6f82654dfd4fda92ec00a41148dce61c5df505821844349f81889ef69404a4bbb13b7f75a9296dd4bba6061117f6cbe31045888cc29e3dc4921f274a7b0062642cc5ee0cce08440e0f1166878c61862d4ddfda934befa665c2cc629db6619dc79d28fa86b0175689d07819580c664e586b244d31ec67c8e451dc4e3ebc68208d3b06e28626a12486e5ccc57498702ad29046e5d837192457171e5011091c9946dd813043efdab4c6da117bb59838b48a0713c81c173bb632f2085728e429a40b7452d2691c49b2d79f60210ee68d75cce964307da1c2a24d0980fb176c87166a02a2c876641889a905a9464a76b5f0b88818df5905517d585cb06ae5142ae1bea5ef3b5a02320da4e9ac4239ce157a0bcc30726704e3c2732c8a6aa1827d8beb402b81c8c6720fbda2d50b871635c9ce38e61fd8d37fa9e216b96e338122921a56c4be9f80e8c034d0454604a8492adb62a34cf6b4dabb064c2f454be25c74ba05150f58b50f9301d5bccf0cf2ae91d24bbbd2c4cb0e2c48cfb1b26b90917261863c22fd8120dd6a037a88b6a328b690ec07eeee09eb15f2bd4fd7ca0e258ed60ef8b2812f101684db25a949278c2a36c6561d54f50148dc936c0dade52f1162cf6267d0716d169ae0c57b8b7d0de290234225926ca3c44a03ad6251174eac0abb6f79e691305c4eb3b4d8a88c685a94f024687716870c4337e371c10c3e882249177ea29404c45e6678ee5cc29128e6fc5e7183831190101f801490d0bb725f289024476e54e6c0f909f8b1724356ec21aa51d65173dde4c1248a214fced078a08af311f7d1782824bbf1ebe039266ccf9f64640cc921fd1db47ece3163c7eee0604469d864ed01c81e06078abf7ab62a7e94b523383244fcd8091e4256aff550dde2ab226ae71c6363d332341e882c95d6e1ce0b317aa7d3c56475e03dc17e78d8dfe4fd1aa086c72e2afe742eaed5d9cdd1fe6ab4bceb036647588581d7dfa431e2610c6eff9a60b63ebf56f75ac3794ce1e83a8a6e3259fbc6f5652808d5fc03517c1cadef6d5bd291c082deeaa3e0a7be6e2f868e56021643fb771325842e77f5fdfdd85ae35fb6d08b5b243ab4473bae0571711e73fa302d56b30f5f3643256efe7e6e0d99aabfb8d124a75fef424429b7461c730c370a72be5dda658a3eeb00294bb733bfadd055f72776141a238872fe41f1ca9d76450b358c2b386b536abefbb322d3f77671dbb03d06e5220f7282a64b068d91974cc8bfa56c8f537c357d26ec68114232a55d04e83fd1fff641431134ce96917d89f27013ec658615417c006221eea1af5ad5e2a0a423cf9df51471efd36ef21e5d35b05b513810a3d48222092dc91d2432e37830e98c73321d0e8d3590a797180f17611bda16fd97f51ea84fa4191cc7d6ce90ee2de219384b11393a7292cb5a4c8cee39a20bb621d5ef138a22142b26ce040dc63bb5311ba5bd19f5cbb82460379227199817b5b6c4b39d3ac8f68dd00902ddf773252535d88b4fced5ccb5c16c1285809a9d2df79bdc5863861007a2c4d10879d873ac62bfd30c79af865b54174460704781e8dc4dc5ecda69bb974edb447cc5fa2a8fab6cc19bd03b400a17f952178a49305e4dd54a615491a4dcbe1a27a1ba8513afc205e1e9340b6e9b29040a160b8a9cc7d09b86a924596253420383bc1477f7d7aa94386de642e974c9718b330fe551fe23afdc3a2f0f76a34c5d7d482bb1f4ebb09a0349b9b2c8d42c0322134581fd629c912165a392a96c36906c55ee0239a9b249e173d6fd55c900c68141f54076475cb05d7f30457406484ebc41c65f98f62a7c842abf1125158be5238441a781a8380890c1abaf58beaf22ec44ce2208e3ee9be3bd734054d060081c674d7ef934e4548a5339814bd75a3d46dc7a06482512cee57d4dc61c076489847f75099605edec931cbe8ab0eca164e9bfe58ce3ebe4422ee169961c7e14dac8ff58831fe547f9171529e4f782e99365c10fc2eefbcbb07c9a3a36db433f2d8e456366e4246cf90884a7f2cfa1f80dc1f22092ddd90e161e2175fa8dfbafbfc4dc3f4672814e8bbe5d14d5d33106248a01241bbf5d9ff2055853a09c65c3baa8a955852d587f3691a280c55857d460809a030153e3ea1660f14919846106d09606531d427290d386b2b6c9da8d27b8d3d879479e1e7be5b6c641c128d3af29f319bca3d797344cff46afaf7af8fd054e29dec3d580ccfadde511a4859c81a5bb25e726f32da4dbe5b5a7d1880149e6f3fe2df68d813397490da1412d0a8d48386bc1c9ee5c32a058dda228b883d621372ed599767c6e573ac471261cbfacf9604670867ad53b92f8306ec52d49edee124847faebf0bd73347f003c8b3e331c89a43ddbc0f38f446b177ea0caf203277370ac4bb326ade667d4814e6f28c31df45619ca51ef40146d977602fabea0e4725fb43c27fe743a6fb5e9025c9fbe066cd54de38e1e09e76cdb739de914a227a069633a85b7d2e0d0bde126a0a674dd424cf72c2ce5c86da3076d82c425c1dd21e58bcf5bb84a917bba8637d77b28aab4deef9e6d4986eae522adb7f11f58b985e6c5c65b04ce6a52da9612a68510552a4442ef41cc67ba319df1ca50713e05c0dd5360b50eddb5a39ceb173ea19b8d47d47432ecef37605dc5c7ccd4a3a403e6501cba670421e673e38a86212e39e48bd5dc785c69fdd315f1e597e7f042ebe7aff0fdd79fb5be82675affe725c02f5aeb5fb9df0baf346e024267e9ec5090f80c2ecd20099f6a4a1471fd02511909cb5dd649d2817838f96e4f5838dd70ac68d97ce257f9a6f00035f380dc3a07d3e5ab0361bf30dacc3af849ffec5e5ffda49f13612f1ce56fa8ee3ff420ab58172436a8cb05ecf8d29c40954a9cbe1a4ed49670333a5bc1f51b38b8b08dfbb1d04c46f660a1d3f13a039d99eec01f9db6776d32ae5a5843ba19073761a0e1737637c7f1f2033c7feb5e3fbcfe0cfe34fc5d07eb97e0f2a3088d55a99e30e961bdc259f5004d0a61c3b88c07472ce4750c76b7484fa6315dd979aae769d8f5e450d63167639ad9a0b1fb27c6683cf6c2c9db566aa8b7778ee5067775810b02f9edb036442319caf7f38979da5ac335ae6db229c9ce4171ef1a41bb438d5bef2e4e7f355fae3c7fee7ee728b48e2a0d767b3751dd3d38b13d72d068a5966bfc95b00fe9991c725dfe59df26487d716182ecb032fa70174ac1f16e600c080a3ec1cc0fb56888d69f87e04ec890ce84035b5e1d04263d1d7948629958c3a7827d2e6cf448bbe27554051fd93e707d0399ea57f87082128fa77be899ef31b249471986ae98567ba085c109db3e85d969dfdb9713d8d7c1414d0778f9f634617c4fabf2b24fef09acc3719de836eaf6a2a81897da1d6ad5331d6b52aecb075ab1e311ccce1ce9d8a09ebb03bb00bd5d5b6d4acf706f39d0ce6fe1fd1b67f78777056c9c497fb386edb9e89e42288a3a76bae10b615bdd984adee89019b63550add12beafdd91078bdbc5eeb7203f18c0093d53705425f5cc3173068e8509b9a42c018a34e445336384db889e136b4a21e8dc12b7bfbfce31f3ffffef1b9b491c020235a7ebe79633b317c84abff9e236c9db99b2f6d86a1053d73686e4846748c0f19ed6f485e1e8aec3f6735051df5fc82ea36ab2952bac660e6d37d8bda701324d814a63728781827215d3068bea7a7fd8cfd2ddd9ee98ab50bba96ff7bf7ebcbf71f9dfc77e7a37be9df8487b5192a1493a21a5a74dead090aba7e5863c8e044849e8a5ca7f215fc01db44b0e47a6bcece7c2b4b4d90a24f53158de7e740e7e9ba94b4a8ed7542a0e260407fb6a1b4834ea3b5032cafc8b4bcffc837e8afe804fd6d535214f2a2fc4846be7016aae01b38608bf91e2e806317f4d5a508262097fc47c59fdd695d5682630ff00d1bd661baf797f427af4bcf84e52fdd1b3f66fa6d31b9943d68f384f28ae8fd06f6b2a985efe57f7b2ecc28d1bf50846132deeef82775ec7161a7830b2ee26073016106ec77c3335556526697fdb7e39fcd18fe284fb3fc1f6304efb39e95003b0000000049454e44ae426082}}{\nonshppict{\pict\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw216\pich72\picwgoal4320\pichgoal1440\macpict\bliptag657880520 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004800d8001102ff0c00fffe0000004800000048000000000000004800d800000000001e0001000a00000000004800d882000000f39a0000000100000000000000000000000000000001000000000000000000000000000040000000000000000000000000000000000000000000004800d8000003000000000000000056726177200000000000000000000000006170706c000004000000040000d8004800480000004800000000f300000100000000000000000000000000000000000000000000000000000000000000000020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff202020ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff7f7f7fff505050ff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff606060ffdfdfdfffffffffffffffffffffffffffafafafff404040ffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff101010ffffffffffffffffff404040ff000000ff606060ffffffffffffffffffffffffffffffffff606060ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff606060ffffffffffffffffff9f9f9fffffffffffefefefff303030ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff303030ff606060ff404040ff000000ff606060ffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ffffffffff606060ff000000ff000000ff000000ff505050ffefefefffffffffff606060ff000000ff000000ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff303030ffefefefff404040ffefefefff303030ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff707070ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff202020ff000000ff000000ff000000ff000000ffbfbfbfff404040ff606060ff202020ff000000ff000000ff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff606060ffbfbfbfff707070ff101010ff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ffefefefff303030ff000000ff000000ff000000ff000000ff303030ffdfdfdfff303030ff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ff101010ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffefefefff202020ff000000ff000000ff000000ffbfbfbfff000000ff9f9f9fffefefefff303030ff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff8f8f8fffffffffff606060ff101010ffcfcfcfffffffffffcfcfcfff202020ff404040ff404040ff202020ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffefefefff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffefefefff202020ff000000ff000000ff000000ffbfbfbfffffffffffefefefff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff8f8f8fffffffffffffffffff9f9f9fffdfdfdfff404040ff000000ff000000ff404040ffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffcfcfcfff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff707070ffffffffffffffffffffffffffffffffff9f9f9fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff505050ffcfcfcfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff606060ffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff303030ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffefefefff707070ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffefefefffffffffffbfbfbfffbfbfbfffdfdfdfff303030ff000000ff000000ff303030ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffff505050ffffffffff606060ff000000ff9f9f9fffffffffff9f9f9fff202020ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff202020ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff101010ffbfbfbfffffffffffefefefffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff000000ff000000ff000000ff202020ffefefefff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffefefefffffffffffcfcfcfff101010ff000000ff606060ffefefefffafafafffffffffffefefefff202020ff000000ff404040ffefefefffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff101010ff9f9f9fffffffffffdfdfdfffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff303030ff000000ff303030ffefefefffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffcfcfcfff303030ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffefefefff707070ff000000ff000000ff000000ff000000ff000000ffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ff000000ff404040ffcfcfcfff303030ff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff303030ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff606060ff303030ffffffffffffffffffffffffff9f9f9fff101010ff101010ff000000ff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff202020ff9f9f9fff101010ff000000ff000000ff000000ff101010ff9f9f9fffefefefff303030ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ff000000ff000000ff404040ff505050ffffffffffffffffffffffffffefefefff707070ff101010ff000000ff000000ff000000ff000000ff404040ff101010ff7f7f7fff404040ff000000ff000000ff000000ff202020ff404040ffcfcfcfffffffffffffffffffefefefff606060ff101010ff000000ff000000ff000000ff000000ff7f7f7fff606060ffbfbfbfff303030ff000000ff000000ff000000ff202020ff7f7f7fff000000ff000000ff000000ff000000ff404040ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff9f9f9fff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffff8f8f8fff101010ff000000ff000000ff000000ff000000ff404040ff8f8f8fff7f7f7fffffffffffcfcfcfff202020ff101010ff000000ff000000ff000000ff000000ff7f7f7fffafafafff404040ff101010ff000000ff000000ff101010ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffbfbfbfff7f7f7fff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fffffffffffefefefff404040ff000000ff505050ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffbfbfbfff101010ff000000ffafafafff303030ff000000ff000000ff000000ff000000ffefefefffffffffffefefefff505050ff000000ff000000ffbfbfbfffafafafff7f7f7fff404040ff707070ffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fff101010ff404040ff000000ff000000ff000000ff404040ffffffffff404040ff606060ff000000ff000000ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff202020ffefefefffffffffffffffffffcfcfcfff303030ff000000ffafafafff505050ff000000ff000000ff000000ff000000ffcfcfcfffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffcfcfcfff202020ff000000ff7f7f7fff707070ff000000ff000000ff000000ff000000ff606060ff505050ff606060ff101010ff000000ff000000ff000000ff101010ff404040ff000000ff000000ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffefefefff505050ff000000ff000000ffafafafff101010ff000000ff000000ff000000ff202020ffefefefff7f7f7fff000000ff000000ff7f7f7fffcfcfcfff7f7f7fff606060ff303030ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffffffffff101010ff000000ff000000ffbfbfbfff303030ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff505050ff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffbfbfbfff303030ffefefefffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffff303030ff000000ff000000ff404040ffffffffffefefefffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffefefefff202020ff000000ff000000ff404040ffffffffffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffafafafff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffffafafafff000000ff000000ff000000ffafafafffffffffff505050ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffcfcfcfff202020ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffffefefefff101010ffcfcfcfffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffefefefff202020ff8f8f8fffbfbfbfffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff707070ff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffff505050ff606060ffbfbfbfffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff7f7f7fff606060ffbfbfbfff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff8f8f8fff606060ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fffafafafffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfff7f7f7fff202020ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffefefefffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff9f9f9fffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffcfcfcfff505050ff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff202020ff505050ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff404040ff101010ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff303030ff202020ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff202020ffffffffffbfbfbfff000000ff000000ff202020ffdfdfdfffffffffff404040ffffffffff404040ff7f7f7fff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffcfcfcfff404040ff404040ff000000ff8f8f8fffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff404040ff101010ff505050ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff000000ff000000ff606060ff707070ff101010ff8f8f8fffffffffffffffffffffffffff404040ff7f7f7fff000000ffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffafafafffffffffffffffffffffffffffcfcfcfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff404040ff000000ff000000ff000000ff606060ffefefefffffffffff000000ff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffafafafff404040ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffdfdfdfff202020ffefefefffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffffffffffcfcfcfff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff101010ff9f9f9fffffffffffefefefff202020ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff000000ff606060ffefefefff202020ff000000ff000000ff000000ff000000ff303030ffefefefff000000ff000000ff606060ffffffffffffffffffbfbfbfff000000ff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ffefefefffffffffffefefefffdfdfdfff202020ffdfdfdfffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffbfbfbfff000000ff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff606060ffffffffffefefefffefefefff000000ff000000ff000000ff404040ffefefefffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff000000ff000000ff000000ffbfbfbfff000000ff000000ff606060ff9f9f9fff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffffffffff404040ffafafafffffffffffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff303030ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ff404040ff101010ff000000ff000000ff000000ffbfbfbfff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff000000ff000000ff000000ff606060ff303030ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff101010ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff606060ff303030ff000000ff000000ff000000ff101010ff505050ff8f8f8fff404040ff606060ff7f7f7fff7f7f7fffdfdfdfff404040ff000000ff000000ff7f7f7fff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff303030ff000000ff000000ff000000ff505050ff101010ff9f9f9fff101010ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff000000ff606060ff101010ff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fff404040ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff000000ff505050ff303030ff7f7f7fff000000ff000000ff000000ff000000ff303030ffcfcfcfff000000ff000000ff404040ffefefefffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefff7f7f7fff000000ff000000ff000000ff303030ff303030ffafafafffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffefefefff303030ff000000ff000000ff000000ff101010ff9f9f9fff404040ff000000ff202020ffcfcfcfffffffffff7f7f7fff404040ff7f7f7fff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff404040ffffffffffffffffff404040ff000000ff000000ff000000ff303030ff303030ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffff9f9f9fff000000ff000000ff000000ff000000ff8f8f8fffbfbfbfff000000ff000000ff000000ffbfbfbfff8f8f8fffdfdfdfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff606060ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffdfdfdfff707070ff606060ff000000ff000000ff000000ff000000ff707070ff101010ff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ff000000ff101010ff101010ffbfbfbfffffffffff9f9f9fff000000ff000000ff000000ff000000ff7f7f7fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff707070ff202020ff000000ff000000ff000000ff000000ff9f9f9fffcfcfcfff101010ff000000ff000000ff000000ff303030ffffffffff707070ff000000ff000000ff000000ff000000ff8f8f8fff303030ff202020ff000000ff000000ff000000ff000000ff101010ff000000ff000000ff000000ffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff9f9f9fff606060ff9f9f9fff303030ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefffafafafff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffff8f8f8fff8f8f8fff505050ff000000ff000000ff000000ff000000ff000000ff505050ffefefefffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff404040ffffffffffffffffffffffffffefefefff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff9f9f9fffffffffffcfcfcfff101010ff000000ff505050ffcfcfcfff101010ff505050ff606060ff202020ff000000ff000000ff505050ffefefefffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffdfdfdfffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffcfcfcfff101010ff000000ff303030ffefefefffffffffffffffffff707070ff000000ff000000ff9f9f9fffefefefffafafafffefefefff505050ff000000ff000000ff303030ff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffafafafffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff202020ffcfcfcfffffffffffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff606060ff303030ff000000ff000000ff000000ffbfbfbfff202020ff202020ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff8f8f8fffffffffffffffffffefefefff303030ff303030ff707070ff303030ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffbfbfbfffcfcfcfff8f8f8fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff404040ff101010ff000000ff303030ff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff8f8f8fff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff505050ffefefefffffffffffffffffffffffffffffffffffffffffff707070ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff9f9f9fffffffffffffffffffffffffffcfcfcfff505050ffefefefff7f7f7fffbfbfbfffffffffffffffffffefefefff707070ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffff404040ff303030ffefefefffdfdfdfff101010ff000000ff000000ff202020ffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ffcfcfcfffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffefefefff606060ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ffcfcfcfffffffffffffffffffffffffffafafafff8f8f8fffffffffffffffffffffffffff9f9f9fff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff202020ffcfcfcfffffffffffffffffffefefefff303030ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ffbfbfbfffbfbfbfffbfbfbfffffffffffffffffffafafafff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff101010ff8f8f8fff303030ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff303030ff404040ff000000ff000000ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff606060ff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff707070ffdfdfdfffffffffffffffffffcfcfcfff303030ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff606060ffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff7f7f7fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffffffffffffffffffefefefff9f9f9fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffff404040ff000000ff404040ffffffffff9f9f9fff7f7f7fff7f7f7fff7f7f7fffcfcfcfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffbfbfbfff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fffafafafffffffffffefefefffbfbfbfffbfbfbfffefefefffefefefffbfbfbfff000000ff000000ff606060ffbfbfbfffcfcfcfffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffdfdfdfffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffcfcfcfff606060ff000000ff000000ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffd47d96ffd47d96ffd47d96ffde9baefff4dfe5fffffffffffffffffffffffffffffffffffffffffffaeff2ffde9baeffd47d96ffd47d96ffd47d96ffe5afbefffffffffffffffffffffffffffffffffffffffffff4dfe5ffeabfcbffeabfcbffffffffffde9baeffd47d96ffd47d96ffde9baefffaeff2ffffffffffffffffffeabfcbffd47d96ffd47d96ffd47d96ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ffafafafffffffffffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffff707070ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff606060ffffffffffffffffff404040ff000000ff303030ff303030ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ff606060ff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffcfcfcfff202020ff000000ff000000ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffffffffffffffffffff000000ff000000ff505050ff202020ff000000ff000000ff000000ff000000ff000000ffafafafffffffffffffffffff7f7f7fff000000ff000000ffafafafff101010ff000000ff000000ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffafafafff202020ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffb6204aff990033ff990033ff990033ff990033ff990033ff990033ffd47d96ffffffffffffffffffffffffffd47d96ffb0103dff990033ff990033ff990033ff990033ff990033ffb0103dffe5afbeffffffffffffffffffffffffffd47d96ff990033ff990033ffcb607eff990033ff990033ff990033ff990033ffb6204afff4dfe5ffc55071ff990033ff990033ff990033ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffff202020ff000000ff505050ffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffdfdfdfff505050ff000000ff000000ff000000ff404040ff606060ff303030ff000000ff000000ff101010ff000000ff404040ffffffffffffffffff606060ff000000ff000000ff404040ff202020ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff202020ff606060ff404040ff000000ff000000ff000000ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff000000ff101010ff505050ff404040ff101010ff000000ff000000ffbfbfbfffffffffffffffffffcfcfcfff101010ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffcfcfcfff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff000000ff000000ff000000ff000000ff303030ff505050ff303030ff000000ff000000ff101010ffefefefffffffffff7f7f7fff000000ff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff000000ff303030ff505050ff404040ff000000ff000000ff000000ff606060ffffffffffffffffffffffffff101010ff000000ff101010ff404040ff101010ff000000ff101010ffdfdfdfff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ff990033ffbb3057ffcb607effc04064ff990033ff990033ffc04064ffffffffffffffffffcb607eff990033ff990033ff990033ffc04064ffc55071ffbb3057ff990033ff990033ff990033ffde9baeffffffffffffffffffd47d96ff990033ff990033ff990033ffb0103dffc55071ffbb3057ff990033ff990033ffb0103dff990033ff990033ffc04064ffc55071ff990033ff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffffffffffffffffffdfdfdfff000000ff000000ff505050ff9f9f9fff000000ff000000ff303030ffdfdfdfffffffffffffffffffffffffffbfbfbfff101010ff000000ff000000ff404040ffffffffffffffffff101010ff000000ff7f7f7fffffffffffefefefff404040ff7f7f7fffefefefffffffffff404040ff000000ff000000ff606060ffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff303030ffefefefffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffefefefff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff606060ff000000ff000000ff505050ffffffffffffffffff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffff8f8f8fff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff606060ffffffffffcfcfcfff000000ff000000ff101010ffbfbfbfffffffffffffffffffffffffffefefefff505050ff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ffcfcfcfffffffffffcfcfcfff202020ffafafafffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffb0103dffeabfcbfffffffffffffffffffffffffffaeff2ffc55071ffc04064ffffffffffde9baeff990033ff990033ffc04064fff4dfe5ffffffffffffffffffffffffffefcfd8ffbb3057ff990033ff990033ffeabfcbffffffffffd47d96ff990033ff990033ffb6204afffaeff2ffffffffffffffffffc55071ff990033ff990033ff990033ffefcfd8ffffffffffffffffffeabfcbff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff707070ffffffffffffffffffffffffff7f7f7fff000000ff000000ffbfbfbfff303030ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffffffffffffffffff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefffffffffffffffffffffffffffffffffff202020ff000000ff606060ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffafafafff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ffdfdfdfffffffffff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefff606060ff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffbfbfbfff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc55071ff990033ff990033ffefcfd8ffffffffffffffffffffffffffffffffffffffffffffffffffde9baeffffffffffb0103dff990033ffbb3057fffffffffffffffffffffffffffffffffffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffd47d96ff990033ff990033ffde9baeffffffffffffffffffffffffffeabfcbff990033ff990033ffcb607effffffffffffffffffffffffffffffffffb6204aff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff202020ffffffffffffffffffdfdfdfff000000ff000000ff202020ff000000ff101010ffffffffffffffffffefefefff101010ff000000ff404040ffefefefff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff404040ffffffffffffffffff505050ff000000ff000000ff404040ff9f9f9fffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff606060ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff202020ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff7f7f7fffffffffff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffefefefff101010ff000000ff000000ff606060ffcfcfcfffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffffffffffffffffffffffffffaeff2ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033fffaeff2ffd47d96ff990033ff990033fff4dfe5fffffffffffffffffffffffffffaeff2ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffafafafffffffffff7f7f7fff000000ff101010ffcfcfcfff000000ff000000ff9f9f9fffffffffff9f9f9fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff202020ff9f9f9fffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff505050ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff9f9f9fff101010ff000000ff000000ff000000ff404040ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff404040ffffffffff202020ff000000ff707070ffffffffff505050ff000000ff303030ffffffffff202020ff000000ff202020ffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffff9f9f9fff202020ff000000ff000000ff000000ff707070ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffdfdfdfff707070ff101010ff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff707070ff000000ff000000ffdfdfdfffffffffffafafafff000000ff000000ff7f7f7fff000000ff000000ff9f9f9fffffffffffcfcfcfff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ffdfdfdfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff707070ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff707070ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffefefefff7f7f7fff000000ff000000ff303030ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffefcfd8ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ffefcfd8ffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff000000ff000000ff404040ffffffffffffffffffffffffff202020ff000000ff000000ff000000ff202020ffffffffffffffffffffffffff101010ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff404040ffffffffffffffffffefefefffdfdfdfffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff8f8f8fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff505050ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfff202020ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffdfdfdfffffffffffffffffffffffffffffffffff606060ff000000ff000000ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffb6204aff990033ffb6204affffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbefff4dfe5ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc04064ff990033ffb6204affffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ffafafafffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffff707070ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ff404040ffffffffff8f8f8fff101010ff404040ffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffdfdfdfff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ff505050ffefefefffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff202020ffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff202020ffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffefefefff505050ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff101010ffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffaeff2ffeabfcbffffffffffffffffffd47d96ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffeabfcbffb0103dffffffffffc04064ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffcb607eff990033ff990033ffd47d96ffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffefefefffffffffffffffffffffffffffefefefff101010ff000000ff000000ff505050ffafafafffbfbfbfff9f9f9fff202020ff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff505050ffbfbfbfff9f9f9fff101010ff000000ff101010ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff707070ff000000ff000000ff101010ff8f8f8fffbfbfbfffbfbfbfff606060ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffff606060ff000000ff000000ff202020ff8f8f8fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ff101010ff7f7f7fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffafafafffffffffffffffffff404040ff000000ff000000ff303030ff9f9f9fffbfbfbfffafafafff606060ff000000ff000000ff101010ffcfcfcfffffffffff202020ff000000ff000000ff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff606060ffffffffff7f7f7fff000000ff000000fffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffffffffffbb3057ff990033ff990033ffc04064ffde9baeffeabfcbffe5afbeffcb607eff990033ff990033fffffffffff4dfe5ffb0103dff990033ff990033ffcb607effe5afbeffeabfcbffde9baeffc04064ff990033ff990033ffbb3057ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff000000ff101010ff505050ff000000ff404040ffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffafafafffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffffeabfcbff990033ff990033ff990033fffffffffffffffffffaeff2ffc04064ff990033ff990033ff990033ff990033ff990033ff990033ff990033ffb0103dffffffffffffffffffefcfd8ffb6204aff990033ff990033ff990033ff990033ff990033ff990033ff990033ffc04064fffaeff2ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ffefefefffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ff202020ff000000ff000000ff202020ff707070ffefefefff9f9f9fff404040ff707070ffffffffffffffffffefefefff7f7f7fff202020ff000000ff000000ff303030ffbfbfbfffffffffffffffffff707070ff404040ff707070ffffffffffffffffffffffffffffffffffffffffff707070ff404040ff707070ffffffffff9f9f9fff404040ff404040ffffffffffffffffff9f9f9fff404040ff707070ffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffff9f9f9fff404040ff000000ff000000ff000000ff505050ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffbfbfbfff505050ff101010ff000000ff000000ff202020ff707070ffdfdfdfffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffff707070ff404040ff9f9f9fffffffffff7f7f7fff000000ff000000ffffffffff9f9f9fff303030ff000000ff000000ff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff505050ff000000ff000000ff000000ff303030ff7f7f7fffefefefffffffffffffffffffffffffffffffffffcfcfcfff505050ff000000ff000000ff101010ff606060ffdfdfdfffffffffffffffffff9f9f9fff404040ff404040fffffffffffffffffffaeff2ffbb3057ff990033ffd47d96ffffffffffffffffffffffffffffffffffde9baeffc04064ff990033ff990033ff990033ffbb3057ffd47d96fffaeff2fffffffffffffffffffffffffffaeff2ffde9baeffbb3057ff990033ff990033ff990033ffc55071ffde9baeffffffffffffffffffffffffffffffffffde9baeffc04064ffc04064ffffffffffffffffffffffffffffffffffffffffffc04064ffc04064ffefcfd8ffffffffffffffffffffffffffffffffffd47d96ffc04064ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffcfcfcfffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff505050ff7f7f7fff7f7f7fff303030ff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff505050ff404040ff404040ff606060ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000700ae00700007000100010003000300040000000d000c001000d800d800d800d800280018003610517569636b54696d65aa20616e6420610000280024003f0d206465636f6d70726573736f7200280030000f1f617265206e656564656420746f20736565207468697320706963747572652e000000a100e007ac00000000000007a86170706c022000006d6e74725247422058595a2007d900020019000b001a000b616373704150504c000000006170706c000000000000000000000000000000000000f6d6000100000000d32d6170706c00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000b64657363000001080000006f6473636d000001780000056c63707274000006e400000038777470740000071c000000147258595a00000730000000146758595a00000744000000146258595a0000075800000014725452430000076c0000000e636861640000077c0000002c625452430000076c0000000e675452430000076c0000000e64657363000000000000001447656e65726963205247422050726f66696c6500000000000000000000001447656e65726963205247422050726f66696c6500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000006d6c7563000000000000001e0000000c736b534b00000028000001786872485200000028000001a06361455300000024000001c87074425200000026000001ec756b55410000002a0000021266724655000000280000023c7a685457000000160000026469744954000000280000027a6e624e4f00000026000002a26b6f4b5200000016000002c86373435a00000022000002de6865494c0000001e00000300646544450000002c0000031e68754855000000280000034a7376534500000026000002a27a68434e00000016000003726a614a500000001a00000388726f524f00000024000003a2656c475200000022000003c67074504f00000026000003e86e6c4e4c000000280000040e6573455300000026000003e874685448000000240000043674725452000000220000045a66694649000000280000047c706c504c0000002c000004a47275525500000022000004d06172454700000026000004f2656e555300000026000005186461444b0000002e0000053e005601610065006f006200650063006e00fd0020005200470042002000700072006f00660069006c00470065006e006500720069010d006b00690020005200470042002000700072006f00660069006c00500065007200660069006c0020005200470042002000670065006e00e800720069006300500065007200660069006c0020005200470042002000470065006e00e9007200690063006f0417043004330430043b044c043d043804390020043f0440043e044404300439043b002000520047004200500072006f00660069006c0020006700e9006e00e9007200690071007500650020005200560042901a75280020005200470042002082725f6963cf8ff000500072006f00660069006c006f0020005200470042002000670065006e0065007200690063006f00470065006e0065007200690073006b0020005200470042002d00700072006f00660069006cc77cbc1800200052004700420020d504b85cd30cc77c004f006200650063006e00fd0020005200470042002000700072006f00660069006c05e405e805d505e405d905dc0020005200470042002005db05dc05dc05d90041006c006c00670065006d00650069006e006500730020005200470042002d00500072006f00660069006c00c1006c00740061006c00e1006e006f00730020005200470042002000700072006f00660069006c666e901a0020005200470042002063cf8ff065874ef64e00822c0020005200470042002030d730ed30d530a130a430eb00500072006f00660069006c0020005200470042002000670065006e0065007200690063039303b503bd03b903ba03cc002003c003c103bf03c603af03bb002000520047004200500065007200660069006c0020005200470042002000670065006e00e9007200690063006f0041006c00670065006d00650065006e0020005200470042002d00700072006f006600690065006c0e420e1b0e230e440e1f0e250e4c002000520047004200200e170e310e480e270e440e1b00470065006e0065006c0020005200470042002000500072006f00660069006c00690059006c00650069006e0065006e0020005200470042002d00700072006f006600690069006c00690055006e006900770065007200730061006c006e0079002000700072006f00660069006c0020005200470042041e04310449043804390020043f0440043e04440438043b044c00200052004700420645064406410020062a06390631064a0641002000520047004200200627064406390627064500470065006e00650072006900630020005200470042002000500072006f00660069006c006500470065006e006500720065006c0020005200470042002d006200650073006b0072006900760065006c007300657465787400000000436f707972696768742032303037204170706c6520496e632e2c20616c6c207269676874732072657365727665642e0058595a20000000000000f35200010000000116cf58595a20000000000000744d00003dee000003d058595a200000000000005a750000ac730000173458595a20000000000000281a0000159f0000b83663757276000000000000000101cd0000736633320000000000010c42000005defffff326000007920000fd91fffffba2fffffda3000003dc0000c06c00a100e000040000000200ff}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The Washington Post\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2005 Wednesday  \par Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Swiss Firm May Cede Bird Flu Drug Rights}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Marc Kaufman, Washington Post Staff Writer\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A Section; A13\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 692 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The manufacturer of the leading drug against avian flu said yesterday it was willing to discuss arrangements for other companies to produce it despite having an exclusive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . \par  A spokeswoman for Roche Holding AG, a Swiss multinational company, said it might agree to allowing both governments and companies to produce the antiviral drug Tamiflu under sub-licensing agreements. \par  The statement came on the same day that Sen. Charles E. Schumer (D-N.Y.) called on Roche to reach an agreement within the next month to permit five American companies to manufacture Tamiflu, or face legisl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion that would strip the company of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Schumer and others have criticized the pace of Roche's e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 forts to meet fast-growing world demand for its product.  \par  "Roche is putting their own interests ahead of world health," Schumer said. "If they don't begin to actually license the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Tamiflu to dramatically increase worldwide production, I am going to pursue a legisl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive remedy a month from today." \par  Officials at the World Health Organization have also indicated concern over the lagging supply of Tamiflu and have referred to the right of nations under international trade treaties to break }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  during health emergencies. \par  Also yesterday, European foreign ministers declared avian flu a global threat; it has been discovered in m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grating water fowl in Greece, Romania and Turkey. The especially dangerous flu has been spreading through the bird population in Asia since 2003 and has infected 117 people, killing at least 60. Health experts fear the virus, which until now has mostly passed directly from birds to humans, could evolve in ways that would allow it to pass easily from human to human, setting the stage for a pandemic that could put millions of people at risk. \par  E.U. health and safety commissioner Markos Kyprianou said most European countries did not have suff}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cient stockpiles of antiviral drugs. \par  "We have not yet reached the level of preparedness that we should have," he said after an emergency meeting in Luxembourg. "This is a global threat, and there is need for international action." \par  Roche officials said the company planned to sharply increase production of the drug worldwide and had r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceived approval to build a new Tamiflu manufacturing plant in the United States. They also said Roche was willing to discuss granting sub-licenses to any government or private company interested in manufacturing Tamiflu or collaborating in its production. Roche had said previously that making Tamiflu was a complex pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess that would take generic drug makers at least two or three years to master. \par  So far, only Taiwan has sent a letter to Roche asking permission to manufacture Tamiflu. But the Indian drug maker }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. announced yesterday that it was seeking a license from Roche to produce a generic version. A }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  spokesman said the company believed it could begin to produce inexpensive versions of the drug by early next year. Tamiflu currently costs $60 for a course of treatment. \par  The government of Thailand, which is near the center of the flu epidemic in birds, has also said it was co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sidering manufacturing its own supply of Tamiflu. \par  The issue of international drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement is a contentious one  --  with public health advocates still angry over the slow pace at which AIDS drugs were made available to poor people in underdeveloped parts of the world, and drug makers adamant that effective }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection is essential to the development of new drugs. \par  Until this year, Indian drug companies did not abide by many international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and produced una}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 proved versions of many medications for distribution to poorer nations. India's entry into the World Trade O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganization has largely ended that practice, leaving many nations without the resources to pay for drugs like Tamiflu. \par  The Bush administration has secured delivery of about 4.3 million doses of Tamiflu and has about 8 million more doses on order. The government has also signed a $100 million contract with the French company Sanofi Pasteur to develop a bird flu vaccine. \par  Correspondent Doug Struck in Toronto contributed to this report. \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AVIAN INFLUENZA (92%); INFLUENZA (91%); HOLDING COMPANIES (90%); ANTIVIRALS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); BIRDS (90%); PHARMACEUTICALS INDUSTRY (89%); LICENSING AGRE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENTS (89%); PHARMACEUTICAL PREPARATION MFG (89%); GENERIC DRUGS (89%); HEALTH D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARTMENTS (78%); EPIDEMICS (78%); TALKS & MEETINGS (78%); INTELLECTUAL PROPERTY LAW (77%); TRADE TREATIES & AGREEMENTS (77%); US DEMOCRATIC PARTY (76%); STATE DEPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENTS & FOREIGN SERVICES (76%); MANUFACTURING FACILITIES (73%); APPROVALS (72%); MULTINATIONAL CORPORATIONS (72%); INTERNATIONAL RELATIONS (72%); TREATIES & AGRE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENTS (71%); INFECTIOUS DISEASE (69%); PUBLIC HEALTH ADMINISTRATION (68%); INTERN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL TRADE (67%); UNITED NATIONS INSTITUTIONS (67%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (96%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (80%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (96%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (80%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (96%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (96%); SIC2834 PHARMACEUTICAL PREPARATIONS (80%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CHARLES SCHUMER (75%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (92%); EUROPE (79%); ASIA (79%); TURKEY (79%); GREECE (74%); LUXEMBOURG (69%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 19, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The Washington Post\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Roche pressed to let others make Tamiflu USA TODAY October 18, 2005, Tuesday, \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_181}{\*\bkmkstart DOC_ID_181_0}{\*\bkmkstart doc_id_43}{\*\bkmkend DOC_ID_181}{\*\bkmkend DOC_ID_181_0}{\*\bkmkend doc_id_43}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_43"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 43 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 USA TODAY\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2005, Tuesday, FINAL EDITION\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Roche pressed to let others make Tamiflu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Julie Schmit\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MONEY; Pg. 3B\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 349 words\par \par Pressure is building on drugmaker Roche to let other companies make Tamiflu, the anti-viral drug seen as the first defense against a potential avian flu pandemic.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sen. Charles Schumer, D-N.Y., Monday asked the Swiss company to temporarily suspend its Tamiflu }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , which runs through 2016, and license the drug to other makers within a month.\par Roche had no comment but had said Friday that it intends to remain Tamiflu's sole maker and that it's loo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing into ways to expand production. Because Tamiflu is hard to make, Roche says, a new drugmaker would need three years to produce Tamiflu.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Schumer says companies in Taiwan and India are prepared to begin production. A major Indian generic-drug maker, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said last week it could produce some Tamiflu by January and would sell it in countries where product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are not recognized.\par Anti-viral drugs reduce the severity of flu symptoms. Roche has not revealed how much Tamiflu it produces, but it says it doubled capacity last year and will do so this year.\par However, governments have ordered far more than Roche can quickly make, and the World Health Organ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zation is also talking with Roche about how production can be increased, Reuters reported Monday.\par The pressure on Roche is similar to that Bayer faced in 2001 over its antibiotic Cipro after anthrax scares in the USA. Bayer ended up tripling production and lowered the price of the drug.\par While generic-drug makers cannot legally sell a patented drug in many countries, the U.S. government and others can cancel }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in emergencies. David Maris, drug analyst with Banc of America Securities, said he cannot recall such a case in recent decades.\par Drugmakers spend hundreds of millions of dollars developing a new drug. In exchange, they get exclusive rights to market the drug for years.\par Forcing Roche to license Tamiflu could discourage others from investing in anti-flu drugs, the industry's main trade association says. Schumer says Roche should be compensated for the Tamiflu that other companies produce for national stockpiles.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (56%); BAC (NYSE) (54%); BAC (LSE) (54%); 8648 (TSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (56%); NAICS551111 OFFICES OF BANK HOLDING COMPANIES (54%); NAICS522110 CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MERCIAL BANKING (54%); SIC6712 OFFICES OF BANK HOLDING COMPANIES (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CHARLES SCHUMER (89%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (55%); WORLD HEALTH ORGANIZATION (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (93%); TAIWAN (79%); INDIA (75%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (56%); BANK OF AMERICA CORP (54%);   WORLD HEALTH ORGANIZATION  (55%); WORLD HEALTH ORGANIZATION (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ; HEALTH CARE  PHARMACEUTICAL PREPARATION MFG (91%); PHARMACEUTICALS I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DUSTRY (90%); ANTIVIRALS (90%); INFECTIOUS DISEASE (90%); INFLUENZA (90%); US DEMOCRA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IC PARTY (90%); GENERIC DRUGS (90%); EPIDEMICS (90%); AVIAN INFLUENZA (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); HEALTH DEPARTMENTS (78%); ANTIBIOTICS (78%); BUSINESS & PROFESSIONAL ASSOCIATIONS (78%); ANTHRAX (73%); DRUG DESIGN & DISCOVERY (73%); PUBLIC HEALTH ADMINISTRATION (73%); DRUG PRICES (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INVALIDATION & REVOCATION (72%); PRICE CUTTING (68%); PRICE CHANGES (68%); LICENSING AGREEMENTS (67%); UNITED NATIONS INSTITUTIONS (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 18, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHOTO, B/W, Roche via Bloomberg News\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Gannett Company, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Fear of a pandemic can be more dangerous than the virus THE DAILY TELEGRAPH(LONDON) October 17, 2005, Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_182}{\*\bkmkstart DOC_ID_182_0}{\*\bkmkstart doc_id_44}{\*\bkmkend DOC_ID_182}{\*\bkmkend DOC_ID_182_0}{\*\bkmkend doc_id_44}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_44"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 44 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE DAILY TELEGRAPH(LONDON)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  17, 2005, Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Fear of a pandemic can be more dangerous than the virus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Features; Letter to the Editor Pg. 019\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 70 words\par \par SIR - Roche should forgo its rights to be the sole manufacturer of Tamiflu and allow companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 C}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 pla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of Bombay to make generic versions of the drug. Full marks to the Indian company for going ahead r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gardless of the prospect of legal battles over the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Shame on Swiss pharmaceutical giant Roche for putting profit above the risks of millions of people dying from avian flu.\par V. Crews\par Beckenham, Kent\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LETTERS & COMMENTS (92%); GENERIC DRUGS (90%); PHARMACEUTICALS INDUSTRY (88%); INFLUENZA (88%); AVIAN INFLUENZA (88%); PHARMACEUTICAL PREPARATION MFG (86%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (85%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (85%); SIC2834 PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 17, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Telegraph Group Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bird Flu: Access to treatment: Avian flu found to be resistant to stockpiled drug, experts warn The Guardian (London) - Final Edition October 15, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_183}{\*\bkmkstart DOC_ID_183_0}{\*\bkmkstart doc_id_45}{\*\bkmkend DOC_ID_183}{\*\bkmkend DOC_ID_183_0}{\*\bkmkend doc_id_45}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_45"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 45 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London) - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  15, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Bird Flu: Access to treatment: Avian flu found to be resistant to stoc}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 piled drug, experts warn}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sarah Boseley\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Home Pages, Pg. 7\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 466 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Tamiflu, the flu drug the UK is stockpiling, may not be as effective a weapon as had been hoped in ste}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ming a flu pandemic, scientists said yesterday.\par  Concerns about the drug were raised as it was revealed that it had failed to work on a Vietnamese girl i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fected with the deadly form of bird flu H5N1. Researchers found that the virus had become resistant to Tamiflu. The possibility that resistance would develop to the drug has long been acknowledged, but it is a blow to the pandemic preparations that it has emerged so quickly. The significance of the discovery led to immediate publication of the researchers' paper by the journal Nature. \par  Yoshihiro Kawaoka from Tokyo University and colleagues report that the girl recovered, but say that the case "raises the concern that oseltamivir (brand name Tamiflu) may not be sufficient to fight a potential H5N1 pandemic". When they used the resistant virus to infect ferrets, however, they found that it was still sensitive to the flu drug zanamivir (Relenza).\par  "It could be useful to stockpile zanamivir as well as oseltamivir in the event of an H5N1 influenza pandemic", the authors say. The circumstances of the case also raise the possibility that the girl was infected by her brother. If the virus mutates to a form that easily jumps from one human to another, a pandemic is inevitable, but there need to be more such cases before we can assume that is happening, the researchers say.\par  Nobel prize-winner Sir John Sulston called for reform of the drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system yesterday to allow faster stockpiling and wider access to antiviral drugs. "A major problem in the decision-making processes of go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernments is that drugs are very highly priced. This is because of the way the intellectual property system works," he said on BBC Radio 4. It rewarded companies for their investment in creating drugs by allowing them to set high prices without competition, but it did not help get universal access. "I think if we can reform intellectual property so as to separate the creative process of research and development from the production of drugs, making them cheaper, we will be a great deal better off," he said.\par  He spoke as the drug company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  announced that it would be making its own copies of Tamiflu, to sell in the developing world. Generic manufacture of the drug is not permitted in the UK, Europe or the US. Intelle}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tual property legislation gives Tamiflu's manufacturer, Roche, a monopoly on sales and marketing .\par  Britain has ordered more than 14m courses, but so far has 2.5m and delivery of the rest will not be comple}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed for another year. No vaccine against the dangerous strain H5N1 bird flu yet exists, because in the pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess of being transmitted to humans and then from human to human, it will mutate.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (51%); SIC2834 PHARMACEUTICAL PREPARATIONS (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (93%); EUROPE (58%);   LONDON, ENGLAND (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (93%); EUROPE (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (98%); AVIAN INFLUENZA (94%); ANTIVIRALS (93%); EPIDEMICS (91%); R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEARCH REPORTS (90%); PHARMACEUTICALS INDUSTRY (89%); SCIENCE NEWS (89%); INTELLE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUAL PROPERTY (89%); INTELLECTUAL PROPERTY LAW (89%); INFECTIOUS DISEASE (89%); SC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENCE & TECHNOLOGY (89%); VIROLOGY (78%); DRUG RESISTANCE (78%); DISASTER PLANNING (78%); DISEASES & DISORDERS (78%); RESEARCH & DEVELOPMENT (76%); NOBEL PRIZES (75%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (73%); VACCINES (72%); WRITERS (66%); AWARDS & PRIZES (64%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (64%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 15, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Indian Company to Make Generic Version of Flu Drug Tamiflu The New York Times October 14, 2005 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_184}{\*\bkmkstart DOC_ID_184_0}{\*\bkmkstart doc_id_46}{\*\bkmkend DOC_ID_184}{\*\bkmkend DOC_ID_184_0}{\*\bkmkend doc_id_46}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_46"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 46 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  14, 2005 Friday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian Company to Make Generic Version of Flu Drug Tamiflu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By DONALD G. McNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 1; Foreign Desk; Pg. 3\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 616 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A major Indian drug company announced yesterday that it would start making a generic version of Tamiflu, the anti-influenza drug that is in critically short supply in the face of a possible epidemic of avian flu.\par   ''Right or wrong, we're going to commercialize and make oseltamivir,'' said Dr. Yusuf K. Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of Bombay, using the drug's generic name and acknowledging that he might face a fight in the Ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an courts with Roche, the Swiss pharmaceutical giant that holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par Although generic manufacturers cannot legally sell the patented drug in the West, all national }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws, including those of the United States, allow governments to cancel }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  during emergencies and either buy generics or force }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders to license their formulas to rivals. \par   A spokeswoman for the Department of Health and Human Services, which has recently ordered 12.3 million doses of Tamiflu from Roche, said she could not comment on the effect of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  announcement. ''Prepa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the world for a pandemic flu outbreak is a top priority, and we're looking at various options in stockpiling drugs and vaccine,'' said the spokeswoman, Christina Pearson. ''But there are a lot of issues, and it's too early to speculate about this right now.'' \par   Roche has been under growing pressure from several countries and the United Nations secretary general, Kofi Annan, to license generic versions of the drug, which eases flu's worst symptoms. \par   The company, which sells Tamiflu for $60 per treatment in the United States, has repeatedly refused to l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cense the generic version, or even to disclose how much it makes, other than saying it plans to increase production ''eightfold.'' A Roche spokesman, Terry Hurley, said yesterday that the company ''fully intends to remain the sole manufacturer of Tamiflu.'' \par   Making the drug involves 10 complex steps, he said, and the company believes that it will take another company ''two to three years, starting from scratch,'' to produce it. \par   Dr. Hamied dismissed that claim, saying that he initially thought it would be too hard but that his scientists had finished reverse-engineering the drug in his laboratories two weeks ago. He said he could have small commercial quantities available as early as January.\par   Asked if he thought Dr. Hamied was making an idle boast, Mr. Hurley declined to comment.\par   }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , India's third-largest drug maker, has copied dozens of Western drugs, including Lipitor and Viagra, and produces raw ingredients for Western drug companies. Its inexpensive H.I.V. drugs, approved by the World Health Organization, are used by 400,000 people worldwide.\par   Dr. Hamied said he would sell generic Tamiflu ''at a humanitarian price'' in developing nations and not aim at the American or European market. ''God forbid the avian flu should strike India,'' he said. ''There is no line of defense.''\par   Under Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws, which were tightened in March, he believes that he can sell the drug in India and in 49 other countries rated ''least developed'' by the United Nations. \par   The new law recognizes }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  filed by Western companies after Jan. 1, 1995, and the Tamiflu }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India was filed with a ''priority date'' of Feb. 26, 1995. Dr. Hamied said he thought the Indian government would be unlikely to fight over a 10-year-old difference of two months, especially if the lives of millions of I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dians were at stake.\par   Scientists in Taiwan and other countries have said they, too, can produce generic Tamiflu, if }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  issues are resolved.\par   Mr. Hurley declined to say whether Roche would fight }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in court, but said, ''If we determine that there has been an infringement, we'd move to protect our rights and interests.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INFLUENZA (94%); ANTIVIRALS (93%); GENERIC PRODUCTS (92%); PHARMACEUTICALS INDUSTRY (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); AVIAN INFLUENZA (90%); DISEASES & DISORDERS (90%); UNI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ED NATIONS INSTITUTIONS (90%); INTELLECTUAL PROPERTY LAW (90%); GENERIC DRUGS (90%); EPIDEMICS (90%); PUBLIC HEALTH ADMINISTRATION (89%); HEALTH DEPARTMENTS (89%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICAL PREPARATION MFG (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (75%); REVERSE ENGINEERING (75%); ENGINEERING (75%); INFECTIOUS DISEASE (74%); VACCINES (73%); APPROVALS (70%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INVALIDATION & REVOCATION (70%) Influenza; Tamiflu (Drug); Drugs (Pharmaceuticals); Inventions and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ; Generic and Brand Name Products; Influenza; Avian I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fluenza  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (85%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS (82%) }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd; Roche Ag; United Nations\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (85%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (92%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (85%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Donald G Jr Mcneil; Yusuf K (Dr) Hamied; Kofi (Sec Gen) Annan\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (88%) UNITED STATES (93%); INDIA (92%); EUROPE (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 14, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Malawi;Local Manufacture of Anti-Aids Drugs Considered Africa News July 13, 2005 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_185}{\*\bkmkstart DOC_ID_185_0}{\*\bkmkstart doc_id_47}{\*\bkmkend DOC_ID_185}{\*\bkmkend DOC_ID_185_0}{\*\bkmkend doc_id_47}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_47"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 47 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2005 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Malawi;\par Local Manufacture of Anti-Aids Drugs Considered}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UN Integrated Regional Information Networks\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 143 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Malawi says it is considering the local production of generic antiretrovirals to ensure an affordable and su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tainable supply.\par According to Malawian Health Minister Hetherwick Ntaba, the stricter }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws recently passed in India were threatening his country's supply of low-cost versions of the life-prolonging drugs. \par Malawi began rolling out free anti-AIDS drugs last year, receiving most of its requirements from Indian gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic drug manufacturers Ranbaxy Laboratories and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , with funding from the Global AIDS Fund.\par Ntaba told London's Financial Times that after Ranbaxy and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  removed some of their antiretrovirals from the World Health Organisation's list of prequalified medications, his country had to wait up to three months to find a new supply.\par [ This report does not necessarily reflect the views of the United Nations ]\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (91%); AIDS & HIV TREATMENT (90%); GENERIC DRUGS (90%); HEALTH D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARTMENTS (90%); PUBLIC HEALTH ADMINISTRATION (90%); AIDS & HIV (90%); GENERIC PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UCTS (88%); PHARMACEUTICALS INDUSTRY (88%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (72%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MFG (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY (NSE) (83%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (83%); SIC2834 PHARMACEUTICAL PREPARATIONS (83%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (83%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HETHERWICK NTABA (75%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (57%); WORLD HEALTH ORGANIZATION (57%); UNITED NATIONS  (56%); UNITED NATIONS (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MALAWI (94%); INDIA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (80%);  UNITED NATIONS (76%); WORLD HEALTH O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATION (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 13, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HIV-Aids and STDs;Global Aids Treatment Drive Takes Off Africa News April 28, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_186}{\*\bkmkstart DOC_ID_186_0}{\*\bkmkstart doc_id_48}{\*\bkmkend DOC_ID_186}{\*\bkmkend DOC_ID_186_0}{\*\bkmkend doc_id_48}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_48"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 48 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  28, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 HIV-Aids and STDs;\par Global Aids Treatment Drive Takes Off}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa Renewal\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 3207 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Rapid increase in number of people receiving ARV medicines\par When a reporter first met seven-year-old Bongani in a hardscrabble shantytown near Johannesburg in 2003, it was evident the child was dying. He was too weak for school, stunted and racked by diarrhoea. There was little question that he, like his deceased parents, was infected with the human immunodeficiency virus that causes AIDS. It seemed equally certain that he would soon lie in a tiny grave next to theirs -- joining the 370,000 South Africans who died from the disease that year.\par But when the journalist, Mr. Martin Plaut of the BBC, returned a year later, he found a healthy, laughing Bo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gani poring over his lesson book. "The transformation," Mr. Plaut wrote last December, "was remarkable." \par That transformation -- and the difference between life and death for Bongani and a growing number of pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple living with HIV and AIDS in Africa -- has resulted from access to anti-retroviral drugs (ARVs) that attack the virus and can dramatically reduce AIDS deaths. For years high costs severely limited their use in Africa. The Joint UN Programme on HIV/AIDS (UNAIDS) estimated that only about 50,000 of the 4 million Africans in urgent need of the drugs were able to obtain them in 2002. But with prices dropping in the face of d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mands for treatment access and competition from generic copies of the patented medications, the politics and economics of AIDS treatment have finally begun to shift.\par In December 2003, the World Health Organization (WHO) announced an unprecedented drive to put 3 mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lion people living with HIV/AIDS in developing countries on ARV treatment by the end of 2005, the "3x5" campaign. Two months later, the US launched an ambitious programme of its own, the President's Eme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gency Plan for AIDS Relief (PEPFAR) -- a 5-year, $15 bn initiative to provide ARV therapy to 2 million people and prevent 7 million new infections by 2008 in 15 countries, including 12 in Africa.\par 'Irresponsible' goal now in sight\par The early results are encouraging. In January 2005, WHO, joined by representatives of the US government, UNAIDS and the multilateral Global Fund to Fight AIDS, Tuberculosis and Malaria, announced that the nu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ber of people receiving ARV treatment in developing countries had increased by 75 per cent during 2004 to over 700,000 -- including an estimated 325,000 in sub-Saharan Africa. In the view of many public health e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 perts, the rapid increase vindicates what some critics derided as WHO's "irresponsible" and unrealistic 3x5 pledge.\par The results also seem to belie predictions that the mix of multilateral and bilateral funding and treatment pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grammes would prove impossible to coordinate and only further burden overstretched health systems in the worst-affected countries. South Africa, Nigeria and India account for over 40 per cent of the total number of people still in need of ARV treatment, and experts say that a focus in those three countries could produce major gains for treatment access in a short time.\par Speaking at a press conference at the World Economic Forum in Davos on 26 January, WHO Director-General Dr. Lee Jong-wook singled out developing countries for much of the credit. "We salute the countries that have now shown us that treatment is possible and can be scaled up even in the poorest settings," he said. "AIDS treatment access is expanding every day thanks to the dedicated work of doctors, nurses, health workers and people living with HIV and AIDS, who are often working under difficult circumstances to turn the dream of universal treatment into a reality." WHO officials assert that at current rates the world is on track to reach the 3x5 goal.\par This upbeat assessment is tempered, however, by an estimated $2 bn shortfall to reach the 3 million mark by the end of this year. That amount is part of the $6 bn in additional resources UNAIDS says is needed in 2005 for the full range of HIV/AIDS programmes in developing regions. The treatment drive in many countries is hampered by severe shortages of trained medical personnel and facilities and by continuing controversies over drug prices and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . "Unless these and other pressing issues are addressed urgently," declared the non-governmental organization Medecins sans Frontieres (MSF), "many of those living with HIV/AIDS in d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 veloping countries will never get access to life-saving treatment or may not be able to survive once on trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment over the long term."\par MSF and other advocacy groups point out that the 700,000 people in ARV treatment represent only about 12 per cent of the nearly 6 million people in developing countries who need it. With the disease taking 8,000 lives daily, and new infections topping 5 million last year alone, MSF declared that "the global picture is bleak... WHO ... and other institutions should be sounding the alarm."\par 'A tremendous determination'\par Whether one views the pill bottle as half empty or half full, the increased availability of anti-AIDS medicines in Africa is very good news. Although the percentage of Africans currently receiving the life-prolonging drugs remains a low 8 per cent of those requiring it -- ARVs are prescribed only for those in the final stages of the disease -- the continental average masks significant advances in some countries.\par In Botswana, the country with the second-highest HIV-infection rate in the world, an estimated 50 per cent of those in need currently receive ARV drugs. This is due in large part to the government's pioneering decision in 2002 to provide the medications free of charge through the public health system.\par Uganda, whose AIDS prevention campaign is already considered a model for effective programmes, now provides ARV treatment to 40 per cent of the 114,000 people who require it. In Cameroon, reports WHO, strong political leadership combined with increased funding assistance and a sharp drop in drug prices has allowed some 12,000 people to begin ARV therapy. Cameroonian authorities say they will triple that number by the end of 2005.\par Overall, notes WHO in its December 2004 3x5 Campaign Report, anti-retroviral medications are now avail}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble at more than 700 sites across the region. The study also found that African ARV patients are equally or more likely than patients in developed countries to maintain the drugs' strict daily treatment schedule. This finding has confounded critics who argued that poor adherence rates would accelerate the emergence of drug-resistant strains of the virus.\par WHO also reported that men and women have roughly equal access to ARVs in Africa under the new trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment programmes. This means that women, who make up 57 per cent of Africans living with the virus, are underrepresented in some countries; but the numbers have allayed, at least for now, fears that women would be excluded from national treatment strategies.\par In Botswana, the country with the second-highest HIV-infection rate in the world, an estimated 50 per cent of those in need currently receive ARV drugs.\par The early success of the treatment drive, says UN Special Envoy for HIV/AIDS in Africa Stephen Lewis, r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 flects the coming together of new resources from the Global Fund and the US government, the technical support and momentum of WHO's 3x5 campaign and a new sense of urgency among African governments and civil society. Mr. Lewis, a former Canadian diplomat known for his criticism of responses to the pandemic by both donors and African governments, told Africa Renewal that in recent months "there has been a huge change for the better" among African political leaders and health officials. "It's like night and day. There is tremendous determination to meet those 3x5 targets."\par The reason for the sudden change, he notes, is that in the hardest-hit countries, HIV/AIDS can no longer be ignored. For some leaders "it was the fear that the country was falling apart, the sense that every indicator was being turned back, from life expectancy to levels of poverty to infant and maternal mortality. It made the political leadership say, 'Oh my God, we've got to turn this around.'" In the worst affected regions, "the pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vasiveness of death is almost unbelievable. They're in a life-and-death battle, and now everybody sees it that way."\par Building capacity\par Despite the progress, obstacles to treatment access remain stubbornly in place. Chief among them is the absence of the public health capacity -- hospitals and clinics, diagnostic and laboratory facilities, trained medical personnel -- to maintain millions of people on the powerful anti-retroviral medications. Although Mr. Lewis estimates that Africa already has the capacity to maintain double the current number of people now on treatment, "the need to increase capacity is huge, and there's a kind of grim, gritted-teeth determination to get it built."\par Part of the problem, notes a recent study by WHO and other international health organizations, is the "fatal flow" of African health professionals to better-paying jobs overseas. The study notes that there are more M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lawian doctors practicing in the UK city of Manchester than in Malawi itself, while Zambia, with one of the highest HIV-infection rates in the world, has lost to foreign employers 550 of the 600 doctors it has trained since independence.\par Malawi and its development partners have responded to the desperate staffing shortage with a programme to improve salaries and working conditions for health professionals and to train a new cadre of health wor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers able to dispense ARVs and provide basic medical services.\par Rebuilding Africa's threadbare public health systems will take time, however, and for millions of people in the last stages of AIDS, time is running out. "Almost everyone would agree that the largest challenge resides around capacity," says Dr. Mark Dybul, the assistant US global AIDS coordinator and chief medical officer for the PEPFAR programme. The US, the Global Fund and WHO programmes therefore focus on "supporting new people on therapy, but simultaneously building new capacity. I don't think it's correct to say that all [the recent increases] have been done using existing capacity."\par One small PEPFAR-supported clinic in Namibia, he notes, had the resources to treat several hundred pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple. "Now they have the capacity to treat a couple of thousand people. They're taking people off the waiting list and putting them on the rolls, because they built new capacity at the same time they began treatment."\par Funding support, technical assistance and drugs and equipment could come from outside, Dr. Dybul told A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rica Renewal. But for the programme to expand, there also needs to be capacity within the country. "And that's got to begin with the national strategy commitment" of the governments and civil societies of affected countries. "What we do is support them... We [all] need to do more, and we're not there yet... but capacity has been expanded over the past year with tremendous success."\par The US programme alone added 155,000 people to the treatment rolls in just eight months in its 15 target countries: Botswana, Cote d'Ivoire, Ethiopia, Kenya, Mozambique, Namibia, Nigeria, Rwanda, Tanzania, Uganda, Zambia, Haiti, Guyana and Vietnam. Dr. Dybul says it is on track to reach the 500,000 mark by June 2006.\par "I think there are a lot of misconceptions about [ARV] drugs," Dr. Dybul adds. "The cost of anti-retroviral therapy is not drugs... The major costs are supporting and training personnel, laboratory capacity and su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 porting those laboratories."\par Dr. Dybul puts the annual cost of ARV treatment in Africa at $1,500- $2,500 per person, with drugs accoun}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing for just $300-$600 of the total. "Arguments about the cost of the drugs are for us a red herring," he e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plains. "That's not the problem right now."\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , pricing controversies\par But controversies over the safety, supply and cost of anti-AIDS drugs have continued. In contrast to Dr. D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bul's assessment, WHO reported last December that "the high cost of ARV drugs remains a barrier to scaling up HIV treatment and care." Prices for the next generation of anti-AIDS drugs, which will be needed as the virus develops resistance to current medications, "remain prohibitively expensive throughout much of the world," the organization noted. It warned that action is needed now to control future costs.\par For more than a decade after the development of the first anti-retrovirals in the late 1980s, their high cost and the complexity of using them kept the life-prolonging medications out of the hands of all but a few very wealthy or very fortunate people in poor countries. At $10,000-$15,000 per year, ARV treatment was simply unaffordable. Efforts by UNAIDS to negotiate discounted prices for developing countries enjoyed only limited success, and the major Northern pharmaceutical companies generally resisted calls to licence inexpensive generic versions of their patented products.\par In 2001, however, an Indian pharmaceutical firm, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  introduced an innovative generic medication that combined three of the most effective anti-retroviral drugs into a single pill, known as the triple fixed dose combination tablet (FDC). Not only was the drug easier to administer than its patented competitors -- two pills a day compared with six or more of some of the patented formulations -- it was available initially for the unheard-of price of $350 per year. After a two-year investigation by WHO's drug prequalification programme, the triple FDC was certified safe and medically equivalent to the patented originals, and went into wide use. With prices now as low as $140 a year, the triple FDC has emerged as the pharmaceutical backbone of the 3x5 campaign and is credited with making it possible to expand ARV treatment.\par But PEPFAR requires its grantees to use only drugs certified by the US Food and Drug Administration (FDA), a policy that, in practice, has meant the programme buys only patented products, mainly from US suppliers. PEPFAR officials say the policy is necessary to ensure the safety and quality of drugs and note that a number of generic ARVs have been removed from the WHO pre-approval list after problems were di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 covered in the certification documents. They also note that foreign generics producers are welcome to su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mit their products for FDA approval under a special "fast track" procedure.\par To date, however, none of the triple FDC drugs favoured in international treatment programmes has secured FDA approval. The result, reported the US government General Accounting Office, is that PEPFAR currently pays about twice as much for anti-retroviral medications as treatment schemes using generics. The agency estimates that the costs could potentially run into hundreds of millions of dollars over the five-year span of the PEPFAR initiative, reducing the number of people who can be treated for the same money.\par In late January, the FDA approved its first generic ARV product, a two-pill package taken twice daily, and applications for other generic products, including triple FDCs, are under review. Treatment advocates we}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 come the development but charge that the failure of the US to adopt the preferred triple FDC tablet is forcing participating countries to manage different supply chains and treatment regimes -- complicating the drive to expand treatment.\par Trade rules threaten affordability\par The extension of 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protections to all but the least developed countries on 1 January 2005, u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 der the World Trade Organization's agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), has also set off alarm bells among advocates and health officials. The agreement makes it more difficult for India and other major exporters of generic drugs to continue to supply developing countries with low-cost ARVs and other vital medicines.\par The current generation of frontline anti-AIDS drugs are exempt from the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules, says Mr. Brook Baker, a professor at Northeastern University in the US and a member of the treatment advocacy group Health Gap. "The problem will be with the next generation of ARVs in the pipeline. TRIPS will prevent the kind of generic competition that has driven prices down in the past."\par In August 2003, the WTO's TRIPS Council, under pressure particularly from African countries to create a public-health exemption to the new rules, reached an agreement to permit the export of generic drugs for public health emergencies. But the exemption is limited and procedurally complex. To date, no country has attempted to use it.\par Mr. Baker also notes that US negotiators are seeking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protections in excess of WTO requirements in regional and bilateral trade talks. These so-called "TRIPS plus" agreements, Global AIDS Fund head Richard Feacham said last year, have the effect of "either pushing [drug] prices up or preventing their fall," further limiting the availability of affordable medications.\par Canada recently amended its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws to permit the pharmaceutical industry to use the WTO exemption, but according to Mr. Richard Elliot, the director of legal research and policy at the Canadian HIV/AIDS Legal Network and a member of the government's Ministerial Council on AIDS, its provisions too are complex and restrictive. So far, he told Africa Renewal, no Canadian company has sought an export license under the new law.\par Short on resources, long on needs\par The rapid expansion of AIDS treatment programmes has brought with it equally dramatic demands for new resources. And while the 3x5 campaign and the US programme have short-term targets, they are creating long-term obligations to the millions of people entering treatment, since ARV therapy must continue for life. When UNAIDS was launched in 1996, the organization noted recently, global spending on the full range of HIV/AIDS initiatives in low- and moderate-income countries was $300 mn. Last year, reports the Washin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ton-based Kaiser Family Foundation, spending topped $6 bn.\par But even that impressive figure, notes the UN's Mr. Lewis, is just half the $12 bn UNAIDS estimates is nee}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed this year to continue expanding treatment programmes and meet education, prevention, counselling and research needs. The Global Fund needs $1 bn this year to cover its commitments, he says. "WHO is short $60 mn for the final vital push on 3x5 and they still don't have it. I don't understand this grudging incrementa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ism by Western countries. We're losing incredible numbers of lives every day."\par UNAIDS estimates that by 2007 $20 bn will be needed for the fight against AIDS, and Mr. Lewis calls on wealthy governments to make major new commitments at the upcoming meeting of the Group of Eight indu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 trialized countries. "We have more money now, but in a few years we'll be fighting desperately for dollars again. Prices for the next generation of drugs are very, very high. They will have to be negotiated down and ways found to make generics."\par "Everywhere we turn we have impediments," he acknowledges. "But we also have a momentum that is u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stoppable. I see the focus everywhere in Africa. Now the commitment is tremendous."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (99%); AIDS & HIV TREATMENT (91%); SEXUALLY TRANSMITTED DISEASE (90%); PUBLIC HEALTH ADMINISTRATION (89%); HEALTH CARE ACCESS (78%); GENERIC DRUGS (78%); ANTIVIRALS (78%); DISEASES & DISORDERS (78%); AIDS POLICY (76%); VIRUSES (76%); M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LARIA (76%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (73%); HEALTH DEPARTMENTS (73%); DEVELOPING COUNTRIES (72%); UNITED NATIONS INSTITUTIONS (71%); TUBERCULOSIS (71%); INTERNATIONAL ASSISTANCE (67%); GENERIC PRODUCTS (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MARTIN PLAUT (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (82%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (94%); SOUTH AFRICA (92%); UNITED STATES (92%); SUB SAHARAN AFRICA (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOHANNESBURG, SOUTH AFRICA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (81%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 2, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore April 12, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_187}{\*\bkmkstart DOC_ID_187_0}{\*\bkmkstart doc_id_49}{\*\bkmkend DOC_ID_187}{\*\bkmkend DOC_ID_187_0}{\*\bkmkend doc_id_49}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_49"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00340039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 49 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Is it the end of cheap drugs from India?;\par Medicine prices may soar in a few years as the country can no longer make generic drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  12, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Yogi Aggarwal\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE Indian pharmaceutical industry is at a cusp. Prices of medicines could start rising sharply in three to five years and Indian companies, which had prospered under the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act of 1970, could see their fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tunes declining as those of the multinationals rise.\par 'What is at stake is the health of the Indian people and even their lives,' says Yusuf Hameid, the Cambridge-educated organic chemist who heads }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , one of India's largest pharmaceutical companies.\par The earlier legislation only recognised 'process' }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and allowed Indian companies to reverse engineer drugs to manufacture them by another route. It led to India having the cheapest medicine prices in the world, typically less than a tenth of those prevailing in neighbouring Pakistan, which largely imported them. \par While trade minister Kamal Nath assured the Indian Parliament when the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Amendment Bill was intr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duced on March 22 that 'strong safeguards and comprehensive provisions' would check any price increases and availability of medicines, the industry, health workers and many parliamentarians were far from co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vinced.\par But if the public protest in India was muted, it was more vocal in African countries which heavily rely on Ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an anti-Aids drugs in their public health programmes. A few days before the Bill was to be voted in Parli}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment, there were demonstrations in Nairobi and Kampala. Many international health NGOs, including the Geneva based Doctors Without Borders (Medecin Sans Frontiers - MSF) came to India to campaign against the bill.\par Michael Angaga, African Regional Co-ordinator of Network of African People Infected with HIV/Aids, said in a telephone conversation: 'Generic drugs from India are used in public hospitals in Nairobi. People cannot a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ford patented drugs manufactured by MNCs in Kenya or other African countries. We appeal to the Indian Parliament to see this as a humanitarian issue since otherwise millions of people will die in Africa as the pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lic health system will collapse. Patented medicines cost as much as US$100, which is a family's monthly i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 come.'\par This feeling was echoed by the MSF, whose spokeswoman, Ellen Thoen, told The Business Times: 'It is very sad and a matter of great concern that India should no longer have process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  which made medicines so affordable. But we realise that India has obligations under the WTO and within that we understand the government could not do otherwise. India has modified the earlier ordinance and we take that as a positive signal.'\par While the amended bill as passed is a vast improvement on the ordinance passed by the government in D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cember 2004 (it was formulated by the earlier BJP-led government in 2003) to meet the January 2005 dea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 line under WTO, it has not used the full flexibility allowed under the trade-related aspects of intellectual pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erty rights (Trips) negotiations.\par Concern\par Many of the provisions also make the domestic pharmaceutical industry uneasy. Some of the amended se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions are worded such that 'they could have been drafted in a multinational company's office' says one o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 server.\par There are several areas of concern. One is whether }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  can be extended beyond the stipulated 20 years by some small change. Another relates to whether patented medicines will compulsorily have to be licensed to Indian manufacturers or if the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder can retain a monopoly over their supply.\par The backdating of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  from 1995 instead of 2005 has also been criticised, and it is feared that the amb}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 guity in the royalty payable could lead to time consuming and expensive litigation. And while Indian comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies will be allowed to export some vital drugs to countries which do not have a manufacturing base, they will not be allowed to sell them in India.\par One paradoxical fact is that while less than 25 new molecules have been discovered in the 10 years from 1995 to 2004, there are some seven to eight thousand applications for }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  pending or in the 'mailbox' in the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  office. This is because most of them are frivolous and even if 90 per cent are rejected by the office, this still leaves several hundred dubious applications which would have to be opposed, opening a Pandora's box of litigation.\par Spokesmen for drug industry associations concede that while many of their objections to the earlier ord}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nance were met, some were not. Says Dara Patel, secretary general of the Indian Drug Manufacturers Ass}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ciation (IDMA): 'Most of our recommendations were accepted but our suggestions on compulsory license procedure and more powers for the government did not get through.'\par 'We are not against }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , we are against monopoly,' explains Dr Hameid of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . 'There is an intimate link between monopoly and prices, greater monopoly leading to higher prices'. He poses a vital and painful question: 'Does the globalisation of healthcare imply that we have the means to treat the sick and needy but are at a liberty to make the terrible choice between profits and lives?'\par To answer that, we have to look at how the first world chose to respond to the Aids epidemic. Before }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  started making retroviral drugs for treating Aids, the annual cost of treatment was US$ 2,000, several times the family income of those afflicted by Aids in Africa and Asia. In 2000, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  came out with a formulation which it offered to the international community for US$800 a year and within a year was able to offer an Aids treatment for under US$300 a year.\par There was an international uproar against the looting by big pharma. 'Everyone suddenly knew that effective, affordable anti-Aids drugs were available from Indian generic manufacturers. The monopoly leading to high prices of drugs the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime had created stood clearly exposed. Thy were forced to drop prices to US $800. This still allowed a huge profit as the cost was around US$100,' says Dr Hameid.\par Monopoly, and the advantage of controlling knowledge for profit lie at the heart of linking intellectual property rights under Trips to trade negotiations under the WTO. India had opposed the new IPR first proposed at the Gatt trade negotiations in the early 1990s, but like many other countries, was browbeaten into submission.\par The target of attack is the 1970 Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act, which has allowed the Indian pharmaceutical industry to become a force to reckon with. In 1971, drug prices in India were as high as in Pakistan and 33 of the top 50 pharmaceutical companies were multinationals who had a 70 per cent market share of the total industry sales of Rs 3.6 billion. (S$126 million).\par By 1996, the industry sale had grown to 109 billion rupees with multinationals having a market share of 34 per cent. By 2004, the industry had further grown to 354 billion rupees and 37 of the top 50 companies were Indian, while the market share of Indian companies had grown to 78 per cent.\par Exports of drugs from India in 2003-04 touched US$3.18 billion while imports were just US$687 million. The wide use of affordable Indian medicines in Africa and Asia also meant that potentially lucrative markets were being lost to US and European drug companies. This had to change.\par Changes\par The powerful multinational drug companies pushed for the changes evident in the December 2004 Ord}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nance. Though they have had to yield a little ground in the bill as passed recently, the Indian industry is now on the defensive. As new patented molecules start coming into the market from 2008, their prices will be much higher.\par Indian companies will lose ground and market share. The people of India will find themselves paying much more for medicines. Many will not be able to afford them. 'In another 20 years,' muses Dr Hameid, 'we'll be back to where we started in 1970 and a large part of Indian industry will have been acquired by the multin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tionals.'\par Unless, that is, further amendments are made in the bill to ensure that affordable medicines continue to reach the Indian people without hindrance.\par The writer is a Mumbai-based journalist who contributes regularly to BT\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  DRUG PRICES (92%); EDITORIALS & OPINIONS (91%); PHARMACEUTICALS INDUSTRY (90%); P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TENTS (90%); LEGISLATION (90%); PATENT LAW (90%); LEGISLATIVE BODIES (90%); GENERIC DRUGS (90%); PHARMACEUTICALS PATENTS (89%); PHARMACEUTICAL PREPARATION MFG (89%); MULTINATIONAL CORPORATIONS (89%); INTELLECTUAL PROPERTY LAW (89%); AIDS & HIV TREATMENT (78%); PRICE INCREASES (78%); AIDS & HIV (78%); MEDICAL CHARITIES (78%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY (78%); NONGOVERNMENTAL ORGANIZATIONS (77%); COMMERCE DEPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENTS (73%); REVERSE ENGINEERING (72%); PROTESTS & DEMONSTRATIONS (72%); PHYSICIANS & SURGEONS (70%); RELIEF ORGANIZATIONS (70%); HOSPITALS (65%); INTERNATIONAL ASSI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TANCE (65%); \par \par  CIPLA LTD (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VIEWS AND OPINIONS; BT Comment Others\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1347 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 11, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;New Law in India Drives Up Africa's Cost of Halting Aids Africa News March 29, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_188}{\*\bkmkstart DOC_ID_188_0}{\*\bkmkstart doc_id_50}{\*\bkmkend DOC_ID_188}{\*\bkmkend DOC_ID_188_0}{\*\bkmkend doc_id_50}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_50"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 50 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  29, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par New Law in India Drives Up Africa's Cost of Halting Aids}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 752 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE Indian government's recent moves to curtail the copying of patented medicines have received a mixed response in SA. Critics warn this threatens the future supply of cheap drugs, but manufacturers hope that India's new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws will boost their prospects.\par Last week India amended its 1970 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act to bring it in line with its World Trade Organisation (WTO) o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ligations. The amendments extend the scope of patentable inventions to include products; previously the law only allowed "process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ", which enabled drug makers to copy other firms' products by making small changes in manufacturing. \par "The 1970 law let the Indians reverse engineer, which is what they became very good at," says Jonathan Berger, a researcher at the AIDS Law Project at the University of the Witwatersrand.\par India's generic AIDS drug industry flourished in the absence of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , and today it supplies drugs to about half of the 700000 people receiving HIV treatment in developing countries, says Marta Darder, the South A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rican advocacy co-ordinator for Medicines Sans Frontieres, which provides treatment to 2500 patients in SA.\par Cheap, high-quality Indian generics such as those made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy have boosted competition, says Berger, driving the price of generic AIDS drugs down to affordable levels for people in the developing world.\par A month's supply of generic antiretroviral medicines typically costs about $30, or 5% of the price paid in d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 veloped countries.\par Because of a last-minute concession to activists, India's new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws do not threaten the supply of g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drugs already on the market, but critics are worried about the supply of drugs in the pipeline.\par Indian generic firms will have to wait three years before they can apply for licences to produce copies of p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tented drugs. If their application is opposed, litigation in courts could hold up the launch of generic versions for years, says Berger.\par The new laws also say that generic companies must pay "reasonable royalties" to a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder which grants them manufacturing licences, but doesn't set a limit.\par Critics fear this will drive up the price of generics, making them too expensive for many patients.\par "It's disappointing to see that India didn't follow recent international trends and set a royalty limit of 4%-5%," says Tenu Avafia, a researcher at the Trade Law Centre for Southern Africa.\par Europe's biggest drug maker, GlaxoSmithKline, tried to charge royalties of 45% for a licence to make copies of its AIDS drugs in SA before it reached a settlement with activists and the Competition Commission, which set royalties at 5%.\par India's new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws include provisions for the issuing of "compulsory licences" in a public emergency, effectively cancelling a drug maker's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights and allowing India to export drugs to countries unable to manufacture them.\par But its ambiguous provisions mean that litigation concerning compulsory licenses could be lengthy and co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plicated, says Avafia. So far no developing country lacking the capacity to manufacture essential medicines has made use of a special WTO mechanism designed to assist them issue compulsory licenses to import such drugs.\par Afavia suggests that South African consumers are in a slightly more fortunate position than many of their African counterparts, as there is a strong local generics industry. Aspen Pharmacare is Africa's largest g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drug maker and will supply a large number of the AIDS drugs provided in government clinics. But wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out competition from other generic companies, prices may eventually rise, he says.\par The National Association of Pharmaceutical Manufacturers, which represents South African generic drug makers, is optimistic.\par The new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws will level the playing field between Indian and local firms, and increase competition, says association chairman Muhammad Bodhania.\par He says the nature of the Indian generics industry is set to change significantly, with firms likely to shift their attention to medicines that are no longer protected by 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . This is the market segment South African firms such as Aspen and Adcock Ingram focus on, because SA has strong }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws.\par Bodhania says local firms that import raw materials from Indian drug makers already comply with South Afr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 can }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws, and so their supplies should not be affected by last week's developments. But he concedes that in the long term there might be problems if the Indian raw materials industry dwindles.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (93%); GENERIC DRUGS (92%); ANTIVIRALS (91%); AIDS & HIV TREATMENT (91%); AIDS & HIV (91%); GENERIC PRODUCTS (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (90%); PHARMACEUTICALS INDUSTRY (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); PHARMACEUTICAL PREPARATION MFG (89%); ROYALTIES (89%); DRUG PRICES (89%); LEGISL}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (89%); DRUG DESIGN & DISCOVERY (78%); INTERNATIONAL TRADE LAW (77%); EMERGING MARKETS (77%); DEVELOPING COUNTRIES (77%); TRADE DEVELOPMENT (76%); INTERNATIONAL TRADE (76%); EXPORT TRADE (76%); PHARMACEUTICALS PRODUCT DEVELOPMENT (75%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERNATIONAL ECONOMIC ORGANIZATIONS (73%); EXPORT CONTROLS (72%); LICENSES & PE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MITS (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (90%); GSK (NYSE) (84%); GSK (LSE) (84%); RANBAXY (NSE) (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (84%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325411 MEDICINAL & BOTANICAL MANUFACTURING (55%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JONATHAN BERGER (62%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (83%); WORLD TRADE ORGANIZATION (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (98%); AFRICA (93%); EUROPE (79%); SOUTHERN AFRICA (79%); SOUTH AFRICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 29, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Drugs Sector Needs Dose of Courage Africa News March 29, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_189}{\*\bkmkstart DOC_ID_189_0}{\*\bkmkstart doc_id_51}{\*\bkmkend DOC_ID_189}{\*\bkmkend DOC_ID_189_0}{\*\bkmkend doc_id_51}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_51"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 51 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  29, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Drugs Sector Needs Dose of Courage}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 802 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA's lower house, the Lok Sabha, has just passed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation that will provide protection for inn}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vators that, to date, has been largely lacking. The new rules - which will grant product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for medicines and other novel technologies - have been heavily criticised by activist organisations such as Medicins Sans Frontieres and Oxfam, which fear it will deny poor people cheap drugs.\par Their concerns are largely misplaced: although they have been watered down, the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules will probably greatly benefit the Indian economy and its people.\par The passage of this legislation highlights some important lessons on industry lobbying for SA's pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal industry. \par The notion that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation will halt the production of cheap generic drugs and stop the world's poorest and most vulnerable from access to treatment is not new. It is, however, largely a false one. A study last year in the journal Health Affairs found that 98% of the World Health Organisation's list of essential medicines were off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Despite the fact that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  cannot stand in the way of treatment, because they do not exist, countless mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lions of people in poor countries cannot obtain these drugs.\par The reason people die of preventable and curable disease and go without even the cheapest medicines is, of course, because of extreme poverty and very often government intransigence.\par According to the United Nations, only 35% of India's population has access to essential medicines, despite it being the world's fourth-largest producer of medicines, most of them cheap generics. One of India's biggest generic drug manufacturers, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  benefited greatly from the lack of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection, not by supplying m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 laria and tuberculosis drugs to India's poor and needy, but because it could supply cardiovascular drugs to wealthy US and European markets.\par Other Indian drug manufacturers, such as Ranbaxy, had, however, been conducting original research for some time. Without protection of future profit streams, there was little incentive to conduct research. This is something that Ranbaxy understood well and so lobbied hard for the government to protect its investment and innovation.\par This is where the South African pharmaceutical industry could learn a thing or two. Government is battling the private sector over drug-pricing regulations that are proving harmful to the producers, distributors and retailers of medicine, and to patients.\par Government has been extremely shrewd in setting one sector of the health-care industry against another so that retailers blame manufacturers for high prices and vice versa.\par The more the South African health-care sector fights itself, the less it is able to fight government. And fight government it must.\par SA's private health-care sector is ranked as one of the best in the world. Government should be trying to e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 courage this sector to expand and continue to innovate and improve, particularly as one news story after a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 other tells of a public health-care sector that is crumbling under heavy demands. Yet government is punis}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the private sector and seems, maliciously, to want to drive it out of existence.\par This is the time for all actors in the private health-care industry to stand together and defend the principles of private enterprise. This self-interested move will not only heal their bottom lines, but will benefit millions of South Africans who require health care.\par Yet, instead of doing this, Innovative Medicines SA (Imsa), one of the research-based drug manufacturer associations, has become amicus curiae, or a friend of the court, to government in the Constitutional Court battle over the drug-price regulations.\par Perhaps Imsa fears that if the court throws the regulations out in their entirety, it might get something even worse and more damaging down the line. Government could even draft new legislation to give the health minister the powers, which she does not currently have, to dictate drug prices.\par However one rationalises Imsa's position, it is depressing.\par It is astonishing that an industry that can make such costly and long-term investments in developing products is so cheap and short-sighted when it comes to public policy.\par Industry has to stand up to government. Government has to be made to understand that nearly all goods, be they hamburgers or life-saving medicines, come from the private sector. Its efforts to strangle the private se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor will harm companies now, and will leave all consumers and the entire country worse off in the long run.\par It may be the health-care industry that is strangled today, but every industry tomorrow. Some savvy lobbying and moral courage from SA's private sector will benefit all of us.\par  - Tren is a director of health advocacy group Africa Fighting Malaria.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); AGENCY RULEMAKING (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC DRUGS (90%); PHARMACEUTICAL PREPARATION MFG (89%); GENERIC PRODUCTS (89%); PRESCRIPTION DRUGS (89%); HEALTH CARE (89%); LOBBYING (89%); PUBLIC HEALTH A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MINISTRATION (88%); MALARIA (79%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (78%); HEALTH CARE ACCESS (77%); DISEASES & DISORDERS (77%); DRUG PRICES (77%); HEALTH D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARTMENTS (77%); POVERTY & HOMELESSNESS (76%); POPULATION SIZE (76%); RESEARCH (73%); RELIEF ORGANIZATIONS (72%); CARDIOVASCULAR DRUGS (71%); TUBERCULOSIS (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (90%); RANBAXY (NSE) (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (53%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (56%); WORLD HEALTH ORGANIZATION (56%); UNITED NATIONS  (54%); UNITED NATIONS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); EUROPE (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (53%); UNITED NATIONS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 29, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Zambia;India's Cheap Medicines Africa News March 29, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_190}{\*\bkmkstart DOC_ID_190_0}{\*\bkmkstart doc_id_52}{\*\bkmkend DOC_ID_190}{\*\bkmkend DOC_ID_190_0}{\*\bkmkend doc_id_52}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_52"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 52 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  29, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Zambia;\par India's Cheap Medicines}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Post\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 776 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA'S enactment of a law making it illegal for their pharmaceutical companies to make generic copies of patented drugs will certainly deprive millions of people across the world of inexpensive life-saving medicines.\par This law was enacted in compliance with India's commitment to the World Trade Organisation's Agreement on Trade-related Aspects of Intellectual Property Rights, or TRIPS.\par This law is very difficult to accept for us who believe that the highest level of political and economic thought was reached when some people became aware that no people and no human being had the right to exploit others, and that the fruits of the efforts and intelligence of each human being should reach all others; that man really had no need to be a wolf, but could be a brother to man.\par And although the Indian Congress Party government has pledged to its leftist allies and other opposition lawmakers that the new law won't push up the medicine prices in the country, we don't see how this will be guaranteed, especially for the export market. \par India's pharmaceutical market has thrived in the last three decades because the country's law had allowed patented drugs to be copied, as long as a different manufacturing process is used to make them. The co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies were legally producing generic versions of medicines that were under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  elsewhere, including the much in demand low-cost AIDS drugs for 50 per cent of nearly one million HIV patients taking antiretroviral medicines in developing countries.\par Some of the AIDS drugs made by reputable Indian companies cost about 5 per cent of the price of similar drugs sold by United States and European Union pharmaceutical companies.\par We know that the news of the new Indian law is honey to the ears of international pharmaceutical companies but this law will spell doom for the access to medicine in poor and developing countries by sky-rocketing the drug prices, making them unaffordable.\par Indian pharmaceutical majors like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy were spearheading making AIDS drugs and exporting them to African nations at a very low cost as compared to multinational pharmaceutical majors. All this seems to be changing now.\par This new law spells long-term disaster for India and other Third World countries in health. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had virtually become a household name in African countries, as its generic or chemically similar AIDS drugs took on mu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tinational companies selling in the market.\par In Africa, exports by Indian companies, helped nose-dive the annual price of antiretroviral treatment down from US $14,000 a decade ago to about $200. They also simplified the therapy by making pills containing three AIDS drugs.\par Generics made up about 15 per cent of India's $10 billion pharmaceutical industry that has 300 large and moderate-sized firms, plus 10,000 small companies, making 8 per cent of the world's drugs. According to pharmaceutical industry statistics, nearly 70 per cent of production is by the top 100 companies and about a third of that is exports, which were rising by 25 per cent a year. Indian companies will no longer be able to make copies of over-priced western drugs, which will affect poor countries around the world.\par But the WTO obligation does not require India to grant }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on new uses of known drugs, or combin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions of known drugs. However, Indian lawmakers have included double-usage }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in their law. A drug like AZT, which was used against cancer in the mid '70s and now used for HIV, can be patented simply on the grounds of new usage.\par And five cancer drugs such as Gefitinib, Temozolomide, Zoledronic acid, Letrozole and Ganciclovir are set to see a multi-fold increase in prices, as a result of this new law. Prices on these drugs will increase between two and 12 times.\par And simply because India is one of the world's biggest producers of generic drugs, this law will have a s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vere ripple effect on many developing countries which depend on imported generic drugs from India.\par Under the agreement on intellectual property at the WTO, India had to introduce amendments to its existing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act by January 1, 2005. Unfortunately, the Indian government waited until the very last minute and then rushed it through the parliament, leaving no space for democratic debate and consideration of wider public health implications.\par We are deeply disturbed and concerned that the Congress Party government has failed to listen to the voi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es of so many people who have entrusted them with their welfare. And it is difficult to accept the Indian go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernment's assurance that it has enough safeguards to protect the interests of the poor. How?\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC PRODUCTS (90%); PHARMACEUTICALS & BIOTECHNOLOGY REGULATORY COMPLIANCE (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); AIDS & HIV TREATMENT (90%); INTELLECTUAL PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERTY LAW (90%); GENERIC DRUGS (90%); AIDS & HIV (90%); ANTIVIRALS (89%); DRUG PRICES (89%); INTERNATIONAL TRADE (89%); EXPORT TRADE (89%); LEGISLATION (89%); DEVELOPING COUNTRIES (89%); LEGISLATORS (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (78%); MULTINATIONAL CORPORATIONS (77%); EXPORT PRICES (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); RANBAXY (NSE) (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (52%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (58%); WORLD TRADE ORGANIZATION (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (95%); AFRICA (93%); ZAMBIA (92%); UNITED STATES (79%); EUROPEAN UNION MEMBER STATES (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 29, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Trade;Indian Move to Hurt Uganda Aids Patients Africa News March 28, 2005 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_191}{\*\bkmkstart DOC_ID_191_0}{\*\bkmkstart doc_id_53}{\*\bkmkend DOC_ID_191}{\*\bkmkend DOC_ID_191_0}{\*\bkmkend doc_id_53}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_53"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 53 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  28, 2005 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Trade;\par Indian Move to Hurt Uganda Aids Patients}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The East African\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 282 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Ugandan Health sect- or has been thrown into panic following an announcement that India - the source of most of the country's generic drugs - will stop manufacturing them. Hardest hit will be victims of HIV/Aids, malaria and tuberculosis, the three diseases that have the greatest toll on society, but which rely heavily on generic drugs. The use of generics drugs increased the number of Aids patients who accessed treatment.\par "Close to three-quarters of all the people on anti-retroviral treatment are on generics. If their availability were to end, their lives would be in danger," Dr Peter Mugenyi, director of the Joint Clinical Research Centre told The EastAfrican last week.\par Dr Mugyenyi said the decline in the prices of generic drugs was due to the pressure brought by producers of brand names. About 85 per cent of the drugs that Uganda buys are generics.\par The new development follows the passing of a law by the Indian parliament last week, which for the first time in three decades commits the country to the international system of copyrights and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Medical experts predicted a rise in the cost of medical treatment as India - one of the cheapest sources of drugs for the past 30 years - effectively put an end to the manufacture of drugs without }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules.\par The impact of the law is that companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy, which produced generic drugs, will cease to manufacture drugs at prices that the poor can afford.\par Ugandan Minister of State for Health Capt Mike Mukula said that Uganda would push for intervention by the World Health Organisation and the UN.\par "The WHO and the UN will have to make this a global issue," Capt Mukula said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (93%); GENERIC PRODUCTS (90%); AIDS & HIV (90%); AIDS & HIV TREATMENT (78%); MALARIA (78%); HEALTH DEPARTMENTS (78%); PUBLIC HEALTH ADMINISTR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (77%); ANTIVIRALS (77%); DISEASES & DISORDERS (77%); DRUG PRICES (77%); MEDICAL R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEARCH (73%); TUBERCULOSIS (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (71%); EXPERIMENTATION & RESEARCH (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); RANBAXY (NSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (54%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MIKE MUKULA (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UGANDA (96%); INDIA (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 30, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Generic drug frenzy BRW March 24, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_192}{\*\bkmkstart DOC_ID_192_0}{\*\bkmkstart doc_id_54}{\*\bkmkend DOC_ID_192}{\*\bkmkend DOC_ID_192_0}{\*\bkmkend doc_id_54}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_54"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 54 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BRW\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Generic drug frenzy}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Beth Quinlivan\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pg. 40-43\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 92 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Increasingly rivalry is anticipated in Australia's burgeoning generic drug sector. Generic manufacturers should benefit as the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of up to 30 well-known branded drugs expire over the three or four years from 2005. IMS Health predicts that the global generic drug market will expand by 22 per cent per year during the five years from 2005. India firms such as Dr Reddy's and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have been achieving rising market share. Paul Duchen, the CEO of Arrow Pharmaceuticals, reports that generics account for roughly 13 per cent of the Australian drug market.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (96%); PHARMACEUTICALS INDUSTRY (91%); GENERIC PRODUCTS (91%); MARKET SHARE (90%); MANUFACTURING OUTPUT (89%) PHARMACEUTICAL INDUSTRY - AUSTRALIA; GENERIC DRUGS - AUSTRALIA; GENERIC DRUGS; BUSINESS FORECASTING - AU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRALIA\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IMS HEALTH PTY LTD; DR REDDY'S LABORATORIES LIMITED; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LIMITED; ARROW PHARMACEUTICALS LIMITED - ASX AWP\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANZSIC: C25 Petroleum, Coal, Chemical and Associated Product Manufacturing\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AUSTRALIA (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 20, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 photographs\par tables\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Abstract\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 ABIX/LexisNexis Australia\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA ALTERS LAW ON DRUG PATENTS The New York Times March 24, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_193}{\*\bkmkstart DOC_ID_193_0}{\*\bkmkstart doc_id_55}{\*\bkmkend DOC_ID_193}{\*\bkmkend DOC_ID_193_0}{\*\bkmkend doc_id_55}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_55"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 55 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2005 Thursday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 INDIA ALTERS LAW ON DRUG }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By DONALD G. McNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 3; Foreign Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1166 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India, a major source of inexpensive AIDS drugs, passed a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law yesterday that groups providing drugs to the world's poorest patients fear will choke off their supply of new treatments. \par  The new law, amending India's 1970 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act, affects everything from electronics to software to med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines, and has been expected for years as a condition for India to join the World Trade Organization.\par   But because millions of poor people in India and elsewhere -- including by some estimates half the AIDS patients in the Third World -- rely on India's generic drug industry, lobbyists for multinational drug companies as well as activists fighting for cheap drugs had descended on New Delhi to try to influence the outcome.\par  The law, which passed by a voice vote in Parliament's upper house yesterday after days of wrangling over amendments in the lower house, was in the end not as restrictive as the drug activists had feared. \par  ''It's very disappointing, but it could have been worse,'' said Daniel Berman, a coordinator of the global a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess campaign for the medical charity Doctors Without Borders. ''All generics could have been removed from the market.''\par  Instead, all the generic drugs already approved in India can still be sold, though sellers must now pay licen}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing fees. There are also provisions allowing companies that make generics to copy drugs in the future.\par  But there are relatively tough criteria for such copying, and activists predicted that prices for newly invented drugs will be much higher, because drug makers will have the same 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  monopolies as they have in the West. As AIDS patients develop resistance to old drugs, new treatments will become less affor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 able, they said.\par  In addition, it is unclear whether makers of generic drugs in other countries, like Brazil, China and Thailand, will fill any increasing demand for cheaper medicines. \par  But India's governing Congress Party, which sponsored the bill, disputed the contention that prices would soar. ''The government will have enormous powers to deal with any unusual price rise,'' said Commerce Mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ister Kamal Nath. \par  All Western countries grant ''product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents'}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ' on new inventions. Since 1970, India has granted ''process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ,'' which allow another inventor to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  the same product as long as it was created by a novel pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess. In pharmaceuticals, that has meant that a tiny tweak in the synthesis of a molecule yields a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Several companies can produce the same drug, creating competition that drives down prices.\par  Before 1970, India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws came from its colonial days, and it had some of the world's highest drug prices. Process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on drugs, fertilizers and pesticides have extended life expectancy and ended regular famines.\par  In Africa, exports by Indian companies, especially }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy Laboratories, helped drive the annual price of antiretroviral treatment down from $15,000 per patient a decade ago to about $200 now. They also simplified therapy by putting three AIDS drugs in one pill. Dr. Yusuf Hamied, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  chairman, called the new law ''a very sad day for India.''\par  But some other Indian drug makers, along with multinational companies, praised it. The International Fede}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ation of Pharmaceutical Manufacturers and Associations, a Geneva-based lobbying group, called the law ''a significant step'' that would let India ''take a leading role in global pharmaceutical research and develo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment.''\par  S. Ramakrishna, chief lobbyist for Pfizer India, a subsidiary of the world's largest drug maker, said the bill's passage abandoned ''the utopian concept that every invention should be as free as air or water,'' according to The International Herald Tribune. \par  In the United States, Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America, the lobbying organization for the American drug industry, said the new law would be ''good for India and good for Indian patients,'' but cautioned that his group was ''still measuring the impact on the overall bill of several last-minute amendments.''\par  Some multinationals had refused to invest in India without stronger }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection, and Indian companies that do original research were also eager for it. \par  But Mr. Berman said a ''mailbox'' created by the government two years ago in which drug makers could d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 posit }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  they hoped to file when the law was amended had 1,500 proposals from Indian companies -- and 7,000 from foreign ones, suggesting the new law would benefit foreign companies more.\par  Under the new law, a maker of generics can apply to copy a patented drug, but only after it has been ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 keted for three years. In addition, the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  owner can object.\par  Also, the generic's maker must pay a ''reasonable'' royalty, although the law does not define reasonable. Two years ago, Mr. Berman noted, the London-based company GlaxoSmithKline demanded 40 percent of the sales proceeds of an AIDS drug it licensed to a South African company. (Under pressure from South A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rican regulators and activists, it later licensed it to three rival companies for only 5 percent.) \par  In 2003, the Swiss drug maker Novartis forced Indian competitors to stop making generic versions of its le}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 kemia drug Glivec, which the Indian companies sold for $2,700 a year. Novartis then priced its version at $27,000 a year, while giving free treatment to a few poor patients. \par  If a drug is desperately needed, the new law allows the government to declare an emergency and cancel its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . But Mr. Berman said India had never declared such an emergency, and for years resisted admitting that it had an AIDS problem. \par  Most governments, including the United States, have such }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  powers, though they use them sparingly. When the Bush administration thought it needed huge supplies of the expensive antibiotic Cipro during the 2001 anthrax scare, it threatened to cancel Bayer's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  if the company did not cut its price. Other cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries permit generic versions of AIDS drugs, but none have been as aggressive as Indian companies about getting them approved by the World Health Organization and exporting them. Generics made by companies in Brazil go mostly to Brazilians. China makes generics, but also has problems with counterfeiting and, like India, is under pressure to comply with W.T.O. rules. \par  The Indian bill was amended to prevent ''evergreening,'' in which }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  owners try to get a new 20-year monopoly by patenting a variant on the same molecule. To win a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the applicant will have to prove the variant works better.\par  An editorial in The Business Standard of India said the law is ''better put together than seemed possible a month or two ago.'' \par  But Loon Gangte, who runs a program in India for people with AIDS, criticized the new law, saying: ''I am using generic AIDS drugs because I can afford the price. Since the bill has passed, when I need new drugs, I won't be able to afford them. I could become one of the casualties.''                                                         \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); AIDS & HIV (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); AIDS & HIV TREATMENT (91%); GENERIC PRODUCTS (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); ANTIVIRALS (90%); LOBBYING (90%); INTELLECTUAL PROPERTY LAW (90%); INTERNATIONAL TRADE (90%); GENERIC DRUGS (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); LEGISLATION (90%); DRUG PRICES (89%); CHEMICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); MEDICAL CHARITIES (78%); APPROVALS (78%); LIFE EXPECTANCY (78%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICAL PREPARATION MFG (77%); RELIEF ORGANIZATIONS (76%); MULTINATIONAL CORP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATIONS (76%); EXPORT TRADE (76%); INTERNATIONAL ASSISTANCE (75%); LEGISLATIVE BODIES (73%); PHYSICIANS & SURGEONS (73%); VOLUNTARY HEALTH ORGANIZATIONS (73%); COMMERCE DEPARTMENTS (71%); PRICE INCREASES (69%); FERTILIZERS (60%); FAMINE (60%) Medicine and Health; Inventions and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ; Law and Legislation; International Trade and World Market; Acquired I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mune Deficiency Syndrome; Drugs (Pharmaceuticals); Lobbying and Lobbyists; Generic and Brand Name Products; Medicine and Health; Prices (Fares, Fees and Rates); Medicine and Health\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (60%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION (83%); DOCTORS WITHOUT BORDERS (55%) World Trade Organization\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY (NSE) (60%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (60%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (60%); SIC2834 PHARMACEUTICAL PREPARATIONS (60%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (60%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Donald G Jr Mcneil\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (79%) INDIA (99%); CHINA (79%); BRAZIL (79%); AFRICA (79%); THAILAND (53%) India\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India Adopts Patent Law Covering Pharmaceuticals The New York Times March 24, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_194}{\*\bkmkstart DOC_ID_194_0}{\*\bkmkstart doc_id_56}{\*\bkmkend DOC_ID_194}{\*\bkmkend DOC_ID_194_0}{\*\bkmkend doc_id_56}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_56"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 56 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2005 Thursday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India Adopts }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Law Covering Pharmaceuticals}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By SARITHA RAI; Anand Giridharadas from The International Herald Tribune contributed reporting from Mumbai for this article.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 5; Business/Financial Desk; INTERNATIONAL BUSINESS; Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 859 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGALORE, India, March 23 \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Makers of generic drugs in India faced an uncertain new playing field on Wednesday after the approval of a bill that would bring India into line with international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law -- over time.\par  The bill, which requires only the signature of President A.P.J. Abdul Kalam, will set an unspecified ''reaso}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 able royalty'' on drugs that are patented. What precisely that will cost India's consumers and companies r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mains to be seen.\par   To receive the royalty, companies will need for the first time to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  their drugs in India; previously, only the process of making the drug was patentable. In the last 10 years, more than 8,900 applications for drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have been filed, and the process to clear them is sure to be slow.  \par  ''The new system will be put to the test once the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -granting process starts rolling, and there are likely to be litigations and disputes initially,'' said Anand Dikshit, director and drug analyst at Rabo India Finance, a unit of Rabobank of the Netherlands. \par  With the new law, analysts said, prices on patented breakthrough drugs would most likely rise to nearly the level in the United States, while prices on more commonly used drugs would most likely rise only moderately. The government has said it would step in if price rises were excessive but has not said how that would be determined. \par  The trade minister, Kamal Nath, said the prices of basic drugs would not rise, according to Bloomberg News. ''Prices are a concern to all of us,'' he said. ''This }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  bill does not make anything happen tomo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 row. No }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  will come into being for the next couple of years.'' \par  India is among the world's top five drug producers in terms of volume, though its $7 billion market does not rank as high in value. Prices are low because of the profusion of generic drug makers and the competition among them. \par  Smaller generic drug makers could be priced out of the market and disappear, analysts said. Yusuf Hamied, the chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a company known for supplying AIDS cocktails in Africa for a third of the price in the West, cited the experience of Italy, which instituted drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in 1984. \par  ''What is the position of indigenous Italian industry today?'' he asked. ''Zilch. They've all been taken over. And from being a net exporter, they've become a net importer of drugs.''\par  And the impact on drugs for critical illnesses would be severe, he added. ''The passage of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  bill, for me personally and for India as a whole, is a very tragic and a very sad day,'' Dr. Hamied said. ''It will be the start of a predictable, long-term tragedy for the country.'' \par  The impact on India's large generic drug makers could be muted. These companies generally make off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  medicines, as well as drugs still protected with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  elsewhere, and these companies are looking ahead. The Organization of Pharmaceutical Producers of India has estimated that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on drugs with sales of $60 billion to $70 billion in the United States will expire between now and 2010.\par  Big pharmaceutical companies hailed the bill's passage by Parliament on Wednesday. Subbaraman Ramkrishna, senior director for corporate affairs at Pfizer Ltd., a subsidiary of the world's largest drug maker, which fought vigorously for }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation, said the lack of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection assumed ''every invention is as easy to make as air or water.''\par  He added, however, that the bill was ambiguous in parts. ''For instance, the act says that the controller of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has a series of wide-ranging discretionary powers to determine all kinds of criteria like 'reasonable affordability,' 'reasonable pricing' and 'reasonable royalty,''' he said. The word ''reasonable'' appears 42 times in the bill, he noted, giving the impression that royalty rates would be imposed subjectively.\par  Some Indian drug makers were optimistic that the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime would draw a surge of investment into pharmaceutical research. Nicholas Piramal, a generics company based in Mumbai, has invested $100 million in research and development in the last couple of years.\par  ''In four to five years, such investment will pay off and Indian firms will start launching low-cost drugs for the global market,'' said Dr. Swati Piramal, director for strategic alliances and communications of Nicholas P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ramal.\par  Specialists also said that the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  bill would stir up the global drug industry in a variety of ways.\par  ''Multinationals will increase outsourcing of contract manufacturing, contract clinical research and contract R.&D. to Indian drug companies,'' said Mr. Dikshit at Rabo India Finance. India's generic drug companies, which until now made money copying best-selling foreign drugs, will have to increase spending on research, he said.\par  Research, given the new protections on drugs, could gain impetus, some felt. Nicholas Piramal has drugs in development to treat colon cancer, diabetes and inflammation, Dr. Piramal said. ''If an Indian company makes a drug whose development costs are under $50 million, compared with a billion-dollar-plus develo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment costs in the West,'' she said, ''we will be able to change the paradigm of drug discovery.''                                         \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (94%); INTELLECTUAL PROPERTY LAW (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (91%); GENERIC DRUGS (91%); DRUG PRICES (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC PRODUCTS (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); PHARMACEUTICAL PREPARATION MFG (89%); BUS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NESS FORECASTS (88%); INDUSTRY ANALYSTS (87%); ROYALTIES (78%); APPROVALS (78%); LE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ISLATION (78%); EXPORT TRADE (77%); IMPORT TRADE (77%); AIDS & HIV TREATMENT (73%); AIDS & HIV (73%); PRICE INCREASES (71%); COMMERCE DEPARTMENTS (64%); LITIGATION (53%) Terms not available from NYTimes\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); COOPERATIEVE CENTRALE RAIFFEISEN-BOERENLEENBANK BA (55%); BLOOMBERG LP (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS522110 COMMERCIAL BANKING (55%); SIC6029 COMMERCIAL BANKS, NEC (55%); SIC6021 NATIONAL COMMERCIAL BANKS (55%); NAICS519130 INTERNET PUBLISHING & BROADCASTING & WEB SEARCH PORTALS (54%); NAICS519110 NEWS SYNDICATES (54%); NAICS511120 PERIODICAL PUBLISHERS (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KARNATAKA, INDIA (58%) INDIA (99%); UNITED STATES (79%); AFRICA (79%); NET}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERLANDS (75%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 24, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Cheap Aids drugs under threat: Body blow to developing states' fight against disease as Indian MPs ban copying of patented products The Guardian (London) - Final Edition March 23, 2005 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_195}{\*\bkmkstart DOC_ID_195_0}{\*\bkmkstart doc_id_57}{\*\bkmkend DOC_ID_195}{\*\bkmkend DOC_ID_195_0}{\*\bkmkend doc_id_57}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_57"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 57 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London) - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  23, 2005\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Cheap Aids drugs under threat: Body blow to developing states' fight against disease as Indian MPs ban copying of patented products}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Randeep Ramesh in New Delhi\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Home Pages, Pg. 2\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 579 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The days of cheap treatments for millions of Aids patients around the world are coming to an end, health agencies warned last night, after the Indian parliament passed a bill that makes it illegal to copy patented drugs.\par  The practice of copying patented drugs has made medicines affordable for patients around the world. The parliament's move was to fulfil India's commitment to the World Trade Organisation's intellectual property regime. \par  The copycat drugs industry in India has forced down the annual cost of Aids treatment from $ 15,000 (\u163\'a37,900) a patient to a little more than $ 200 in less than 10 years.\par  The country's "generics" pharmaceutical industry now provides treatment to half the 700,000 HIV-infected people in developing countries.\par  The supply of cheap medicines was only possible because Indian law hitherto had no product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 straints.\par  Critics say the new law will cut off the pipeline of inexpensive future drugs, such as the "three-in-one pill" of anti-retrovirals for Aids sufferers.\par  "Under the new legislation we will see new medicines only available for the rich, while old treatments will be for the poor," said Ellen't Hoen, the director of policy ad vocacy and research at the relief agency Medecins sans Frontieres.\par  "Many people are building up resistance to the first generation of drugs and will need the newer treatments. But without the Indian drugs industry, where will they get cheap drugs from?"\par  Campaigners say African countries, where health budgets are already stretched, will find it almost imposs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble to fund the new medicines.\par  "In Cameroon we pay $ 200 a year for each Aids patient's treatment, which is an Indian generic manufactu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er's product," said Fatima Hassan of South Africa's Treatment Action Campaign. "The latest drugs are only supplied by western multinationals and they cost $ 4,800 a year. We cannot afford those prices."\par  Under the legislation, if a generics manufacturer wants to copy a patented drug, the Indian government will have to issue a compulsory licence. The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder gets a royalty, but does not have to consent.\par  But, Ms Hoen says, there are two big problems with the new regime: pharmaceutical companies can tie up such licences in court for years, and there is no ceiling on royalties.\par  "In South Africa, Glaxo tried to charge a 45% royalty. What we are looking at is a lot of work for lawyers."\par  Activists were hoping for a review of the bill and a longer public debate on the issues - Indian MPs were gi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 en only a weekend to read the bill and a couple of days to debate it.\par  Although there were last-minute concessions, many within the industry say the bill bears the footprint of mu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tinational drug companies who considered Indian generic manufacturers to be "pirates".\par  Ranjit Shahani, managing director of Novartis India, said: "(The bill) will move India towards the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  mainstream and support and encourage innovation and investments in research and development."\par  Many in the generics industry say what is being given away goes against the national interest. Yusuf Hameid, the head of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  one of the main generic manufacturers of HIV drugs, says India can "not afford monopolies".\par  He added: "Medicines in India used to be unaffordable until we adopted our }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws in the 1970s.\par  "Our population and pattern of diseases means we have to increase affordability and accessibility."\par  India's aids orphans, p19\par  Links\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (58%);   WORLD TRADE ORGANIZATION  (57%); WORLD TRADE ORGANIZATION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (57%); WORLD TRADE ORGANIZATION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (58%); GSK (LSE) (58%); BIOC (EGX) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); SOUTH AFRICA (92%); CAMEROON (79%); AFRICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); SOUTH AFRICA (92%); CAMEROON (79%); AFRICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LEGISLATIVE BODIES (90%); AIDS & HIV (90%); HEALTH DEPARTMENTS (90%); PUBLIC HEALTH ADMINISTRATION (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC DRUGS (90%); INTELLECTUAL PROPERTY LAW (90%); DISEASES & DISORDERS (90%); LEGISLATION (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); AIDS & HIV TREATMENT (90%); PHARMACEUTICALS INDUSTRY (89%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICAL PREPARATION MFG (89%); GENERIC PRODUCTS (89%); BUDGETS (78%); ANTIVIRALS (78%); INTELLECTUAL PROPERTY (77%); ROYALTIES (77%); MULTINATIONAL CORPORATIONS (76%); D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VELOPING COUNTRIES (76%); RELIEF ORGANIZATIONS (76%); PHARMACEUTICALS PRODUCT D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VELOPMENT (74%); MEDICAL CHARITIES (73%); INTERNATIONAL ASSISTANCE (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 23, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Microsoft and Pfizer Suing 2 Web Sites That Sell Pills The New York Times February 11, 2005 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_196}{\*\bkmkstart DOC_ID_196_0}{\*\bkmkstart doc_id_58}{\*\bkmkend DOC_ID_196}{\*\bkmkend DOC_ID_196_0}{\*\bkmkend doc_id_58}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_58"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 58 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2005 Friday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Microsoft and Pfizer Suing 2 Web Sites That Sell Pills}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By SAUL HANSELL\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 5; Business/Financial Desk; Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 650 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Microsoft and Pfizer took coordinated legal action yesterday against two groups sending junk e-mail me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sages that offer illegal generic versions of Viagra, Pfizer's best-selling drug for erectile dysfunction. \par  The two companies filed separate lawsuits against the people behind the CanadianPharmacy site at www.cndpharmacy.com, and the operators of Pharmacy Direct at www.myepharmacydirect.com. \par  The Microsoft suits, filed in Washington State court, claim each group sent deceptive junk e-mail messages, known as spam, that violated federal and state antispam laws and flooded users of its MSN Hotmail service. Pfizer's suits, filed in federal court in Manhattan, accuse the sites of violating its trademark and of unfair competition.\par  Microsoft has been active in suing suspected spammers, including several online pharmacies. In August, Pfizer took legal action against 30 Web sites selling a generic version of Viagra. \par  But this was the first time the companies had worked together, jointly hiring private investigators to track down the operators of the two sites. \par  That investigation has been inconclusive so far, so the lawsuits were filed against unnamed defendants. This has become a standard practice in fighting spammers; once a suit has been filed, the plaintiff can su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 poena records from credit card companies and Internet providers to determine the identity of the spammers and pill merchants.\par  Aaron Kornblum, a lawyer for Microsoft, said that in both cases the spam messages appeared to come from a network of different mailers. The spammers are typically paid a commission by the merchant. In both cases the drugs appeared to have been manufactured in India and shipped to buyers in the United States. \par  Until recently, India did not enforce drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  granted in the United States, and there is a vibrant bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ness in that country making knockoffs of popular drugs. Since Viagra is still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , it is illegal to sell generic versions in the United States. \par  Beth Levine, the general counsel for Pfizer's domestic pharmaceutical group, said Pfizer ordered pills from both sites. One package of pills came from }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a well-known Indian pharmaceutical maker. Others came in an unmarked brown envelope. She said Pfizer had not tested the pills to determine their content, but said those taking such pills risked consuming dangerous impurities. \par  While neither site appears to be affiliated with an actual pharmacy in Canada, Mr. Kornblum said there were some indications that some of the operators of the CanadianPharmacy site were in Montreal. \par  Legitimate Canadian pharmacies have been fighting for the right to sell drugs to people in the United States. This cross-border trade, though illegal, has become popular because the drugs are often much cheaper in Canada. \par  David MacKay, executive director of the Canadian International Pharmacy Association, a trade group of I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ternet drug sellers, praised the lawsuits. \par  ''For the first time in my life, I actually support Pfizer, and I hope they clobber these guys,'' he said. ''They are rogue operators without licenses that tarnish our image.''\par  Separately, Microsoft filed three additional suits against other groups of online pill purveyors, and Pfizer has challenged Internet domain names that include its trademarks, like www.half-price-viagra.com.\par  Hundreds of Web sites sell drugs illegally, said William Hubbard, the associate commissioner of the Food and Drug Administration. He said there had been a few reports of health problems stemming from such sales, and the F.D.A.'s tests had found many drugs with impurities and improperly labeled dosages. \par  The F.D.A. has taken action against many site operators in the United States, and has engaged foreign a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thorities to help out as well. But he said the problem was difficult to control. \par  ''We shut one site down in London and it was back up in Holland in a week,'' he said.      \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EMAIL MARKETING (93%); LITIGATION (93%); SUITS & CLAIMS (91%); ELECTRONIC MAIL (91%); UROGENITAL DISORDERS & INJURIES (90%); PHARMACEUTICALS INDUSTRY (90%); GENE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IC DRUGS (90%); PRESCRIPTION DRUGS (90%); SEXUAL DYSFUNCTION (90%); SUBPOENAS (90%); GENERIC PRODUCTS (90%); PHARMACIES (89%); PHARMACEUTICAL PREPARATION MFG (89%); CONTROLLED SUBSTANCES CRIME (78%); INTERNET & WWW (78%); SPAM REGULATION (78%); RESTRAINT OF TRADE (78%); LAWYERS (78%); BUSINESS TORTS (77%); RETAIL PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS (77%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (74%); CORPORATE COUNSEL (73%); INVESTIGATIVE SERVICES (72%); TRADEMARK INFRINGEMENT (72%); INVESTIGATION & SECURITY SERVICES (72%); LAW COURTS & TRIBUNALS (71%); EXECUTIVES (71%); INTERNATIONAL TRADE (60%); CREDIT CARDS (51%); PAYMENT CARDS & SERVICES (51%) Sex; Computers and the Internet; Electronic Mail; Generic and Brand Name Products; Viagra (Drug); Drugs (Pharmaceuticals); Suits and Lit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gation; Sex; Impotence\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (92%); MICROSOFT CORP (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Microsoft Corp; Pfizer Inc; CanadianPharmacy; Pharmacy Direct\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (92%); PFEB (BRU) (92%); PFE (NYSE) (92%); MSFT (NASDAQ) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (92%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (92%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (92%); NAICS511210 SOFTWARE PUBLISHERS (90%); SIC7372 PREPACKAGED SOFTWARE (90%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Saul Hansell\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW YORK, NY, USA (79%); MONTREAL, QC, CANADA (51%) WASHINGTON, USA (92%); NEW YORK, USA (79%); QUEBEC, CANADA (51%) UNITED STATES (95%); CANADA (94%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DIA (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 11, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Nigeria;How Safe Are Anti-Retroviral Drugs? Africa News February 8, 2005 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_197}{\*\bkmkstart DOC_ID_197_0}{\*\bkmkstart doc_id_59}{\*\bkmkend DOC_ID_197}{\*\bkmkend DOC_ID_197_0}{\*\bkmkend doc_id_59}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_59"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00350039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 59 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  8, 2005 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Nigeria;\par How Safe Are Anti-Retroviral Drugs?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 This Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1044 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 In the fight against AIDS, there is an increasing variety of drugs available to help relieve the symptoms for unlucky sufferers. Properly administered and manufactured, anti-retroviral (ARVs) drugs can help the victims of AIDS live longer and more useful lives. However, the widespread use in Africa of poor quality generic co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ies of these drugs is threatening to undermine their clinical effectiveness, bringing with them the possibility of new, drug-resistant strains of HIV.\par ARVs are no silver bullet. They do not cure AIDS. What they do, however, is to allow sufferers to live more normal lives. Putting a patient on ARVs is a long-term commitment, since the course of drugs must continue for life. The World Health Organisation (WHO) is responsible for recommending which particular ARVs are suitable for use in each part of the world. Currently there are about 89 products on the WHO pre-qualified list, 54 of which are anti-retrovirals for the treatment of HIV/AIDS. \par The WHO is not a regulatory authority, and neither does it have the facilities nor experts to test and certify the quality of generic ARVs. Egged on by NGOs such as Medecins Sans Frontiers and the Clinton Found}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, the WHO has bet its shirt on recommending mass treatment programmes based on ARVs that have been copied from drugs patented by pharmaceutical companies. The WHO figures this is the cheapest way to get drugs to the millions who need them. Unfortunately, this short-sightedness has put the safety of seve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al thousands of patients at risk.\par Late last year the Indian generics manufacturer, Ranbaxy, withdrew seven of its medicines because it could not guarantee they were potent enough for patients. This followed hot on the heels of the WHO's decision to de-list from its list of pre-qualified drugs two other antiretroviral medicines manufactured by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and six generic ARV medicines manufactured by Hetero Drugs Limited of India.\par This delisting proved to be an embarrassment for the WHO and the NGOs who had been arguing that gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ics manufacturers in India, South Africa and Thailand could safely make sophisticated multi-dose combin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions of AIDS drugs by mixing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  medicines. In reality, it soon emerged that these manufacturers were turning out copies that were not exact replicas of the patented drugs. This problem was further compounded because of gross discrepancies between the data supplied by manufacturers for drug registration purposes and non-compliance with international guidelines on Good Clinical Practices and Good Laboratory Practices.\par One has to ask why these drugs got the WHO's seal of approval in the first place. None of these drugs would have been deemed satisfactory to either the European or U.S. health authorities and were never submitted to them for approval. But these poor- quality copies were still approved for use in Nigeria.\par In December last year, Nsikak Ekpe, President of AIDS Alliance in Nigeria, said he was worried about irreg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 larities in the procedure for the approval of ARVs. He also said that some of his members were being given ARVs that had been de-listed by the WHO. Meanwhile, the National Food and Drug Administration Control (NAFDAC) still insisted that those de-listed ARVs were safe.\par So where does this leave Nigerians who are already suffering from AIDS? Certainly, ramping up the use of cheap generic ARVs could increase the number of people receiving treatment. However, mounting evidence shows this strategy to be ill-conceived and dangerous.\par Firstly, laboratory findings have not confirmed that most of these generic ARVs dissolve properly into the bloodstream to lower virus levels. Secondly, and more importantly, these drugs are a significant contributor to the development of drug-resistant strains of HIV/AIDS. Thirdly, generic copies of patented AIDS drugs can deliver a weak dose to patients which allows the virus to adapt and then mutate. This could quickly render the currently available generic ARVs useless, and put the WHO's AIDS strategy back to square one.\par Despite all this, African countries have continued to get second grade medicines. These same, unsafe drugs would never be offered to patients in the west without the officials of WHO going to jail. Why should we in Africa put up with this?\par Some African countries are awake to the dangers of these poor quality generics. Uganda has suspended the importation of ARVs from the Indian manufacturer Ranbaxy, and has further advised patients to discontinue their usage.\par In spite of the glaring evidence, this has not stopped the campaigning of AIDS activists who continue to focus myopically on the price of generic ARVs. But if they continue to insist on having poor second-grade drugs on account of price while ignoring quality, safety and efficacy, the plight of those already infected will be made far worse. AIDS activists attitude to treating victims with cheap but poor quality drugs is tantamount to grad}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al and slow killing.\par Several progressive African countries have long ago realized that generic ARVs are not the only answer to the AIDS problem. Uganda and Senegal have managed to bring their infection rates under control through comprehensive education and awareness programmes. Their governments have also collaborated with the private sector to build clinics from where safe, quality and tested ARVs can be distributed. These are the things all African governments should be doing.\par It is reprehensible to make available to Africans generic pre-qualify drugs of which the WHO itself has issued this disclaimer: "Inclusion in the list does not constitute an endorsement, or warranty of the fitness, of any product for a particular purpose, including in regard of its safety and efficacy in the treatment of HIV/AIDS."\par HIV victims in Africa deserve better than to have untested and poor quality ARVs foisted on them by the WHO and western NGOs. Africans deserve high quality medicines which would pass muster in the west, or risk rising drug-resistance and increasing illness. The WHO's current strategy of fighting AIDS is nothing but a sticking plaster on a massive wound, and it is fast becoming unstuck.\par  Ayodele is coordinator of the Institute of Public Policy Analysis based in Lagos\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (94%); AIDS & HIV (93%); AIDS & HIV TREATMENT (91%); INFECTIOUS DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASE (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC DRUGS (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); PHARMACEUTICAL PREPARATION MFG (89%); GENERIC PRODUCTS (89%); NO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GOVERNMENTAL ORGANIZATIONS (89%); HEALTH DEPARTMENTS (89%); RELIEF ORGANIZATIONS (88%); DRUG RESISTANCE (78%); LIFE EXPECTANCY (78%); PUBLIC HEALTH ADMINISTRATION (75%); APPROVALS (72%); PHARMACEUTICALS & BIOTECHNOLOGY REGULATORY COMPLIANCE (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (54%); RANBAXY (NSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (64%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (64%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (54%); SIC2834 PHARMACEUTICAL PREPARATIONS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HILLARY RODHAM CLINTON  (55%); HILLARY RODHAM CLINTON (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (92%); WORLD HEALTH ORGANIZATION (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NIGERIA (94%); AFRICA (92%); INDIA (92%); THAILAND (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HETERO DRUGS LTD (61%);  WORLD HEALTH ORGANIZATION (92%);  HETERO DRUGS LTD (64%); RANBAXY LABORATORIES LTD (54%);  WORLD HEALTH ORGANIZATION  (92%); WORLD HEALTH ORGANIZATION (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 9, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Aspen Aids Drugs Receive U.S. Regulatory Approval Africa News January 26, 2005 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_198}{\*\bkmkstart DOC_ID_198_0}{\*\bkmkstart doc_id_60}{\*\bkmkend DOC_ID_198}{\*\bkmkend DOC_ID_198_0}{\*\bkmkend doc_id_60}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_60"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 60 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 January}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2005 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Aspen Aids Drugs Receive U.S. Regulatory Approval}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 509 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medicines regulator gives SA company approval to supply generic drugs through Bush's five-year emerge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cy programme\par JSE Securities Exchange SA-listed Aspen Pharmacare, Africa's biggest generic drug maker, has won US regulatory approval for some of its AIDS drugs.\par This opens the way for it to supply the medicines to developing countries through the Bush administration's $15bn programme to fight the disease.\par By the end of last year, about 39,4-million people were infected with HIV and as many as 6- million needed treatment with anti- retroviral (ARV) AIDS medicines, according to the United Nations. \par Aspen is the first generic supplier to have won access to the President's Emergency Plan for AIDS Relief (Pepfar) in the US through its registration with the US Food and Drug Administration (FDA). "It's a hell of a milestone for us. I don't think many people would have bet on a company from SA being the first to get (FDA) accreditation," said Aspen CEO Stephen Saad.\par The company won FDA approval for its drug manufacturing plant in Port Elizabeth last month, which is a pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 requisite for FDA registration of its drugs.\par No other generic drug makers with voluntary licences to make copies of patented AIDS drugs had obtained FDA approval for their manufacturing facilities, he said.\par The FDA has given "tentative approval" for Aspen's co-packaged versions of nevirapine tablets and a pill combining lamivudine and zidovudine. Tentative approval is granted when the drugs are still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the US.\par GlaxoSmithKline, the world's biggest maker of AIDS drugs, holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the combined lamivudine and zidovudine pill , which is branded Combivir, while Boehringer Ingelheim holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on nevirapine, which is branded Viramune.\par This combination is the world's most widely used triple cocktail regimen, but is not the most widely used in SA.\par Saad said Aspen was seeking FDA approval for other generic AIDS drugs, but declined to provide details. FDA approval means Pepfar funds can be used to purchase Aspen's approved drugs for treatment pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grammes in countries where the local regulatory authorities have approved their use.\par The five-year Pepfar programme, announced in 2003, targets 15 of the countries hardest hit by HIV/AIDS Botswana, Cote d'Ivoire, Ethiopia, Guyana, Haiti, Kenya, Mozambique, Namibia, Nigeria, Rwanda, SA, Ta}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zania, Uganda, Vietnam and Zambia.\par Pepfar had so far spent $78m in SA, said US embassy spokeswoman Judy Moon.\par Saad said Aspen had applied to the South African Medicines Control Council (MCC) for registration of the combined pack.\par He said Aspen was also seeking regulatory approval for its generic AIDS drugs in the UK and with the World Health Organisation (WHO).\par Aspen is one of three companies, along with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy, that won contracts to provide generic AIDS drugs to the programmes supported by the Clinton Foundation, which requires manufacturers to register their drugs with a regulatory body such as the MCC, or obtain approval from the WHO.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (95%); AIDS & HIV (95%); GENERIC DRUGS (93%); APPROVALS (91%); ANTIVIRALS (91%); PHARMACEUTICAL PREPARATION MFG (90%); PHARMACEUTICALS I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DUSTRY (90%); DRUG & MEDICAL DEVICES APPROVAL (90%); FDA APPROVALS (90%); FDA REVIEW (90%); US FEDERAL GOVERNMENT (90%); PRESCRIPTION DRUGS (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (87%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (79%); HEALTH DEPARTMENTS (79%); DISEASES & DISORDERS (79%); GENERIC PRODUCTS (78%); UNITED NATIONS INSTITUTIONS (78%); STOCK EXCHANGES (78%); INTERNATIONAL ASSISTANCE (78%); US PRESIDENTS (77%); PUBLIC HEALTH ADMINISTRATION (76%); CONTRACT AWARDS (72%); DEVELOPING COUNTRIES (72%); EMBASSIES & CONSULATES (71%); ACCREDITATION (67%); CONTRACTS & BIDS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); APN (JSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (50%); RANBAXY (NSE) (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (53%); NAICS325411 MEDIC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAL & BOTANICAL MANUFACTURING (50%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UCTS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STEPHEN SAAD (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION  (94%); FOOD & DRUG ADMINISTRATION (94%); UNITED NATIONS  (57%); UNITED NATIONS (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (94%); SOUTH AFRICA (93%); AFRICA (92%); COTE D'IVOIRE (92%); KENYA (79%); UGANDA (79%); HAITI (79%); MOZAMBIQUE (79%); BOTSWANA (79%); NIGERIA (79%); TANZANIA, UNITED REPUBLIC OF (79%); NAMIBIA (79%); ETHIOPIA (79%); RWANDA (79%); ZAMBIA (79%); UNITED KINGDOM (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC  (90%); GLAXOSMITHKLINE PLC (90%); ASPEN PHARMACARE HOLDINGS LTD (58%); BOEHRINGER INGELHEIM GMBH  (53%); BOEHRINGER INGELHEIM GMBH (53%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (50%); RANBAXY LABORATORIES LTD (50%);   FOOD & DRUG ADMINISTRATION  (94%); FOOD & DRUG ADMINISTRATION (94%); UNITED NATIONS  (57%); UNITED NATIONS (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 January 26, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kenya;Are Days of Cheap ARVs Over? Africa News January 6, 2005 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_199}{\*\bkmkstart DOC_ID_199_0}{\*\bkmkstart doc_id_61}{\*\bkmkend DOC_ID_199}{\*\bkmkend DOC_ID_199_0}{\*\bkmkend doc_id_61}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_61"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 61 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 January}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2005 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Kenya;\par Are Days of Cheap ARVs Over?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Nation\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1042 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The cost of antiretoviral drugs could start going up as India - the largest producer of cheap generics - co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 form to World Trade Organisation regulations on foreign }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par India's drug industry has entered a new era this year when laws recognising foreign }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  take effect, en}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing a copycat trade that has fostered local pharmaceutical firms for three decades and helped bring cheaper Aids drugs to Kenya and elsewhere.\par By a presidential decree, India has now met a World Trade Organisation commitment to recognise foreign }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  from January 1, the culmination of a 10-year process. The change will become law if ratified by pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 liament next month. \par India has allowed its pharmaceutical makers to copy drugs patented abroad since the early 1970s, as long as they used different manufacturing processes.\par The allowance helped a few, such as Ranbaxy Laboratories, grow into global challengers and made medic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions cheaper for the poorer masses who often need them most.\par Till 2000, antiretroviral (ARV) drugs were not accessible to the vast majority of people living with HIV/Aids here in Kenya and most parts of Africa.\par Prices started falling in 2000 when manufacturers from India introduced generic versions of ARVs and now this drugs are available to a bigger population of infected persons in Kenya. This has been possible mainly because of the absence of a product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime in India. Now the introduction of a product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime would prevent generic companies in India from repeating this miracle.\par Groups such as Doctors Without Borders and Health Gap say the changes in India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws would have a major effect on pricing and availability of Aids drugs.\par But the pharmaceutical industry in India says Aids activists are raising a false alarm about the effects of pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 posed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law changes. The activists say the changes would bring higher prices for Aids drugs manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tured in India and reduce competition. But drug companies' representatives say that's not the case.\par The changes are unlikely to be felt immediately because the new rules do not apply to drugs patented before 1995, so }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd can continue selling its widely distributed version of the HIV treatment AZT. Even copies of drugs patented between 1995 and the introduction of the law are unlikely to be withdrawn.\par The Indian government and foreign companies say medicine prices are unlikely to shoot up, because 95 per cent of the drugs sold in India are older molecules. At least it is estimated that users might not feel the pinch for about two years, thanks to a full pipeline of pilfered generics.\par But from now, if Glaxo-SmithKline say, should come out with a new drug, it will be available in India only when Glaxo launches it - at a price set by Glaxo. Consequently it will mean such new drugs will only be available to Africa at prices dictated by pharmaceuticals from the West.\par Considering that already there is a significant ARVs drug resistance buildup in Kenya and the emergence of new HIV strains new drugs will be required for the affected persons but with this law now they may have to buy these at much higher prices.\par This will now mean individuals and corporates offering their employees ARVs will have to revise their med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal budgets upwards as new drugs come on stream. It will also force the goverment to review it national ARVs programme in light of the expected higher cost.\par Those in support of the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  legislation say it will benefit India in several ways. These include i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 creased investment in the country and the likelihood that Indian scientists and researchers will remain at home instead of seeking jobs in the United States and elsewhere.\par Indeed, some people argue that the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law will ultimately strengthen India's drug industry. The pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spect of better }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection has already attracted foreign drug firms looking to take advantage of r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 search costs that by some estimates are one seventh those in the United States.\par Hoffman-LaRoche, Bayer, Aventis and Chiron have recently announced plans to make India a regional base for supplies, and several others, including Novartis, AstraZeneca, Eli Lilly and Glaxo-SmithKline, are opening clinical research labs.\par This new investment may help stem the flight of top talent in biotechnology. "Over 15 percent of the RD sc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 entists working in the U.S. pharmaceutical industry are from India. The new RD environment can reverse this brain drain," says Dr Ajit Dangi, director general of the Organization of Pharmaceutical Producers of India.\par India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  freeloading began back in 1972, when Parliament granted }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights only to manufacturing processes, rather than to the end products themselves. Indian pharmaceutical firms were able to take new drugs developed abroad, reverse-engineer the manufacturing process and begin churning out generics. The drugmakers thrived.\par Local firms went from controlling 30 per cent of the Indian drug market in 1972 to 75 per cent today. Deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oping-world consumers, and even some in Western markets, enjoyed the benefits of low prices and the quick introduction of the latest wonder drugs, created and tested at others' expense. Today India exports generic drugs to 200 countries.\par Lawmakers reckon that $650 million worth of the local generics market will vaporize in a few years.\par Multinationals such as GlaxoSmithKline , Pfizer Inc, Novartis AG and Aventis, who have been forced to watch Indian firms eat into their market share, await the new environment with cautious optimism.\par "It is certainly a milestone that product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  will be recognised in India," said S Ramkrishna, senior dire}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor, corporate affairs at Pfizer India "There is already a mindset change in the industry in India and also the global industry's perception of India.\par This will definitely encourage multinationals to invest in India, provided the product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law is implemen}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed and policed well," says Ranjit Shahani, president of the Organisation of Pharmaceutical Producers of I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia and the head of Novartis India.\par Whatever spin doctors from the west say consumers will feel a pinch in the next two or three years as prices start heading skyward. That's when the free ride will really be over.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC PRODUCTS (92%); PHARMACEUTICALS INDUSTRY (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); PHARMACEUTICAL PREPARATION MFG (90%); DRUG PRICES (90%); AIDS & HIV TREATMENT (90%); AIDS & HIV (90%); INTELLECTUAL PROPERTY LAW (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (89%); AGENCY RULEMA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 K}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (78%); ANTIVIRALS (78%); POPULATION SIZE (78%); GENERIC DRUGS (78%); LEGISLATIVE BO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IES (77%); LEGISLATION (77%); PRICE CHANGES (76%); MANUFACTURING OUTPUT (74%); RELIEF ORGANIZATIONS (73%); PRICE INCREASES (71%); MEDICAL CHARITIES (68%); PHYSICIANS & SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEONS (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (85%); GSK (LSE) (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%); RANBAXY (NSE) (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (85%); SIC2834 PHARMACEUTICAL PREPARATIONS  (85%); SIC2834 PHARMACEUTICAL PREPARATIONS (85%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325411 MEDICINAL & BOTANICAL MANUFACTURING (69%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (91%); WORLD TRADE ORGANIZATION (91%); DOCTORS WITHOUT BORDERS  (54%); DOCTORS WITHOUT BORDERS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (99%); KENYA (94%); AFRICA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC  (85%); GLAXOSMITHKLINE PLC (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (84%); RANBAXY LABORATORIES LTD (69%);   WORLD TRADE ORGANIZATION  (91%); WORLD TRADE O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATION (91%); DOCTORS WITHOUT BORDERS  (54%); DOCTORS WITHOUT BORDERS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 January 5, 2005\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2005 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India courts investors with drug patents THE DAILY TELEGRAPH(LONDON) December 31, 2004, Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_200}{\*\bkmkstart DOC_ID_200_0}{\*\bkmkstart doc_id_62}{\*\bkmkend DOC_ID_200}{\*\bkmkend DOC_ID_200_0}{\*\bkmkend doc_id_62}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_62"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 62 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE DAILY TELEGRAPH(LONDON)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  31, 2004, Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India courts investors with drug }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Rosie Murray-West City Correspondent\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 City; City Diary Pg. 38\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 414 words\par \par INDIA's flourishing pharmaceutical sector will be forced to recognise foreign pate nts for the first time from tomorrow - ending the regime that has put the country at the forefront of the generic drug industry.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The country has allowed pharmaceutical businesses to copy drugs patented abroad since the early 1970s, as long as they used different manufacturing processes from the original manufacturers. This has given India a vibrant industry of scientists who are able to copy drugs quickly and get them on to the international market as soon as global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  barriers are removed. \par From tomorrow , however, India has said it will honour a pledge to the World Trade Organisation to reco}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nise foreign }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  This will become law if it is ratified by parliament at its next session in February.\par Although the new rules do not apply to drugs patented before 1995, meaning that Indian pharmaceutical g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ants such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  can continue selling its widely distributed version of HIV treatment AZT, the country hopes the new rules will encourage foreign investment in India.\par Global players such as Glaxo Smithkline and Novartis have already formed research partnerships with Indian companies because of their reputation for good science, combined with low costs.\par Ranjit Shahani, president of the Organisation of Pharmaceutical Producers of India, said: "This will definitely encourage multinationals to invest in India, providing the product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law is implemented and policed well." Mr Shahani is also the head of Novartis India.\par The Indian government says prices for pharmaceutical products inside the country are unlikely to rise, since 95pc of all drugs sold in India were patented before 1995.\par There are also indications that drugs patented after 1995 and before the introduction of the new law will not be withdrawn from the market.\par In an attempt to anticipate the changes that will be forced by the law, companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy have been attempting to find new revenue streams, such as doing contract research for other pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal companies. Ranbaxy, which suffered a blow recently after its Aids drugs were removed from the WHO approved list, has also said that it wishes to become a cutting-edge pharmaceutical research company in its own right.\par There are more than 5,000 drug companies in India, where the growth has been fuelled by the lack of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection. Analysts say the rule change will lead to more mergers and takeovers in India.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (97%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); PHARMACEUTICAL PREPARATION MFG (90%); INTELLECTUAL PROPERTY LAW (90%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC DRUGS (90%); AIDS & HIV TREATMENT (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (89%); LEGISLATION (88%); AGENCY RULEMAKING (88%); PHARMACEUTICALS ASSOCIATIONS (78%); CHEMICALS RESEARCH (78%); FOREIGN INVESTMENT (78%); AIDS & HIV (78%); MULTINATIONAL CORPORATIONS (78%); BUSINESS FORECASTS (78%); PHARMACEUTICAL CHEMISTRY (78%); RESEARCH & DEVELOPMENT (77%); TAKEOVERS (77%); INTERNATIONAL TRADE (75%); MERGERS (71%); ALLIANCES & PAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERSHIPS (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (91%); NVS (NYSE) (91%); NOVN (SWX) (91%); GSK (NYSE) (90%); GSK (LSE) (90%); BIOC (EGX) (90%); RANBAXY (NSE) (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (91%); SIC2834 PHARMACEUTICAL PREPARATIONS (91%); NAICS339115 OPHTHALMIC GOODS MANUFACTURING (91%); SIC3851 OPHTHALMIC GOODS (91%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (55%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOSEPH C PAPA (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (57%); WORLD TRADE ORGANIZATION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (99%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (91%); NOVARTIS AG (91%); GLAXOSMITHKLINE PLC (90%); RANBAXY L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BORATORIES LTD (55%);   WORLD TRADE ORGANIZATION  (57%); WORLD TRADE ORGANIZATION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 31, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Telegraph Group Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Whether document is privileged The Times (London) December 2, 2004, Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_201}{\*\bkmkstart DOC_ID_201_0}{\*\bkmkstart doc_id_63}{\*\bkmkend DOC_ID_201}{\*\bkmkend DOC_ID_201_0}{\*\bkmkend doc_id_63}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_63"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 63 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  2, 2004, Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Whether document is privileged}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Features; 79\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 395 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  CHANCERY DIVISION. Published December 2, 2004. Schering Corporation v }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd and Another. B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fore Mr Justice Laddie. Judgment November 10, 2004.\par  When considering whether a document headed "without prejudice" was to be treated as such, the court had to determine whether or not the document was genuinely intended to be a negotiating document. \par  Mr Justice Laddie so held in the Chancery Division in allowing the application of the defendants, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd and Neolab Ltd, to strike out }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement proceedings commenced by the claimant, the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  ow}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er, Schering Corporation.\par  The managing director of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had written to the claimant's chief executive in a letter headed "without pre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 j}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 udice", stating that the claimant's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was invalid and that it would avoid revocation if an alternative co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mercial solution could be found, that was acceptable to both parties.\par  The claimant did not reply to the letter but, instead, commenced the instant proceedings, basing its alleg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions of infringement solely on the contents of the letter.\par  Accordingly, if the contents of the letter were to be treated as privileged, the claimant had no material upon which to rely and the claim should be struck out.\par  Mr Colin Birss for the defendants; Mr Simon Thorley, QC, for Schering.\par  MR JUSTICE LADDIE said that in order to determine whether correspondence was a bona fide negotiating document, the court had to look at the intention of the author and how the document would be received by a reasonable recipient.\par  Although the heading "without prejudice" did not conclusively make that document privileged, it was some indication that the author intended it to be so treated and, in many cases, the recipient would receive it on the understanding that the heading indicated that the author intended attempting negotiation.\par  It was clear from South Shropshire DC v Amos ((1986) 1 WLR 1271) that an opening shot in negotiations could amount to without-prejudice correspondence and hence be privileged.\par  In the instant case, it was apparent that the author of the letter wished to negotiate, so that the letter was an invitation to the claimant to negotiate and the heading "without prejudice" reinforced that.\par  Accordingly, the letter was covered by privilege and the claimant could not rely on it.\par  Solicitors: Taylor Wessing; Bird & Bird.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (94%); SIC2834 PHARMACEUTICAL PREPARATIONS (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Law report  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); INTELLECTUAL PROPERTY LAW (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INVALID}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION & REVOCATION (90%); WRITERS (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRINGEMENT (77%); EXECUTIVES (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MR JUSTICE LADDIE (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 2, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Times Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;Goodbye to Cheap Indian Aids Drugs? Africa News November 26, 2004 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_202}{\*\bkmkstart DOC_ID_202_0}{\*\bkmkstart doc_id_64}{\*\bkmkend DOC_ID_202}{\*\bkmkend DOC_ID_202_0}{\*\bkmkend doc_id_64}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_64"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 64 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2004 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par Goodbye to Cheap Indian Aids Drugs?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Inter Press Service\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1225 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 As India moves to meet a New Year's Day deadline to comply with the Trade Related Aspects of Intellectual Property Rights (TRIPS) regime of the World Trade Organisation (WTO) the cheap, generic anti-AIDS drugs that this country is famed for could be a thing of the past.\par On Nov.19, the World Health Organisation (WHO) announced that the Hyderabad-based pharmaceutical Hetero Drugs Limited, had voluntarily withdrawn all six of its generic antiretroviral (ARV) drugs from the world body's list of approved drugs following concerns about their laboratory tests.\par ARVs are substances used to kill or inhibit the multiplication of retroviruses such as HIV.\par It was the third time since June that an Indian company has removed anti-AIDS drugs following WHO inspe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions which claimed that bioequivalence tests -- meant to show the drugs have the same effect as the original patented brands - were faulty. And this has deeply upset those involved in fighting the global HIV/AIDS ep}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 demic. \par Earlier this month Indian pharmaceutical giant Ranbaxy pulled its AIDS drugs off the WHO's list after the global body also claimed there were discrepancies in the equivalency tests. It followed the removal by India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of two HIV/AIDS drugs in June for similar problems..\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is the Indian company credited with introducing the 'dollar-a-day' treatment that dramatically tran}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 formed drug access for HIV-infected people around the world.\par But the fact of the matter remains.\par Both Ranbaxy and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  were able to prove to WHO, before the voluntary pull-off, that their ARVs met the global body's bioequivalence standards -- though not before their world business had taken a knock that benefited the manufacturers of costlier patented drugs.\par That initially led to charges from non-governmental organisations (NGOs) that the world health body was acting at the behest of western pharmaceutical giants.\par However, things, now, have become more complicated.\par Why did the two Indian pharmaceutical companies pull their ARVs from the market, if they had insisted all along that their drugs met WHO pre-qualification standards?\par "We are concerned over the withdrawals. Earlier it was WHO which dropped the drugs. This time the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies are doing it own their own. We may ask the Drugs Controller of India (DCGI) to look into the issue," a senior health official told IPS.\par WHO's pre-qualification list was created to guide procurement by aid agencies and donors interested in fighting the global HIV/AIDS epidemic and includes more than 60 ARVs made by both patented and generic drug manufacturers.\par According to the internationally-known drug policy expert, Mira Shiva, the actual culprit in the whole debacle involving Hetero, Ranbaxy and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was actually the WTO and not WHO.\par Shiva who is attached to the Voluntary Health Association of India (VHAI), a leading health NGO, said Indian pharmaceutical companies that specialise in cheap generics drugs could face legal action, initiated by the WTO, if they continued to manufacture and sell them after Jan. 1, 2005.\par "The TRIPS regime (in the WTO structure) has been identified as one of the worst international trade r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gimes and resistance to it in developing countries has come from farmers, public interest and human rights minded social action groups, as well as drug and health activists," Shiva told IPS.\par TRIPS agreement, introduced in the late 1990s, defines how products can be protected from piracy. A major criticism has been that in its current form, intellectual property rights regimes (IPR) -- like TRIPS -- serve to stifle competition. For poor nations it makes developing their own industries independently more costly, if at all possible.\par "Excessively high levels of intellectual property protection required by TRIPS have shifted the balance away from the public interest, towards the monopolistic privileges of IPR holders," said Martin Khor of the Mala}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sia-based Third World Network. "This undermines sustainable development objectives, including eradicating poverty, meeting public health needs, conserving biodiversity, protecting the environment and the realisation of economic, social and cultural rights."\par Shiva pointed out that a TRIPS review was due in 2000 but was never carried out although the WHO was both aware and concerned about the effect the regime would cause to drug prices and access especially in the developing countries.\par So far, India's pharmaceutical business has followed the fiercely nationalistic India }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act of 1970 that fostered the phenomenal growth of the industry that came to be hailed by the United Nations Council for Trade and Development (UNCTAD) as a model for developing countries.\par According to a World Bank study in the mid-1990's prices for four typical drugs were ten times more expe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sive in neighbouring Pakistan, 17 times more expensive in Britain and 37 times more expensive in the United States than in India.\par The Indian law has safeguards for both inventors as well as users but recognizes process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  as against the product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime required by TRIPS/WTO.\par An amendment to the Act, designed to meet the WHO deadline is slated to be tabled by the government du}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the winter session of the Indian Parliament next month. If the government fails to get a consensus, it is expected to resort to an ordinance.\par India signed the relevant WTO agreement on the issue in 1995 as part of its economic liberalisation under a Congress government but the party lost the elections in the following year because of widespread public pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ception that globalisation had benefited only a small elite.\par The Congress party had to wait eight years before it could return to power in May on a promise to pursue liberalisation "with a human face." But Kamal Nath its current minister for commerce and industry said the country could not avoid taking at least "credible steps" to fulfill its multi-lateral obligations.\par Political opposition to the bill that would amend the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act has come from the major communist parties united as the Left Front, which provides critical support to the Congress-led coalition government.\par "The Jan. 1 deadline should not be used as a plea to rush through legislation for which the country may have to pay a heavy price later," said D. Raja, National Secretary of the Communist Party of India (CPI).\par In the meanwhile Poornima Mane, director for social mobilisation and communication at UNAIDS, the U.N. body charged with fighting HIV/AIDS said patients should continue using Ranbaxy and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  drugs that are available in the market.\par "We want to clarify this so that patients do not panic. This (the voluntary withdrawals) does not mean that the drugs are not good. The worst thing will be if people stop using these drugs and develop resistance," she said.\par But Mane said both UNAIDS and WHO were monitoring the situation in India "since this country will have to follow the WTO restrictions coming up next year and also because it is the biggest producer of generic drugs."\par India itself has 5.1 million people afflicted with HIV according to the 'AIDS Epidemic Update', an annual r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 port prepared by UNAIDS and WHO and released here this week. Globally, the number of the HIV-afflicted people has reached 39.4 million up from the 36.6 million estimated in 2002.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (94%); AIDS & HIV (94%); ANTIVIRALS (92%); INTERNATIONAL ECONOMIC ORGANIZATIONS (90%); INTERNATIONAL TRADE (90%); PHARMACEUTICAL PREPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION MFG (89%); EPIDEMICS (89%); NONGOVERNMENTAL ORGANIZATIONS (89%); INTELLECTUAL PROPERTY LAW (89%); PHARMACEUTICALS INDUSTRY (89%); GENERIC DRUGS (89%); PUBLIC HEALTH ADMINISTRATION (89%); DISEASES & DISORDERS (89%); RELIEF ORGANIZATIONS (89%); PUBLIC POLICY (78%); PHARMACEUTICALS & BIOTECHNOLOGY REGULATORY COMPLIANCE (78%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (77%); PRESCRIPTION FORMULARIES (77%); HEALTH DEPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENTS (77%); VIRUSES (75%); GENERIC PRODUCTS (72%); DRUG POLICY (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%); RANBAXY (NSE) (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MIRA SHIVA (74%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (91%); WORLD TRADE ORGANIZATION (91%); WORLD HEALTH ORGANIZATION  (90%); WORLD HEALTH ORGANIZATION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANDHRA PRADESH, INDIA (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYDERABAD, INDIA (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HETERO DRUGS LTD (66%);  WORLD TRADE ORGANISATION (84%);  HETERO DRUGS LTD (72%); RANBAXY LABORATORIES LTD (55%);  WORLD TRADE ORGANIZATION  (91%); WORLD HEALTH ORGANIZATION  (90%); WORLD HEALTH ORGANIZATION (90%); WORLD TRADE ORGAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ZATION (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 29, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Generic drug doubts cause HIV alarm Canberra Times (Australia) November 24, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_203}{\*\bkmkstart DOC_ID_203_0}{\*\bkmkstart doc_id_65}{\*\bkmkend DOC_ID_203}{\*\bkmkend DOC_ID_203_0}{\*\bkmkend doc_id_65}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_65"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 65 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Canberra Times (Australia)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2004 Wednesday Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Generic drug doubts cause HIV alarm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Brendan Grabau\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A; Pg. 19\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 884 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 C AN YOU imagine the outcry if a pharmaceuticalcompany in the United States withdrew more than a dozen vital medicines from resource-poor countries to treat HIV/AIDS?Then why is it that when a manufacturer of generic medicines in India informs the World Health Organisation that it is withdrawing all its antiretroviral medicines that treat individuals living with HIV/AIDS, there is barely a murmur?The answer is clear. Too many health-care policy-makers have insisted that generic medicines are a better option because they are incorrectly perceived as being cheaper, rather than being concerned about quality and efficacy of treatments for infected individuals.Once again generic medicines are proving to be anything but a panacea for all ills.  If the current situation continues unabated, the fight to overcome the global HIV/AIDS epidemic with generic versions may actually become part of the problem, not the solution.Ranbaxy Laboratories is one of the major producers of generic HIV/AIDS medicines in India, but the company has found discrepancies in its manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turing documentation relating to data that supports that generic medicines are in fact bioequivalent with the originator patented medicines. Generic manufacturers must demonstratethat their copy is chemically and biologically equivalent and must have the same bio-availability and plasma concentrations to the patented original product already approved on the market.And now, a third generic medicines manufacturerhas wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 drawn all six of its antiretroviral drugs from the WHO's list of approved drugs because of concerns about their laboratory tests. "There are certainly major concerns about the testing, about the quality of it, about the situ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion that has been found by these inspections [of generic medicines]," the WHO has warned. Are we about to see a generic medicines-induced global health crisis?The recent voluntary withdrawal by generic medicines manufacturers follows the removal by the WHO earlier this year of three other antiretroviral medicines man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 factured by Ranbaxyand two antiretroviral medicines made by a second Indian generic medicines manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The WHO said there was non-compliance with international guidelines on Good Clinical Practi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es and Good Laboratory Practices. The latest withdrawal has provoked an aggressive response from Public Interest Watch which has accused Medecins Sans Frontieres for taking a cavalier approach to the withdra}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al of the generic HIV/AIDS medicines.  It has accused MSF of putting substandard AIDS drugs on the market in 27 countries, with the very real possibility of having caused new strains of drug-resistant HIV to emerge. Public Interest Watch, a US based non-profit organisation that highlights abuses of public funds by non-profit groups and private industry, has called on MSF to clarify whether it is, following provisions in the Human Declaration on Human Rights to obtain informed-consent agreements from patients being administered g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drugs rather than branded products.Paul Lalvani from the Global Fund to Fight AIDS, Tuberculosis and Malaria (an organisation that provides money for HIV/AIDS programs in 95 countries, at least 10 of which use generic medicines manufactured by Ranbaxy), said the withdrawal was likely to cause a lot of confusion in countries and ministries of health, and cause some countries to question confidence in the WHO system. About 38 million people are infected with the human immunodeficiency virus (HIV), which severely affects the immune system rendering the body vulnerable to opportunisticdiseases such as tuberculosis and pne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 monia.  Two-thirds are in sub-Saharan Africa, but Asia and Eastern Europe are seen as the new key battl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grounds.  China has warned that HIV/AIDS has spread to every level of its society and the UN is worried that the country could see 10 million people infected in six years. More than 20 million people have died of AIDS since it was first detected in 1981. The WHO has set a target of giving three million poor people access to antiretroviral drugs by the end of 2005, but it is behind schedule with the tally now about 440,000. One of the more successful programs leading the pursuit of this goal is the Accelerated Access program, a partnership that includes UNAIDS, WHO, the World Bank and research-based pharmaceutical companies. the program has about 50,000 people on antiretroviral therapythroughout the world. When it comes to dealing with su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cessfully with HIV/AIDS, the words of Australian Prime Minister John Howard at APEC are precise, "It's not just a question of more and more billions of dollars being made available by wealthy countries."High-quality HIV/AIDS medicines and compliancewith those medicines are critical to the overall success of treatment programs, both for the individual or the wider community. Lack of compliance can result in drug resistance and transmission of drug-resistant strains of HIV.As the co-discoverer of the HIV/AIDS virus, Dr Robert Gallo has warned that poor adherence to treatment poses a serious risk of multiple drug-resistant mutants of HIV that can cause new kinds of epidemics in the future.Brendan Grabau is the managing director of Brendan J. Grabau & Associates Pty Ltd, professional development consultants.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (96%); AIDS & HIV (93%); AIDS & HIV TREATMENT (92%); GENERIC PRODUCTS (91%); ANTIVIRALS (90%); PUBLIC HEALTH ADMINISTRATION (90%); NONPROFIT O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATIONS (89%); INTELLECTUAL PROPERTY LAW (87%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); DISEASES & DISORDERS (78%); PRESCRIPTION FORMULARIES (78%); PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATION MFG (78%); DRUG & MEDICAL DEVICES APPROVAL (78%); MEDICAL CHARITIES (78%); DRUG RESISTANCE (78%); PATIENT CONSENT (77%); EPIDEMICS (77%); MALARIA (77%); HEALTH CARE (76%); TEST LABORATORIES (73%); HEALTH DEPARTMENTS (73%); INSPECTIONS (72%); T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BERCULOSIS (72%); HEALTH CARE POLICY (72%); RELIEF ORGANIZATIONS (72%); INTERNATIONAL ASSISTANCE (66%); APPROVALS (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY (NSE) (69%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (69%); SIC2834 PHARMACEUTICAL PREPARATIONS (69%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (69%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (77%); WORLD HEALTH ORGANIZATION (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (93%); UNITED STATES (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (69%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%);   WORLD HEALTH ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION  (77%); WORLD HEALTH ORGANIZATION (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 23, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Federal Capital Press of Australia Pty Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India Kicks the Habit Newsweek November 22, 2004 Atlantic Edition \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_204}{\*\bkmkstart DOC_ID_204_0}{\*\bkmkstart doc_id_66}{\*\bkmkend DOC_ID_204}{\*\bkmkend DOC_ID_204_0}{\*\bkmkend doc_id_66}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_66"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 66 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newsweek\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2004 Atlantic Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India Kicks the Habit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Seema Singh\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS; Pg. 56\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 969 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 HIGHLIGHT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Local drugmakers have built a thriving industry on pilfering }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The party ends in January.\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 When Anglo-Swedish drug giant AstraZeneca launched its anti-ulcer drug Losec in 1989 in Europe and the United States, it was an instant blockbuster. Before the company had a chance to sell the drug in India, ho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ever, local firms had already flooded the market with cheap generics. In 1990 Dr. Reddy's Laboratories (DRL) in Hyderabad, the country's second-largest drug company, introduced Omez, a Losec knockoff, for 13 cents a tablet, and soon other Indian companies had joined the race, driving the price down further. Today Omez is DRL's flagship drug, accounting for 3 percent of its $440 million turnover. AstraZeneca, which had invested millions in developing the drug, never bothered trying to compete.\par There's hardly a multinational drug company in the world that couldn't tell a similar tale. The reason: India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system offers virtually no protection for new drugs, and its pharmaceutical companies are among the best in the world at producing knockoffs. But soon the free ride will be over. On Jan. 1, a new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law is expected to bring India in line with other countries in the World Trade Organization. That will mark the end of three decades of market protection that has allowed Indian firms to concentrate on low-cost manufacturing without having to pay for new-drug research. The change is already forcing India's drug companies to bolster R&D to better compete with the big multinationals. And it spells an end to quick and cheap genetic drugs for consumers in India as well as its export markets in the Middle East, Asia and Latin America.\par India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  freeloading began back in 1972, when Parliament granted }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights only to manufacturing processes, rather than to the end products themselves. Indian pharmaceutical firms were able to take new drugs developed abroad, reverse-engineer the manufacturing process and begin churning out generics. The drugmakers thrived. Local firms went from controlling 30 percent of the Indian drug market in 1972 to 75 pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cent today. Developing-world consumers, and even some in Western markets, enjoyed the benefits of low prices and the quick introduction of the latest wonder drugs, created and tested at others' expense. Today India exports generic drugs to 200 countries.\par Drugmakers won't feel the pinch for about two years, thanks to a full pipeline of pilfered generics. But the change is already reverberating through boardrooms and research labs. Starting in January, if Glaxo-SmithKline, say, should come out with a new drug, it will be available in India only when Glaxo launches it--at a price set by Glaxo. Lawmakers reckon that $650 million worth of the local generics market will vaporize in a few years. "It's a big event," says Satish Reddy, DRL's managing director.\par In anticipation of the Big Bang, the larger Indian drug companies have pushed hard to increase their share of the U.S. and European generics markets, challenging }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders in the courts. At the same time they've sought alliances with many of the same firms they were suing. Indian firms bring to the table an expertise in low-cost manufacturing, distribution networks and low-wage labor; they seek drug licenses and research partnerships. Ranbaxy Laboratories, the largest Indian drugmaker, is now helping GlaxoSmithKline identify new drugs and perform clinical trials in India; in return, Glaxo handles late-stage drug development. DRL has forged similar alliances with Denmark's Novo Nordisk and Novartis. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , which made headlines a few years ago for exporting cheap HIV/AIDS drugs to South Africa, now has tie-ups with five U.S. generic dru}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 makers, who are interested in }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  presence in 150 countries.\par Indian firms have also had some success in beefing up R&D in anticipation of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  changes. Woc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 hardt has developed two new potential antibacterial drugs, and is scouting for partners to develop and ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ket them in Europe. And last month Glenmark Pharma licensed a potential asthma drug to Forest Labs in the United States for $190 million, the biggest licensing deal ever for an Indian drug company.\par Indeed, some people argue that the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law will ultimately strengthen India's drug industry. The pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spect of better }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection has already attracted foreign drug firms looking to take advantage of r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 search costs that by some estimates are one seventh those in the United States. Hoffman-LaRoche, Bayer, Aventis and Chiron have recently announced plans to make India a regional base for supplies, and several others, including Novartis, AstraZeneca, Eli Lilly and Glaxo-SmithKline, are opening clinical research labs. This new investment may help stem the flight of top talent in biotechnology. "Over 15 percent of the R&D scientists working in the U.S. pharmaceutical industry are from India. The new R&D environment can reverse this brain drain," says Dr. Ajit Dangi, director general of the Organization of Pharmaceutical Producers of I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia.\par Still, the transition may be painful. Many of India's 20,000 drug firms are small- and medium-size companies that don't have abundant drugs in the pipeline. Analysts predict a spate of consolidation and bankruptcies. Foreign firms may also gain market share at the expense of local firms. Although drug majors may lower prices for some drugs in the Indian market, they may be reluctant to do so for others, particularly those used for rare conditions. The Indian government will be able to force down prices only in an emergency. Fears that the new laws will take India back to pre-1972 days, when multinational monopolies set high prices and n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 glected research on the diseases of the poor, are probably overblown. But consumers will feel a pinch in the next two or three years as prices start heading skyward. That's when the free ride will really be over.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (93%); PHARMACEUTICAL PREPARATION MFG (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); RESEARCH & DEVELOPMENT (90%); GASTROINTESTINAL AGENTS (90%); GENE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IC PRODUCTS (89%); INTELLECTUAL PROPERTY LAW (88%); EXPORT TRADE (87%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); LEGISLATIVE BODIES (78%); PRESCRIPTION DRUGS (78%); GENERIC DRUGS (78%); PHARMACEUTICALS PRODUCT DEVELOPMENT (78%); TEST LABORATORIES (76%); EXPORT PRICES (75%); MANUFACTURING OUTPUT (74%); REVERSE ENGINEERING (73%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (73%); MULTINATIONAL CORPORATIONS (73%); GENE BASED DRUGS (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASTRAZENECA PLC (92%); GLAXOSMITHKLINE PLC (85%); DR REDDY'S LABORATORIES LTD (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (55%); WORLD TRADE ORGANIZATION (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AZN (STO) (92%); AZN (NYSE) (92%); AZN (LSE) (92%); GSK (NYSE) (85%); GSK (LSE) (85%); BIOC (EGX) (85%); RDY (NYSE) (58%); DRREDDY (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (58%); SIC2835 IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYDERABAD, INDIA (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANDHRA PRADESH, INDIA (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (98%); EUROPE (92%); UNITED STATES (92%); LATIN AMERICA (79%); MIDDLE EAST (79%); ASIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 16, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHOTO: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  assembly line churns out cheap knockoffs, including of AIDS drugs (right); GRAPHIC(chart): GENERIC ENGINEERING: India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws let drugmakers copy the formulas of pop}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lar name brands and sell the generic versions at a fraction of the price (graphic omitted)\par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Newsweek\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS policy in shambles The Washington Times November 17, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_205}{\*\bkmkstart DOC_ID_205_0}{\*\bkmkstart doc_id_67}{\*\bkmkend DOC_ID_205}{\*\bkmkend DOC_ID_205_0}{\*\bkmkend doc_id_67}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_67"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 67 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Washington Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  17, 2004 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS policy in shambles}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By James K. Glassman, SPECIAL TO THE WASHINGTON TIMES\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COMMENTARY; Pg. A16\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 768 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The strategy of fighting AIDS in Africa with questionable generic drugs made in developing countries now lies in shambles as an Indian company withdrew its medicines last week because it can't guarantee they are p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tent enough.\par It's time now for the United Nations and its number-one financial angel, the United States, to reverse a policy that not only has failed to slow the AIDS epidemic but is almost certainly making people sicker.\par The use of unverified generics - which are copies of drugs developed and patented by research pharmace}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tical companies in the United States and Europe - has been aggressively promoted by U.N. agencies like the World Health Organization and by non-governmental organizations like Doctors Without Borders, based in Paris, and the Clinton Foundation, established by the former president.\par The WHO and NGOs have been claiming that generic companies in India, South Africa, Thailand and els}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 where can make sophisticated multi-dose combinations of AIDS drugs by cobbling together patented med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines. Instead, the generic makers are turning out to be the gang that can't copy straight. \par The ostensible reason for the WHO strategy is cost, but the research firms sell drugs in Africa at big di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 counts or give them away. A study by the Hudson Institute found that, on average, patented drugs cost less than generics in poor countries.\par The real reason for the strategy is vicious political animosity toward the United States and the research pharmaceutical companies. Such antagonism can kill.\par At the root of the current debacle is a simple question: Do people sick with AIDS in Kampala and Kinshasa deserve the same medicines as patients in Copenhagen and Chicago? Of course they do. But U.N. agencies and their NGO pals don't act that way. The WHO maintains a list of about 90 drugs that it "pre-qualifies" for relief agencies. But the list is maintained by a tiny staff with no facilities for testing, and the WHO does not warrant safety or effectiveness. Drugs on the list are now floating all over Africa.\par By contrast, American authorities have insisted on spending the $15 billion from President Bush's global AIDS program, the world's largest, only on drugs - generic or patented - that meet the standards of the U.S. Food and Drug Administration.\par The FDA even set up a fast-track process to speed approval of AIDS drugs made in developing countries. But, so far, there have been no takers - a fact that arouses suspicions about the generics.\par On Nov. 9, the Indian firm Ranbaxy, considered the best of the generic makers, withdrew all its AIDS drugs from the WHO list. That action followed WHO de-listings in spring and summer of five drugs made by Ranbaxy and another Indian company, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The moves vindicated U.S. policy, but the cost to sick Africans - and to the reputation of the WHO - is deva}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tating. In addition, legal sources say NGOs that have been distributing the generics could face lawsuits from affected patients.\par No one knows how many people have been taking deficient medicines. There is no effective system to alert these patients or to get them on other therapies - the procedure in the U.S. and Europe.\par The WHO has taken a cavalier attitude toward recent blunders, stating that, while "in principle," patients should get off the de-listed drugs, they don't have to. And, incredibly, Daniel Berman of Doctors Without Bo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ders told The Washington Post, "We are not worried about the safety of our patients. . . . We can't make an equation that if a drug is removed from the list it's not a good drug."\par The danger extends beyond Africa. A poorly made copy of a patented drug may deliver a dose of medicine so weak that the virus could adapt to it through mutation and become resistant. These new viruses would require far more expensive drugs - or drugs that don't even exist today. Such strains could migrate to cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries like the United States, where AIDS deaths have declined significantly, thanks to medicines developed in the late 1990s.\par Last summer, the respected American Foundation for AIDS Research sternly warned that a flood of untested generics, made by more than two dozen companies in developing nations, "could lead to widespread misu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es and eventually to drug resistance, eradicating years of progress." That worry is fast becoming reality. At the very least, Congress should investigate the U.N. strategy and reconsider American funding. Stubborn advocates of the current policy must stop playing deadly political games with the world's health.\par James K. Glassman is a fellow at the American Enterprise Institute and host of the Web site TechCentra}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Station.com.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (96%); NONGOVERNMENTAL ORGANIZATIONS (91%); PHARMACEUTICALS INDUSTRY (90%); EPIDEMICS (90%); GENERIC PRODUCTS (90%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC DRUGS (90%); MEDICAL RESEARCH (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); AIDS POLICY (90%); DEVELOPING COUNTRIES (90%); RELIEF ORGANIZATIONS (90%); PR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SCRIPTION DRUGS (90%); INFECTIOUS DISEASE (90%); UNITED NATIONS INSTITUTIONS (90%); DISEASES & DISORDERS (90%); US FEDERAL GOVERNMENT (89%); ANTIVIRALS (89%); AIDS & HIV TREATMENT (89%); HEALTH DEPARTMENTS (78%); DRUG & MEDICAL DEVICES APPROVAL (78%); INTERNATIONAL RELATIONS (77%); INTERNATIONAL ASSISTANCE (77%); US PRESIDENTS (76%); PUBLIC POLICY (76%); PUBLIC HEALTH ADMINISTRATION (76%); MEDICAL CHARITIES (73%); PH}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 Y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SICIANS & SURGEONS (70%); APPROVALS (69%); LITIGATION (59%) commentary-aids-policy-in-shambles-6; treaty and international organisation; health organisations; medical research; disease; epidemic and plague; government; litigation; non government organizations (NGO); AIDS; pharmaceutical\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); RANBAXY LABORATORIES LTD (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (90%); UNITED NATIONS (84%); DOCTORS WIT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OUT BORDERS (56%); HUDSON INSTITUTE (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); RANBAXY (NSE) (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (51%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (53%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (96%); AFRICA (94%); EUROPE (79%); THAILAND (79%); INDIA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 17, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright  2004 The Washington Times LLC\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Tests lead to recall of cheap Aids drugs: Move by generics manufacturer hits the WHO's targets for Africa The Guardian (London) - Final Edition November 11, 2004 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_206}{\*\bkmkstart DOC_ID_206_0}{\*\bkmkstart doc_id_68}{\*\bkmkend DOC_ID_206}{\*\bkmkend DOC_ID_206_0}{\*\bkmkend doc_id_68}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_68"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 68 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London) - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  11, 2004\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Tests lead to recall of cheap Aids drugs: Move by generics manufactu}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 er hits the WHO's targets for Africa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sarah Boseley, Health editor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Foreign Pages, Pg. 18\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 667 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The campaign to get cheap Aids drugs to millions of Africans was dealt a blow yesterday when a manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turer in India admitted it could not prove the quality of its medicines and withdrew them from the list approved by the World Health Organisation.\par  Ranbaxy's action will strengthen the arguments of those in the US who have insisted that the cheap copies, known as generics, are unproven and potentially unsafe.\par  Those running the $ 15bn emergency plan for Aids relief, launched by President George Bush, back the use of the expensive brand-name drugs from the big multinational pharmaceutical companies which invented them - and which stand to make considerable profits if they are bought in large quantities for developing countries.\par  But campaigners say poor countries can only afford generics. Buying cheap copies will allow the limited money for Aids relief to go further and save many more lives, they say. \par  Generics companies, considered pirates by the multinationals that have }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Aids drugs in Europe and North America, have undercut the price of originals in poor countries where }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  do not apply. A year's treatment that once cost $ 10,000 can now cost less than $ 200.\par  Ranbaxy, one of the leading generics manufacturers in India, has played a part in India's economic gains. It not only supplies Aids drugs to developing countries but also many generic versions of off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  medicines to Europe.\par  According to the WHO, the company has withdrawn all 10 of its Aids drugs because of "discrepancies in the documentation" which was submitted to the organisation to prove that they were "bio-equivalent" to the orig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nal drugs.\par  This year, under pressure from the US, the WHO sent in its inspectors to laboratories contracted by Ranbaxy and the other big Indian generics producer, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  The inspectors were checking studies which appeared to show that the drugs worked as well as the orig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nals had been properly carried out. They discovered flaws in the process and removed three Ranbaxy Aids medicines and two produced by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  from its list of approved drugs. It asked the manufacturers to run their own checks on the contract labs.\par  Now Ranbaxy, having done that, has taken all its Aids drugs off the list.\par  It appears that the raw data from the small trials in humans carried out by the contract labs - to show, for instance, that the concentration of the generic drug in the bloodstream is the same as with the original - is not consistent with the results given to the WHO.\par  Ranbaxy's Aids drugs are used in at least nine developing countries, according to the Global Fund for Aids, TB and Malaria, which gives financial support to developing countries to buy medicines. At least $ 2m of Global Fund money has been spent by developing countries on Ranbaxy drugs.\par  Those countries - Benin, Central African Republic, Ivory Coast, Honduras, India, Malawi, Moldova, Mongolia and Swaziland - should now in principle switch to other Aids drugs, but in practice, the WHO acknowledges, it may be difficult to find alternatives. Ranbaxy is already planning to commission new studies of its drugs in the hope of getting them back on the approved list.\par  Medecins sans Frontieres, whose volunteer doctors use Ranbaxy's Aids drugs, says it will switch to others where it can. But although it supports the WHO approval process, known as pre-qualification, it is a new d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 velopment, according to Daniel Berman of MSF.\par  "Brazil had 100,000 people on (generic) treatment and didn't have the requirement," he said. "We feel like these removals are growing pains of pre-qualification."\par  Generics are essential to reaching the target of 3 million people on Aids treatment by 2005, set by the WHO.\par  Ranbaxy's problems may affect its sales in the lucrative markets of the developed world, which include the NHS. It is understood regulators are now asking for more information. Nobody at Ranbaxy was available for comment yesterday.\par  guardian.co.uk/aids\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%);   WORLD HEALTH ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION  (90%); WORLD HEALTH ORGANIZATION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (90%); WORLD HEALTH ORGANIZATION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY (NSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); UNITED STATES (94%); AFRICA (94%); EUROPE (92%); MOLDOVA, R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PUBLIC OF (79%); MALAWI (79%); COTE D'IVOIRE (79%); NORTH AMERICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); UNITED STATES (94%); AFRICA (94%); EUROPE (92%); MOLDOVA, REPU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LIC OF (79%); MALAWI (79%); COTE D'IVOIRE (79%); NORTH AMERICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC PRODUCTS (94%); PHARMACEUTICALS INDUSTRY (90%); DEVELOPING COUNTRIES (90%); GENERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); AIDS & HIV TREATMENT (90%); PR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SCRIPTION FORMULARIES (89%); PUBLIC HEALTH ADMINISTRATION (89%); TEST LABORATORIES (86%); PRESCRIPTION DRUGS (78%); HEALTH DEPARTMENTS (78%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PHARMACEUTICAL PREPARATION MFG (78%); MALARIA (78%); DRUG & MEDICAL DEVICES APPROVAL (78%); MULTINATIONAL CORPORATIONS (75%); TUBERCULOSIS (73%); ECONOMIC CONDITIONS (72%); APPROVALS (72%); INTERNATIONAL ASSISTANCE (71%); US PRESIDENTS (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 11, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore November 4, 2004 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_207}{\*\bkmkstart DOC_ID_207_0}{\*\bkmkstart doc_id_69}{\*\bkmkend DOC_ID_207}{\*\bkmkend DOC_ID_207_0}{\*\bkmkend doc_id_69}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_69"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00360039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 69 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India's pharma ache;\par The upcoming amendment to the Indian }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Act may lead to i}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 creased competition from MNCs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  4, 2004 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par YOGI AGGARWAL\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE Indian pharmaceutical industry finds itself at a cusp. Depending on how the government approaches the necessary amendment to the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act, the fast-growing sector could find itself stalled or poised for a further push.\par Cheap and good: The Act has allowed India to manufacture patented drugs at a fraction of the cost in the West, making the sector the third-largest in the world\par Ever since the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act was enacted in 1970 to allow for reverse engineering of patented drug mo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ecules, the pharmaceutical business in India has galloped ahead using new processes to make medicines at some of the lowest prices in the world.\par Multinational drug companies have not been able to compete with the low prices of the aggressive Indian upstarts who have pushed up their market share since 1970 from under 30 per cent to 72 per cent. Growing at over 20 per cent a year, the 370-billion rupee (S$13.6 billion) Indian pharma sector is the third largest in the world in volume, but much lower down in value of output because of the low prices. \par But now the Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act is to be amended under Trips (Trade Related Intellectual Property in Services) of the World Trade Organization and the question uppermost in the minds of participants is whether the go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernment will be able to protect Indian interests by resisting pressure from multinational drug giants.\par As the amendment to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act comes before parliament in the weeks ahead, the crucial battle b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tween the contending interests is between exclusive marketing rights demanded by the multinationals and compulsory licensing which the Indian companies want.\par Exclusive marketing rights for the drugs still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  would mean that the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holding companies would retain the exclusive right to import or locally manufacture the drugs. They could keep production down to push prices up, says T R Gopalakrishnan, assistant secretary-general of the Indian Drug Manufacturers Association (IDMA).\par Making drugs for the poor\par Compulsory licensing would imply that any company would have the right to manufacture a generic (non-branded) version of the drug, provided it pays the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder a royalty. It would also allow Indian comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies to export much-needed patented drugs to the less developed countries which need them but don't have manufacturing facilities.\par Another anxiety voiced by Indian companies is that the bill may do away with the pre-grant opposition proc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dure. This is a mechanism to stop frivolous }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  which could otherwise take years to defeat in the courts. In the absence of pre-grant opposition, around 6,000 applications are pending which would escape public scrutiny.\par A petition to the prime minister signed by several health-related NGOs states that public scrutiny is crucial in light of the fact that less than 500 drugs have been granted marketing approvals in India between 1995-2004 -- indicating that the rest are trivial applications.\par Hence, pre-grant opposition is absolutely essential for blocking trivial }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . The 1970 }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act and the thrust it gave to making drugs through another route was a watershed in the Indian pharmaceutical industry. Though only some 50 patented drugs are currently manufactured in the country they are widely used and account for around a fifth of total drugs sold in the country.\par More important, the reverse engineering has helped develop the kind of expertise which the Indian pharma industry now has and which could take it to the top in a couple of decades. Indian companies are adopting a number of strategies to get there.\par One way used by leading companies like Ranbaxy and Dr Reddy's is to challenge in US courts a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for a popular drug which has expired but which the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder has extended beyond the normal 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  period by the stratagem of making a minor change.\par They have been helped in this by a ruling of the US Food and Drug Administration (FDA), which gives excl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sive generic marketing rights for six months to a company which is successful in prevailing over a branded drug maker in court.\par Generic drug manufacturers around the world led by the giant Israeli company Teva are increasingly adop}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing this strategy. In 2002, around 83 such cases were filed by generics companies. In 2001, Dr Reddy won a case against the giant Eli Lilly over a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on its anti-depressant Prozac.\par Though it cost the company over US$1 million to fight the case, it earned around US $70 million in those six months. Similarly, Ranbaxy challenged Glaxo SmithKline over the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for the anti-biotic Ceftin. When it won, the rewards were tremendous for Ceftin now accounts for 40 per cent of all Ranbaxy's sales in the US.\par These are not the only successes. A notable achievement has been that of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the Indian firm that did groundbreaking work in developing an affordable Aids treatment mode. Western companies were marketing their anti-AIDS drugs for US$12,000 per person per year.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  came out with a formulation for US$350 and it kept reducing the price. Their drug is now used in over 90 countries.\par The major driving force is globalisation, using India as the manufacturing base, noted Y K Hamied, chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in a recent speech. Once the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act is amended, many multinational companies will see the great advantage in using India as a manufacturing and research base.\par With a low-cost labour force and readily available technical skills, drug manufacturing costs in India are less than half of what they are in the West. The drug giants would not only manufacture here for the local market but also for export.\par Exports now account for sales of around 140 billion rupees, says Mr Gopalakrishnan, or around 35 per cent of the total industry turnover, up nearly ten times from 14.9 billion rupees in 1993. This may increase, but multinationals manufacturing for export would eat into the share of Indian companies. R&D and the deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 opment of new molecules is another area of growth.\par It costs around US$500-600 million to develop and clinically test a new drug. This could be done in India for as little as US$15-20 million, says Mr Gopalakrishnan. While only a handful of Indian companies can curren}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ly risk spending such amounts, many of the drug giants are likely to shift part of their R&D efforts to India.\par Other growth areas are indigenous medical systems like ayurveda and health tourism. The plants needed for ayurvedic medicines need careful cultivation and cannot be done on the large scale that the drug giants would need.\par And, while their efficacy has been demonstrated over the centuries, they are unlikely to meet the strict repr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ducible needs of modern medical science. It will be left to Indian companies to use ayurvedic medicines.\par Though still small, medical tourism, with people coming to India for the low-cost medical treatment and ope}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ations is also growing. The new high-tech hospitals being built around the country are already being used by foreign patients.\par Despite the possibilities, the risks cannot be dismissed. Dr Hamied expressed it with sadness: 'The achiev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments of the indigenous pharmaceutical industry over the past few decades have been outstanding. Howe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er, all this is likely to be diluted by India's agreeing to adopt Trips by January 2005. Our government has u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fortunately failed to appreciate the far-reaching implications of its action.'\par The writer is a Mumbai-based journalist who contributes regularly to BT.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  PATENTS (95%); PHARMACEUTICALS INDUSTRY (94%); PATENT LAW (91%); PHARMACEUTICALS PATENTS (90%); MULTINATIONAL CORPORATIONS (90%); INTELLECTUAL PROPERTY LAW (90%); PHARMACEUTICALS ASSOCIATIONS (78%); HEADS OF STATE & GOVERNMENT (78%); ENGINEE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (78%); INTELLECTUAL PROPERTY (78%); MARKET SHARE (78%); PHARMACEUTICAL PREPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION MFG (77%); IMPORT TRADE (76%); HOLDING COMPANIES (75%); PRICE INCREASES (74%); PRICE CHANGES (74%); REVERSE ENGINEERING (73%); BUSINESS & PROFESSIONAL ASSOCI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (73%); PRIME MINISTERS (73%); MANUFACTURING FACILITIES (72%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (72%); EXPORT TRADE (71%); NONGOVERNMENTAL ORGANIZATIONS (70%); PETITIONS (63%); \par \par  INDIAN DRUG MANUFACTURERS ASSOCIATION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mviews\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1251 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 3, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HIV-Aids and STDs;Vaccine, Treatment and PEPFAR Developments Africa News October 20, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_208}{\*\bkmkstart DOC_ID_208_0}{\*\bkmkstart doc_id_70}{\*\bkmkend DOC_ID_208}{\*\bkmkend DOC_ID_208_0}{\*\bkmkend doc_id_70}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_70"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 70 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2004 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 HIV-Aids and STDs;\par Vaccine, Treatment and PEPFAR Developments}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kaisernetwork.org\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1668 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Seven European Countries Call for Increased Research Coordination in HIV/AIDS Vaccine Development\par [Oct 20, 2004]\par Health ministers from seven European countries on Tuesday during a meeting in Paris called for increased research coordination in the development of an HIV/AIDS vaccine but "sidestepped" committing additional funds to the effort, AFP/Yahoo! News reports. Health ministers or their representatives from the United Kin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dom, France, Germany, Italy, the Netherlands, Spain and Sweden and a representative from the European Commission said that the development of an effective vaccine is an "absolute necessity ... (and) integral part of a broad strategy of global prevention." They also emphasized the need for "greater collaboration" among scientists working on vaccine development, saying that researchers should "pool their results in order to maxim[ize] progress," according to AFP/Yahoo! News. \par Funding\par Despite the European ministers' support for HIV/AIDS vaccine research, the officials did not pledge any add}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional funds to vaccine development efforts, AFP/Yahoo! News reports (AFP/Yahoo! News, 10/19). Del}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gates at the AIDS Vaccine '04 conference in August called for increased financial and political commitment to develop an effective HIV/AIDS vaccine, saying that $12 billion to $18 billion is needed over the next decade for research and clinical trials (Kaiser Daily HIV/AIDS Report, 8/31). Current spending on HIV/AIDS vaccine development is approximately $650 million annually, which is less than 1% of total spending on all HIV/AIDS product development, according to the International AIDS Vaccine Initiative (AFP/Yahoo! News, 10/19). The European Commission has contributed $125 million over the past four years to HIV/AIDS research, and member countries hope to increase spending to $1.25 billion over the next decade, the Financial Times r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports (Arnold, Financial Times, 10/20). According to E.C. representative Octavi Quintana Trias, the European Union is "ready to make an effort" to increase funding, but E.U. member countries also must pledge additio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al contributions, according to AFP/Yahoo! News.\par G8 Meeting\par French Health Minister Philippe Douste-Blazy hosted Tuesday's meeting in order to "forg[e] a single Europ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an view" on the issue of HIV/AIDS vaccine development in advance of a Group of Eight meeting on Thursday in Washington, D.C., AFP/Yahoo! News reports. The G8 meeting is scheduled to focus on the Global HIV Vaccine Enterprise, which aims to speed development of a vaccine and increase research collaboration (AFP/Yahoo! News, 10/19). G8 leaders from the United States, Japan, Germany, France, Britain, Italy, Ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ada and Russia in June at a summit in Sea Island, Ga., announced the formation of the enterprise, which calls for the establishment of HIV vaccine development centers throughout the world, the expansion of manufacturing capabilities, the creation of standardized measurement systems, the construction of clinics for trials and the creation of rules allowing regulatory authorities in different countries to recognize the results of foreign clinical trials. In addition, the initiative will encourage scientists from developing nations to play a larger role in the search for a vaccine. A coordinating center for the initiative will be established in the United States using a proposed $15 million in initial funding from President Bush (Kaiser Daily HIV/AIDS Report, 6/14).\par More European Influence\par During Thursday's G8 meeting, France is expected to "lead a push" for an increased European influence in vaccine efforts, which currently are led by the United States, the Times reports. Douste-Blazy and French Research Minister Francois D'Aubert on Tuesday in an opinion piece in the French newspaper Le Figaro expressed concern that Europe lags behind the United States in HIV/AIDS research, the Times reports. "While more than a third of the vaccine candidates currently being developed globally have come from Eur}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pean research, 90% of the clinical tests are being carried out in the U.S.," they wrote, adding, "Given the strength of its commitment to fighting AIDS and its research capability, France should be at the forefront of such an initiative." However, British officials are concerned that a French initiative to gain more influence over vaccine development could "trigger a damaging stand-off" with the United States, according to the Times. Therefore, British officials plan to act as mediators between France and the United States and pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pose that a joint research initiative include more scientists from developing countries such as India and South Africa. "We need the best brains in the world working together on this, so we need to get European scientists working with scientists from the U.S. as well as from developing countries," British Junior Minister for International Development Gareth Thomas said (Financial Times, 10/20).\par Generic Drug Maker Ranbaxy To Resubmit Three AIDS Drugs Dropped From WHO Treatment List\par [Oct 20, 2004]\par Indian generic drug manufacturer Ranbaxy plans to resubmit to the World Health Organization by the end of the year three generic antiretroviral drugs that the organization removed from its list of prequalified HIV treatments, according to Ranbaxy CEO Brian Tempest, Reuters reports (Reuters, 10/18). WHO in August removed the medications -- including a fixed-dose combination of lamivudine, stavudine and nevirapine in two strengths and a lamivudine, zidovudine combination pill -- after inspecting the contract research organ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zation that conducted tests to determine whether the medications were bioequivalent to the patented ve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sions. WHO decided to remove the drugs after determining that the testing lab failed to meet international standards of clinical and laboratory practices, marking the second time this year that the organization has removed generic AIDS medications from its list of prequalified drugs. WHO in June removed Indian generic drug manufacturer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  versions of lamivudine and zidovudine from its approved HIV treatment list b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause of problems detected during a similar inspection of an independent laboratory that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had hired to conduct its bioequivalence studies (Kaiser Daily HIV/AIDS Report, 8/6).\par FDA Approval\par Ranbaxy also plans to submit the drugs for FDA approval by the end of the year in an effort to include the drugs in the President's Emergency Plan for AIDS Relief, according to Reuters (Reuters, 10/18). PEPFAR is a five-year, $15 billion program that directs funding to 12 African nations -- Botswana, Ethiopia, Cote d'Ivoire, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda and Zambia -- as well as Haiti, Guyana and Vietnam (Kaiser Daily HIV/AIDS Report, 10/14). PEPFAR so far has "refused" to buy g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drugs approved by WHO because U.S. officials say that FDA should be involved in determining med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines' quality, Reuters reports. However, if Ranbaxy gains FDA approval for its generic antiretrovirals, they could be distributed in countries included under PEPFAR. The medications would not be sold in the United States because of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection laws. "What happened was unfortunate and we are re-doing all the bi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 equivalence studies around the world, and we will be filing with the WHO and [FDA] by the end of the year," Tempest said (Reuters, 10/18).\par Harvard School of Public Health Behind in Administering PEPFAR Grant for HIV/AIDS Treatment Programs\par [Oct 20, 2004]\par The Harvard School of Public Health is "dramatically behind schedule" in administering a $107 million grant from the President's Emergency Plan for AIDS Relief to help place 75,000 HIV/AIDS patients in Africa on antiretroviral drugs, the Boston Herald reports. PEPFAR awarded HSPH the grant in March to help admini}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ter antiretrovirals in Nigeria, Tanzania and Botswana. However, the school currently is providing medication to only 1,500 out of a first-year treatment goal of 8,000 new patients in Nigeria, according to project head Phyllis Kanki. She added that the school is treating only 200 new patients in Tanzania out of a projected first-year goal of 3,000 patients. "We started slowly on purpose, to make sure everything is working properly," Kanki said, adding that in Tanzania "everything was delayed because the government was making a very large purchase for the whole country. Now we should be able to get going." In Botswana, the government wanted to utilize the Harvard program to monitor and train medical personnel working in government clinics rather than open a Harvard-run clinic, according to Kanki. Therefore, the HSPH program will "get credit for the 2,000 new patients each month that are being treated at government clinics" in the country, according to the Herald.\par Leadership 'Questions'\par The current number of new patients being treated under the Harvard program allegedly has "alarmed" Ha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vard University President Lawrence Summers and "raised questions about the program's leadership," the Herald reports. "Summers is apoplectic. He sees a major scandal brewing here," an unnamed source who is close to Summers said, according to the Herald. Summers also is "reportedly disappointed with Kanki's pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 formance" and has "apparently questioned her qualifications," the Herald reports. Kanki holds a degree in veterinary medicine from the University of Minnesota and a doctorate in virology from HSPH. She has worked on the HIV/AIDS epidemic in Africa for almost 20 years, according to the Herald. However, a spokesperson for Summers "denied that he had said anything derogatory about Kanki or her program" and that it is "[a]bsoutely untrue that Larry Summers is putting out any (such) word," the Herald reports. Catholic Relief Services and the Elizabeth Glaser Pediatric AIDS Foundation, which also have received PEPFAR grants, said they each have enrolled approximately 5,000 new patients (Strahinich, Boston Herald, 10/19).\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (96%); AIDS & HIV TREATMENT (94%); VACCINES (94%); DRUG DESIGN & DISCOVERY (93%); HEALTH DEPARTMENTS (90%); BIOLOGICS MFG (90%); RESEARCH (90%); PU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LIC HEALTH ADMINISTRATION (90%); TALKS & MEETINGS (90%); SEXUALLY TRANSMITTED DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASE (90%); EUROPEAN UNION INSTITUTIONS (89%); INTERNATIONAL ECONOMIC ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (89%); INTERNATIONAL ASSISTANCE (89%); AIDS POLICY (78%); INTERNATIONAL ECONOMIC DEVELOPMENT (78%); CONFERENCES & CONVENTIONS (78%); ALLIANCES & PARTNERSHIPS (78%); PHARMACEUTICALS PRODUCT DEVELOPMENT (78%); MEDICAL RESEARCH (78%); VA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CINATION & IMMUNIZATION (73%); PRODUCT DEVELOPMENT (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 YHOO (NASDAQ) (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS519130 INTERNET PUBLISHING & BROADCASTING & WEB SEARCH PORTALS (93%); NAICS517110 WIRED TELECOMMUNICATIONS CARRIERS (93%); SIC7375 INFORMATION R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIEVAL SERVICES (93%); SIC7373 COMPUTER INTEGRATED SYSTEMS DESIGN (93%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS511110 NEWSPAPER PUBLISHERS  (81%); SIC2711 NEWSPAPERS: PUBLISHING, OR PUBLIS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING & PRINTING (81%); NAICS511110 NEWSPAPER PUBLISHERS (81%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPEAN COMMISSION  (57%); EUROPEAN COMMISSION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (95%); FRANCE (95%); EUROPEAN UNION MEMBER STATES (93%); GERMANY (93%); ITALY (93%); NETHERLANDS (92%); UNITED STATES (92%); SPAIN (92%); UNITED KINGDOM (92%); CANADA (79%); JAPAN (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DISTRICT OF COLUMBIA, USA (79%); GEORGIA, USA (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PARIS, FRANCE (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FRENCH RESEARCH (56%);  EUROPEAN COMMISSION (62%);  YAHOO INC (93%); F}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NANCIAL TIMES GROUP  (81%); FINANCIAL TIMES GROUP (81%);  EUROPEAN COMMISSION  (57%); EUROPEAN COMMISSION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 20, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 George W. Bush: AIDS warrior: Attacking the U.S. administration for indifference to AIDS is like attacking it for inadequate defence spending: The fact is the United States is far and away the leader in the global AIDS fight The Gazette (Montreal, Quebec) July 22, 2004 Thursday Final Edition \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_209}{\*\bkmkstart DOC_ID_209_0}{\*\bkmkstart doc_id_71}{\*\bkmkend DOC_ID_209}{\*\bkmkend DOC_ID_209_0}{\*\bkmkend doc_id_71}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_71"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 71 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Gazette (Montreal, Quebec)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2004 Thursday Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 George W. Bush: AIDS warrior: Attacking the U.S. administration for i}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 difference to AIDS is like attacking it for inadequate defence spending: The fact is the United States is far and away the leader in the global AIDS fight}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SOURCE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Washington Post\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEBASTIAN MALLABY\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Editorial / Op-ed; Pg. A23\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 868 words\par \par In the past few years,AIDS activists have worked miracles. They have shaken rich governments awake, causing international AIDS funding to rise 15-fold. They have beaten back big pharma's jihad against cheap, nonbrand medicines, creating an opportunity to treat millions of people in poor countries.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 But the activists, or at least some of them, are in danger of tipping from heroism into shrill anti-Americanism. The sound bites from last week's AIDS conference in Bangkok, Thailand, were straight out of a Michael Moore movie. \par Inconveniently for those who enjoy stereotypes, the Bush administration is far and away the leader in the global AIDS fight. This year, the United States will spend $2.4 billion on the pandemic, nearly twice as much as all other donor governments combined.\par Attacking the Bush team for indifference to AIDS is like attacking it for inadequate defence spending. But when Randall Tobias, the U.S. global AIDS co-\par ordinator, addressed the Bangkok gathering last week, he had to endure 10 minutes of furious heckling b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fore he could get a word in edgewise.\par What triggers this hostility? The activists' first complaint is that U.S. AIDS spending will finance programs to promote sexual abstinence and fidelity. Never mind only seven per cent of the money will be spent this way; the abstinence agenda is derided as some kind of kooky anti-scientific plot cooked up by President George W. Bush's evangelical supporters.\par Yet the plotters actually include such very unevangelical people as Edward Green, a Harvard medical a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thropologist (and liberal Democrat) who has written a book on AIDS prevention. Green has shown how Uganda's success in cutting HIV infection rates from 21 per cent to six per cent depended crucially on teac}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing abstinence.\par In the first half of the 1990s, the number of young Ugandans engaging in premarital sex plummeted; by 1995, fully 95 per cent of Ugandans reported they were either abstaining or monogamous.\par Elsewhere in Africa, experience also supports the Bush administration's desire to make abstinence and fidel}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty part of its prevention strategy.\par The evidence from Botswana, South Africa, Kenya and Zimbabwe suggests there's no clear link between the availability of condoms and reduced HIV rates: All four countries have plenty of condoms yet plenty of infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion.\par Meanwhile in South Africa, the single most promising development is that reported rates of teenage sexual activity have fallen for three years straight, disproving the notion there's no point in telling youths to change their behavior. In sum, it is not the Bush administration that is ignoring the evidence. It is Bush's critics.\par The activists' second complaint about the U.S. AIDS program is that it is hostile to generic medicines. Until recently, this was true. Perhaps because of its ties to the big pharmaceutical companies that sell patented drugs, the administration has been scandalously slow to allow cheaper generic copies to be used in its pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams.\par But in May the Bush team finally announced generics were OK, subject only to a six-week review by the Food and Drug Administration to determine safety and efficacy.\par The activists do not believe the FDA's change is for real, and their suspicions are reinforced by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , a lea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing Indian producer of generic AIDS drugs. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  charming joint managing director, Amar Lulla, explains to anyone who calls he would love to get his drugs approved for distribution in U.S.-financed programs in the poor world but that the Bush administration's fine print is cluttered with obstacles.\par On close inspection, however, these obstacles aren't serious.\par For example, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  best known AIDS medicine is called Triomune; it combines three separate antiviral drugs in one pill, simplifying treatment. Lulla says the FDA has not explained whether or not he needs to demonstrate the safety of combining the drugs this way, in which case }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  would have to conduct prohib}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tively expensive clinical trials.\par But anyone who goes to www.fda.gov/oc/initiatives/hiv/hivguidance.html, will find the explanation that Lulla says he's waiting for. Attachment B lists three-drug cocktails the FDA already accepts as safe, among them one combining stavudine, lamivudine and nevirapine, the three constituents of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Triomune.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  also says it worries if it files an FDA application, it might be sued by U.S. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders. But the FDA's rules allow }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to file a statement certifying its pills are intended for sale outside the United States, a m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 noeuvre that would almost certainly eliminate the risk of being sued for U.S. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement.\par None of this is to deny that the Bush administration panders to the religious right on some issues, or that it's cozy with pharmaceutical lobbyists.\par And yet the bottom line on the Bush administration's AIDS initiative is that it is huge and serious. The AIDS activists at last week's conference, whose motives are doubtless honourable as well, would do better to red}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rect their heckling to countries such as Japan and South Korea, which give shockingly little to the cause. When you're fighting an enemy that takes 8,000 lives a day, it pays to pick your targets wisely.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (96%); AIDS POLICY (91%); DEFENSE SPENDING (90%); EDITORIALS & OPI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IONS (90%); PHARMACEUTICALS INDUSTRY (89%); US FEDERAL GOVERNMENT (89%); LIBERALISM (78%); GENERIC DRUGS (78%); SEX EDUCATION (78%); EPIDEMICS (78%); ADOLESCENTS (77%); INFECTIOUS DISEASE (75%); US DEMOCRATIC PARTY (74%); POLITICAL PARTIES (73%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MFG (72%); GENERIC PRODUCTS (72%); PREVENTION & WELLNESS (69%); RELIGION (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (96%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGKOK, THAILAND (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 QUEBEC, CANADA (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (99%); UGANDA (94%); AFRICA (93%); SOUTH AFRICA (92%); THAILAND (92%); ZIMBABWE (79%); KENYA (79%); BOTSWANA (79%); CANADA (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 22, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: KEVIN LAMARQUE, REUTERS; U.S. President George W. Bush hugs Ugandan children orphaned by AIDS or conflict during a 2003 visit to Africa. Uganda's anti-AIDS program - one of the most successful in Africa - uses condoms but emphasizes abstinence and fidelity.; Graphic;Diagram: (See hard copy for graphic)\par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 CanWest Interactive, a division of\par CanWest Global Communications Corp.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS Activists Misfiring The Washington Post July 19, 2004 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_210}{\*\bkmkstart DOC_ID_210_0}{\*\bkmkstart doc_id_72}{\*\bkmkend DOC_ID_210}{\*\bkmkend DOC_ID_210_0}{\*\bkmkend doc_id_72}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_72"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 72 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\shppict{\pict{\*\picprop\shplid1027{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLine}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw7620\pich2540\picwgoal4320\pichgoal1440\pngblip\bliptag657880520 89504e470d0a1a0a0000000d49484452000000d8000000480803000000a398cb9c00000300504c5445ffffff000000404040bfbfbf7f7f7fccccccefefef9900331010103030309f9f9f606060cfcfcfdfdfdf2020208f8f8f505050707070afafafd47d96c04064eabfcbde9baefaeff2b0103df4dfe5e5afbecb607ebb3057c55071b6204aefcfd8000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000335c3c3e00000c254944415478daed1b8972dbb6720192004f9152e2a449dad7ffffacccbc695ed234b12d89120f106f770152b41cc94ae31ef1043316491c8b5dec89050cf0a33cf1a256df079ef22bfb87f1fe49b22b11e99394432944004f5014950588bf335ea4615516ee35470a965fec54082c288b2af40aa7ce2ec30148faa000e797ac6b78f779a2aceeea0e958c485b49fc94274551c4f4c8e82b13893aa78f13903c7e4835b3f02205c76953ff3c594a798430972443a471e409c202ea83040951297e9ca66c06a488b1e7592f9189f012ba683ec94f7972ded44fcbbf811dabf7b5857d74d2a21bc6827e6f82654dfd4fda92ec00a41148dce61c5df505821844349f81889ef69404a4bbb13b7f75a9296dd4bba6061117f6cbe31045888cc29e3dc4921f274a7b0062642cc5ee0cce08440e0f1166878c61862d4ddfda934befa665c2cc629db6619dc79d28fa86b0175689d07819580c664e586b244d31ec67c8e451dc4e3ebc68208d3b06e28626a12486e5ccc57498702ad29046e5d837192457171e5011091c9946dd813043efdab4c6da117bb59838b48a0713c81c173bb632f2085728e429a40b7452d2691c49b2d79f60210ee68d75cce964307da1c2a24d0980fb176c87166a02a2c876641889a905a9464a76b5f0b88818df5905517d585cb06ae5142ae1bea5ef3b5a02320da4e9ac4239ce157a0bcc30726704e3c2732c8a6aa1827d8beb402b81c8c6720fbda2d50b871635c9ce38e61fd8d37fa9e216b96e338122921a56c4be9f80e8c034d0454604a8492adb62a34cf6b4dabb064c2f454be25c74ba05150f58b50f9301d5bccf0cf2ae91d24bbbd2c4cb0e2c48cfb1b26b90917261863c22fd8120dd6a037a88b6a328b690ec07eeee09eb15f2bd4fd7ca0e258ed60ef8b2812f101684db25a949278c2a36c6561d54f50148dc936c0dade52f1162cf6267d0716d169ae0c57b8b7d0de290234225926ca3c44a03ad6251174eac0abb6f79e691305c4eb3b4d8a88c685a94f024687716870c4337e371c10c3e882249177ea29404c45e6678ee5cc29128e6fc5e7183831190101f801490d0bb725f289024476e54e6c0f909f8b1724356ec21aa51d65173dde4c1248a214fced078a08af311f7d1782824bbf1ebe039266ccf9f64640cc921fd1db47ece3163c7eee0604469d864ed01c81e06078abf7ab62a7e94b523383244fcd8091e4256aff550dde2ab226ae71c6363d332341e882c95d6e1ce0b317aa7d3c56475e03dc17e78d8dfe4fd1aa086c72e2afe742eaed5d9cdd1fe6ab4bceb036647588581d7dfa431e2610c6eff9a60b63ebf56f75ac3794ce1e83a8a6e3259fbc6f5652808d5fc03517c1cadef6d5bd291c082deeaa3e0a7be6e2f868e56021643fb771325842e77f5fdfdd85ae35fb6d08b5b243ab4473bae0571711e73fa302d56b30f5f3643256efe7e6e0d99aabfb8d124a75fef424429b7461c730c370a72be5dda658a3eeb00294bb733bfadd055f72776141a238872fe41f1ca9d76450b358c2b386b536abefbb322d3f77671dbb03d06e5220f7282a64b068d91974cc8bfa56c8f537c357d26ec68114232a55d04e83fd1fff641431134ce96917d89f27013ec658615417c006221eea1af5ad5e2a0a423cf9df51471efd36ef21e5d35b05b513810a3d48222092dc91d2432e37830e98c73321d0e8d3590a797180f17611bda16fd97f51ea84fa4191cc7d6ce90ee2de219384b11393a7292cb5a4c8cee39a20bb621d5ef138a22142b26ce040dc63bb5311ba5bd19f5cbb82460379227199817b5b6c4b39d3ac8f68dd00902ddf773252535d88b4fced5ccb5c16c1285809a9d2df79bdc5863861007a2c4d10879d873ac62bfd30c79af865b54174460704781e8dc4dc5ecda69bb974edb447cc5fa2a8fab6cc19bd03b400a17f952178a49305e4dd54a615491a4dcbe1a27a1ba8513afc205e1e9340b6e9b29040a160b8a9cc7d09b86a924596253420383bc1477f7d7aa94386de642e974c9718b330fe551fe23afdc3a2f0f76a34c5d7d482bb1f4ebb09a0349b9b2c8d42c0322134581fd629c912165a392a96c36906c55ee0239a9b249e173d6fd55c900c68141f54076475cb05d7f30457406484ebc41c65f98f62a7c842abf1125158be5238441a781a8380890c1abaf58beaf22ec44ce2208e3ee9be3bd734054d060081c674d7ef934e4548a5339814bd75a3d46dc7a06482512cee57d4dc61c076489847f75099605edec931cbe8ab0eca164e9bfe58ce3ebe4422ee169961c7e14dac8ff58831fe547f9171529e4f782e99365c10fc2eefbcbb07c9a3a36db433f2d8e456366e4246cf90884a7f2cfa1f80dc1f22092ddd90e161e2175fa8dfbafbfc4dc3f4672814e8bbe5d14d5d33106248a01241bbf5d9ff2055853a09c65c3baa8a955852d587f3691a280c55857d460809a030153e3ea1660f14919846106d09606531d427290d386b2b6c9da8d27b8d3d879479e1e7be5b6c641c128d3af29f319bca3d797344cff46afaf7af8fd054e29dec3d580ccfadde511a4859c81a5bb25e726f32da4dbe5b5a7d1880149e6f3fe2df68d813397490da1412d0a8d48386bc1c9ee5c32a058dda228b883d621372ed599767c6e573ac471261cbfacf9604670867ad53b92f8306ec52d49edee124847faebf0bd73347f003c8b3e331c89a43ddbc0f38f446b177ea0caf203277370ac4bb326ade667d4814e6f28c31df45619ca51ef40146d977602fabea0e4725fb43c27fe743a6fb5e9025c9fbe066cd54de38e1e09e76cdb739de914a227a069633a85b7d2e0d0bde126a0a674dd424cf72c2ce5c86da3076d82c425c1dd21e58bcf5bb84a917bba8637d77b28aab4deef9e6d4986eae522adb7f11f58b985e6c5c65b04ce6a52da9612a68510552a4442ef41cc67ba319df1ca50713e05c0dd5360b50eddb5a39ceb173ea19b8d47d47432ecef37605dc5c7ccd4a3a403e6501cba670421e673e38a86212e39e48bd5dc785c69fdd315f1e597e7f042ebe7aff0fdd79fb5be82675affe725c02f5aeb5fb9df0baf346e024267e9ec5090f80c2ecd20099f6a4a1471fd02511909cb5dd649d2817838f96e4f5838dd70ac68d97ce257f9a6f00035f380dc3a07d3e5ab0361bf30dacc3af849ffec5e5ffda49f13612f1ce56fa8ee3ff420ab58172436a8cb05ecf8d29c40954a9cbe1a4ed49670333a5bc1f51b38b8b08dfbb1d04c46f660a1d3f13a039d99eec01f9db6776d32ae5a5843ba19073761a0e1737637c7f1f2033c7feb5e3fbcfe0cfe34fc5d07eb97e0f2a3088d55a99e30e961bdc259f5004d0a61c3b88c07472ce4750c76b7484fa6315dd979aae769d8f5e450d63167639ad9a0b1fb27c6683cf6c2c9db566aa8b7778ee5067775810b02f9edb036442319caf7f38979da5ac335ae6db229c9ce4171ef1a41bb438d5bef2e4e7f355fae3c7fee7ee728b48e2a0d767b3751dd3d38b13d72d068a5966bfc95b00fe9991c725dfe59df26487d716182ecb032fa70174ac1f16e600c080a3ec1cc0fb56888d69f87e04ec890ce84035b5e1d04263d1d7948629958c3a7827d2e6cf448bbe27554051fd93e707d0399ea57f87082128fa77be899ef31b249471986ae98567ba085c109db3e85d969dfdb9713d8d7c1414d0778f9f634617c4fabf2b24fef09acc3719de836eaf6a2a81897da1d6ad5331d6b52aecb075ab1e311ccce1ce9d8a09ebb03bb00bd5d5b6d4acf706f39d0ce6fe1fd1b67f78777056c9c497fb386edb9e89e42288a3a76bae10b615bdd984adee89019b63550add12beafdd91078bdbc5eeb7203f18c0093d53705425f5cc3173068e8509b9a42c018a34e445336384db889e136b4a21e8dc12b7bfbfce31f3ffffef1b9b491c020235a7ebe79633b317c84abff9e236c9db99b2f6d86a1053d73686e4846748c0f19ed6f485e1e8aec3f6735051df5fc82ea36ab2952bac660e6d37d8bda701324d814a63728781827215d3068bea7a7fd8cfd2ddd9ee98ab50bba96ff7bf7ebcbf71f9dfc77e7a37be9df8487b5192a1493a21a5a74dead090aba7e5863c8e044849e8a5ca7f215fc01db44b0e47a6bcece7c2b4b4d90a24f53158de7e740e7e9ba94b4a8ed7542a0e260407fb6a1b4834ea3b5032cafc8b4bcffc837e8afe804fd6d535214f2a2fc4846be7016aae01b38608bf91e2e806317f4d5a508262097fc47c59fdd695d5682630ff00d1bd661baf797f427af4bcf84e52fdd1b3f66fa6d31b9943d68f384f28ae8fd06f6b2a985efe57f7b2ecc28d1bf50846132deeef82775ec7161a7830b2ee26073016106ec77c3335556526697fdb7e39fcd18fe284fb3fc1f6304efb39e95003b0000000049454e44ae426082}}{\nonshppict{\pict\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw216\pich72\picwgoal4320\pichgoal1440\macpict\bliptag657880520 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004800d8001102ff0c00fffe0000004800000048000000000000004800d800000000001e0001000a00000000004800d882000000f39a0000000100000000000000000000000000000001000000000000000000000000000040000000000000000000000000000000000000000000004800d8000003000000000000000056726177200000000000000000000000006170706c000004000000040000d8004800480000004800000000f300000100000000000000000000000000000000000000000000000000000000000000000020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff202020ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff7f7f7fff505050ff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff606060ffdfdfdfffffffffffffffffffffffffffafafafff404040ffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff101010ffffffffffffffffff404040ff000000ff606060ffffffffffffffffffffffffffffffffff606060ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff606060ffffffffffffffffff9f9f9fffffffffffefefefff303030ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff303030ff606060ff404040ff000000ff606060ffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ffffffffff606060ff000000ff000000ff000000ff505050ffefefefffffffffff606060ff000000ff000000ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff303030ffefefefff404040ffefefefff303030ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff707070ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff202020ff000000ff000000ff000000ff000000ffbfbfbfff404040ff606060ff202020ff000000ff000000ff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff606060ffbfbfbfff707070ff101010ff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ffefefefff303030ff000000ff000000ff000000ff000000ff303030ffdfdfdfff303030ff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ff101010ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffefefefff202020ff000000ff000000ff000000ffbfbfbfff000000ff9f9f9fffefefefff303030ff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff8f8f8fffffffffff606060ff101010ffcfcfcfffffffffffcfcfcfff202020ff404040ff404040ff202020ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffefefefff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffefefefff202020ff000000ff000000ff000000ffbfbfbfffffffffffefefefff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff8f8f8fffffffffffffffffff9f9f9fffdfdfdfff404040ff000000ff000000ff404040ffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffcfcfcfff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff707070ffffffffffffffffffffffffffffffffff9f9f9fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff505050ffcfcfcfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff606060ffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff303030ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffefefefff707070ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffefefefffffffffffbfbfbfffbfbfbfffdfdfdfff303030ff000000ff000000ff303030ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffff505050ffffffffff606060ff000000ff9f9f9fffffffffff9f9f9fff202020ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff202020ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff101010ffbfbfbfffffffffffefefefffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff000000ff000000ff000000ff202020ffefefefff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffefefefffffffffffcfcfcfff101010ff000000ff606060ffefefefffafafafffffffffffefefefff202020ff000000ff404040ffefefefffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff101010ff9f9f9fffffffffffdfdfdfffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff303030ff000000ff303030ffefefefffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffcfcfcfff303030ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffefefefff707070ff000000ff000000ff000000ff000000ff000000ffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ff000000ff404040ffcfcfcfff303030ff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff303030ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff606060ff303030ffffffffffffffffffffffffff9f9f9fff101010ff101010ff000000ff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff202020ff9f9f9fff101010ff000000ff000000ff000000ff101010ff9f9f9fffefefefff303030ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ff000000ff000000ff404040ff505050ffffffffffffffffffffffffffefefefff707070ff101010ff000000ff000000ff000000ff000000ff404040ff101010ff7f7f7fff404040ff000000ff000000ff000000ff202020ff404040ffcfcfcfffffffffffffffffffefefefff606060ff101010ff000000ff000000ff000000ff000000ff7f7f7fff606060ffbfbfbfff303030ff000000ff000000ff000000ff202020ff7f7f7fff000000ff000000ff000000ff000000ff404040ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff9f9f9fff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffff8f8f8fff101010ff000000ff000000ff000000ff000000ff404040ff8f8f8fff7f7f7fffffffffffcfcfcfff202020ff101010ff000000ff000000ff000000ff000000ff7f7f7fffafafafff404040ff101010ff000000ff000000ff101010ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffbfbfbfff7f7f7fff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fffffffffffefefefff404040ff000000ff505050ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffbfbfbfff101010ff000000ffafafafff303030ff000000ff000000ff000000ff000000ffefefefffffffffffefefefff505050ff000000ff000000ffbfbfbfffafafafff7f7f7fff404040ff707070ffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fff101010ff404040ff000000ff000000ff000000ff404040ffffffffff404040ff606060ff000000ff000000ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff202020ffefefefffffffffffffffffffcfcfcfff303030ff000000ffafafafff505050ff000000ff000000ff000000ff000000ffcfcfcfffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffcfcfcfff202020ff000000ff7f7f7fff707070ff000000ff000000ff000000ff000000ff606060ff505050ff606060ff101010ff000000ff000000ff000000ff101010ff404040ff000000ff000000ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffefefefff505050ff000000ff000000ffafafafff101010ff000000ff000000ff000000ff202020ffefefefff7f7f7fff000000ff000000ff7f7f7fffcfcfcfff7f7f7fff606060ff303030ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffffffffff101010ff000000ff000000ffbfbfbfff303030ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff505050ff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffbfbfbfff303030ffefefefffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffff303030ff000000ff000000ff404040ffffffffffefefefffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffefefefff202020ff000000ff000000ff404040ffffffffffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffafafafff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffffafafafff000000ff000000ff000000ffafafafffffffffff505050ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffcfcfcfff202020ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffffefefefff101010ffcfcfcfffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffefefefff202020ff8f8f8fffbfbfbfffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff707070ff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffff505050ff606060ffbfbfbfffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff7f7f7fff606060ffbfbfbfff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff8f8f8fff606060ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fffafafafffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfff7f7f7fff202020ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffefefefffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff9f9f9fffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffcfcfcfff505050ff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff202020ff505050ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff404040ff101010ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff303030ff202020ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff202020ffffffffffbfbfbfff000000ff000000ff202020ffdfdfdfffffffffff404040ffffffffff404040ff7f7f7fff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffcfcfcfff404040ff404040ff000000ff8f8f8fffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff404040ff101010ff505050ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff000000ff000000ff606060ff707070ff101010ff8f8f8fffffffffffffffffffffffffff404040ff7f7f7fff000000ffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffafafafffffffffffffffffffffffffffcfcfcfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff404040ff000000ff000000ff000000ff606060ffefefefffffffffff000000ff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffafafafff404040ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffdfdfdfff202020ffefefefffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffffffffffcfcfcfff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff101010ff9f9f9fffffffffffefefefff202020ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff000000ff606060ffefefefff202020ff000000ff000000ff000000ff000000ff303030ffefefefff000000ff000000ff606060ffffffffffffffffffbfbfbfff000000ff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ffefefefffffffffffefefefffdfdfdfff202020ffdfdfdfffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffbfbfbfff000000ff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff606060ffffffffffefefefffefefefff000000ff000000ff000000ff404040ffefefefffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff000000ff000000ff000000ffbfbfbfff000000ff000000ff606060ff9f9f9fff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffffffffff404040ffafafafffffffffffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff303030ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ff404040ff101010ff000000ff000000ff000000ffbfbfbfff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff000000ff000000ff000000ff606060ff303030ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff101010ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff606060ff303030ff000000ff000000ff000000ff101010ff505050ff8f8f8fff404040ff606060ff7f7f7fff7f7f7fffdfdfdfff404040ff000000ff000000ff7f7f7fff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff303030ff000000ff000000ff000000ff505050ff101010ff9f9f9fff101010ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff000000ff606060ff101010ff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fff404040ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff000000ff505050ff303030ff7f7f7fff000000ff000000ff000000ff000000ff303030ffcfcfcfff000000ff000000ff404040ffefefefffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefff7f7f7fff000000ff000000ff000000ff303030ff303030ffafafafffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffefefefff303030ff000000ff000000ff000000ff101010ff9f9f9fff404040ff000000ff202020ffcfcfcfffffffffff7f7f7fff404040ff7f7f7fff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff404040ffffffffffffffffff404040ff000000ff000000ff000000ff303030ff303030ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffff9f9f9fff000000ff000000ff000000ff000000ff8f8f8fffbfbfbfff000000ff000000ff000000ffbfbfbfff8f8f8fffdfdfdfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff606060ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffdfdfdfff707070ff606060ff000000ff000000ff000000ff000000ff707070ff101010ff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ff000000ff101010ff101010ffbfbfbfffffffffff9f9f9fff000000ff000000ff000000ff000000ff7f7f7fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff707070ff202020ff000000ff000000ff000000ff000000ff9f9f9fffcfcfcfff101010ff000000ff000000ff000000ff303030ffffffffff707070ff000000ff000000ff000000ff000000ff8f8f8fff303030ff202020ff000000ff000000ff000000ff000000ff101010ff000000ff000000ff000000ffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff9f9f9fff606060ff9f9f9fff303030ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefffafafafff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffff8f8f8fff8f8f8fff505050ff000000ff000000ff000000ff000000ff000000ff505050ffefefefffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff404040ffffffffffffffffffffffffffefefefff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff9f9f9fffffffffffcfcfcfff101010ff000000ff505050ffcfcfcfff101010ff505050ff606060ff202020ff000000ff000000ff505050ffefefefffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffdfdfdfffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffcfcfcfff101010ff000000ff303030ffefefefffffffffffffffffff707070ff000000ff000000ff9f9f9fffefefefffafafafffefefefff505050ff000000ff000000ff303030ff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffafafafffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff202020ffcfcfcfffffffffffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff606060ff303030ff000000ff000000ff000000ffbfbfbfff202020ff202020ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff8f8f8fffffffffffffffffffefefefff303030ff303030ff707070ff303030ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffbfbfbfffcfcfcfff8f8f8fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff404040ff101010ff000000ff303030ff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff8f8f8fff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff505050ffefefefffffffffffffffffffffffffffffffffffffffffff707070ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff9f9f9fffffffffffffffffffffffffffcfcfcfff505050ffefefefff7f7f7fffbfbfbfffffffffffffffffffefefefff707070ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffff404040ff303030ffefefefffdfdfdfff101010ff000000ff000000ff202020ffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ffcfcfcfffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffefefefff606060ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ffcfcfcfffffffffffffffffffffffffffafafafff8f8f8fffffffffffffffffffffffffff9f9f9fff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff202020ffcfcfcfffffffffffffffffffefefefff303030ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ffbfbfbfffbfbfbfffbfbfbfffffffffffffffffffafafafff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff101010ff8f8f8fff303030ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff303030ff404040ff000000ff000000ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff606060ff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff707070ffdfdfdfffffffffffffffffffcfcfcfff303030ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff606060ffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff7f7f7fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffffffffffffffffffefefefff9f9f9fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffff404040ff000000ff404040ffffffffff9f9f9fff7f7f7fff7f7f7fff7f7f7fffcfcfcfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffbfbfbfff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fffafafafffffffffffefefefffbfbfbfffbfbfbfffefefefffefefefffbfbfbfff000000ff000000ff606060ffbfbfbfffcfcfcfffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffdfdfdfffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffcfcfcfff606060ff000000ff000000ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffd47d96ffd47d96ffd47d96ffde9baefff4dfe5fffffffffffffffffffffffffffffffffffffffffffaeff2ffde9baeffd47d96ffd47d96ffd47d96ffe5afbefffffffffffffffffffffffffffffffffffffffffff4dfe5ffeabfcbffeabfcbffffffffffde9baeffd47d96ffd47d96ffde9baefffaeff2ffffffffffffffffffeabfcbffd47d96ffd47d96ffd47d96ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ffafafafffffffffffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffff707070ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff606060ffffffffffffffffff404040ff000000ff303030ff303030ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ff606060ff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffcfcfcfff202020ff000000ff000000ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffffffffffffffffffff000000ff000000ff505050ff202020ff000000ff000000ff000000ff000000ff000000ffafafafffffffffffffffffff7f7f7fff000000ff000000ffafafafff101010ff000000ff000000ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffafafafff202020ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffb6204aff990033ff990033ff990033ff990033ff990033ff990033ffd47d96ffffffffffffffffffffffffffd47d96ffb0103dff990033ff990033ff990033ff990033ff990033ffb0103dffe5afbeffffffffffffffffffffffffffd47d96ff990033ff990033ffcb607eff990033ff990033ff990033ff990033ffb6204afff4dfe5ffc55071ff990033ff990033ff990033ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffff202020ff000000ff505050ffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffdfdfdfff505050ff000000ff000000ff000000ff404040ff606060ff303030ff000000ff000000ff101010ff000000ff404040ffffffffffffffffff606060ff000000ff000000ff404040ff202020ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff202020ff606060ff404040ff000000ff000000ff000000ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff000000ff101010ff505050ff404040ff101010ff000000ff000000ffbfbfbfffffffffffffffffffcfcfcfff101010ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffcfcfcfff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff000000ff000000ff000000ff000000ff303030ff505050ff303030ff000000ff000000ff101010ffefefefffffffffff7f7f7fff000000ff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff000000ff303030ff505050ff404040ff000000ff000000ff000000ff606060ffffffffffffffffffffffffff101010ff000000ff101010ff404040ff101010ff000000ff101010ffdfdfdfff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ff990033ffbb3057ffcb607effc04064ff990033ff990033ffc04064ffffffffffffffffffcb607eff990033ff990033ff990033ffc04064ffc55071ffbb3057ff990033ff990033ff990033ffde9baeffffffffffffffffffd47d96ff990033ff990033ff990033ffb0103dffc55071ffbb3057ff990033ff990033ffb0103dff990033ff990033ffc04064ffc55071ff990033ff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffffffffffffffffffdfdfdfff000000ff000000ff505050ff9f9f9fff000000ff000000ff303030ffdfdfdfffffffffffffffffffffffffffbfbfbfff101010ff000000ff000000ff404040ffffffffffffffffff101010ff000000ff7f7f7fffffffffffefefefff404040ff7f7f7fffefefefffffffffff404040ff000000ff000000ff606060ffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff303030ffefefefffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffefefefff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff606060ff000000ff000000ff505050ffffffffffffffffff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffff8f8f8fff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff606060ffffffffffcfcfcfff000000ff000000ff101010ffbfbfbfffffffffffffffffffffffffffefefefff505050ff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ffcfcfcfffffffffffcfcfcfff202020ffafafafffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffb0103dffeabfcbfffffffffffffffffffffffffffaeff2ffc55071ffc04064ffffffffffde9baeff990033ff990033ffc04064fff4dfe5ffffffffffffffffffffffffffefcfd8ffbb3057ff990033ff990033ffeabfcbffffffffffd47d96ff990033ff990033ffb6204afffaeff2ffffffffffffffffffc55071ff990033ff990033ff990033ffefcfd8ffffffffffffffffffeabfcbff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff707070ffffffffffffffffffffffffff7f7f7fff000000ff000000ffbfbfbfff303030ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffffffffffffffffff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefffffffffffffffffffffffffffffffffff202020ff000000ff606060ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffafafafff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ffdfdfdfffffffffff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefff606060ff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffbfbfbfff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc55071ff990033ff990033ffefcfd8ffffffffffffffffffffffffffffffffffffffffffffffffffde9baeffffffffffb0103dff990033ffbb3057fffffffffffffffffffffffffffffffffffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffd47d96ff990033ff990033ffde9baeffffffffffffffffffffffffffeabfcbff990033ff990033ffcb607effffffffffffffffffffffffffffffffffb6204aff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff202020ffffffffffffffffffdfdfdfff000000ff000000ff202020ff000000ff101010ffffffffffffffffffefefefff101010ff000000ff404040ffefefefff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff404040ffffffffffffffffff505050ff000000ff000000ff404040ff9f9f9fffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff606060ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff202020ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff7f7f7fffffffffff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffefefefff101010ff000000ff000000ff606060ffcfcfcfffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffffffffffffffffffffffffffaeff2ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033fffaeff2ffd47d96ff990033ff990033fff4dfe5fffffffffffffffffffffffffffaeff2ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffafafafffffffffff7f7f7fff000000ff101010ffcfcfcfff000000ff000000ff9f9f9fffffffffff9f9f9fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff202020ff9f9f9fffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff505050ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff9f9f9fff101010ff000000ff000000ff000000ff404040ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff404040ffffffffff202020ff000000ff707070ffffffffff505050ff000000ff303030ffffffffff202020ff000000ff202020ffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffff9f9f9fff202020ff000000ff000000ff000000ff707070ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffdfdfdfff707070ff101010ff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff707070ff000000ff000000ffdfdfdfffffffffffafafafff000000ff000000ff7f7f7fff000000ff000000ff9f9f9fffffffffffcfcfcfff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ffdfdfdfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff707070ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff707070ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffefefefff7f7f7fff000000ff000000ff303030ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffefcfd8ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ffefcfd8ffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff000000ff000000ff404040ffffffffffffffffffffffffff202020ff000000ff000000ff000000ff202020ffffffffffffffffffffffffff101010ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff404040ffffffffffffffffffefefefffdfdfdfffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff8f8f8fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff505050ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfff202020ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffdfdfdfffffffffffffffffffffffffffffffffff606060ff000000ff000000ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffb6204aff990033ffb6204affffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbefff4dfe5ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc04064ff990033ffb6204affffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ffafafafffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffff707070ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ff404040ffffffffff8f8f8fff101010ff404040ffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffdfdfdfff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ff505050ffefefefffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff202020ffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff202020ffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffefefefff505050ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff101010ffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffaeff2ffeabfcbffffffffffffffffffd47d96ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffeabfcbffb0103dffffffffffc04064ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffcb607eff990033ff990033ffd47d96ffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffefefefffffffffffffffffffffffffffefefefff101010ff000000ff000000ff505050ffafafafffbfbfbfff9f9f9fff202020ff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff505050ffbfbfbfff9f9f9fff101010ff000000ff101010ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff707070ff000000ff000000ff101010ff8f8f8fffbfbfbfffbfbfbfff606060ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffff606060ff000000ff000000ff202020ff8f8f8fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ff101010ff7f7f7fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffafafafffffffffffffffffff404040ff000000ff000000ff303030ff9f9f9fffbfbfbfffafafafff606060ff000000ff000000ff101010ffcfcfcfffffffffff202020ff000000ff000000ff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff606060ffffffffff7f7f7fff000000ff000000fffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffffffffffbb3057ff990033ff990033ffc04064ffde9baeffeabfcbffe5afbeffcb607eff990033ff990033fffffffffff4dfe5ffb0103dff990033ff990033ffcb607effe5afbeffeabfcbffde9baeffc04064ff990033ff990033ffbb3057ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff000000ff101010ff505050ff000000ff404040ffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffafafafffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffffeabfcbff990033ff990033ff990033fffffffffffffffffffaeff2ffc04064ff990033ff990033ff990033ff990033ff990033ff990033ff990033ffb0103dffffffffffffffffffefcfd8ffb6204aff990033ff990033ff990033ff990033ff990033ff990033ff990033ffc04064fffaeff2ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ffefefefffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ff202020ff000000ff000000ff202020ff707070ffefefefff9f9f9fff404040ff707070ffffffffffffffffffefefefff7f7f7fff202020ff000000ff000000ff303030ffbfbfbfffffffffffffffffff707070ff404040ff707070ffffffffffffffffffffffffffffffffffffffffff707070ff404040ff707070ffffffffff9f9f9fff404040ff404040ffffffffffffffffff9f9f9fff404040ff707070ffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffff9f9f9fff404040ff000000ff000000ff000000ff505050ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffbfbfbfff505050ff101010ff000000ff000000ff202020ff707070ffdfdfdfffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffff707070ff404040ff9f9f9fffffffffff7f7f7fff000000ff000000ffffffffff9f9f9fff303030ff000000ff000000ff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff505050ff000000ff000000ff000000ff303030ff7f7f7fffefefefffffffffffffffffffffffffffffffffffcfcfcfff505050ff000000ff000000ff101010ff606060ffdfdfdfffffffffffffffffff9f9f9fff404040ff404040fffffffffffffffffffaeff2ffbb3057ff990033ffd47d96ffffffffffffffffffffffffffffffffffde9baeffc04064ff990033ff990033ff990033ffbb3057ffd47d96fffaeff2fffffffffffffffffffffffffffaeff2ffde9baeffbb3057ff990033ff990033ff990033ffc55071ffde9baeffffffffffffffffffffffffffffffffffde9baeffc04064ffc04064ffffffffffffffffffffffffffffffffffffffffffc04064ffc04064ffefcfd8ffffffffffffffffffffffffffffffffffd47d96ffc04064ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffcfcfcfffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff505050ff7f7f7fff7f7f7fff303030ff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff505050ff404040ff404040ff606060ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000700ae00700007000100010003000300040000000d000c001000d800d800d800d800280018003610517569636b54696d65aa20616e6420610000280024003f0d206465636f6d70726573736f7200280030000f1f617265206e656564656420746f20736565207468697320706963747572652e000000a100e007ac00000000000007a86170706c022000006d6e74725247422058595a2007d900020019000b001a000b616373704150504c000000006170706c000000000000000000000000000000000000f6d6000100000000d32d6170706c00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000b64657363000001080000006f6473636d000001780000056c63707274000006e400000038777470740000071c000000147258595a00000730000000146758595a00000744000000146258595a0000075800000014725452430000076c0000000e636861640000077c0000002c625452430000076c0000000e675452430000076c0000000e64657363000000000000001447656e65726963205247422050726f66696c6500000000000000000000001447656e65726963205247422050726f66696c6500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000006d6c7563000000000000001e0000000c736b534b00000028000001786872485200000028000001a06361455300000024000001c87074425200000026000001ec756b55410000002a0000021266724655000000280000023c7a685457000000160000026469744954000000280000027a6e624e4f00000026000002a26b6f4b5200000016000002c86373435a00000022000002de6865494c0000001e00000300646544450000002c0000031e68754855000000280000034a7376534500000026000002a27a68434e00000016000003726a614a500000001a00000388726f524f00000024000003a2656c475200000022000003c67074504f00000026000003e86e6c4e4c000000280000040e6573455300000026000003e874685448000000240000043674725452000000220000045a66694649000000280000047c706c504c0000002c000004a47275525500000022000004d06172454700000026000004f2656e555300000026000005186461444b0000002e0000053e005601610065006f006200650063006e00fd0020005200470042002000700072006f00660069006c00470065006e006500720069010d006b00690020005200470042002000700072006f00660069006c00500065007200660069006c0020005200470042002000670065006e00e800720069006300500065007200660069006c0020005200470042002000470065006e00e9007200690063006f0417043004330430043b044c043d043804390020043f0440043e044404300439043b002000520047004200500072006f00660069006c0020006700e9006e00e9007200690071007500650020005200560042901a75280020005200470042002082725f6963cf8ff000500072006f00660069006c006f0020005200470042002000670065006e0065007200690063006f00470065006e0065007200690073006b0020005200470042002d00700072006f00660069006cc77cbc1800200052004700420020d504b85cd30cc77c004f006200650063006e00fd0020005200470042002000700072006f00660069006c05e405e805d505e405d905dc0020005200470042002005db05dc05dc05d90041006c006c00670065006d00650069006e006500730020005200470042002d00500072006f00660069006c00c1006c00740061006c00e1006e006f00730020005200470042002000700072006f00660069006c666e901a0020005200470042002063cf8ff065874ef64e00822c0020005200470042002030d730ed30d530a130a430eb00500072006f00660069006c0020005200470042002000670065006e0065007200690063039303b503bd03b903ba03cc002003c003c103bf03c603af03bb002000520047004200500065007200660069006c0020005200470042002000670065006e00e9007200690063006f0041006c00670065006d00650065006e0020005200470042002d00700072006f006600690065006c0e420e1b0e230e440e1f0e250e4c002000520047004200200e170e310e480e270e440e1b00470065006e0065006c0020005200470042002000500072006f00660069006c00690059006c00650069006e0065006e0020005200470042002d00700072006f006600690069006c00690055006e006900770065007200730061006c006e0079002000700072006f00660069006c0020005200470042041e04310449043804390020043f0440043e04440438043b044c00200052004700420645064406410020062a06390631064a0641002000520047004200200627064406390627064500470065006e00650072006900630020005200470042002000500072006f00660069006c006500470065006e006500720065006c0020005200470042002d006200650073006b0072006900760065006c007300657465787400000000436f707972696768742032303037204170706c6520496e632e2c20616c6c207269676874732072657365727665642e0058595a20000000000000f35200010000000116cf58595a20000000000000744d00003dee000003d058595a200000000000005a750000ac730000173458595a20000000000000281a0000159f0000b83663757276000000000000000101cd0000736633320000000000010c42000005defffff326000007920000fd91fffffba2fffffda3000003dc0000c06c00a100e000040000000200ff}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The Washington Post\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2004 Monday  \par Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS Activists Misfiring}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sebastian Mallaby\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Editorial; A17\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 919 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  In the past few years, global AIDS activists have worked miracles. They have shaken rich governments awake, causing international AIDS funding to rise 15-fold. They have beaten back big pharma's jihad against cheap, non-brand medicines, creating an opportunity to treat millions of people in poor countries. But the a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tivists, or at least some of them, are in danger of tipping from heroism into shrill anti-Americanism. The sound bites from last week's AIDS conference in Bangkok were straight out of a Michael Moore movie. \par  Inconveniently for those who enjoy stereotypes, the Bush administration is  far and away the leader in the global AIDS fight. This year the United States will spend $2.4 billion on the pandemic, nearly twice as much as all other donor governments combined; attacking the Bush team for indifference to AIDS is like attacking it for inadequate defense spending. But when Randall Tobias, the U.S. global AIDS coordinator, addressed the Bangkok gathering last week, he had to endure  10 minutes of furious heckling before he could get a word in  edgewise.  \par  What triggers this hostility? The activists' first complaint is that U.S. AIDS spending will finance programs to promote sexual abstinence and fidelity. Never mind that only 7 percent of the money will  be spent this way; the abstinence agenda is derided as some kind of kooky anti-scientific plot cooked up by President Bush's evangelical supporters. Yet the plotters actually include very un-evangelical people  such as Edward Green, a Harvard medical anthropologist (and liberal Democrat) who's written a book on AIDS prevention. Green has shown how Uganda's success in cutting HIV infection rates from 21 percent to 6 percent depended cr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cially on teaching abstinence. In the first half of the 1990s, the number of young Ugandans engaging in pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 marital sex plummeted; by 1995, fully 95 percent of Ugandans reported that they were either abstaining or monogamous. \par  Elsewhere in Africa, experience also supports the Bush administration's desire to make abstinence and f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 delity part of its prevention strategy. The evidence from Botswana, South Africa, Kenya and Zimbabwe su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gests that there's no clear link between the availability of condoms and reduced HIV rates: All four countries have plenty of condoms yet plenty of infection. Meanwhile in South Africa, the single most promising deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 opment is that reported rates of teenage sexual activity have fallen for three years straight, disproving the notion that there's no point in telling youths to change their behavior. In sum, it is not the Bush administration that is ignoring the evidence. It is Bush's critics. \par The activists' second complaint about the U.S. AIDS program is that it is hostile to generic medicines. Until recently, this was true: Perhaps because of its ties to the big pharmaceutical companies that sell patented drugs, the administration has been scandalously slow to allow cheaper generic copies to be used in its pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams. But in May the Bush team finally announced that generics were okay, subject only to a six-week r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 view by the Food and Drug Administration to determine safety and efficacy. \par  The activists do not believe the FDA's change is for real, and their suspicions are reinforced by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , a leading Indian producer of generic AIDS drugs. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  charming joint managing director, Amar Lulla, e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plains to anyone who calls that he would love to get his drugs approved for distribution in U.S.-financed pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams in the poor world but that the Bush administration's fine print is cluttered with obstacles. \par  On close inspection, however, these obstacles aren't serious. For example, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  best known AIDS med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cine is called Triomune; it combines three separate antiviral drugs in one pill, simplifying treatment. Lulla says the FDA has not explained whether he needs to demonstrate the safety of combining the drugs this way, in which case }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  would have to conduct prohibitively expensive clinical trials. But if you go to www.fda.gov/oc/initiatives/hiv/hivguidance.html, you'll find the explanation that Lulla says he's waiting for. Attachment B lists three-drug cocktails that the FDA already accepts as safe, among them one combining stavudine,  lamivudine and nevirapine, the three constituents of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Triomune. \par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  also says it worries that if it files an FDA application, it may be sued by U.S. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders. But the FDA's rules allow }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to file a statement certifying that its pills are intended for sale outside the United States, a maneuver that would almost certainly eliminate the risk of being sued for U.S. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement. \par  None of this is to deny that the Bush administration panders to the religious right on some issues, or that it's cozy with pharmaceutical lobbyists. After misrepresentations on issues from tax policy to Iraq intelligence, the suspicion with which Team Bush is greeted is partly of its own making. And of course some criticisms of the administration's AIDS program remain fair, notably that it shortchanges multilateral efforts against the killer. \par  And yet the bottom line on the Bush administration's AIDS initiative is that it is huge and serious. The AIDS activists at last week's conference, whose motives are doubtless honorable as well, would do better to red}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rect their heckling to countries such as Japan and South Korea, which give shockingly little to their cause. When you're fighting an enemy that takes 8,000 lives a day, it pays to pick your targets wisely.  \par mallabys@washpost.com \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (95%); AIDS POLICY (91%); EDITORIALS & OPINIONS (90%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS INDUSTRY (89%); US FEDERAL GOVERNMENT (89%); EPIDEMICS (78%); LIBERALISM (78%); GENERIC DRUGS (78%); SEX EDUCATION (78%); ADOLESCENTS (77%); INFECTIOUS DISEASE (75%); US DEMOCRATIC PARTY (74%); DEFENSE SPENDING (73%); POLITICAL PARTIES (73%); PHARMACEUTICAL PREPARATION MFG (72%); PREVENTION & WELLNESS (69%); RELIGION (64%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGKOK, THAILAND (92%) UNITED STATES (97%); UGANDA (93%); SOUTH AFRICA (92%); THAILAND (92%); KENYA (79%); BOTSWANA (79%); ZIMBABWE (79%); AFRICA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 19, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DOCUMENT-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Column\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Washington Post\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS;Daily HIV/Aids Report Africa News July 15, 2004 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_211}{\*\bkmkstart DOC_ID_211_0}{\*\bkmkstart doc_id_73}{\*\bkmkend DOC_ID_211}{\*\bkmkend DOC_ID_211_0}{\*\bkmkend doc_id_73}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_73"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 73 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  15, 2004 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS;\par Daily HIV/Aids Report}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kaisernetwork.org\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 6123 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bangkok Daily Update\par Fifth Day of XV International AIDS Conference Sees New Money for Global Fund, Focus on Tuberculosis\par [Jul 15, 2004]\par At an evening musical event hosted by former South African president Nelson Mandela, a $50 million pledge was announced from the Bill & Melinda Gates Foundation to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Mandela called for others to do the same.\par "It is going to take much more than the resources of the Gates Foundation to achieve the scale up required to fund the fight against AIDS, TB and malaria," he said, adding, "We need to build the public-private par}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nership that is the vision of the Global Fund. We challenge everyone to help fund the fund now."\par Pledges to the Global Fund beyond 2004 fall far short of its projected need to fight the epidemic. In its first 30-plus months of operation, the Global Fund has committed $3 billion to programs in 128 countries. Dr. H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lene Gayle is with the Gates Foundation. \par "Thanks in large part to the fund, many more people in developing countries now have access to HIV preve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion and care and life-saving interventions for TB and malaria than just two years ago," she said.\par However, there are some concerns, namely among U.S. officials, that the Global Fund is not the most eff}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cient way to get money to local AIDS programs.\par Earlier in the day, Mandela, who battled tuberculosis while in prison during apartheid, spoke about the need to improve TB detection and get patients treated sooner.\par "The world has made defeating AIDS its top priority," he said, adding, "This is a blessing, but TB remains ignored. Today we are calling on the world to recognize we can't fight AIDS unless we do much more to fight TB as well."\par TB kills an estimated one-third of AIDS patients.\par Finally, researchers continued on a familiar theme at the conference -- the need to give women more preve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion options. Dr. Zeda Rosenberg of the International Partnership for Microbicides discussed why HIV infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion rates are rising at startling rates among women.\par "For women in many parts of the world, being poor, young and married are the most significant risk factors for acquiring HIV infection," she said.\par In many areas of the world, women's societal status makes it impossible to for them to insist their partners use condoms or be monogamous. Microbicides, topical virus killers that women can use before intercourse, would give them power to protect themselves. But viable microbicides are at least five years from becoming reality (Jill Braden, Kaiser Daily HIV/AIDS Report, 7/14).\par Video highlights of today's conference sessions are available online from kaisernetwork.org.\par XV International AIDS Conference\par U.S. Will Not Meet U.N. Secretary General's Request To Contribute $1B Annually to Global Fund, Tobias Says\par  [Jul 15, 2004]\par U.S. Ambassador Randall Tobias, head of the State Department Office of the Global AIDS Coordinator, on Wednesday said that the United States will not fulfill a request from U.N. Secretary-General Kofi Annan to contribute $1 billion annually to the Global Fund to Fight AIDS, Tuberculosis and Malaria, Reuters reports (Hirschler, Reuters, 7/14). Annan in an interview with BBC World Service on the sidelines of the XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference in Bangkok, Thailand, requested that the United States and the European Union each contribute $1 billion per year to the fund (Kaiser Daily HIV/AIDS Report, 7/14). The House Appropri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions Committee on Friday approved by voice vote a $19.4 billion foreign aid spending bill for fiscal year 2005, which includes $2.2 billion for HIV/AIDS, tuberculosis and malaria initiatives. Although the approved funding -- most of which will go to AIDS programs -- meets President Bush's request for FY 2005, an appr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 priations subcommittee allocated a larger portion of the money to the Global Fund than Bush had requested. Bush's proposed FY 2005 budget, which is $1.9 billion more than the total amount the subcommittee a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 proved, includes $2.8 billion for international HIV/AIDS, TB and malaria programs. That amount includes $1.45 billion for the Office of the Global AIDS Coordinator, which will administer the President's Emergency Plan for AIDS Relief, and $200 million for the Global Fund. Because the draft spending bill would double the requested Global Fund contribution to $400 million, less money would go to PEPFAR (Kaiser Daily HIV/AIDS Report, 7/13). "The president has requested $200 million for next year and I think that is more than adequate to meet the requirements of the Global Fund in terms of getting money out for putting programs in place," Tobias said (Reuters, 7/14).\par Global Fund\par Tobias said that although the Global Fund is "a very promising vehicle and a critically important part" of the fight against AIDS, it is "a young venture and still maturing" (Boseley, Guardian, 7/15). Tobias said that the United States prefers to spend the majority of its AIDS funding through PEPFAR because it is an "effective mechanism to ensure that small and effective organizations can improve their work and get money fast in order to address urgent needs within communities" (Apiradee, Bangkok Post, 7/15). PEPFAR is the fastest way to "get that money to work," Tobias said. In contrast, the proposed $200 million FY 2005 contribution to the fund will end up "sitting in the World Bank in Geneva," Tobias said, adding that the Global Fund policy of waiting until enough money has accumulated to ensure completion of programs would "actually slow down" the fight against AIDS (Maugh, Los Angeles Times, 7/15). However, Annan said that the Global Fund is "ready to go," adding, "If individual governments begin to set up their own initiatives, they start from scratch, it takes longer; the money that they hold will not be spent for a long time" (Nolen, Globe and Mail, 7/15).\par Reaction\par U.N. Special Envoy for HIV/AIDS in Africa Stephen Lewis said that the Global Fund is the "most effective instrument against the pandemic," adding that PEPFAR represents the same "go-it-alone" approach that the Bush administration used for the war in Iraq. Lewis said that the United States eventually would accept the Global Fund's multinational approach to the epidemic in the same way that it is now seeking help from other nations in Iraq, according to the San Francisco Chronicle (Russell, San Francisco Chronicle, 7/15). Lewis added, "The American money going to 15 countries is not leadership on AIDS. It's a significant role, but the Global Fund is in 120 countries, ... respond[ing] to the problem in a far more universal way" (Reuters, 7/14). A senior figure connected with the fund said, "Everyone has gone out of their way to give (PEPFAR) a lot of support, but people have reached a limit." The Bush administration's suspicion of the fund is frustrating some of those working to fight global AIDS, he added, according to the Globe and Mail (Globe and Mail, 7/15).\par Cambodian Sex Workers Protest at XV IAC Session, Say Gilead Sciences' Viread Clinical Trials Unethical\par [Jul 15, 2004]\par A group of about 30 Cambodian commercial sex workers on Tuesday interrupted a session at the XV Inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 national AIDS Conference on antiretroviral drugs to protest a planned clinical trial using Gilead Sciences' Viread, the San Francisco Chronicle reports. About 30 demonstrators took over the stage for 15 minutes du}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the Gilead-sponsored session, shouting that the company "uses sex workers for free." Gilead is planning to evaluate whether Viread -- which is known generically as tenofovir and is FDA-approved for use as a treatment for HIV infection -- is effective at reducing the risk of HIV infection. The sex workers demanded that Gilead stop the trial or provide lifetime health care for any study participants who become HIV-positive, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to the Chronicle. Dr. James Rooney, Gilead vice president for clinical affairs, said that the study, which involves the use of a placebo, meets the strict ethical guidelines applied to all vaccine trials, the Chronicle reports. For example, all of the women participating in the trial will be counseled about and su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plied with condoms. However, critics of the study said that such counseling is only cursory. The sex workers said that in order for the study to be useful, some of the participants will have to become HIV-positive, ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing them "pawns in a corporate drug development scheme," according to the Chronicle (Russell, San Fra}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cisco Chronicle, 7/14).\par Bangkok Notebook\par Governments, Organizations Must Implement HIV/AIDS Prevention Programs for Displaced Persons, IAC Panel Says\par [Jul 15, 2004]\par Governments and international organizations must make commitments to implement HIV/AIDS prevention programs targeted at migrant workers, refugees and other mobile populations, participants of a session on displaced populations and AIDS said on Thursday at the XV International AIDS Conference in Bangkok, Thailand. These groups face many inequalities that facilitate the spread of HIV, including poverty, exploit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, separation from families and partners and a disruption in familiar social environments that influence b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 haviors in established communities. Because most migrant workers lack HIV/AIDS awareness; have poor access to treatment, voluntary testing and counseling; and have no job security, many are not treated until they need emergency care, according to Dr. Cynthia Maung, who cares for displaced populations on Thailand's border with Burma. Migrants and other displaced populations "experience continuing oppression that most people hope to leave behind" when they leave their original areas, she said. Christine Amongin Aporu, minister of state for disaster preparedness and refugees in Uganda, urged national leaders to declare their commitment to HIV/AIDS prevention for displaced populations and increase funding for such programs. In addition, she called on nations to fully fund the Global Fund to Fight AIDS, Tuberculosis and Malaria, which has granted money to some programs focusing on displaced persons, and urged the United States to honor its commitment of providing $3.5 billion in 2005 through the President's Emergency Plan for AIDS R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lief.\par Mandatory Testing Denounced\par Paul Spiegel, senior HIV/AIDS technical officer with the U.N. High Commissioner for Refugees, and Irene Fernandez of CARAM Asia, denounced mandatory HIV testing for asylum seekers. HIV testing is often a r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quirement for entry into a country, and many countries do not accept HIV-positive refugees. Fernandez said that mandatory testing "sparks fear" and can cause refugees to falsify information or never be documented. She added that required testing increases inequality, discrimination and stigmatization and can create a false sense of security among the host community because they may believe that no HIV-positive people are a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lowed entry. Spiegel said that HIV testing must be accompanied by pre- and post-test counseling and a sy}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tem for HIV care and treatment must be available to people who test HIV-positive. Several panel members also called for the inclusion of migrants and other displaced persons in HIV/AIDS prevention programs. Fe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nandez said, "HIV-positives can be catalysts for change. Without their involvement, no program will succeed" (Alyson Browett, Kaiser Daily HIV/AIDS Report, 7/15).\par A webcast of the session is available online from kaisernetwork.org.\par Global Challenges\par Gates Foundation Announces $50M Contribution to the Global Fund at XV International AIDS Conference\par [Jul 15, 2004]\par The Bill & Melinda Gates Foundation on Thursday at the XV International AIDS Conference in Bangkok, Thailand, announced it will contribute an additional $50 million to the Global Fund to Fight AIDS, Tubercul}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sis and Malaria, bringing its total contribution to $150 million, the AP/Billings Gazette reports. Dr. Helene Gayle, director of the Gates Foundation HIV, TB and Reproductive Health Program, made the announc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment at an evening event hosted by former South African President Nelson Mandela. "The Global Fund is an extraordinary model for financing the fight against AIDS, TB and malaria," Gayle said, adding, "We urge go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernments, the private sector and other donors to dramatically increase their contributions to the fund -- their generosity can help save millions of lives" (AP/Billings Gazette, 7/15). Mandela, who came out of retirement to attend the conference, said that the Gates Foundation's contribution was an important sign of leadership in the fight against HIV/AIDS, TB and malaria.\par Funding Shortfall\par Although the Global Fund has enough money -- $3.8 billion -- to meet its needs through the end of the year, it has received pledges for a total of only $2 billion for 2005 through 2008, which is far below the $3.6 billion the fund estimates it will need in 2005 alone. Global Fund Executive Director Richard Feachem said, "We applaud the leadership by the Gates Foundation in making this contribution and signaling its continued su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 port for the Global Fund -- especially at this critical moment when increased funding is so important. This will help leverage further funds from additional donors." Since it began funding projects in 2002, the Global Fund has approved proposals for almost 300 grants for projects in 128 countries.\par 46664 Campaign\par The session featured the premiere of "46664: The Message," a film based on the 46664 concert held in Cape Town in November 2003 (Gates Foundation release, 7/15). Mandela launched "46664" -- named after his prison number during his nearly 20-year incarceration at the South African prison Robben Island -- in O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tober 2003 as a phone and Internet campaign to raise awareness and money to fight HIV/AIDS in Africa. Mandela officially retired from public life on June 1 to complete his autobiography, but decided to make the trip to Bangkok to address the delegates following the film's screening (Kaiser Daily HIV/AIDS Report, 7/8).\par A webcast of the session and the film will be available online from kaisernetwork.org after 12 p.m. on Friday, July 16.\par Nelson Mandela Says Global AIDS Fight Should Include Efforts To Combat TB; Gates Foundation Awards $45M for AIDS/TB Research\par [Jul 15, 2004]\par Global efforts to fight the HIV/AIDS epidemic should include efforts to combat tuberculosis -- which is often a "death sentence" for people living with HIV-- former South African President Nelson Mandela said on Thur}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day at the XV International AIDS Conference in Bangkok, Thailand, Reuters reports. About 14 million of the 38 million HIV-positive people worldwide are coinfected with TB, 70% of who live in sub-Saharan Africa, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to Reuters. Mandela said, "The world has made defeating AIDS its top priority. This is a blessing, but TB remains ignored." He added, "We cannot win the battle against AIDS if we do not also fight TB." Mandela said that TB is "too often a death sentence for people with AIDS," adding, "It does not have to be this way" (Schuettler, Reuters, 7/15). Mandela said that although a cure for TB has existed for the past five decades, what has been lacking is the "will and the resources to quickly diagnose people with TB and get them the treatment they need" (Joshi, Associated Press, 7/15).\par Gates Grant\par The Bill & Melinda Gates Foundation on Thursday announced a $44.7 million grant aimed at curbing HIV-related TB, the Seattle Post-Intelligencer reports (Paulson, Seattle Post-Intelligencer, 7/15). The grant will go to the Consortium to Respond Effectively to the AIDS-TB Epidemics, or CREATE, which is led by researc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers from Johns Hopkins University in Baltimore, Md., according to the Baltimore Sun (Bor, Baltimore Sun, 7/15). CREATE also includes researchers from the London School of Hygiene and Tropical Medicine, Aurum Health Research in South Africa, the University of Zambia, Stellenbosch University of South Africa, the M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nicipal Health Secretariat of Rio de Janeiro, in addition to the World Health Organization and CDC, the Wall Street Journal reports (Chase, Wall Street Journal, 7/15). The grant will fund three studies to evaluate the use of the antibiotic isoniazid on people living with HIV. One of the studies, which will recruit participants from Zambia and South Africa, will include school- and community-based TB education and examine the benefits of administering isoniazid to all members of a households that have TB patients. Another study, based in South Africa, will focus on the impact of isoniazid on gold miners in the country, and a study in Brazil will e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 amine the effect of isoniazid on HIV-positive people with TB who are taking antiretroviral drugs (Gates r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lease, 7/15). The standard treatment for TB is directly observed treatment, short course -- or DOTS -- which involves health care workers observing TB patients taking medicine daily over several months, according to the Post-Intelligencer.\par Reaction\par Dr. Richard Chaisson, head of the JHU Center for Tuberculosis Research, said, "The traditional strategies for controlling tuberculosis don't work in communities with high rates of HIV." He added, "We're challenging the dogma here," saying, "The problem is that the dogma is not right and the DOTS approach is not enough." Dr. Helene Gayle, director of the HIV, TB and Reproductive Health program for the Gates Foundation, said, "We can't fight AIDS unless we also fight TB" (Seattle Post-Intelligencer, 7/15). "DOTS is great when HIV isn't a major problem. But once HIV moves in, control is undermined," Gayle said, adding, "DOTS just can't seem to catch up" (Wall Street Journal, 7/15).\par A webcast of Mandela's speech, as well as additional coverage of the conference, is available online from kaisernetwork.org.\par SABC News on Wednesday reported on Nelson's statements on HIV and TB coinfections (SABC News, 7/14). The complete segment is available online in RealPlayer\par Voucher Program for Injection Drug Users in China, Vietnam Could Help Contain Spread of HIV, Study Says\par [Jul 15, 2004]\par A voucher program for injection drug users in China and Vietnam could help contain the spread of HIV, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to a study released on Wednesday by Cambridge, Mass.-based Abt Associates at the XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference in Bangkok, Thailand, the Wall Street Journal reports. The program, which was launched by Abt and funded by NIH and the Ford Foundation, involves trained peer educators -- who also are injection drug users -- distributing to other drug users vouchers that can be exchanged at local pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cies for clean needles and syringes. In some cases, the vouchers can be exchanged for medicines and co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 doms, according to the Journal. The local police have agreed not to interfere with the program -- which ta}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gets injection drug users in the "remote" mountains on the border between Vietnam and China -- and pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 macists and health authorities support the project, the Journal reports. The study, which is based on data from the first year of the program, shows that although HIV transmission has not stopped completely, the number of new infections has decreased, according to Abt researcher Ted Hammett. HIV/AIDS prevalence among injection drug users has reached close to 20% on the Chinese side of the border and as high as 47% on the Vietnamese side. The program is set to run for another year, according to the Journal (Naik, Wall Street Journal, 7/15).\par Asian Leaders Have 'Window of Opportunity' To Avert HIV/AIDS Crisis, Report Says\par [Jul 15, 2004]\par Asian leaders can avert an HIV/AIDS crisis if they act quickly to break social taboos, attack stigma, encou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 age prevention programs and provide access to treatment and support systems for HIV-positive people, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to an Asia Pacific Leadership Forum report released Tuesday at the XV International AIDS Confe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence in Bangkok, Thailand, Agence France-Presse reports. "Political leaders in Asia and the Pacific have a precious window of opportunity to save millions of people from HIV infection. But to succeed, they will need to drastically increase spending on AIDS and scale up prevention, care and treatment programs," APLF members said (Agence France-Presse, 7/13). APLF, which is funded by Australia, Japan, New Zealand, the United Kingdom, the United States and the European Union, is an initiative founded in 2001 to promote e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fective leadership and intensify commitment to fighting HIV (UNAIDS release, 7/13). According to the report, more than seven million of the world's 38 million HIV-positive people live in the Asia-Pacific region. Of those, about one million became infected in 2003 alone. The report noted that India, where 5.1 million HIV-positive people live, "is second only to South Africa as the country with the greatest number of people living with HIV" (Agence France-Presse, 7/13). However, the report said that India -- as well as other countries in the region, including Indonesia and China -- is beginning to treat the problem with greater urgency. Anand Panyarachun, former prime minister of Thailand and chair of the APLF steering committee, said, "In a society where there are religious, social, cost and other constraints, it's even more vital to have political leadership" to combat HIV/AIDS. The report called on governments in the region to encourage civil society, nongovernmental o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganizations, community groups and people with HIV/AIDS to help formulate a response to the disease (U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS release, 7/13).\par Discrimination, Gender Inequality Challenge HIV/AIDS Prevention Efforts in South Asia\par [Jul 15, 2004 ]\par Discrimination against people with HIV/AIDS and gender inequality remain the two most formidable cha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lenges to HIV/AIDS prevention efforts in South Asia, according to a satellite session on Tuesday at the XV International AIDS Conference, according to a UNAIDS release. "There are two epidemics spreading -- AIDS, and the stigma against people living with HIV," Zahir Uddin Swapon, secretary general of the Parli}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mentary Group on HIV/AIDS and a member of Bangladesh's parliament, said. Participants at the session, which was organized by the UNAIDS South Asian Intercountry Team and South Asia's Theme Group on HIV/AIDS, said that to counter the stigma of the disease, nations must protect the rights of people with HIV/AIDS, form partnerships between health and education sectors and amend laws criminalizing margina}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ized groups vulnerable to the disease. In addition, Dr. Nafis Sadik, special envoy to the U.N. secretary ge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eral for HIV/AIDS in Asia and the Pacific and chair of the session, said that women in South Asia "have less opportunity to protect themselves" from the disease. Data suggest a close link between the status of women and their vulnerability to HIV, according to the release. Kathleen Cravero, deputy executive director of U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS, said, "Until women and girls have equal access to effective HIV prevention and treatment services, there is little hope to beat the epidemic" (UNAIDS release, 7/13).\par Time Examines HIV Incidence Among Injection Drug Users, Pregnant Women, Young People in Thailand\par [Jul 15, 2004]\par Time magazine's June 19 issue examines Thailand's recent increase in HIV incidence among young people, pregnant women and injection drug users. Several factors have contributed to the growing number of infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions, including a complacency toward condom use and public education in a country that was once hailed as a "rare success story in the global battle to contain the AIDS epidemic," Time reports (Gorman, Time, 6/19). The complete article is available online.\par Drug Access\par Medicines Sans Frontieres Announces Results of Study of Generic Fixed-Dose Combination Antiretrovirals in Developing Countries\par [Jul 15, 2004]\par Medicines sans Frontieres on Wednesday at the XV International AIDS Conference presented the results of the first large-scale study of generic fixed-dose combination antiretroviral drugs in developing countries, the New York Times reports. The study, which expanded on a "much smaller" study that was published in the July 3 issue of the Lancet, was conducted in 21 countries using a generic FDC containing lamivudine, nev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rapine and stavudine. Indian drug makers }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy Laboratories each make a version of the drug (Altman, New York Times, 7/15). Patients can take the generic FDC as one pill twice a day, and it costs about $140 per person per year. A regimen of the same three drugs purchased separately from }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  hol}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers GlaxoSmithKline, Bristol-Myers Squibb and Boehringer-Ingelheim requires six pills a day and costs about $562 per patient per year (Kaiser Daily HIV/AIDS Report, 7/2). MSF since 2002 has treated a total of 12,058 HIV-positive adults with antiretrovirals, and 6,861 of them received FDCs, according to Dr. Alexandra Calmy, an HIV/AIDS adviser for MSF. Of the patients who received FDCs, 51 of them had to change medicines b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause of side effects from one or more of the drugs contained within the FDC; patients who switched to a new regimen had to take 13 or more pills daily, according to the Times. MSF found that the one-year survival probability was 82.4% among recipients of FDCs, Calmy said, according to the Times. In addition, CD4+ cell counts among FDC recipients increased by an average of 137 cells/mm3 per year. However, FDCs failed to work in 12% of HIV-positive people in a subset of 477 people, according to the study, Times reports. Calmy said that the results offered a "very robust outcome, and the findings are important for the Global Fund [to Fight AIDS, Tuberculosis and Malaria] and other groups that are recommending" FDCs (New York Times, 7/15).\par WHO Adds Lamivudine, Three Versions of Flucanozole to List of Recommended AIDS-Related Medicines\par [Jul 15, 2004]\par The World Health Organization on Tuesday announced that it has added a generic version of antiretroviral lamivudine and three versions of the antifungal medication flucanozole to its list of recommended AIDS-related medicines, Reuters/Yahoo! News reports. In a statement released at the XV International AIDS Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ference in Bangkok, Thailand, WHO officials announced the approval of Strides Arcolab's 150 mg tablet of the antiretroviral lamivudine, an alternative to a generic form of the same drug produced by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that was removed from the WHO prequalification list in June (Reuters/Yahoo! News, 7/13). Dr. Lembit Rago, WHO's coordinator for quality assurance and safety of medicines, said in June that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  versions of lamivudine and zidovudine were removed from the list because of problems detected during a routine inspection of an independent laboratory that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had hired to conduct bioequivalence studies of the drugs. WHO routinely conducts inspections among makers of drugs included on its list of medicines that are approved for purchase by United Nations agencies. (Kaiser Daily HIV/AIDS Report, 6/16). In addition, WHO said that it added three different dosages of the antifungal treatment fluconazole made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to its prequalification list this week (Reuters, 7/13).\par Botswana Antiretroviral Drug Distribution Program Will Reach 50,000 People by 2005, Health Minister Says\par [Jul 15, 2004]\par Botswana Health Minister Lesego Motsumi on Tuesday at the XV International AIDS Conference in Bangkok, Thailand, said that the country will meet by next year its target of distributing antiretroviral drugs at no cost to about 50% of those who need them -- about 50,000 HIV-positive people, Reuters reports. Currently, 17,400 people are receiving antiretroviral therapy through the country's public health service; an additional 6,700 receive the medications from the private sector, Reuters reports (Reuters, 7/13). Dr. Patson Mazonde, dep}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty permanent health secretary, said that the program had enrolled 28,000 people in 17 locations and expa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sion is planned to 15 more sites this year (SAPA, 7/13). Botswana's program is "a case study for Africa" that represents "what it will take to successfully introduce ARV therapy on a mass scale," the Ministry of Health said in a statement (South African Press Association, 7/12). However, a "crucial problem" has been that few people are undergoing HIV testing, according to Earnest Darkoh, head of operations for Botswana's national antiretroviral treatment program, Reuters reports. Botswana introduced voluntary routine HIV testing in Ja}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 uary, and HIV-positive diagnoses have increased, according to Reuters (Reuters, 7/13).\par London's Guardian on Thursday profiled Botswana's drug program (Carroll, Guardian, 7/15). The full article is available online.\par Merck Licenses Antiretroviral Drug Efavirenz to South African Pharmaceutical Company Thembalami\par [Jul 15, 2004]\par Drug company Merck announced on Tuesday that it has agreed to grant a nonexclusive, royalty-free license to South African drug company Thembalami Pharmaceuticals to produce and sell a generic version of its antiretroviral drug efavirenz, the AP/Springfield News Sun reports. Merck sells efavirenz under the brand-name Stocrin at a not-for-profit price to countries in the Southern African Development Community. The l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cense covers both public and private sector sale of the drug in SADC member countries, and Thembalami will donate a portion of its proceeds from efavirenz sales to the MSD Msizi Cares Trust -- an organization that supports the fight against HIV/AIDS in South Africa. Thembalami CEO Sotse Segoneco also will become a member of the organization's board of trustees (AP/Springfield News Sun, 7/13). Merck said it issued the license to speed access to antiretroviral drugs in South Africa and other countries affected by HIV/AIDS, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to Reuters (Reuters, 7/13). About 20,000 HIV-positive people in South Africa are taking the drug and under the government's national drug plan, the number is expected to grow to 50,000 by the end of the year, South Africa's Business Day reports (Cohen, Business Day, 7/14).\par HIV-Positive Patients in Asia at High Risk of Developing Drug Resistance Due to Inconsistent Treatment, Lack of Monitoring\par [Jul 15, 2004]\par HIV-positive people in China and other parts of Asia are at a high risk of developing resistance to antiretrov}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ral drugs because of the range of available drugs, inconsistent treatment and a lack of monitoring and cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 seling, experts said at the XV International AIDS Conference in Bangkok, Thailand, Agence France-Presse reports. For example, 50% of 500 rural Chinese HIV-positive people who took nevirapine for up to 11 months have become resistant to the drug, which is a standard component of antiretroviral triple therapy, according to Shao Yiming, director of the China Centers of Disease Control's Department of Virology and Immunology. Shao said that China provided the drugs free of charge, but medical personnel failed to inform patients that they had to take the drugs consistently. Many patients stopped taking the drugs for periods of time or stopped taking them altogether because of side effects. "The free drugs program was meant to ... save lives, but we should have considered whether it was sustainable," Shao said. Kevin Frost, director of TREAT Asia, said, "There's a lot of concern that we're going to begin seeing resistance to nevirapine on a more wid}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spread basis here, and I think that's of significant concern when it's such a critical component of every first-line treatment regimen in the region" (Agence France-Presse, 7/13).\par Newsweek Examines 'Grass-Roots' Efforts To Provide HIV/AIDS Treatment in Sub-Saharan Africa\par  [Jul 15, 2004]\par Newsweek in its July 19 issue examined the "grass-roots" efforts of organizations such as Medecins Sans Frontieres and Treatment Action Campaign in sub-Saharan Africa to "mobilize millions of people" to seek HIV/AIDS treatment and create health infrastructure capable of delivering care. Although antiretroviral drug costs have dropped by 98% in the past several years and several initiatives -- including the President's Emergency Plan for AIDS Relief, the Global Fund to Fight AIDS, Tuberculosis and Malaria and the World Health Organization's 3 by 5 Initiative -- have issued grants or helped design programs to provide treatment, less than 2% of sub-Saharan Africa's HIV-positive people are receiving treatment. According to Newsweek, many countries that have received grants are not ready to absorb the money, partly because many health care workers are moving to wealthier countries and those remaining are "overwhelmed and exhausted." O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganizations such as TAC and MSF have set up home-based care initiatives, where trained community volu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 teers help patients adhere to drug regimens, establish voluntary test sites and organize support groups that "stand up" to the stigma attached to HIV/AIDS. Such programs have proven that "grass-roots involvement is critical" to the fight against HIV/AIDS, Newsweek reports (Cowley, Newsweek, 7/19).\par Opinion\par Kaiser Daily HIV/AIDS Report Summarizes Editorials, Opinion Pieces on the XV International AIDS Confe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence\par [Jul 15, 2004]\par Several newspapers have published editorials in response to the XV International AIDS Conference taking place this week in Bangkok, Thailand. Summaries of some of the editorials and opinion pieces appear below:\par Arizona Republic: Because HIV/AIDS is increasingly affecting women, there needs to be a "coordinated push" to develop and test microbicides so that women can protect themselves against the virus, a Republic editorial says (Arizona Republic, 7/14).\par Financial Times: Advocates "must remember" that financial aid is not the only factor in combating HIV/AIDS and issues such as poverty, a Times editorial says. Improved governance and free trade are more important to encouraging growth and reducing poverty, the editorial concludes (Financial Times, 7/14).\par Thailand's Nation: There is no reason that the need for affordable HIV/AIDS drugs in developing countries and pharmaceutical companies' need for "sufficiently attractive" financial returns "remain mutually exclusive," a Nation editorial says. Both sides should "learn to accommodate one another's needs and concerns," the editorial concludes (Nation, 7/14).\par New York Times: The HIV/AIDS epidemic in Asia is at a "tipping point," and the world -- especially Asian n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions -- must increase access to antiretroviral drugs, prevention efforts and funding for global HIV/AIDS initi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tives, a Times editorial says (New York Times, 7/14).\par Wall Street Journal: Although HIV/AIDS advocates "insist on condoms for supposedly non-infectious sexual trysts," Ugandan President Yoweri Museveni spoke of "love and commitment" at the conference when he said abstinence is the best way to prevent HIV/AIDS -- a method that has proved successful in reducing the country's prevalence rate, a Journal editorial says (Wall Street Journal, 7/14).\par Wichita Eagle: Although much progress has been made in the global effort to combat HIV/AIDS, "much more remains to be done," an Eagle editorial says. The conference is an opportunity to build on that success, and it would be a "terrible waste if it gets bogged down in finger-pointing," the editorial concludes (Wichita Eagle, 7/13).\par Opinion Pieces\par Phil DiSorbo, Albany Times Union: With the global HIV/AIDS epidemic "worse[ning]," the U.S. public needs to become more personally active in the global effort to combat the disease, Times Union columnist DiSorbo writes in an opinion piece (Albany Times Union, 7/14).\par Joseph Dolman, Long Island Newsday: When Museveni on Tuesday said that abstinence is the best way to prevent HIV, "it seems logical" that he did so to stay "on the good side of [President] Bush" for financial re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sons, Newsday columnist Dolman writes in an opinion piece. Prevention methods were not "faring all that well" before Museveni's remarks, and they are now "weaker still," Dolman concludes (Long Island Newsday, 7/14).\par James Glassman, Manchester Union Leader: The United States is providing funding for and access to drugs, health care facilities and training for health care workers to fight AIDS, Glassman, a fellow at the American Enterprise Institute, writes in a Union Leader opinion piece. The United States should not attend the next conference in 2006 to "fend off insults from ingrates and morons," Glassman concludes (Manchester Union Leader, 714).\par Yoweri Museveni, Asian Wall Street Journal: Individual behavior change and personal responsibility -- based on knowledge -- offer the "best protection against AIDS and other future epidemics," Museveni writes in a Journal opinion piece (Asian Wall Street Journal, 7/14).\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); TUBERCULOSIS (91%); MALARIA (90%); FOUNDATIONS (90%); CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FERENCES & CONVENTIONS (89%); AIDS & HIV TREATMENT (78%); EPIDEMICS (78%); DISEASES & DISORDERS (78%); PUBLIC PRIVATE PARTNERSHIPS (74%); PREVENTION & WELLNESS (71%); D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VELOPING COUNTRIES (67%); WOMEN (66%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NELSON ROLIHLAHLA MANDELA (92%); KAISER DAILY HIV (92%); RANDALL TOBIAS (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BILL & MELINDA GATES FOUNDATION  (90%); BILL & MELINDA GATES FOUND}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (92%); UNITED STATES (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 15, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS;Daily HIV/Aids Report Africa News July 14, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_212}{\*\bkmkstart DOC_ID_212_0}{\*\bkmkstart doc_id_74}{\*\bkmkend DOC_ID_212}{\*\bkmkend DOC_ID_212_0}{\*\bkmkend doc_id_74}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_74"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 74 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  14, 2004 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS;\par Daily HIV/Aids Report}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kaisernetwork.org\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 9442 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bangkok Daily Update\par Focus of XV International AIDS Conference Turns to U.S. HIV/AIDS Policy, Women and Youth\par [Jul 14, 2004]\par As U.S. Global AIDS Coordinator Ambassador Randall Tobias prepared to address the XV International AIDS Conference in Bangkok, Thailand, protests overtook applause. After several minutes, activists quieted down, and Tobias defended U.S. HIV/AIDS policy. "It is time -- in fact, it is past time -- to move forward from this point," he said, adding, "Too much time has been lost already."\par Daily protests against the United States and other G8 countries have peppered the conference. Grievances include drug pricing and funding policies, as well as a perceived single-minded reliance on abstinence as the main weapon against AIDS. \par "I want to get something straight about the U.S. position on prevention, because there seems to be a lot of confusion and misinformation," Tobias said, adding, "Preventing AIDS is not a multiple-choice test. There is no one right way to preventing the spread of this pandemic. Those who want to simplify the solution to just one method -- any one method -- do not understand the complexity of the problem."\par In an interview with <a ="http://www.kaisernetwork.org/">kaisernetwork.org</a>, Tobias, on the eve of his departure from Bangkok, seemed uncertain about the real need for a conference such as this. "You really need to say, 'Was the value that was generated by this kind of a conference worth that kind of money or could part of that money be spent more efficiently in some other directions in order to fight HIV/AIDS?'"\par Also today, delegates focused on women and youth, who in some areas of the world represent the majority of new HIV cases. Professor Dennis Altman of La Trobe University in Australia said that information is a powerful tool.\par "Both conservatives and liberals place great emphasis on choice. Advice just to say no, which we hear from the U.S., is equivalent in some ways to advice to always follow safer sex and injecting practices. But before we have choice, we need both knowledge and resources to act on that knowledge. Yet estimates from most parts of the poor world suggest a continuing ignorance about HIV and the basic measures to control it," he said.\par It's a theme heard often at this conference: a one-size-fits-all approach will never work. It will take a broad coalition -- from religious leaders to governments -- to stop the spread of HIV (Jill Braden, Kaiser Daily HIV/AIDS Report, 7/14).\par XV International AIDS Conference\par U.S. Global AIDS Coordinator Tobias Addresses XV International AIDS Conference; Speech Interrupted by Protestors\par  [Jul 14, 2004]\par U.S. Ambassador Randall Tobias, head of the <a ="http://www.state.gov/">State Department</a> <a ="http://www.state.gov/s/gac/">Office of the Global AIDS Coordinator, on Wednesday defended U.S. AIDS policies in a speech at the XV International AIDS Conference that was delayed because of interruptions by protestors, <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5668124">Reuters</a> reports (Hirschler [1], Reuters, 7/14). About 50 protestors stood in front of the stage chanting "Bush Lies, Mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lions Die" (<a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5664567">Reuters</a>, 7/14). The protestors also carried a placard that resembled a $15 billion check -- the amount that Bush pledged to spend over five years through his President's Emergency Plan for AIDS Relief -- but the check was made out to pharmaceutical companies and "right-wing extremists," according to the Associated Press (Associated Press, 7/14). The United States has been criticized throughout the conference for its support of funding for abstinence-only education as well as its policies on generic antiretroviral drugs, the <a ="http://www.ajc.com/health/content/shared/health/ap/ap_story.html/Health/AP.V8626.AP-AIDS-Meeting.html">AP/Atlanta Journal Constitution reports. Tobias said that the United States is spending nearly twice as much as all other donor governments combined. "At this point, perhaps the most critical mistake we can make is to allow this pandemic to divide us," Tobias said, adding, "We are striving toward the same goal -- a world free of HIV/AIDS. When 8,000 lives are lost to AIDS every day, division is a luxury we cannot a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ford." Tobias also said that although the United States is not against condom use, Uganda's "ABC" preve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion campaign -- which stands for Abstinence, Be faithful and use Condoms -- shows that condoms are not the only effective means of preventing HIV transmission. "Abstinence works, being faithful works, condoms work," Tobias said, adding, "Each has its place" (Joshi, AP/Atlanta Journal-Constitution, 7/14).\par Drugs\par Tobias also responded to criticism over the Bush administration's refusal to use PEPFAR money to purchase generic antiretroviral drugs that have not been approved by FDA, according to Reuters. "It is a moral imper}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive that families in programs funded by the United States in the developing world have the same assurances as American families that the drugs they use are safe and effective," Tobias said (Reuters, 7/14). He added, "America will not have one health standard for her own citizens and a lower standard of 'good enough' for those suffering elsewhere" (AP/Atlanta Journal-Constitution, 7/14). Dr. Anthony Fauci, head of the NIH <a ="http://www.niaid.nih.gov/">National Institute of Allergy and Infectious Diseases, also at the conference d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fended the requirement, saying that the drugs could be used if they pass a new FDA expedited review pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess (Maugh, <a ="http://www.latimes.com/la-fg-aids14jul14,1,574388.story">Los Angeles Times, 7/14). U.S. officials in May created the expedited process to review new products that combine FDA-approved HIV/AIDS drugs into a fixed-dose pill and new co-packaging of existing treatments (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=23828">Kaiser Daily HIV/AIDS Report, 5/21).\par Trade Negotiations\par Tobias also responded to allegations from European delegates and French President Jacques Chirac that the United States is pressuring developing countries to give up the right to make generic drugs -- including antiretroviral drugs -- in exchange for free trade agreements (Agence France-Presse, 7/14). Chirac in a wri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ten statement to the conference said on Tuesday that the U.S. methods concerning generic drugs in free trade negotiations have been "tantamount to blackmail" (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24708">Kaiser Daily HIV/AIDS Report, 7/13). U.S. trade officials are negotiating a series of agreements to strengthen }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection of brand-name drugs, including antiretrovirals. In many countries, including the United States, generic drug makers often win approval for their drugs by proving that the products are equivalent to the brand-name drugs. However, new agreements sought by the United States would prevent countries trading with the Uni}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed States from approving for five years generic drug applications if data submitted by the generic companies is based on data originally compiled by the brand-name manufacturer. The agreements would in effect grant temporary exclusivity to brand name drug makers (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24671">Kaiser Daily HIV/AIDS Report, 7/12). Lieve Fransen, head of the European delegation to the conference, on Wednesday said that Chirac's statement "represented very much the message from Europe in general," adding, "There is a danger that the [United States] would go into major bilateral trade agreements that don't follow the agreements that we have all made" about generic drugs (Agence France-Presse, 7/14).\par A kaisernetwork.org webcast of Tobias' speech, as well as an exclusive kaisernetwork.org interview with T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bias is available <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1175#tobias">online</a>.\par APM's "Marketplace" on Tuesday reported on the French criticism. The segment includes comments from Claude Barfield, resident scholar and director of science and technology policy studies at the American E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 terprise Institute, and Ellen Shaffer, CPA director for the <a ="http://www.cpath.org/">Center for Policy Ana}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ysis on Trade and Health (Palmer, "Marketplace," APM, 7/13). The complete segment is available <a ="http://marketplace.publicradio.org/shows/2004/07/13_mpp.html">online</a> in RealPlayer.\par U.S. Should Show Same Commitment to AIDS That It Shows to Terrorism Prevention, Annan Says\par [Jul 14, 2004]\par The United States should give the same funding commitment to combating HIV/AIDS as it does to antiterro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ism efforts, U.N. Secretary-General Kofi Annan said Tuesday in an interview with <a ="http://news.bbc.co.uk/2/hi/africa/3245014.stm">BBC World Service</a> on the sidelines of the XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference in Bangkok, Thailand (Gracie, BBC World Service, 7/13). While the United States is spending large amounts of money on terrorism prevention, it has not fulfilled its promise to combat the spread of HIV/AIDS, Annan said, according to <a ="http://news.bbc.co.uk/1/hi/health/3888753.stm">BBC News</a>. He added that he hopes the United States can contribute $1 billion per year to the <a ="http://www.theglobalfund.org/en/about/how/">Global Fund to Fight AIDS, Tuberculosis and Malaria and the European Union can contribute an additional $1 billion, BBC News reports (BBC News, 7/13). "[W]e hear a lot about terrorism. And we are worried about weapons of mass destruction because of their potential to kill thousands. What is the response?" he said. According to Annan, the Untied States has "natural leadership capacity" because of its resources and size. Annan said he has spoken with President Bush about global HIV/AIDS funding. He said that Bush was "engaged" and "quite moved ... but of course now we need a step forward to put resources to it" (Associated Press, 7/13). Bush last year announced the President's Emerge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cy Plan for AIDS Relief, a five-year, $15 billion plan to fight HIV/AIDS in 14 African and Caribbean countries and Vietnam (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24359">Kaiser Daily HIV/AIDS Report, 6/23). Annan said that while the donations to the Global Fund are large, they are not enough to reach the group's goal (Asia Pacific News Agencies, 7/13).\par Reaction\par AIDS advocates "cheer[ed]" Annan's remarks on Tuesday, according to an AIDS Policy Project release. "The world's pre-eminent diplomat has just accused the world's most powerful government of failing to stop the deaths of thousands of people," Kate Krauss of the AIDS Policy Project said, adding, "It's true, and perhaps this statement will spur a closer, more critical examination of the Bush administration's AIDS policies" (AIDS Policy Project release, 7/13). However, Anthony Fauci, director of the <a ="http://www.niaid.nih.gov/default.htm">National Institute of Allergy and Infectious Diseases, said that the United States is working to combat the HIV/AIDS pandemic (VOA News, 7/13). Randall Tobias, head of the State Department's <a ="http://www.state.gov/s/gac/">Office of the Global AIDS Coordinator, said, "The president has requested $200 million for next year, and I think that is more than adequate to meet the r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quirements of the Global Fund in terms of getting money out for putting programs in place (Hirschler, <a ="http://story.news.yahoo.com/news?tmpl=story&cid=578&ncid=578&e=6&u=/nm/20040714/ts_nm/aids_dc">Reuters/Yahoo! News, 7/14).\par BBC's "<a ="http://www.bbc.co.uk/worldservice/programmes/worldupdate/">World Update": The segment includes comments from Fauci (Buchan, "World Update," BBC, 7/13). The complete segment is available <a ="http://www.bbc.co.uk/worldservice/ondemand/rams/wup28033__2004.ram">online</a> in RealPlayer.\par WBUR's "On Point": The segment includes comments from David Gartner, policy director at the <a ="http://www.globalaidsalliance.org/">Global AIDS Alliance</a> ("On Point," WBUR, 7/13). The complete segment is available <a ="http://www.onpointradio.org/shows/2004/07/20040713_b_main.asp">online</a> in RealPlayer, Quicktime and Windows Media.\par "The World" -- a production of <a ="http://www.bbc.co.uk/worldservice/index.shtml">BBC World Service</a>, PRI and <a ="http://main.wgbh.org/wgbh/">WGBH Boston</a>: The segment includes comments from Greg Berman, author of the book "The Invisible People: How the U.S. Has Slept Through The Global AIDS Pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 demic"; Annan; and Fauci (Clark, "The World," PRI, 7/13). The complete segment is available <a ="http://www.theworld.org/content/07131.wma">online</a> in Windows Media.\par Bangkok Notebook\par Young People Must Be Involved in Development of HIV/AIDS Prevention, Care, Treatment Programs, Piot Says\par [Jul 14, 2004]\par Young people must be involved in the development of HIV/AIDS prevention, care and treatment programs because "adults need help getting it right," <a ="http://www.unaids.org/">UNAIDS</a> Executive Director Peter Piot said on Wednesday during a "Meet the Leaders" session on youth and AIDS at the <a ="http://www.aids2004.org/">XV International AIDS Conference</a> in Bangkok, Thailand. Piot said that young people should be involved in the decision-making processes of AIDS organizations not only because it makes "good sense but it is also a democratic right because it's about the future of entire nations." He also said that more attention must be directed toward HIV/AIDS among women and girls. The panel also included David Ross of the <a ="http://www.lshtm.ac.uk/">London School of Hygiene and Tropical Medicine, who spoke on behalf of the UNAIDS Interagency Task Team on Young People; John Stover, vice president of the <a ="http://www.policyproject.com/">POLICY Project</a>/<a ="http://www.tfgi.com/index.cfm">Futures Group</a>; and Yinka Jegede-Ekepe, head of the Nigerian Community of Women Living with HIV/AIDS. The session, titled "At the Crossroads: Accelerating Youth Access to HIV/AIDS Services," provided a forum for youth from nations around the world -- including Indonesia, Australia, Thailand and the United Kingdom -- to ask questions of the panel members. Piot urged young people to organize, develop strategies and goals and identify their allies to become equal partners with adults in the fight against AIDS (Alyson Browett, Kaiser Daily HIV/AIDS Report, 7/14).\par A <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1186">webcast</a> of this session, as well as additional coverage of the conference, is available online from <a ="http://www.kaisernetwork.org/">kaisernetwork.org</a>.\par Global Challenges\par Bush Administration Policies Could Make PEPFAR Difficult To Implement, GAO Report Says\par [Jul 14, 2004]\par The Bush administration's policies on generic antiretroviral drugs and other issues could make the impleme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tation of the <a ="http://www.state.gov/s/gac/rl/or/c11652.htm">President's Emergency Plan for AIDS Relief difficult, according to a <a ="http://www.gao.gov/">Government Accountability Office</a> <a ="http://www.gao.gov/new.items/d04784.pdf">report</a> released Tuesday to conicide with the XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference, <a ="http://www.usatoday.com/news/health/2004-07-13-bush-aids_x.htm">USA Today reports (Sternberg, USA Today, 7/14). The five-year, $15 billion PEPFAR program directs funding to 12 African nations -- Botswana, Ethiopia, Cote d'Ivoire, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda and Zambia -- as well as Haiti, Guyana and Vietnam in Asia (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24359">Kaiser Daily HIV/AIDS Report, 6/23). The GAO report, requested by Rep. Jim Kolbe (R-Ariz.), is based on interviews with <a ="http://www.usaid.gov/">USAID</a> and <a ="http://www.cdc.gov/">CDC</a> officials who work in the 14 Africa and Caribbean countries that were the initial focus of the plan. Although Kolbe said that the report shows that the program is "running very well," he said that there are "problems at all kinds of levels." For i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stance, most of the staff interviewed also said that they have not received specific guidelines on whether they can use PEPFAR money to purchase generic antiretroviral drugs. Such confusion has made it difficult for U.S. officials to develop national treatment programs in the focus nations, especially the four nations that already use generic drugs, according to USA Today. In addition, the report notes that a federal regulation usually used to control large purchases of items -- such as furniture -- limits the government's ability to make bulk purchases exceeding $100,000. The requirement means that larger drug purchases have to be a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 proved by officials in Washington, D.C., which can take several months, according to USA Today. One of the greatest challenges seems to be coordinating government agencies and nongovernmental organizations, as well as providing technical assistance and drug provision without requiring large amounts of paperwork for developing countries, Kolbe said (USA Today, 7/14).\par Generic Drugs\par Joia Mukherjee, medical director of <a ="http://www.pih.org/">Partners in Health</a>, which expects to r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceive at least $1 million in PEPFAR funding for fiscal year 2005, said that the requirements have been "very confusing," adding, "You're trying to figure out who can buy what with what money." To circumvent the policy, many countries have started using PEPFAR funding to train health workers, pay salaries and buy other equipment, and they have used money from other sources to buy generic drugs. An unnamed official from an organization that received a large PEPFAR grant said that such a solution is "a compromise that wasn't a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceptable before." However, Ambassador Randall Tobias, head of the Office of the Global AIDS Coordinator, on Tuesday said that the United States "respect[s] local governments' decisions as to how best to manage their HIV/AIDS programs." He added, "In the event that a country elects to use non-U.S. funding to purchase copy drugs that have not been approved for quality and safety by the U.S., [PEPFAR] will support nonpha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 maceutical aspects of the country's care, treatment and prevention programs, and will do whatever is nece}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sary to maintain integrated systems of care" (Nakashima/Brown, <a ="http://www.washingtonpost.com/wp-dyn/articles/A48026-2004Jul13.html">Washington Post, 7/14).\par The New York Times on Wednesday examined the progress of PEPFAR (Sontag et al., New York Times, 7/14). The complete article is available <a ="http://www.nytimes.com/2004/07/14/health/14aids.html">online</a>.\par 15 Million AIDS Orphans Worldwide, 12 Million in Sub-Saharan Africa, Report Says\par [Jul 14, 2004]\par The total number of children throughout the world who have lost one or both parents to AIDS-related causes has reached 15 million, and the number of AIDS orphans in sub-Saharan Africa increased to about 12 million in 2003, according to a joint report by <a ="http://www.unaids.org/en/default.asp">UNAIDS</a>, <a ="http://www.unicef.org/">UNICEF</a> and <a ="http://www.usaid.gov/">USAID</a> released on Tuesday at the <a ="http://www.aids2004.org/">XV International AIDS Conference</a>, <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5650892">Reuters</a> reports (Re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ney, Reuters, 7/13). The joint report, titled "<a ="http://www.unicef.org/publications/index_22212.html">Children on the Brink 2004," is the fourth biennial edition and is based on surveys conducted by the three agencies (<a ="http://www.mg.co.za/Content/l3.asp?ao=118687">IPS/Mail & Guardian, 7/14). The report shows that the number of orphans worldwide is expected to reach 18.4 million by 2010, according to Reuters. The report also shows that:\par Although there are more older orphans than younger orphans, almost 50% of children who have lost at least one parent are younger than age 12; 12% are younger than age five (Reuters, 7/13).\par Between 2001 and 2003, more than three million children lost at least one parent to AIDS-related causes (USA Today, 7/14).\par Only 17 countries at the end of 2003 had national policies aimed at AIDS orphans and related issues.\par In five Southern African countries, 15% of all children lost one or both parents in 2003 -- most due to AIDS-related causes.\par Although Asia has lower HIV prevalence than other regions of the world, it has the highest number of o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 phans from all causes -- 87.6 million.\par AIDS is more likely than any other illness to lead children to lose one or more parents (Reuters, 7/13).\par UNICEF Executive Director Carol Bellamy said, "It is a tidal wave of children who have lost one of more of their parents," adding, "It has the possibility of destabilizing societies quite dramatically." She said that "[m]uch too little" is being done to address the needs of orphans worldwide, according to Reuters. Bellamy said, "Simple things could make a big difference when it comes to AIDS orphans and could give these chi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dren an opportunity for the future" (Reuters, 7/13). The report calls for countries to improve health care and access to education and to support community and family programs that provide care for AIDS orphans, <a ="http://www.voanews.com/article.cfm?objectID=8CC47812-174A-49A8-B972F6EC95F6900E">VOA News reports (Baragona, VOA News, 7/13).\par Reaction\par Dr. Joanne Carter, legislative director for <a ="http://www.results.org/website/article.asp?id=19">RESULTS</a> -- an international antihunger and a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tipoverty group -- said, "In some ways orphans are one of the orphaned issues at this conference," adding, "It's clear that what is left in the wake of the AIDS pandemic is these kids. These kids are the futures of their society and they have been largely forgotten by the global community." U.S. Rep. Barbara Lee (D-Calif.) -- the only member of Congress attending the conference -- said that the orphan crisis is "mindboggling," ad}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing, "The world cannot stand by and watch this occur" (Reuters, 7/13). USAID Assistant Administrator for Global Health Anne Pederson said, "We must also reach out to children whose parents are sick and dying, the children in households that no longer have an income earner, the children in families that have stretched their income to care for extra children and orphans and the very many children whose greatest fear is that AIDS will take one or both of their parents" (VOA News, 7/13). UNAIDS Executive Director Peter Piot said that Asia -- which accounts for 60% of the world's population -- could "soon be faced with a serious orphan crisis unless it takes urgent steps to stop the epidemic." He added, "To avoid having millions more children become orphaned due to AIDS, countries must do everything they can to prevent people from becoming newly infected in the first place" (UNICEF <a ="http://www.unicef.org/media/media_22247.html">release</a>, 7/13). <a ="http://www.globalaidsalliance.org/">Global AIDS Alliance</a> Policy Director David Gartner said that the report is a "wake-up call that we hope will finally cause the rest of the world to address this disastrous pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lem" (GAA release, 7/13).\par Clients of Commercial Sex Workers Will Determine Course of HIV/AIDS Epidemic in Asia, East-West Center Says\par [Jul 14, 2004]\par The male clients of commercial sex workers will determine the course of the HIV/AIDS epidemic in Asia, Tim Brown, a researcher at the <a ="http://www.eastwestcenter.org/">East-West Center</a>, said this week at the XV International AIDS Conference in Bangkok, Thailand, the <a ="http://www.sun-sentinel.com/features/health/sns-ap-aids-meeting-asias-epidemics,0,2013733.story?coll=sns-ap-health-headlines">AP/South Florida Sun-Sentinel reports (Ross, AP/South Florida Sun-Sentinel, 7/12). According to the <a ="http://www.unaids.org/bangkok2004/report.html">2004 UNAIDS Report of the Global AIDS Epide}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic released by <a ="http://unaids.org/">UNAIDS</a> on July 6, Asia accounts for 60% of the world's popul}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion and has experienced some of the "sharpest" increases in numbers of HIV cases. In Asia, the epidemic is still largely concentrated among injection drug users, men who have sex with men, commercial sex workers and clients of sex workers and their sexual partners, according to the report (<a ="http://www.kaisernetwork.org/daily_reports/rep_hiv_recent_rep.cfm?dr_cat=1&show=yes&dr_DateTime=06-Jul-04">Kaiser Daily HIV/AIDS Report, 7/6). According to Brown, the Asian epidemic eventually will cross over from high-risk groups to the general population through male drug users and female commercial sex workers to their sexual partners. "Men who visit prostitutes are going to be the crux of the Asian epidemic," Brown said, adding, "It's the men who drive this."\par Economics\par An increase in affluence also has resulted in a rise in the number of men who visit commercial sex workers, according to the <a ="http://search.ft.com/search/article.html?id=040714000775&query=asia+aids&vsc_appId=totalSearch&state=Form">Financial Times. During Thailand's economic boom during the early 1990s, almost 20% of Thai men reported regularly visiting commercial sex workers -- a figure that now has decreased to around 10% (Kazmin, Financial Times, 7/14). The "fate" of HIV/AIDS in Asia, Brown says, therefore depends on the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ditions in the commercial sex industry, including the frequency that men visit commercial sex workers, the control of other STDs, the frequency of condom use among commercial sex workers and their clients and the control of mother-to-child transmission if partners of clients of commercial sex workers are infected. The clean needles provision also is considered important because delaying the spread of HIV from injection drug users to commercial sex workers provides the time to implement condom promotion initiatives.\par Women\par Unlike in sub-Saharan Africa, it is "unlikely" that women will drive the Asian HIV/AIDS epidemic, and HIV prevalence among men in the region will remain twice as high as among women, according to Brown. "Women in Asia largely have sex within marriage and, for the most part, premarital sex is mostly confined to their future husband," he said, adding, "On the other hand, the men are generally given a great deal of lat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tude in Asia. Sex remains a part of Asian business culture and that creates an imbalance and creates the demand for sex workers." However, Helene Gayle, director of <a ="http://www.gatesfoundation.org/GlobalHealth/HIVAIDSTB/">HIV/AIDS and TB and <a ="http://www.gatesfoundation.org/GlobalHealth/ReproductiveChildHealth/">Reproductive and Child Health at the Bill & Melinda Gates Foundation and the incoming president of the <a ="http://www.ias.se/">International AIDS Society</a>, said that sexual behavior among Asian women is changing. Young women may not "a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 here to the sexual mores" of previous generations and casual sex is becoming more frequent, increasing concern about HIV/AIDS in the region, Gayle said (AP/South Florida Sun-Sentinel, 7/12). Political leaders say that Asia's "conservative family values" will help reduce the spread of HIV, according to the Times. But the Times reports that the "relative concentration" of the disease among high-risk groups could make effe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive prevention programs, such as condom promotion, "still have a big impact in reducing the spread of HIV" (Financial Times, 7/14).\par Drug Access\par South Africa To Stop Recommending Nevirapine for Use by Itself for Mother-to-Child HIV Transmission, Medicines Control Council Says\par [Jul 14, 2004]\par South Africa's Medicines Control Council on Tuesday said that the government would stop recommending that the antiretroviral drug nevirapine be administered alone to reduce mother-to-child HIV transmission b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause its use significantly increases the chance of drug resistance, <a ="http://www.alertnet.org/thenews/newsdesk/L13352242.htm">Reuters</a> reports (Quinn, Reuters, 7/13). Although the regimen has become increasingly common in clinics throughout Africa, MCC recommended against administering a single dose of nevirapine to a pregnant woman before childbirth and also said that the drug is more effective when used in combination with other antiretrovirals, the <a ="http://www.nytimes.com/2004/07/14/international/africa/14afri.html">New York Times reports (LaFraniere, New York Times, 7/14). According to an MCC statement, "using nevirapine as a monotherapy for this pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pose show[s] significant resistance of up to 50 percent," Reuters reports (Reuters, 7/13). The once-controversial drug had pitted AIDS advocates against a government reluctant to distribute nevirapine. Ho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ever, since the AIDS advocacy group Treatment Action Campaign won a lawsuit against the government that forced provision of nevirapine, there has been little evidence of dangerous side effects from the drug, as the government had once claimed. Without nevirapine -- which is taken by women during labor and administered to infants following birth -- about 25% of infants born to HIV-positive women contract the disease from their mothers; however, with the now-routine administration of the drug, the incidence of mother-to-child HIV transmission is about 8%, according to doctors. Caesarean-section deliveries and bottle feeding -- as o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 posed to breastfeeding, which can transmit HIV to infants -- also help to reduce the risk of vertical HIV transmission (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24125">Kaiser Daily HIV/AIDS Report, 6/9).\par Recommendations\par MCC now recommends administering nevirapine in combination with zidovudine, the Times reports (New York Times, 7/14). MCC said it "believes that the risk-benefit profile of nevirapine monotherapy has changed and therefore no longer recommends its use for the prevention of mother-to-child transmission of HIV." Kevin McKenna, a spokesperson for German pharmaceutical company <a ="http://www.boehringer-ingelheim.com/corporate/home/home.asp">Boehringer Ingelheim -- which holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to nevirapine -- said that the company does not object to using the drug as a combination treatment, but he added that he is concerned that MCC could withdraw the use of nevirapine altogether. McKenna said, "We will be taking it up with MCC very shortly." TAC Secretary Mark Heywood said, "We think that it would be wrong of the gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment to simply withdraw nevirapine. What the government needs to do is to introduce, as soon as possible, access to double-drug regimens or triple-drug regimens for pregnant women" (Reuters, 7/13). Nathan G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ffen, national manager of TAC, said, "We think the change in protocol ... is something we should welcome," adding, "But in the meanwhile, they must continue with their programs" (McDonough, <a ="http://www.voanews.com/article.cfm?objectID=4B40F887-ECE1-410A-A61494678C5BF772&title=S%2E%20Africa%20Group%20Says%20Use%20of%20AIDS%20Drug%20May%20Harm%20Pregnant%20Women&catOID=45C9C789-88AD-11D4-A57200A0CC5EE46C&categoryname=Africa">VOA News, 7/13).\par Reaction\par Public health experts and HIV/AIDS advocates attending the <a ="http://www.aids2004.org/">XV Internatio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al AIDS Conference</a> in Bangkok, Thailand, said that MCC's decision represents another example of the government's "reluctance to confront the AIDS epidemic head-on," according to the Times. Joep Lange, <a ="http://www.ias.se/">International AIDS Society</a> president and co-chair of the AIDS conference, said that MCC's decision sends a "totally wrong message," adding, "We know that in many settings the single dose of nevirapine ... is better than nothing" (New York Times, 7/14). <a ="http://www.harvard.edu/">Harvard University</a> <a ="http://aids.harvard.edu/">AIDS Institute</a> Executive Director Richard Marlink, who serves as scientific director for the <a ="http://www.pedaids.org/">Elizabeth Glaser Pediatric AIDS Found}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, said that South Africa's decision could influence other countries in Africa. "In those rural places, women coming into labor probably will not use it now. We're saving a whole lot of lives with a simple dose," he said, adding, "Yes, you should add [zidovudine] or other drugs -- if you have it. But how many places have it?" Dr. Glenda Gray, co-director of the HIV Perinatal Research Unit at <a ="http://www.chrishanibaragwanathhospital.co.za/bara/index.jsp">Chris Hani Baragwanath Hospital in Sow}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 to, said that nevirapine is the "backbone" of most mother-to-child HIV transmission prevention programs, the <a ="http://www.boston.com/news/world/asia/articles/2004/07/14/s_africa_wont_urge_aids_drug_in_labor/">Boston Globe reports. She added, "We mustn't jeopardize children's lives by not using nevirapine when we have no other option. I don't think women should be without any intervention while we're looking for that magic bullet." Timothy Farley, coordinator of sexually transmitted diseases and reproductive-tract infections for the World Health Organization, said that one dose of nevirapine "is very practical and very easy to deliver." He added that doctors and health workers should use a combination of nevirapine and zidovudine "when feas}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble" (Boston Globe, 7/14).\par Ministry of Health\par The South African <a ="http://196.36.153.56/doh/ministry/index.html">Ministry of Health</a> on Tuesday said it would not curb the use of nevirapine despite the MCC regulation, the <a ="http://www.washingtonpost.com/wp-dyn/articles/A47951-2004Jul13.html">Washington Post reports. Ho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ever, the ministry said that it must review the program because of the MCC decision, ministry spokesperson Sibani Mngadi said. Mngadi said that significantly cutting the program or canceling the program was not an option, according to the Post. "We are not going to stop our efforts to stop mother-to-child transmission," Mngadi said (Timberg, Washington Post, 7/14).\par Dr Allen Rosenfield, Dean of the <a ="http://www.columbia.edu/">Columbia University</a>'s <a ="http://www.mailman.hs.columbia.edu/">Mailman School of Public Health and a member of the Kaiser Family Foundation Board, talks with Kaiser's Jackie Judd about the latest efforts to treat pregnant women in the developing world who are HIV positive.\par Medicines Sans Frontieres Presents Data Showing Antiretroviral Therapy Can Improve Survival in Develo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing Countries\par [Jul 14, 2004]\par Administering antiretroviral drug treatment to people with HIV/AIDS in developing countries can "dramatically increase survival," according to a study presented by Medicines Sans Frontieres Monday at the XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference in Bangkok, Thailand, <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5643121">Reuters</a> reports (Re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ney, Reuters, 7/12). MSF examined data from its treatment programs in 16 countries -- which include 12,000 people living with HIV/AIDS -- according to the <a ="http://www.boston.com/news/nation/articles/2004/07/13/study_finds_aids_drugs_succeed_in_poor_nations/">Boston Globe. About 40% of patients enrolled in the programs were given a prognosis of one year to live because their CD4+ cell levels were below 50 cells per mm3. After one year of treatment, the median i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 crease in CD4+ cell counts across all patients was 135; after two years, the median increase was 208, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to the report. The report shows that patients taking antiretroviral drugs had a two-year survival rate of 85.3%, the Globe reports (Donnelly, Boston Globe, 7/13).\par Treatment Costs\par Although the cost of first-line antiretroviral drug regimens has dropped significantly, MSF said that more a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral drug price reductions are needed to help counter the cost of second-line treatments, Reuters r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports. MSF provides treatment for 13,000 people in 25 countries, and most participants receive first-line drugs, according to Reuters. Some drug makers have reduced the prices of their antiretroviral treatments by up to 90%, and the cost of fixed-dose combination generic treatments cost about $200 per person, per year, MSF said, according to Reuters. However, if a patient develops resistance to these medicines and moves to the second-line treatment, the price increases to $5,000 per patient, per year. Dr. Alexandra Calmy, an HIV/AIDS adviser for MSF, said, "Unless this situation changes, per-patient costs will skyrocket and people will die needlessly" (Reuters, 7/12). MSF spokesperson Kris Torgeson said that there is "still ... not enough being done to rapidly scale up access to treatment for all those who need it" (Collins, <a ="http://www.voanews.com/article.cfm?objectID=992C9133-E86D-4F8B-BEDFDCD4A4D2E23F&title=Medical%20Group%20Says%20AIDS%20Drugs%20Help%20Survival%20Rate%20in%20Developing%20Countries&catOID=45C9C786-88AD-11D4-A57200A0CC5EE46C&categoryname=Health%20%26%20Medicine">VOA News, 7/12).\par Children\par MSF officials on Tuesday said that treating HIV-positive children in developing countries is an "uphill battle," <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5653311">Reuters</a> reports. MSF said that there are about 2.5 million HIV-positive children in the world and about 700,000 new HIV cases du}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the last year. About 50% of HIV-positive children die from AIDS-related causes before age two, MSF said. Dr. David Wilson, medical coordinator for MSF in Thailand, said, "Up until now [children] have been a discriminated minority," adding, "We need to pay more attention to them. They are not just small adults. There are specific issues in terms of diagnosis and specific terms of treatment" (Reaney, Reuters, 7/13). A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to <a ="http://news.bbc.co.uk/2/hi/health/3892583.stm">BBC News</a>, standard tests to determine a patient's HIV status are unreliable in infants younger than 18 months, and monitoring drug treatment also is difficult in children because most commercially available machines that check CD4+ cell counts are not adapted for use in children (BBC News, 7/14).\par Treatment Cost and Access for Children\par Antiretroviral drug treatment for children currently costs "several times more" than adult treatment, according to <a ="http://allafrica.com/stories/200407140016.html">SAPA/AllAfrica.com</a>. According to MSF, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral treatment in pediatric formulations -- oral solutions and syrups -- is about $1,300 per patient, per year, compared with about $200 per adult patient, per year. Pediatric drugs also are not available in fixed-dose combinations. In addition, the drug zidovudine costs about $1,200 per adult patient, per year, compared with about $2,846 per child patient per year (SAPA/AllAfrica.com, 7/14). Fernando Pascual, an MSF pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 macist, said that HIV incidence among children is "neglected by [drug] companies," adding, "They will not produce formulations for children unless there is pressure from the international community" (Reaney, Re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ters, 7/13). Children also do not have access to treatment programs because medical staff are not adequat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ly skilled, according to MSF official Arnaud Janin. In Malawi, 45,000 patients receive antiretroviral drugs -- none of whom are children -- and only 5% of the 13,000 patients whom MSF have put on its antiretroviral program are younger than age 13 (Agence France-Presse, 7/14).\par Actions\par Dr. Omokhudu Idogho of Action Aid Nigeria said he is calling upon African countries to develop policies that would require 30% of pharmaceutical companies' budgets to be set aside for producing pediatric drugs. "Apart from South Africa, most African countries do not have the capacity for mass production," Idogho said, adding, "Therefore, we must move fast because European and American pharmacies do not feel the pre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sure to produce the drugs for us. If we don't produce them fast enough, then we're going to lose more lives" (SAPA/AllAfrica.com, 7/14). Thai health officials recently announced that it will launch a pediatric version of its generic combination antiretroviral drug next year to simplify the treatment of HIV-positive children, accor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to the Government Pharmaceutical Organization. According to GPO Managing Director Thongchai Tha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ichachart, the drug is currently in clinical trials and the agency hopes to have it available by the middle of next year. The GPO-VIR drug combines generic equivalents of stavudine, lamivudine and nevirapine but is currently only available to patients who are at least age 10. Patients younger than age 10 either have to take powder or liquid formulations or split the tablet. Thongchai said that there are currently about 5,000 Thai chi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dren with HIV who need antiretroviral treatment (<a ="http://www.reuters.co.uk/newsArticle.jhtml?type=healthNews&storyID=5665675A\u223\'a7ion=news">Reuters</a>, 7/14).\par Kaiser Daily HIV/AIDS Report Summarizes Recent Developments in AIDS Drug Research, Access\par [Jul 14, 2004]\par Several drug makers announced developments in HIV/AIDS treatments intended to increase drug access in developing countries. Summaries of recent news articles appear below.\par GlaxoSmithKline and <a ="http://www.boehringer-ingelheim.com/corporate/home/home.asp">Boehringer Ingelheim on Monday announced that the companies will accelerate development of a combination pill co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 taining GSK's Combivir and Boehringer's Viramune. The combination treatment was recommended by the <a ="http://www.who.int/en/">World Health Organization</a> for treating HIV in developing countries, Dow Jones News reports. The company plans to seek approval under a new FDA expedited review process (Dow Jones News, 7/12). The process is designed to review new products that combine FDA-approved HIV/AIDS drugs into a fixed-dose pill and new co-packaging of existing treatments (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=23764">Kaiser Daily HIV/AIDS Report, 5/18).\par Thai health officials on Saturday said the government may produce generic versions of Merck's Stocrin, known generically as efavirenz, and Abbott Laboratories' Kaletra, a combination pill containing lopinavir and ritonavir, Reuters reports. Officials plan to use the pill to treat the 20%, or 250,000, HIV-positive Thai people who are resistant to GPO-VIR, a combination of stavudine, lamivudine and nevirapine produced by the Go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernment Pharmaceutical Association (Reuters, 7/12).\par Indian drug company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has patented its combination pill Triomune in South Africa, Reuters/Wall Street Journal reports. The pill, which is taken twice daily, contains generic versions of GSK's lamivudine, <a ="http://www.bms.com/landing/data/index.html">Bristol-Meyers Squibb's stavudine and Boehringer's nevira}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ine, all of which are }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -protected. However, Bristol-Meyers Squibb spokesperson Tracy Furey said the company does not plan to seek damages for }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is seeking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for the drug in 17 other African countries, Reuters/Wall Street Journal reports (Reuters/ Wall Street Journal, 7/13).\par Science & Medicine\par Microbicide Trials To Be Aimed at Women Due to Growing HIV/AIDS Impact on Female Population\par  [Jul 14, 2004]\par As the HIV/AIDS epidemic increasingly impacts women worldwide, clinical trials of microbicides to prevent the sexual transmission of HIV will include women, and a product could be on the market in five years, Dr. Zeda Rosenberg, CEO of the not-for-profit <a ="http://www.ipm-microbicides.org/">International Partnership for Microbicides, said on Wednesday at the <a ="http://www.aids2004.org/">XV International AIDS Confe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence</a>, <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5665362">Reuters</a> reports. HIV/AIDS experts believe that a "partially effective" microbicide could prevent 2.5 million HIV infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions over three years, according to Reuters (Reaney, Reuters, 7/14). Microbicides include a range of pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts such as gels, films, sponges and other products that could help prevent the sexual transmission of HIV and other sexually transmitted diseases. Although HIV is transmitted primarily through heterosexual inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 course in much of Africa and Asia, no female-controlled HIV prevention method currently is widely available (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=22842">Kaiser Daily HIV/AIDS Report, 3/24). In addition, approximately 48% of adults living with HIV/AIDS worldwide are women, and 57% of people living with HIV/AIDS in sub-Saharan Africa are women, according to a report released on Wednesday by UNAIDS, the United Nations Development Fund for Women and the United Nations Popul}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion Fund, according to a UNAIDS <a ="http://www.unaids.org/NetTools/Misc/DocInfo.aspx?=http://gva-doc-owl/WEBcontent/Documents/pub/Media/Press-Releases02/PR_Women-AIDS_14Jul04_en.pdf">release</a>. The report, titled "<a ="http://www.unaids.org/NetTools/Misc/DocInfo.aspx?=http://gva-doc-owl/WEBcontent/Documents/pub/Publications/External-Documents/UNFPA_UNAIDS_UNIFEM_womenAIDS_en.pdf">Women and HIV/AIDS: Confronting the Cr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sis," said that women ages 15-24 in sub-Saharan Africa are three times more likely to be infected with HIV than men of similar age. In addition, women in sub-Saharan Africa also know less about HIV/AIDS than men and women's knowledge about the disease is often "rendered useless" by discrimination and violence against women (UNAIDS release [1], 7/14). An effective microbicide would be important for women in r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 source-poor countries whose husbands refuse to use condoms, according to the <a ="http://www.nytimes.com/2004/07/14/international/asia/14bang.html">New York Times (Altman, New York Times, 7/14). An effective microbicide also could help protect men who have sex with men against HIV infe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, according to a UNAIDS release (UNAIDS <a ="http://www.unaids.org/NetTools/Misc/DocInfo.aspx?LANG=en&=http%3a%2f%2fgva-doc-owl%2fWEBcontent%2fDocuments%2fpub%2fMedia%2fPress-Releases02%2fPR_TMV-BKK_14Jul04_en%26%2346%3bpdf">release</a> [2], 7/14).\par Microbicide Tests Underway\par Several microbicides are undergoing clinical trials that by the end of 2004 will involve more than 28,000 women in the United States, Africa and Asia, according to the Times (New York Times, 7/14). An effective microbicide would kill HIV in semen, block the virus from attaching to a target cell or prevent HIV from mult}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plying if the virus enters a target cell, according to Reuters (Reuters, 7/14). Two microbicides -- one called Savvy, which is made by Biosyn, and another called Carraguard, which was developed by the <a ="http://www.popcouncil.org/biomed/carraguard.html">Population Council -- are currently undergoing efficacy testing in Ghana and South Africa respectively, according to the Times (New York Times, 7/14). Four add}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional microbicides also will begin testing soon, according to Reuters (Reuters, 7/14). Rosenberg said that developing an effective microbicide is especially important because an effective HIV vaccine could be many years away, according to the Associated Press. She said, "When you can have a partially protective vaccine in 15 years or a partially protective microbicide in five years, it makes a whole lot of sense now to focus on microbicides" (Ross, Associated Press, 7/14). Rosenberg also said that although microbicides "will not be magic bullets" and "probably will never be as effective as condoms, ... even a partially effective microbicide could save millions of lives" (New York Times, 7/14).\par House Appropriations Subcommittee Commits $30M for Microbicide Research\par The House Appropriations Subcommittee on Foreign Operations has allocated $30 million in the USAID budget for microbicide research, which is an $8 million increase over the last fiscal year's funding level, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to an <a ="http://www.microbicide.org/">Alliance for Microbicide Development</a> release. "Alar}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ingly, the face of AIDS has become increasingly female" -- with women accounting for more than 50% of people living with AIDS worldwide and 60% of those in Africa, Polly Harrison, director of AMD, said. She added, "Microbicides would give women everywhere power over AIDS in a way like never before by allowing them to protect themselves from the epidemic, even in societies where they lack the economic or societal standing to control their sexual encounters." Although AMD "applaud[s]" the increase in microbicide research funding, Harrison said, "[M]icrobicide funding is still woefully inadequate and greater leadership is needed" (AMD release, 7/13).\par NPR's "Morning Edition" on Wednesday reported on the development of microbicides to help prevent the transmission of HIV for women who may not be able to negotiate condom use. The segment includes co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments from <a ="http://www.icrw.org/">International Center for Research on Women</a> President Geeta Gupta; International Planned Parenthood Federation Director-General Steven Sindling; Sara Whitehead, head of microbicide research for a collaboration between <a ="http://www.cdc.gov/">CDC</a> and Thailand; and a Ugandan HIV/AIDS advocate who advocated abstinence at the conference (Knox, "Morning Edition," NPR, 7/14). The complete segment is available <a ="http://www.npr.org/dmg/dmg.php?prgCode=ME&showDate=14-Jul-2004&segNum=14&mediaPref=RM">online</a> in RealPlayer.\par Media & Society\par Global Media AIDS Initiative Announces New Public HIV/AIDS Education Initiatives at XV International AIDS Conference\par [Jul 14, 2004]\par Actor and AIDS advocate Richard Gere and <a ="http://www.mtv.com/">MTV</a> President Bill Roedy on Tuesday at a Global Media AIDS Initiative press conference at the <a ="http://www.aids2004.org/">XV Inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 national AIDS Conference</a> announced several public HIV/AIDS education campaigns primarily targeting youth in the United States, Russia and China, <a ="http://www.usatoday.com/news/health/2004-07-13-gere-aids_x.htm">USA Today reports (Sternberg, USA Today, 7/13). MTV is a partner in the Global Media AIDS Initiative, an alliance between the <a ="http://www.un.org/">United Nations</a> and the media that was ge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erated through a partnership between <a ="http://www.unaids.org/">UNAIDS</a> and the <a ="http://www.kff.org/">Kaiser Family Foundation</a>, with financial support from the Bill & Melinda Gates Foundation (Kaiser Family Foundation <a ="http://www.kff.org/entpartnerships/phip071304nr.cfm">release</a>, 7/13). As a part of the initiative, Gere announced agreements with two of India's largest entertainment networks and a 24-hour news station to d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 velop AIDS public services announcements (USA Today, 7/13). Speaking at the briefing, Gere and Roedy criticized the Bush administration's focus on abstinence in AIDS education, <a ="http://story.news.yahoo.com/news?tmpl=story&cid=1508&ncid=751&e=7&u=/afp/20040713/hl_afp/health_aids_mtv">AFP/Yahoo! News reports. Roedy said that although MTV has been "criticized quite a bit" for its commercials and programs encouraging condom use, the company will "continue to take those risks" (AFP/Yahoo! News, 7/13). Gere said that the United States will "hopefully have another administration in about four months ... and along with that some sanity on the subject." He added that AIDS "to this planet, to this time and place" is the "most important issue" (<a ="http://www.news24.com/News24/World/News/0,,2-10-1462_1556906,00.html">AFP/News24.com</a>, 7/13). Under the initiative, 22 media companies have pledged to use their influence to educate people worldwide about HIV/AIDS. Most companies pledged to use PSAs, expanded news coverage and documentaries to education the public. Many participants agreed to weave AIDS-related stories into entertainment programs, recruit other media outlets to join the campaign and provide their campaign materials free-of-charge to other broadcast outlets (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=21719">Kaiser Daily HIV/AIDS Report, 1/16).\par New Campaigns\par The Kaiser Family Foundation on Tuesday announced several new programs as part of the initiative:\par The Russian Media Partnership to Combat HIV/AIDS on Tuesday announced that donors had committed $26 million for the first year of a three-year collaborative initiative coordinated by <a ="http://www.gazprom.ru/eng/">Gazprom-Media</a>, <a ="http://www.tpaa.net/index.html">Transatlantic Partners Against AIDS, UNAIDS, the Kaiser Family Foundation and <a ="http://www.viacom.com/">Viacom</a>. The money will be used to develop public service announcements, train journalists, distribute informational resources and hold special events. RMP issued a challenge to Ru}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sian and international partners to increase funding to $200 million over three years.\par The Gere Foundation India Trust in partnership with <a ="http://www.gatesfoundation.org/GlobalHealth/HIVAIDSTB/IndiaAIDSInitiative/IAI.htm">Avahan-India AIDS Initiative, Gates Foundation, Kaiser Family Foundation and STAR India announced the launch of the Heroes Project, a three-year campaign to combat HIV/AIDS in India. STAR India/<a ="http://www.startv.com/eng/abus_starcare.cfm">STAR Care</a>, a division of the STAR Group Limited has made a commitment worth $14 million over three years for public service messages, entertainment pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gramming and news coverage on radio and television. The first television message, featuring Indian cricket star Rahul Dravid, is scheduled to debut this month.\par China Central Television and MTV China are working together to raise awareness about HIV/AIDS in China with a PSA that will air nationwide on local cable and satellite television. The campaign is conducted as part of "Staying Alive," a global youth public education campaign conducted by <a ="http://www.mtv.com/mtvinternational/">MTV Networks International</a> with UNAIDS, Family Health Inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 national, Kaiser Family Foundation, World Bank and others. MTV also plans to launch a Mandarin language version of its staying alive Web site, staying-alive/org.\par MTV International and the International Academy of Television Arts and Sciences will host a summit on HIV/AIDS for senior creative executives from international broadcast companies on Nov. 23 to develop ideas for HIV-focused programming. The summit will coincide with the 32nd International Emmy Awards in New York City (Kaiser Family Foundation release, 7/13).\par A kaisernetwork.org webcast of the session is available <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1203">online</a>.\par Kaiser Daily HIV/AIDS Report Summarizes Media Coverage of International HIV/AIDS Issues\par [Jul 14, 2004]\par Several U.S. and international broadcast programs have included features on HIV/AIDS in response to the XV International AIDS Conference in Bangkok, Thailand, from July 11-16. Summaries of the coverage a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pear below.\par ABCNews' "World News Tonight": The segment profiles South Hospice in Port Shepstone, South Africa, where African parents who are dying of AIDS-related illnesses are creating memory books for the children they will leave behind when they die (Lee, "World News Tonight," ABCNews, 7/13). The complete transcript is available <a ="http://abcnews.go.com/sections/WNT/World/AIDS_memory_box_040713-1.html">online</a>.\par ABCNews' "World News Tonight": The segment reports of the spread of HIV/AIDS in India among comme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cial sex workers and truck drivers and includes comments from Ashok Alexander, director of the India AIDS Initiative and Dr. Shipla Merchant of the National AIDS Committee of India (Litke, "World News Tonight," ABCNews, 7/13). A video excerpt of the segment is available online in RealPlayer.\par BBC's "<a ="http://www.bbc.co.uk/worldservice/programmes/worldtoday/">World Today": Multiple audio fe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tures on HIV/AIDS and reports from the conference are available <a ="http://www.bbc.co.uk/worldservice/programmes/worldtoday/news/story/2004/07/040709_aidsconference.shtml">online</a>.\par NPR's "All Things Considered": The segment reports on how the increase in HIV/AIDS in Africa is affecting families and economies (Beaubien, "All Things Considered," NPR, 7/13). The complete segment is available <a ="http://www.npr.org/dmg/dmg.php?prgCode=ATC&showDate=13-Jul-2004&segNum=12&mediaPref=RM">online</a> in RealPlayer.\par "The World" -- a production of <a ="http://www.bbc.co.uk/worldservice/index.shtml">BBC World Service</a>, PRI and <a ="http://main.wgbh.org/wgbh/">WGBH Boston</a>: The segment includes an interview with an HIV/AIDS advocate in Uganda (Bader, "The World," PRI, 7/13). The complete segment is available <a ="http://www.theworld.org/content/07132.wma">online</a> in Windows Media.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (95%); AIDS POLICY (90%); PROTESTS & DEMONSTRATIONS (89%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VIEWS (78%); PUBLIC POLICY (78%); EMBASSIES & CONSULATES (78%); AIDS & HIV REPORTING (78%); INTERNATIONAL ASSISTANCE (78%); COLLEGE & UNIVERSITY PROFESSORS (62%); DRUG PRICES (55%); RELIGION (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KAISER DAILY HIV (93%); RANDALL TOBIAS (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GROUP OF EIGHT (G8)  (83%); GROUP OF EIGHT (G8) (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (94%); THAILAND (93%); AUSTRALIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGKOK, THAILAND (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 14, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Early Tests for U.S. in Its Global Fight on AIDS The New York Times July 14, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_213}{\*\bkmkstart DOC_ID_213_0}{\*\bkmkstart doc_id_75}{\*\bkmkend DOC_ID_213}{\*\bkmkend DOC_ID_213_0}{\*\bkmkend doc_id_75}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_75"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 75 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  14, 2004 Wednesday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Early Tests for U.S. in Its Global Fight on AIDS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 This article was reported by Deborah Sontag, Sharon LaFraniere and Michael Wines, and was wri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ten by Ms. Sontag.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 2; Foreign Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 3655 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Bush administration did not consult with Mozambique last year before designating the country as a be}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eficiary of its emergency AIDS plan. Mozambique was simply informed that it would be one of 12 African n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions, and 15 countries overall, awarded substantial financial assistance. \par  The pledge of big money was certainly welcome, said Francisco Songane, the Mozambican health minister; AIDS has lowered life expectancy in Mozambique to 38. But the approach, perceived by many Mozambicans as arrogant and neocolonial, was not. \par  Mozambique, in southeastern Africa, had spent considerable time developing a national strategy to combat its high rate of H.I.V. infection. Other international donors had agreed to pool their contributions and let the Mozambicans control their own health programs. Thus, Mozambican officials recoiled when the Americans said earlier this year, ''We want to move quickly, and we know that your government doesn't have the capac}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty,'' Mr. Songane said. \par  The Bush administration wanted the bulk of its funding to go toward more costly brand-name antiretroviral drugs for treatment programs run by nongovernmental organizations. But Mozambique had already decided to treat its people with 3-in-1 generic pills, which were cheaper and simpler to take. Also, Mozambique did not want an American program dependent on costly foreign consultants, N.G.O.'s and the largesse of foreign political leaders, that would run parallel to its own. \par  There were confrontational meetings in Washington and in Maputo, the capital of Mozambique. And in the end, to the surprise of many, the Bush administration agreed to give Mozambique the kind of help it really wanted, by strengthening its laboratories, blood-transfusion centers and the Health Ministry itself -- albeit indirectly, through a grant to Columbia University. \par  ''What I witnessed in Mozambique was a disaster averted,'' said Dr. Steven Gloyd, an international health specialist at the University of Washington who works with Mozambique. ''So, for countries like Mozambique, this may turn out to be a positive intervention, even though it could be a lot more.'' \par  Seventeen months after President Bush announced his five-year, $15 billion emergency AIDS initiative, the program is belatedly getting under way, and surprising some critics of what is seen as its go-it-alone a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 proach. In some cases, the plan is proving to be more adaptive and collaborative than had been expected, especially when countries are strong enough to stand their ground.\par  The plan is already directing considerable money into health clinics, laboratories, testing centers and ho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pices, AIDS treatment, prevention of H.I.V. and care of orphans. \par  For every Mozambique, however, where Washington has altered its plans to meet local objections, there is a Zambia, where local officials are in the dark. The Zambian health minister, Brian Chituwo, said his gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment did not have a formal meeting on the program with the American ambassador until May, 15 months after Zambia's role was announced. Further, he said, on everything but blood-transfusion services, which were negotiated, the Americans' plans for Zambia have ''all come from Washington.'' The American plan, one senior United Nations official said, ''has created turbulence wherever it has gone.'' But another, Michel Sidibe, praised the Americans for making a ''major shift'' in May by signing ''a declaration of harmonization'' in which they pledged to coordinate their anti-AIDS activities with other donors. \par  The president's program, a centerpiece of his compassionate conservativism, has been a prime topic of conversation at the International AIDS Conference in Bangkok -- and a magnet for some protests. On Tue}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day, President Jacques Chirac of France accused the United States of blackmailing developing countries into bartering their right to produce generic H.I.V. drugs for free-trade agreements. American officials di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 missed the charge as groundless. \par  After decades when the pandemic in Africa spread unchecked, billions in anti-AIDS money is suddenly pledged to assist the continent, and questions about how to channel that outpouring have taken center stage. The administration's AIDS effort is under sharp scrutiny because it so big, so unabashedly Washin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ton-dominated and tinged by the administration's political ideology. \par  Many critics see big pharmaceutical companies behind the Bush administration's preference for costlier brand-name drugs, conservative Christians behind its heavy promotion of abstinence, and hard-line unilate}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 alists behind its decision to bypass the Global Fund to Fight AIDS, Tuberculosis and Malaria in creating its own plan.\par  Randall L. Tobias, a former chief executive of the Eli Lilly & Company drug group and a Republican donor who became the administration's global AIDS coordinator last October, lamented the politicized environment and suggested that critics refocus their antagonism. ''The enemy here ought to be apathy, denial and sti}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ma,'' he said. ''I don't know why people spend so much time fighting each other.'' \par  Still, the administration's refusal thus far to use its money to buy generics is complicating the roll-out of its own emergency plan. Like the Mozambicans, other African officials have resisted the distribution of brand name drugs as first-line therapy. As a result, in a half a dozen or more of the focus countries, the gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments themselves or other donors are picking up most of the cost of life-saving drugs.\par  The goal set by President Bush in January 2003 was to treat two million people in five years. Under the plan, an estimated 6,000 to 10,000 people have started on antiretroviral drugs so far, according to a Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gressional appropriations expert. The global AIDS office could not give a figure. In the slums of Lusaka, Zambia, American money was put to use quickly this spring renovating four clinics and training workers to distribute drugs. American doctors worked in concert with a local health official to salvage a stockpile of go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernment AIDS drugs that were about to expire. \par  In late April, they started handing out drugs that ward off death for some very ill people, and within two months, they had 700 patients on antiretroviral therapy. \par  ''There was a patient whose family had sadly sent her off to a hospice'' to die, said Jeffrey Stringer, a doctor from the University of Alabama who is running the program. Recently, a health worker escorted the patient back home. ''And there was a woman who couldn't crawl who has now gained weight and is walking around.'' \par  Dr. Stringer, who is working in collaboration with the Elizabeth Glaser Pediatric AIDS Foundation in Los A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 geles, noted that he had not voted for President Bush. But he had to admit, he said, ''They ponied up.''\par  Other American experts are more skeptical. \par  ''Sure, off the bat, you can put 5,000'' on antiretroviral drugs, said Josh Ruxin, an assistant clinical professor of public health at Columbia and a consultant to Rwanda and Nigeria. ''They're easy to ID, they're terribly sick, they need drugs now, they live in cities, they have cell phones. So that's the low-hanging fruit. But then what happens? You quickly reach a point where you can't treat more people unless you develop the national health systems, and that is not something I've heard the American government commit to in a big way.'' \par  For Bush, a 'Work of Mercy'Mr. Bush presented the President's Emergency Fund for AIDS Relief in his 2003 State of the Union address, which also began the countdown to the war in Iraq. He called it a ''work of me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cy,'' offering the soft power of American humanitarianism to counterbalance the imminent use of military force. \par  ''As our nation moves troops and builds alliances to make our world safer, we must also remember our cal}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing as a blessed country to make this world better,'' he said. \par  Mr. Bush declared a five-year goal of getting 2 million into treatment, preventing 7 million infections and providing care to 10 million infected people and AIDS orphans in what he called the most afflicted countries in Africa and the Caribbean. \par  The 14 focus countries named were: Botswana, Ethiopia, Guyana, Haiti, Ivory Coast, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda and Zambia. Vietnam was added last month at Congress's insistence that there be another nation from a different region.\par  The sheer ambition of the proposal stunned advocates for huge increases in global AIDS funding into a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plause. Jeffrey Sachs, the Columbia University economist, called the president's commitment ''historic'' and a ''breakthrough.''\par  But at a time when American power was being imposed and questioned in the military arena, the AIDS plan struck some as another kind of unilateralism. They feared that Mr. Bush's program would undermine the mu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tilateral Global Fund, which assists eight times as many countries, including India, China and Russia, whose infection rates are rising rapidly. And these experts thought it was retrogressive in its reliance on American universities, faith-based organizations and nongovernmental organizations, whose ability to pay higher sal}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ries could drain workers from local public health systems that should be reinforced instead. \par  Dr. Paul Zeitz, executive director of the Global AIDS Alliance, said advocates were baffled. ''We thought the international community had come to a consensus that there needed to be a new way of doing business where we all worked together and helped strengthen national capacities,'' he said. \par  When he took office, Mr. Bush had inherited a kind of global momentum toward an international AIDS fund, and a drumbeat for action was building at home, too. Senators Bill Frist and John Kerry formed a bipartisan team to fight for greater American involvement. The Rev. Franklin Graham, who delivered the invocation at Mr. Bush's inauguration, was catalyzing the evangelical community to get over its aversion to the disease and confront it as part of its mission.\par  The push for an international fund was led by, among others, Mr. Sachs and Secretary General Kofi Annan at the United Nations. But the Bush administration was a major force in shaping the Global Fund as an ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pendent, multilateral, public-private partnership, and not a World Bank or United Nations program. \par  The Global Fund's approach was conceived as a reaction against years of inefficient and often ineffective foreign development programs. The idea was to funnel aid from multiple donors to the affected countries and let them run their own health programs, thereby eliminating waste, duplication and burdensome demands on patients.\par  Yet it took a couple of years for the Global Fund, which is based in Geneva, to persuade countries to deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 op plans that could be financed, and to get the money flowing from government coffers into health care. The Bush administration was impatient, and concerned that other countries were not contributing their share. The Global Fund did not seem the ideal repository for the billions it wanted to pour into the pandemic. \par  After the 2003 State of the Union address, Richard Feacham, executive director of the Global Fund, said: ''There was to some degree a mood in Washington of dichotomy'' between the president's plan and the Global Fund. ''People felt the need to make a choice and see a rivalry. We worked extremely hard to convey the message that the world needs both. You can't stop the pandemic in 15 countries. The Global Fund is in 130. We also focus on TB and malaria, the greatest killer of African children.''\par  Right after the State of the Union address, Tommy G. Thompson, the secretary of health and human se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices, became the new chairman of the Global Fund, which made some European donors fear an American takeover. But Mr. Bush has instead moved to pull back. In his budget request for 2004, he sought to reduce America's contribution. And in his 2005 request, he is asking for a 60 percent cut in the contribution.\par  Congress, however, refused the Global Fund's allocation for 2004, instead nearly tripling the administration's request. It also increased the global financing to $2.4 billion, of which $1.9 billion goes for H.I.V./AIDS (and the rest for tuberculosis and malaria). Several members of Congress complained that $2.4 billion was not a lot of money for a global health emergency, especially compared with more than $100 billion spent on mil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tary operations in Iraq. \par  The global AIDS coordinator's office, in fact, had only $488 million in new money this year. It also used old money in new ways, though. By the end of the 2004 budget year, it will have committed -- but not yet spent -- $865 million, one-fifth of which is committed to faith-based groups. Some $253 million will go toward trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment programs, but the drug issue has made spending that money more difficult than expected.\par  Generic Drugs vs. Brand Names''We are using generics here because they are cheaper,'' Mr. Songane of Mozambique said. ''And apart from being cheaper, they are prepared in a manner which is simple for our patients, and even simpler for our staff.''\par  Like Mozambique, many countries prefer generics because they can be used to treat more people and b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause, given }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  problems, only generics now come in fixed-dose combinations, which combine three drugs in one tablet, improving adherence to pill-taking schedules.\par  Foreign-made 3-in-1 pills have been approved by the World Health Organization and purchased in bulk by the Global Fund and many developing countries. But the Bush administration is insisting on brand-name a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral drugs because the generics have not been reviewed by the Food and Drug Administration. The F.D.A., Mr. Tobias said, is the most stringent regulatory authority in the world and should make the determ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nation whether drugs for an American overseas program are safe and effective, and of the highest quality. \par  Mr. Tobias noted that the World Health Organization recently withdrew two generic antiretroviral drugs made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of India from its list of approved treatments. (Its fixed dose tablets remain on the list.) This, he su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gested, cast doubt on the W.H.O.'s screening procedures. \par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has said that the problem lay not with the product but with a contract research laboratory that it no longer uses. Tests are being repeated in different labs, and the company says it is confident that the drugs will be back on the approved list soon.\par  Further, earlier this month, researchers who studied }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Triomune reported in the Lancet medical jou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nal, that fixed-dose generic AIDS drugs work as well as brand-name drugs, according to the first clinical trial. Triomune costs as little as $140 a year per patient, compared with about $562 for the brand-name versions in the 3-in-1 pill.\par  In early spring, the Americans discovered that resistance to their rule on brand-name drugs was coming even from the American organizations who were getting multicountry, multiyear grants to set up treatment programs. The American organizations, which are expected to receive more than $600 million over five years, are the Harvard School of Public Health; the Glaser foundation; the Joseph L. Mailman School of Pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lic Health at Columbia University; and a faith-based consortium led by Catholic Relief Services. \par  Some expressed their preferences for generics outright. Barry R. Bloom, the dean of public health at Ha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vard, said, ''The Indian pills are terrific -- you take just two a day.'' Allan Rosenfield, dean at Mailman, issued a statement urging the Bush administration to allow American money to purchase generics.\par  At an American-initiated conference in Botswana in late March, Jacqueline Patterson, who manages the program for a Protestant medical association that is part of the Catholic Relief Services' consortium, declared that most mission hospitals and clinics in Africa and the Caribbean were already using fixed-dose combin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions and wanted to continue. She read comments from the field that voiced a collective anxiety about the imposition of brand-name drugs, resulting in fewer people in treatment and more skipping doses and sharing pills. \par  With countries like Mozambique, Namibia and Rwanda holding fast to their positions that generics would be their first-line drugs, American officials realized that their assistance in those places would be limited. They would be able to provide medicine for children, for whom only brand-name drugs are available, and for those adults, say, who had developed a resistance to the generics. But essentially, they would be providing tec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nical support for the drug treatment program rather than the drugs themselves.\par  In May, the Bush administration announced that it would set up a new expedited review for generic a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretrovirals, including the 3-in-1 pills. If approved, the drugs would be eligible for use in the AIDS plan, it said.\par  An executive at an American foundation engaged in global AIDS work said it remained to be seen whether ''the F.D.A. process is real, a stalling tactic, or ultimately a tool for the R-and-D companies.'' But, he said, his foundation was encouraging foreign drug companies to submit dossiers to the agency.\par  So far, no foreign drug companies have applied for the expedited review. William F. Haddad, an American representative for }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , said the Indian company was left with unanswered questions about the accelerated approval process. ''When they come back to us with answers, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  will make up its mind about whether to apply,'' he said. ''But the bottom line is that this is a political act, not a scientific one. Why is the World Health Organization's stamp of approval O.K. for the World Bank and the Global Fund and not for the U.S.?''\par  Abstinence vs. Condoms With its focus on treatment, Mr. Bush's plan is profoundly changing a two-decades-long emphasis on H.I.V. prevention as the American strategy abroad. The prevention efforts are continuing but, on Congress's mandate, they are being given a new emphasis on abstinence, with $86 mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lion devoted this year to promoting abstinence.\par  World Relief International, the humanitarian arm of the National Association of Evangelicals, is to receive $9.6 million over five years to promote abstinence. Deborah Dortzbach, international director for its H.I.V./AIDS programs, said World Relief would use a network of churches, schools and ''Choose Life'' clubs in Haiti, Kenya, Rwanda and Mozambique. \par  ''We teach abstinence as an opportunity,'' she said, ''as a way to delay the gift of sexuality and its pleasures until they can experience it with responsibility.'' \par  A guide for World Relief instructors includes a detailed chapter on condom use and how to negotiate the use of a condom with a reluctant partner. Ms. Dortzbach acknowledged, however, that many pastors were relu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tant to discuss condoms at all with youths and needed some persuasion to mention them during marriage counseling. \par  Any discussion of condoms, Ms. Dortzbach said, emphasized that condoms were not perfectly safe and that ''the only guarantee for protection is abstinence,'' which is the Bush administration's message. \par  That message is predicated on the success of the ABC model in Uganda, which stands for Abstain, Be Faithful, Condomize. Critics say, however, that the Americans are paying too little attention to ''C.'' \par  The American government is probably buying more condoms now than at any time in its history, Mr. Tobias said, but Congress did not want a broad distribution of condoms to be the primary prevention tool, as it has been historically. In Africa, too, some experts question the efficacy of condoms, given that infection rates continue to climb as many men refuse to use them.\par  The Bush administration's strategy does suggest condoms for ''high risk'' individuals like prostitutes, so}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 diers, drug users and ''serodiscordant'' couples. But critics say everybody in a sub-Saharan country with a sky-high infection rate is high risk.\par  ''In their approach, they ignore the basic reality that a large share of unmarried adolescents are already se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ually active and so at high risk,'' said Jodi L. Jacobson, executive director of the Center for Health and Ge}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 der Equity in Maryland. ''They also ignore the fact that marriage doesn't protect married teens and women from H.I.V., and that sexual violence and coercion are facts of life.''\par  The Longer Term In Maputo, health officials said that they were struck by the Americans' obsession with numeric goals. \par  ''To see an increase in numbers of people on antiretrovirals, that was their only concern,'' said Mr. Songane, the health minister. ''But this is a complex disease. We can not judge the success of our fight just by the numbers of people on treatment.''\par  The Mozambicans wanted to move gradually and to strengthen their health sector at the same time. They did not want to neglect other health issues, like malaria, childhood diseases and maternal health. They did not want to use nongovernmental organizations where the Americans would pay the salaries, buy the drugs and purchase the vehicles that would travel to the villages to distribute the drugs. \par  ''In one year, two years' time, who is going to follow those people?'' he asked. ''When the N.G.O. is gone, who is going to take over?''\par  Dr. Paul Farmer, an American renowned for his treatment programs in rural Haiti, said international projects intending to help poor countries should pay heed, as Mozambique does, to the need to integrate AIDS trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment with overall health care.\par  ''When you're in a clinic in rural Haiti and someone comes in with a broken arm or in obstructed labor, you can't say, 'Sorry, we only do AIDS prevention and care,''' said Dr. Farmer, a Harvard professor. ''The massive loss of life due to H.I.V. disease is only one symptom of a very sick world in which hundreds of millions are going without any modern medical care at all. Addressing AIDS properly offers a chance to set some of this right.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); AIDS POLICY (90%); INTERNATIONAL ASSISTANCE (90%); PUBLIC HEALTH ADMINISTRATION (89%); HEALTH DEPARTMENTS (89%); AIDS & HIV TREATMENT (89%); BUDGETS (77%); HEALTH CARE POLICY (76%); INTERNATIONAL ECONOMIC DEVELOPMENT (75%); INTERNATIONAL RELATIONS (75%); NONGOVERNMENTAL ORGANIZATIONS (73%); ANTIVIRALS (72%); EMBASSIES & CONSULATES (72%); BLOOD TRANSFUSIONS (67%); HOSPICE (67%); CLINICS & OUTPATIENT SERVICES (50%) Acquired Immune Deficiency Syndrome; Foreign Aid  ; Tests and Tes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing; Orphans and Orphanages; Acquired Immune Deficiency Syndrome; Finances; Budgets and Budgeting\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS (59%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (89%) George W (Pres) Bush; Deborah Sontag; Sharon Lafraniere; Michael Wines\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MOZAMBIQUE (99%); UNITED STATES (99%); ZAMBIA (94%); AFRICA (94%) Africa; Mozambique; United States\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 14, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: Aggrey Mwiindwa, 32, is counseled at a clinic in Lusaka, Zambia, about drugs he gets under an American program that has renovated four clinics. (Photo by Lori Waselchuk for The New York Times)(pg. A1)\par Dorcas Mwisha, 13, who apparently was born with H.I.V., at a clinic in Lusaka, Zambia, with her aunt, Rose Akebu. Both of Dorcas's parents died of AIDS before she was 3. (Photo by Lori Waselchuk for The New York Times)\par Randall L. Tobias, coordinator of the United States global AIDS program, got an H.I.V. test in April in Mozambique. (Photo by Themba Hadebe/Associated Press)(pg. A10)Chart: ''Focused on H.I.V.''Percent of people age 15-49 with H.I.V. or AIDS in 2003 in countries included in President Bush's Emergency Plan for AIDS Relief.Graph tracks the percentage of people age 15-49 with H.I.V. in the following cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries:BotswanaSouth AfricaNamibiaZambiaMozambiqueTanzaniaIvory CoastKenyaHaitiNigeriaRwandaEth}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 opiaUgandaGuyanaVietnam(Countries with higher percentages [in the aforementioned list] are placed at the top in descending order\par  those closer to the bottom have lower percentages of H.I.V. infected people.)(Source by Joint United N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions Program on H.I.V./AIDS)(pg. A10)      \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;Cipla Patents Generic Drug Africa News July 13, 2004 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_214}{\*\bkmkstart DOC_ID_214_0}{\*\bkmkstart doc_id_76}{\*\bkmkend DOC_ID_214}{\*\bkmkend DOC_ID_214_0}{\*\bkmkend doc_id_76}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_76"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 76 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2004 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 Cipla Patents}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Generic Drug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The East African Standard\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 382 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , a pioneer in supplying cheap generic Aids drugs in Africa, has patented its three-in-one comb}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nation tablet Triomune in South Africa, in a move that will surprise many industry watchers.\par The company is also seeking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the product in 17 other countries in Africa, the epicentre of the Aids pandemic.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  confirmed the move after the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  were uncovered by people familiar with the Aids situation atten}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the 15th International Aids Conference in Bangkok. \par "The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has been granted in South Africa ... this is our invention," Amar Lulla, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  joint managing director, told Reuters in Bombay.\par Triomune contains copies of three drugs - GlaxoSmithKline's lamivudine, Bristol-Myers Squibb's stavudine and Boehringer Ingelheim's nevirapine - which are themselves still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  argues its scientists found the way to put them together to produce the combination pill, which needs to be taken only twice a day.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have also been filed in the Democratic Republic of Congo, Namibia and the 15 members of the Afr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 can Regional Industrial Property Organisation - Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Sierra Leone, Somalia, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.\par Fixed-dose combination drugs from generic producers such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have been lauded by AIDS activists as a cheap, convenient alternative to more expensive patented brand medicines. According to charity ActionAid, they can be bought for as little as $140 per patient a year compared with $470 for patented products.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  entry into the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  arena may offer it commercial protection from rivals looking to copy its know-how in combining the three original medicines. But it could prove politically embarrassing.\par Lulla declined to comment on }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  pricing strategy, although he said the firm would consider licensing the drug to whoever wanted it in South Africa. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is registered to sell cheap antiretroviral drugs in a total of 65 countries worldwide.\par Until recently, doubts had persisted about the clinical effectiveness of copycat fixed-dose combinations. But a study published in Britain's The Lancet medical journal this month found Triomune performed as well as brand drugs in Cameroon.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (92%); GENERIC DRUGS (91%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICAL PREPARATION MFG (90%); GENERIC PRODUCTS (90%); AIDS & HIV TREATMENT (90%); INTELLECTUAL PROPERTY LAW (90%); PHARMACEUTICALS INDUSTRY (90%); PRESCRI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION DRUGS (90%); AIDS & HIV (90%); ANTIVIRALS (89%); RESEARCH REPORTS (88%); INFECTIOUS DISEASE (74%); EPIDEMICS (71%); PRICE MANAGEMENT (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (92%); BMY (NYSE) (58%); GSK (NYSE) (58%); GSK (LSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2834 PHARMACEUTICAL PREPARATIONS  (58%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325411 MEDICINAL & BOTANICAL MANUFACTURING (58%); SIC5122 DRUGS, DRUG PROPRI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TARIES, & DRUGGISTS' SUNDRIES (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AMAR LULLA (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICAN REGIONAL INTELLECTUAL PROPERTY ORGANIZATION (55%); ACTIO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AID INTERNATIONAL  (54%); ACTIONAID INTERNATIONAL (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (94%); AFRICA (94%); INDIA (92%); KENYA (79%); MALAWI (79%); GAMBIA (79%); GHANA (79%); UGANDA (79%); MOZAMBIQUE (79%); BOTSWANA (79%); SWAZILAND (79%); ZIMBABWE (79%); TANZANIA, UNITED REPUBLIC OF (79%); NAMIBIA (79%); LESOTHO (79%); SUDAN (79%); SOMALIA (79%); CAMEROON (79%); CONGO, THE DEMOCRATIC REPUBLIC OF THE (79%); SIERRA LEONE (79%); ZAMBIA (79%); THAILAND (71%); UNITED KINGDOM (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (74%); BANGKOK, THAILAND (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (54%);  ACTIONAID (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 12, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;Daily HIV/Aids Report Africa News July 13, 2004 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_215}{\*\bkmkstart DOC_ID_215_0}{\*\bkmkstart doc_id_77}{\*\bkmkend DOC_ID_215}{\*\bkmkend DOC_ID_215_0}{\*\bkmkend doc_id_77}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_77"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 77 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2004 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par Daily HIV/Aids Report}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kaisernetwork.org\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 11362 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bangkok Daily Update\par Discussion at XV International AIDS Conference Focuses on How To Provide Antiretroviral Drugs to Deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oping World\par [Jul 13, 2004]\par Delegates and speakers at the XV International AIDS Conference in Bangkok, Thailand, on Tuesday called for broader accessibility to antiretroviral treatment, as access to HIV/AIDS medications continues to elude millions around the world. Jim Kim, who heads the World Health Organization project tasked with scaling up treatment -- the <a ="http://www.who.int/3by5/about/en/">3 by 5 Initiative</a> -- expressed shame over the six million people who have died of AIDS since the conference last met two years ago. "By these measures of human life, the ones that really matter, we have failed and we have failed miserably to do enough in the precious time that has passed since Barcelona," he said.\par Protestors agreed, arguing that the availability of cheap generic drugs would remove the largest barrier to access. But first, advocates said that brand-name pharmaceutical companies must forgo their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for certain drugs in developing countries. Hank McKinnell, CEO of <a ="http://www.pfizer.com/">Pfizer</a>, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gued that forgoing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  will dry-up innovation. "People living with HIV are going to need a steady stream of new therapies as this virus mutates and currently available treatments fail patients. If 'Access for All' is all that we do in the first sense, access for those needing medicines today, then the theme of future IAS confe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ences will surely be 'Why are treatments failing patients?'" \par However, maintaining research and development should not keep needed medications from people who cannot afford them, according to Walden Bello from the University of the Philippines. "R&D for HIV drugs and other essential medicines is no longer efficient within a corporate context. Big pharma is more interested in protecting its 20% margin, provided by monopolistic pricing based on }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  than in providing drugs to people with little purchasing power."\par Neither side denies there is a need to provide these medications; they just disagree on the best way to get them to the millions of people who need them (Jill Braden, Kaiser Daily HIV/AIDS Report, 7/13).\par Video highlights of the day's events are available <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1178">online</a>.\par Bangkok Notebook\par Kaiser Family Foundation Senior Visiting Fellow Jackie Judd Discusses XV IAC Events With Science R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 porter Jon Cohen\par [Jul 13, 2004]\par Kaiser Family Foundation Senior Visiting Fellow Jackie Judd each day during the <a ="http://www.aids2004.org/">XV International AIDS Conference</a> is interviewing Science magazine corr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spondent Jon Cohen about news coming out of the conference. On Monday, Jon discussed an opening ce}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 emony that did not go as planned, and on Tuesday he talked about the bold admission by World Health O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganization HIV/AIDS Program Director Jim Kim, who said that the world has "failed miserably" to provide treatment to HIV-positive people worldwide. The interviews are available <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1181">online</a> from ka}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sernetwork.org (Kaiser Daily HIV/AIDS Report, 7/13).\par Global Challenges\par Costs for Antiretroviral Drug Treatment, HIV Prevention, AIDS Orphan Care in Developing Countries Will Be $12B by 2005, UNAIDS Report Says\par [Jul 13, 2004]\par The cost of providing antiretroviral drug treatment, care for AIDS orphans and HIV prevention in services in developing countries is expected to reach $12 billion by 2005 and could reach $20 billion by 2007, according to a report released Monday by UNAIDS, the <a ="http://sfgate.com/cgi-bin/article.cgi?f=/c/a/2004/07/13/MNG2B7KGJQ1.DTL">San Francisco Chronicle reports. The bulk of the increase reflects the cost of expanding treatment from fewer than 500,000 people to six million HIV-positive people by 2007, as well as the provision of essential services, according to the report (Russell, San Franci}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 co Chronicle, 7/13). According to the report, titled "Financing the Expanded Response to AIDS," funding for next year is still anticipated to fall short by $6 billion in 2005, even though total global spending to combat HIV/AIDS increased from $1.2 billion in 2000 to $6 billion in 2004. UNAIDS researchers used new data from 78 countries on "actual costs" for prevention, care, treatment, orphan support, policy, advocacy and admini}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 trative programs to complete the report. Bilateral support for the efforts to combat the HIV/AIDS pandemic has increased 64% among leading donor countries between 2000 and 2002. UNAIDS predicts that bilateral spending will reach $1.3 billion by the end of 2004, according to a UNAIDS <a ="http://www.unaids.org/NetTools/Misc/DocInfo.aspx?LANG=en&=http%3a%2f%2fgva-doc-owl%2fWEBcontent%2fDocuments%2fpub%2fMedia%2fPress-Releases02%2fPR_Funding-BKK_12Jul04_en%26%2346%3bpdf">release</a>.\par U.S. Spending\par According to the report, the United States is the leading bilateral donor "in terms of absolute dollars," the r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lease said (UNAIDS release, 7/12). The House Appropriations Committee on Friday approved by voice vote a $19.4 billion foreign aid spending bill for fiscal year 2005, <a ="http://www.reuters.com/newsArticle.jhtml?type=topNews&storyID=5633849">Reuters</a> reports. The foreign aid bill provides $2.2 billion for HIV/AIDS, tuberculosis and malaria initiatives. Some critics have called the amount "inadequate" compared with the funding provided for the war on terror and post-war Iraq, Reuters reports (Willard, Reuters, 7/9). Although the approved funding -- most of which will go to AIDS pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams -- meets President Bush's request for FY 2005, an appropriations subcommittee allocated a larger portion of the money to the <a ="http://www.theglobalfund.org/en/">Global Fund to Fight AIDS, Tuberculosis and Malaria than Bush had requested. Bush's proposed FY 2005 budget, which is $1.9 billion more than the total amount the subcommittee approved, includes $2.8 billion for international HIV/AIDS, TB and malaria programs. That amount includes $1.45 billion for the <a ="http://www.state.gov/">State Department</a> <a ="http://www.state.gov/s/gac/">Office of the Global AIDS Coordinator, which will administer the <a ="http://www.state.gov/s/gac/rl/or/c11652.htm">President's Emergency Plan for AIDS Relief, and $200 mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lion for the Global Fund. Because the draft spending bill would double the requested Global Fund contrib}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion to $400 million, less money would go to PEPFAR. The $2.2 billion approved by the House subcommittee combined with an anticipated $600 million in funding from the Labor-HHS-Education appropriations bill would bring overall global AIDS, TB and malaria spending to $2.8 billion for FY 2005 (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24395">Kaiser Daily HIV/AIDS Report, 6/24).\par Funding Gap Getting Worse?\par UNAIDS Director of Evaluation Dr. Paul De Lay said, "Unless more resources are directed toward the global response, the gap between the need and available resources will grow significantly in coming years" (U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS release, 7/12). The situation could be worsened by a lack of inexpensive second-line treatments for HIV-positive people who develop resistance to first-line drugs, according to the Chronicle. Because about 10% to 20% of people living with HIV/AIDS who take antiretroviral drugs develop resistance, some adv}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cates predict the costs for providing second-line treatments to cause a "sort of balloon payment down the road," the Chronicle reports.\par Global Fund\par Advocates are "step[ping] up their campaign" for wealthy countries to increase their donations to the Global Fund. Richard Feachem, executive director of the fund, said that it would not be possible to reach the fund's 2005 $3.5 billion goal if wealthy countries do not increase contributions, according to the Chronicle (San Francisco Chronicle, 7/13). U.N. Special Envoy for HIV/AIDS in Africa Stephen Lewis said that funding co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cerns have put efforts to combat HIV/AIDS "on the knife's edge of the chasm," adding, "Either we continue the flow of funds and continue to increase treatment and make people feel there's hope, or we suffer a dreadful setback in responding to the pandemic." Ambassador Randall Tobias, head of the State Department Office of the Global AIDS Coordinator, said that the United States is "certainly going to continue to contribute to the Global Fund," but he added, "We need to put more emphasis on getting [the money already contribu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed to the fund] put to work." <a ="http://www.globalaidsalliance.org/">Global AIDS Alliance</a> President Paul Zeitz said that the funding situation amounts to a "battle between a U.S. go-it-alone approach and mult}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lateralism" (Nakashima, Washington Post, 7/13).\par Abstinence Best Way To Prevent HIV/AIDS, Ugandan President Museveni Says\par  [Jul 13, 2004]\par Abstinence is the best way to curb the spread of HIV/AIDS, Ugandan President Yoweri Museveni said during a plenary session on the first full day of the XV International AIDS Conference in Bangkok, Thailand, <a ="http://www.reuters.co.uk/newsPackageArticle.jhtml?type=topNews&storyID=545616A\u223\'a7ion=news">Reuters</a> reports (Schuettler, Reuters, 7/12). Museveni has said that the country's HIV prevention slogan, "ABC" -- Abstinence, Be faithful, use Condoms -- could be used elsewhere in Africa to stem the spread of HIV. M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 seveni said that the "C" is meant to be a "fallback position," a "means of last resort" if a person "cannot ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 age A and B." Museveni also has said that the country has the funding, supplies and infrastructure in place to begin treating the 60,000 HIV-positive people in the country who need antiretroviral drugs (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24461">Kaiser Daily HIV/AIDS Report, 6/29). Museveni said, "I look at condoms as an improvisation, not a solution," adding that he favors "optimal relationships based on love and trust instead of institutional mistrust which is what the condom is all about" (Reuters, 7/12). Museveni said that in some societies, sexual intercourse "is so elaborate that co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 doms are a hindrance" (<a ="http://www.ajc.com/news/content/news/0704/12aids.html">AP/Atlanta Journal-Constitution, 7/12). "Let the condom be used by people who cannot abstain, cannot be faithful, or are e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tranged," he added (BBC News, 7/12). Museveni's comments contradict the opinion of some health experts who support condom use as a first-line defense against HIV infection, according to Reuters (Reuters, 7/12).\par Reaction\par International AIDS Society President and conference Co-Chair Joep Lange said, "Condoms are effective, but you have to look at different cultures in each country." Dr. Tim Brown, director of the UNAIDS Collaborating Center at the <a ="http://www.eastwestcenter.org/">East-West Center</a> in Hawaii, said that condoms, in addition to abstinence, are an "essential component" of HIV/AIDS prevention campaigns, Reuters reports. Brown said, "We need to move our prevention programs back to prevention science, and the one thing that is very clear for young people is that the best programs are those that provide full information," including info}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mation on abstinence, sexually transmitted diseases and condoms (Reuters, 7/12). <a ="http://www.ippf.org/">International Planned Parenthood Federation</a> Director-General Steven Sinding said, "The religious-focused or oriented groups denigrate condoms, and believe that serious efforts to control [HIV] can be successful without recourse to condoms, and we don't believe that" (BBC News, 7/12). Rep. Barbara Lee (D) -- the only member of Congress to attend the conference -- said that the Bush administr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion uses "ideology, not science, to dictate policy," according to Reuters (Reuters, 7/12). "In an age where five million people are newly infected each year and women and girls too often do not have the choice to a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stain, an abstinence until marriage program is not only irresponsible, it's really inhumane," Lee said (Joshi, <a ="http://www.washingtontimes.com/world/20040712-094622-5261r.htm">AP/Washington Times, 7/13). She added, "Abstaining from sex is oftentimes not a choice, and therefore their only hope in preventing HIV infection is the use of condoms" (Reuters, 7/12).\par BBC's "<a ="http://www.bbc.co.uk/worldservice/programmes/worldupdate/">World Update" on Monday r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ported on abstinence as a method of preventing HIV/AIDS. The segment includes comments from Sinding (Hogg, "World Update," BBC, 7/12). The complete segment is available <a ="http://www.bbc.co.uk/worldservice/ondemand/rams/wup28014__2004.ram">online</a> in RealPlayer.\par Fight Against HIV/AIDS Hindered by Duplicated Efforts, XV International AIDS Conference Participants Say\par [Jul 13, 2004]\par The duplication of efforts by donors in the fight against AIDS is leading to waste and inefficiency and slowing the fight against the disease, a panel of experts at the XV International AIDS Conference said on Monday, the <a ="http://www.nytimes.com/2004/07/13/international/asia/13aids.html">New York Times reports. In a session titled "Funding the Response to HIV/AIDS: Why Are Donors Not Working Together?" moderator Hank McKinnell, CEO of Pfizer, said that the donor community is "pledging, moving and disbursing funds and materials at unprecedented rates." However, an overall "lack of agreement on approaches and key issues among the donors themselves has ... led to delays or problems in program implementation and coordin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion," Dr. Biziwick Mwale, executive director of the National AIDS Commission in Malawi, said. The partic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pants agreed that standardized measures to monitor the costs and effectiveness of prevention efforts as well as the adoption of U.N. recommendations on using resources efficiently are needed to improve coordination among donors and developing countries. However, participants offered no formal proposals, saying that it would "take more time to resolve the complexities involved in the relationships between donors and recipient countries," according to the Times (Altman, New York Times, 7/13).\par A kaisernetwork.org webcast of the session is available <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1193">online</a>.\par Chinese Premier Wen Jiabao Appeals to Government, Public for Help in Fighting HIV/AIDS\par [Jul 13, 2004]\par Chinese Premier Wen Jiabao on Saturday ahead of the <a ="http://www.aids2004.org/">XV International AIDS Conference</a> in Bangkok, Thailand, released a public appeal for "all levels of government and the entire society [to] attach great importance to preventing and controlling AIDS," London's <a ="http://www.guardian.co.uk/aids/story/0,7369,1259101,00.html">Guardian</a> reports (Boseley, Guardian, 7/12). The Chinese government estimates that there are 840,000 HIV-positive people in the country and that 80,000 people have AIDS; however, some experts believe that those figures are an underestimate. The United Nations estimates that there are at least one million HIV-positive people in China (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24484">Kaiser Daily HIV/AIDS Report, 6/30). Wen said that the rural areas where most of the population lives presented the greatest cha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lenge because of "backward hygiene and medical conditions" and because people in rural areas "are not well educated about legal and health issues" (Agence France-Presse, 7/9). Wen's statement, which was pu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lished on the front page of Chinese newspapers, called on Chinese scientists to "work hard to develop new drugs and optimize therapies" and said that prevention would be a "long-term, arduous task." In addition, Wen said that the country would invest more in the fight against the disease (Guardian, 7/12). Wen also called for expanded HIV testing -- 90% of HIV-positive people in the country are unaware of their status, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to government figures (Agence France-Presse, 7/9). UNAIDS Executive Director Peter Piot on Mo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day at a session on nongovernmental AIDS organizations in China said that Wen's statement showed that "China means business when it comes to AIDS." However, he said that the country must address AIDS-related stigma and other social issues, such as injection drug use, commercial sex workers and their clients and men who have sex with men (Associated Press, 7/12).\par Medical Students\par China plans to send 1,300 medical students to rural areas to help with HIV/AIDS prevention programs during their summer break, <a ="http://story.news.yahoo.com/news?tmpl=story&cid=571&ncid=751&e=5&u=/nm/20040710/hl_nm/aids_china_dc">Reuters</a> reports (Reuters, 7/12). The program is part of the country's AIDS education campaign that 12 government departments, ministries and organizations launched on Saturday. In addition, the go}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ernment will distribute millions of posters on AIDS prevention to rural villages, urban communities, univers}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ties and schools throughout the country. The education campaign also will include "face-to-face" AIDS ed}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cation for women ages 15 to 49 in 51 counties. Khalid Malik, U.N. resident coordinator in China, said that the program is one of the biggest HIV prevention initiatives in the world (Xinhua News Agency, 7/10).\par ABCNews' "<a ="http://abcnews.go.com/Sections/Nightline/">Nightline</a>" on Monday focused on HIV/AIDS in Russia and China, two countries where HIV prevalence rates are "exploding." The segment on China examines the unsafe blood collection practices that facilitated HIV transmission in the country and the stigma HIV/AIDS patients experience. The segment includes comments from UNAIDS Executive Director Peter Piot (Wright, "Nightline," ABCNews, 7/12). The segment on Russia examines the lack of needle-exchange programs in cities with high rates of injection drug use and profiles an orphanage serving HIV-positive children. According to "Nightline," Russian President Vladimir Putin has spoken exactly one se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tence about HIV/AIDS (Litke, "Nightline," ABCNews, 7/12). A video excerpt of the segment on China is avai}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 able online in RealPlayer.\par Most Global Fund Grant Programs Performing as Expected, Some Underperforming, Fund Report Says\par [Jul 13, 2004]\par Twelve of the first 25 programs that received funding from the <a ="http://www.theglobalfund.org/en/">Global Fund to Fight AIDS, Tuberculosis and Malaria more than one year ago are either on schedule or ahead of schedule for meeting their goals, according to a report released on Monday at the XV International AIDS Conference, <a ="http://www.guardian.co.uk/international/story/0,3604,1258976,00.html">London's Guardian reports (Boseley, Guardian, 7/12). The report analyzed the first 25 grants for HIV, TB and malaria programs in operation for one year between May 1, 2003, and April 30, 2004 (Global Fund <a ="http://www.theglobalfund.org/en/media_center/press/pr_040711b.asp">release</a>, 7/11). The report, t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tled "A Force for Change: The Global Fund at 30 Months," also says that eight programs that received grants from the Global Fund are below target and five programs are underperforming. Of the five programs consi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ered to be underperforming, two are in Sri Lanka, two are in Senegal and one is in Tanzania, according to the report (Guardian, 7/12). Other countries -- such as Honduras, which placed nearly twice as many people on antiretroviral treatment as planned -- are "substantial overachievers," according to the release. The 25 programs have provided interventions such as testing, treatment and care to 2.3 million people and trained 340,000 people to administer antiretroviral drugs, according to the report. Sixty percent of Global Fund grants go to AIDS programs, through which about 12,000 people have received antiretroviral drugs, the r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 port says, according to the Guardian. Global Fund Executive Director Richard Feachem said that in five years, more than 1.6 million people are expected to be receiving antiretroviral treatment through programs receiving fund money (Guardian, 7/12). He added, "We hope this report is an indication that the innovative ways in which the Global Fund works are beginning to make the impact envisioned at its creation 30 months ago. The systems work and the Global Fund is ready to dramatically expand funding to countries fighting the three pandemics" (Global Fund release, 7/12).\par More Funding Needed\par Any delay in funding from major donors to the Global Fund will affect the group's efforts to fight the three di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eases, especially HIV/AIDS, Feachem said, Thailand's Nation reports. The Global Fund needs $1.65 billion to fund projects through this year and an additional $3.56 billion in funds next year, according to Feachem (Arthit, Nation, 7/12). The Global Fund has approved grants to nearly 300 programs in 130 countries thus far; 25 of them have been running for more than one year, according to the Guardian (Guardian, 7/12). The group is planning to launch the fifth round of grants in November and the sixth round in the middle of 2005, but it will not be able to proceed without the necessary funds, according to the Nation. Donations to the Global Fund are expected to peak at $3 billion per year by 2008, with more than half of the total dedicated to AIDS programs (Nation, 7/12).\par Kaisernetwork.org on Tuesday webcasted a Global Fund <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1222">session</a> and a <a ="http://www.kaisernetwork.org/health_cast/hcast_index.cfm?display=detail&hc=1193">session</a> on cooperation among donors in the fight against AIDS. The webcasts and other coverage are available <a ="http://www.kaisernetwork.org/aids2004/kffsyndication.asp?show=portal.html">online</a>.\par More Than 35 M Working-Age Adults Living with HIV/AIDS, International Labor Organization Report Says\par [Jul 13, 2004]\par About 36.5 million adults of working age are HIV-positive and about 28 million working-age adults have died from AIDS-related causes since the beginning of the epidemic, according to a report released on Sunday by the International Labor Organization at the <a ="http://www.aids2004.org/">XV International AIDS Confe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence</a> in Bangkok, Thailand, <a ="http://www.voanews.com/article.cfm?objectID=A5A874E1-ED77-47DA-8B61D9FAC9FF1190&title=ILO%20Says%20HIV%2DAIDS%20Takes%20Heavy%20Toll%20%20at%20%20Workplace&catOID=45C9C786-88AD-11D4-A57200A0CC5EE46C&categoryname=Health%20%26%20Medicine">VOA News reports. ILO surveyed workers between the ages of 15 and 64 in 50 countries and found that HIV/AIDS is "one of the biggest cau}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es of mortality in the working world," according to VOA News. The report, titled "<a ="http://www.ilo.org/public/english/protection/trav/aids/publ/global_est/index.htm">HIV/AIDS and Work: Global Estimates, Impact and Response," shows that if access to antiretroviral drug treatment is not i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 creased, the number of workers who die from AIDS-related causes will increase to 48 million by 2010 and 74 million by 2015, according to the report. In addition, about two million people by 2005 and four million by 2015 will be too ill to work and will have "dropped out of the labor force," Odile Frank, the report's author, said. The loss of workers at their most productive stage in life costs the world approximately $25 billion a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nually, according to the report (Schlein, VOA News, 7/1). In addition, young women -- who are usually r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sponsible for caring for family members with HIV and other family members in addition to often being r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sponsible for subsistence farming -- account for the largest increases in HIV-prevalence rates worldwide, the report says, according to <a ="http://news.xinhuanet.com/english/2004-07/12/content_1591227.htm">Xinhuanet</a>. The combination of these factors "jeopardizes their capacity" to provide food for the household and care for family members, Xinhuanet reports (Xinhuanet, 7/11). ILO D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rector-General Juan Somavia said, "HIV/AIDS is not only a human crisis, it is a threat to sustainable global, social and economic development," adding that the loss of life from AIDS-related causes and the "debilitating effects of the illness will lead not only to a reduced capacity to sustain production and employment, reduce poverty and promote development, but will be a burden borne by all societies -- rich and poor alike" (Xinhua News Agency, 7/11).\par 'Brain Drain' of African Health Workers Slowing Fight Against AIDS, Physicians for Human Rights Report Says\par [Jul 13, 2004]\par A "brain drain" of health care workers from Africa is "further crippling ... already fragile" health care infrastru}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tures throughout the continent, as it "struggl[es]" to provide HIV/AIDS drugs and treatment to hundreds of thousands of people, according to a <a ="http://www.phrusa.org/">Physicians for Human Rights</a> report to be released Thursday, the <a ="http://www.nytimes.com/2004/07/13/international/africa/13afri.html?pagewanted=all">New York Times r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports. The report, titled "An Action Plan to Prevent Brain Drain," proposes specific measures to slow the m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gration of African health care workers to wealthier nations and increase staff in African health care facilities. Recommendations include calling upon developed nations to:\par Reimburse African countries for the loss of African-educated health professionals;\par Combat their own health care worker shortages by training more people domestically rather than recruiting workers from developing countries; and\par Work with international organizations to directly support higher salaries or other forms of reimbursement for underpaid African health professionals.\par The report advocates limiting recruitment of African health professionals by developed countries and private organizations, saying, "The balance will be best achieved when policies that make it more difficult for health professionals to emigrate, such as restrictions on recruitment, are implemented in the context of improving working conditions, fairer salaries and other advances in health professionals' ability to enjoy their rights." However, the report recognizes the difficulty in accomodating both the rights of African health care workers to seek better living conditions and the rights of African patients to receive adequate health care, according to the Times. "Everyone says it's not sustainable to pay salaries. But we're facing the worst health crisis in human history. Let's do things outside the box," Holly Burkhalter, PHR's U.S. policy director, said (Dugger, New York Times, 7/13).\par France Criticizes United States for 'Pressuring' Developing Countries To Give Up Producing Generic Drugs, Including Antiretrovirals\par [Jul 13, 2004]\par French President Jacques Chirac in a written statement to the <a ="http://www.aids2004.org/">XV Intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional AIDS Conference</a> said on Tuesday that the United States is "pressuring" developing countries to give up the right to make generic drugs -- including antiretroviral drugs -- in exchange for free trade agre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments, the <a ="http://www.kansascity.com/mld/kansascity/news/world/9142736.htm">AP/Kansas City Star reports. Chirac said that U.S. methods concerning generic drugs in free trade negotiations have been "ta}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tamount to blackmail." Mireille Guigaz, France's global ambassador on AIDS, said, "The United States wants to put pressure on developing countries who try to stand up for their own industries." A U.S. official, speaking on condition of anonymity, called Chirac's allegations "nonsense," and said that trade agreements entered into by the United States would be consistent with <a ="http://www.wto.org/">World Trade Organization</a> rules that allow developing countries to produce generic drugs (Joshi, AP/Kansas City Star, 7/13).\par Australia Pledges To More Than Double Funding To Fight AIDS in Asia-Pacific Region\par [Jul 13, 2004]\par Australian Foreign Minister Alexander Downer announced on Sunday at the Second Asia-Pacific Ministerial Meeting on HIV/AIDS in Bangkok that Australia would more than double to $437 million its funding to fight HIV/AIDS in the Asia-Pacific region, the <a ="http://smh.com.au/articles/2004/07/11/1089484229581.html?oneclick=true">Sydney Morning Herald r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports (Pollard, Sydney Morning Herald, 7/12). Downer did not specify whether the funding would go toward the <a ="http://www.theglobalfund.org/en/">Global Fund to Fight AIDS, Tuberculosis and Malaria or ind}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pendent programs, saying only that the money "will mostly be spent" in the Asia-Pacific region, the Associa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed Press reports (Associated Press, 7/11). Australia also will provide $2.2 million to the <a ="http://www.ausaid.gov.au/hottopics/hivaids/aplsf.cfm">Asia-Pacific Leadership Forum on HIV/AIDS, Dow}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er said (Sydney Morning Herald, 7/12). Downer also announced the appointment of Annmaree O'Keeffe, a senior official with Australia's Agency for International Development, as the country's first special represent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive on HIV/AIDS, the Sydney Daily Telegraph reports (Sydney Daily Telegraph, 7/12). "[HIV/AIDS] is not just a health issue; it is a human security issue, it is an issue that can tear apart the fabric of societies and cause deep economic damage," Downer said (Sydney Morning Herald, 7/12). He added that Australia's main co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cern was for Papua New Guinea and Cambodia. Downer said, "We do have strong HIV/AIDS programs that we are running in Papua New Guinea. But I think the growth in the problem there is serious" (Associated Press, 7/12).\par Several U.S. and international broadcast programs reported on strategies for fighting HIV/AIDS in Thailand and the South Pacific:\par Australian Broadcasting Corporation's "<a ="http://www.abc.net.au/ra/asiapac/default.htm">Asia Pacific</a>": The segment includes comments from World Health Organizations's Dr. Jack Chow; <a ="http://www.unaids.org/en/default.asp">UNAIDS</a> Executive Director Peter Piot; and Relaki Ngawu, an HIV-positive AIDS advocate from Nigeria (Lloyd, "Asia Pacific," ABC, 7/13). The complete segment is avail}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble <a ="http://www.abc.net.au/ra/asiapac/programs/m914586.asx">online</a> in Windows Media.\par NPR's "Talk of the Nation": The segment will examine how to maintain political will in fighting HIV/AIDS (Neary, "Talk of the Nation," NPR, 7/13). The complete segment will be available <a ="http://www.npr.org/programs/totn/">online</a> in RealPlayer and Windows Media after the broadcast. E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panded NPR coverage is available <a ="http://www.npr.org/healthscience/aids2004/">online</a>.\par Xtra Broadband News: The segment includes comments from Dr. Kathleen Cravero, deputy executive dire}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor of UNAIDS; Helen Leslie, a New Zealand government official; and Rachael Le Mesurier of the <a ="http://www.nzaf.org.nz/">New Zealand AIDS Foundation</a> (Glennie, Xtra Broadband News, 7/13). The complete segment is available online in Windows Media.\par Vietnam Population Policy Should Highlight Reproductive Health, HIV/AIDS Initiatives, Official Says\par [Jul 13, 2004]\par Le Thi Thu, minister of Vietnam's <a ="http://www.danang.gov.vn/home/view.asp?id=79&id_theloai=392&id_tin=3288">Committee for Population, Family and Children, on Friday at a meeting marking World Population Day called for the nation to work t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gether to implement a population policy, including HIV/AIDS initiatives and reproductive health care for ad}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lescents and pregnant women, BBC News reports. The government should focus on developing reproductive health and HIV/AIDS policies, in addition to raising awareness about contraception and providing medical services in inaccessible areas. Le said that population growth in Vietnam could impede the plan's impleme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tation, according to BBC News. The number of women who reach reproductive age each year is three times higher than the number of women who are outside of that age range (BBC News, 7/11).\par USA Today Profile\par <a ="http://www.usatoday.com/news/health/2004-07-11-vietnam-aids_x.htm">USA Today on Monday pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 filed HIV/AIDS initiatives in Vietnam, which is the only country outside of Africa and the Caribbean eligible for funds under the five-year, $15 billion <a ="http://www.state.gov/s/gac/rl/or/c11652.htm">President's Eme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gency Plan for AIDS Relief (Sternberg, USA Today, 7/12). Although there are currently about 200,000 HIV-positive people in Vietnam, some analysts predict that number could increase eightfold to one million people by 2010. Senior Bush administration officials said that the administration "considers that Vietnam is a place where the American people's money can really make a tremendous impact because it is on the brink of a very explosive epidemic" (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24636">Kaiser Daily HIV/AIDS Report, 7/9). According to Ambassador Randall Tobias, head of the State Department's <a ="http://www.state.gov/s/gac/">Office of the Global AIDS Coordinator, the HIV/AIDS epidemic in Vietnam is concentrated among high-risk groups such as injection drug users and commercial sex workers. Currently, fewer than 300 of the approximately 130,000 HIV/AIDS patients in Vietnam receive treatment, and there is only one doctor for every 11,250 HIV/AIDS patients in the country. With the additional $10 million in funding from PEPFAR, Vietnam plans to provide HIV/AIDS treatment to more patients nationwide; establish preve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, treatment and care programs in walled rehabilitation camps where tens of thousands of commercial sex workers and drug addicts -- half of whom are HIV-positive -- are "warehoused"; and enlist several faith-based organizations to become active in HIV/AIDS initiatives, according to USA Today. Tobias said that the United States will not finance needle-exchange programs in Vietnam. Tim Brown, senior fellow at the <a ="http://www.eastwestcenter.org/">East-West Center</a>, in Bangkok on Sunday criticized the administr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion's restriction on needle exchange programs as well as its reluctance to promote condom use (USA T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day, 7/12).\par XV International AIDS Conference\par Protestors Demanding Increased Antiretroviral Drug Access 'Disrupt' Events During XV International AIDS Conference\par [Jul 13, 2004]\par Protestors demanding increased antiretroviral drug access on Tuesday "disrupted" several events during the XV International AIDS Conference in Bangkok, Thailand, Agence France-Presse reports. Approximately 30 AIDS advocates "stormed" the main debating arena at the conference while Pfizer CEO Hank McKinnell was preparing to speak, according to Agence France-Presse. The demonstrators carried banners saying, "Patient rights, not }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights" and chanted "Free the people, break the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 " Some AIDS advocates have cri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 icized developed countries for not giving sufficient funding to fighting HIV/AIDS and have blamed some pharmaceutical companies for the high price of antiretrovirals, according to Agence France-Presse. Me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bers of the French AIDS advocacy group <a ="http://www.actupparis.org/">ACT UP-Paris</a> on Tuesday "jeered" French Minister for Development and Cooperation Xavier Darcos as he was preparing to deliver a speech on behalf of French President Jacques Chirac, according to Agence France-Presse. The protestors chanted, "10,000 deaths [from AIDS-related causes] per day, Darcos wants more." In his speech on behalf of Chirac, Darcos said that France would like to see $3 billion annually from Europe, the United States and ot}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er donors to the <a ="http://www.theglobalfund.org/en/">Global Fund To Fight AIDS, Tuberculosis and Mala}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ia, according to Agence France-Presse (Agence France-Presse, 7/13). Some AIDS advocates also said that the conference's Global Village community, an area set aside for community gatherings and activities, was an "insincer[e ]" effort by conference organizers to recognize HIV-positive people because it was "completely ignored" by the world leaders and celebrities attending the conference, according to Thailand's Nation. Pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 son Suwannawong, chair of the Thai Treatment Action Group, said, "How could the organizers say we come here to learn from one another when those big names didn't even bother to show up where we are," adding, "Didn't they say they want to learn from people really living with the disease?" Princess Zulu, an AIDS adv}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cate from Zambia, said, "You just invited us to be tokens to make your conference look good," adding, "If you want to fight AIDS, you have to listen to us because the virus is in our veins" (Nantiya, Nation, 7/13).\par Five Pharmaceutical Companies Close Booths During Protest\par Five pharmaceutical companies -- <a ="http://www.gsk.com/index.htm">GlaxoSmithKline</a>, <a ="http://www.bms.com/landing/data/index.html">Bristol-Myers Squibb</a>, Merck, <a ="http://www.abbott.com/">Abbott Laboratories</a> and <a ="http://www.roche.com/">Roche</a> -- closed their booths on the conference's exhibition floor when a group of protestors arrived to ask the companies to sign a "Treatment Access Pledge" that would commit the companies to "stand down" from }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  enforc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment in developing countries, according to an AIDS Healthcare Foundation release. Two pharmaceutical companies -- <a ="http://www.gilead.com/wt/home">Gilead</a> and <a ="http://www.boehringer-ingelheim.com/corporate/home/home.asp">Boehringer Ingelheim -- kept their booths open and addressed the protestors, according to the release. The protestors who presented the pledge included AIDS advocates from South Africa, the United States, Thailand and Uganda. Michael Weinstein, AHF president, said, "We want to acknowledge and thank both Boehringer Ingelheim and Gilead for being willing to hear our concerns and engage in discussion," adding, "Some are in agreement with our position on }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  enforcement in the developing world, particularly a company like Gilead, which doesn't even register drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in many r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 source-poor countries" (AHF release, 7/13).\par The <a ="http://www.abc.net.au/news/newsitems/200407/s1153170.htm">Australian Broadcasting Corpor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion on Tuesday reported on the protests about drug prices and the lack of HIV/AIDS funding. The audio r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 port includes an interview with McKinnell (Lloyd, ABC, 7/13). The complete segment is available <a ="http://www.abc.net.au/reslib/200407/r25247_62453.ram">online</a> in RealPlayer and <a ="http://www.abc.net.au/reslib/200407/r25247_62454.asx">online</a> in Windows Media.\par Drug Access\par Brazil, Seven Other Countries To Form Alliance To Share Antiretroviral Drug Manufacturing, Technology I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 formation\par [Jul 13, 2004]\par Brazil and seven other countries plan to establish an alliance aimed at improving the manufacture of drugs -- including antiretroviral drugs -- by sharing information on technologies, the Associated Press reports. Brazil, Russia, China, India, South Africa, Ukraine, Thailand and Nigeria are set to formally announce the partne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ship during the <a ="http://www.aids2004.org/">XV International AIDS Conference</a> in Bangkok, Thailand, through July 16, according to the Brazilian <a ="http://portal.saude.gov.br/saude/">Ministry of Health</a>. In a statement, the health ministry said that the alliance will focus on two issues: "investments for the produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of new drugs, and the improvement of the capacity of local production of generics." In addition, the all}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ance will help bolster negotiations for low-cost antiretrovirals and "speed up the dissemination of new tec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nologies," according to the Associated Press (Radowitz, Associated Press, 7/10). Brazil's <a ="http://www.aids.gov.br/indexpingl.htm">National STD/AIDS Programme, which is considered to be one of the most progressive in the world, manufactures and distributes generic versions of antiretrovirals to HIV-positive people. Although the health ministry has recorded 310,310 AIDS cases, experts estimate that there are 600,000 HIV-positive people in the country (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=23957">Kaiser Daily HIV/AIDS Report, 5/28). The country also managed to negotiate discounts with pharmaceutical companies "simply by threatening to break the rules if treatments became too costly" when it entered the World Trade Organization -- which mandates compliance with trademark rules, according to the <a ="http://www.billingsgazette.com/index.php?id=1&display=rednews/2004/07/06/build/health/35-aids-drug.inc">AP/Milwaukee Journal Sentinel. Brazil's drug program has cut the number of AIDS-related deaths in half in four years and has kept approximately 100,000 HIV/AIDS patients alive, the AP/Journal Sentinel reports. The country spends $175 million a year -- or 1.5% of its health budget -- on antiretrovirals alone (A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor, AP/Milwaukee Journal Sentinel, 7/12). Jarbas Barbosa, secretary of sanitary vigilance for the Ministry of Health, said, "If India or China have a product that isn't protected by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  we will use the agreement to transfer technology and vice versa." Brazilian officials also plan to meet with British health officials at the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ference to discuss the HIV/AIDS epidemic in Bolivia, according to the Ministry of Health statement, the Ass}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ciated Press reports (Associated Press, 7/10).\par Lack of Doctors, Health Workers in Developing Countries Hinders Fight Against AIDS, TREAT Asia Report Says\par [Jul 13, 2004]\par Shortages of doctors, nurses and health care workers in developing countries are hindering efforts to distri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ute antiretroviral drugs to people living with HIV/AIDS in the most-affected areas, according to a <a ="http://www.amfar.org/cgi-bin/iowa/asia/about/index.html?record=15">report</a> released by the American Foundation for AIDS Research and the <a ="http://www.amfar.org/cgi-bin/iowa/asia/index.html">Therapeutics Research, Education and AIDS Training in Asia at this week's <a ="http://www.aids2004.org/">XV International AIDS Conference</a>, in Bangkok, Thailand, the Asian Wall Street Journal reports (Chase/Efrati, Asian Wall Street Journal, 7/13). The report includes a table that co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pares the number of trained doctors to HIV-positive people in 13 Asian countries. Researchers found that Japan had the best ratio with one doctor for every 24 HIV-positive people, followed by Taiwan, Hong Kong, Singapore and the Philippines. Vietnam had the worst ratio with one doctor for every 11,250 HIV-positive people, followed by Thailand with one doctor for every 6,700 HIV-positive people, Indonesia with one doctor for every 4,630 HIV-positive people and China with one doctor for every 4,200 HIV-positive people, the r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 port says. There are fewer than 200 doctors in China who are trained to administer antiretroviral treatment, the report says (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24617">Kaiser Daily HIV/AIDS Report, 7/8).\par Deep Roots\par This shortage of health care workers in developing countries has "deep roots," including illiteracy, lack of e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucation, poverty and famine, according to the Wall Street Journal (Chase/Efrati, Wall Street Journal, 7/13). "The race is to scale up the infrastructure," Kevin Frost, TREAT Asia director, said, adding, "Hand in hand with the availability of treatment is the need to provide it safely." Dr. Patrick Li, principal investigator for TREAT Asia in Hong Kong, said that it is important for HIV-positive people to receive counseling and instru}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions on when and how to take antiretroviral treatments because "[i]f the complicated regimen is not adhered to, the patients may become resistant to the drugs and it will be even harder to treat them later." (Mitchell, <a ="http://www.reuters.co.uk/newsArticle.jhtml?type=healthNews&storyID=5647425A\u223\'a7ion=news">Reuters</a>, 7/12). Without counseling and instruction, "desperate" patients are self-treating, taking incorrect doses, sharing medications with HIV-positive family members or "just dropping out of treatment," the Journal reports (Wall Street Journal, 7/13). Physicians, nurses and "a range" of other health care professionals and comm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nity volunteers should be recruited and trained in affected countries, Helene Gayle, director of <a ="http://www.gatesfoundation.org/GlobalHealth/HIVAIDSTB/">HIV/AIDS and TB and <a ="http://www.gatesfoundation.org/GlobalHealth/ReproductiveChildHealth/">Reproductive and Child Health at the Bill & Melinda Gates Foundation, said, the Asian Wall Street Journal reports. UNAIDS Executive Director Peter Piot said that some young U.S. and European doctors are also "filling some gaps," according to the Asian Wall Street Journal (Asian Wall Street Journal, 7/13).\par Politics and Policy\par Kerry Calls for Doubling of U.S. Funding for Global HIV/AIDS Efforts, Ending Ban on Immigrants With HIV\par [Jul 13, 2004]\par Presumptive Democratic presidential nominee Sen. <a ="http://www.johnkerry.com/front/splash.html">John Kerry</a> (Mass.) on Saturday said that if elected he would double U.S. funding for global HIV/AIDS pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams and would seek to lift a U.S. ban on HIV-positive immigrants, Agence France-Presse reports. In a statement released to coincide with the opening of the XV International AIDS Conference, which is being held in Bangkok, Thailand, Kerry said, "I will turn up the diplomatic pressure to seek similar increases from our partners. I will provide rapid distribution of quality medicines, including generic affordable, safe and effe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive drugs" (Agence France-Presse, 7/10). "We cannot fight AIDS without adequate weapons to prevent new infections and without providing treatment for the millions already living with HIV and AIDS. "The Bush a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ministration has hampered U.S. efforts with policies created to appease its political constituencies, putting ideology before science," Kerry said in the statement(Kerry campaign <a ="http://www.johnkerry.com/pressroom/releases/pr_2004_0710.html">release</a>, 7/10). President Bush last year annouced his five-year, $15 billion <a ="http://www.state.gov/s/gac/rl/or/c11652.htm">President's Emergency Plan for AIDS Relief, which some AIDS advocates have criticized for its slow response and e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 phasis on abstinence-only education (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24409">Kaiser Daily HIV/AIDS Report, 6/25). Kerry said he also would "work with Congress to lift the immigration ban on HIV-positive pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple that has prohibited the United States from hosting" the International AIDS conference. The United States tests all new immigrants for HIV, and if an immigrant tests positive for the disease, he or she generally is d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nied admission, according to Agence France-Presse (Agence France-Presse, 7/10). "As president, I will work side by side with our international partners, faith-based, nongovernmental, affected communities and private sector groups in order to strengthen the capacity for sustained response by those on the front lines," Kerry said, adding, "A 'go it alone' approach to the war on AIDS is not how we will succeed; only in partnership can we have a chance of defeating this deadly disease" (Kerry campaign release, 7/10).\par Science & Medicine\par USA Today Examines Efforts To Develop AIDS Vaccine\par [Jul 13, 2004]\par USA Today on Tuesday examined efforts to develop an HIV/AIDS vaccine, which researchers at the XV I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ternational AIDS Conference in Bangkok, Thailand, on Monday said is "all but starting over" after two de}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ades of work (Sternberg, USA Today, 7/13). According to a report by the International AIDS Vaccine Initiative released Monday, the effort needs almost a doubling of funds, and researchers might have to start over if the current approach fails. More than 30 vaccines are in clinical trials, compared with a handful two years ago, according to the IAVI report. However, of the 30 vaccine candidates being researched in 19 countries, only one has reached the final testing phase, according to the IAVI report. IAVI has called for $1.3 billion in fun}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing for vaccine development. IAVI President and CEO Seth Berkley said that annual spending on vaccine research is about $650 million -- less than 1% of the total spending on all HIV/AIDS product development (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=24674">Kaiser Daily HIV/AIDS Report, 7/12). According to USA Today, AIDSVAX, the only AIDS vaccine to complete two large-scale clin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal trails, "proved a flop." In addition, most of the 30 vaccine candidates are "relatively untested" and "so si}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ilar that if one fails, they all might fail," USA Today reports. Further, conducting human clinical trials of va}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cine candidates could prove "challenging" because the countries with the largest numbers of HIV-positive people lack the resources to study thousands of patients, according to USA Today reports (USA Today, 7/13).\par New York Times Examines 'Growing Interference From Conservatives' in Sexual Health Research\par [Jul 13, 2004]\par The New York Times on Sunday examined what some sexual health experts believe is a "growing interfe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence from conservatives in and out of government with their work in research, education and disease pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vention." According to the Times, such interference has consisted of reduced financing for sexual health pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams and an "overall chilling effect" on research in the field. "Programs almost have to hide what they do," Richard Parker, a professor at the Mailman School of Public Health at <a ="http://www.mailman.hs.columbia.edu/index.html">Columbia University</a> and co-chair of the International Working Group on Sexuality and Social Policy, said. IWGSSP in June released a report that cited what it called "sex policing" by the Bush administration as well as inquiries by members of Congress regarding NIH research grants, the Times reports (Navarro, New York Times, 7/11). Earlier this year, conservative House members questioned at least 10 NIH research grants, including grants for studies on emergency contrace}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, Asian sex workers in San Francisco and women's response to pornography. NIH staff were required to review the grants to determine whether the projects "were relevant to the public health needs of our country," used methodology that was "scientifically and ethically appropriate," had been "properly reviewed and funded by NIH" and received funding that was proportional "relative to the burden of sexually related diseases as compared to other diseases" (<a ="http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint=1&DR_ID=21951">Kaiser Daily HIV/AIDS Report, 1/30). Andrea Lafferty, executive director of the Traditional Values Coalition, said that her group is challenging research grants that "don't pass the ... test," adding, "There's an arrogance in the scientific co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 munity that they know better than the average American" (New York Times, 7/11).\par Public Health & Education\par HIV Prevention Programs Emphasizing 'Ethnic Pride, Communication Skills' Increase Condom Usage, Study Says\par [Jul 13, 2004]\par Sexually active African-American teenage girls, who are at high risk for contracting HIV, were less likely to engage in sex without a condom after taking part in an HIV prevention program that "emphasiz[ed] ethnic pride and communication skills," according to a study published in the July 14 issue of the <a ="http://jama.ama-assn.org/cgi/content/abstract/292/2/171">Journal of the American Medical Association, which focuses on HIV/AIDS, and presented Sunday at the XV International AIDS Conference in Bangkok, Thailand, <a ="http://www.newsday.com/news/health/ny-hsteen113888258jul11,0,1711920.story">Long I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 land Newsday reports (Rabin, Long Island Newsday, 7/11). Ralph DiClemente of Emory University's <a ="http://www.sph.emory.edu/">Rollins School of Public Health</a> and colleagues from December 1996 to April 1999 studied 522 sexually active black girls between the ages of 14 and 18. About half of the partic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pants were separated into an intervention group, which offered information on ethnic and gender pride, communication skills, HIV/AIDS, condom use and healthy relationships. The other half of the participants were offered information on exercise and nutrition. Researchers evaluated the intervention program on the basis of different behavior change factors, including condom use and number of sexual partners, according to the <a ="http://www.washingtontimes.com/national/20040710-113547-2629r.htm">Washington Times. Researchers did not evaluate the program based on an increase in sexual abstinence because "they thought the goal was unrealistic," the Times reports (Howard Price, Washington Times, 7/11). After 12 months, 73% of the 251 girls in the intervention program reported using condoms regularly in the previous 30 days, co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pared with 56% of the participants in the control group. The girls in the intervention group also were more likely to turn down unsafe sexual advances; slightly less likely to start sexual relationships with new partners; slightly less likely to report pregnancies; and had more favorable attitudes toward condoms, according to the study, Newsday reports (Long Island Newsday, 7/11). Researchers concluded that it is "compellingly urgent" to develop new HIV prevention programs that target high-risk groups (Washington Times, 7/11).\par Kaiser Daily HIV/AIDS Report Summarizes Features on HIV/AIDS Among Blacks in United States\par [Jul 13, 2004]\par Several newspapers this week published features on HIV/AIDS among blacks in the United States to coi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cide with the opening of the <a ="http://www.aids2004.org/">XV International AIDS Conference</a> taking place this week in Bangkok, Thailand. Summaries of the features appear below:\par "AIDS: Darkening in America," <a ="http://www.usnews.com/usnews/issue/040712/health/12wilson.htm">U.S. News & World Report: U.S. News & World Report on Monday profiled <a ="http://www.blackaids.org/">Black AIDS Institute</a> Founder Phill Wilson. Although the development of effective antiretroviral therapy in 1996 caused a shift in the pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ception of HIV/AIDS from an epidemic of young, white, gay men, to an epidemic centered on Africa, the Ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ibbean and Eastern Europe, the "constant epidemic in people of color" -- which is "having a devastating e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fect in black communities" in the United States -- has been "ignored," Wilson said. Over the last five years, Wilson has worked to obtain support from civil rights leaders, the black media, seven black fraternities and sororities and historically black colleges and universities to make HIV/AIDS education a priority. According to Wilson, individuals and local organizations must "bridge the gap" between the "overwhelmingly white" med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal community and the "increasingly black" HIV community, adding, "We are faced with the worst health di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 aster that our community has seen in the last century. What I do is ordinary. It's only extraordinary because we're not all doing it" (Brink, U.S. News & World Report, 7/12).\par "Black Church Has Vital Role in Fighting AIDS," <a ="http://www.chicagotribune.com/news/printedition/chi-0407120205jul12,1,2064933.column">Chicago Tribune: HIV/AIDS is a "reality about which everybody needs to be concerned," and African-American churches are starting HIV/AIDS prevention programs "not a moment too soon," the Tribune reports. Although black churches historically have avoided addressing HIV/AIDS or issues of sexuality, HIV/AIDS education and outreach is "particularly important" in light of recent studies showing an increase in HIV incidence among black male college students. Trinity United Church of Christ's HIV/AIDS ministry, which started in 1992, includes workshops on prevention, treatment options and living with HIV/AIDS, as well as a youth sexuality project that includes HIV/AIDS education (Turner Trice, Chicago Tribune, 7/12).\par "Danger on the Down Low," Houston Chronicle: African-American women who remain faithful to their sexual partners and have no history of injection drug use but who contract HIV from their husbands or boyfriends are "part of a troubling trend" in new HIV infections, the Chronicle reports. Some observers say that the i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 crease in the number of HIV cases linked to heterosexual sex among black women stems from men "on the down low" -- black men who have sex with men but do not mention their male relationships to their female sex partners, friends or family members -- but researchers do not know whether the phenomenon is to blame. CDC spokesperson Karlie Stanton said that although researchers know the phenomenon is a factor, "we don't know how big a factor it is" (Kever, Houston Chronicle, 7/10).\par "HIV Alarm for Mid-Age Blacks," New York Post: An increasing number of black men between the ages of 40 and 54 are testing HIV-positive, according to a study by New York City health officials presented Monday at the conference. City officials, who began collecting and reporting data on HIV in 2000, found that out of the more than 75,000 HIV-positive people in the city, one in 15 is a black middle-aged man and one in 10 is fo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eign-born, primarily in the Caribbean, Africa or South America. Of the city's 11,039 black, middle-aged, HIV-positive men, 1,523 men had developed AIDS at the time of diagnosis, which city scientists said indicates that many were "long infected but not tested until symptomatic" (Edozien, New York Post, 7/12).\par "Inequities in Health, Race? Among African Americans, Disease Rates Are Higher and Care Is Inferior," <a ="http://www.philly.com/mld/inquirer/9121368.htm?1c">Philadelphia Inquirer: The "tragic phenomenon" that blacks suffer higher rates of diseases -- including HIV/AIDS -- and the issue of minority health disparities in rates of illness and quality of care "finally seems to have hit the mainstream," the Inquirer reports. According to the Inquirer, "pressure is mounting" on researchers, health care providers, lawmakers, insurance comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies and other businesses to address "what is arguably one of the nation's worst public health crises." The "uncomfortable but unavoidable" conclusion that health care workers "like everyone else, bring their biases to work" have led some researchers to believe that a potential long-term solution to minority health disparities is to increase the number of minorities in medicine, academia and other areas that influence research, fun}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing and policy, the Inquirer reports (Smith, Philadelphia Inquirer, 7/10).\par The Black AIDS Institute has <a ="http://www.blackaids.org/bangkok/">additional conference coverage</a> relating to blacks and AIDS.\par Media & Society\par Kaiser Daily HIV/AIDS Report Summarizes Media Coverage of International HIV/AIDS Issues\par [Jul 13, 2004]\par Several U.S. and international broadcast programs have included features on HIV/AIDS in response to the XV International AIDS Conference in Bangkok, Thailand, from July 11-16. Summaries of the coverage a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pear below.\par Australian Broadcasting Corporation's "<a ="http://www.abc.net.au/ra/asiapac/default.htm">Asia Pacific</a>": The segment reports on the world's AIDS orphans and includes comments from Carol Bellamy, executive director of UNICEF (Thompson, "Asia Pacific," ABC, 7/13). The complete segment is available <a ="http://www.abc.net.au/ra/asiapac/programs/m914590.asx">online</a> in Window Media.\par BBC's "<a ="http://news.bbc.co.uk/2/hi/talking_point/talking_point_programme/default.stm">Talking Point": The segment includes comments from Dr. Jim Kim, director of WHO's HIV/AIDS program and Jack Summe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 side, head of health promotion at the Terrence Higgins Trust. Complete video of the program in RealPlayer is available <a ="http://www.bbc.co.uk/newsa/n5ctrl/progs/talkingpoint/04/11jul.ram">online</a>. A complete audio version of the program is available <a ="http://www.bbc.co.uk/newsa/n5ctrl/progs/talkingpoint/04/11jul_audio.ram">online</a> in RealPlayer. In addition, an interactive discussion board about abstinence is available <a ="http://news.bbc.co.uk/2/hi/talking_point/3870335.stm">online</a>.\par NPR's "Day to Day": The segment will examine how gender inequality in South Africa is contributing to the spread of HIV/AIDS ("Day to Day," NPR, 7/13). The complete segment will be available online in RealPlayer and Windows Media after the broadcast. Expanded NPR coverage is available <a ="http://www.npr.org/healthscience/aids2004/">online</a>.\par NPR's "Morning Edition" on Tuesday profiled the Indian drug company <a ="http://www.}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 com/">}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 </a> and the debate over drug makers that produce generic versions of brand-name antiretroviral drugs to treat people with HIV/AIDS in developing countries (Wilson, "Morning Ed}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion," NPR, 7/13). The complete segment is available <a ="http://www.npr.org/dmg/dmg.php?prgCode=ME&showDate=13-Jul-2004&segNum=13&mediaPref=RM">online</a> in RealPlayer. Expanded NPR coverage is available <a ="http://www.npr.org/healthscience/aids2004/">online</a>.\par PBS' "NewsHour with Jim Lehrer": The segment profiles Botswana's HIV testing and antiretroviral drug pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams. The segment includes comments from Dr. Ernes Darkoh, director of Botswana's antiretroviral pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gram; Richard Holbrooke, former U.N. ambassador and president of the <a ="http://www.businessfightsaids.org/">Global Business Coalition on HIV/AIDS; Dr. Banu Kahn, head of the Botswanan HIV/AIDS program; Botswanan President Festus Mogae; and Thai Sen. Mechai Viravaidya (de Sam Lazaro, "NewsHour with Jim Lehrer," PBS, 7/12). The complete transcript is available <a ="http://www.pbs.org/newshour/bb/health/july-dec04/botswana_7-12.html">online</a>. The complete se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment is available <a ="http://audio.pbs.org:8080/ramgen/newshour/expansion/2004/07/12/fl28.rm?altplay=fl28.rm">online</a> in RealPlayer. Expanded PBS coverage of the conference is available <a ="http://www.pbs.org/newshour/health/aids/aids2004/">online</a>.\par WAMU's "The Diane Rehm Show": The NPR-syndicated show in the first hour of the broadcast will include a panel discussion of research findings and policy debates from the conference. Guests on the program will include Dr. Kathleen Cravero, deputy executive director of <a ="http://www.unaids.org/en/default.asp">UNAIDS</a>; Dr. Anthony Fauci, director of the NIH <a ="http://www.niaid.nih.gov/">National Institute of Allergy and Infectious Diseases; David Gartner, policy dire}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor for the <a ="http://www.globalaidsalliance.org/">Global AIDS Alliance</a>; and Dr. Joseph O'Neill, deputy coordinator and chief medical officer in the <a ="http://www.state.gov/">State Department</a>'s <a ="http://www.state.gov/s/gac/">Office of the Global AIDS Coordinator</a> (Page, "The Diane Rehm Show," WAMU, 7/13). The complete segment will be available online in RealPlayer after the broadcast.\par Opinion\par Kaiser Daily HIV/AIDS Report Summarizes Editorials, Opinion Pieces on Global HIV/AIDS Epidemic\par [Jul 13, 2004]\par Several newspapers have published editorials and opinion pieces focusing on HIV/AIDS-related issues to mark the XV International AIDS Conference, which began on Sunday in Bangkok, Thailand, and runs through July 16. Summaries of some of the editorials and opinion pieces appear below:\par <a ="http://www.azcentral.com/arizonarepublic/opinions/articles/0712mon1-12.html">Arizona Republic: While the "threat" of the global AIDS epidemic "has never been higher," the world's "ability to control it has never been greater," a Republic editorial says. Education, prevention, outreach and treatment strategies, along with increased funding commitments to global initiatives, are the most effective ways of controlling the spread of HIV/AIDS, the editorial concludes (Arizona Republic, 7/12).\par <a ="http://www.chicagotribune.com/news/opinion/chi-0407120187jul12,1,1440465.story?coll=chi-newsopinion-hed">Chicago Tribune: Because the HIV/AIDS epidemic "keeps outpacing efforts to contain it," more needs to be done to distribute antiretroviral drugs -- including reconsidering FDA's policy to retest g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric drugs that have already been vetted by the <a ="http://www.who.int/en">World Health Organiz}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion</a>, a Tribune editorial says. The double-processing is "unwarranted and only delays delivery of esse}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tial medicines," the Tribune concludes (Chicago Tribune, 7/12).\par <a ="http://www.latimes.com/news/opinion/editorials/la-ed-aids12jul12,1,1201813.story?coll=la-news-comment-editorials">Los Angeles Times: Without better training on how to teach health care workers HIV prevention methods, children are "more likely to repeat the mistakes of their parents and continue to spread the disease," a Times editorial says, concluding, "[T]he war on AIDS can be won only with a fight on many fronts, not just by giving poor countries more cash to buy drugs" (Los Angeles Times, 7/12).\par <a ="http://www.miami.com/mld/miamiherald/news/opinion/9133199.htm?ERIGHTS=-5144001735320941980miami::kennedyb@advisory.com&KRD_RM=8ooxsrrtwrqouwtqwwqooooooobN">Miami Herald: The "fundamental barrier" to stemming the HIV/AIDS epidemic is not ability but will, a Herald ed}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 torial says. While counseling, outreach and public-awareness campaigns provide knowledge and expertise, financial commitments on the part of wealthy nations -- including the United States -- ultimately make preve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion and treatment measures effective, the editorial says, concluding, "The United States should -- and easily can do its share" (Miami Herald, 7/12).\par <a ="http://www.startribune.com/stories/561/4872618.html">Minneapolis Star Tribune: Because the global HIV/AIDS epidemic has worsened since the 2002 International AIDS Conference in Barcelona, Spain, HIV/AIDS advocates must continue to "hammer away at the trilogy of what works": education and awareness programs, prevention and treatment while wealthy nations must financially "fully support" global initiatives, a Star Tribune editorial says (Minneapolis Star Tribune, 7/13).\par <a ="http://www.nj.com/opinion/ledger/editorials/index.ssf?/base/news-2/1089445905139970.xml">Newark Star-Ledger: Both the successes and failures of the continuing fight against the HIV/AIDS epidemic provide "a lesson to learn" -- HIV/AIDS can be contained with resources and leadership that require an adequate and sustained financial commitment from the United States and other wealthy nations, a Star-Ledger editorial says (Newark Star-Ledger, 7/10).\par Salt Lake City Deseret Morning News: AIDS is "more than a global health crisis" because it creates the p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tential for the development and proliferation of terrorism worldwide, a Morning News editorial says. Global HIV/AIDS initiatives therefore would save lives and "stem the spread of terrorist activities," the editorial co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cludes (Deseret Morning News, 7/11).\par Opinion Pieces\par Enriqueta Bond, <a ="http://www.washingtonpost.com/wp-dyn/articles/A43460-2004Jul11.html">Washington Post: The global HIV/AIDS epidemic has recently overshadowed the "accelerating" malaria epidemic that has affected more people in the past two decades than HIV/AIDS, Bond, president of the <a ="http://www.bwfund.org/">Burroughs Wellcome Fund</a>, writes in a Post opinion piece (Washington Post, 7/12).\par Jane Eisner, <a ="http://www.philly.com/mld/inquirer/news/editorial/">Philadelphia Inquirer: It is a "shame" that the United States has to choose between funding prevention initiatives and treating people living with HIV/AIDS, Inquirer columnist Eisner writes in an opinion piece. Because both approaches are necessary, the United States should be "compassionate enough to do more than one," Eisner concludes (Philadelphia I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quirer, 7/11).\par Desmond Tutu, <a ="http://www.guardian.co.uk/business/story/0,3604,1259032,00.html">Guardian</a>: Even the "greatest speeches do not save lives ... [a]id does," Tutu, former archbishop of Cape Town, South Africa, says in a London Guardian opinion piece. To combat global HIV/AIDS and poverty, wealthy nations should "tak[e] action" on international trade regulations and debt owed by developing countries and "[d]ramatically" increase aid to "heal not only the physical suffering of the poor south, but also the moral su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fering of the rich north," Tutu concludes (Guardian, 7/12).\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); ANTIVIRALS (92%); PHARMACEUTICAL PREPARATION MFG (90%); AIDS & HIV TREATMENT (90%); PHARMACEUTICALS INDUSTRY (90%); RESEARCH & DEVELOPMENT (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (87%); GENERIC DRUGS (78%); PRESCRIPTION DRUGS (78%); DEVELOPING COUNTRIES (78%); HEALTH CARE ACCESS (77%); FOUNDATIONS (76%); HEALTH DEPARTMENTS (73%); PUBLIC HEALTH ADMINISTRATION (72%); RESEARCH (70%); GENERIC PRODUCTS (67%); MONOPOLIZATION (61%); UNITED NATIONS INSTITUTIONS (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (58%); PFEB (BRU) (58%); PFE (NYSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KAISER DAILY HIV (96%); JON COHEN (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (57%); WORLD HEALTH ORGANIZATION (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THAILAND (92%); PHILIPPINES (78%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGKOK, THAILAND (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (63%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 13, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC AIDS PILL GETS PATENT IN AFRICA WALL STREET JOURNAL ABSTRACTS July 13, 2004, Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_216}{\*\bkmkstart DOC_ID_216_0}{\*\bkmkstart doc_id_78}{\*\bkmkend DOC_ID_216}{\*\bkmkend DOC_ID_216_0}{\*\bkmkend doc_id_78}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_78"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 78 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WALL STREET JOURNAL ABSTRACTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2004, Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GENERIC AIDS PILL GETS }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  IN AFRICA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section D; Page 3, Column 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 40 words\par \par \par India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented a three-in-one combination tablet called Triomune in South Africa; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is also seeking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the product in 17 other countries in Africa (M)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (95%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (95%); SIC2834 PHARMACEUTICAL PREPARATIONS (95%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (95%); SOUTH AFRICA (92%); INDIA (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (95%);  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA;   AFRICA (95%); SOUTH AFRICA (92%); INDIA (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUGS (PHARMACEUTICALS); GENERIC AND BRAND NAME PRODUCTS; INVENTIONS AND }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  TRIOMUNE (DRUG);   AIDS & HIV TREATMENT (90%); AIDS & HIV (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC PRODUCTS (90%); GENERIC DRUGS (88%); ANTIVIRALS (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 13, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 JOURNAL-CODE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  WSJ\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company: Abstracts\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC AIDS PILL GETS PATENT IN AFRICA WALL STREET JOURNAL ABSTRACTS July 13, 2004, Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_217}{\*\bkmkstart DOC_ID_217_0}{\*\bkmkstart doc_id_79}{\*\bkmkend DOC_ID_217}{\*\bkmkend DOC_ID_217_0}{\*\bkmkend doc_id_79}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_79"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00370039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 79 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WALL STREET JOURNAL ABSTRACTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2004, Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GENERIC AIDS PILL GETS }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  IN AFRICA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section D; Page 3, Column 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 40 words\par \par \par India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd, a pioneer in supplying cheap generic AIDS drugs in Africa, has patented a three-in-one combination tablet called Triomune in South Africa; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is also seeking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the product in 17 other countries in Africa (M)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (95%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (95%); SIC2834 PHARMACEUTICAL PREPARATIONS (95%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (95%); SOUTH AFRICA (92%); INDIA (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (95%);  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA;   AFRICA (95%); SOUTH AFRICA (92%); INDIA (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUGS (PHARMACEUTICALS); GENERIC AND BRAND NAME PRODUCTS; INVENTIONS AND }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  TRIOMUNE (DRUG);   AIDS & HIV TREATMENT (90%); AIDS & HIV (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC PRODUCTS (90%); GENERIC DRUGS (88%); ANTIVIRALS (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 14, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 JOURNAL-CODE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  WSJ\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company: Abstracts\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda;Drugs Worry Aids Patients Africa News July 7, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_218}{\*\bkmkstart DOC_ID_218_0}{\*\bkmkstart doc_id_80}{\*\bkmkend DOC_ID_218}{\*\bkmkend DOC_ID_218_0}{\*\bkmkend doc_id_80}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_80"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 80 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  7, 2004 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda;\par Drugs Worry Aids Patients}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Monitor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 183 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Anti-Aids activists have raised the red flag after the World Health Organisation refused to endorse two co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mon generic drugs used to treat HIV/Aids.\par The medicines which are made by Indian generic drugs giant, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  were taken off WHO's list of pre-qualified drugs after they failed to meet the health standards during a regular review in June. \par " Many patients use these drugs. What are they expected to do" asked Major Ruranga Rubamaramira of N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional Guidance and Empowerment Network for People Living with HIV/Aids.\par In June WHO announced that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Lamivudine (3TC) and Zidovudine (AZT) tablet offerings had failed a crucial test known as the bio-equivalence test during a routine evaluation.\par The Head of Drug testing at the Uganda's National Drug Authority (NDA), Florence Nakachwa told The Mon}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tor on Saturday that the controversy over ARVs, two drugs reflected the tension within the global pharmace}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tical industry.\par She explained that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders like GlaxoSmithKline were locking horns with generic drug manufactures that made cheaper versions of their innovations.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (92%); AIDS & HIV (92%); AIDS & HIV TREATMENT (91%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS INDUSTRY (90%); PRESCRIPTION DRUGS (90%); ANTIVIRALS (90%); PUBLIC HEALTH A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MINISTRATION (88%); HEALTH DEPARTMENTS (78%); PHARMACEUTICAL PREPARATION MFG (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (91%); WORLD HEALTH ORGANIZATION (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UGANDA (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (50%);  NATIONAL DRUG AUTHORITY (79%); WORLD HEALTH O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANISATION (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 6, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS;Daily HIV/Aids Report Africa News July 7, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_219}{\*\bkmkstart DOC_ID_219_0}{\*\bkmkstart doc_id_81}{\*\bkmkend DOC_ID_219}{\*\bkmkend DOC_ID_219_0}{\*\bkmkend doc_id_81}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_81"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 81 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  7, 2004 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS;\par Daily HIV/Aids Report}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Kaisernetwork.org\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 4531 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Global Challenges\par Number of New HIV Cases Increases Worldwide, Many Concentrated in Asia, UNAIDS Report Says\par [Jul 07, 2004]\par The 2004 UNAIDS Report of the Global AIDS Epidemic released by UNAIDS on Tuesday in advance of the XV International AIDS Conference illustrates "daunting trends" and an increasing "need for assistance" in the world's fight against the pandemic, the Boston Globe reports (Donnelly, Boston Globe, 7/7). According to the report, which for the first time includes revised HIV prevalence for previous years based on improved met}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 odology and more comprehensive country surveillance data, five million new HIV cases were reported worldwide last year -- the most cases reported in any single year since the beginning of the epidemic. The report shows that the number of people living with HIV increased from 35 million in 2001 to 38 million in 2003. The report also shows that nearly three million people died from AIDS-related causes in 2003. In add}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, almost 50% of new HIV cases worldwide were among people ages 15 to 24, and women comprised almost 50% of people living with HIV, the report says (Kaiser Daily HIV/AIDS Report, 7/6). \par Asian Crisis\par Although sub-Saharan Africa remains the most affected region in the world with about 25 million HIV-positive people, the report shows that Asia could "face an AIDS catastrophe" if the region does not make bigger strides in combating the disease, the Financial Times reports (Dyer/Marcelo, Financial Times, 7/6). Asia, which accounts for 60% of the world's population, has 7.4 million HIV-positive people and has experienced some of the "sharpest" increases in numbers of HIV cases, the report says. In Asia, the epidemic is still "largely concentrated" among injection drug users, men who have sex with men, commercial sex workers and clients of sex workers and their sexual partners, according to the report (Kaiser Daily HIV/AIDS Report, 7/6). However, the Asian epidemic is "fast moving into the general population," Kathleen Cravero, deputy executive director of UNAIDS, said. The report shows that of the five million new HIV cases reported in 2003, nearly 1.2 million occurred in Asia, the New York Times reports. In addition, China, Indonesia and Vietnam account for 50% of the Asian population and are seeing "rapidly ... expanding" epidemics, the report says. HIV epidemics are "much harder to stop" after HIV prevalence begins to exceed 1% -- the prevalence level that most epidemiologists use to define a generalized HIV epidemic -- than before prevalence reaches 1%, according to Cravero, the Times reports. Because "many countries [in Asia] have prevalence rates less than 1%, and some are hovering around 1%," there is a "small window of opportunity" to curb the spread of HIV in Asia, Cravero said. "If we miss it, it will slam shut forever," and "we will see an epidemic the likes of which we never imagined," Cravero said, adding, "You either drive [the Asian HIV/AIDS epidemic] down now through maximum scaling up of prevention or you spend exponentially more money and energy trying to drive it down" (Altman, New York Times, 7/7).\par India\par India has 5.1 million people living with HIV, up from about four million in 2002, according to the Globe (Bo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ton Globe, 7/7). The epidemic in India, which now ranks second behind South Africa for the most HIV/AIDS cases in the world, stems from "widespread ignorance" about HIV, according to the Chicago Tribune. In add}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, the "down low" phenomenon -- in which men have sex with men but do not mention their male relatio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ships to their female sex partners, friends or family members -- is an "emerging concern," the Tribune r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports. NIH National Institute of Allergy and Infectious Diseases Director Anthony Fauci said that although only a small percentage of the India's population of one billion is HIV-positive, "you're talking tens of millions of additional infections" if the number of cases doubles or triples, the Tribune reports. He added that he is concerned that "several Asian countries [have] a gross underestimate, not only of what is actually going on but what the potential is" for the HIV/AIDS epidemic, adding, "You have the potential for an explosion that, given the numbers of people who live in Asia, could potentially dwarf what we're seeing in Africa" (Graham, Chicago Tribune, 7/7). However, the Indian government has said that the rate of increase in the number of HIV cases in 2003 "had slowed" compared with statistics for 2002, according to the Financial Times. India's National AIDS Control Organization Director Meenakshi Datta Ghosh said, "There is no galloping AIDS ep}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 demic in India" (Financial Times, 7/6).\par Prevention, Treatment Among Women\par To help curb the spread of HIV in Asia and elsewhere, countries must "vastly increase" prevention and treatment efforts, Cravero said, according to the Times. However, prevention and treatment programs in Asia "largely miss" women and girls, who often do not have the option of abstaining from sex and have "little co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 trol" over whether their partners use condoms or remain faithful, according to Cravero, the Times reports (New York Times, 7/7). However, the epidemic's "feminization" is most apparent in sub-Saharan Africa, where 57% of HIV-positive adults are women and 75% of young people living with HIV are female, the report says, according to AFP/Yahoo! News. In the region's "male-dominated culture," women are the caregivers and therefore "bear the largest AIDS burden," the report says, according to AFP/Yahoo! News (AFP/Yahoo! News, 7/6). UNAIDS Executive Director Peter Piot said that the "ABC" model of prevention -- Abstinence, Be faithful, use Condoms -- is "pretty irrelevant" for women in Africa. Many women in the region face "violent, nonconsensual sex," according to the Mail & Guardian (Mail & Guardian, 7/7). He added that teenage girls in the region often have their first sexual experience with a man who is five to 15 years older, which "introduces extremely high-risk situations to girls, who are already more vulnerable" (Maugh, Los Angeles Times, 7/7). Cravero said, "Most of the women and girls, as much in Asia as in Africa, don't have the option to abstain [from sex] when they want to," adding, "Women who are the victims of violence are in no position to negot}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ate anything, nevermind faithfulness and condom use" (Nakashima, Washington Post, 7/7). Piot said that "[t]o ensure women become less infected, we have to target men," adding, "We are getting into a need for quite fundamental and long-ranging behavior change. We have to change norms in society" (Mail & Guard}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an, 7/7).\par NBC's "Nightly News" on Tuesday reported on the study. The segment includes comments from Dr. Wafaa El-Sadr, a professor of epidemiology at Columbia University's Mailman School of Public Health and Piot (B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zell, "Nightly News," NBC, 7/6). The complete segment is available online in Windows Media.\par Thailand to Launch Revitalized HIV/AIDS Awareness Campaign Aimed at Nation's Youth\par [Jul 07, 2004]\par Thailand at the close of the XV International AIDS Conference next week will launch a revitalized HIV/AIDS awareness campaign to promote condom use among the nation's youth, Thai Public Health Minister Sudarat Keyuraphan said Tuesday, the Bangkok Post reports. The campaign will target young people between the ages of 14 and 25, an age group whose "ignorance" about condom use has become a "prime concern" for Thai health officials, Sudarat said, according to the Bangkok Post. Approximately one-third of sexually active young people are not using condoms, primarily because of confidence in their partners, according to Health Ministry surveys. Health officials fear that such high-risk behavior could make young people increasingly at risk for HIV. "They worry about getting pregnant more than AIDS," Sudarat said (Bangkok Post, 7/7). Tee}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 agers and young adults worldwide are at the greatest risk of HIV infection, especially female teenagers, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to a UNAIDS report released Tuesday, Xinhua News Agency reports (Xinhua News Agency, 7/7). As part of the new campaign, the government will install more condom vending machines throughout the cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 try, especially near secondary schools, Charal Trinvuthipong, director general of the Disease Control D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 partment, said. Seven thousand machines already have been installed nationwide, including 5,000 in Ban}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 kok, which offer condoms for about 12 cents each -- one-tenth the price of condoms sold at drug and co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 venience stores. Local singers also will be asked to take part in the campaign to promote condom use and inform teenagers about the risks of HIV/AIDS (Bangkok Post, 7/7).\par Increased Risk\par Teenagers are increasingly at risk because they are too young to have learned from the public education campaigns the government launched a decade ago, Hakan Bjorkman, U.N. deputy resident for HIV/AIDS programs in Thailand, said (VOA News, 7/6). Thailand was one of the first "hard hit" countries to recognize and address HIV/AIDS in the early 1990s. The country initiated programs to encourage condom use, esp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cially among commercial sex workers, and implemented antiretroviral drug programs to prevent mother-to-child HIV transmission (Kaiser Daily HIV/AIDS Report, 7/6). HIV/AIDS cases in the country decreased from 140,000 in 1991 to 21,000 in 2003, according to UNAIDS (Bangkok Post, 7/7). "Young people, the really young people, they come on the scene, so to speak, become sexually active -- they weren't around in the early '90s when this big campaign was going on," Bjorkman said, adding, "So they come out, they don't use condoms, they experiment with drugs ... they're very vulnerable" (VOA News, 7/6). Thai Sen. Mechai V}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ravaidya, who is known as the "condom king" for spearheading the national condom promotion initiative 10 years ago, said that Thailand has become complacent about HIV education in recent years, Reuters reports. "In the last two or three years, we have fallen into a state of hibernation in terms of public education," Mechai said, adding, "A new generation hasn't heard much about HIV. They think it's gone" (Schuettler, Reuters, 7/6).\par A kaisernetwork.org video feature -- prepared by Fred de Sam Lazaro, who also is a correspondent for the "NewsHour with Jim Lehrer" -- includes interviews with people who are on front lines of efforts to fight HIV/AIDS in Thailand. The video is the fourth in a series of spotlights from kaisernetwork.org on local efforts around the world to combat the HIV/AIDS epidemic. The other features -- which examine HIV/AIDS in Haiti, Brazil and India -- also are available online.\par South Asia Lacks Leadership, Strategy for Fighting HIV/AIDS, World Bank Officials Say\par [Jul 07, 2004]\par South Asia lacks the leadership and strategy necessary for confronting the region's HIV/AIDS epidemic, World Bank officials last week said at a news conference ahead of the XV International AIDS Conference, the Taipei Times reports (Taipei Times, 7/5). Asia accounts for 60% of the world's population and has exp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rienced some of the sharpest increases in numbers of HIV cases, according to the 2004 UNAIDS Report of the Global AIDS Epidemic. Asia has 7.4 million HIV-positive people, the report said (Kaiser Daily HIV/AIDS Report, 7/6). Although the World Bank has set aside $380 million annually to address AIDS in the region, much of the money has not been spent because of a lack of programs, World Bank Vice President for South Asia Praful Patel said. The officials said that political leaders have "wasted time arguing" about the number of people with the disease instead of implementing programs to address it, according to the Times (Taipei Times, 7/5). "We are facing exactly the same situation in South Asia now where this disease has gained a foothold and absolutely there is no serious strategy to address it," Patel said. There are approximately 4.6 million HIV-positive people living in India, almost two-thirds of South Asia's total number of infected individ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 als, and the epidemic has progressed from being concentrated in high-risk groups to a generalized epidemic in six of the country's 28 states (Agence France-Presse, 6/30).\par Women, Other Groups\par The epidemic is also increasingly affecting women, previously considered a low-risk group, according to I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia's National AIDS Control Agency's Project Director Meenakshi Datta Ghosh, VOA News reports. "We used to believe that for every eight men getting the infection maybe one woman will get it," Ghosh said, ad}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing, "But now we believe that is not so. For every eight men getting (HIV) maybe three women will be getting it" (VOA News, 7/6). Other countries in the region, such as Pakistan, Bangladesh and Nepal, have low HIV prevalence among the general population but high prevalence among injection drug users and commercial sex workers. However, the size of these subpopulations is "frightening," and could lead to an increase in HIV prevalence in the region, Patel said. For example, although HIV prevalence among the general population of Nepal is 0.5%, the prevalence among injection drug users is as high as 68% (Agence France-Presse, 6/30). The lack of leadership in fighting the disease could be a setback in the economic development of the region, Jean-Louis Sarbib, World Bank vice president for development, said. The epidemic could reduce economic growth by as much as 1% and could lead to a 1% to 3% increase in health expenditures, according to World Bank estimates (Taipei Times, 7/5).\par HIV-Positive Employees Still Face Discrimination in Thai Business Sector, Nation Reports\par [Jul 07, 2004]\par Thailand's business leaders have not fulfilled a promise to reduce discrimination against HIV-positive e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ployees in the country's business sector, Thailand's Nation reports. Thai business leaders attending an inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 national summit in 2001 agreed to take steps to reduce discrimination in the work force. However, recent complaints received by the country's Centre for AIDS Rights show that Thai employers have asked job appl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cants to submit blood for HIV tests, have screened employees during annual medical exams and fired HIV-positive employees. A recent survey conducted by the Thailand Business Coalition on AIDS of 510 bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nesses found that the percentage of companies conducting compulsory pre-employment HIV testing fell from 27% in 2001 to 12% in 2004, TBCA Executive Director Anthony Pramualratana said, according to the Nation. The survey also found that the percentage of companies that said they would not terminate HIV-positive e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ployees has decreased from 64% in 2001 to 41% currently, the Nation reports.\par Reaction\par CAR program officer Sathien Tanprom said that although companies claim they do not discriminate on the basis of HIV status, many companies do so in practice, the Nation reports. CAR and the Thai AIDS Access Foundation say that discrimination against HIV-positive employees amounts to a violation of human rights that "fl[ies] in the face" of the country's commitment to ensuring that at least 50% of companies establish HIV/AIDS-friendly policies by 2003, according to the Nation. Sathien said, "Although many employers verba}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ly promised to stop preventing the hiring of workers with HIV, none dared make it a formal company policy." Only a "handful" of companies in Thailand have adopted all of the HIV-friendly workplace policies, Anthony said, according to the Nation. These policies include anti-discrimination training, prevention programs and workplace support networks. Ignorance among upper management is largely responsible for the lack of HIV-friendly programs, according to Anthony, the Nation reports (Nation, 7/5). However, the Thai government after the XV International AIDS Conference plans to launch a campaign focused on employers and creating better job opportunities for HIV-positive employees, the Bangkok Post reports. The campaign aims to e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 courage factories to employ more HIV/AIDS patients and includes an educational campaign about how HIV is transmitted (Bangkok Post, 7/7).\par Social Welfare\par Advocates also are criticizing the Thai government for denying people living with HIV/AIDS equal access to antiretroviral drugs, the Bangkok Post reports. The government's requirement that HIV/AIDS patients who receive public health services through the country's Social Welfare Fund pay extra for antiretrovirals that cost more than $120 per month is "unacceptable" because they already contribute part of their income to the fund, AAF Director Nimit Tien-udom said, according to the Nation. All workers must contribute 5% of their monthly salaries to the fund, and employers contribute an equal amount per employee. Unlike the National Health Care Program -- which allows HIV/AIDS patients access to generic antiretrovirals for 75 cents per month -- workers covered by the Social Health program pay the difference in cost for any drug treatment re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 imen that exceeds the fund's budget (Bangkok Post, 7/7).\par U.S., Thai HIV/AIDS Advocates To Protest Opening of XV International AIDS Conference\par [Jul 07, 2004]\par More than 1,000 HIV/AIDS advocates and HIV-positive people in Bangkok, Thailand, on Sunday are pla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ning to protest at the opening of the XV International AIDS Conference, to call for improved access to a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral treatment for people living with HIV, among other issues, Thailand's Nation reports. Nimit Tien-udom, director of Thailand's AIDS Access Foundation -- which is organizing the protest with U.S.-based Health GAP and the Thai Network of People Living With HIV/AIDS -- said that he wants the conference to "live up to its theme" of "Access for All," according to the Nation (Nantiya, Nation, 7/7). Demonstrators plan to protest "failures of government worldwide" to take sufficient steps to combat the HIV/AIDS pandemic, Agence France-Presse reports. The advocates said that "government inactivity, ... political obstruction and free trade pacts" could worsen the HIV/AIDS pandemic, according to Agence France-Presse. Health GAP Director Asia Russell said that the United States and other countries seem to be "backtracking" on funding pledges while the amount of money needed to effectively combat the disease is increasing, Agence France-Presse reports. She added that President Bush is requesting a reduction in AIDS funding from fiscal year 2004 to FY 2005, according to Agence France-Presse (Agence France-Presse, 7/6). The House Foreign Operations Appropriations Subcommittee in June by voice vote approved a $19.4 billion draft foreign aid spending bill for FY 2005, including $2.2 billion for global AIDS, tuberculosis and malaria programs. Although the approved funding -- most of which will go to AIDS programs -- meets Bush's request for FY 2005, the subcommittee allocated a larger portion of the money to the Global Fund to Fight AIDS, Tuberculosis and Malaria than Bush had requested. Bush's proposed FY 2005 budget, which is $1.9 billion more than the total amount the subcommittee approved, includes $2.8 billion for international HIV/AIDS, TB and malaria pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams, including $1.45 billion for the State Department Office of the Global AIDS Coordinator, which will a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 minister the President's Emergency Plan for AIDS Relief, and $200 million for the Global Fund (Kaiser Daily HIV/AIDS Report, 6/24).\par Access for All?\par Russell also said that the advocates were concerned about the high cost of registration for the conference, according to the Nation (Nation, 7/7). The early registration fee for the conference was $800 and standard registration was $900; however, after May 1 the fee rose to $1,000, which comes to $1,250 including Thai tax. Although the conference fees include access to all conference sessions and copies of related doc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ments and reports, meals and accommodations are not included in the price (Kaiser Daily HIV/AIDS Report, 6/29). Russell said, "To tackle HIV/AIDS is partly about an exchange of information between scientists and infected people. But such a high price damages opportunities for an open exchange." Nimit said that the price of registration could provide a person living with HIV in Thailand with antiretroviral treatment for about three years, according to the Nation (Nation, 7/7). Kamol Upakaew of the Thai Network of People Living With HIV/AIDS said that although the conference theme of Access for All is an "admirable goal," it is not likely to happen, according to the Associated Press (Associated Press, 7/6). Russell said that in the two years since the 2002 International AIDS Conference in Barcelona, Spain, six million people have died from AIDS-related causes and another 10 million have tested HIV-positive, adding, "The lessons that the international comm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nity has been unwilling to learn in countries in Africa we appear to be poised to relive" elsewhere (Agence France-Presse, 7/6).\par Webcasts and other coverage of the XV International AIDS Conference will be available online at kaiserne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 work.org/aids2004. Kaisernetwork.org will serve as the conference's official webcaster.\par San Francisco Chronicle Continues Five-Part Series Examining AIDS in India\par [Jul 07, 2004]\par In advance of the XV International AIDS Conference in Bangkok, Thailand, next week, when "[w]orld atte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion will focus on the threat AIDS poses to Asia," the San Francisco Chronicle on Sunday began a five-part series on AIDS in India. Experts believe that the "key" to HIV/AIDS trends in Asia lie with India, the most populous nation in the world, according to the Chronicle. Other articles in the series focused on women and AIDS; AIDS among the country's commercial sex workers; and prevention campaigns at truck stops (Kaiser Daily HIV/AIDS Report, 7/6). A summary of the fourth article in the series appears below:\par "Drugs for a Few: Disease Strikes Five Million--Only the Lucky Get Medicine, Government's Slack Taken up by Tireless Informal Network:" Although there are more people living with HIV in India than in any other cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 try besides South Africa, HIV/AIDS prevention is "underfunded, treatment is spotty" and access to brand-name drugs is a "luxury saved for the wealthy or the lucky," the Chronicle reports. However, India's "best weapon" against AIDS may be its "vast network" of "mom-and-pop" nongovernmental organizations that a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dress the disease, according to the Chronicle.\par Chronicle medical writer Sabin Russell traveled to India for five weeks earlier this year as part of a fellowship from the Kaiser Family Foundation (Russell, San Francisco Chronicle, 7/7).\par Drug Access\par World Trade Organization Generic Drug Deal Not Being Implemented, Leaving Developing Countries Wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out Antiretrovirals, UNAIDS Says\par [Jul 07, 2004]\par Some countries have not taken steps to implement a World Trade Organization agreement that allows d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 veloping countries to waive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws to import generic drugs, including antiretroviral drugs, UNAIDS E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ecutive Director Peter Piot said, Reuters reports (Reuters, 7/6). WTO negotiators in August 2003 reached an agreement to allow developing countries to issue a compulsory license in order to import generic drugs if the country confirms that it cannot domestically manufacture them (Kaiser Daily HIV/AIDS Report, 5/24). Only Mozambique, Malaysia and Canada have adopted legislation to implement the agreement, Piot said on Tuesday (Reuters, 7/6). The Canadian Parliament in May adopted a bill (C-9) that would would amend the country's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws to permit the government to order the override of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to allow certain pharmace}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tical manufacturers to produce and export generic drugs -- including antiretrovirals -- for use in developing countries (Kaiser Daily HIV/AIDS Report, 5/13). Although the price of antiretrovirals in developing countries has decreased by more than 90%, only 440,000 of the six million people in the developing world that need treatment have access to the drugs, Reuters reports. Piot also said that it is important to ensure that the quality of generic antiretroviral drugs matches that of brand-name drugs. "We don't only want and need cheap drugs, we need top quality medicines," Piot said, adding, "There is no compromise possible on quality ... that would be immoral" (Reuters, 7/6).\par The San Francisco Chronicle on Wednesday profiled Indian pharmaceutical company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  which produces the generic fixed-dose combination antiretroviral Triomune and other antiretrovirals (Russell, San Francisco Chronicle, 7/7). Triomune combines three different medicines into one pill that is taken twice a day and costs as little as $140 per person per year (Kaiser Daily HIV/AIDS Report, 4/29). The full article is available online.\par Lack of Political Will, Drug Shortages Impede South African AIDS Drug Program, Study Says\par [Jul 07, 2004]\par A lack of political will and a shortage of antiretroviral drugs have impeded the rollout of South Africa's natio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al antiretroviral drug program, according to a report released on Saturday by the South African treatment a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vocacy group Treatment Action Campaign and the AIDS Law Project of Johannesburg, South Africa's Witw}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tersrand University, AFP/Independent Online reports. TAC and ALP compiled the report -- the "First Monito}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing Report of the Antiretroviral Rollout," which is the first to measure progress since the plan was announced in November 2003 -- using information from provincial health departments and from the South African D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 partment of Health (AFP/Independent Online, 7/3). Officials expect 50,000 HIV-positive people to be on a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral drugs by the end of the year and 1.4 million people to be on the drugs by 2009, at a total cost of $700 million (Kaiser Daily HIV/AIDS Report, 4/27). However, the report says that during the seven months after the plan was announced, less than 10,000 people have started treatment (AFP/Independent Online, 7/3). Sibani Mngadi, a spokesperson for South African Health Minister Manto Tshabalala-Msimang, said that the number of people currently receiving antiretroviral treatment is less than 5,000, AFP/Yahoo! News r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ports. Mngadi also said that there are slightly more than 30 health facilities that provide antiretrovirals throughout South Africa, according to AFP/Yahoo! News (AFP/Yahoo! News, 7/6). Although the district and provincial governments have put a "great deal of effort" into implementing the program, the national gover}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment has not "matched" the effort, the report said. In addition, the report said that communication about the plan was "extremely weak," adding that the health department "violate[d] the right to access health care se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices by operating secretly and refusing to make important information available" (Health-e News, 7/5). For example, although lists of approved treatment sites are available on the internet and to the media, the list of treatment sites has not been published for "ordinary South Africans who have some access to radio, telev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sion and/or newspapers," the report said, adding that television advertisements about the program have "disappeared" ("First Monitoring Report of the Antiretroviral Rollout," 7/3).\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (96%); EPIDEMICS (90%); AIDS & HIV REPORTING (90%); DISEASE REPOR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (89%); EPIDEMIOLOGY (89%); DISEASES & DISORDERS (89%); POPULATION SIZE (79%); TRENDS (78%); POPULATION & DEMOGRAPHICS (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS511110 NEWSPAPER PUBLISHERS  (82%); SIC2711 NEWSPAPERS: PUBLISHING, OR PUBLISHING & PRINTING (82%); NAICS511110 NEWSPAPER PUBLISHERS (82%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KAISER DAILY HIV (97%); KATHLEEN CRAVERO (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASIA (96%); CHINA (79%); AFRICA (79%); INDONESIA (79%); SUB SAHARAN AFRICA (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FINANCIAL TIMES LTD (65%);  CHICAGO TRIBUNE (61%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 7, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda;Patients Worried of Aids Drugs Africa News July 5, 2004 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_220}{\*\bkmkstart DOC_ID_220_0}{\*\bkmkstart doc_id_82}{\*\bkmkend DOC_ID_220}{\*\bkmkend DOC_ID_220_0}{\*\bkmkend doc_id_82}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_82"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 82 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2004 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda;\par Patients Worried of Aids Drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Monitor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 277 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HIV/Aids activists have raised the red flag after the World Health Organisation (WHO) refused to endorse two common generic drugs used to treat HIV/Aids.\par The medicines, which are made by Indian generic drugs giant, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , were taken off WHO's list of pre-qualified drugs after they failed to meet the health standards during a regular review in June. \par "Many patients use these drugs. It's alarming that they have been disqualified. What are patients expected to do," asked Maj. Rubaramira Ruranga of the National Guidance and Empowerment Network for People Living with HIV/Aids.\par In June, WHO announced that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Lamivudine (3TC) and Zidovudine (AZT) tablet offerings had failed a crucial bio-equivalence test. The test is done by checking the blood of volunteers to determine whether levels of the generic drug are similar to the original medicine made by the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder.\par GlaxoSmithKline holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . On Saturday, the head of drug testing at the Ugandas National Drug A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thority, Florence Nakachwa, told The Monitor that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders were locking horns with generic drug ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ufactures that made cheaper versions of their innovations.\par "Our responsibility is to offer cost-effective solutions to poor Ugandans who desperately need the drugs. We cannot afford patented ones," she said.\par Ms Elizabeth Namagala, the in charge of anti-retroviral drugs in the Ministry of Health, earlier told said WHO's decision did not affect the batch of the free Aids drugs that were recently distributed in different ce}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tres.\par "They were not among the drugs we brought in," she said. "But the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  drugs will be back on the list within a month."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (94%); GENERIC DRUGS (93%); AIDS & HIV (93%); ANTIVIRALS (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); HEALTH DEPARTMENTS (90%); PRESCRIPTION DRUGS (90%); PUBLIC HEALTH ADMINISTRATION (90%); PHARMACEUTICALS INDUSTRY (78%); PHARMACEUTICAL PRE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ARATION MFG (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (94%); WORLD HEALTH ORGANIZATION (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UGANDA (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (53%);  UGANDAS NATIONAL DRUG AUTHORITY (73%); WORLD HEALTH ORGANISATION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 6, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Study Finds Generic AIDS Drug Effective The New York Times July 2, 2004 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_221}{\*\bkmkstart DOC_ID_221_0}{\*\bkmkstart doc_id_83}{\*\bkmkend DOC_ID_221}{\*\bkmkend DOC_ID_221_0}{\*\bkmkend doc_id_83}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_83"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 83 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  2, 2004 Friday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Study Finds Generic AIDS Drug Effective}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By DONALD G. McNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 1; Foreign Desk; Pg. 5\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 859 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The first clinical trial of generic AIDS drugs in a simple 3-in-1 pill has found that they work as well as brand-name drugs, researchers are reporting today. \par    Because of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  problems, brand-name drugs for first-line treatment do not come in 3-in-1 pills, and medicines that are deeply discounted for poor countries by their makers usually still cost more than generics.\par    The issue is important because the United States has refused to let the $15 billion that President Bush has committed to fighting AIDS in the third world be used for generic drugs, arguing that there is not enough proof they are effective.\par    Normally, the makers of generics need only prove that their drugs are chemically identical to brand-name drugs. But because of the skepticism about generics, Doctors Without Borders, a charity that wants to use the drugs widely in Africa and Asia, and the University of Montpellier's Research Institute for Development in France, which does scientific research benefiting poor countries, did the study to confirm that the drugs worked in the field. \par    The research was overseen by the French National Agency for Research on AIDS, a leading European research institution, and was published in the July 3 issue of the medical journal The Lancet.\par    The trial followed 60 patients in two hospitals in Cameroon for 24 weeks who took Triomune, a combination of nevirapine, stavudine and lamivudine made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. of Mumbai, India. The drugs are also known as NVP, d4T and 3TC or under the brand names Viramune, Zerit and Epivir.\par    One Triomune pill is taken twice a day, which helps patients take all their medicine and makes it nearly impossible to sell or give away part of a handful of pills -- a practice, common in poor countries, that can e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 courage the virus to mutate drug-resistant strains and kill patients.\par    Nearly all the patients in Cameroon were in advanced stages of AIDS. By the end of the trial, 80 percent had the amount of virus circulating in their blood driven to very low levels. Most had increases in CD-4 cells, the immune-system cells that the virus attacks. \par    Most importantly, said Dr. Michel Kazatchkine, director of France's AIDS research agency, the levels of the three drugs in the blood was the same as would be expected from three mainstream drug brands. \par    A spokesman for the Pharmaceutical Research and Manufacturers of America, the lobbying group for the brand-name drug industry, said it had no comment on the study.\par    Only one patient dropped out because of adverse drug reactions.\par    Dr. Richard G. A. Feachem, executive director of the Global Fund to Fight Aids, Tuberculosis and Malaria, called the study ''extremely good news.'' \par    The fund buys generics approved by the World Health Organization, including Triomune, so ''this gives strong scientific support for the procurement policies the Global Fund has been pursuing for 18 months,'' he said.\par    Dr. Kazatchkine said it would also reassure African countries that had been buying W.H.O.-approved g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nerics because they were the cheapest.\par    The Bush administration, under the president's emergency plan for AIDS relief, will not yet buy generic AIDS drugs, a stance that has put it in opposition to the rest of the world.\par    But on May 16, the Bush administration announced that companies that make generic drugs could apply to have their drugs approved by the Food and Drug Administration and that the usual $500,000 application fee would be waived. \par    None have applied yet, but several are expected to soon, said Dr. Mark R. Dybul, the medical adviser to the office of Randall L. Tobias, the administration's global AIDS coordinator.\par    Several calls and messages to Ambassador Tobias's office asking for comment on the Lancet study were not returned. \par    }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was not involved in the Cameroon study, said Amar Lulla, the company's joint managing director, and he said he had not seen the Lancet article. But ''it is not surprising,'' he said, after reading a copy. An unpublished study of 1,200 patients in India followed for two years ''found that our drugs are clinically effic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cious,'' he said. \par    Similar pills are made by Ranbaxy Laboratories Ltd., another Indian company. Companies in South Africa, Brazil and elsewhere are expected to follow suit. \par    As of last month, Doctors Without Borders was treating 13,000 patients in poor countries with 3-in-1 pills made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or Ranbaxy.\par    ''We're getting good results in weight gain, CD-4 rise and viral load,'' said Daniel Berman, co-director of the medical charity's campaign for access to inexpensive drugs. \par    The only brand-name antiretroviral in a 3-in-1 pill is GlaxoSmithKline's Trizivir, which the company co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cedes is not an ideal starting regimen because it consists of three drugs in the same class, instead of a mix of classes.\par    In the past, brand-name companies said they could not cooperate to combine their drugs into one pill out of fear of prosecution under antitrust laws. But when the Bush administration made its May 16 announcement, which also encouraged the development of 3-in-1 pills, five brand-name companies quickly said they would discuss collaborating.      \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (97%); AIDS & HIV TREATMENT (93%); GENERIC PRODUCTS (92%); GENERIC DRUGS (92%); PRESCRIPTION DRUGS (91%); ANTIVIRALS (91%); MEDICAL CHARITIES (90%); R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEARCH INSTITUTES (90%); INTERNATIONAL ASSISTANCE (90%); RESEARCH REPORTS (90%); PHARMACEUTICALS PRODUCT DEVELOPMENT (90%); INTERNATIONAL RELATIONS (90%); DEVE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPING COUNTRIES (90%); PHARMACEUTICALS INDUSTRY (89%); INFECTIOUS DISEASE (87%); E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PERIMENTATION & RESEARCH (78%); MALARIA (78%); HEALTH DEPARTMENTS (78%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL CHEMISTRY (78%); CLINICAL TRIALS (78%); CHEMICALS RESEARCH (78%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MFG (78%); ADVERSE DRUG EVENT REPORTING (78%); MEDICAL R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEARCH (78%); PHYSICIANS & SURGEONS (77%); PHARMACEUTICALS ASSOCIATIONS (76%); LO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BYING (75%); RELIEF ORGANIZATIONS (73%); DRUG INTERACTIONS & SIDE EFFECTS (73%); PU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LIC HEALTH ADMINISTRATION (73%); TUBERCULOSIS (73%); PHARMACEUTICALS TRADE (73%); DRUG RESISTANCE (73%); SCIENCE FUNDING (72%); VIRUSES (72%); EXECUTIVES (70%); SCIENCE NEWS (67%); SCIENCE & TECHNOLOGY (67%); UNITED NATIONS INSTITUTIONS (67%); APPROVALS (66%) Acquired Immune Deficiency Syndrome; Drugs (Pharmaceuticals); Generic and Brand Name Pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts; Foreign Aid; United States International Relations; Third World and Developing Countries; Acquired Immune Deficiency Syndrome\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (82%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DOCTORS WITHOUT BORDERS (83%) Doctors Without Borders  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (82%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (82%); SIC2834 PHARMACEUTICAL PREPARATIONS (82%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (79%) Donald G Jr Mcneil; George W (Pres) Bush\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (54%) UNITED STATES (93%); CAMEROON (92%); ASIA (92%); AFRICA (92%); FRANCE (90%); INDIA (79%); SOUTH-EASTERN ASIA (79%) Africa; Far East, South and Southeast Asia and Pacific Areas\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 2, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;World Health Body Scraps Two Generic Antiretrovirals Africa News June 18, 2004 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_222}{\*\bkmkstart DOC_ID_222_0}{\*\bkmkstart doc_id_84}{\*\bkmkend DOC_ID_222}{\*\bkmkend DOC_ID_222_0}{\*\bkmkend doc_id_84}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_84"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 84 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2004 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par World Health Body Scraps Two Generic Antiretrovirals}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Cape Argus\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 263 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Health Organisation has pulled two generic anti-retroviral drugs from its approved HIV drugs list, but al}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 hough the two are registered in South Africa, they are not being administered in the Western Cape.\par The SA Medicines Control Council is investigating the drugs, registrar Precious Matsoso said at a briefing ahead of Health Minister Manto Tshabalala-Msimang's budget speech in parliament yesterday. \par According to an article in the New York Times on Wednesday, the two drugs are made by Indian company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  They are both generic drugs: lamivudine, also known as 3TC, and zidovudine, also known as AZT.\par Lembit Rago, an official of the Geneva-based organisation, is quoted as saying the problem lay in a routine check which found the manufacturer had not proved its generic versions were biologically equivalent to the patented drugs.\par The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the two drugs is held by GlaxoSmithKline.\par Dr Fareed Abdullah, head of the Western Cape's Aids programme, moved quickly yesterday to avert fears, saying that although the two drugs were used in treatment programmes here, these are branded products and not generic versions.\par The first-line treatment in the Western Cape includes the anti-retrovirals 3TC, D4T and efavirenz.\par Tshabalala-Msimang used the delisting yesterday to support her contention that the anti-retroviral roll-out should be done slowly and with all necessary caution.\par "Now even the WHO is beginning to withdraw ARVs from the market," she said.\par "Some of our people are on these medicines and we need to re-sit around the table."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (97%); GENERIC DRUGS (94%); AIDS & HIV TREATMENT (91%); AIDS & HIV (91%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PHARMACEUTICALS INDUSTRY (78%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICAL PREPARATION MFG (77%); HEALTH DEPARTMENTS (73%); PUBLIC HEALTH ADMINISTRATION (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HEALTH ORGANISATION (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MANTO TSHABALALA-MSIMANG (78%); GLAXOSMITHKLINE (53%);  HEALTH ORGANIS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 18, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 U.N. Agency Drops 2 Drugs For AIDS Care Worldwide The New York Times June 16, 2004 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_223}{\*\bkmkstart DOC_ID_223_0}{\*\bkmkstart doc_id_85}{\*\bkmkend DOC_ID_223}{\*\bkmkend DOC_ID_223_0}{\*\bkmkend doc_id_85}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_85"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 85 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  16, 2004 Wednesday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 U.N. Agency Drops 2 Drugs For AIDS Care Worldwide}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By LAWRENCE K. ALTMAN and DONALD G. MCNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 1; Foreign Desk; Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 541 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The World Health Organization has pulled two generic antiretroviral drugs from its list of approved H.I.V. drugs that are most often used in poor countries, saying a routine check found the manufacturer had not proved that they were biologically equivalent to patented drugs.\par  It is the first time that W.H.O. has removed any H.I.V. drug from its list, Lembit Rago, an official of the Gen}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 va-based agency, said yesterday.\par  Dr. Rago said the problem was found during routine tests that the agency conducts among drugs it finds acceptable for procurement by United Nations agencies. But, he said, the problem was not expected to inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fere with W.H.O.'s initiative to treat three million H.I.V.-infected people, mostly in Africa, by next year. \par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , an Indian company that has been in the forefront of getting generic drugs approved for use in poor countries, made the two generic drugs, lamivudine, which is also known as 3TC, and zidovudine, which is also known as AZT.\par  The action follows the Bush administration's recent announcement of a significant shift in its AIDS policy to allow the purchase of cheaper generic drugs for Africa and the Caribbean. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said the situation was ''on the mend'' and that it expected its drugs to be put back on the list within a matter of weeks.\par  The problem was detected during an inspection of an independent laboratory that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had hired to co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duct bioequivalence studies among volunteers whose blood had been tested after they took the generic drugs. The tests were devised to determine whether the concentration of the generic drug in the blood was the same as in its patented counterpart. Dr. Rago did not provide the name of the company that did the tes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing.\par  A review found that the company's documents did not meet the standards known as good clinical and labo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 atory practice, Dr. Rago said in a telephone interview from Washington, where he was attending a meeting.\par  Despite the inspection's findings, the generic drugs may be bioequivalent to the patented drugs. But W.H.O. had to remove them because the documentation was lacking, Dr. Rago said.\par  Inspections have found similar problems with the bioequivalency of many drugs in countries in Europe and the United States, Dr. Rago said. He also said many developing countries do not require bioequivalency tes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing.\par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  chairman, Dr. Yusuf K. Hamied, said the problem was due to inadequate record keeping in the tes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing laboratory in Bombay. Dr. Hamied, reached by telephone in London, said that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  lamivudine has been tested for bioequivalency in a laboratory in the United States and approved by the Food and Drug A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ministration and that he would submit that data to the health agency. \par  Dr. Hamied said the testing was done for the American drug agency because }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  hopes to sell generic lamivudine when an American }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expires in 2006.\par  W.H.O. did not issue a news release about the problem after it was detected in May. Dr. Rago said such an announcement was not necessary because his agency had informed other United Nations agencies about the problem and had posted the delisting on its Web site, www.who.int.\par  GlaxoSmithKline of Britain holds the American }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on lamivudine (3TC) and zidovudine (AZT).                              \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (94%); ANTIVIRALS (93%); AIDS & HIV (93%); PUBLIC HEALTH ADMI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ISTRATION (91%); AIDS & HIV TREATMENT (91%); UNITED NATIONS INSTITUTIONS (90%); HEALTH DEPARTMENTS (90%); GENERIC PRODUCTS (90%); INTELLECTUAL PROPERTY LAW (89%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PROVALS (89%); US FEDERAL GOVERNMENT (89%); TEST LABORATORIES (89%); DRUG & MEDICAL DEVICES APPROVAL (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); INSPECTIONS (89%); DEVELO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING COUNTRIES (89%); PHARMACEUTICALS INDUSTRY (78%); US FDA APPROVALS (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (77%); INTERVIEWS (76%); AIDS POLICY (74%) Acquired Immune Deficiency Syndrome; Drugs (Pharmaceuticals); Generic and Brand Name Products  ; Lamivudine-3tc (Drug); Zidovudine (Drug); Tests and Testing; Acquired Immune Deficiency Syndrome\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (83%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (93%); UNITED NATIONS (91%); FOOD & DRUG ADMINISTRATION (59%) World Health Organization; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd; Food and Drug Administration\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (83%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (83%); SIC2834 PHARMACEUTICAL PREPARATIONS (83%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Lawrence K Altman; Donald G Jr Mcneil\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (51%) UNITED STATES (95%); AFRICA (93%); EUROPE (79%); CARIBBEAN ISLANDS (79%) Africa\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 16, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore June 7, 2004 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_224}{\*\bkmkstart DOC_ID_224_0}{\*\bkmkstart doc_id_86}{\*\bkmkend DOC_ID_224}{\*\bkmkend DOC_ID_224_0}{\*\bkmkend doc_id_86}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_86"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 86 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Indian drug firms stand to gain much from WTO talks;\par Potential to carve out slice of US$15b US generics market}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  7, 2004 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Yogi Aggarwal in Bombay\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A HUGE opportunity awaits Indian pharmaceutical companies - if India plays its cards right during the u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 coming World Trade Organisation (WTO) negotiations.\par A research report by investment bankers JM Morgan Stanley says Indian companies have opportunities in the US$15 billion generics market in the US, and can also expect to capture a part of the US$33 billion ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ket in challenging }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for drugs that have been unduly extended by US and European companies.\par Other segments where Indian companies could score is in novel drug delivery systems and subcontracting much of the research to develop new drugs.\par In a document called Vision 21, global consulting firm McKinsey & Co estimated the total market for Indian companies to be around US$25 billion by the end of the decade, up from around US$7 billion now. \par T R Gopalakrishnan, assistant secretary general of the Indian Drug Manufacturers Association, the leading industry body, said: 'Everything boils down to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime that is coming.\par 'If there are balanced }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws that allow Indian companies to export freely as per the Doha Declaration (of the WTO) under conditions agreed upon under Trips (trade-related intellectual property rights), the going will be good. But non-trade barriers should not be allowed to distort trade.'\par Under the 1970 Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Act, pharmaceutical companies in India used 'reverse engineering' to man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facture drugs to bypass US }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws. This has enabled them to manufacture drugs for the Indian market at less than one-tenth the cost in the West.\par But multinational companies have vigorously opposed Indian companies' attempts to develop cheaper drugs, including anti-Aids drugs. Indian companies like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  could sell an anti-Aids drug in Africa for as little as US$250 for a year's treatment, compared to a cost to the patient of US$15,000 a year using Western form}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lations.\par William Haddard, a US expert on generic drugs, commented: 'The poor nations of the world now look to India to provide them with safe, effective and affordable medicines. But it is ironic that India, with enormous pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lems of its own, should be the hope of the Third World.'\par US and European pharmaceutical companies, meanwhile, have been furious at the enormous loss in profits, and the matter has not yet been fully settled despite the acrimony. With the rules of the game changing in 2005 - when }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws are to be more strictly enforced - the fine print of the new rules will become more important.\par Some points of contention are compulsory licensing to manufacture drugs in developing countries in times of emergency, and whether the cut-off date for allowing the manufacture of patented drugs by third countries is 1995 or 2005.\par If India handles its case at the WTO well, there could be tremendous opportunities after 2005. Drugs with an annual sale of some US$55 billion to US$65 billion are going off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the next five years. But the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders can be counted on to try all manner of stratagems to extend the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  periods.\par Despite a price erosion to around one-forth the original price, the market is still worth around US$15 billion, and Indian companies should be able to capture at least part of this potential.\par Indian companies could also be a subcontractor for the testing of a new drug. It costs some US $600 million to US$900 million to develop a new molecule, much of this cost in testing. A McKinsey & Co. report says I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dian companies could get a chunk of this by conducting clinical trials.\par Bioinformatics is also a very promising area with a market potential of US$2 billion. While India has been lax in exploiting the potential of its indigenous herbal systems of medicine, this could change in the next decade.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  PHARMACEUTICALS INDUSTRY (94%); PHARMACEUTICAL PREPARATION MFG (93%); PATENTS (91%); TRADE DEVELOPMENT (91%); PHARMACEUTICALS ASSOCIATIONS (90%); PATENT LAW (90%); INTELLECTUAL PROPERTY LAW (90%); INTERNATIONAL TRADE (90%); PHARMACEUTICALS PATENTS (89%); GENERIC PRODUCTS (89%); INTERNATIONAL ECONOMIC ORGANIZATIONS (89%); AIDS & HIV TREATMENT (78%); DRUG DELIVERY SYSTEMS (78%); DRUG DESIGN & DISCOVERY (78%); EXPORT TRADE (78%); ENGINEERING (78%); MULTINATIONAL CORPORATIONS (78%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TELLECTUAL PROPERTY (78%); GENERIC DRUGS (78%); DEVELOPING COUNTRIES (78%); INVES}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT BANKING (77%); CONSULTING SERVICES (74%); REVERSE ENGINEERING (71%); \par \par  CIPLA LTD (90%); MCKINSEY & CO INC (83%); MORGAN STANLEY (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE NEWS; South Asia\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 632 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 6, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The lab pirates teaching the West how to fill the world's prescriptions India's pharmaceutical expertise is fast making it a global player, writes Rosie Murray-West THE DAILY TELEGRAPH(LONDON) June 01, 2004, Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_225}{\*\bkmkstart DOC_ID_225_0}{\*\bkmkstart doc_id_87}{\*\bkmkend DOC_ID_225}{\*\bkmkend DOC_ID_225_0}{\*\bkmkend doc_id_87}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_87"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 87 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE DAILY TELEGRAPH(LONDON)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  01, 2004, Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 The lab pirates teaching the West how to fill the world's prescriptions India's pharmaceutical expertise is fast making it a global player, writes Rosie Murray-West}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Rosie Murray-West\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 City Pg. 31\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1207 words\par \par HAVE you ever heard of a company called Ranbaxy? If not, check your medicine cabinet - you'll probably find at least one of its products among the stash of prescription pills you should have thrown out years ago.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 There may be a few other names you don't recognise nestled among the products branded Glaxo Smithkline and Astrazeneca. If you find capsules made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Dr Reddy's too, then your medicine cabinet is more authentically Indian than the chicken tikka masala you had last night.\par Don't be alarmed - unless, of course, you're a scientist in a UK pharmaceutical company. The employees who have developed and then made these drugs are probably far better qualified than their counterparts here, and many of them speak better English too. However, they cost far less to employ than you or me, which is just one of the reasons why India is driving a coach and elephants through the world's pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal industry. \par India already produces 22pc of the world's generic drugs, and is expected to capture a third of this vast ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ket by 2007. But now it wants to become dominant in pharmaceutical research and development too. Last October, Glaxo announced that it had signed a research and development deal with Ranbaxy - setting off alarm bells all over the industry. After all, Ranbaxy's $1billion of sales last year were built on making cheap copies of existing drugs, a process that Sir Richard Sykes, former Glaxo chairman, once likened to 17th-century piracy.\par But far from suggesting that Ranbaxy's staff should be sporting wooden legs and parrots, Glaxo's chief e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ecutive, Jean-Pierre Garnier, believes that 200 scientists in a business complex just outside Delhi can help him discover early stage drugs. Glaxo itself employs 16,000 research scientists.\par What has India got that the UK hasn't? Apart from the obvious cost benefits, it has some stunning expertise. There has been such a relaxed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime in India that companies such as Ranbaxy have been legally cloning new drugs for years - getting round what laws there are by refining the manufacturing of the products in a process called reverse engineering.\par It is a skill they can apply to new products as well. Recently, Ranbaxy's scientists slightly embarrassed the rest of the world's research and development experts by producing a once-a-day version of Bayer's patented antibiotic Ciprobay, which the German giant had not managed itself. It then licensed the technology back to Bayer - getting a fat royalty for its trouble.\par This is how Ranbaxy - once a small family-run generic drug company, has turned itself into a global powe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 house with a valuation that would grace the FTSE 100. It is also the only Indian company headed by a Bri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 on. Brian Tempest, once a scientist at Beecham, reckons he now feels more at home in Delhi than in his n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive Lancashire. "Sometimes, I look in the mirror and I think, 'who's that white guy?'," he said.\par However well the company is growing, it is about to face the challenge of its life. India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws are b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing brought into line with the rest of the world next year, meaning that you will no longer be able to buy cut-price versions of the whizziest new products in the back streets of Delhi. It also means that Ranbaxy, Re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dy's and the rest are going to have to find some other way of making money. Mr Tempest reckons his co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany can become a research-based business, competing directly with giants such as Pfizer, Glaxo and AstraZeneca, by concentrating on the business areas in which it excels such as urology, anti-infection drugs and respiratory drugs.\par "We can spend less, and get more", he says. Every room in the Ranbaxy complex carries a copy of the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany's mission statement, and every Ranbaxian (as they call themselves), can quote it. By 2012 the comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ny wants to be a $5billion business with a strong presence in proprietary prescription products - that's the stuff that isn't generic. Given the determination with which it seems to pursue its goals, the likes of Glaxo should be very afraid.\par The company, like its Indian rivals, is concentrating on bringing back homegrown talent which has fled to the US. The head of R&D, Dr Rashmi Barbhaiya, spent 23 years with Bristol Myers Squibb in New Jersey. "There was an opportunity here, which is why I came back," he said. "India is on the cusp of becoming a global player in the pharmaceutical industry."\par He hopes to have 300 research scientists by the end of the year, many of them Indian nationals lured back from the States by the possibility of an exciting career nearer home. His research facility is in the business complex of Gurgaon, Delhi's version of Canary Wharf, where many other Indian pharmaceutical companies are also setting up shop.\par There may be cows wandering around outside, but inside the research and development laboratories ever}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thing is shiny and clean. "Pharmaceuticals is going to be the next big thing in India after IT," says Mr Barbhaiya. "We've been in contact with 16 Indian-born scientists in the US and many of them have accepted jobs here. I'm tremendously excited." By his estimates, one in ten researchers in US pharmaceutical comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies are Indian-born. He describes the Glaxo collaboration as "just a small part of what we are doing".\par Outside the area of research, too, the Indian pharmaceutical industry has huge advantages. In Dewas, in the centre of the country, Ranbaxy has been producing pills and potions for years.\par The facility is approved by the US FDA - seen by many as the gold standard for pharmaceutical regulation - as well as a number of other drug regulators. Inside, all is sparkling, and workers wearing a variety of strange-looking protective gear are churning out drugs Britons will pick up from their chemist in six weeks' time.\par Most of the factory's workers have degrees in a relevant science, yet the starting wage is just 10,000 rupees a month (under pounds 130). "It's a very good salary, much more than they make in the call centres," says a factory manager. It's not a labour rate more developed countries can match.\par The same goes for carrying out contract clinical trials, not an area that Ranbaxy has gone into, but Indian rivals are linking with global pharma businesses to carry out clinical trials more cheaply. "We've got all the diseases under the sun here," said one executive. "It's cheap, too". Some detractors are alarmed about ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing India into the world's drug testing centre from an ethical perspective, but economically it certainly makes sense. Chief executives, including Mr Garnier, have said recently that they expect to do more of their drug testing in India.\par Even the recent shock election result, which pushed the pharmaceutical companies' shares down sharply, hasn't dented Ranbaxy's confidence. Asked how the company saw the elections, a spokesman said: "The industry is looking for a stable government that can provide economic progress, and carry the reforms pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cess forward. The cabinet is balanced, and the industry holds Mr Chidambaram [the new finance minister] in high esteem."\par Whatever happens politically, India's pharmaceutical juggernaut looks unstoppable. The rest of the world can only jump on the back and hold on for the ride.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); PHARMACEUTICAL PREPARATION MFG (90%); PRESCRIPTION DRUGS (90%); RESEARCH & DEVELOPMENT (89%); GENERIC DRUGS (89%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (86%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (85%); REVERSE ENGINEERING (78%); EXPERIMENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION & RESEARCH (78%); DRUG DESIGN & DISCOVERY (77%); NEW PRODUCTS (76%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS PRODUCT DEVELOPMENT (76%); CHEMICALS RESEARCH (75%); PHARMACEUTICAL CHEMISTRY (75%); ANTIBIOTICS (73%); FAMILY COMPANIES (73%); EXECUTIVES (63%); STOCK I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DEXES (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); BIOC (EGX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (90%); AZN (STO) (90%); AZN (NYSE) (90%); AZN (LSE) (90%); RANBAXY (NSE) (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (90%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JEAN-PIERRE GARNIER (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (93%); UNITED KINGDOM (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DELHI, INDIA (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (90%); ASTRAZENECA PLC (90%); RANBAXY LABORATORIES LTD (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 1, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Telegraph Group Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Drugs for the Poor Collect Dust As Council Drags Its Feet Africa News April 18, 2004 Sunday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_226}{\*\bkmkstart DOC_ID_226_0}{\*\bkmkstart doc_id_88}{\*\bkmkend DOC_ID_226}{\*\bkmkend DOC_ID_226_0}{\*\bkmkend doc_id_88}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_88"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 88 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2004 Sunday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Drugs for the Poor Collect Dust As Council Drags Its Feet}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sunday Times\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 559 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Medicines Control Council (MCC) is restricting public access to affordable medicines by delaying their registration for years, generic drug companies charged this week.\par South Africa' s third-largest generic manufacturer, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro, supported by other pharmaceutical comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies, has instructed its attorneys to take action.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro has more than 60 products waiting for registration and a large number of them had met the MCC's requirements for safety and efficacy, the company contends. It said one of the drugs was a generic of nevirapine, a key Aids drug required for the government's treatment programme. \par The MCC approved the drug in April 2003, but had still not authorised the package insert, thereby preventing registration. The approval of package inserts was the final step before registration - and this was holding up more than half the products.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro's chief executive Jerome Smith said: "Such approval should really be no more than an admi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istrative formality."\par He added that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  had instructed its attorneys "to take all and any steps as may be necessary to address the situation" because it had been unable to resolve the problem through "discussion, negotiation and co-operation with the MCC and the Registrar of Medicines [Precious Matsoso]".\par Another manufacturer, who asked not to be identified, released figures showing that the registration time for its products had more than doubled since 1998.\par At that time, it took an average of 15 months to register 12 of its products. By 2002 this had risen to 41 months for 13 products.\par Another manufacturer said that, on average, it took about 39 months to register a product.\par MCC chairman Professor Peter Eagles responded to the complaints, saying: "The MCC is committed to re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istering drugs in as short a time as possible."\par But an executive of another generic company said of the registration delays: "There's an absolute deadlock. If you say something against them, you're put at the bottom of the pile.\par "You can get two, three or four companies that are inefficient, but it's unlikely that 120 companies will all be inefficient at once."\par He also claimed that the MCC was "delaying the registration of new chemical entities which could treat co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ditions where there aren't currently drugs to treat them".\par Dr Mzi Mabenge, the executive director of the National Association of Pharmaceutical Manufacturers, said he was against taking legal action, as the MCC was looking at a way to speed up the package insert pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lems by authorising package insert templates.\par Although Mabenge advocated a conciliatory approach to the council in the monthly meetings of the Industry Task Group - saying that members largely supported this approach - other members maintained that it had failed.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Medpro medical adviser Dr Skhumbuzo Ngozwana said: "The executive director has, in the past, r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 peatedly tried to set up meetings with the MCC, and has repeatedly been rebuffed."\par Ngozwana proposed to other association members that they ask the Health Ministry or presidency to inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vene - since the delays conflicted with the government's support for generic drug use.\par Vicki Ehrich, chief operating officer of the Pharmaceutical Manufacturers' Association, which represents the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -protected industry, declined to comment on the matter.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); GENERIC DRUGS (91%); APPROVALS (90%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC PRODUCTS (90%); HEALTH CARE ACCESS (90%); PHARMACEUTICAL PREPARATION MFG (89%); PHARMACEUTICALS ASSOCIATIONS (89%); DELAYS & POSTPONEMENTS (78%); BUSINESS & PROFESSIONAL ASSOCIATIONS (78%); TALKS & MEETINGS (78%); NEW CHEMICALS (78%); LA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 W}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 YERS (77%); AIDS & HIV TREATMENT (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CMP (JSE) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SKHUMBUZO NGOZWANA (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MEDICINES CONTROL COUNCIL (97%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  MEDPRO (90%);  MEDICINES CONTROL COUNCIL (97%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 19, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Activists against Africa;HIV/AIDS fight takes wrong turn The Washington Times April 8, 2004, Thursday, Final Edition \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_227}{\*\bkmkstart DOC_ID_227_0}{\*\bkmkstart doc_id_89}{\*\bkmkend DOC_ID_227}{\*\bkmkend DOC_ID_227_0}{\*\bkmkend doc_id_89}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_89"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00380039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 89 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Washington Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  8, 2004, Thursday, Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Activists against Africa; \par HIV/AIDS fight takes wrong turn}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Robert Goldberg, SPECIAL TO THE WASHINGTON TIMES\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPED; Pg. A19\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 857 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Two million people die from malaria each year. According to the conventional wisdom, many of them died in the past decade because the necessary medicines were unavailable and unaffordable. But that's not true. They died, according to a sobering study by Amir Attaran in the Lancet, a prestigious British medical journal, because the principal group that buys and distributes these drugs - The Global Fund to Fight AIDS, Tuberc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 losis and Malaria - bought cheaper and less effective generic medicines to appease the activist organizations and liberal foundations who fight against intellectual property protections for innovative drugs.\par Mr. Attaran's article clearly showed that the cheaper approach cost more in lost lives and long-term medical expenditures than use of brand-name, newer anti-malarial medicines. The Global Fund and the World Health Organization [WHO] actively lobbied against using the better drugs when the article came out and retreated only after withering editorials in the Wall Street Journal and New York Times endorsed his view. \par Now, the Global Fund and the WHO - with the help of Bill Clinton - are hell-bent on imposing the same failed approach in the procurement and purchase of an untested combination of HIV drugs and shoving it down the throats of Third World countries in a take-it-or-leave-it fashion. At a conference held in Botswana, these o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ganizations joined forces with activists and generic lobbyists to force the United States to spend every dime of its $15 billion AIDS initiative on this deadly dose. Predictably, activists are claiming that the Bush admi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istration's refusal to go along with their generics-only approach is simply an effort to protect the profits of big drug companies.\par That's not true. There are virtually no }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the countries under discussion on any of the drugs in que}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion. According to Doctors Without Borders' own price lists, many of the generic drugs and drug combinations are not cheaper than brand medicines sold at discounted prices. This week, Mr. Clinton recycled a claim made months ago that he's enticed companies to virtually give away their medicines under the right cond}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions in order to put more pressure on the Bush administration. It is simply talk and nothing more: At present, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  the large Indian generic company, has balked at lowering the price for the HIV drugs it sells to the I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dian government.\par The real issue is that African nations want evidence that lumping three generic versions of three HIV drugs into one pill is safe or effective. The WHO and the activists that support it don't want any testing to determine if this combination works or if the drugs' manufacturers - none of whom have to meet any international man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facturer or bioavailability standards - are producing bogus drugs. In doing so, the WHO and activists are i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 noring the WHO's own internationally accepted standards for evidence that drugs are safe and work as promised.\par African public health officials are demanding that their people receive generic medicines that are as good as those Americans get. An official from Botswana's medicines control agency told the WHO that it needed to "hold all drugs to the same high standard. We want to see the data because we have an obligation to protect people. The African regulators aren't being unreasonable by asking the generic companies to show them the data." Eric Kari-Kari Boatleng of Ghana's Food and Drug Board responded to activist fury that Africans wer}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 n't willing to go without American-style quality assurances by stating: "Yes, people are dying in Africa, but should we throw out standards and buy anything?"\par Africans seem to understand what the activists care nothing about. As Precious Matsoso of the Medicines Control Council of South Africa noted, "Poor quality means poor access. We have to keep this in mind as we look for solutions that can turn the tide. We have to balance quality and need." Responding to activists and generic drug lobbyists who were furious at the Africans, Sego Lamelekoko Ramotlhwa, of MASA, the natio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al HIV treatment program arm of the African Comprehensive HIV/AIDS Partnership in Botswana, stated, "Generics should be held to the same standard because bad products have broad implications."\par For many activists, the fight against AIDS is just another front in a more important fight, the fight against medical progress. The very idea that private ingenuity and private investment drive medical progress drives the activists wild. But while they jet around the world fighting their ideological jihad, millions of sick people in the Third World are waiting - and waiting - for the medicines that could save their lives.\par So far the Bush administration and our FDA have stood shoulder to shoulder with these courageous folk. America should continue to work directly with African health officials to assure that the AIDS drugs they are getting are the best medicines money can buy, not the kind of drugs that advance the activists' political agenda.\par Robert Goldberg is director of the Manhattan Institute's Center for Medical Progress.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (91%); MALARIA (91%); EDITORIALS & OPINIONS (90%); GENERIC DRUGS (90%); LOBBYING (90%); AIDS & HIV TREATMENT (89%); PRESCRIPTION DRUGS (89%); US FEDERAL GOVERNMENT (87%); PHARMACEUTICALS INDUSTRY (78%); PUBLIC HEALTH ADMINISTRATION (78%); DRUG PRICES (78%); ANTI-INFECTIVES (78%); PRICE CHANGES (76%); GENERIC PRODUCTS (76%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (75%); INTELLECTUAL PROPERTY LAW (75%); HEALTH DEPARTMENTS (73%); MEDICAL CHARITIES (73%); TUBERCULOSIS (71%); AIDS & HIV POLICY (71%); INTELLECTUAL PROPERTY (71%); PRODUCT INNOVATION (70%); INTERNATIONAL ASSISTANCE (70%); RELIEF O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATIONS (70%); UNITED NATIONS INSTITUTIONS (68%); PRICE CUTTING (67%); PHYSICIANS & SURGEONS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (51%); SIC2834 PHARMACEUTICAL PREPARATIONS (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BILL CLINTON (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (90%); WORLD HEALTH ORGANIZATION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (93%); AFRICA (93%); BOTSWANA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW YORK, USA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WALL STREET JOURNAL (56%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (51%);   WORLD HEALTH ORGANIZATION  (90%); WORLD HEALTH ORGANIZATION (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 8, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Washington Times LLC\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Deal reached for cheaper AIDS drugs; UN, World Bank and other groups join up to send generic medicine to poor countries The Globe and Mail (Canada) April 6, 2004 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_228}{\*\bkmkstart DOC_ID_228_0}{\*\bkmkstart doc_id_90}{\*\bkmkend DOC_ID_228}{\*\bkmkend DOC_ID_228_0}{\*\bkmkend doc_id_90}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_90"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 90 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Globe and Mail (Canada)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2004 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Deal reached for cheaper AIDS drugs; \par UN, World Bank and other groups join up to send generic medicine to poor countries}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MAGGIE FOX, Reuters News Agency\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTERNATIONAL NEWS; Pg. A14\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 551 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WASHINGTON \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The United Nations, the World Bank, the Global Fund to fight AIDS, Tuberculosis and Malaria, along with former U.S. president Bill Clinton announced this morning that they have set up a joint plan to buy and di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tribute cheap, generic AIDS drugs in poor countries.  \par  In a clear jab at the U.S. government, they said they have negotiated discounts of 50 per cent or more on HIV diagnostic tests and on drugs, the safety of which has been questioned by U.S. President George W. Bush's administration. \par  "Simply put, the Clinton Foundation will negotiate the drug prices, Unicef will employ its procurement capac}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty and the Global Fund and World Bank will provide the funding," Stephen Lewis, United Nations Special E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 voy for HIV/AIDS in Africa, announced in a statement. \par  "There will be protocols and administrative requirements, of course, but nothing should now stand in the way of rolling out treatment to hundreds of thousands - soon to be millions - in the immediate future." \par  And they will be cheap, Mr. Lewis said. \par  "We're talking of fixed-dose combinations of generic drugs, prequalified by the World Health Organization, to be purchased overwhelmingly from generic companies based in India, at prices as low as $140 [U.S.] per person per year." \par  This is about a third to one-half of the lowest discounted price now offered. In contrast, HIV cocktails can cost more than $10,000 a year when made with name-brand drugs in industrialized countries. \par  Mr. Bush's AIDS advisers have questioned the safety of these generic drugs and have proposed not using U.S. aid dollars to buy them. But AIDS activist groups, the international relief group M\u200\'e9decins sans fronti\u203\'e8res and some members of the U.S. Congress have accused the administration of bowing to pressure from co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies that make expensive, brand-name HIV drugs. \par  Generic drug-makers have raced to copy the drugs more cheaply, especially in Brazil and India. Mr. Cli}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ton's administration fought those manufacturers at first, then agreed not to oppose them. \par  Spurred to act by Mr. Lewis, the Canadian government introduced a bill last fall allowing countries skirting }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws to copy brand-name drugs in order to help fight AIDS, tuberculosis and malaria in Africa and elsewhere without risk of prosecution. \par  "These medicines are critical components of the four regimens recommended by the World Health Organ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zation as first-line treatment for AIDS," the groups said. "In developing countries outside of Brazil, such life-sustaining therapy is available to fewer than 200,000 people living with the virus, though almost six million require it." \par  The statement named Aspen Pharmacare Holdings in South Africa; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India; Hetero Drugs Limited in India, Ranbaxy Laboratories in India; and Matrix Laboratories in India as the companies participating in the plan. \par  "The prices available for these tests under the agreement include machines, training, regents and maint}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nance and are up to 80-per-cent cheaper than otherwise available in the market," the UN said. \par  "We regard AIDS as being the single most important issue at the moment in Africa because of the devasta}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing effect that it has had throughout the continent, and it is not something that is deferrable to discussions of economic or other issues," World Bank President James Wolfensohn said. \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (95%); GENERIC DRUGS (94%); INTERNATIONAL ECONOMIC ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (93%); ANTIVIRALS (91%); UNITED NATIONS INSTITUTIONS (91%); AIDS & HIV TREATMENT (91%); MALARIA (90%); US PRESIDENTS (90%); PRESCRIPTION DRUGS (90%); DEVELOPMENT BANKS (90%); INTERNATIONAL ASSISTANCE (90%); INTERNATIONAL RELATIONS (90%); PUBLIC HEALTH ADMINISTRATION (89%); HEALTH DEPARTMENTS (89%); TUBERCULOSIS (89%); HOLDING COMPANIES (89%); DEVELOPING COUNTRIES (89%); LEGISLATIVE BODIES (78%); AIDS & HIV TES}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (78%); US FEDERAL GOVERNMENT (78%); AIDS POLICY (78%); LEGISLATION (78%); PHARMACY BENEFITS (77%); DRUG PRICES (77%); GENERIC PRODUCTS (77%); MEDICAL DIAGNOSTICS  SCREENING & TESTING (76%); RELIEF ORGANIZATIONS (70%); INTELLECTUAL PROPERTY LAW (62%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (60%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (50%) AIDS; prescription drugs; foreign aid\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (60%); HETERO DRUGS LTD (60%); MYLAN LABORAT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RIES LTD (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (55%); ASPEN PHARMACARE HOLDINGS LTD (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS (94%); UNITED NATIONS CHILDREN'S FUND (57%); WORLD HEALTH ORGANIZATION (55%) United Nations; World Bank\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY (NSE) (60%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (55%); APN (JSE) (50%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (60%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (60%); SIC2834 PHARMACEUTICAL PREPARATIONS (60%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (60%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BILL CLINTON (90%); GEORGE W BUSH (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (96%); INDIA (94%); AFRICA (93%); BRAZIL (92%); CANADA (79%); SOUTH AFRICA (79%) Africa\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 16, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Globe and Mail, a division of CTVglobemedia Publishing Inc.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Plan to Bring Generic AIDS Drugs to Poor Nations The New York Times April 6, 2004 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_229}{\*\bkmkstart DOC_ID_229_0}{\*\bkmkstart doc_id_91}{\*\bkmkend DOC_ID_229}{\*\bkmkend DOC_ID_229_0}{\*\bkmkend doc_id_91}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_91"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 91 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2004 Tuesday  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Plan to Bring Generic AIDS Drugs to Poor Nations}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By DONALD G. McNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section F; Column 3; Health & Fitness; Pg. 6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1033 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Four organizations with an interest in international health announced yesterday that they would join forces to help more than 100 countries get inexpensive generic AIDS drugs and discounted AIDS tests.\par  If they succeed, generic drugs made by Indian and South African companies could reach virtually every poor country at prices as low as $140 per patient per year.\par   The organizations are the William J. Clinton Presidential Foundation; the Global Fund to Fight AIDS, Tube}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 culosis and Malaria; the World Bank; and Unicef. Arranging the deal would be a coup for the Clinton Found}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, which cannot by itself raise the billions of dollars for treatment. The foundation needs the financial clout of the Global Fund and the World Bank, which have each spent about $1.5 billion on the disease, and of Unicef, which procures drugs for many countries too poor or too disorganized to negotiate the complex world of pharmaceuticals and international trade rules. \par  It was unclear yesterday, however, whether the ambitious plan would be realized. The drug and diagnostics companies named in the deal have not all agreed to sell their products at the low prices they offered to a few African and Caribbean countries under two other deals brokered by the Clinton Foundation last year.\par  An executive of the Global Fund conceded that it was ''a mistake on our part'' to announce the deal before making sure all the suppliers were in agreement.\par  Nonetheless, the executive, Anil Soni, chief adviser to the Global Fund's executive director, said the organ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zations wanted to signal quickly that they endorsed the use of the generics approved by the World Health Organization. The Bush administration has questioned whether American taxpayer dollars should be spent on generic drugs instead of pricier patented ones.\par  ''We want to make clear to our recipients that it is possible to purchase generics that are up to the W.H.O. quality standard,'' Mr. Soni said.\par  The drug makers named in the announcement included Aspen Pharmacare of South Africa and four Indian makers, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd., Ranbaxy Laboratories Ltd., Hetero Drugs Ltd. and Matrix Laboratories Ltd.\par  The diagnostic test makers were two American companies, Beckman Coulter Inc. and Becton Dickinson & Company; and three European companies, Bayer Diagnostics, a unit of the Bayer HealthCare Group; b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oMerieux; and Roche Diagnostics, a division of F. Hoffmann-La Roche Ltd. They hold }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on CD-4 and viral load tests, which tell whether antiretroviral drugs are working.\par  In January, the Clinton Foundation announced that it had brokered deals for the diagnostics companies to provide the testing machines, as well as chemicals and training in a dozen African and Caribbean countries at discounts up to 80 percent. \par  When news of yesterday's announcement began leaking on Friday, two top executives of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the first company to offer an AIDS triple-therapy cocktail for less than $300, complained that they had not been co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sulted.\par  Dr. Yusuf K. Hamied, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  chairman, said yesterday that his company had sold its drugs for $240 to $280 per patient per year in 59 countries. He said that his company was not willing to expand the number of ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 kets, now seven, where it offers the drugs for $140 until he had ''something in writing'' from the foundation and the fund.\par  ''That doesn't mean I don't intend to participate,'' Dr. Hamied said. ''I want to know more.''\par  A spokesman for Ranbaxy, which makes the only other W.H.O.-approved three-in-one drug combination, said that the official who dealt with the Clinton Foundation could not yet confirm whether the company would participate.\par  At Aspen Pharmacare, Stavros Nicolaou, vice president for trade development, said it would sell its first-line cocktail, a two-drug pill and a one-drug pill, through the foundation for roughly $140, but only in Africa.\par  Prasad Nimmagadda, chief executive of Matrix, said his company only supplied raw materials but would be willing to expand its capacity.\par  A spokeswoman for Becton, Dickinson said the company ''was aware'' of the announcement but had not decided whether to offer low prices elsewhere. A spokeswoman for Beckman Coulter said whether the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany would cooperate would depend on the bidding process.\par  The other companies could not be reached. \par  Ira Magaziner, chairman of the Clinton Foundation's AIDS initiative, said bringing all the participants in line for the complicated buying deals would take time.\par  ''We're going to pave the way for this deal to be extended to many countries,'' Mr. Magaziner said. ''That doesn't flick a light switch and make a deal.'' \par  The agreement is politically delicate because it pits former President Bill Clinton's endorsement of generics against what appears to be the prevailing opinion of the Bush administration, which has not allowed taxpayer dollars to be used to buy them.\par  President Bush's secretary of health and human services, Tommy G. Thompson, is chairman of the board of the Global Fund, to which the United States is a major contributor. The announcement, planned last week, was delayed until the secretary could be told about it.\par  Mr. Soni, said he did not expect resistance from the Bush administration because buying generic drugs was ''consistent with policies that were approved in 2002'' for the fund.\par  Lost in the publicity over the previous foundation deals were the strict conditions each country must meet to qualify for the $140 price.\par  Dr. Hamied said each country must submit large, irrevocable purchase orders and pay cash. Someone other than the drug company must bear the costs of registering each drug in each country, which might include lobbying Parliament or fighting }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  lawsuits. There also must be a guaranteed supply of the raw active ingredients at fixed prices.\par  Each country must also show how it will keep cheap drugs from being diverted and resold in wealthy cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries, Mr. Soni said. \par  Dr. Hamied said he had been repeatedly asked for the $140 price by countries and charities unaware of the strict conditions. ''It caused us a lot of damage,'' he said.\par  But he added, ''If someone wanted to give me an advance of $50 million and guarantee that I supply them for five years, I might do it for $120.''\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (94%); AIDS & HIV (92%); AIDS & HIV TREATMENT (91%); DEVELO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT BANKS (90%); ANTIVIRALS (90%); AIDS & HIV TESTING (89%); PHARMACEUTICALS INDUSTRY (89%); PHARMACEUTICAL PREPARATION MFG (89%); INFECTIOUS DISEASE (89%); GENERIC PRODUCTS (89%); EXECUTIVES (87%); CHEMICALS (86%); RELIEF ORGANIZATIONS (78%); MALARIA (78%); HEALTH DEPARTMENTS (78%); PHARMACY BENEFITS (78%); INTERNATIONAL ASSISTANCE (78%); MEDICAL DIAGNOSTICS  SCREENING & TESTING (78%); INTERNATIONAL TRADE LAW (78%); DISEASES & DISORDERS (78%); HEALTH CARE (76%); PUBLIC HEALTH ADMINISTRATION (76%); US PRESIDENTS (76%); UNITED NATIONS INSTITUTIONS (75%); INTERNATIONAL TRADE (73%); T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BERCULOSIS (73%); SURGICAL & MEDICAL INSTRUMENT MFG (72%); INTERNATIONAL ECONOMIC ORGANIZATIONS (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (63%) Terms not available from NYTimes\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (85%); BECKMAN COULTER INC (84%); MYLAN LABORATORIES LTD (84%); BECTON DICKINSON & CO (83%); HETERO DRUGS LTD (63%); RANBAXY LABORATORIES LTD (63%); ASPEN PHARMACARE HOLDINGS LTD (58%); BAYER DIAGNOSTICS SA (52%); BAYER HEALTHCARE AG (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS CHILDREN'S FUND (83%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (85%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (85%); BOX (FRA) (83%); BDX (NYSE) (83%); RANBAXY (NSE) (63%); APN (JSE) (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (85%); SIC2834 PHARMACEUTICAL PREPARATIONS (85%); NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UFACTURING (85%); NAICS334516 ANALYTICAL LABORATORY INSTRUMENT MANUFACTURING (84%); NAICS334513 INSTRUMENTS & RELATED PRODUCTS MANUFACTURING FOR MEASURING, DISPLAYING & CONTROLLING INDUSTRIAL PROCESS VARIABLES (84%); SIC3845 ELECTROMED}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL & ELECTROTHERAPEUTIC APPARATUS (84%); SIC3821 LABORATORY APPARATUS & FURN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TURE (84%); NAICS339112 SURGICAL & MEDICAL INSTRUMENT MANUFACTURING (83%); SIC3841 SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (83%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (63%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (63%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BILL CLINTON (90%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (93%); CARIBBEAN ISLANDS (92%); DOMINICAN REPUBLIC (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 6, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: A boy with the AIDS virus at an orphanage in the Dominican Republic. An effort has b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gun to supply poor countries with cheaper AIDS drugs. (Photo by European Pressphoto Agency)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Coalition Expands AIDS Drug Plan; Over 100 Nations May Get Discounts The Washington Post April 6, 2004 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_230}{\*\bkmkstart DOC_ID_230_0}{\*\bkmkstart doc_id_92}{\*\bkmkend DOC_ID_230}{\*\bkmkend DOC_ID_230_0}{\*\bkmkend doc_id_92}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_92"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 92 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\shppict{\pict{\*\picprop\shplid1028{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLine}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw7620\pich2540\picwgoal4320\pichgoal1440\pngblip\bliptag657880520 89504e470d0a1a0a0000000d49484452000000d8000000480803000000a398cb9c00000300504c5445ffffff000000404040bfbfbf7f7f7fccccccefefef9900331010103030309f9f9f606060cfcfcfdfdfdf2020208f8f8f505050707070afafafd47d96c04064eabfcbde9baefaeff2b0103df4dfe5e5afbecb607ebb3057c55071b6204aefcfd8000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000335c3c3e00000c254944415478daed1b8972dbb6720192004f9152e2a449dad7ffffacccbc695ed234b12d89120f106f770152b41cc94ae31ef1043316491c8b5dec89050cf0a33cf1a256df079ef22bfb87f1fe49b22b11e99394432944004f5014950588bf335ea4615516ee35470a965fec54082c288b2af40aa7ce2ec30148faa000e797ac6b78f779a2aceeea0e958c485b49fc94274551c4f4c8e82b13893aa78f13903c7e4835b3f02205c76953ff3c594a798430972443a471e409c202ea83040951297e9ca66c06a488b1e7592f9189f012ba683ec94f7972ded44fcbbf811dabf7b5857d74d2a21bc6827e6f82654dfd4fda92ec00a41148dce61c5df505821844349f81889ef69404a4bbb13b7f75a9296dd4bba6061117f6cbe31045888cc29e3dc4921f274a7b0062642cc5ee0cce08440e0f1166878c61862d4ddfda934befa665c2cc629db6619dc79d28fa86b0175689d07819580c664e586b244d31ec67c8e451dc4e3ebc68208d3b06e28626a12486e5ccc57498702ad29046e5d837192457171e5011091c9946dd813043efdab4c6da117bb59838b48a0713c81c173bb632f2085728e429a40b7452d2691c49b2d79f60210ee68d75cce964307da1c2a24d0980fb176c87166a02a2c876641889a905a9464a76b5f0b88818df5905517d585cb06ae5142ae1bea5ef3b5a02320da4e9ac4239ce157a0bcc30726704e3c2732c8a6aa1827d8beb402b81c8c6720fbda2d50b871635c9ce38e61fd8d37fa9e216b96e338122921a56c4be9f80e8c034d0454604a8492adb62a34cf6b4dabb064c2f454be25c74ba05150f58b50f9301d5bccf0cf2ae91d24bbbd2c4cb0e2c48cfb1b26b90917261863c22fd8120dd6a037a88b6a328b690ec07eeee09eb15f2bd4fd7ca0e258ed60ef8b2812f101684db25a949278c2a36c6561d54f50148dc936c0dade52f1162cf6267d0716d169ae0c57b8b7d0de290234225926ca3c44a03ad6251174eac0abb6f79e691305c4eb3b4d8a88c685a94f024687716870c4337e371c10c3e882249177ea29404c45e6678ee5cc29128e6fc5e7183831190101f801490d0bb725f289024476e54e6c0f909f8b1724356ec21aa51d65173dde4c1248a214fced078a08af311f7d1782824bbf1ebe039266ccf9f64640cc921fd1db47ece3163c7eee0604469d864ed01c81e06078abf7ab62a7e94b523383244fcd8091e4256aff550dde2ab226ae71c6363d332341e882c95d6e1ce0b317aa7d3c56475e03dc17e78d8dfe4fd1aa086c72e2afe742eaed5d9cdd1fe6ab4bceb036647588581d7dfa431e2610c6eff9a60b63ebf56f75ac3794ce1e83a8a6e3259fbc6f5652808d5fc03517c1cadef6d5bd291c082deeaa3e0a7be6e2f868e56021643fb771325842e77f5fdfdd85ae35fb6d08b5b243ab4473bae0571711e73fa302d56b30f5f3643256efe7e6e0d99aabfb8d124a75fef424429b7461c730c370a72be5dda658a3eeb00294bb733bfadd055f72776141a238872fe41f1ca9d76450b358c2b386b536abefbb322d3f77671dbb03d06e5220f7282a64b068d91974cc8bfa56c8f537c357d26ec68114232a55d04e83fd1fff641431134ce96917d89f27013ec658615417c006221eea1af5ad5e2a0a423cf9df51471efd36ef21e5d35b05b513810a3d48222092dc91d2432e37830e98c73321d0e8d3590a797180f17611bda16fd97f51ea84fa4191cc7d6ce90ee2de219384b11393a7292cb5a4c8cee39a20bb621d5ef138a22142b26ce040dc63bb5311ba5bd19f5cbb82460379227199817b5b6c4b39d3ac8f68dd00902ddf773252535d88b4fced5ccb5c16c1285809a9d2df79bdc5863861007a2c4d10879d873ac62bfd30c79af865b54174460704781e8dc4dc5ecda69bb974edb447cc5fa2a8fab6cc19bd03b400a17f952178a49305e4dd54a615491a4dcbe1a27a1ba8513afc205e1e9340b6e9b29040a160b8a9cc7d09b86a924596253420383bc1477f7d7aa94386de642e974c9718b330fe551fe23afdc3a2f0f76a34c5d7d482bb1f4ebb09a0349b9b2c8d42c0322134581fd629c912165a392a96c36906c55ee0239a9b249e173d6fd55c900c68141f54076475cb05d7f30457406484ebc41c65f98f62a7c842abf1125158be5238441a781a8380890c1abaf58beaf22ec44ce2208e3ee9be3bd734054d060081c674d7ef934e4548a5339814bd75a3d46dc7a06482512cee57d4dc61c076489847f75099605edec931cbe8ab0eca164e9bfe58ce3ebe4422ee169961c7e14dac8ff58831fe547f9171529e4f782e99365c10fc2eefbcbb07c9a3a36db433f2d8e456366e4246cf90884a7f2cfa1f80dc1f22092ddd90e161e2175fa8dfbafbfc4dc3f4672814e8bbe5d14d5d33106248a01241bbf5d9ff2055853a09c65c3baa8a955852d587f3691a280c55857d460809a030153e3ea1660f14919846106d09606531d427290d386b2b6c9da8d27b8d3d879479e1e7be5b6c641c128d3af29f319bca3d797344cff46afaf7af8fd054e29dec3d580ccfadde511a4859c81a5bb25e726f32da4dbe5b5a7d1880149e6f3fe2df68d813397490da1412d0a8d48386bc1c9ee5c32a058dda228b883d621372ed599767c6e573ac471261cbfacf9604670867ad53b92f8306ec52d49edee124847faebf0bd73347f003c8b3e331c89a43ddbc0f38f446b177ea0caf203277370ac4bb326ade667d4814e6f28c31df45619ca51ef40146d977602fabea0e4725fb43c27fe743a6fb5e9025c9fbe066cd54de38e1e09e76cdb739de914a227a069633a85b7d2e0d0bde126a0a674dd424cf72c2ce5c86da3076d82c425c1dd21e58bcf5bb84a917bba8637d77b28aab4deef9e6d4986eae522adb7f11f58b985e6c5c65b04ce6a52da9612a68510552a4442ef41cc67ba319df1ca50713e05c0dd5360b50eddb5a39ceb173ea19b8d47d47432ecef37605dc5c7ccd4a3a403e6501cba670421e673e38a86212e39e48bd5dc785c69fdd315f1e597e7f042ebe7aff0fdd79fb5be82675affe725c02f5aeb5fb9df0baf346e024267e9ec5090f80c2ecd20099f6a4a1471fd02511909cb5dd649d2817838f96e4f5838dd70ac68d97ce257f9a6f00035f380dc3a07d3e5ab0361bf30dacc3af849ffec5e5ffda49f13612f1ce56fa8ee3ff420ab58172436a8cb05ecf8d29c40954a9cbe1a4ed49670333a5bc1f51b38b8b08dfbb1d04c46f660a1d3f13a039d99eec01f9db6776d32ae5a5843ba19073761a0e1737637c7f1f2033c7feb5e3fbcfe0cfe34fc5d07eb97e0f2a3088d55a99e30e961bdc259f5004d0a61c3b88c07472ce4750c76b7484fa6315dd979aae769d8f5e450d63167639ad9a0b1fb27c6683cf6c2c9db566aa8b7778ee5067775810b02f9edb036442319caf7f38979da5ac335ae6db229c9ce4171ef1a41bb438d5bef2e4e7f355fae3c7fee7ee728b48e2a0d767b3751dd3d38b13d72d068a5966bfc95b00fe9991c725dfe59df26487d716182ecb032fa70174ac1f16e600c080a3ec1cc0fb56888d69f87e04ec890ce84035b5e1d04263d1d7948629958c3a7827d2e6cf448bbe27554051fd93e707d0399ea57f87082128fa77be899ef31b249471986ae98567ba085c109db3e85d969dfdb9713d8d7c1414d0778f9f634617c4fabf2b24fef09acc3719de836eaf6a2a81897da1d6ad5331d6b52aecb075ab1e311ccce1ce9d8a09ebb03bb00bd5d5b6d4acf706f39d0ce6fe1fd1b67f78777056c9c497fb386edb9e89e42288a3a76bae10b615bdd984adee89019b63550add12beafdd91078bdbc5eeb7203f18c0093d53705425f5cc3173068e8509b9a42c018a34e445336384db889e136b4a21e8dc12b7bfbfce31f3ffffef1b9b491c020235a7ebe79633b317c84abff9e236c9db99b2f6d86a1053d73686e4846748c0f19ed6f485e1e8aec3f6735051df5fc82ea36ab2952bac660e6d37d8bda701324d814a63728781827215d3068bea7a7fd8cfd2ddd9ee98ab50bba96ff7bf7ebcbf71f9dfc77e7a37be9df8487b5192a1493a21a5a74dead090aba7e5863c8e044849e8a5ca7f215fc01db44b0e47a6bcece7c2b4b4d90a24f53158de7e740e7e9ba94b4a8ed7542a0e260407fb6a1b4834ea3b5032cafc8b4bcffc837e8afe804fd6d535214f2a2fc4846be7016aae01b38608bf91e2e806317f4d5a508262097fc47c59fdd695d5682630ff00d1bd661baf797f427af4bcf84e52fdd1b3f66fa6d31b9943d68f384f28ae8fd06f6b2a985efe57f7b2ecc28d1bf50846132deeef82775ec7161a7830b2ee26073016106ec77c3335556526697fdb7e39fcd18fe284fb3fc1f6304efb39e95003b0000000049454e44ae426082}}{\nonshppict{\pict\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw216\pich72\picwgoal4320\pichgoal1440\macpict\bliptag657880520 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004800d8001102ff0c00fffe0000004800000048000000000000004800d800000000001e0001000a00000000004800d882000000f39a0000000100000000000000000000000000000001000000000000000000000000000040000000000000000000000000000000000000000000004800d8000003000000000000000056726177200000000000000000000000006170706c000004000000040000d8004800480000004800000000f300000100000000000000000000000000000000000000000000000000000000000000000020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff202020ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff7f7f7fff505050ff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff606060ffdfdfdfffffffffffffffffffffffffffafafafff404040ffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff101010ffffffffffffffffff404040ff000000ff606060ffffffffffffffffffffffffffffffffff606060ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff606060ffffffffffffffffff9f9f9fffffffffffefefefff303030ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff303030ff606060ff404040ff000000ff606060ffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ffffffffff606060ff000000ff000000ff000000ff505050ffefefefffffffffff606060ff000000ff000000ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff303030ffefefefff404040ffefefefff303030ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff707070ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff202020ff000000ff000000ff000000ff000000ffbfbfbfff404040ff606060ff202020ff000000ff000000ff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff606060ffbfbfbfff707070ff101010ff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ffefefefff303030ff000000ff000000ff000000ff000000ff303030ffdfdfdfff303030ff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ff101010ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffefefefff202020ff000000ff000000ff000000ffbfbfbfff000000ff9f9f9fffefefefff303030ff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff8f8f8fffffffffff606060ff101010ffcfcfcfffffffffffcfcfcfff202020ff404040ff404040ff202020ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffefefefff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffefefefff202020ff000000ff000000ff000000ffbfbfbfffffffffffefefefff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff8f8f8fffffffffffffffffff9f9f9fffdfdfdfff404040ff000000ff000000ff404040ffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffcfcfcfff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff707070ffffffffffffffffffffffffffffffffff9f9f9fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff505050ffcfcfcfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff606060ffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff303030ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffefefefff707070ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffefefefffffffffffbfbfbfffbfbfbfffdfdfdfff303030ff000000ff000000ff303030ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffff505050ffffffffff606060ff000000ff9f9f9fffffffffff9f9f9fff202020ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff202020ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff101010ffbfbfbfffffffffffefefefffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff000000ff000000ff000000ff202020ffefefefff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffefefefffffffffffcfcfcfff101010ff000000ff606060ffefefefffafafafffffffffffefefefff202020ff000000ff404040ffefefefffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff101010ff9f9f9fffffffffffdfdfdfffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff303030ff000000ff303030ffefefefffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffcfcfcfff303030ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffefefefff707070ff000000ff000000ff000000ff000000ff000000ffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ff000000ff404040ffcfcfcfff303030ff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff303030ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff606060ff303030ffffffffffffffffffffffffff9f9f9fff101010ff101010ff000000ff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff202020ff9f9f9fff101010ff000000ff000000ff000000ff101010ff9f9f9fffefefefff303030ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ff000000ff000000ff404040ff505050ffffffffffffffffffffffffffefefefff707070ff101010ff000000ff000000ff000000ff000000ff404040ff101010ff7f7f7fff404040ff000000ff000000ff000000ff202020ff404040ffcfcfcfffffffffffffffffffefefefff606060ff101010ff000000ff000000ff000000ff000000ff7f7f7fff606060ffbfbfbfff303030ff000000ff000000ff000000ff202020ff7f7f7fff000000ff000000ff000000ff000000ff404040ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff9f9f9fff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffff8f8f8fff101010ff000000ff000000ff000000ff000000ff404040ff8f8f8fff7f7f7fffffffffffcfcfcfff202020ff101010ff000000ff000000ff000000ff000000ff7f7f7fffafafafff404040ff101010ff000000ff000000ff101010ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffbfbfbfff7f7f7fff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fffffffffffefefefff404040ff000000ff505050ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffbfbfbfff101010ff000000ffafafafff303030ff000000ff000000ff000000ff000000ffefefefffffffffffefefefff505050ff000000ff000000ffbfbfbfffafafafff7f7f7fff404040ff707070ffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fff101010ff404040ff000000ff000000ff000000ff404040ffffffffff404040ff606060ff000000ff000000ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff202020ffefefefffffffffffffffffffcfcfcfff303030ff000000ffafafafff505050ff000000ff000000ff000000ff000000ffcfcfcfffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffcfcfcfff202020ff000000ff7f7f7fff707070ff000000ff000000ff000000ff000000ff606060ff505050ff606060ff101010ff000000ff000000ff000000ff101010ff404040ff000000ff000000ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffefefefff505050ff000000ff000000ffafafafff101010ff000000ff000000ff000000ff202020ffefefefff7f7f7fff000000ff000000ff7f7f7fffcfcfcfff7f7f7fff606060ff303030ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffffffffff101010ff000000ff000000ffbfbfbfff303030ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff505050ff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffbfbfbfff303030ffefefefffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffff303030ff000000ff000000ff404040ffffffffffefefefffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffefefefff202020ff000000ff000000ff404040ffffffffffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffafafafff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffffafafafff000000ff000000ff000000ffafafafffffffffff505050ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffcfcfcfff202020ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffffefefefff101010ffcfcfcfffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffefefefff202020ff8f8f8fffbfbfbfffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff707070ff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffff505050ff606060ffbfbfbfffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff7f7f7fff606060ffbfbfbfff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff8f8f8fff606060ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fffafafafffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfff7f7f7fff202020ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffefefefffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff9f9f9fffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffcfcfcfff505050ff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff202020ff505050ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff404040ff101010ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff303030ff202020ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff202020ffffffffffbfbfbfff000000ff000000ff202020ffdfdfdfffffffffff404040ffffffffff404040ff7f7f7fff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffcfcfcfff404040ff404040ff000000ff8f8f8fffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff404040ff101010ff505050ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff000000ff000000ff606060ff707070ff101010ff8f8f8fffffffffffffffffffffffffff404040ff7f7f7fff000000ffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffafafafffffffffffffffffffffffffffcfcfcfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff404040ff000000ff000000ff000000ff606060ffefefefffffffffff000000ff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffafafafff404040ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffdfdfdfff202020ffefefefffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffffffffffcfcfcfff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff101010ff9f9f9fffffffffffefefefff202020ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff000000ff606060ffefefefff202020ff000000ff000000ff000000ff000000ff303030ffefefefff000000ff000000ff606060ffffffffffffffffffbfbfbfff000000ff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ffefefefffffffffffefefefffdfdfdfff202020ffdfdfdfffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffbfbfbfff000000ff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff606060ffffffffffefefefffefefefff000000ff000000ff000000ff404040ffefefefffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff000000ff000000ff000000ffbfbfbfff000000ff000000ff606060ff9f9f9fff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffffffffff404040ffafafafffffffffffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff303030ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ff404040ff101010ff000000ff000000ff000000ffbfbfbfff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff000000ff000000ff000000ff606060ff303030ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff101010ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff606060ff303030ff000000ff000000ff000000ff101010ff505050ff8f8f8fff404040ff606060ff7f7f7fff7f7f7fffdfdfdfff404040ff000000ff000000ff7f7f7fff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff303030ff000000ff000000ff000000ff505050ff101010ff9f9f9fff101010ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff000000ff606060ff101010ff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fff404040ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff000000ff505050ff303030ff7f7f7fff000000ff000000ff000000ff000000ff303030ffcfcfcfff000000ff000000ff404040ffefefefffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefff7f7f7fff000000ff000000ff000000ff303030ff303030ffafafafffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffefefefff303030ff000000ff000000ff000000ff101010ff9f9f9fff404040ff000000ff202020ffcfcfcfffffffffff7f7f7fff404040ff7f7f7fff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff404040ffffffffffffffffff404040ff000000ff000000ff000000ff303030ff303030ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffff9f9f9fff000000ff000000ff000000ff000000ff8f8f8fffbfbfbfff000000ff000000ff000000ffbfbfbfff8f8f8fffdfdfdfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff606060ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffdfdfdfff707070ff606060ff000000ff000000ff000000ff000000ff707070ff101010ff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ff000000ff101010ff101010ffbfbfbfffffffffff9f9f9fff000000ff000000ff000000ff000000ff7f7f7fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff707070ff202020ff000000ff000000ff000000ff000000ff9f9f9fffcfcfcfff101010ff000000ff000000ff000000ff303030ffffffffff707070ff000000ff000000ff000000ff000000ff8f8f8fff303030ff202020ff000000ff000000ff000000ff000000ff101010ff000000ff000000ff000000ffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff9f9f9fff606060ff9f9f9fff303030ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefffafafafff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffff8f8f8fff8f8f8fff505050ff000000ff000000ff000000ff000000ff000000ff505050ffefefefffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff404040ffffffffffffffffffffffffffefefefff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff9f9f9fffffffffffcfcfcfff101010ff000000ff505050ffcfcfcfff101010ff505050ff606060ff202020ff000000ff000000ff505050ffefefefffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffdfdfdfffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffcfcfcfff101010ff000000ff303030ffefefefffffffffffffffffff707070ff000000ff000000ff9f9f9fffefefefffafafafffefefefff505050ff000000ff000000ff303030ff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffafafafffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff202020ffcfcfcfffffffffffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff606060ff303030ff000000ff000000ff000000ffbfbfbfff202020ff202020ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff8f8f8fffffffffffffffffffefefefff303030ff303030ff707070ff303030ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffbfbfbfffcfcfcfff8f8f8fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff404040ff101010ff000000ff303030ff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff8f8f8fff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff505050ffefefefffffffffffffffffffffffffffffffffffffffffff707070ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff9f9f9fffffffffffffffffffffffffffcfcfcfff505050ffefefefff7f7f7fffbfbfbfffffffffffffffffffefefefff707070ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffff404040ff303030ffefefefffdfdfdfff101010ff000000ff000000ff202020ffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ffcfcfcfffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffefefefff606060ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ffcfcfcfffffffffffffffffffffffffffafafafff8f8f8fffffffffffffffffffffffffff9f9f9fff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff202020ffcfcfcfffffffffffffffffffefefefff303030ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ffbfbfbfffbfbfbfffbfbfbfffffffffffffffffffafafafff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff101010ff8f8f8fff303030ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff303030ff404040ff000000ff000000ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff606060ff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff707070ffdfdfdfffffffffffffffffffcfcfcfff303030ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff606060ffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff7f7f7fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffffffffffffffffffefefefff9f9f9fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffff404040ff000000ff404040ffffffffff9f9f9fff7f7f7fff7f7f7fff7f7f7fffcfcfcfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffbfbfbfff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fffafafafffffffffffefefefffbfbfbfffbfbfbfffefefefffefefefffbfbfbfff000000ff000000ff606060ffbfbfbfffcfcfcfffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffdfdfdfffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffcfcfcfff606060ff000000ff000000ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffd47d96ffd47d96ffd47d96ffde9baefff4dfe5fffffffffffffffffffffffffffffffffffffffffffaeff2ffde9baeffd47d96ffd47d96ffd47d96ffe5afbefffffffffffffffffffffffffffffffffffffffffff4dfe5ffeabfcbffeabfcbffffffffffde9baeffd47d96ffd47d96ffde9baefffaeff2ffffffffffffffffffeabfcbffd47d96ffd47d96ffd47d96ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ffafafafffffffffffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffff707070ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff606060ffffffffffffffffff404040ff000000ff303030ff303030ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ff606060ff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffcfcfcfff202020ff000000ff000000ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffffffffffffffffffff000000ff000000ff505050ff202020ff000000ff000000ff000000ff000000ff000000ffafafafffffffffffffffffff7f7f7fff000000ff000000ffafafafff101010ff000000ff000000ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffafafafff202020ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffb6204aff990033ff990033ff990033ff990033ff990033ff990033ffd47d96ffffffffffffffffffffffffffd47d96ffb0103dff990033ff990033ff990033ff990033ff990033ffb0103dffe5afbeffffffffffffffffffffffffffd47d96ff990033ff990033ffcb607eff990033ff990033ff990033ff990033ffb6204afff4dfe5ffc55071ff990033ff990033ff990033ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffff202020ff000000ff505050ffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffdfdfdfff505050ff000000ff000000ff000000ff404040ff606060ff303030ff000000ff000000ff101010ff000000ff404040ffffffffffffffffff606060ff000000ff000000ff404040ff202020ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff202020ff606060ff404040ff000000ff000000ff000000ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff000000ff101010ff505050ff404040ff101010ff000000ff000000ffbfbfbfffffffffffffffffffcfcfcfff101010ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffcfcfcfff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff000000ff000000ff000000ff000000ff303030ff505050ff303030ff000000ff000000ff101010ffefefefffffffffff7f7f7fff000000ff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff000000ff303030ff505050ff404040ff000000ff000000ff000000ff606060ffffffffffffffffffffffffff101010ff000000ff101010ff404040ff101010ff000000ff101010ffdfdfdfff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ff990033ffbb3057ffcb607effc04064ff990033ff990033ffc04064ffffffffffffffffffcb607eff990033ff990033ff990033ffc04064ffc55071ffbb3057ff990033ff990033ff990033ffde9baeffffffffffffffffffd47d96ff990033ff990033ff990033ffb0103dffc55071ffbb3057ff990033ff990033ffb0103dff990033ff990033ffc04064ffc55071ff990033ff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffffffffffffffffffdfdfdfff000000ff000000ff505050ff9f9f9fff000000ff000000ff303030ffdfdfdfffffffffffffffffffffffffffbfbfbfff101010ff000000ff000000ff404040ffffffffffffffffff101010ff000000ff7f7f7fffffffffffefefefff404040ff7f7f7fffefefefffffffffff404040ff000000ff000000ff606060ffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff303030ffefefefffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffefefefff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff606060ff000000ff000000ff505050ffffffffffffffffff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffff8f8f8fff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff606060ffffffffffcfcfcfff000000ff000000ff101010ffbfbfbfffffffffffffffffffffffffffefefefff505050ff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ffcfcfcfffffffffffcfcfcfff202020ffafafafffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffb0103dffeabfcbfffffffffffffffffffffffffffaeff2ffc55071ffc04064ffffffffffde9baeff990033ff990033ffc04064fff4dfe5ffffffffffffffffffffffffffefcfd8ffbb3057ff990033ff990033ffeabfcbffffffffffd47d96ff990033ff990033ffb6204afffaeff2ffffffffffffffffffc55071ff990033ff990033ff990033ffefcfd8ffffffffffffffffffeabfcbff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff707070ffffffffffffffffffffffffff7f7f7fff000000ff000000ffbfbfbfff303030ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffffffffffffffffff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefffffffffffffffffffffffffffffffffff202020ff000000ff606060ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffafafafff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ffdfdfdfffffffffff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefff606060ff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffbfbfbfff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc55071ff990033ff990033ffefcfd8ffffffffffffffffffffffffffffffffffffffffffffffffffde9baeffffffffffb0103dff990033ffbb3057fffffffffffffffffffffffffffffffffffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffd47d96ff990033ff990033ffde9baeffffffffffffffffffffffffffeabfcbff990033ff990033ffcb607effffffffffffffffffffffffffffffffffb6204aff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff202020ffffffffffffffffffdfdfdfff000000ff000000ff202020ff000000ff101010ffffffffffffffffffefefefff101010ff000000ff404040ffefefefff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff404040ffffffffffffffffff505050ff000000ff000000ff404040ff9f9f9fffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff606060ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff202020ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff7f7f7fffffffffff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffefefefff101010ff000000ff000000ff606060ffcfcfcfffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffffffffffffffffffffffffffaeff2ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033fffaeff2ffd47d96ff990033ff990033fff4dfe5fffffffffffffffffffffffffffaeff2ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffafafafffffffffff7f7f7fff000000ff101010ffcfcfcfff000000ff000000ff9f9f9fffffffffff9f9f9fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff202020ff9f9f9fffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff505050ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff9f9f9fff101010ff000000ff000000ff000000ff404040ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff404040ffffffffff202020ff000000ff707070ffffffffff505050ff000000ff303030ffffffffff202020ff000000ff202020ffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffff9f9f9fff202020ff000000ff000000ff000000ff707070ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffdfdfdfff707070ff101010ff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff707070ff000000ff000000ffdfdfdfffffffffffafafafff000000ff000000ff7f7f7fff000000ff000000ff9f9f9fffffffffffcfcfcfff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ffdfdfdfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff707070ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff707070ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffefefefff7f7f7fff000000ff000000ff303030ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffefcfd8ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ffefcfd8ffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff000000ff000000ff404040ffffffffffffffffffffffffff202020ff000000ff000000ff000000ff202020ffffffffffffffffffffffffff101010ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff404040ffffffffffffffffffefefefffdfdfdfffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff8f8f8fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff505050ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfff202020ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffdfdfdfffffffffffffffffffffffffffffffffff606060ff000000ff000000ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffb6204aff990033ffb6204affffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbefff4dfe5ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc04064ff990033ffb6204affffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ffafafafffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffff707070ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ff404040ffffffffff8f8f8fff101010ff404040ffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffdfdfdfff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ff505050ffefefefffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff202020ffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff202020ffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffefefefff505050ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff101010ffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffaeff2ffeabfcbffffffffffffffffffd47d96ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffeabfcbffb0103dffffffffffc04064ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffcb607eff990033ff990033ffd47d96ffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffefefefffffffffffffffffffffffffffefefefff101010ff000000ff000000ff505050ffafafafffbfbfbfff9f9f9fff202020ff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff505050ffbfbfbfff9f9f9fff101010ff000000ff101010ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff707070ff000000ff000000ff101010ff8f8f8fffbfbfbfffbfbfbfff606060ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffff606060ff000000ff000000ff202020ff8f8f8fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ff101010ff7f7f7fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffafafafffffffffffffffffff404040ff000000ff000000ff303030ff9f9f9fffbfbfbfffafafafff606060ff000000ff000000ff101010ffcfcfcfffffffffff202020ff000000ff000000ff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff606060ffffffffff7f7f7fff000000ff000000fffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffffffffffbb3057ff990033ff990033ffc04064ffde9baeffeabfcbffe5afbeffcb607eff990033ff990033fffffffffff4dfe5ffb0103dff990033ff990033ffcb607effe5afbeffeabfcbffde9baeffc04064ff990033ff990033ffbb3057ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff000000ff101010ff505050ff000000ff404040ffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffafafafffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffffeabfcbff990033ff990033ff990033fffffffffffffffffffaeff2ffc04064ff990033ff990033ff990033ff990033ff990033ff990033ff990033ffb0103dffffffffffffffffffefcfd8ffb6204aff990033ff990033ff990033ff990033ff990033ff990033ff990033ffc04064fffaeff2ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ffefefefffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ff202020ff000000ff000000ff202020ff707070ffefefefff9f9f9fff404040ff707070ffffffffffffffffffefefefff7f7f7fff202020ff000000ff000000ff303030ffbfbfbfffffffffffffffffff707070ff404040ff707070ffffffffffffffffffffffffffffffffffffffffff707070ff404040ff707070ffffffffff9f9f9fff404040ff404040ffffffffffffffffff9f9f9fff404040ff707070ffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffff9f9f9fff404040ff000000ff000000ff000000ff505050ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffbfbfbfff505050ff101010ff000000ff000000ff202020ff707070ffdfdfdfffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffff707070ff404040ff9f9f9fffffffffff7f7f7fff000000ff000000ffffffffff9f9f9fff303030ff000000ff000000ff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff505050ff000000ff000000ff000000ff303030ff7f7f7fffefefefffffffffffffffffffffffffffffffffffcfcfcfff505050ff000000ff000000ff101010ff606060ffdfdfdfffffffffffffffffff9f9f9fff404040ff404040fffffffffffffffffffaeff2ffbb3057ff990033ffd47d96ffffffffffffffffffffffffffffffffffde9baeffc04064ff990033ff990033ff990033ffbb3057ffd47d96fffaeff2fffffffffffffffffffffffffffaeff2ffde9baeffbb3057ff990033ff990033ff990033ffc55071ffde9baeffffffffffffffffffffffffffffffffffde9baeffc04064ffc04064ffffffffffffffffffffffffffffffffffffffffffc04064ffc04064ffefcfd8ffffffffffffffffffffffffffffffffffd47d96ffc04064ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffcfcfcfffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff505050ff7f7f7fff7f7f7fff303030ff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff505050ff404040ff404040ff606060ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000700ae00700007000100010003000300040000000d000c001000d800d800d800d800280018003610517569636b54696d65aa20616e6420610000280024003f0d206465636f6d70726573736f7200280030000f1f617265206e656564656420746f20736565207468697320706963747572652e000000a100e007ac00000000000007a86170706c022000006d6e74725247422058595a2007d900020019000b001a000b616373704150504c000000006170706c000000000000000000000000000000000000f6d6000100000000d32d6170706c00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000b64657363000001080000006f6473636d000001780000056c63707274000006e400000038777470740000071c000000147258595a00000730000000146758595a00000744000000146258595a0000075800000014725452430000076c0000000e636861640000077c0000002c625452430000076c0000000e675452430000076c0000000e64657363000000000000001447656e65726963205247422050726f66696c6500000000000000000000001447656e65726963205247422050726f66696c6500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000006d6c7563000000000000001e0000000c736b534b00000028000001786872485200000028000001a06361455300000024000001c87074425200000026000001ec756b55410000002a0000021266724655000000280000023c7a685457000000160000026469744954000000280000027a6e624e4f00000026000002a26b6f4b5200000016000002c86373435a00000022000002de6865494c0000001e00000300646544450000002c0000031e68754855000000280000034a7376534500000026000002a27a68434e00000016000003726a614a500000001a00000388726f524f00000024000003a2656c475200000022000003c67074504f00000026000003e86e6c4e4c000000280000040e6573455300000026000003e874685448000000240000043674725452000000220000045a66694649000000280000047c706c504c0000002c000004a47275525500000022000004d06172454700000026000004f2656e555300000026000005186461444b0000002e0000053e005601610065006f006200650063006e00fd0020005200470042002000700072006f00660069006c00470065006e006500720069010d006b00690020005200470042002000700072006f00660069006c00500065007200660069006c0020005200470042002000670065006e00e800720069006300500065007200660069006c0020005200470042002000470065006e00e9007200690063006f0417043004330430043b044c043d043804390020043f0440043e044404300439043b002000520047004200500072006f00660069006c0020006700e9006e00e9007200690071007500650020005200560042901a75280020005200470042002082725f6963cf8ff000500072006f00660069006c006f0020005200470042002000670065006e0065007200690063006f00470065006e0065007200690073006b0020005200470042002d00700072006f00660069006cc77cbc1800200052004700420020d504b85cd30cc77c004f006200650063006e00fd0020005200470042002000700072006f00660069006c05e405e805d505e405d905dc0020005200470042002005db05dc05dc05d90041006c006c00670065006d00650069006e006500730020005200470042002d00500072006f00660069006c00c1006c00740061006c00e1006e006f00730020005200470042002000700072006f00660069006c666e901a0020005200470042002063cf8ff065874ef64e00822c0020005200470042002030d730ed30d530a130a430eb00500072006f00660069006c0020005200470042002000670065006e0065007200690063039303b503bd03b903ba03cc002003c003c103bf03c603af03bb002000520047004200500065007200660069006c0020005200470042002000670065006e00e9007200690063006f0041006c00670065006d00650065006e0020005200470042002d00700072006f006600690065006c0e420e1b0e230e440e1f0e250e4c002000520047004200200e170e310e480e270e440e1b00470065006e0065006c0020005200470042002000500072006f00660069006c00690059006c00650069006e0065006e0020005200470042002d00700072006f006600690069006c00690055006e006900770065007200730061006c006e0079002000700072006f00660069006c0020005200470042041e04310449043804390020043f0440043e04440438043b044c00200052004700420645064406410020062a06390631064a0641002000520047004200200627064406390627064500470065006e00650072006900630020005200470042002000500072006f00660069006c006500470065006e006500720065006c0020005200470042002d006200650073006b0072006900760065006c007300657465787400000000436f707972696768742032303037204170706c6520496e632e2c20616c6c207269676874732072657365727665642e0058595a20000000000000f35200010000000116cf58595a20000000000000744d00003dee000003d058595a200000000000005a750000ac730000173458595a20000000000000281a0000159f0000b83663757276000000000000000101cd0000736633320000000000010c42000005defffff326000007920000fd91fffffba2fffffda3000003dc0000c06c00a100e000040000000200ff}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The Washington Post\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2004 Tuesday  \par Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Coalition Expands AIDS Drug Plan; \par Over 100 Nations May Get Discounts}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Shankar Vedantam, Washington Post Staff Writer\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A Section; A01\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 822 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A year-old deal that offers AIDS drugs at a steep discount to 16 countries has been expanded to all the world's poor nations, a key step toward making treatment available to millions of vulnerable patients.  \par Broadening the program to more than 100 countries could dramatically increase the number of AIDS patients being treated and offers hope that the World Health Organization (WHO) might achieve its goal of getting  3 million poor people  on antiretroviral therapy by 2005, advocates said. \par The groups that negotiated the agreement -- the World Bank, the Global Fund, UNICEF and the Clinton Foundation -- combine for the first time some of the largest funding agencies with those that have the best public health expertise, including  WHO. \par Missing, however, was one prominent funder: the U.S. government, which has its own plan to help AIDS p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tients in poor countries. The $15 billion U.S. plan seeks to buy medicines involving multiple combinations of pills from Western pharmaceutical companies that hold }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the drugs, while yesterday's deal will rely on fixed-dose medicines made in India and South Africa, which combine three drugs in one pill.   \par Despite the agreement, the participants said, the ambitious "3 by 5" target set by  WHO faces daunting cha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lenges, mostly because of a lack of public health infrastructure to deliver the medicines in the poorest cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries. But quality drugs at affordable prices are an essential first step.  \par The cheapest  test-and-drug  combination will cost about $200 per patient per year under the new agre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment. \par "It's not a good excuse to say, 'I won't give lower-priced drugs because they don't have infrastructure,' " said Ira Magaziner, chairman of the Clinton Foundation's AIDS initiative, referring to the historical resistance by some U.S. and European pharmaceutical companies to efforts to provide steeply discounted generic med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines to the world's poorest AIDS patients. \par Of about 6 million people with AIDS in poor countries, only 200,000 currently receive the treatment that can save their lives. The  manufacturers who are to supply the generic medicines will make them available at about one-third to one-half the cost of the cheapest prices being offered by companies in wealthy countries. \par Countries that want to get medicines under the agreement will have to build up health systems to deliver them  to patients and prevent diversion of the drugs to rich countries, where they could be resold at sizable profits. \par "The program could fall apart if black marketeers get in and start diverting medicines,"  Magaziner said.  \par Some poor countries already have the public health infrastructure to sign on to the new program immediat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ly, while others may take months or even years before they have a system that can test patients and deliver the medicines correctly, he said. \par The new agreement takes advantage of the complementary strengths of the four organizations that worked it out. \par "For us, it is not a problem with money, it is a problem of using the money appropriately and being able to implement the project," said Yolanda Taylor, senior specialist for procurement/health at the World Bank. She said the bank had committed $1.6 billion for AIDS, and about 75 percent of that money remains to be spent.  \par The Global Fund is a public-private partnership that raises money to fight AIDS, tuberculosis and malaria. UNICEF has expertise in procuring drugs, assessing demand and creating distribution networks. By banding together, the groups expect to guarantee generic manufacturers large sales, along with longer contracts and bigger upfront payments -- all of which lower the risk for  manufacturers and  the cost for  participating cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries.  \par "We need low prices, we want the lowest prices possible," said Liza Barrie, a spokeswoman for UNICEF. "And the Clinton Foundation needs volume. So it's a question of marrying different priorities. We can get them volume that they need to get the prices that we want." \par  Anil Soni, adviser to the executive director of the Global Fund, said the groups would welcome the U.S. government into the agreement if it were willing to sign off on using fixed-dose combinations of AIDS med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines. The signatories to yesterday's agreement stressed that they were abiding by international intellectual property laws, which now allow countries to import generic drugs to fight fatal illnesses  such as AIDS. The groups are also open to buying medicines from Western pharmaceutical companies if  the firms can match the price being offered by generic manufacturers, they said.  \par The suppliers of the generic medicines under the agreement are South Africa's Aspen Pharmacare Holdings and four companies from India: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Hetero Drugs; Ranbaxy Laboratories; and Matrix Laboratories. The AIDS tests will come from Western manufacturers: Beckman Coulter Inc.; Becton, Dickinson and Company; Bayer Diagnostics; bioMerieux; and Roche Diagnostics. \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (94%); AIDS & HIV TREATMENT (92%); ANTIVIRALS (91%); POOR POPULATION (90%); UNITED NATIONS INSTITUTIONS (90%); PUBLIC HEALTH ADMINISTRATION (90%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS INDUSTRY (89%); GENERIC DRUGS (89%); DRUG PRICES (89%); PRESCRIPTION DRUGS (89%); PHARMACEUTICAL PREPARATION MFG (88%); HEALTH DEPARTMENTS (78%); VU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERABLE HEALTH POPULATIONS (78%); AIDS POLICY (78%); INTERNATIONAL ASSISTANCE (78%); DEVELOPMENT BANKS (78%); RELIEF ORGANIZATIONS (71%); INTERNATIONAL ECONOMIC O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATIONS (70%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (90%); UNITED NATIONS CHILDREN'S FUND (57%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (79%); UNITED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 6, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Washington Post\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PLAN TO BATTLE AIDS WORLDWIDE IS FALLING SHORT The New York Times March 28, 2004 Sunday Correction Appended \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_231}{\*\bkmkstart DOC_ID_231_0}{\*\bkmkstart doc_id_93}{\*\bkmkend DOC_ID_231}{\*\bkmkend DOC_ID_231_0}{\*\bkmkend doc_id_93}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_93"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 93 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  28, 2004 Sunday \par Correction Appended  \par Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PLAN TO BATTLE AIDS WORLDWIDE IS FALLING SHORT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By DONALD G. McNEIL Jr.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section 1; Column 6; Foreign Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1393 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Three years after the United Nations declared a worldwide offensive against AIDS and 14 months after Pre}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ident Bush promised $15 billion for AIDS treatment in poor countries, shortages of money and battles over }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have kept antiretroviral drugs from reaching more than 90 percent of the poor people who need them. \par  Progress in distributing the drugs, which have sharply cut the death rate in the United States and other Western countries, has been excruciatingly slow despite steep drops in their prices. \par  As a result, only about 300,000 people in the world's poorest nations are getting the drugs, of six million who need them, according to the World Health Organization. \par  Experts, advocacy groups and health officials agree that the delays, compounded by inadequate medical facilities and training in very poor countries, are likely to persist unless spending is stepped up sharply. \par  Early this month, Stephen Lewis, the special United Nations envoy for AIDS in Africa, conceded that the W.H.O.'s ambitious plan to have three million people in treatment by 2005 -- announced on Dec. 1, World AIDS Day -- was already collapsing from a lack of money. Donations to the Global Fund to Fight AIDS, T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 berculosis and Malaria are now about $1.6 billion a year, barely 20 percent of what Secretary General Kofi Annan said was needed when he created the fund in 2001.  \par  Saying that global contributions come to a tiny fraction of what is being spent on military operations and building civilian institutions in Iraq and Afghanistan, Mr. Lewis added that if the W.H.O. program failed, ''there are no excuses left, no rationalizations to hide behind, no murky slanders to justify indifference -- there will only be the mass graves of the betrayed.'' \par  While Mr. Bush promised in his 2003 State of the Union address to spend $15 billion over five years on AIDS in Africa and the Caribbean, his budget requests have fallen far short of that goal. For the most recent donation to the Global Fund, he requested only $200 million, although Congress authorized $550 million. \par  Nor have Europe and Asia been as generous as the fund had hoped. \par  Dr. Richard G. A. Feachem, a Briton who is the fund's executive director, put a brave face on the situation, describing current donations as ''a steep upward flight path to our cruising altitude, which we anticipate to be $8 billion.'' To get there in the fund's first two years would be ''inconceivable,'' he added. He is lobbying Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gress for $1.2 billion for 2005. \par  At the same time, few people in poor countries have been able to get lower-priced generic antiretroviral drugs. While the generic drugs have been approved by the W.H.O., endorsed by the World Bank and used in several African countries, the Bush administration has so far paid only for medicines that are still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and cost much more. \par  For example, Daniel Berman, co-director of the Doctors Without Borders campaign for low-cost drugs, said that in Zimbabwe his organization planned to treat 1,000 patients with drugs from two approved Indian g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric makers, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. and Ranbaxy Laboratories Ltd. \par  Both companies combine three antiretrovirals so that a day's dose is just two pills and the cost is $244 to $292 per patient per year. Meanwhile, Mr. Berman said, the Centers for Disease Control in Atlanta plans to pay for the treatment of 1,000 Zimbabweans, buying the same three drugs separately from GlaxoSmithKline, Bristol-Myers Squibb and Boehringer-Ingelheim. The best prices available in Africa from those companies, he said, add up to $562 a year, and a daily dose is six pills. \par  Advocates of cheap drugs say the Bush administration has yielded to pressure from the pharmaceutical lo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 by to find ways to reject the generics. \par  On Friday, Senators Edward M. Kennedy, Democrat of Massachusetts, and John McCain, Republican of Arizona, wrote a joint letter to the White House urging it to accept W.H.O.-approved generics. \par  In a separate letter, Representative Henry A. Waxman, Democrat of California, accused the administration of trying to set standards for Indian generics higher than those for American ones. \par  A spokesman for Randall L. Tobias, the administration's AIDS coordinator, said any suggestion that he was snubbing generics was ''utter nonsense.'' \par  ''We will buy whatever drug is safe and effective at the lowest possible price,'' said the spokesman, Dr. Mark R. Dybul. ''We don't care if it's made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or Ranbaxy, in South Africa or Brazil or Nigeria.''\par  Mr. Tobias has scheduled a meeting in Botswana for Monday to ascertain whether the W.H.O.'s approval process is rigorous enough.\par  Dr. Lembit Rago, who leads the W.H.O. assessments, said he used ''absolutely the same principles'' as the Food and Drug Administration, and borrowed his inspectors from regulatory agencies in Canada, France, Germany, Sweden and Switzerland. As soon as his office approved the Indian pills, he said, ''a very cold wind began to blow from the U.S.'' \par  ''It is no secret that Pharma is lobbying against us in a big way,'' he said. \par  A spokesman for the Pharmaceutical Research and Manufacturers Association of America, the industry's American lobbying group, said his association was ''not involved in any way in this.'' But he called the Indian drugs ''new combinations that have not been appropriately treated.'' \par  Dr. Dybul said Mr. Tobias wanted to see all the data the Indian companies gave the W.H.O. \par  A W.H.O. spokeswoman said the agency signed confidentiality agreements, but she said the Bush admi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istration could ask the Indian companies for the data. \par  Against that backdrop, prices for both branded and generic medicines have plunged in the last two years. Last October, a foundation organized by former President Bill Clinton announced an agreement with Indian and South African generic makers to sell the drugs for $140 per patient per year if large orders were guara}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 teed, payment was in cash and the drug maker did not have to pay the legal and lobbying costs of getting each drug licensed in each country. \par  In January, Mr. Clinton announced that he had brokered another price-cut deal with five companies making AIDS tests. One of the companies, Becton, Dickinson & Company, dropped the cost of its CD-4 count, which measures immune cells, to as little as $3, from a high of $10. \par  On Dec. 9, with little fanfare, an important step took place in South Africa. Two pharmaceutical giants, Glaxo and Boehringer-Ingelheim, agreed to grant licenses to produce AIDS drugs to four generic companies from India and South Africa. \par  The companies will be allowed to sell the drugs anywhere in sub-Saharan Africa. In return, Glaxo and Boehringer will get royalties of 5 percent of sales. Under the threat of heavy fines, the companies had backed down from their original plan: a license for one small generic maker supplying only South Africa's public hospitals and royalties of 15 percent to 30 percent. \par  The Canadian government has proposed a law encouraging its drug makers to make cheap copies of drugs to treat AIDS and malaria for export to poor countries. The bill is bogged down in Parliament. \par  Treatment plans have varied wildly in different countries. South Africa, with the world's largest number of AIDS patients, was slow to roll out nationwide treatment because of years of opposition by President Thabo Mbeki. India, which has the second largest number, has been slow to negotiate low prices with its own g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 neric companies. Brazil makes its own generic drugs. Romania buys only brand-name drugs, but its epide}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic is confined to about 10,000 people. \par  Nigeria, Africa's most populous country, has had trouble running even so much as a pilot program for 15,000 of an estimated 3.5 million infected people. Many of the country's 25 treatment centers, which were selling the drugs at a subsidized price of $85 a year, ran dry in September and did not get new supplies until Febr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ary. \par  Malaysia is the only country to exercise a ''compulsory license'' right under trade treaties to ignore a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and import generics, said James P. Love, director of the Consumer Project on Technology, a group that is pushing for cheaper drugs. Uganda, Mozambique and Zambia may soon do the same, he said, but China backed away from doing so for fear of American trade retaliation. ''They're using older drugs that are already off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in China,'' he said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (97%); UNITED NATIONS INSTITUTIONS (92%); PUBLIC HEALTH ADMINISTR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (91%); HEALTH DEPARTMENTS (90%); AIDS & HIV TREATMENT (90%); AIDS POLICY (90%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERNATIONAL RELATIONS (90%); US PRESIDENTS (89%); ANTIVIRALS (89%); GENERIC DRUGS (89%); BUDGETS (89%); MALARIA (78%); INTERNATIONAL ASSISTANCE (78%); DELAYS & POS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PONEMENTS (78%); DRUG PRICES (77%); PHARMACEUTICALS INDUSTRY (77%); LOBBYING (76%); US FEDERAL GOVERNMENT (76%); EXECUTIVES (73%); TUBERCULOSIS (73%); DEFENSE SPEN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); DEATHS & DEATH RATES (72%); GENERIC PRODUCTS (70%); HEALTH CARE (69%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PROVALS (69%); INTERNATIONAL ECONOMIC ORGANIZATIONS (68%) Acquired Immune Deficiency Syndrome; Finances; Foreign Aid; Inventions and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ; Drugs (Pharmaceuticals); Finances; Budgets and Budgeting; Acquired Immune Deficiency Syndrome; Prices (Fares, Fees and Rates)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS (93%); WORLD HEALTH ORGANIZATION (91%); DOCTORS WIT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OUT BORDERS (91%) United Nations; World Health Organization\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (91%) Donald G Jr Mcneil; George W (Pres) Bush\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (94%); AFRICA (94%); EUROPE (79%); CARIBBEAN ISLANDS (79%); ASIA (79%); IRAQ (79%); AFGHANISTAN (69%); NORTH & SOUTH AMERICAS (57%) United States\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 28, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 31, 2004\par \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Because of an editing error, a front-page article on Sunday about the difficulty of distributing drugs to AIDS patients in poor countries referred incorrectly to President Bush's January 2003 plan to spend $15 billion over five years to fight AIDS in the third world. While United States spending thus far has not kept pace with the plan, the president has issued a five-year budget plan that foresees reaching it; his requests have not fallen short of the goal.\par \par \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photos: The Doctors Without Borders clinic in Khayelitsha, South Africa, has used generic drugs successfully in treating AIDS. Above left, drugs are prepared at the clinic. At right, Carlos Cordero, left, a counselor at the clinic, tells an AIDS patient, AimZ, seated, to take two pills daily. (Photo by Francesco Ziz}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 la/Magnum, for Doctors Without Borders)\par  (Photo by Pep Bonet/Doctors Without Borders)(pg. 22)Chart: ''AIDS Treatment Needs Unmet''In much of the world, few people with conditions requiring antiretroviral drugs actually get the medicines.Chart shows pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 centage of people needing AIDS treatment who receive it in the world.A comparison of drug therapy needs of the Americas and Africa:AMERICAS84% of 250,000 people needing treatment get it.AFRICA2% of 4,400,000 people needing treatment get it.(Source by World Health Organization report as of November 2003)(pg. 22)Map of the world highlights countries with people needing AIDS treatment who receive it. (pg. 22)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK loses third court case in as many weeks Chemist & Druggist March 27, 2004 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_232}{\*\bkmkstart DOC_ID_232_0}{\*\bkmkstart doc_id_94}{\*\bkmkend DOC_ID_232}{\*\bkmkend DOC_ID_232_0}{\*\bkmkend doc_id_94}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_94"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 94 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Chemist & Druggist\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  27, 2004\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GSK loses third court case in as many weeks}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pg. 8\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 285 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  by Sasa Jankovic\par  GlaxoSmithKline has lost a High Court }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  case on its Seretide salmeterol and fluticasone combination inhaler.\par  Generics companies }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Neolab, Generics UK, IVAX and Arrow Generics brought the case, claiming the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on GSK's biggest product was invalid simply because combining the two products in a single inhaler was not inventive but merely obvious. Mr Justice Pumfrey decided the claim of obviousness was "ove}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 whelmingly strong".\par  Mr Justice Pumfrey also raised concerns as to how Dr Garth Rapeport, GSK's senior vice-president, Centre of Excellence for Drug Discovery, Respiratory and Inflammatory Diseases, telephoned one of the expert wi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nesses retained by the claimants to inform him that "he could no longer expect Glaxo to be friends with him".\par  Such was the judge's concern regarding Dr Rapeport's conduct that he considered referring the matter to the Attorney-General.\par  The existing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Seretide in the UK (sold as Advair in the USA) expires in 2013 but if this new judg}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment is upheld, generic versions could be available in the UK as early as next October. UK sales of Seretide account for 6 per cent of its global pounds 2.2 billion market.\par  This is the third court defeat for GSK this month. On March 5 the Court of Appeal ruled in favour of parallel importers Dowelhurst and Swingward in a trade mark infringement action concerning the manner in which they repackaged imported pharmaceutical products.\par  On March 15 the Court of Appeal found against GSK in a case relating to the importation of AIDS products into the UK.\par  GSK is considering whether to appeal against this latest judgement.\par  For more information: www.gsk.com\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GlaxoSmithKline (GSK); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Neolab; Generics UK; IVAX; Arrow Generics  GLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OSMITHKLINE PLC (91%); GENERICS COS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (87%); GLAXOSMITHKLINE (74%); GlaxoSmithKline (GSK); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Neolab; Generics UK; IVAX; Arrow Generics GLAXOSMITHKLINE PLC (91%); GENERICS COS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (87%); GLAXOSMITHKLINE (74%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GB United Kingdom, ECGB United Kingdom, EC\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GB United Kingdom, ECGB United Kingdom, EC\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Market data; (2834) Pharmaceutical Preparations  GENERIC PRODUCTS (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); ECONOMIC NEWS (90%); IMPORT TRADE (90%); INTERNATIONAL TRADE (90%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS INDUSTRY (90%); APPEALS (89%); APPELLATE DECISIONS (89%); DECISIONS & RU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INGS (89%); SETTLEMENTS & DECISIONS (89%); LAW COURTS & TRIBUNALS (78%); LAWYERS (75%); ATTORNEYS GENERAL (73%); WITNESSES (73%); PHARMACEUTICAL PRODUCT DEVELO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (73%); AIDS & HIV (70%); TRADEMARKS (50%); Market data; (2834) Pharmaceutical Preparations GENERIC PRODUCTS (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); ECONOMIC NEWS (90%); IMPORT TRADE (90%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERNATIONAL TRADE (90%); PHARMACEUTICALS INDUSTRY (90%); APPEALS (89%); APPELLATE DECISIONS (89%); DECISIONS & RULINGS (89%); SETTLEMENTS & DECISIONS (89%); LAW COURTS & TRIBUNALS (78%); LAWYERS (75%); ATTORNEYS GENERAL (73%); WITNESSES (73%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PRODUCT DEVELOPMENT (73%); AIDS & HIV (70%); TRADEMARKS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MR JUSTICE PUMFREY (71%); GARTH RAPEPORT (69%);  MR JUSTICE PUMFREY (71%); GARTH RAPEPORT (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 31, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 English\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Magazine\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 CMP Information Ltd\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WHITE HOUSE GETS PRESSURE ON AIDS PLAN WALL STREET JOURNAL ABSTRACTS March 25, 2004, Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_233}{\*\bkmkstart DOC_ID_233_0}{\*\bkmkstart doc_id_95}{\*\bkmkend DOC_ID_233}{\*\bkmkend DOC_ID_233_0}{\*\bkmkend doc_id_95}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_95"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 95 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WALL STREET JOURNAL ABSTRACTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2004, Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 WHITE HOUSE GETS PRESSURE ON AIDS PLAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BY SARAH LUECK\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Page 4, Column 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 44 words\par \par \par Bush administration is under pressure from World Health Organization and AIDS activists to allow Global Fund to Fight AIDS to spend money on generic AIDS drugs in Africa, over protests of pharmaceutical co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies that hold }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on drugs; photo, chronology (M)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION; GLAXOSMITHKLINE PLC; BRISTOL-MYERS SQUIBB CO; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; RANBAXY LABORAT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RIES LTD; GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (90%); GSK (LSE) (90%); BMY (NYSE) (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (93%); UNITED STATES (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (90%); GLAXOSMITHKLINE PLC  (90%); BRISTOL-MYERS SQUIBB CO  (90%); RANBAXY LABORATORIES LTD (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (59%); BRISTOL-MYERS SQUIBB US (59%); BRISTOL-MYERS SQUIBB INTERNATIONAL (59%);   WORLD HEALTH ORGANIZATION  (91%); WORLD HEALTH ORGANIZATION (91%);  WORLD HEALTH ORGAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ZATION; GLAXOSMITHKLINE PLC; BRISTOL-MYERS SQUIBB CO; BOEHRINGER INGELHEIM INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NATIONAL GMBH; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD; RANBAXY LABORATORIES LTD; GLOBAL FUND TO FIGHT AIDS, T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BERCULOSIS AND MALARIA; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA;   AFRICA (93%); UNITED STATES (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ACQUIRED IMMUNE DEFICIENCY SYNDROME; ; DRUGS (PHARMACEUTICALS); GENERIC AND BRAND NAME PRODUCTS; INVENTIONS AND }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964    PHARMACEUTICALS INDUSTRY (92%); AIDS & HIV (92%); PUBLIC HEALTH ADMINISTRATION (91%); AIDS & HIV TREATMENT (90%); HEALTH DEPARTMENTS (90%); AIDS & HIV POLICY (90%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC DRUGS (90%); UNITED NATIONS INSTITUTIONS (88%); MALARIA (87%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (86%); ANTIVIRALS (86%); TUBERCULOSIS (85%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSH, GEORGE W (PRES); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 25, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 JOURNAL-CODE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  WSJ\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Combination\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The New York Times Company: Abstracts\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 International The Globe and Mail (Canada) March 22, 2004 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_234}{\*\bkmkstart DOC_ID_234_0}{\*\bkmkstart doc_id_96}{\*\bkmkend DOC_ID_234}{\*\bkmkend DOC_ID_234_0}{\*\bkmkend doc_id_96}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_96"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 96 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Globe and Mail (Canada)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2004 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 International}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 REPORT ON BUSINESS: THE WALL STREET JOURNAL; What's News; Pg. B6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 80 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GlaxoSmithKline PLC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said a U.K. court has ruled against the company in a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  case involving its ast}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ma drug Seretide. The High Court ruled that the drug maker's combination }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Seretide isn't valid b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause it isn't inventive enough. The ruling, which applies only in the United Kingdom, marks a victory for four generic companies hoping to launch their versions of Seretide - }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964  Ltd.,Generics U.K.,Ivax Corp.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 Arrow Generics}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Glaxo said it may appeal the judgment.  \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); SETTLEMENTS & DECISIONS (91%); APPEALS (90%); PHARMACEUTICAL PREPARATION MFG (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); DEC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SIONS & RULINGS (90%); PHARMACEUTICAL DRUG & DEVICES LITIGATION (90%); LAW COURTS & TRIBUNALS (88%); ASTHMA (85%) drugs; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (96%); TEVA PHARMACEUTICAL INDUSTRIES LTD (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (72%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GlaxoSmithKline PLC\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (96%); GSK (LSE) (96%); BIOC (EGX) (96%); TEVA (TASE) (72%); TEVA (NYSE) (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (72%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (96%); SIC2834 PHARMACEUTICAL PREPARATIONS (96%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (72%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (92%) Great Britain\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 16, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Globe and Mail, a division of CTVglobemedia Publishing Inc.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK loses generic battle The Guardian (London) - Final Edition March 20, 2004 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_235}{\*\bkmkstart DOC_ID_235_0}{\*\bkmkstart doc_id_97}{\*\bkmkend DOC_ID_235}{\*\bkmkend DOC_ID_235_0}{\*\bkmkend doc_id_97}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_97"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 97 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London) - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2004\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GSK loses generic battle}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Heather Stewart\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian City Pages, Pg. 28\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 349 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  GlaxoSmithKline yesterday lost a high court battle to defend its top-selling asthma drug, Seretide, against an Indian drug-maker which plans to market a lower-cost copy of it by the end of next year.\par  Mr Justice Pumfrey accepted the argument of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , and three fellow generics manufacturers, that the UK }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for Seretide should be overturned on grounds of its "obviousness". GSK combined two of its existing drugs - Flovent and Serevent - to form Seretide, which is its best selling drug. \par  Sales in Britain constitute only 6% of the \u163\'a32.2bn market for Seretide, which is sold as Advair in the US. GSK's share price dropped to its lowest level this year after the news, before recovering to close up 1% at \u163\'a310.74, as investors judged that declining UK sales would have only a moderate effect on GSK's revenues.\par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  said yesterday it intended to challenge the Seretide }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in other markets, including the US. "Yes, of course, we will," said Amar Lulla, its joint managing director. "Different countries have different processes. But it was absolutely obvious - there is nothing novel here."\par  With the UK }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on both of Seretide's component drugs due to run out next year, Mr Lulla said he was confident his firm could produce a competitor product soon afterwards. "We have in process our own clinical trials," he said. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and the other generic firms involved in yesterday's case cannot rely on GSK's research to prove the safety of their versions of the drug, because it has "data exclusivity" over its trial results until 2008.\par  GSK also has separate }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the delivery devices for Seretide, its Diskus inhaler and its Metered Dose Inhaler, which do not run out for six years. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holds 85% of the Indian drug-inhaler market, so Mr Lulla said he was confident it could find a way of providing Seretide to patients.\par  GSK said that it did not rule out an appeal against yesterday's judgment. Analysts said the ruling would e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 courage generics firms to mount a series of challenges against the Seretide }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  across Europe in the coming years.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (85%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); BIOC (EGX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (85%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (92%); UNITED KINGDOM (90%); EUROPE (77%);   LONDON, EN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LAND (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (92%); UNITED KINGDOM (90%); EUROPE (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (90%); PHARMACEUTICAL PREPARATION MFG (90%); DRUG DELIVERY SYSTEMS (89%); APPEALS (89%); GENERIC PRODUCTS (89%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS PRODUCT DEVELOPMENT (79%); LAW COURTS & TRIBUNALS (78%); AEROSOL DRUGS (78%); BUSINESS FORECASTS (78%); GENERIC DRUGS (78%); ASTHMA (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AMAR LULLA (89%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 20, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK LOSES PATENT CASE ON TOP ASTHMA DRUG The Independent (London) March 20, 2004, Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_236}{\*\bkmkstart DOC_ID_236_0}{\*\bkmkstart doc_id_98}{\*\bkmkend DOC_ID_236}{\*\bkmkend DOC_ID_236_0}{\*\bkmkend doc_id_98}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_98"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 98 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Independent (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2004, Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 GSK LOSES }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  CASE ON TOP ASTHMA DRUG}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OUR CITY STAFF\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 First Edition; BUSINESS; Pg. 55\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 299 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  GLAXOSMITHKLINE LOST a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  case on its biggest-selling asthma drug in the High Court in London yesterday, paving the way for generic versions to take a bite out of its business in the UK.\par  India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and other generic firms had challenged a key }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Seretide - also known as Advair - which expires in 2013 on the grounds of obviousness. Mr Justice Pumfrey said the claimants' case was overwhelmingly strong.\par  Given the relatively small size of the British market, the financial impact of a defeat will be limited but indu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 try analysts believe it could damage sentiment and raise fears about }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  threats in other markets.\par  The case rested on whether GSK scientists took a truly inventive step in combining two older drugs, Flovent and Serevent, to make Seretide/Advair. In the event, Justice Pumfrey ruled the combination was entirely o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vious.\par  A spokesperson for Europe's biggest drugmaker said it was considering an appeal.\par  The victory for generic manufacturers means they could launch cheap generic versions of the inhaled ast}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ma treatment as early as October 2005, although it may be later if other GSK defences hold.\par  GSK also has data exclusivity claims on the product which run through 2008 and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  covering the d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices used to deliver it into the lungs that are valid until 2011 and 2012.\par  The chief executive of GSK, Jean-Pierre Garnier, acknowledged during a post-results analyst meeting last month that the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protecting Seretide/Advair was not as strong in the UK as in the United States, but said winning or losing in the London court would make no difference in the all-important US market.\par  Analysts at JP Morgan calculate that loss of UK }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection could slice some 1.2 per cent off the group's 2008 earnings per share.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (88%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); JPMORGAN CHASE & CO (57%);   HIGH COURT (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HIGH COURT (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); BIOC (EGX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); JPM (NYSE) (57%); JPM (LSE) (57%); 8634 (TSE) (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS551111 OFFICES OF BANK HOLDING COMPANIES (57%); NAICS523999 MISCELLANEOUS FINANCIAL INVESTMENT ACTIVITIES (57%); NAICS522110 COMMERCIAL BANKING (57%); SIC6022 STATE COMMERCIAL BANKS (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (91%); INDIA (90%); UNITED STATES (79%); EUROPE (77%);   LONDON, ENGLAND (88%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED KINGDOM (91%); INDIA (90%); UNITED STATES (79%); EUROPE (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (93%); ASTHMA (93%); PHARMACEUTICALS INDUSTRY (90%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL DRUG & DEVICES LITIGATION (90%); APPEALS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC PRODUCTS (90%); GENERIC DRUGS (90%); LAW COURTS & TRIBUNALS (78%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); INDUSTRY ANALYSTS (75%); COMPANY EARNINGS (75%); EARNINGS PER SHARE (50%); EXECUTIVES (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JEAN-PIERRE GARNIER (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 20, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 Independent Print Ltd\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Glaxo loses patent case on asthma drug The Irish Times March 20, 2004 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_237}{\*\bkmkstart DOC_ID_237_0}{\*\bkmkstart doc_id_99}{\*\bkmkend DOC_ID_237}{\*\bkmkend DOC_ID_237_0}{\*\bkmkend doc_id_99}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_99"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000b00000063006900740065005f00690064005f00390039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 99 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Irish Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 March}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2004\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Glaxo loses }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  case on asthma drug}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CITY EDITION; BUSINESS AND FINANCE; IN SHORT; Pg. 16\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 88 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  GlaxoSmithKline Plc lost a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  case on its biggest-selling asthma drug in the London high court yeste}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day, paving the way for generic versions to take a bite out of its UK business. \par India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd, US-based Ivax Corp and two other generic firms had challenged a key }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Seretide - also known as Advair - which expires in 2013, on the grounds of obviousness. Justice Pumfrey said the claimants' case was overwhelmingly strong.\par A spokesman for Europe's biggest drugmaker said it was considering an appeal.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (97%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (84%); TEVA PHARMACEUTICAL INDUSTRIES LTD (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (97%); GSK (LSE) (97%); BIOC (EGX) (97%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%); TEVA (TASE) (72%); TEVA (NYSE) (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (97%); SIC2834 PHARMACEUTICAL PREPARATIONS (97%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IRELAND  INDIA (90%); UNITED KINGDOM (72%); EUROPE (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (90%); UNITED KINGDOM (72%); EUROPE (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (90%); PHARMACEUTICAL DRUG & DEVICES LITIGATION (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC DRUGS (90%); ASTHMA (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICAL PREPARATION MFG (89%); LAW COURTS & TRIBUNALS (88%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 March 20, 2004\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2004 The Irish Times\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Dose of turf war: Indian generic drugmakers are waging ferocious battle with global conglomerates bent on protecting their patents The Gazette (Montreal, Quebec) December 27, 2003 Saturday Final Edition \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_238}{\*\bkmkstart DOC_ID_238_0}{\*\bkmkstart doc_id_100}{\*\bkmkend DOC_ID_238}{\*\bkmkend DOC_ID_238_0}{\*\bkmkend doc_id_100}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_100"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 100 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Gazette (Montreal, Quebec)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  27, 2003 Saturday Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Dose of turf war: Indian generic drugmakers are waging ferocious battle with global conglomerates bent on protecting their }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SOURCE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 New York Times\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SARITHA RAI\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business; Pg. B4\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 902 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGALORE, India\par \par At 2 that cool winter morning last year when news trickled in that Dr. Reddy's Laboratories had successfully challenged the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on a blockbuster hypertension drug in a New Jersey court, jubilant senior executives uncorked a bottle of champagne.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By daybreak, however, the celebration at Dr. Reddy's, a leading Indian drugmaker based in Hyderabad, had come to an abrupt end. The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder, Pfizer Inc., loath to give up rights to the drug Norvasc, with worldwide sales of $3.8 billion U.S. last year, announced it would take the challenge to a higher court.\par One year later, Dr. Reddy's version of the drug is still on hold, awaiting an imminent ruling from federal court in Washington, even though the company received final approval from the U.S. Food and Drug Administr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion. Pfizer has sued the agency over that approval, too. \par The Norvasc dispute is only one of many battles being fought between increasingly aggressive Indian gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic drugmakers and global drug companies increasingly fierce about protecting their turf.\par For decades, Indian drugmakers honed their copycat skills under a domestic policy that allowed them to make copies of best-selling, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -protected drugs and sell them domestically or in unregulated countries as long as they used a different manufacturing process.\par Now generics companies like Dr. Reddy's and Ranbaxy Laboratories, two of India's largest, all eager to e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pand in or enter foreign markets, are combining their re-engineering skills with legal ingenuity to challenge }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  held by the world's leading drug companies.\par The intense overseas focus comes in part because India's domestic market is stagnant, with hundreds of manufacturers vigorously competing with versions of every big brand-name drug.\par More urgent, however, is a looming deadline for India to recognize international product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  granted a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ter 1995, to comply with World Trade Organization requirements. Under that agreement, a product-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system will replace the current process-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system in India in 2005.\par The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  fights over the United States' $17-billion generics market are particularly ferocious.\par "The U.S. is an attractive market for Indian exporters, whether shoes, software or drugs," G.V. Prasad, chief executive of Dr. Reddy's, said. "It is huge, fast-growing and offers the biggest margins."\par Changing regulations in America, like the FDA's banning of multiple }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  extensions on a particular drug, have combined with a push by the federal government, faced with an aging population and squeezed health-care budgets, to encourage the entry of more low-cost, generic drugs into the market despite the stiff r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sistance of the rich and politically powerful global drugmakers.\par Several of India's top drugmakers, including Dr. Reddy's and Ranbaxy, already earn much of their export revenue from selling bulk ingredients and generics in the U.S.\par North America accounted for $123 million, or 32 per cent of Dr. Reddy's $380 million in revenues for the year ended in March. In the first nine months of the year, Ranbaxy's revenues in the U.S. totalled $304 million, or 42 per cent of the company's total sales.\par India can produce drugs at a fraction of what it costs to make them in the West. And, according to Jyot}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vardhan Jaipuria, head of research at DSP Merrill Lynch, "Indian generics have been generating much hig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er margins in the U.S. by being among the earliest to enter the market when }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expire."\par The first generics maker to request and receive approval to sell a drug - the so-called first to file - gets excl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sive marketing rights in the U.S. market for six months. After that, other generics companies often pile in and prices drop.\par So, increasingly, leading Indian drugmakers are busy filing applications with the FDA to market a generic.\par Indian chemists can reverse-engineer a patented molecule within months. Copies of global brands like Pfi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 z}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er's top-selling cholesterol drug, Lipitor, and Bristol-Myers Squibb's popular anticlotting drug Plavix were sold in India within two years of those drugs' global introduction. These reverse-engineered drugs were then e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ported to unregulated markets in Asia and Africa, sometimes a whole decade before their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expired in the U.S.\par India's total drug exports, including those to the U.S. and Europe, grew from $1.8 billion in the year ended March 2001 to $2.5 billion in the 2003 fiscal year, according to the Organization of Pharmaceutical Producers of India, a trade group.\par Demand for Indian generics has enabled Indian drugmakers to pour money into their manufacturing facilities. Currently, they have 60 plants approved by the FDA, the highest number outside the U.S.\par Holders of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the U.S. have been busy filing lawsuits to battle the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges the generics makers file with the FDA\par William J. Heller, chair of the Intellectual Property and Information Technology practice at McCarter & En}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lish, a Newark, N.J.-based law firm that represents many brand-name pharmaceutical companies, including Pfizer, though not in the Norvasc dispute, said the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges undermine basic }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law.\par "Generics will whittle away the incentive to innovate, jeopardize the investment into new and much-needed drugs, and, with shortcuts to approval, will sacrifice consumer safety in the name of cheaper and less safe and effective medicines," he said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICAL PREPARATION MFG (92%); PHARMACEUTICALS INDUSTRY (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); GENERIC DRUGS (90%); GENERIC PRODUCTS (89%); US FEDERAL GOVERNMENT (89%); PRESCRIPTION DRUGS (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); EXPORT TRADE (87%); LITIGATION (77%); DRUG & MEDICAL DEVICES APPROVAL (77%); E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 X}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ECUTIVES (77%); INTERNATIONAL TRADE (76%); APPROVALS (74%); HYPERTENSION (73%); MU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TINATIONAL CORPORATIONS (72%); LAW COURTS & TRIBUNALS (72%); DECISIONS & RULINGS (72%); SUITS & CLAIMS (70%); AGING (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (92%); RANBAXY LABORATORIES LTD (82%); DR REDDY'S LABORATORIES LTD (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION  (56%); FOOD & DRUG ADMINISTRATION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (92%); PFEB (BRU) (92%); PFE (NYSE) (92%); RANBAXY (NSE) (82%); RDY (NYSE) (58%); DRREDDY (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (92%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (92%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (92%); SIC2834 PHARMACEUTICAL PREPARATIONS  (92%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2835 IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANDHRA PRADESH, INDIA (72%); QUEBEC, CANADA (59%); KARNATAKA, INDIA (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (96%); UNITED STATES (95%); NORTH AMERICA (79%); CANADA (59%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 27, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: SANTOSH VERMA, BLOOMBERG NEWS; A }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD employee works in the steroid manufacturing area of the company's plant in Kurkumb, India, which produces generic versions of brand-name allergy drugs.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business\par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 CanWest Interactive, a division of\par CanWest Global Communications Corp.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTERNATIONAL BUSINESS; Generic Drugs From India Prompting Turf Battles  The New York Times December 26, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_239}{\*\bkmkstart DOC_ID_239_0}{\*\bkmkstart doc_id_101}{\*\bkmkend DOC_ID_239}{\*\bkmkend DOC_ID_239_0}{\*\bkmkend doc_id_101}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_101"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 101 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2003 Friday  \par  Late Edition - Final \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 INTERNATIONAL BUSINESS; \par Generic Drugs From India Prompting Turf Battles}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  By SARITHA RAI \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 2; Business/Financial Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1699 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BANGALORE, India  \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 At 2 that cool winter morning last year when news trickled in that Dr. Reddy's Laboratories had successfully challenged the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on a blockbuster hypertension drug in a New Jersey court, jubilant senior executives uncorked a bottle of Champagne.\par      By daybreak, however, the celebration at Dr. Reddy's, a leading Indian drug maker based in Hyderabad, had come to an abrupt end. The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder, Pfizer Inc., loath to give up rights to the drug, Norvasc, with its worldwide sales of $3.8 billion last year, had announced that it would take the challenge to a higher court. \par  One year later, the introduction of Dr. Reddy's version of the drug is still on hold, awaiting an imminent ruling from federal court in Washington, even though the company received final approval from the United States Food and Drug Administration. Pfizer has sued the agency over that approval, too. \par The Norvasc dispute is just one of many battles being fought between increasingly aggressive Indian gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ics makers and global drug companies increasingly fierce about protecting their turf.\par For decades, Indian drug makers honed their copycat skills under a domestic policy that allowed them to make copies of best-selling, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -protected drugs and sell them domestically or in unregulated countries as long as they used a different manufacturing process.\par Now generics companies like Dr. Reddy's and Ranbaxy Laboratories, two of India's largest, and even smal}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er ingredients manufacturers like Matrix Laboratories and Shasun Chemicals & Drugs, all eager to expand in or enter foreign markets, are combining their re-engineering skills with legal ingenuity to challenge }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  held by the world's leading drug companies. \par The intense overseas focus comes in part because the domestic market is stagnant, with hundreds of man}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 facturers vigorously competing with versions of every big brand name drug. More urgent, however, is a loo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing deadline for the country to recognize international product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  granted after 1995, to comply with World Trade Organization requirements. Also under that agreement, a product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system will replace the current process }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system in India. Both changes are to take effect in 2005. \par The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  fights over the United States' $17 billion generics market are particularly ferocious.\par "The U.S. is an attractive market for Indian exporters, whether shoes, software or drugs," said G.V. Prasad, chief executive of Dr. Reddy's. "It is huge, fast-growing and offers the biggest margins."\par Besides, changing regulations in America, like the F.D.A.'s banning of multiple }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  extensions on a pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ticular drug, have combined with a push by the federal government, faced with an aging population and squeezed health care budgets, to encourage the entry of more low-cost, generic drugs into the market d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 spite the stiff resistance of the rich and politically powerful global drug makers. \par Several of India's top drug makers, including Dr. Reddy's and Ranbaxy, already earn much of their export revenue from selling bulk ingredients and generics in the United States. \par The North American market accounted for $123 million, or 32 percent of Dr. Reddy's total $380 million rev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nues for the year ended in March. In the first nine months of the year, Ranbaxy's revenues in the United States totaled $304 million, or 42 percent of the company's total sales.\par India can produce drugs at a fraction of what it costs to make them in the West. And, according to Jyot}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vardhan Jaipuria, head of research at DSP Merrill Lynch, "Indian generics have been generating much hig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er margins in the U.S. by being among the earliest to enter the market when }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expire."\par The first generics maker to request and receive approval to sell a drug -- the so-called first to file -- gets e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 clusive marketing rights in the United States market for six months. After that, other generics companies o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ten pile in and prices drop.\par So, increasingly, leading Indian drug makers are busy filing applications with the F.D.A. to market a generic. \par Indian chemists can reverse engineer a patented molecule within months. Copies of global brands like Pfi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 z}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er's top-selling cholesterol drug Lipitor and Bristol-Myers Squibb's popular anticlotting drug Plavix were sold in India within two years of those drugs' global introduction. These reverse-engineered drugs were then e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ported to unregulated markets in Asia and Africa, sometimes a whole decade before their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expired in the United States.\par India's total drug exports, including those to the United States and Europe, grew from $1.8 billion in the year ended March 2001 to $2.5 billion in the 2003 fiscal year, according to the Organization of Pharmaceutical Producers of India, a trade group.\par Demand for Indian generics has enabled Indian drug makers to pour money into their manufacturing oper}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions. Currently, they have 60 plants approved by the Food and Drug Administration, the highest number outside the United States.\par Predictably, the holders of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the United States have been busy filing lawsuits to battle the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges the generics makers file with the F.D.A. William J. Heller, head of the Intellectual Property and Information Technology practice at McCarter & English, a Newark-based law firm that represents many brand-name pharmaceutical companies, including Pfizer, though not in the Norvasc dispute, said the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges undermine the basic tenets of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law. "Generics will whittle away the incentive to innovate, jeopardize the investment into new and much-needed drugs, and, with shortcuts to approval, will sacrifice consumer safety in the name of cheaper and less safe and effective medicines," he said.\par To keep generic competitors from eating into the blockbusters' profits, companies like Pfizer and Gla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oSmithKline have also been patenting the component chemicals and processes in addition to the drug itself.\par Drugs with combined annual sales of $60 billion to $70 billion in the United States are expected to go off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  between now and 2010.\par According to Ajay Sharma, a Bombay-based drug industry analyst for Credit Lyonnais's CLSA Asia Pacific Markets unit, Ranbaxy, based in New Delhi and with $950 million in revenues last year, and the Hyderabad-based, $400 million Dr. Reddy's, have between them challenges over drugs with $30 billion worth of sales, including several first-to-file applications. These include a Ranbaxy challenge over Lipitor, Pfizer's choleste}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ol-lowering drug, and Dr. Reddy's challenge on Zofran, GlaxoSmithKline's medication for chemotherapy-induced nausea.\par Ranbaxy's American operations, which started up nearly a decade ago, began marketing products in 1998. It is now among the 10 largest players in the United States generics market and one of the country's fastest-growing drug companies, with a wide range of products including bulk ingredients, non-branded generic ve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sions of off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  drugs and branded generics.\par A top seller is its generic form of GlaxoSmithKline's Ceftin antibiotic, introduced in March 2002 after a bitter legal battle that Glaxo lost on appeal. Sales of the drug have exceeded $200 million, and were largely r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sponsible for the 47 percent jump in Ranbaxy's United States revenue for the first nine months of the year. The drug maker was the sole generic seller of Ceftin for 15 months because there were no other challengers. Competitors are now jumping in, and sales of Ranbaxy's generic are declining.\par Industry experts say that Ranbaxy, with 25 pending approvals, including 12 potential first-to-file, has one of the best pipelines in the generics industry.\par The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenge that set off the current flurry, however, was by Dr Reddy's. In mid-2001, the drug ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er got a 180-day marketing exclusivity to sell a 40 milligram generic capsule of fluoxetine, a version of Eli Lilly's antidepressant Prozac, whose standard dose is 20 milligrams. Mr. Prasad, Dr. Reddy's chief executive, said that "we anticipated the launch of Prozac 40 milligram capsules by the innovator and we were ready with our version in a few months."\par Dr. Reddy's United States unit was established in 1992 but did not start commercial production of generics until 2000. Before graduating to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenges, it developed and marketed drug ingredients and off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  generics.\par Among its 20 pending challenges is one over Eli Lilly's schizophrenia drug Zyprexa, which had United States sales of $2.8 billion in 2002, and Pfizer's anti-depressant Zoloft, with sales last year of $2.4 billion in the country.\par The company's generic pipeline, Mr. Prasad said, has "the potential of launching drugs whose branded sales last year exceeded $18 billion."\par Indian drug makers have had their setbacks, however. The Bombay-based }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. had to stop supplying Omeprazole, the main ingredient in the generic version of AstraZeneca's Prilosec made by the Andrx Corp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ration, a Florida-based generic drug maker, after Andrx lost its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  battle with AstraZeneca. (Andrx has since teamed up with Schwarz Pharma of Germany, which was able to win its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  challenge and intr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce the generic.)\par The litigation process is a long and expensive one, something only a few Indian companies can afford. And even if the legal battle is won, distribution in the United States poses another hurdle since Indian generics makers have neither a large portfolio nor a wide marketing network. Ranbaxy has made a beginning by building a franchisee network, but Dr. Reddy's lags behind. \par None of this has stopped Indian drug makers from dreaming big. \par Although it may be a while before a blockbuster drug innovated in India hits the world market, the first steps have been taken. In October, Ranbaxy and its opponent in the generic Ceftin battle, GlaxoSmithKline, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nounced a five-year drug discovery and development collaboration, the first research alliance between an Indian drug maker and a global drug firm. Dr. Reddy's recently forged a partnership with Novartis to develop a new medicine for diabetes.\par "In the 1980's, Western drug makers sneered at India's drug entrepreneurs asking, 'Who are these ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 caps?"' said Dr. K. Anji Reddy, chairman and founder of Dr. Reddy's. "Today, they are staggered by our ne}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er-say-die attitude."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); PHARMACEUTICAL PREPARATION MFG (91%); GENERIC PRODUCTS (91%); CHEMICALS (90%); CHEMICALS MFG (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (90%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); CHEMICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); INTERNATIONAL TRADE (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); US FEDERAL GOVERNMENT (88%); HYPERTENSION (78%); DRUG & MEDICAL DEVICES APPROVAL (77%); EXECUTIVES (77%); LITIGATION (77%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL DRUG & DEVICES LITIGATION (77%); SUITS & CLAIMS (75%); US FDA APPROVALS (75%); APPROVALS (73%); DECISIONS & RULINGS (72%); LAW COURTS & TRIBUNALS (72%); MULTIN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL CORPORATIONS (72%); CONSUMER PROTECTION (71%); EXPORT TRADE (70%); CONSU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ER LAW (67%); AGING (50%) MEDICINE AND HEALTH;  INVENTIONS AND }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ;  GENERIC AND BRAND NAME PRODUCTS;  INTERNATIONAL TRADE AND WORLD MARKET;  SUITS AND LITIGATION;  DRUGS (PHARMACEUTICALS);  FINANCES;  PRICES (FARES, FEES AND RATES);  CONSUMER PR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TECTION\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (92%); MYLAN LABORATORIES LTD (90%); RANBAXY LABORATORIES LTD (82%); DR REDDY'S LABORATORIES LTD (58%); SHASUN PHARMACEUTICALS LTD (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION (56%) RANBAXY LABORATORIES; DR REDDY'S LABORATORIES \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (92%); PFEB (BRU) (92%); PFE (NYSE) (92%); RANBAXY (NSE) (82%); RDY (NYSE) (58%); DRREDDY (NSE) (58%); SHASUNPHAR (NSE) (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (92%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (92%); SIC2835 IN VITRO & IN VIVO DIAGNOSTIC SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STANCES (58%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RAI, SARITHA \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANDHRA PRADESH, INDIA (90%); KARNATAKA, INDIA (58%) INDIA (98%); UNITED STATES (94%) INDIA\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 26, 2003  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photos: A scientist watches the processing of a generic drug in the research-and-development section of a plant owned by Dr. Reddy's Laboratories in Hyderabad, India. (Photo by Namas Bhojani for The New York Times)(pg. C1); Employees of Dr. Reddy's Laboratories, a generic drug maker in Hyderabad, I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia, operate an automatic bottle packager. (Photo by Namas Bhojani for The New York Times); G.V. Prasad is vice chairman and chief executive of Dr. Reddy's Laboratories of India. (Photo by Namas Bhojani for The New York Times)(pg. C4)      \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pioneering spirit of a drugmaker New Straits Times (Malaysia) December 9, 2003, Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_240}{\*\bkmkstart DOC_ID_240_0}{\*\bkmkstart doc_id_102}{\*\bkmkend DOC_ID_240}{\*\bkmkend DOC_ID_240_0}{\*\bkmkend doc_id_102}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_102"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 102 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 New Straits Times (Malaysia)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  9, 2003, Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Pioneering spirit of a drugmaker}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 By Koh Lay Chin\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Health; Pg. 7\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 885 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IT was a simple idea, but it made their competitors knock their heads on\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 the wall. When Dr Reddy's Laboratories, the first Indian drugmaker to list\par in the United States, found out that Prozac users were typically\par prescribed two 20mg tablets a day, they started manufacturing 40mg\par capsules of Fluoxetine, a generic version of the anti-depressant produced\par by Eli Lilly's.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 This innovation was passed and patented by the US Food and Drug\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Authority (USFDA) and Dr Reddy's Labs was given six months of exclusivity\par to sell it - making a whopping US$60 million (RM228 million).\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "Our marketing team had its ear on the ground. It was so simple," said\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Rammohan Rao, Dr Reddy's Labs corporate communications assistant manager. \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 To say their competitors were taken aback is an understatement, and many\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pharmaceutical companies are now looking at this kind of angle of\par opportunity.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 For Dr Reddy's Labs, said Rao, it was a combination of seizing the\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 opportunity and having an organisation which cultivates an innovative\par mindset.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Dr Reddy's Labs is one of India's largest pharmaceutical companies and\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 currently has a market capitalisation in India of approximately US$800\par million.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 It is a vertically integrated producer of bulk active ingredients for\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 the pharmaceutical industry and a developer and manufacturer of finished\par dosage forms.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Fluoxetine is one of many significant achievements over the last several\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 years.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The company is no longer just a maker of copycat drugs. It is bulldozing\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 into many areas an Indian company would "not dream of, or even dare to\par dream", said Rao in an interview at Dr Reddy's Labs office in Hyderabad,\par India.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The brainchild of Kallam Anji Reddy, son of a south Indian turmeric\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 farmer, Dr Reddy's Labs started in 1984 mainly in the bulk actives (APIs)\par business, APIs being the main ingredients in drug capsules.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Before that, Reddy was a scientist working with the Indian Government,\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 and was based in Hyderabad with a team collaborating with the Russians in\par pharmaceuticals research and production.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "He decided to start on his own. He realised it was the right time as\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 people really needed the medicines and they could become more readily\par available if private companies played a greater role in that."\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Reddy had a powerful weapon on his side, experience in both research and\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 production, which was very rare as people usually only had one or the\par other.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 However, in a short time, many players emerged in the pharmaceutical\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 business in India and the market was flooded with bulk actives. It had\par become "commoditised".\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "Price margins were reduced. Despite that, Reddy made it big because his\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 approach was different. While other players were manufacturing easy-to-\par produce generics, he decided to produce the difficult-to-manufacture\par ones," Rao said.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 These included drugs like ciprofloxacin, a German company's successful\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 antibiotic, which were being imported from Europe by Indian formulation\par drugmakers such as Ranbaxy Laboratories and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A lot of research went into manufacturing these drugs, making it\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 difficult for other companies to copy, thereby ensuring Dr Reddy's Labs'\par acceleration into the high-end business.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 In regulated markets like the US, Japan and Australia, these drugs are\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sold as generics and are not branded, unlike in the unregulated markets\par like India and China.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The company's pioneering attitude has seen it launch operations in other\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 countries, hold a diversified folio of businesses and engage in drug\par discovery.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The latter is its pride and joy, and Dr Reddy's Labs now has a stable of\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eight molecules or New Chemical Entities (NCEs) which are the building\par blocks of drugs.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Multinationals spend billions on research each year and invent new\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 molecules with irregularity - it takes a lot of financial strength to\par launch a new molecule due to the number of trials it has to go through.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 That is why, when one of a new class of anti-diabetes molecules was\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 discovered several years ago, it was snapped up by Novo Nordisk, a leading\par Danish pharmaceutical company.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "We sold it because it had passed the animal trials successfully and the\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 clinical trials had been very expensive. At that time we had only the\par financial strength to take it to that stage but if we had the money, we\par probably could have taken it further," said Rao.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 But since Dr Reddy's Labs knows that generics are not the future and\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 discovery is key, its dream of launching a molecule of its own might soon\par be a reality. For now however, it is concentrating on increasing its\par financial strength through its core businesses in bulk actives, generics\par and formulations.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "This all goes to funding our discovery programme, our number one\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 priority. Our vision is to be a discovery-led, global pharmaceutical\par company," he said.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The company is always looking for new opportunities and has sales and\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 manufacturing facilities as well as joint ventures in other countries.\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 What about Malaysia? And the challenges facing pharmaceutical companies\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 as a whole?\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 "Malaysia is a good market and opportunities are always there. What\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 companies have to do is get ready for the product }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime and get\par accepted by the USFDA. That should be the long-term strategy."\par  The writer can be contacted at laych@nstp.com.my\par                                 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (95%); PHARMACEUTICAL PREPARATION MFG (93%); ANTIDEPRESSANTS (90%); GENERIC PRODUCTS (89%); CENTRAL NERVOUS SYSTEM DRUGS (78%); TEST LABORATORIES (78%); GENERIC DRUGS (78%); MARKET CAPITALIZATION (74%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERVIEWS (63%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RDY (NYSE) (90%); DRREDDY (NSE) (90%); LLY (SWX) (57%); LLY (NYSE) (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (90%); SIC2835 IN VITRO & IN VIVO DIAGNOSTIC SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STANCES (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INDIA (94%); UNITED STATES (94%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANDHRA PRADESH, INDIA (73%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DR REDDY'S LABORATORIES LTD (90%); ELI LILLY & CO (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 9, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 (STF) - Dr Reddy's Laboratories, the first Indian drugmaker to list in theUnited States, sees its future in the research and development of newdrugs. KOH LAY CHIN writes.\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 New Straits Times Press (Malaysia) Berhad\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;World Health Organisation Announces Approval of Generic Antiretrovirals Africa News December 2, 2003 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_241}{\*\bkmkstart DOC_ID_241_0}{\*\bkmkstart doc_id_103}{\*\bkmkend DOC_ID_241}{\*\bkmkend DOC_ID_241_0}{\*\bkmkend doc_id_103}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_103"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 103 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 December}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  2, 2003 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par World Health Organisation Announces Approval of Generic Antiretrov}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 rals}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UN Integrated Regional Information Networks\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 538 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The World Health Organisation (WHO) on Monday officially approved and recommended the use of three generic versions of an antiretroviral (ARV) drug for people living with HIV/AIDS.\par The move will immediately help to increase availability of ARVs, by giving a seal of approval to drugs curren}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ly available for US $270 per person per year, as opposed to about US $700 for patented ARVs.\par The announcement in Nairobi that the generic versions, known as Fixed-Dose Combinations (FDCs), had been approved on quality, safety and efficacy grounds was made at the launch of a UN plan - known as "3 by 5" - to treat three million people with ARVs by 2005. \par The newly approved FDCs, produced by Indian companies }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy, combine three essential drug components in each pill - lamivudine, stavudine and nevirapine. This means only two tablets need to be taken per day. Current patented drugs are produced by separate international pharmaceutical companies, which have not cooperated to combine their medicines into a single pill, resulting in patients having to take several pills a day at different times.\par "The 3 by 5 strategy recommends simplified AIDS treatment regimens so that countries can quickly expand access to antiretroviral medicines," said Dr Vladimir Lepakhin, WHO Assistant Director-General for Health Technology and Pharmaceuticals, in a statement. "These new products will help the countries which are hardest-hit by the AIDS epidemic get easy-to-take AIDS medicines to the people who need them most u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gently."\par The single-pill combinations are "a major breakthrough" for AIDS treatment in poor countries, said WHO. They reduce the number of pills, improve reliability and security of supplies, are easier to take, and ensure that the right dosage is being taken by each patient.\par WHO is now recommending four different ARV regimens - down from 35 - one of which is the FDC pill.\par For patients who did not respond to the FDCs first time around, more expensive patented "blister packs" pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duced by international pharmaceutical companies were still recommended, said Dr Peter Graaff, technical officer with WHO. "Triple therapy combinations [FDCs] are not suitable for people coinfected with TB," he said.\par He added that it was important to keep the international companies on board in the struggle against HIV/AIDS. "Yes there is a price difference at the moment, but we also want to ensure that as much as poss}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble the [pharmaceutical] industry stays in the game. We need innovation, we need new products," he said. "For every product on the market we need competition."\par Dr Morten Restrup, President of the International Council of Medecins sans Frontieres (MSF), welcomed the WHO move but said the target price for treatment still remained too high at US $400 per person per month.\par "WHO's drug price targets lack ambition and do not reflect prices that are currently available," he said. "T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day drug prices have fallen by another 50 percent. WHO should encourage this trend in order that universal access to AIDS treatment becomes a reality."\par Indian-based }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has just offered ARVs to MSF and other organsiations at a cut-price of only US $140 per person per year.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (95%); APPROVALS (93%); AIDS & HIV (93%); AIDS & HIV TREATMENT (92%); GENERIC DRUGS (91%); PUBLIC HEALTH ADMINISTRATION (91%); PHARMACEUTICALS INDUSTRY (90%); HEALTH DEPARTMENTS (90%); AIDS POLICY (89%); NEW PRODUCTS (89%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAL PREPARATION MFG (88%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); DISEASES & DISORDERS (78%); DRUG PRICES (78%); EPIDEMICS (73%); MEDICAL CHARITIES (73%); RELIEF ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (73%); HEALTH CARE ACCESS (67%); MULTINATIONAL CORPORATIONS (67%); INTERN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL ASSISTANCE (67%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (56%); RANBAXY (NSE) (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (56%); SIC2834 PHARMACEUTICAL PREPARATIONS (56%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (56%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOSEPH C PAPA (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (97%); WORLD HEALTH ORGANIZATION (97%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KENYA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAIROBI, KENYA (88%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 2, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Welcome news for Aids patients Sunday Times (South Africa) November 30, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_242}{\*\bkmkstart DOC_ID_242_0}{\*\bkmkstart doc_id_104}{\*\bkmkend DOC_ID_242}{\*\bkmkend DOC_ID_242_0}{\*\bkmkend doc_id_104}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_104"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 104 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sunday Times (South Africa)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  30, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Welcome news for Aids patients}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Nicholas Neveling\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Economy, Business & Finance; Pg. 22\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 261 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LIFE-SAVERS: The cost of antiretrovirals is being slashed\par  Welcome news for Aids patients\par  A LANDMARK announcement this month by the Clinton Presidential Foundation will see the cost of Aids drugs to developing countries drastically reduced.\par  In a venture with two Indian pharmaceutical companies and South Africa's Aspen Pharmacare, the found}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion will bring down the cost of antiretrovirals per patient from $ 11 000 a year to $ 140 a year. \par  "This is a revolutionary announcement and will reduce the cost of anti-retrovirals to between US30c and US40c a day," says Stavros Nicolaou, vice-president of the National Association of Pharmaceutical Manufa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 turers, a local pharmaceutical industry body.\par  "This is particularly relevant to South Africa given the government's announcement of an antiretroviral trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment campaign," says Nicolaou.\par  The three companies involved in the venture are producers of generic drugs, which come into the market cheaper than branded medicines. With the foundation's funding they will be able to further drive down prices.\par  India-based Ranbaxy and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are not bound by international intellectual property laws, as these only come into effect in that country in 2005.\par  Aspen has entered into voluntary licence agreements with multinationals that research and develop a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretrovirals to produce generics of their branded medicines.\par  "The multinationals have seen the release of their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  under voluntary licence as a form of corporate social investment rather than a money-spinner," says Nicolaou.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RANBAXY LABORATORIES LTD (55%);  RANBAXY LABORATORIES LTD (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (94%); INDIA (79%);  SOUTH AFRICA (94%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (94%); INDIA (79%);  SOUTH AFRICA (94%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Surveys, Pharmaceutical Industry, Medicine  ANTIVIRALS (93%); PHARMACEUTICALS I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DUSTRY (92%); AIDS & HIV TREATMENT (91%); PHARMACEUTICAL PREPARATION MFG (90%); AIDS & HIV (88%); GENERIC DRUGS (88%); CORPORATE GIVING (78%); DEVELOPING COUNTRIES (77%); FOUNDATIONS (73%); PHARMACEUTICALS ASSOCIATIONS (72%); MULTINATIONAL CORPOR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (71%); GENERIC PRODUCTS (68%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (66%); LICENSING AGREEMENTS (66%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (66%); Surveys, Pharmaceutical Industry, Medicine ANTIVIRALS (93%); PHARMACEUTICALS INDUSTRY (92%); AIDS & HIV TREATMENT (91%); PHARMACEUTICAL PREP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RATION MFG (90%); AIDS & HIV (88%); GENERIC DRUGS (88%); CORPORATE GIVING (78%); DEVE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 OPING COUNTRIES (77%); FOUNDATIONS (73%); PHARMACEUTICALS ASSOCIATIONS (72%); MU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TINATIONAL CORPORATIONS (71%); GENERIC PRODUCTS (68%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (66%); LICENSING AGREEMENTS (66%); INTELLECTUAL PROPERTY LAW (66%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HILLARY RODHAM CLINTON  (91%); HILLARY RODHAM CLINTON (91%);  HILLARY R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DHAM CLINTON  (91%); HILLARY RODHAM CLINTON (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 December 2, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Paper\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Times Media Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa Gears Up for AIDS Fight   The New York Times November 21, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_243}{\*\bkmkstart DOC_ID_243_0}{\*\bkmkstart doc_id_105}{\*\bkmkend DOC_ID_243}{\*\bkmkend DOC_ID_243_0}{\*\bkmkend doc_id_105}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_105"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 105 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  21, 2003 Friday  \par  Late Edition - Final \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa Gears Up for AIDS Fight }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  By NICOLE ITANO\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section W; Column 4; Business/Financial Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1120 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOHANNESBURG, Nov. 20  \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The South African generic drug maker Aspen Pharmacare made the country's first small batch of generic antiretroviral drugs in July to more publicity than demand. \par       But as the government rolls out its new national antiretroviral program, the company is expecting to pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce billions of life-prolonging tablets at its 150 million rand ($23 million) factory, due to open early next year. \par  This week, the South African cabinet approved a plan to distribute free antiretroviral drugs as soon as feas}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble, and the country's generic drug manufacturers are gearing up to produce enough of the low-cost drugs for the millions who will eventually receive the once-unaffordable treatment. \par  According to government estimates, as many as 53,000 people could be receiving the drugs by early next year and close to one million by February 2008. Several other African countries are also beginning national treatment programs and may buy drugs from South Africa. \par  Despite the large numbers, most people close to the industry say that with intense public pressure to keep drug costs low, profit margins will be thin. Most of the financial benefit to producers, they say, will come from spreading fixed overhead costs, like electricity, over a wider product base.\par  "I think they're all aware that it's a very low-margin business," says Muhammad Bodhania, chairman of the National Association of Pharmaceutical Manufacturers, which represents most of the country's generic drug makers. But, he added, many companies feel a social responsibility and are worried about consumers simply disappearing. "If you do nothing about AIDS and you're unable to provide antiretrovirals at an affordable price, people won't be able to buy other drugs because they will be dead," Mr. Bodhania said. "It sounds crude, it is a something these companies are thinking about."\par  He added: "There is a social responsibility aspect to it that in the context of South Africa you can't ignore. We're not a purely capitalistic country." \par  South Africa said it would work with up to four drug makers, and most people expect those partners to be generic manufacturers. The Clinton Foundation, which is helping South Africa and 15 other African and Ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ibbean countries and territories develop treatment plans, announced deals last month with four generic drug makers -- Aspen and three Indian producers -- to provide antiretrovirals to their national programs at what will be the world's lowest prices.\par  One Indian producer, Ranbaxy Laboratories of Delhi, has started a South African antiretroviral joint venture with Adcock Ingram (Tiger Brands), and another, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of Bombay, has a subsidiary in Cape Town (}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -Medpro) that also intends to enter the generic market.\par  According to the Clinton Foundation agreement, governments working with it will pay $140 a person a year for one common triple-drug therapy combination, which until now sold for about $255. And that price is e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pected to go down as the number of patients taking the drugs increases, since producers have also pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ised to pass on any cost savings.\par  Currently, only about 280,000 people in the developing world take antiretroviral drugs -- 130,000 of them in Brazil alone -- but the Clinton Foundation countries are expected to put two million more people on treatment by 2008, half of those in South Africa, which has the world's largest number of H.I.V.-positive people. The United Nations estimates that five million South Africans are infected.\par  "What we felt was that particularly with the generic companies, because there is so little treatment going on in the developing world, they were only getting small, sporadic orders and were not able to scale up produ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion with the kind of efficiencies that would allow them to reduce production costs," said Ira Magaziner, chairman of the Clinton Foundation's H.I.V./AIDS initiative. \par  The intense pressure from AIDS groups to keep prices low makes the generic antiretroviral business fina}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cially difficult and a potential public relations minefield. No company wants to be seen as making too much money from a global health crisis, yet the business must be both sustainable and profitable enough to attract new entrants.\par  Aspen's chief operating officer, Linda Phillip, said that generics were priced 10 to 20 percent below brand-name drugs, and those prices slip as competitors enter the market.\par  With antiretrovirals, she noted, the initial pricing has to be far less than a new generic would typically fetch. "It's a very socially emotional disease," she said. "And the worst thing you could do is go to market just under the originator price." \par  Aspen is not the only new entrant to the generic antiretroviral industry. Although no one knows exactly how many new companies there are, many people say the global business is expanding rapidly in anticipation of greater demand. Brazil said recently that it would help Mozambique build an antiretroviral factory, and a Ugandan company, Quality Chemicals, has said that it will start producing the drugs by 2005. \par  But the South African companies are taking a slightly different tack from producers in most other countries and are working to secure voluntary licenses from the drug developers before starting production. Since most antiretroviral drugs are still under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , the bulk of generics has been produced in countries that do not uphold international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  or have issued compulsory licenses on the ground that AIDS is a national emergency.\par  Aspen has already been granted several voluntary licenses for antiretroviral drugs, while Thembalani -- the South African-Indian joint venture -- and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -Medpro are in negotiations with big drug companies. Generic makers say most of those companies have been responsive. \par  "Thus far we've had a favorable response from them," said Michael Norris, chief executive of Adcock. "They see the benefit for us to be able to use their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights to produce cost-effective antiretrovirals."\par  Observers say the big pharmaceutical companies are taking a softer approach to their antiretroviral }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , since their highly publicized lawsuit against South Africa in 2001 over its law allowing the importation and production of patented generics in certain cases. (The suit was ultimately abandoned.) \par  The companies say that they are doing their part to combat the epidemic in Africa by offering discounted drugs to nonprofit organizations and by helping to build treatment centers.\par  "All this does is just help to further the reach," said David Rosen, associate director of corporate affairs for Bristol-Myers Squibb, which says it will no longer enforce its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on the drug stavudine, also known as d4t and marketed under the brand-name Zerit in sub-Saharan Africa.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (93%); ANTIVIRALS (92%); PHARMACEUTICALS INDUSTRY (90%); AIDS & HIV (90%); PHARMACEUTICAL PREPARATION MFG (90%); PRESCRIPTION DRUGS (90%); AIDS & HIV TREATMENT (90%); NEW PRODUCTS (89%); GENERIC PRODUCTS (89%); DRUG PRICES (78%); HEALTH CARE COSTS (78%); CORPORATE SOCIAL RESPONSIBILITY (77%); PHARMACEUTICALS ASSOCIATIONS (73%); APPROVALS (72%); BUSINESS & PROFESSIONAL ASSOCIATIONS (72%); COMPANY PROFITS (67%); JOINT VENTURES (60%) Terms not available from NYTimes. \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASPEN PHARMACARE HOLDINGS LTD (91%); RANBAXY LABORATORIES LTD (61%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 C}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 APN (JSE) (91%); RANBAXY (NSE) (61%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (54%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (91%); SIC2834 PHARMACEUTICAL PREPARATIONS (91%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (61%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (61%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOHANNESBURG, SOUTH AFRICA (78%); CAPE TOWN, SOUTH AFRICA (58%); MU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BAI, INDIA (51%); DELHI, INDIA (51%) SOUTH AFRICA (95%); CARIBBEAN ISLANDS (79%); AFRICA (79%); INDIA (51%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 November 21, 2003  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: Aspen Pharmacare made its first anti-AIDS drugs in July, but the company is expecting to produce billions oflife-prolonging tablets at its 150 million rand ($23 million) factory, due to open early next year. (pg. W7) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 India's drug makers gain clout The Globe and Mail (Canada) November 13, 2003 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_244}{\*\bkmkstart DOC_ID_244_0}{\*\bkmkstart doc_id_106}{\*\bkmkend DOC_ID_244}{\*\bkmkend DOC_ID_244_0}{\*\bkmkend doc_id_106}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_106"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 106 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Globe and Mail (Canada)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 November}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2003 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 India's drug makers gain clout}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOANNA SLATER\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 REPORT ON BUSINESS: THE WALL STREET JOURNAL; Pg. B10\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 595 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BOMBAY \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  During his 21 years as a researcher at U.S. drug titan Bristol-Myers Squibb Co., Rashmi Barbhaiya gave little thought to the pharmaceutical industry in his native India. His impression, shared by many, was that I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dian firms were good only at copying drugs invented by others. \par  These days, Mr. Barbhaiya thinks differently - and for good reason. India's pharmaceutical companies are emerging as potential partners for Western drug firms, and even as significant competitors.  \par  Now head of research and development at }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 Ranbaxy Laboratories Ltd.,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  India's largest drug company, Mr. Barbhaiya, 51 years old, is at the forefront of this transformation. Late last month, Ranbaxy announced a deal with }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GlaxoSmithKline PLC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to collaborate on research. The agreement is the first for the large Anglo-American company in the developing world and shows how the outsourcing of work abroad is extending into higher-value, skill-based fields. \par  Indeed, companies such as General Motors, General Electric and Ford are already tapping Indian science and engineering talent for sophisticated research and development and auto design. \par  A few years ago, Glaxo's partnership with Ranbaxy would have been unthinkable. Indian pharmaceutical firms earned the ire of Western companies by copying their drugs and selling generic versions cheaply in the local market. \par  Now, the tune has changed considerably. After announcing the alliance with Ranbaxy, Jean-Pierre Garnier, Glaxo's chief executive officer, said the idea "is to combine their skill sets, which include excellent chemistry, with our technology infrastructure." \par  There also is regulatory logic to the deal. India is adopting a Western-style }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  regime that takes effect in 2005, making it impossible for local companies to copy new medicines invented elsewhere. To find new av}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nues for growth, the top Indian companies are boosting exports to other markets and investing in research. Those exports will jump to more than $1.4-billion (U.S.) this year, up from $330-million in 1998, according to a recent Morgan Stanley report. \par  As a result, Indian drug firms are "emerging as a credible force in the global pharmaceutical industry," the report says. "They are poised to compete in the global pharmaceutical markets, likely more than many inve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tors realize." \par  Already, India's top drug makers have had considerable success penetrating the U.S. market. There, co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 panies such as Ranbaxy, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 Dr. Reddy's Laboratories Ltd.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964  Ltd.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have gained a reputation as ine}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pensive and reliable suppliers both of bulk ingredients for drugs and of finished pills. Their generic copies, at times tweaked or improved versions of the original, rely on skills gained during years of reverse-engineering. And their costs are some of the lowest in the industry - as little as one-eighth those in the U.S. for the se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vices of a laboratory chemist. \par  Recently, Indian firms have also gained stature in American courts. Some have taken on big Western drug makers through a series of high-profile lawsuits over }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on blockbuster drugs. In a coup, Dr. Reddy's on Nov. 3 received final approval from the U.S. Food and Drug Administration to sell a generic version of Pfizer Inc.'s Norvasc, a hypertension drug with nearly $4-billion in annual sales. \par  In fact, Glaxo and Ranbaxy were locked in a bitter }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  battle only two years ago. Glaxo tried to prevent Ranbaxy from selling a generic version of its antibiotic Ceftin in the U.S., and lost the case on appeal. The drug is now Ranbaxy's best-selling product, with more than $100-million in sales a year. \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (97%); PHARMACEUTICAL PREPARATION MFG (92%); RESEARCH & DEVELOPMENT (90%); GENERIC DRUGS (89%); ENGINEERING (89%); CHEMICALS RESEARCH (78%); EMERGING MARKETS (77%); OUTSOURCING (77%); DEVELOPING COUNTRIES (77%); ALLIANCES & PARTNERSHIPS (76%); GENERIC PRODUCTS (76%); REVERSE ENGINEERING (69%); EXPORT PROMOTION (63%); EXECUTIVES (50%) pharmaceuticals industry; companies; alliances\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (93%); BRISTOL-MYERS SQUIBB CO (93%); RANBAXY LABOR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TORIES LTD (84%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (84%); DR REDDY'S LABORATORIES LTD (62%); GENERAL MOTORS CO (56%); GENERAL ELECTRIC CO (56%); MORGAN STANLEY (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Ranbaxy Laboratories Ltd.; GlaxoSmithKline PLC\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (93%); GSK (LSE) (93%); BIOC (EGX) (93%); BMY (NYSE) (93%); RANBAXY (NSE) (84%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%); RDY (NYSE) (62%); DRREDDY (NSE) (62%); GM (NYSE) (56%); GNE (PAR) (56%); GEC (LSE) (56%); GE (SWX) (56%); GE (NYSE) (56%); MS (NYSE) (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (93%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (93%); SIC2834 PHARMACEUTICAL PREPARATIONS (93%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (84%); SIC2835 IN VITRO & IN V}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VO DIAGNOSTIC SUBSTANCES (62%); NAICS336112 LIGHT TRUCK & UTILITY VEHICLE MANUFA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TURING (56%); NAICS336111 AUTOMOBILE MANUFACTURING (56%); NAICS336412 AIRCRAFT E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GINE & ENGINE PARTS MANUFACTURING (56%); NAICS335222 HOUSEHOLD REFRIGERATOR & HOME FREEZER MANUFACTURING (56%); NAICS335210 SMALL ELECTRICAL APPLIANCE MAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FACTURING (56%); NAICS523120 SECURITIES BROKERAGE (52%); SIC6211 SECURITY BROKERS, DEALERS, & FLOTATION COMPANIES (52%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JEAN-PIERRE GARNIER (57%) Rashmi Barbhaiya\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MUMBAI, INDIA (73%) INDIA (97%); UNITED STATES (94%) India\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 16, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The Globe and Mail, a division of CTVglobemedia Publishing Inc.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Will US Opt for Copies Or Generics? Africa News October 30, 2003 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_245}{\*\bkmkstart DOC_ID_245_0}{\*\bkmkstart doc_id_107}{\*\bkmkend DOC_ID_245}{\*\bkmkend DOC_ID_245_0}{\*\bkmkend doc_id_107}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_107"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 107 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  30, 2003 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Will US Opt for Copies Or Generics?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 806 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IT IS likely that within the next week or so congress will approve appropriations for US President George Bush's AIDS plan. The amount, set to be $2bn in new money every year for the next five, will be used to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 prove education about AIDS and treat those with the killer plague.\par One thorny question is: what drugs will the US administration and US Agency for International Development buy with their share of the money?\par The major drug companies, like Merck and Pfizer, which developed the drugs, want to supply them. But there is stiff political, activist and foreign corporate opposition to this, with claims that the brand drug prices are too high and that cheaper generics, from firms in India, Brazil and soon Canada, should be used. \par Some of Bush's advisers are advocates for generic drug use.\par There is undoubtedly a danger to innovation of reducing reliance on brand-name drugs in favour of generics. But regardless of this, recent activities at health activist group Medecins Sans Frontieres (Doctors Without Borders) have raised another question are all generic drugs equal?\par Brand-name drugs are of high quality. But generics are a different matter. A genuine generic is a drug bio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quivalent to the branded drug in other words, indistinguishable from it. This is important because a doctor prescribing a generic medicine has to expect it will perform as well. All branded drugs have passed US Food and Drug Administration (FDA)- style regulations of production quality processes. Many will be approved by the qualification system of the World Health Organisation (WHO). But some groups, such as Medecins Sans Frontieres, prescribe drugs, which they approve without recourse to a separate authority.\par These drugs could be as good as those passing FDA regulations, but the certainty is lower. Safety has been a concern promoted by the branded drugs industry, and they have played it up for all its worth, but it is a wo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rying problem.\par Medecins Sans Frontieres is adept at manipulating the WHO into following certain approaches and practices. So when the group says we need "simplified treatment guidelines" they are really saying, we don't need to monitor the safety of drugs as much as before. The WHO, which also wants to promote simplified treatment guidelines, may be convinced of the group's own statements: "As (Mede cins Sans Frontieres) was one of the first NGOs providing ARV (antiretroviral) therapy, the WHO requested that (the group) document its pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 curement experiences in 10 countries where it has ARV treatment programmes, so others could benefit from what has been learnt."\par The problems with treating patients with less certain drugs are threefold: it may enhance drug resistance if formulations are not as good; second-line treatments (with newer and more costly drugs) will have to be brought on line sooner, increasing overall costs; and if resistance builds up doctors won't know if the drug is less effective, or if its formulations are just incorrect, so useful drugs may be discarded too early. The ev}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dence from Medecins Sans Frontieres' work is instructive here.\par It has treated 3556 patients in 10 countries, from Thailand to Mozambique, in the past three years and is di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cussing second-line treatments in most locations, at a high cost of $2388 a person a year. Treatment began in most of these places in the past two years, indicating resistance has built up relatively quickly, indicative, but not conclusive, evidence of inferior drugs.\par The main drug they bought for at least seven countries is a fixed-dose antiretroviral produced by Indian manufacturer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . It is not prequalified by WHO, and has not been passed by other reputable agencies. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  standards are considered relatively high by industry insiders, but Medecins Sans Frontieres is using its own judgment in this matter.\par It may be producing some form of drug "copy", which is not the same as a generic. It is possible that to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 crease standards from a copy to a proper generic, costs could rise by 20%.\par And the likelihood the WHO will follow the group's approach and approve copies, not generics, is increasing. The new WHO AIDS head is Paulo Teixeira, who used to run Brazil's well-regarded but }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -threatening HIV programme. Drug resistance is higher (about 6% and rising) in Brazil than most other locations, possibly due to lower quality drugs.\par Cutting corners when millions of people have a disease is understandable, and the copies may be as good as the generics and branded drugs, but doubt remains. If the Bush administration opts to buy generic drugs it should ensure those drugs are bioequivalent to branded drugs, and not something different.\par  Dr Bate is a visiting fellow of the American Enterprise Institute and a director of health advocacy group Afr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ca Fighting Malaria.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC PRODUCTS (91%); PRESCRIPTION DRUGS (91%); APPROVALS (90%); INFE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIOUS DISEASE (90%); AIDS POLICY (90%); PHARMACEUTICALS INDUSTRY (90%); GENERIC DRUGS (90%); AIDS & HIV (90%); INTERNATIONAL ASSISTANCE (90%); RELIEF ORGANIZATIONS (89%); ME}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICAL CHARITIES (87%); AIDS & HIV TREATMENT (78%); APPROPRIATIONS (78%); US FEDERAL GOVERNMENT (78%); US PRESIDENTS (78%); NONGOVERNMENTAL ORGANIZATIONS (76%); HEALTH DEPARTMENTS (76%); DRUG & MEDICAL DEVICES APPROVAL (76%); ANTIVIRALS (76%); DRUG SAFETY (76%); PHYSICIANS & SURGEONS (72%); HEALTH CARE COSTS (71%); DRUG PRI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ES (71%); PUBLIC HEALTH ADMINISTRATION (70%); INTERNATIONAL ECONOMIC ORGANIZATIONS (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (90%); PFEB (BRU) (90%); PFE (NYSE) (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FOOD & DRUG ADMINISTRATION  (82%); FOOD & DRUG ADMINISTRATION (82%); US AGENCY FOR INTERNATIONAL DEVELOPMENT (57%); DOCTORS WITHOUT BORDERS  (55%); DOCTORS WITHOUT BORDERS (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (96%); BRAZIL (79%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DOCTORS WITHOUT BORDERS (81%); FOOD & DRUG ADMINISTRATION (80%); AGENCY FOR INTERNATIONAL DEVELOPMENT (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 30, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS Plan Would Cut Drug Costs For Poor; WHO Would Provide 3-in-1 Pill to Nations The Washington Post October 25, 2003 Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_246}{\*\bkmkstart DOC_ID_246_0}{\*\bkmkstart doc_id_108}{\*\bkmkend DOC_ID_246}{\*\bkmkend DOC_ID_246_0}{\*\bkmkend doc_id_108}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_108"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 108 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\shppict{\pict{\*\picprop\shplid1029{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLine}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw7620\pich2540\picwgoal4320\pichgoal1440\pngblip\bliptag657880520 89504e470d0a1a0a0000000d49484452000000d8000000480803000000a398cb9c00000300504c5445ffffff000000404040bfbfbf7f7f7fccccccefefef9900331010103030309f9f9f606060cfcfcfdfdfdf2020208f8f8f505050707070afafafd47d96c04064eabfcbde9baefaeff2b0103df4dfe5e5afbecb607ebb3057c55071b6204aefcfd8000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000335c3c3e00000c254944415478daed1b8972dbb6720192004f9152e2a449dad7ffffacccbc695ed234b12d89120f106f770152b41cc94ae31ef1043316491c8b5dec89050cf0a33cf1a256df079ef22bfb87f1fe49b22b11e99394432944004f5014950588bf335ea4615516ee35470a965fec54082c288b2af40aa7ce2ec30148faa000e797ac6b78f779a2aceeea0e958c485b49fc94274551c4f4c8e82b13893aa78f13903c7e4835b3f02205c76953ff3c594a798430972443a471e409c202ea83040951297e9ca66c06a488b1e7592f9189f012ba683ec94f7972ded44fcbbf811dabf7b5857d74d2a21bc6827e6f82654dfd4fda92ec00a41148dce61c5df505821844349f81889ef69404a4bbb13b7f75a9296dd4bba6061117f6cbe31045888cc29e3dc4921f274a7b0062642cc5ee0cce08440e0f1166878c61862d4ddfda934befa665c2cc629db6619dc79d28fa86b0175689d07819580c664e586b244d31ec67c8e451dc4e3ebc68208d3b06e28626a12486e5ccc57498702ad29046e5d837192457171e5011091c9946dd813043efdab4c6da117bb59838b48a0713c81c173bb632f2085728e429a40b7452d2691c49b2d79f60210ee68d75cce964307da1c2a24d0980fb176c87166a02a2c876641889a905a9464a76b5f0b88818df5905517d585cb06ae5142ae1bea5ef3b5a02320da4e9ac4239ce157a0bcc30726704e3c2732c8a6aa1827d8beb402b81c8c6720fbda2d50b871635c9ce38e61fd8d37fa9e216b96e338122921a56c4be9f80e8c034d0454604a8492adb62a34cf6b4dabb064c2f454be25c74ba05150f58b50f9301d5bccf0cf2ae91d24bbbd2c4cb0e2c48cfb1b26b90917261863c22fd8120dd6a037a88b6a328b690ec07eeee09eb15f2bd4fd7ca0e258ed60ef8b2812f101684db25a949278c2a36c6561d54f50148dc936c0dade52f1162cf6267d0716d169ae0c57b8b7d0de290234225926ca3c44a03ad6251174eac0abb6f79e691305c4eb3b4d8a88c685a94f024687716870c4337e371c10c3e882249177ea29404c45e6678ee5cc29128e6fc5e7183831190101f801490d0bb725f289024476e54e6c0f909f8b1724356ec21aa51d65173dde4c1248a214fced078a08af311f7d1782824bbf1ebe039266ccf9f64640cc921fd1db47ece3163c7eee0604469d864ed01c81e06078abf7ab62a7e94b523383244fcd8091e4256aff550dde2ab226ae71c6363d332341e882c95d6e1ce0b317aa7d3c56475e03dc17e78d8dfe4fd1aa086c72e2afe742eaed5d9cdd1fe6ab4bceb036647588581d7dfa431e2610c6eff9a60b63ebf56f75ac3794ce1e83a8a6e3259fbc6f5652808d5fc03517c1cadef6d5bd291c082deeaa3e0a7be6e2f868e56021643fb771325842e77f5fdfdd85ae35fb6d08b5b243ab4473bae0571711e73fa302d56b30f5f3643256efe7e6e0d99aabfb8d124a75fef424429b7461c730c370a72be5dda658a3eeb00294bb733bfadd055f72776141a238872fe41f1ca9d76450b358c2b386b536abefbb322d3f77671dbb03d06e5220f7282a64b068d91974cc8bfa56c8f537c357d26ec68114232a55d04e83fd1fff641431134ce96917d89f27013ec658615417c006221eea1af5ad5e2a0a423cf9df51471efd36ef21e5d35b05b513810a3d48222092dc91d2432e37830e98c73321d0e8d3590a797180f17611bda16fd97f51ea84fa4191cc7d6ce90ee2de219384b11393a7292cb5a4c8cee39a20bb621d5ef138a22142b26ce040dc63bb5311ba5bd19f5cbb82460379227199817b5b6c4b39d3ac8f68dd00902ddf773252535d88b4fced5ccb5c16c1285809a9d2df79bdc5863861007a2c4d10879d873ac62bfd30c79af865b54174460704781e8dc4dc5ecda69bb974edb447cc5fa2a8fab6cc19bd03b400a17f952178a49305e4dd54a615491a4dcbe1a27a1ba8513afc205e1e9340b6e9b29040a160b8a9cc7d09b86a924596253420383bc1477f7d7aa94386de642e974c9718b330fe551fe23afdc3a2f0f76a34c5d7d482bb1f4ebb09a0349b9b2c8d42c0322134581fd629c912165a392a96c36906c55ee0239a9b249e173d6fd55c900c68141f54076475cb05d7f30457406484ebc41c65f98f62a7c842abf1125158be5238441a781a8380890c1abaf58beaf22ec44ce2208e3ee9be3bd734054d060081c674d7ef934e4548a5339814bd75a3d46dc7a06482512cee57d4dc61c076489847f75099605edec931cbe8ab0eca164e9bfe58ce3ebe4422ee169961c7e14dac8ff58831fe547f9171529e4f782e99365c10fc2eefbcbb07c9a3a36db433f2d8e456366e4246cf90884a7f2cfa1f80dc1f22092ddd90e161e2175fa8dfbafbfc4dc3f4672814e8bbe5d14d5d33106248a01241bbf5d9ff2055853a09c65c3baa8a955852d587f3691a280c55857d460809a030153e3ea1660f14919846106d09606531d427290d386b2b6c9da8d27b8d3d879479e1e7be5b6c641c128d3af29f319bca3d797344cff46afaf7af8fd054e29dec3d580ccfadde511a4859c81a5bb25e726f32da4dbe5b5a7d1880149e6f3fe2df68d813397490da1412d0a8d48386bc1c9ee5c32a058dda228b883d621372ed599767c6e573ac471261cbfacf9604670867ad53b92f8306ec52d49edee124847faebf0bd73347f003c8b3e331c89a43ddbc0f38f446b177ea0caf203277370ac4bb326ade667d4814e6f28c31df45619ca51ef40146d977602fabea0e4725fb43c27fe743a6fb5e9025c9fbe066cd54de38e1e09e76cdb739de914a227a069633a85b7d2e0d0bde126a0a674dd424cf72c2ce5c86da3076d82c425c1dd21e58bcf5bb84a917bba8637d77b28aab4deef9e6d4986eae522adb7f11f58b985e6c5c65b04ce6a52da9612a68510552a4442ef41cc67ba319df1ca50713e05c0dd5360b50eddb5a39ceb173ea19b8d47d47432ecef37605dc5c7ccd4a3a403e6501cba670421e673e38a86212e39e48bd5dc785c69fdd315f1e597e7f042ebe7aff0fdd79fb5be82675affe725c02f5aeb5fb9df0baf346e024267e9ec5090f80c2ecd20099f6a4a1471fd02511909cb5dd649d2817838f96e4f5838dd70ac68d97ce257f9a6f00035f380dc3a07d3e5ab0361bf30dacc3af849ffec5e5ffda49f13612f1ce56fa8ee3ff420ab58172436a8cb05ecf8d29c40954a9cbe1a4ed49670333a5bc1f51b38b8b08dfbb1d04c46f660a1d3f13a039d99eec01f9db6776d32ae5a5843ba19073761a0e1737637c7f1f2033c7feb5e3fbcfe0cfe34fc5d07eb97e0f2a3088d55a99e30e961bdc259f5004d0a61c3b88c07472ce4750c76b7484fa6315dd979aae769d8f5e450d63167639ad9a0b1fb27c6683cf6c2c9db566aa8b7778ee5067775810b02f9edb036442319caf7f38979da5ac335ae6db229c9ce4171ef1a41bb438d5bef2e4e7f355fae3c7fee7ee728b48e2a0d767b3751dd3d38b13d72d068a5966bfc95b00fe9991c725dfe59df26487d716182ecb032fa70174ac1f16e600c080a3ec1cc0fb56888d69f87e04ec890ce84035b5e1d04263d1d7948629958c3a7827d2e6cf448bbe27554051fd93e707d0399ea57f87082128fa77be899ef31b249471986ae98567ba085c109db3e85d969dfdb9713d8d7c1414d0778f9f634617c4fabf2b24fef09acc3719de836eaf6a2a81897da1d6ad5331d6b52aecb075ab1e311ccce1ce9d8a09ebb03bb00bd5d5b6d4acf706f39d0ce6fe1fd1b67f78777056c9c497fb386edb9e89e42288a3a76bae10b615bdd984adee89019b63550add12beafdd91078bdbc5eeb7203f18c0093d53705425f5cc3173068e8509b9a42c018a34e445336384db889e136b4a21e8dc12b7bfbfce31f3ffffef1b9b491c020235a7ebe79633b317c84abff9e236c9db99b2f6d86a1053d73686e4846748c0f19ed6f485e1e8aec3f6735051df5fc82ea36ab2952bac660e6d37d8bda701324d814a63728781827215d3068bea7a7fd8cfd2ddd9ee98ab50bba96ff7bf7ebcbf71f9dfc77e7a37be9df8487b5192a1493a21a5a74dead090aba7e5863c8e044849e8a5ca7f215fc01db44b0e47a6bcece7c2b4b4d90a24f53158de7e740e7e9ba94b4a8ed7542a0e260407fb6a1b4834ea3b5032cafc8b4bcffc837e8afe804fd6d535214f2a2fc4846be7016aae01b38608bf91e2e806317f4d5a508262097fc47c59fdd695d5682630ff00d1bd661baf797f427af4bcf84e52fdd1b3f66fa6d31b9943d68f384f28ae8fd06f6b2a985efe57f7b2ecc28d1bf50846132deeef82775ec7161a7830b2ee26073016106ec77c3335556526697fdb7e39fcd18fe284fb3fc1f6304efb39e95003b0000000049454e44ae426082}}{\nonshppict{\pict\picscalex100\picscaley100\piccropl0\piccropr0\piccropt0\piccropb0\picw216\pich72\picwgoal4320\pichgoal1440\macpict\bliptag657880520 0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000004800d8001102ff0c00fffe0000004800000048000000000000004800d800000000001e0001000a00000000004800d882000000f39a0000000100000000000000000000000000000001000000000000000000000000000040000000000000000000000000000000000000000000004800d8000003000000000000000056726177200000000000000000000000006170706c000004000000040000d8004800480000004800000000f300000100000000000000000000000000000000000000000000000000000000000000000020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff202020ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff7f7f7fff505050ff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff606060ffdfdfdfffffffffffffffffffffffffffafafafff404040ffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff101010ffffffffffffffffff404040ff000000ff606060ffffffffffffffffffffffffffffffffff606060ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff606060ffffffffffffffffff9f9f9fffffffffffefefefff303030ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff303030ff606060ff404040ff000000ff606060ffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ffffffffff606060ff000000ff000000ff000000ff505050ffefefefffffffffff606060ff000000ff000000ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff303030ffefefefff404040ffefefefff303030ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff707070ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff202020ff000000ff000000ff000000ff000000ffbfbfbfff404040ff606060ff202020ff000000ff000000ff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff606060ffbfbfbfff707070ff101010ff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff606060ffefefefff303030ff000000ff000000ff000000ff000000ff303030ffdfdfdfff303030ff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ff101010ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffefefefff202020ff000000ff000000ff000000ffbfbfbfff000000ff9f9f9fffefefefff303030ff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff8f8f8fffffffffff606060ff101010ffcfcfcfffffffffffcfcfcfff202020ff404040ff404040ff202020ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffefefefff7f7f7fffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffefefefff202020ff000000ff000000ff000000ffbfbfbfffffffffffefefefff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff8f8f8fffffffffffffffffff9f9f9fffdfdfdfff404040ff000000ff000000ff404040ffffffffffefefefff707070ffefefefffffffffffffffffffffffffffffffffffcfcfcfff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff707070ffffffffffffffffffffffffffffffffff9f9f9fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff505050ffcfcfcfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff606060ffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff303030ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffefefefff707070ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffefefefffffffffffbfbfbfffbfbfbfffdfdfdfff303030ff000000ff000000ff303030ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffff505050ffffffffff606060ff000000ff9f9f9fffffffffff9f9f9fff202020ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff202020ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff101010ffbfbfbfffffffffffefefefffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff000000ff000000ff000000ff202020ffefefefff404040ff000000ff000000ff404040ffefefefff303030ff000000ff303030ffefefefffefefefffffffffffcfcfcfff101010ff000000ff606060ffefefefffafafafffffffffffefefefff202020ff000000ff404040ffefefefffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff101010ff9f9f9fffffffffffdfdfdfffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff303030ff000000ff303030ffefefefffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffcfcfcfff303030ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffefefefff707070ff000000ff000000ff000000ff000000ff000000ffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff606060ff000000ff404040ffcfcfcfff303030ff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff303030ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff606060ff303030ffffffffffffffffffffffffff9f9f9fff101010ff101010ff000000ff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff303030ff202020ff9f9f9fff101010ff000000ff000000ff000000ff101010ff9f9f9fffefefefff303030ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ff000000ff000000ff404040ff505050ffffffffffffffffffffffffffefefefff707070ff101010ff000000ff000000ff000000ff000000ff404040ff101010ff7f7f7fff404040ff000000ff000000ff000000ff202020ff404040ffcfcfcfffffffffffffffffffefefefff606060ff101010ff000000ff000000ff000000ff000000ff7f7f7fff606060ffbfbfbfff303030ff000000ff000000ff000000ff202020ff7f7f7fff000000ff000000ff000000ff000000ff404040ff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff9f9f9fff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffff8f8f8fff101010ff000000ff000000ff000000ff000000ff404040ff8f8f8fff7f7f7fffffffffffcfcfcfff202020ff101010ff000000ff000000ff000000ff000000ff7f7f7fffafafafff404040ff101010ff000000ff000000ff101010ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffbfbfbfff7f7f7fff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fffffffffffefefefff404040ff000000ff505050ff000000ff000000ff000000ff303030ffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffbfbfbfff101010ff000000ffafafafff303030ff000000ff000000ff000000ff000000ffefefefffffffffffefefefff505050ff000000ff000000ffbfbfbfffafafafff7f7f7fff404040ff707070ffffffffffffffffff404040ff000000ff000000ff000000ff606060ff000000ff000000ff000000ff000000ff8f8f8fff101010ff404040ff000000ff000000ff000000ff404040ffffffffff404040ff606060ff000000ff000000ff000000ff000000ff303030ff303030ff000000ff000000ff000000ff202020ffefefefffffffffffffffffffcfcfcfff303030ff000000ffafafafff505050ff000000ff000000ff000000ff000000ffcfcfcfffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffcfcfcfff202020ff000000ff7f7f7fff707070ff000000ff000000ff000000ff000000ff606060ff505050ff606060ff101010ff000000ff000000ff000000ff101010ff404040ff000000ff000000ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffffefefefff505050ff000000ff000000ffafafafff101010ff000000ff000000ff000000ff202020ffefefefff7f7f7fff000000ff000000ff7f7f7fffcfcfcfff7f7f7fff606060ff303030ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffffffffff101010ff000000ff000000ffbfbfbfff303030ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff505050ff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffbfbfbfff303030ffefefefffffffffffffffffff404040ff000000ff000000ff404040ffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffff303030ff000000ff000000ff404040ffffffffffefefefffffffffff8f8f8fff000000ff000000ff000000ffbfbfbfffefefefff202020ff000000ff000000ff404040ffffffffffffffffffcfcfcfff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffafafafff000000ff000000ff000000ffbfbfbfffdfdfdfffffffffffafafafff000000ff000000ff000000ffafafafffffffffff505050ff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffcfcfcfff202020ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffffefefefff101010ffcfcfcfffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff404040ffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffefefefff202020ff8f8f8fffbfbfbfffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff707070ff202020ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff7f7f7fffffffffff505050ff606060ffbfbfbfffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff7f7f7fff606060ffbfbfbfff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff8f8f8fff606060ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fffafafafffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffffffffffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffbfbfbfff7f7f7fff202020ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffefefefffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ff9f9f9fffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ffffffffffcfcfcfff505050ff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff202020ff505050ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffbfbfbfff000000ff000000ff000000ff000000ff404040ff101010ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff000000ff000000ff000000ff000000ff303030ff202020ff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff000000ff202020ffffffffffbfbfbfff000000ff000000ff202020ffdfdfdfffffffffff404040ffffffffff404040ff7f7f7fff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff000000ff000000ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffcfcfcfff404040ff404040ff000000ff8f8f8fffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff404040ff101010ff505050ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff000000ff000000ff606060ff707070ff101010ff8f8f8fffffffffffffffffffffffffff404040ff7f7f7fff000000ffcfcfcfff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ffafafafffffffffffffffffffffffffffcfcfcfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff404040ff000000ff000000ff000000ff606060ffefefefffffffffff000000ff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffafafafff404040ffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff000000ff000000ff000000ff7f7f7fffffffffffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffbfbfbfff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffdfdfdfff202020ffefefefffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff707070ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffffffffffcfcfcfff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff000000ff000000ff000000ff101010ff9f9f9fffffffffffefefefff202020ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff000000ff000000ff000000ff606060ffefefefff202020ff000000ff000000ff000000ff000000ff303030ffefefefff000000ff000000ff606060ffffffffffffffffffbfbfbfff000000ff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ffefefefffffffffffefefefffdfdfdfff202020ffdfdfdfffffffffffffffffff404040ff000000ff000000ff404040ffffffffff404040ff000000ff000000ff404040ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff404040ff000000ff000000ff303030ffffffffffdfdfdfffbfbfbfff000000ff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff606060ffffffffffefefefffefefefff000000ff000000ff000000ff404040ffefefefffffffffff000000ff000000ff000000ffbfbfbfffffffffffffffffffafafafff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ff000000ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff101010ff000000ff000000ff000000ffbfbfbfff000000ff000000ff606060ff9f9f9fff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff000000ffcfcfcfffffffffff404040ff000000ff000000ff404040ffffffffffffffffff404040ffafafafffffffffffffffffff7f7f7fff000000ff000000ff000000ffffffffffffffffff404040ff000000ff000000ff303030ffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff000000ff000000ff303030ff404040ff101010ff000000ff000000ff000000ffbfbfbfff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfff606060ff000000ff000000ff000000ff000000ff000000ff606060ff303030ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ff000000ff000000ff101010ff606060ff101010ff000000ff000000ff000000ff000000ff303030ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff606060ff303030ff000000ff000000ff000000ff101010ff505050ff8f8f8fff404040ff606060ff7f7f7fff7f7f7fffdfdfdfff404040ff000000ff000000ff7f7f7fff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffff303030ff000000ff000000ff000000ff505050ff101010ff9f9f9fff101010ff000000ff000000ff000000ff606060ffffffffff404040ff000000ff000000ff000000ff606060ff101010ff9f9f9fff000000ff000000ff000000ff000000ff9f9f9fff404040ff000000ff000000ff000000ffffffffffffffffffffffffff000000ff000000ff000000ff000000ff505050ff303030ff7f7f7fff000000ff000000ff000000ff000000ff303030ffcfcfcfff000000ff000000ff404040ffefefefffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefff7f7f7fff000000ff000000ff000000ff303030ff303030ffafafafffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffefefefff303030ff000000ff000000ff000000ff101010ff9f9f9fff404040ff000000ff202020ffcfcfcfffffffffff7f7f7fff404040ff7f7f7fff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff404040ffffffffffffffffff404040ff000000ff000000ff000000ff303030ff303030ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffff9f9f9fff000000ff000000ff000000ff000000ff8f8f8fffbfbfbfff000000ff000000ff000000ffbfbfbfff8f8f8fffdfdfdfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff606060ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffdfdfdfff707070ff606060ff000000ff000000ff000000ff000000ff707070ff101010ff000000ff000000ff000000ff606060ff8f8f8fff000000ff000000ff000000ff000000ff000000ff101010ff101010ffbfbfbfffffffffff9f9f9fff000000ff000000ff000000ff000000ff7f7f7fffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffff707070ff202020ff000000ff000000ff000000ff000000ff9f9f9fffcfcfcfff101010ff000000ff000000ff000000ff303030ffffffffff707070ff000000ff000000ff000000ff000000ff8f8f8fff303030ff202020ff000000ff000000ff000000ff000000ff101010ff000000ff000000ff000000ffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff9f9f9fff606060ff9f9f9fff303030ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffffffffffdfdfdfff101010ff000000ff000000ff000000ff303030ffefefefffafafafff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff000000ff000000ff000000ffbfbfbfff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffff8f8f8fff8f8f8fff505050ff000000ff000000ff000000ff000000ff000000ff505050ffefefefffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff101010ff000000ff8f8f8fffffffffffffffffffcfcfcfff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffffffffffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff404040ffffffffffffffffffffffffffefefefff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ff9f9f9fffffffffffcfcfcfff101010ff000000ff505050ffcfcfcfff101010ff505050ff606060ff202020ff000000ff000000ff505050ffefefefffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffbfbfbfff000000ff000000ff000000ffbfbfbfffffffffffdfdfdfffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffcfcfcfff101010ff000000ff303030ffefefefffffffffffffffffff707070ff000000ff000000ff9f9f9fffefefefffafafafffefefefff505050ff000000ff000000ff303030ff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffafafafffefefefff606060ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff202020ffcfcfcfffffffffffffffffffffffffffffffffffffffffffdfdfdfff303030ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff606060ff303030ff000000ff000000ff000000ffbfbfbfff202020ff202020ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff8f8f8fffffffffffffffffffefefefff303030ff303030ff707070ff303030ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffbfbfbfffcfcfcfff8f8f8fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff404040ff101010ff000000ff303030ff606060ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff8f8f8fff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff505050ffefefefffffffffffffffffffffffffffffffffffffffffff707070ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff9f9f9fffffffffffffffffffffffffffcfcfcfff505050ffefefefff7f7f7fffbfbfbfffffffffffffffffffefefefff707070ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffafafafff707070ffffffffffffffffffbfbfbfff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffdfdfdfff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff9f9f9fffffffffffffffffffffffffffffffffffffffffff404040ff303030ffefefefffdfdfdfff101010ff000000ff000000ff202020ffffffffffffffffffffffffffffffffff9f9f9fff707070ffffffffffffffffffffffffffffffffffffffffffffffffff8f8f8fff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff606060ffefefefffffffffffffffffffffffffffffffffff9f9f9fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ffcfcfcfffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffefefefff606060ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ffcfcfcfffffffffffffffffffffffffffafafafff8f8f8fffffffffffffffffffffffffff9f9f9fff707070ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff505050ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff202020ffcfcfcfffffffffffffffffffefefefff303030ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ffbfbfbfffbfbfbfffbfbfbfffffffffffffffffffafafafff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ffbfbfbfff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff101010ff8f8f8fff303030ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff000000ff8f8f8fff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff303030ff404040ff000000ff000000ff000000ff101010ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ff606060ff303030ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff707070ffdfdfdfffffffffffffffffffcfcfcfff303030ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff606060ffffffffffefefefff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffccccccffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff7f7f7fff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffcfcfcfff404040ff606060ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffefefefff303030ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffcfcfcfffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffffffffffffffffffefefefff9f9f9fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffff404040ff000000ff404040ffffffffff9f9f9fff7f7f7fff7f7f7fff7f7f7fffcfcfcfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffdfdfdfffbfbfbfffcfcfcfffffffffffbfbfbfff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fffafafafffffffffffefefefffbfbfbfffbfbfbfffefefefffefefefffbfbfbfff000000ff000000ff606060ffbfbfbfffcfcfcfffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffbfbfbfffbfbfbfffdfdfdfffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffefefefff9f9f9fff7f7f7fff7f7f7fff7f7f7fffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff7f7f7fff7f7f7fff7f7f7fff8f8f8fffdfdfdfffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff7f7f7fff7f7f7fff7f7f7fffdfdfdfffffffffffffffffffcfcfcfff606060ff000000ff000000ffbfbfbfffbfbfbfffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffd47d96ffd47d96ffd47d96ffde9baefff4dfe5fffffffffffffffffffffffffffffffffffffffffffaeff2ffde9baeffd47d96ffd47d96ffd47d96ffe5afbefffffffffffffffffffffffffffffffffffffffffff4dfe5ffeabfcbffeabfcbffffffffffde9baeffd47d96ffd47d96ffde9baefffaeff2ffffffffffffffffffeabfcbffd47d96ffd47d96ffd47d96ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffdfdfdfffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ffafafafffffffffffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffff707070ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff000000ff606060ffffffffffffffffff404040ff000000ff303030ff303030ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ff606060ff000000ff000000ff000000ff000000ff000000ff606060ffffffffffffffffffffffffffffffffffcfcfcfff202020ff000000ff000000ff000000ff000000ff000000ff303030ff8f8f8fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffffffffffcfcfcfff303030ff000000ff000000ff000000ff000000ff000000ff000000ff606060ffefefefffffffffffffffffffffffffff000000ff000000ff505050ff202020ff000000ff000000ff000000ff000000ff000000ffafafafffffffffffffffffff7f7f7fff000000ff000000ffafafafff101010ff000000ff000000ff000000ff000000ff000000ff404040ffefefefffffffffffffffffffffffffffffffffffafafafff202020ff000000ff000000ff000000ff000000ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffafafafff101010ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeffb6204aff990033ff990033ff990033ff990033ff990033ff990033ffd47d96ffffffffffffffffffffffffffd47d96ffb0103dff990033ff990033ff990033ff990033ff990033ffb0103dffe5afbeffffffffffffffffffffffffffd47d96ff990033ff990033ffcb607eff990033ff990033ff990033ff990033ffb6204afff4dfe5ffc55071ff990033ff990033ff990033ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffff202020ff000000ff505050ffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffdfdfdfff505050ff000000ff000000ff000000ff404040ff606060ff303030ff000000ff000000ff101010ff000000ff404040ffffffffffffffffff606060ff000000ff000000ff404040ff202020ff000000ff000000ff9f9f9fffffffffff404040ff000000ff000000ff000000ff202020ff606060ff404040ff000000ff000000ff000000ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff000000ff101010ff505050ff404040ff101010ff000000ff000000ffbfbfbfffffffffffffffffffcfcfcfff101010ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ff000000ff000000ff000000ff404040ffcfcfcfff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff000000ff000000ff000000ff000000ff303030ff505050ff303030ff000000ff000000ff101010ffefefefffffffffff7f7f7fff000000ff000000ff000000ff000000ff202020ff606060ff404040ff101010ff000000ff000000ff303030ffefefefffffffffffffffffff9f9f9fff000000ff000000ff000000ff303030ff505050ff404040ff000000ff000000ff000000ff606060ffffffffffffffffffffffffff101010ff000000ff101010ff404040ff101010ff000000ff101010ffdfdfdfff404040ff000000ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ff990033ffbb3057ffcb607effc04064ff990033ff990033ffc04064ffffffffffffffffffcb607eff990033ff990033ff990033ffc04064ffc55071ffbb3057ff990033ff990033ff990033ffde9baeffffffffffffffffffd47d96ff990033ff990033ff990033ffb0103dffc55071ffbb3057ff990033ff990033ffb0103dff990033ff990033ffc04064ffc55071ff990033ff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffffffffffffffffffffffffffbfbfbfff000000ff000000ff000000ffdfdfdfffffffffffffffffffffffffffdfdfdfff000000ff000000ff505050ff9f9f9fff000000ff000000ff303030ffdfdfdfffffffffffffffffffffffffffbfbfbfff101010ff000000ff000000ff404040ffffffffffffffffff101010ff000000ff7f7f7fffffffffffefefefff404040ff7f7f7fffefefefffffffffff404040ff000000ff000000ff606060ffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ff303030ffefefefffffffffffffffffffcfcfcfff000000ff000000ff606060ffffffffffffffffff202020ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffefefefff101010ff000000ff101010ffafafafffffffffffffffffffffffffffefefefff606060ff000000ff000000ff505050ffffffffffffffffff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffff8f8f8fff000000ff000000ffafafafffffffffff7f7f7fff000000ff000000ff000000ff8f8f8fffffffffffffffffffffffffffefefefff606060ff000000ff000000ff606060ffffffffffcfcfcfff000000ff000000ff101010ffbfbfbfffffffffffffffffffffffffffefefefff505050ff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ffcfcfcfffffffffffcfcfcfff202020ffafafafffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffb0103dffeabfcbfffffffffffffffffffffffffffaeff2ffc55071ffc04064ffffffffffde9baeff990033ff990033ffc04064fff4dfe5ffffffffffffffffffffffffffefcfd8ffbb3057ff990033ff990033ffeabfcbffffffffffd47d96ff990033ff990033ffb6204afffaeff2ffffffffffffffffffc55071ff990033ff990033ff990033ffefcfd8ffffffffffffffffffeabfcbff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff707070ffffffffffffffffffffffffff7f7f7fff000000ff000000ffbfbfbfff303030ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffffffffffffffffff000000ff000000ff505050ffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefffffffffffffffffffffffffffffffffff202020ff000000ff606060ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffafafafff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ffdfdfdfffffffffff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff000000ffefefefff606060ff000000ff000000ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffefefefffbfbfbfff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc55071ff990033ff990033ffefcfd8ffffffffffffffffffffffffffffffffffffffffffffffffffde9baeffffffffffb0103dff990033ffbb3057fffffffffffffffffffffffffffffffffffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffd47d96ff990033ff990033ffde9baeffffffffffffffffffffffffffeabfcbff990033ff990033ffcb607effffffffffffffffffffffffffffffffffb6204aff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffff202020ff000000ff202020ffffffffffffffffffdfdfdfff000000ff000000ff202020ff000000ff101010ffffffffffffffffffefefefff101010ff000000ff404040ffefefefff000000ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff404040ffffffffffffffffff505050ff000000ff000000ff404040ff9f9f9fffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff606060ff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff202020ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff7f7f7fffffffffff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff9f9f9fffefefefff101010ff000000ff000000ff606060ffcfcfcfffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffffffffffffffffffffffffffaeff2ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbeff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033fffaeff2ffd47d96ff990033ff990033fff4dfe5fffffffffffffffffffffffffffaeff2ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffafafafffffffffff7f7f7fff000000ff101010ffcfcfcfff000000ff000000ff9f9f9fffffffffff9f9f9fff000000ff000000ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffefefefff303030ff000000ff000000ff000000ff202020ff9f9f9fffffffffffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff303030ff000000ff505050ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffff9f9f9fff101010ff000000ff000000ff000000ff404040ffcfcfcfffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffe5afbeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff404040ffffffffff202020ff000000ff707070ffffffffff505050ff000000ff303030ffffffffff202020ff000000ff202020ffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffff9f9f9fff202020ff000000ff000000ff000000ff707070ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffdfdfdfff707070ff101010ff000000ff000000ff000000ffbfbfbfffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffeabfcbff990033ff990033ffeabfcbffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff707070ff000000ff000000ffdfdfdfffffffffffafafafff000000ff000000ff7f7f7fff000000ff000000ff9f9f9fffffffffffcfcfcfff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffff505050ff000000ff404040ffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ffdfdfdfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff404040ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff101010ff000000ff707070ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff101010ff000000ff707070ffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff707070ff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff8f8f8fffffffffffffffffffffffffffffffffffefefefff7f7f7fff000000ff000000ff303030ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffefcfd8ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033fff4dfe5ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffde9baeff990033ff990033ffefcfd8ffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff000000ff000000ff404040ffffffffffffffffffffffffff202020ff000000ff000000ff000000ff202020ffffffffffffffffffffffffff101010ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffefefefff000000ff000000ff404040ffffffffffffffffffefefefffdfdfdfffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffff8f8f8fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffff505050ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff9f9f9fffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfff202020ff000000ff202020ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffcfcfcfffffffffffdfdfdfffffffffffffffffffffffffffffffffff606060ff000000ff000000ffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffb6204aff990033ffb6204affffffffffffffffffffffffffffffffffffffffffffffffffffffffffe5afbefff4dfe5ff990033ff990033ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffc04064ff990033ffb6204affffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ff000000ffafafafffffffffffffffffffffffffff8f8f8fff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffff707070ff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff505050ff000000ff000000ff404040ffffffffff8f8f8fff101010ff404040ffffffffffffffffffffffffffafafafff000000ff000000ffbfbfbfff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffdfdfdfff000000ff000000ff202020ffefefefffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffbfbfbfff000000ff000000ff505050ffefefefffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff202020ffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff101010ffdfdfdfffffffffffffffffffffffffffffffffffcfcfcfff000000ff000000ff202020ffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ff404040ffefefefff505050ff000000ff8f8f8fffffffffffffffffffffffffff606060ff000000ff101010ffffffffff7f7f7fff000000ff000000fffffffffffffffffffffffffffaeff2ffeabfcbffffffffffffffffffd47d96ff990033ff990033ffcb607effffffffffffffffffffffffffffffffffffffffffeabfcbffb0103dffffffffffc04064ff990033ff990033ffde9baeffffffffffffffffffffffffffffffffffffffffffcb607eff990033ff990033ffd47d96ffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ff000000ff202020ffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffefefefffffffffffffffffffffffffffefefefff101010ff000000ff000000ff505050ffafafafffbfbfbfff9f9f9fff202020ff000000ff000000ff000000ff404040ffffffffff7f7f7fff000000ff000000ff505050ffbfbfbfff9f9f9fff101010ff000000ff101010ffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffff707070ff000000ff000000ff101010ff8f8f8fffbfbfbfffbfbfbfff606060ff000000ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffff606060ff000000ff000000ff202020ff8f8f8fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff000000ff101010ff7f7f7fffbfbfbfffbfbfbfff707070ff000000ff000000ff000000ffafafafffffffffffffffffff404040ff000000ff000000ff303030ff9f9f9fffbfbfbfffafafafff606060ff000000ff000000ff101010ffcfcfcfffffffffff202020ff000000ff000000ff7f7f7fffbfbfbfff7f7f7fff000000ff000000ff606060ffffffffff7f7f7fff000000ff000000fffffffffffffffffff4dfe5ffb0103dff990033ffc04064ffffffffffffffffffbb3057ff990033ff990033ffc04064ffde9baeffeabfcbffe5afbeffcb607eff990033ff990033fffffffffff4dfe5ffb0103dff990033ff990033ffcb607effe5afbeffeabfcbffde9baeffc04064ff990033ff990033ffbb3057ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff606060ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff000000ff101010ff505050ff000000ff404040ffffffffffefefefff303030ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffff404040ff000000ff404040ffffffffffffffffffffffffffffffffffffffffff404040ff000000ff404040ffffffffff7f7f7fff000000ff000000ffffffffffffffffff7f7f7fff000000ff404040ffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff404040ff000000ff000000ffbfbfbfffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffff606060ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffafafafffffffffffffffffffffffffff000000ff000000ff7f7f7fffffffffffffffffffffffffffffffffffffffffff404040ff000000ff7f7f7fffffffffff7f7f7fff000000ff000000ff404040ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff9f9f9fffffffffffffffffffffffffffefefefff505050ff000000ff000000ff000000ff000000ff000000ff000000ff000000ff101010ffcfcfcfffffffffffffffffffcfcfcfff101010ff000000ff000000ff000000ff000000ff000000ff101010ffdfdfdfffffffffff7f7f7fff000000ff000000ffffffffffffffffffeabfcbff990033ff990033ff990033fffffffffffffffffffaeff2ffc04064ff990033ff990033ff990033ff990033ff990033ff990033ff990033ffb0103dffffffffffffffffffefcfd8ffb6204aff990033ff990033ff990033ff990033ff990033ff990033ff990033ffc04064fffaeff2ffffffffffffffffffd47d96ff990033ff990033ffffffffffffffffffffffffffffffffffffffffff990033ff990033ffeabfcbffffffffffffffffffffffffffffffffffc04064ff990033ffc04064ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfff000000ffefefefffffffffffffffffffffffffffffffffffffffffffcfcfcfff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffefefefff707070ff202020ff000000ff000000ff202020ff707070ffefefefff9f9f9fff404040ff707070ffffffffffffffffffefefefff7f7f7fff202020ff000000ff000000ff303030ffbfbfbfffffffffffffffffff707070ff404040ff707070ffffffffffffffffffffffffffffffffffffffffff707070ff404040ff707070ffffffffff9f9f9fff404040ff404040ffffffffffffffffff9f9f9fff404040ff707070ffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffff9f9f9fff404040ff000000ff000000ff000000ff505050ffbfbfbfffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffbfbfbfff505050ff101010ff000000ff000000ff202020ff707070ffdfdfdfffffffffffffffffffffffffffffffffff404040ff404040ff9f9f9fffffffffffffffffffffffffffffffffffffffffff707070ff404040ff9f9f9fffffffffff7f7f7fff000000ff000000ffffffffff9f9f9fff303030ff000000ff000000ff101010ff505050ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff505050ff000000ff000000ff000000ff303030ff7f7f7fffefefefffffffffffffffffffffffffffffffffffcfcfcfff505050ff000000ff000000ff101010ff606060ffdfdfdfffffffffffffffffff9f9f9fff404040ff404040fffffffffffffffffffaeff2ffbb3057ff990033ffd47d96ffffffffffffffffffffffffffffffffffde9baeffc04064ff990033ff990033ff990033ffbb3057ffd47d96fffaeff2fffffffffffffffffffffffffffaeff2ffde9baeffbb3057ff990033ff990033ff990033ffc55071ffde9baeffffffffffffffffffffffffffffffffffde9baeffc04064ffc04064ffffffffffffffffffffffffffffffffffffffffffc04064ffc04064ffefcfd8ffffffffffffffffffffffffffffffffffd47d96ffc04064ffd47d96ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfdfdfffbfbfbfffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffbfbfbfff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ffbfbfbfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffafafafff000000ff000000ff9f9f9fffffffffffffffffffffffffffffffffffffffffffffffffff404040ff000000ff101010ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff101010ff000000ff101010ffcfcfcfffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff606060ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff000000ff000000ff000000ff505050ff7f7f7fff7f7f7fff303030ff000000ff000000ff101010ffefefefffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff101010ff000000ff000000ff000000ff000000ff000000ff000000ff303030ffcfcfcfffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff7f7f7fff000000ff000000ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffefefefff8f8f8fff505050ff404040ff404040ff606060ffafafafffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff9f9f9fff404040ff404040ffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff000700ae00700007000100010003000300040000000d000c001000d800d800d800d800280018003610517569636b54696d65aa20616e6420610000280024003f0d206465636f6d70726573736f7200280030000f1f617265206e656564656420746f20736565207468697320706963747572652e000000a100e007ac00000000000007a86170706c022000006d6e74725247422058595a2007d900020019000b001a000b616373704150504c000000006170706c000000000000000000000000000000000000f6d6000100000000d32d6170706c00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000b64657363000001080000006f6473636d000001780000056c63707274000006e400000038777470740000071c000000147258595a00000730000000146758595a00000744000000146258595a0000075800000014725452430000076c0000000e636861640000077c0000002c625452430000076c0000000e675452430000076c0000000e64657363000000000000001447656e65726963205247422050726f66696c6500000000000000000000001447656e65726963205247422050726f66696c6500000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000006d6c7563000000000000001e0000000c736b534b00000028000001786872485200000028000001a06361455300000024000001c87074425200000026000001ec756b55410000002a0000021266724655000000280000023c7a685457000000160000026469744954000000280000027a6e624e4f00000026000002a26b6f4b5200000016000002c86373435a00000022000002de6865494c0000001e00000300646544450000002c0000031e68754855000000280000034a7376534500000026000002a27a68434e00000016000003726a614a500000001a00000388726f524f00000024000003a2656c475200000022000003c67074504f00000026000003e86e6c4e4c000000280000040e6573455300000026000003e874685448000000240000043674725452000000220000045a66694649000000280000047c706c504c0000002c000004a47275525500000022000004d06172454700000026000004f2656e555300000026000005186461444b0000002e0000053e005601610065006f006200650063006e00fd0020005200470042002000700072006f00660069006c00470065006e006500720069010d006b00690020005200470042002000700072006f00660069006c00500065007200660069006c0020005200470042002000670065006e00e800720069006300500065007200660069006c0020005200470042002000470065006e00e9007200690063006f0417043004330430043b044c043d043804390020043f0440043e044404300439043b002000520047004200500072006f00660069006c0020006700e9006e00e9007200690071007500650020005200560042901a75280020005200470042002082725f6963cf8ff000500072006f00660069006c006f0020005200470042002000670065006e0065007200690063006f00470065006e0065007200690073006b0020005200470042002d00700072006f00660069006cc77cbc1800200052004700420020d504b85cd30cc77c004f006200650063006e00fd0020005200470042002000700072006f00660069006c05e405e805d505e405d905dc0020005200470042002005db05dc05dc05d90041006c006c00670065006d00650069006e006500730020005200470042002d00500072006f00660069006c00c1006c00740061006c00e1006e006f00730020005200470042002000700072006f00660069006c666e901a0020005200470042002063cf8ff065874ef64e00822c0020005200470042002030d730ed30d530a130a430eb00500072006f00660069006c0020005200470042002000670065006e0065007200690063039303b503bd03b903ba03cc002003c003c103bf03c603af03bb002000520047004200500065007200660069006c0020005200470042002000670065006e00e9007200690063006f0041006c00670065006d00650065006e0020005200470042002d00700072006f006600690065006c0e420e1b0e230e440e1f0e250e4c002000520047004200200e170e310e480e270e440e1b00470065006e0065006c0020005200470042002000500072006f00660069006c00690059006c00650069006e0065006e0020005200470042002d00700072006f006600690069006c00690055006e006900770065007200730061006c006e0079002000700072006f00660069006c0020005200470042041e04310449043804390020043f0440043e04440438043b044c00200052004700420645064406410020062a06390631064a0641002000520047004200200627064406390627064500470065006e00650072006900630020005200470042002000500072006f00660069006c006500470065006e006500720065006c0020005200470042002d006200650073006b0072006900760065006c007300657465787400000000436f707972696768742032303037204170706c6520496e632e2c20616c6c207269676874732072657365727665642e0058595a20000000000000f35200010000000116cf58595a20000000000000744d00003dee000003d058595a200000000000005a750000ac730000173458595a20000000000000281a0000159f0000b83663757276000000000000000101cd0000736633320000000000010c42000005defffff326000007920000fd91fffffba2fffffda3000003dc0000c06c00a100e000040000000200ff}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The Washington Post\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2003 Saturday  \par Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS Plan Would Cut Drug Costs For Poor; \par WHO Would Provide 3-in-1 Pill to Nations}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Shankar Vedantam, Washington Post Staff Writer\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A Section; A01\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1133 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA Oct. 24\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The World Health Organization will disclose next week the first details of a global AIDS strategy to bring low-cost drugs to 3 million people in poor countries, a plan that top officials said will eventually include endors}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment of pills that combine three HIV drugs in a single tablet. \par The endorsement of the three-in-one pills is expected to be controversial because they could violate a variety of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Only about 300,000 people are receiving AIDS medicine in the regions targeted by WHO. \par The strategy is also expected to call for treating patients at the first sign of symptoms, rather than waiting for tests to confirm infection by HIV, the virus that causes AIDS, and to allow nurses and community organiz}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions to dispense the medicines. As a first step, WHO will issue a list next week of the "first line" medicines to be used in poor countries.  \par  One "fixed-dose" combination already is being sold by a generic-drug manufacturer in India, and several others are in the pipeline. Health experts here said the single-pill combinations would offer huge benefits by providing medication that would work for about 80 percent of patients in an easy-to-use and low-cost form. \par If the pills proved popular and effective, the Bush administration could face a politically difficult choice b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tween high-priced patented drugs and low-cost combination generics as it implements its own five-year pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gram to fight AIDS in Africa and elsewhere. \par Unlike generic AIDS medicines that copy a single drug's formula, each of the new combination pills could infringe on several }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in one stroke, taking the conflict between providing   lifesaving medicines and protecting intellectual property rights into uncharted waters. \par  "If we have this regimen in fixed-dose combinations, it will be the best," Paulo Teixeira, director of WHO's HIV/AIDS Department, said in an interview. "I hope very soon we will have more and more fixed-dose co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 binations." \par  The combination pills are expected to be part of a broad strategy that the health agency will soon outline to reach its "3 by 5" target. Teixeira and others said the effort could press ahead without the all-in-one pills, but such medicines would be the best way to rapidly increase the number of people receiving   lifesaving ther}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pies. \par Of the 3 million patients targeted worldwide, nearly 2 million are in Africa; the rest are scattered across Asia and Latin America. \par  Activist groups have championed the "fixed-dose" approach. The International Federation of Pharmaceutical Manufacturers Associations opposes the approach, however, contending that combination pills have not been rigorously tested and would make it easier for counterfeit drugs to enter the market. \par  The pending WHO announcement will mark the second important development in days in the effort to i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 crease access to AIDS medicines. On Thursday, the William J. Clinton Presidential Foundation, founded by former president Bill Clinton, announced agreements with three generic-drug manufacturers in India and one in South Africa to dramatically lower the price of AIDS drugs. Ira Magaziner, chairman of the foundation's HIV/AIDS Initiative, said three fixed-dose combination pills were covered by the agreement, at an annual cost of  $132 to  $240 per patient. \par  Meeting WHO's goal of providing treatment to an additional 2.7 million AIDS patients by the end of 2005 means 100,000 people would need to be started on medication every month. Several officials here privately conceded that the target is unrealistic, but all said it will spur a long-overdue international effort. More than 5 million people in poor countries need AIDS medication but are not receiving it, health specialists estimate. \par Teixeira said the ultimate goal is to radically expand access to AIDS treatment in poor countries. \par  "We will say, you don't need to get care only from doctors; let's train nurses, community organizations and families," he said. "We're changing the paradigm of AIDS treatment." Teixeira is credited for having rapidly increased access to HIV treatment in his native Brazil. Half of all patients in poor countries now being treated for AIDS are Brazilians. \par  The fixed-dose approach has several advantages, as well as a few drawbacks. Peter Graaff, an AIDS med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cine policy expert at WHO, said the biggest advantage may be in getting people to take the medicine on the right schedule. Taking combinations of separate pills can be difficult, and supply problems with any one me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 icine can upset the entire regimen, he said. That could make it more likely that patients would develop and pass along resistant strains of the virus. However, some patients on fixed-dose medicines may experience side effects caused by just one of the medicines in the combination, Graaff said, and packaging the drugs in a combination tablet would limit the flexibility to switch patients to a different drug combination. \par  One combination medicine, called Triomune, developed by the Indian pharmaceutical company  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is being used in Africa. It combines the medicines 3TC (lamivudine), d4T (stavudine) and nevirapine. \par  India is not part of the global system on intellectual property rights, but is expected to sign on by 2005. U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 der recently negotiated exceptions to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system, poor countries can allow local manufacturers to duplicate   lifesaving generic medicines, and to export them after completing  arrangements that carve out limited exceptions to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . \par  Negotiating those "compulsory licensing" arrangements is expected to be much more complicated for the fixed-drug combinations. \par  Thomas Kanyok, who works in a WHO program that develops medicines for poor countries, said the threat of compulsory licensing could prompt multinational pharmaceutical companies to develop their own fixed-dose combination medicines or license other manufacturers to make them. \par  The other large variable in the equation is the U.S. government, which has pledged $15 billion to fight AIDS in Africa and the Caribbean over five years. \par  "Will that be used to buy generics, or will there be stipulations to buy from a U.S. manufacturer?" Kanyok asked. \par  Harvey Bale, director general of the international pharmaceutical federation, said that generic fixed-dose combination drugs have not being thoroughly tested and that WHO's endorsement would encourage counte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 feit drugs. \par  "We're going to start treating 3 million by 2005," he said. "The question is, are we going to help 3 million by 2005?" \par  But Ellen 't Hoen, spokeswoman for the Campaign for Access to Essential Medicines of the nonprofit group Doctors Without Borders, said combination pills are essential to fight AIDS in poor countries. \par  "WHO would have to say that this is the way to go," she said. "That implicitly says that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  shouldn't stand in the way."  \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (92%); AIDS POLICY (91%); HEALTH DEPARTMENTS (90%); HEALTH CARE COSTS (90%); GENERIC DRUGS (90%); DRUG PRICES (90%); AIDS & HIV TREATMENT (90%); INFE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIOUS DISEASE (90%); INTELLECTUAL PROPERTY LAW (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); UNITED NATIONS INSTITUTIONS (89%); PHARMACEUTICALS INDUSTRY (78%); ANTIVIRALS (78%); INTELLECTUAL PROPERTY (78%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); CIVIC & SOCIAL ORGANIZATIONS (78%); PUBLIC HEALTH ADMINISTRATION (78%); PHARMACEUTICAL PREPARATION MFG (77%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRINGEMENT (76%); COUNTERFEIT DRUGS (73%); GENERIC PRODUCTS (73%); BUSINESS & PROFESSIONAL ASSOCIATIONS (73%); PHARMACEUTICALS PRODUCT DEVELOPMENT (72%); HEALTH CARE ACCESS (70%); PHARMACEUTICALS ASSOCIATIONS (69%); INTERVIEWS (67%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION (94%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (92%); LATIN AMERICA (79%); ASIA (79%); INDIA (79%); UNITED STATES (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 25, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The Washington Post\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;The Bottom Line Africa News October 24, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_247}{\*\bkmkstart DOC_ID_247_0}{\*\bkmkstart doc_id_109}{\*\bkmkend DOC_ID_247}{\*\bkmkend DOC_ID_247_0}{\*\bkmkend doc_id_109}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_109"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100300039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 109 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2003 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par The Bottom Line}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 926 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Competition Commission Steps On State's Toes\par THE Competition Commission has rushed in where government has so far feared to tread, with its accus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion that drug firms GlaxoSmithKline and Boehringer Ingelheim have been charging unfair prices for their p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tented AIDS drugs.\par The commission believes the firms are stifling competition as they have licensed only one local company, Aspen Pharmacare, to manufacture generic copies of their life- prolonging AIDS medicines. The authority wants the Competition Tribunal to force them to issue more generic manufacturing licences and allow other companies, such as India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , to export to SA.\par Glaxo and Boehringer argue their AIDS drug prices in SA are among the lowest in the world. This is true, and Glaxo did cut the price of its two-drug combination, Combivir, last week (announcing it in London just hours before the commission's bombshell). But the patented drugs are still more expensive than the generics made by companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy. \par The commission's stance has cost Glaxo the glowing media coverage it would have been hoping for, but far more worrying to the company is the uncertainty that has been created over the future of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection in SA.\par Will this open the way for more }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to be overthrown, and will other developing countries follow suit?\par The commission's motivation is puzzling, especially if it ends up setting a precedent that crosses sectoral boundaries and threatens intellectual property in other industries. That would send a shudder through the boardrooms of all companies that have invested heavily in research they thought was protected by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par In terms of World Trade Organisation rules, governments are entitled to override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  when there is a public healthcare crisis, for which the AIDS epidemic surely qualifies. So why is the commission dabbling in an area that ought to be the domain of government?\par  Durban Deep defence\par DURBAN Roodepoort Deep went on the offensive when issuing its results for the September quarter yeste}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 day. The message was that although it is having to cut jobs, the worst is over and nobody should forget that it has also created plenty of employment in SA over the years.\par The increase in the company's net loss for the quarter comes as no surprise; Durban Deep has had to revise its strategy and retrench 3000 employees after betting on a weak rand. The currency's appreciation against the dollar has, though, made nonsense of a strategy based on mining high volumes of very low-grade reef to maximise the ounces of gold extracted.\par Now only medium and better grades are being targeted at its South African operations.\par The upshot is that production at its remaining North West operations will fall 5%.\par Still, Durban Deep will continue to mine about 1-million ounces of gold a year on what should be a sustain}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble basis.\par Strangely, the strategy revision does not include pay cuts for top executives chairman and CEO Mark Wellesley-Wood's generous package makes him SA's bestpaid gold company executive.\par  Investors not bolting\par YOU need nerves of steel to run Iscor these days. Severely criticised for implementing import parity pricing, facing a slump in domestic demand, with dollar costs up by 36% and unions spitting mad about planned r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 trenchments, one could almost sympathise with Iscor executives. Fortunately, they receive exceptionally generous packages, details of which were revealed recently.\par Yesterday's announcement that headline earnings a share for the quarter to September had fallen 41% compared with the corresponding three months last year might have been expected to send the share price tumbling. Instead, it jumped almost 3%.\par This is partly because the markets knew Iscor was having a tough time, and partly because there is an e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pectation that the radical cost-cutting exercise that is presently under way will help to restore Iscor's bottom line to respectability.\par The turnaround at the Saldanha plant has helped keep Iscor in the black, and the feeling is that if the group can limp through the current period of rand strength, weak global steel prices and a lame local economy, it will be in a good position to be making serious money this time next year.\par In the meantime, Iscor is ungeared, cash-flush and on the acquisition trail.\par If it can take out and streamline some of its domestic competitors, its dominance of the South African market will become even more pronounced.\par That is sure to cheer Iscor's shareholders far more than its domestic customers.\par  SA-built UK success\par SELESTIA, a wholly owned subsidiary of Old Mutual, is achieving remarkable success in the highly compet}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive UK fund supermarket industry. On offer to direct investors or financial intermediaries is a "one-stop shop" of investment funds and administrative functions.\par Selestia has a choice of 409 funds managed by 47 different fund managers, creating a clear audit trail for compliance purposes. The Selestia platform, which launched in the UK in 2001, was built in SA and all new developments of the investment tools continue to take place "in house" at Old Mutual's offices in Cape Town.\par However, the model has been designed specifically for the UK market and Old Mutual has no plan to roll out a fund supermarket to the local market at present.\par This is mainly because of the greater choice of funds available in the UK, although South African investors are also far less likely to consult an independent adviser about their investment portfolio.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); PHARMACEUTICAL PREPARATION MFG (91%); AIDS & HIV TREATMENT (91%); ANTITRUST & TRADE LAW (90%); ANTIVIRALS (90%); DRUG PRICES (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); INTELLECTUAL PROPERTY LAW (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); AIDS & HIV (90%); GENERIC PRODUCTS (79%); TRADE DEVELOPMENT (78%); GENERIC DRUGS (78%); PRICE CHANGES (77%); LAYOFFS (76%); EXPORT TRADE (75%); EPIDEMICS (72%); PRICE CUTTING (72%); COMPANY LOSSES (71%); INTERNATIONAL TRADE LAW (70%); DEVELOPING COUNTRIES (70%); CURRENCIES (68%); GOLD MINING (63%); WAGES & SALARIES (61%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); APN (JSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (57%); RANBAXY (NSE) (55%); DROOY (NASDAQ) (53%); DRD (JSE) (53%); DRD (BRU) (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS  (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (58%); NAICS325411 MEDIC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAL & BOTANICAL MANUFACTURING (55%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UCTS (55%); NAICS212221 GOLD ORE MINING (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COMPETITION COMMISSION (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (93%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (72%);  COMPETITION COMMISSION (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 24, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;Clinton, Aspen to Cut Price of Aids Drugs Africa News October 24, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_248}{\*\bkmkstart DOC_ID_248_0}{\*\bkmkstart doc_id_110}{\*\bkmkend DOC_ID_248}{\*\bkmkend DOC_ID_248_0}{\*\bkmkend doc_id_110}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_110"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 110 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  24, 2003 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par Clinton, Aspen to Cut Price of Aids Drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 471 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SA's largest generic drug manufacturer, Aspen Pharmacare, has joined Indian pharmaceutical companies Ranbaxy, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Matrix Laboratories in reaching an agreement with the Clinton Foundation to lower the price of AIDS drugs.\par The Clinton Foundation, which is backed by former US president Bill Clinton, will assist African and Caribb}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an governments obtain cheaper AIDS drugs by pooling the manufacturing capacity of the four companies. It says it will be able to provide one of the most commonly used triple drug combinations stavudine, lamiv}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dine, and nevirapine $140 a person a year, about one-third cheaper than that of the developing world. \par "This pricing is likely to become a benchmark for the (South African) government once it starts providing a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tiretroviral AIDS medicines," said Aspen deputy CEO Gus Attridge. An estimated 4-million people in sub-Saharan Africa need antiretroviral medicines, about 500000 of them in SA, but few have access to the drugs.\par Aspen's ability to supply other countries with generic AIDS drugs will depend on the conditions laid down by the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -holding pharmaceutical companies when they granted licences to Aspen, and by the regulatory requirements in the export destinations.\par For example, its licence from Boehringer Ingelheim limits the sale of generic nevirapine to the South African public sector, and it would have to renegotiate its licence conditions with Boehringer if it wanted to export the drugs. None of Aspen's generic AIDS drug licences cover sales to the Caribbean.\par In addition to the Boehringer licence, Aspen has permission from GlaxoSmithKline to make generic copies of AZT, 3TC and the two combined as Combivir, which it can sell in sub-Saharan Africa.\par Bristol-Myers Squibb's has said it will not enforce its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rights in sub-Saharan Africa to its antiretroviral drug stavudine, which Aspen has already starting manufacturing.\par This is the only one of Aspen's generic AIDS drugs that has been registered by the Medicines Control Cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cil, but approval is expected shortly for the others, said Attridge.\par He said Aspen's profit margins on the expected generic AIDS drug business would be "wafer thin."\par Aspen was planning to finish construction of a R150m production plant early next year, which would signif}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cantly boost production capacity, he said.\par The Clinton Foundation has been working with the four drug companies for the past nine months, looking at ways to reduce their costs and scale up production of the AIDS drugs used to prolong the lives of people i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fected with HIV, and prevent mother-to-child transmission of the virus.\par "This agreement represents a big breakthrough in our efforts to begin treatment programmes in places where, until now, there has been virtually no medicine, and therefore no hope," Clinton said.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (96%); AIDS & HIV (94%); PHARMACEUTICALS INDUSTRY (93%); GENERIC DRUGS (93%); PHARMACEUTICAL PREPARATION MFG (92%); ANTIVIRALS (92%); DRUG PRICES (90%); PRICE CHANGES (90%); MANUFACTURING SECTOR PERFORMANCE (78%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PLANT CAPACITY (78%); EMERGING MARKETS (77%); MANUFA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TURING OUTPUT (76%); GENERIC PRODUCTS (73%); US PRESIDENTS (72%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (72%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PROVALS (71%); VIRUSES (69%); INTELLECTUAL PROPERTY LAW (67%); COMPANY PROFITS (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BMY (NYSE) (90%); GSK (NYSE) (90%); GSK (LSE) (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); APN (JSE) (58%); RANBAXY (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (91%); SIC2834 PHARMACEUTICAL PREPARATIONS  (90%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (58%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BILL CLINTON (85%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CLINTON FOUNDATION (86%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (93%); CARIBBEAN ISLANDS (92%); UNITED STATES (90%); SUB SAHARAN A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 F}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RICA (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASPEN PHARMACARE (95%);  CLINTON FOUNDATION (86%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 24, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Aids-Drugs Price War is Far From Over Africa News October 20, 2003 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_249}{\*\bkmkstart DOC_ID_249_0}{\*\bkmkstart doc_id_111}{\*\bkmkend DOC_ID_249}{\*\bkmkend DOC_ID_249_0}{\*\bkmkend doc_id_111}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_111"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 111 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  20, 2003 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Aids-Drugs Price War is Far From Over}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 603 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Commission recommends drug firms be forced to allow cheaper generics\par THE Competition Commission's recommendation last week that drug firms GlaxoSmithKline and Boe hringer Ingelheim be forced to allow cheap generic copies of their AIDS drugs to reach the South African market goes to the heart of the pricing war being waged by AIDS activists.\par The Treatment Action Campaign and the other activist groups that initially brought the complaint to the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mission last year argue that, despite recent cuts, the prices charged by the pharmaceutical firms for their life-prolonging AIDS medicines are still excessively high.\par "These drugs are not like aspirin, you can't substitute one with another," says Jonathon Berger, a researcher with the AIDS Law Project which represents the complainants. \par The commission said Boe hringer and Glaxo had contravened the Competition Act by abusing their dominant spots in their respective antiretroviral markets, engaging in restrictive practices such as denying competitors access to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par "Of course we have dominant market position (with nevirapine), we invented it," says Boe hringer spokesman Kevin McKenna. He says the commission's finding is "absolutely false, misleading and mischievous", as Boe hringer's South African arm has gone to great lengths to reduce the local price of nevirapine.\par It sells nevirapine to the private sector in SA at R360 (excluding VAT) for a month's supply, down from just more than R1100 in 2001. McKenna says the parent company is sympathetic to further price reductions.\par "We cannot possibly match generic prices, but we've slashed the price of Viramune to the pain threshold. It's wrong to say we are preventing access," he says.\par He emphasises that the firm has granted Aspen Pharmacare a voluntary licence to manufacture generic nevirapine.\par The drug is still awaiting registration by the Medicines Control Council, and once registered may only be sold to the public sector which does not yet provide antiretrovirals to AIDS patients. McKenna says the licence stipulates public sector sale since that is where there is greatest demand for the low price drugs. Berger di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 agrees, saying patients in both the public and private sectors need a sustainable supply of affordable AIDS drugs.\par Glaxo, which dominates the AIDS drugs market, holds }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on AZT (branded Retrovir), lamivudine (3TC), and the two combined (Combivir).\par However, as the commission was issuing a media statement on its ruling last Thursday, Glaxo said it had slashed its public sector prices of its drugs in developing countries, and extended the licence it had given to Aspen for manufacturing generics to include the private sector, and other sub-Saharan countries.\par As with generic nevirapine, Aspen still awaits registration of its generic versions of Glaxo's drugs. Glaxo and Boe hringer say the commission's announcement took them by surprise.\par Boe hringer says an earlier complaint of excessive pricing brought against them by the local arm of Indian firm }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was dismissed. Glaxo has quietly been negotiating with complainants.\par Neither Berger nor Glaxo's lawyer Anthony Norton will say what has been discussed. It is likely pressure is being brought to bear on Glaxo to issue more voluntary licences for its medicines and thus drive price co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 petition in the generics market.\par It is still possible for the complainants to withdraw their case, but it will not necessarily help the drug firms since the commission would not be bound by such a settlement, and could still refer the matter to the Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 petition Tribunal for prosecution.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (93%); PHARMACEUTICAL PREPARATION MFG (92%); AIDS & HIV TREA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (91%); PHARMACEUTICALS INDUSTRY (91%); ANTIVIRALS (91%); GENERIC PRODUCTS (90%); PRICE CHANGES (90%); GENERIC DRUGS (90%); DRUG PRICES (90%); PRICE CUTTING (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (88%); PARENT COMPANIES (78%); NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (78%); HOLDING COMPANIES (78%); RESTRAINT OF TRADE (77%); DEVELOPING COUNTRIES (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); APN (JSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS  (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KEVIN MCKENNA (76%); JONATHON BERGER (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AMERICA (90%); SOUTH AFRICA (72%); AFRICA (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 20, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Foreign Firms Block Generic Aids Drugs Africa News October 17, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_250}{\*\bkmkstart DOC_ID_250_0}{\*\bkmkstart doc_id_112}{\*\bkmkend DOC_ID_250}{\*\bkmkend DOC_ID_250_0}{\*\bkmkend doc_id_112}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_112"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 112 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  17, 2003 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Foreign Firms Block Generic Aids Drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 551 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Competition Commission has ruled that drug companies GlaxoSmithKline and Boehringer Ingelheim abused their dominant market positions in respect of antiretroviral medicines, and has decided to refer the case to the Competition Tribunal.\par The move comes as drug companies come under increasing pressure from AIDS activists worldwide over the price of their patented AIDS medicines, and their limited efforts to issue licences for the manufacture of cheaper generic copies.\par "Our investigation revealed that each of the firms has refused to license their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to generic manufactu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers in return for a reasonable royalty," said commissioner Menzi Simelane. \par "We believe this is feasible and that consumers will benefit from cheaper generic versions of the drugs co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cerned . Granting licences will provide for competition between firms and their generic competitors."\par The case stems from a complaint brought by a group of AIDS activists, including the Treatment Action Ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 paign, and union leaders last year. They accused the two firms of excessive pricing of antiretroviral med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines. The latest development adds impetus to their efforts to bring down the price of antiretroviral med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines, particularly in the private sector.\par "It's excellent news," said Jonathon Berger, a researcher with AIDS Law Project, which filed the original complaint.\par Boehringer holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  for nevirapine, marketed as Viramune. Glaxo holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on AZT (bran}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed Retrovir), lamivudine (3TC), and the two combined (combivir). Both firms issued voluntary licences to JSE-listed Aspen Pharmacare to manufacture generics, but have stipulated the drugs may be used only in the public sector.\par However, Glaxo announced yesterday it had extended Aspen's licence to include manufacture for the private sector, and sub-Saharan Africa. Production has not yet started, as Aspen still needs the medicines to be re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 istered by the Medicines Control Council.\par Glaxo spokeswoman Vicki Ehrich said the commission's announcement had taken the firm by surprise, as the commission had previously given Glaxo an undertaking that it would not refer the matter to the tribunal while Glaxo was in negotiation with the complainants.\par "We do not believe there is any basis for an allegation of excessive pricing, because we have the lowest prices in the private sector (in SA) of anywhere in the world," she said.\par The commission plans to recommend that the tribunal order Glaxo and Boehringer to provide information on its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in return for "reasonable" royalties, in effect ordering the two firms to issue additional licences for the manufacture of generic antiretrovirals. It is also recommending the firms be fined 10% of their annual turnover from antiretroviral drugs in SA for every year they were in contravention of the Competition Act.\par "We don't understand the conclusions they've reached," said Boehringer spokesman Kevin McKenna. "A similar complaint was lodged against us two years ago by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -Medpro, and in August we were informed that we were not a dominant company and were not guilty of excessive pricing of viramune."\par Zolile Ntukwana, the commission's compliance division manager, said both parties were entitled to begin n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gotiations for a consent order similar to an out-of-court settlement.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ANTIVIRALS (95%); GENERIC PRODUCTS (92%); AIDS & HIV TREATMENT (92%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICALS INDUSTRY (92%); GENERIC DRUGS (92%); AIDS & HIV (91%); PHARMACEUTICAL PREPARATION MFG (90%); ANTITRUST & TRADE LAW (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); DRUG PRICES (90%); INVESTIGATIONS (90%); AIDS POLICY (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); ROYALTIES (78%); RESTRAINT OF TRADE (78%); LICENSES & PERMITS (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); APN (JSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS  (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KEVIN MCKENNA (56%); VICKI EHRICH (56%); JONATHON BERGER (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 COMPETITION COMMISSION (61%); AIDS LAW PROJECT (56%); MEDICINES CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TROL COUNCIL (56%); COMPETITION TRIBUNAL (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (79%); SUB SAHARAN AFRICA (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE (73%); ZOLILE NTUKWANA (56%);  COMPETITION COMMISSION (61%); AIDS LAW PROJECT (56%); MEDICINES CONTROL COUNCIL (56%); COMPETITION TRIBUNAL (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 17, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pharmaceutical companies charging unfair prices for essential Aids medicines, says South African commission: Ruling opens the door for cut-price HIV drugs The Guardian - Final Edition October 17, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_251}{\*\bkmkstart DOC_ID_251_0}{\*\bkmkstart doc_id_113}{\*\bkmkend DOC_ID_251}{\*\bkmkend DOC_ID_251_0}{\*\bkmkend doc_id_113}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_113"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 113 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian - Final Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 October}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  17, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Pharmaceutical companies charging unfair prices for essential Aids medicines, says South African commission: Ruling opens the door for cut-price HIV drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Sarah Boseley Health editor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Foreign Pages, Pg. 17\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 796 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Grassroots activists in South Africa gained an important victory yesterday over two giant pharmaceutical companies, including Britain's GlaxoSmithKline, which could open the door to cheap Aids drugs being avai}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 able across the hard-hit continent.\par  South Africa's competition commission announced that it had accepted the case, argued by the Treatment Action Campaign and other groups, that the high charges made by GSK and Boehringer Ingelheim for Aids drugs were unfair.\par  The companies had engaged in restrictive practices by refusing licences to other firms making their own low-cost generic versions of Aids drugs, the commission said.\par  Those companies, such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India, are regularly accused of piracy by the multi nationals, which, through the courts and by lobbying friendly governments such as the US in trade negotiations, have vigo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ously defended the 20-year }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on their drugs. \par  But the commission's statement yesterday leaves the large companies staring at the potential wreckage of their carefully crafted drug policies in Africa.\par  GlaxoSmithKline has led the way in cutting the prices of its Aids drugs in Africa. The bombshell dropped on the day GSK announced another reduction, with a fanfare that included an endorsement from Britain's inte}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 national development secretary, Hilary Benn.\par  But yesterday's cuts still left GSK's drugs at a higher price than those of the Indian generic companies. The GSK price of the two-drug treatment Combivir will be cut to Dollars 273 (pounds 164) a patient a year. But the generic firms' drugs are still much cheaper. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  version sells at Dollars 197 and Ranbaxy's is priced at Dollars 265. Both treatments are approved by the World Health Organisation.\par  GSK's answer has been to license one generic company - South Africa's own Aspen - to produce its drugs, but these are some way off reaching the market and there is no guarantee the prices will be low unless there is competition.\par  The competition commission is now referring the case to its tribunal for a final decision. But the commi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sion's recommendations are trenchant and will be received with enthusiasm by Aids activists.\par  Menzi Simelane, a member of the commission, said: "Each of the firms has refused to license their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to generic manufacturers in return for a reasonable royalty. We believe this is feasible and that consumers will benefit from cheaper generic versions of the drugs. Granting licences will also provide for competition between firms and their generic competitors."\par  The commission is to ask the tribunal to make an order saying generic firms should be allowed to sell their drugs in South Africa. It is also to recommend a penalty of 10% of the multinationals' annual turnover from Aids drugs sold in South Africa - for each year the pharmaceuticals are found to have violated the 1998 competition act. In practice this is not likely to be a substantial fine since so few people have been able to buy the drugs in South Africa.\par  Jonathan Berger, a lawyer with the Treatment Action Campaign, which brought the case about a year ago, said companies could still come to an agreed resolution on the case. It was also possible that the tribunal would rule in the companies' favour. But if the tribunal followed the commission's advice, cheap drugs could quickly arrive in South Africa, a country which has the highest number of infected people in the world.\par  "}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy's products are already registered for use in South Africa," Mr Berger said. "It is only the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  standing in the way of them being used."\par  GlaxoSmithKline was shellshocked by the commission's statement, not least because it had just received a letter from a senior investigator saying the case would not be referred to the tribunal. A spokesman said it was still in discussions with the commission.\par  Mr Berger said the price cuts and the TAC case were linked, but he thought GSK's action was a result of the broad campaign led by TAC together with the government statement in August saying it would put together a treatment programme for the country's HIV/ Aids sufferers - which left the pharmaceuticals "as the only ones who haven't come to the table properly".\par  * A total of pounds 26m is to be shared out among a dozen or more Caribbean countries to help fight HIV/Aids. The UN's global fund to fight Aids, tuberculosis and malaria will help fund Guyana, Haiti, Belize, Jamaica and the nine countries making up the Organisation of Eastern Caribbean States. An estimated 2.4% of people in the Caribbean have HIV. Previously, the only country in the region to have had help from the fund was Haiti.\par  Links\par  www.thelancet.com Aids drugs\par  unaids.org UN HIV/Aids programme\par  guardian.co.uk/aids\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); BOEHRINGER INGELHEIM GMBH (57%); RANBAXY LABORATORIES LTD (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); BIOC (EGX) (92%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); RANBAXY (NSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); SIC5122 DRUGS, DRUG PROPRIETARIES, & DRUGGISTS' SUNDRIES (57%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (54%); SIC2833 MEDI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INAL CHEMICALS & BOTANICAL PRODUCTS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (96%); AFRICA (92%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SOUTH AFRICA (96%); AFRICA (92%); INDIA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (95%); PHARMACEUTICAL PREPARATION MFG (92%); AIDS & HIV TREATMENT (91%); ANTIVIRALS (91%); UNFAIR PRICING (90%); AIDS & HIV (90%); DRUG PRICES (90%); GENERIC PRODUCTS (89%); GENERIC DRUGS (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); HEALTH DEPARTMENTS (77%); RESTRAINT OF TRADE (76%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (75%); LAW COURTS & TRIBUNALS (74%); PUBLIC POLICY (74%); LOBBYING (74%); PRICE CUTTING (72%); DRUG POLICY (72%); APPROVALS (72%); ECONOMIC DEVELOPMENT (69%); MULTINATIONAL CORPORATIONS (66%); PUBLIC HEALTH ADMINISTRATION (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JONATHAN BERGER (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 October 17, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS;Are Generic Drugs As Cheap As They Are Priced? Africa News September 15, 2003 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_252}{\*\bkmkstart DOC_ID_252_0}{\*\bkmkstart doc_id_114}{\*\bkmkend DOC_ID_252}{\*\bkmkend DOC_ID_252_0}{\*\bkmkend doc_id_114}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_114"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 114 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 September}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  15, 2003 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 AIDS;\par Are Generic Drugs As Cheap As They Are Priced?}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 African Church Information Service\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1043 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Ask a common Kenyan what generic drugs are, and the likely response will be, "I have no idea". Others simply know them as "cheap drugs", while some consider them "poor quality medicine". This comes as no surprise, for there is still insufficient information on these drugs, that are slowly but surely finding their way into the shelves of pharmaceutical companies and chemists. AANA Correspondent, Janet Adongo, provides some insight.\par Isaac Okello, a primary school teacher in western Kenya remarks: "I recently went to purchase some amo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ycillin from a nearby chemist, and I was surprised when the lady asked me if I wanted the cheaper one or the more expensive one. The price difference was over Ksh 100 (US$ 1.33), but everything else [appeared] the same." \par Seeking some explanation, Okello was informed that the cheaper medicine was generic. "But that was all she could tell me. Not trusting the cheaper one, I went ahead to buy the more expensive one," he says.\par Like Okello, many Kenyans, except in very desperate situations, prefer to buy what they believe is the "orig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nal" product, and this, they determine by the price. What turns out to be far much cheaper than expected, is often regarded with suspicion. Generic medicine falls in this category.\par According to Encarta Reference Library, all drugs have three names, these being, a chemical name, which describes the exact structure of the drug; a generic name; and a brand or trade name as given by an autho}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ised manufacturer.\par If a company holds the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on a drug, thereby having exclusive rights to make and sell it, the commodity is available under one brand name only. After the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  expires, typically after 17-20 years, other comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies can also manufacture and market it under the generic name, or give it a new brand name.\par As raised by Okello, a major confusion posed by generic drugs is the broad difference in pricing, which cr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ate suspicion over their efficacy.\par Professor Isaac Kibwage of the University of Nairobi, an expert on medical drugs, observes that generic medicine is as safe as branded equivalents, since the latter have already passed the safety tests.\par Sophie-Marie Scouflaire of Medecins Sans Frontieres, reiterates that "a generic drug is interchangeable with the original product. The difference between the two is that generics are no longer covered by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ."\par According to pharmacists, the gap in pricing between generics and branded drugs is because the former, having already been marketed under their original names, do not require research and development costs like the latter.\par Thus, several manufacturers can produce them, and the competition will significantly reduce the price. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  create market monopolies and keep prices high.\par That could explain why about a third of all prescriptions written in the United States are for generic drugs. In certain states, pharmacists must issue a generic drug unless the doctor states otherwise.\par In Kenya, the Pfizer manufactured drug, flucanozole, for cryptococcal meningitis, has a wholesale price of US$ 6.36 a capsule. Generics of the same quality are available outside Kenya for only US$ 0.2.\par In Brazil, the price of AIDS drugs fell by 82 percent over five years, as a result of competition brought about by introduction of generic medicine. About 100,000 people are now on antiretroviral therapy.\par At present, only a staggering 0.001 per cent of the 25 million people infected with HIV in Africa receive anti-retroviral drugs, which are now known to significantly prolong the lives of people with HIV. In contrast, the same are freely available in most of the West.\par As a result, an Indian based pharmaceutical company, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , has created a generic version of Combivir, a combination of AIDS drugs, AZT and 3TC, in one pill.\par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is offering a cocktail of drugs for about US$ 600 per person per year to governments. The same drug combination would cost US$ 10,000 - 15,000 a year from manufacturers in the West.\par A major drug company, GlaxoSmithkline, has already contested the Indian proposal, threatening legal action. Interestingly, the world's top five drugs companies' income is equivalent to twice the combined GDP of sub-Saharan Africa countries.\par One of the fears expressed over the sudden influx of generic drugs into the Kenyan market is the country's lack of strong surveillance and regulatory procedures, that may leave loophole to fake generics.  The United States had a similar experience.\par In the late 1980s, the United States Justice Department conducted an investigation on charges that generic drug manufacturers falsified test results and bribed government employees in order to get their products a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 proved.\par To reassure the public of the integrity of the drugs, the government undertook to inspect the country's 20 leading generic drug manufacturers, and re-analyse samples from the 30 top-selling generic drugs to ensure that they were indeed what they claimed to be.\par The agency also revamped its generic drug approval procedures to prevent possible further deception. As a result, more than two-dozen generic drugs were recalled from the market, and the sales of well over 100 others temporarily suspended because of proven or alleged fraud and irregularities.\par But unlike the US case where generic drug companies have been put to task to ensure that the drugs are of high quality, Kenya's National Drug Quality Control Laboratory has once been charged by parliamentarians as being moribund and understaffed.\par In 2001, the then health minister, Prof Sam Ongeri, had to rush to its defence after a fellow legislator, Dr Newton Kulundu, said the laboratory was ineffective, thereby making Kenya the second largest dumping ground for cheap generic drugs, after Nigeria.\par Officials at the laboratory affirm that importers and pharmaceutical companies are exploiting the poor survei}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lance mechanism of the Government.\par Speaking on condition of anonymity, they point out that the first drug batches presented to them would in most cases pass the quality test.\par This gives the drug a clean bill of health. However, once cleared, some companies alter the drug's quality in subsequent batches as a way of maximising profits.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (93%); GENERIC PRODUCTS (89%); PHARMACISTS (89%); CHEMISTRY (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (86%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PHARMACEUTICALS INDUSTRY (78%); PHARMACEUTICAL PREPARATION MFG (77%); COLLEGE & UNIVERSITY PROFESSORS (75%); A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIBIOTICS (73%); MEDICAL CHARITIES (72%); RESEARCH & DEVELOPMENT (71%); PRIMARY SCHOOLS (71%); INTELLECTUAL PROPERTY LAW (69%); IMAGE MARKETING & ADVERTISING (69%); LICENSING AGREEMENTS (67%); INTERNATIONAL ASSISTANCE (60%); RELIEF ORGANIZATIONS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ISAAC OKELLO (69%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KENYA (93%); UNITED STATES (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAIROBI, KENYA (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 16, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda;Ugandans Outdo Americans in Aids Drugs Compliance Africa News September 5, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_253}{\*\bkmkstart DOC_ID_253_0}{\*\bkmkstart doc_id_115}{\*\bkmkend DOC_ID_253}{\*\bkmkend DOC_ID_253_0}{\*\bkmkend doc_id_115}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_115"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 115 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 September}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2003 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda;\par Ugandans Outdo Americans in Aids Drugs Compliance}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Monitor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 663 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Aids: Ugandans complying well in taking drugs\par Ugandans living with HIV/Aids are less likely to develop resistance to anti-retroviral drugs than their Amer}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 can counterparts, a recent study has shown.\par The study done in Botswana, Senegal, South Africa and Uganda, showed that the 29 Ugandan patients su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 veyed were taking 91 percent of their pills.\par The results of the study, published in Thursday's edition of the US daily, The New York Times, show that Ugandans were doing better than American patients whose compliance lies at 70 percent.\par This has dispelled fears that Africans cannot manage the strict dosage of Aids drugs, hence running a risk of causing severe drug-resistance worldwide. \par Dr David Bangsberg, a professor of medicine at the University of California in San Francisco, studied the compliance patterns in the United States and Africa.\par "Though poor, more than 80 percent of the Ugandans had jobs?and most earned less than $50 [Shs 100,000] a month. Most were women in their 30s, and paying $27 [Shs 54,000] a month for their twice-a-day, three-drugs-in-one pill called Triomune, made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. of Bombay," the paper reported.\par Prof. John Rwomushana, the director of Aids Research and Policy Development at the Uganda Aids Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mission, told The Monitor yesterday that the high compliance levels are attributable to the newness of the drugs in Uganda.\par Rwomushana said that the Aids Commission, in its own study, had found similarly high compliance levels among Ugandans.\par He also said that unlike in the West where people have had access to the drugs for several years, anti-retrovirals are just picking up in Uganda and, therefore, pose less risks of drug resistance.\par At least 150,000 Ugandans with Aids need anti-retrovirals.\par Government is in advanced stages of making available free drugs to all Ugandans who need them.\par "When we get a chance to live again, we take it seriously. [The people in the West] take it for granted, and some of them don't even give up alcohol, smoking, and the rest," Maj. Rubaramira Ruranga, a Ugandan who has lived with the virus for more than 18 years, said yesterday.\par "Ugandans who get a chance to get these drugs really cherish them, so there can be no drug resistance in the short run."\par He also said that he has a CD4 count of more than 1,000, a fact that points to consistent use of the drugs. A person living with HIV needs to start using drugs when the CD4 count falls to below 200.\par "I will use these drugs for a long time," he said. According to the New York Times, Dr Merle A. Sande, a pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fessor at the University of Utah Medical School who also works in Uganda, said that extended families in Uganda help buy drugs for a member and in a sense that compels him or her to not fail them with the drugs.\par "If the whole family is pooling its resources to pay for you," he said, "you damn well better take your drugs."\par The paper also quotes Dr Elly Katabira of Makerere University Medical School. He attributes the good co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pliance levels in Uganda to the stage at which patients start therapy, which makes the drug look like a mir}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cle worker.\par Other African countries such as Botswana and South Africa also showed good compliance rates of 85 pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cent and 95 percent respectively, a trend widely attributed to the generic drugs' presence.\par Pharmaceutical companies in India are now making triple drug cocktails in as few as two pills a day, a tec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nique unknown in the United States due to }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws.\par People living with HIV in the United States have to take several pills a day to complete the three-drug comb}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nation, which makes adherence difficult.\par A USAID administrator kicked off a storm in 2001 when he said that anti-retrovirals would not work in Africa because many Africans do not use clocks and do not know what Western time is.\par The study comes in the wake of the discovery that 10 percent of all new HIV infections in Europe are r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sistant to at least one drug.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (92%); AIDS & HIV (91%); DRUG RESISTANCE (90%); ANTIVIRALS (90%); COLLEGE & UNIVERSITY PROFESSORS (88%); RESEARCH REPORTS (78%); GRADUATE & PROFESSIONAL SCHOOLS (69%); FAMILY (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (68%); SIC2834 PHARMACEUTICAL PREPARATIONS (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNIVERSITY OF CALIFORNIA  (56%); UNIVERSITY OF CALIFORNIA (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UGANDA (99%); UNITED STATES (97%); BOTSWANA (92%); AFRICA (92%); SENEGAL (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALIFORNIA, USA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SAN FRANCISCO, CA, USA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNIVERSITY OF CALIFORNIA (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 5, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africans Outdo U.S. Patients In Following AIDS Therapy   The New York Times September 3, 2003 Wednesday Correction Appended \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_254}{\*\bkmkstart DOC_ID_254_0}{\*\bkmkstart doc_id_116}{\*\bkmkend DOC_ID_254}{\*\bkmkend DOC_ID_254_0}{\*\bkmkend doc_id_116}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_116"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 116 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 September}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  3, 2003 Wednesday \par Correction Appended  \par  Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Africans Outdo U.S. Patients In Following AIDS Therapy }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964   By DONALD G. McNEIL Jr. \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 1; Foreign Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1465 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Contradicting long-held prejudices that have clouded the campaign to bring AIDS drugs to millions of people in Africa, evidence is emerging that AIDS patients there are better at following their pill regimens than Amer}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cans are. \par      Some doctors, politicians and pharmaceutical executives have argued that it is unsafe to send millions of doses of antiretroviral drugs to Africa, for fear that incomplete pill-taking will speed the mutation of drug-resistant strains that could spread around the world. \par  The danger already exists: nearly 10 percent of all new H.I.V. infections in Europe are resistant to at least one drug.\par For Africa, the issue is particularly touchy because it is tinged with racism. In 2001, for example there was an outcry when the director of the United States Agency for International Development said that AIDS drugs "wouldn't work" in Africa because many Africans don't use clocks and "don't know what Western time is." \par Now surveys done in Botswana, Uganda, Senegal and South Africa have found that on average, AIDS p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tients take about 90 percent of their medicine. The average figure in the United States is 70 percent, and it is worse among subgroups like the homeless and drug abusers.\par Compliance has become easier because drugmakers from India and elsewhere are beginning to make triple-therapy cocktails that come in as few as two pills a day. (These are not available in the United States yet b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cause of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  problems -- no Western company makes all three drugs for an ideal cocktail.)\par After nearly a decade of watching Africans die because AIDS drugs cost $10,000 or more a year per patient, rich nations began pledging aid after generic competition in 2001 drove prices down to about $300 a year. Last week the World Trade Organization agreed to alter its rules to give poor nations more access to life sa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing medicines.\par But as with any epidemic moving through a poor and ill-educated populace, the threat of disaster clings like a shroud. Patients in badly supervised programs have been caught selling pills or sharing with desperate rel}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tives -- acts of greed or mercy that could lead to doomsday strains of the virus.\par Anti-retroviral therapy "is the No. 1 priority for the developing world," said Robert C. Gallo, director of the I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stitute for Human Virology and a pioneer in researching H.I.V., the virus that causes AIDS. "But it will be a tragic mistake if it's not done right. You'll have 'Eureka!' and 'Thank you, America!' for two or three years -- but then you'll get multi-drug resistance, and whoops. . . ."\par Drug-resistant strains are inevitable, doctors say, and turn up in every illness from malaria in Africa to chi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dren's ear infections in Manhattan. Hard-to-cure variants evolve spontaneously in response to drugs. But they are more likely to grow and be passed on if patients skip doses, because triple therapy often suppres}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es even mutant strains. To avoid an epidemic of incurable AIDS, new drugs must be discovered faster than old ones become useless.\par Africa can still do better than the West, they say, by avoiding old mistakes. Today's drugs are more potent and no one will spend years on one drug, thereby breeding resistance, as many Westerners did on AZT b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fore triple therapy emerged in 1996.\par Moreover, doctors say, most African patients are zealous about their regimens. They are also more truthful when estimating their adherence, said Dr. David Bangsberg, a professor of medicine at the University of California in San Francisco who has studied compliance patterns here and abroad.\par On average, he said, American patients tell their doctors that they are doing 20 percentage points better than they really are -- that is, a patient who says he takes 90 percent of his pills will, when tested with una}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nounced home pill counts or electronic pill-bottle caps, turn out to be taking 70 percent.\par A study of 29 Ugandan patients found that, on average, they estimated that they were taking 93 percent of pills and proved to be taking 91 percent.\par Though poor, more than 80 percent of the Ugandans had jobs, though most earned less than $50 a month. Most were women in their 30's, and paying $27 a month for their twice-a-day, three-drugs-in-one pill called Triomune, made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd. of Bombay.\par In many such cases, explained Dr. Merle A. Sande, a University of Utah medical school professor who also works in Uganda, the whole extended family, possibly with several infected members, will chip in so that one member will be saved to care for the children.\par "If the whole family is pooling its resources to pay for you," he said, "you damn well better take your drugs.\par "That's a whole different scenario from the U.S., where patients get free medicine, and if they change ther}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 py, will let a month's worth go to waste." \par Several doctors in Africa said their patients were highly motivated because they had seen friends or family die. Most come in only when deathly ill, so the drugs seem to perform a miracle, making them well enough to go back to work. And even $1 a day is a lot, so they treat it as "an investment," said Dr. Elly Katabira of Ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erere University Medical School in Uganda.\par In Botswana, with the world's highest infection rate, pill counts on 400 of the 10,000 patients on therapy showed that 85 percent were taking their pills flawlessly, said Dr. Ernest Darkoh, the national program ma}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ager. "If you loosen the criteria a little -- missing a dose by two hours, for example -- you get about 90 pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cent," he added.\par There are a few exceptions, he admitted: "Some people bring back their pill containers saying, 'Thank you, but my traditional healer told me not to take these.' "\par However, some programs are not as good as others.\par In Nigeria, Africa's most populous country, an ambitious, widely praised plan to get generic drugs to 15,000 citizens has been hampered by bureaucracy, corruption and a scarcity of laboratories.\par Dr. Ernest Ekong, an AIDS specialist at the Military Reference Hospital in Lagos who has made Nigeria's case at international conferences, at first said adherence so far has been "no problem." Then he began to qualify that.\par Some patients, he said, have felt so well that they shared pills with friends who could afford the $10 monthly charge.\par Some who developed "nevirapine rash," or nerve tingling, cut back.\par "And," he admitted, "a very small percentage are selling their drugs."\par Non-adherence, he said, is worst among patients with co-infections that require more pills -- tuberculosis p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tients, for example, must also take four antibiotics.\par No formal resistance study has been done, but Nigerian doctors are worried about a few patients who are taking all their pills but not getting better -- a sign that they might have resistant strains.\par The best adherence seems to come under tight supervision.\par A recent study in Cape Town found that older patients, patients who took pills twice a day instead of three times, and patients who spoke the same language as clinic staff members tended to do best.\par In May 2001, Africa's best-known pilot project was opened by Doctors Without Borders in a crowded, dirt-poor black township near Cape Town called Khayelitsha.\par Because the drugs were then scarce, the charity set high hurdles for patients, so high that only 550 of the clinic's 5,000 visitors are taking medication now. It reports extraordinarily high levels of compliance.\par Pill counts by social workers show that, after six months on treatment, 96 percent of the patients are still ta}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing 95 percent of their pills.\par As a surer but more expensive backup, blood tests see how many have minuscule levels of virus, an indic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion that they have faithfully taken their pills.\par After six months, 91 percent do; at 18 months, 83 percent do.\par "That's pretty good," said Dr. Eric Goemaere, the program's director. "Certainly better than what you see in most North American studies."\par To qualify for treatment, patients must give up all alcohol and drugs; complete three months of taking a si}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple antibiotic; be on time for four clinic appointments in a row; reveal to their families that they are H.I.V. pos}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive; and choose a friend who must come to counseling, make sure all pills are taken and report problems to a nurse.\par Dr. Bangsberg expressed surprise at how demanding the clinic was.\par "Imagine trying to impose the no-drinking rule in San Francisco," he said.\par Such standards are tough but necessary, Dr. Goemaere said. Binge drinking is the norm in South African townships, he said, and studies show that patients with histories of alcohol abuse or depression are the worst at taking their pills.\par "There are certainly parts of Africa where you wouldn't want to try this -- in Congo, for example," he said. "But 65 percent of South Africa is urbanized. People know how to take a taxi and get to an appointment -- and how to take their pills." \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (95%); AIDS & HIV TREATMENT (95%); ANTIVIRALS (91%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS INDUSTRY (90%); DISEASES & DISORDERS (89%); INFECTIOUS DISEASE (89%); DRUG R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SISTANCE (89%); MALARIA (78%); GENERIC DRUGS (78%); EPIDEMICS (78%); DEVELOPING COU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRIES (78%); EXECUTIVES (77%); VIROLOGY (76%); VIRUSES (76%); INTERNATIONAL ECONOMIC DEVELOPMENT (73%); TRADE DEVELOPMENT (73%); RACE & RACISM (73%); PHYSICIANS & SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEONS (73%); INTERNATIONAL TRADE (73%); HEALTH CARE ACCESS (73%); EAR NOSE & THROAT DISORDERS (70%); INTERNATIONAL ECONOMIC ORGANIZATIONS (70%); PHARMACEUTICAL PRE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ARATION MFG (66%) ACQUIRED IMMUNE DEFICIENCY SYNDROME;  DRUGS (PHARMACEUTICALS);  INTERNATIONAL TRADE AND WORLD MARKET \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 US AGENCY FOR INTERNATIONAL DEVELOPMENT (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MCNEIL, DONALD G JR \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW YORK, NY, USA (50%) NEW YORK, USA (50%) AFRICA (98%); UNITED STATES (95%); UGANDA (92%); SENEGAL (92%); BOTSWANA (92%); INDIA (79%); EUROPE (79%) AFRICA;  BOTSWANA;  UGANDA;  SENEGAL;  SOUTH AFRICA;  INDIA\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 3, 2003  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 4, 2003\par \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Because of an editing error, a front-page article on Wednesday comparing Africans' and Americans' ability to take AIDS drugs on time misattributed a comment about American patients. The r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 searcher who said that when those patients change their pill regimens, they often "let a month's worth go to waste," was Dr. David Bangsberg of the University of California, San Francisco, not Dr. Merle A. Sande of the University of Utah.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore September 2, 2003 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_255}{\*\bkmkstart DOC_ID_255_0}{\*\bkmkstart doc_id_117}{\*\bkmkend DOC_ID_255}{\*\bkmkend DOC_ID_255_0}{\*\bkmkend doc_id_117}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_117"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 117 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 WTO drug deal to spark competition}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 September}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  2, 2003 Tuesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par By RAVI KANTH IN GENEVA\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE landmark agreement to override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  provisions for addressing HIV/Aids, tuberculosis, and malaria in poor countries reached among 146 members of the World Trade Organization on Saturday is expected to result in intense competition among leading generic drug producers, analysts said.\par The historic deal will help poor countries avoid being drowned in complying with complex }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules that provide monopoly-marketing rights to pharmaceutical giants such as Pfizer, Merck, and GlaxoSmithKline Wellcome.\par It would provide political and legal clarity to the use of what is called the compulsory-licensing instrument in the trade-related intellectual property rights , said Faisal Ismail, the South African trade envoy to the WTO. \par Under the agreement - in which Singapore's Ambassador to the WTO, Vanu Gopala Menon, played a major role - poor developing countries lacking manufacturing facilities to produce latest patented drugs could issue a compulsory licence to a third government that would enable its generic producers to supply the much-needed drug at affordable prices.\par Leading global generic drug producers in Canada, India, Brazil, Israel, the United States and Switzerland are expected to jump into fray once poor countries in Africa declare their intention to issue compulsory licences to manufacture the latest drugs for HIV/Aids, said a Geneva-based trade analyst. The compulsory licence allows WTO members to revoke the rights of a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder to address serious public health problems, but the existing law says that production under compulsory licensing must be predominantly for domestic co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sumption.\par To overcome this provision for poor countries with insufficient facilities to manufacture pharmaceutical pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ucts, WTO members had to struggle hard for almost two years to arrive at Saturday's agreement.\par Asked whether Canadian generic companies would export medicines under this route, the Canadian amba}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sador to WTO, Sergio Marchi, said he would imagine all generic producers would be able to compete for any compulsory licence issued under Paragraph 6 mechanism of the Doha Trips (trade-related intellectual pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erty rights) and Public Health agreement.\par Intense competition between generic producers could lead to downward pressure on prices of most of the important life-saving drugs needed to combat HIV/Aids, an Indian pharmaceutical industry analyst said.\par Significantly, shares of leading India generic drug companies like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ranbaxy and Reddy Labs have ri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 en steadily over the last few days in anticipation of the WTO agreement.\par Rich countries such as the US, Japan, Canada, and the EU members cannot use this agreement as impor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ers, while nations like South Korea, Hong Kong, and Singapore among others voluntarily said they would not use it except in grave public health emergencies.\par However, Oxfam and MSF (Medicines sans Frontiers) criticised the WTO agreement saying it watered down the goals set out in the Doha declaration and would make the implementation ineffectual.\par With tightened safeguards, the agreement would not help achieve the objective of letting poor countries gain easy access to cheap copies of patented medicines, said a representative of the Penang-based Third World Network.\par 'We do not agree with this, and we are confident that we could use the compulsory licensing provisions wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out much hindrance,' said Mr Ismail of South Africa.\par Until now, many countries found it difficult to use compulsory licence when faced with serious public health crisis because of arm-twisting by the US administration and its pharmaceutical companies, said a Geneva-based }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law analyst.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  PHARMACEUTICALS INDUSTRY (91%); PHARMACEUTICAL PREPARATION MFG (91%); PATENTS (90%); LICENSING AGREEMENTS (90%); PATENT LAW (90%); AIDS & HIV (90%); INTELLECTUAL PROPERTY LAW (90%); GENERIC DRUGS (90%); DEVELOPING COUNTRIES (90%); INTERNATIONAL TRADE (90%); MALARIA (90%); INTERNATIONAL ECONOMIC ORGANIZATIONS (90%); AIDS & HIV TREATMENT (89%); PHARMACEUTICALS PATENTS (89%); TRADE TREATIES & AGREEMENTS (89%); PUBLIC HEALTH ADMINISTRATION (89%); INDUSTRY ANALYSTS (89%); INTELLECTUAL PROPERTY (89%); EMBASSIES & CONSULATES (89%); BUSINESS FORECASTS (89%); INTERNATIONAL TRADE LAW (89%); TUBERCULOSIS (78%); EXPORT TRADE (78%); TREATIES & AGREEMENTS (78%); PHARMACEUTICALS TRADE (78%); IMPORT TRADE (78%); CONTROLLED SUBSTANCES CRIME (77%); GENERIC PRODUCTS (77%); PHARMACEUTICALS & BIOTECHNOLOGY REGULATORY CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PLIANCE (76%); RELIEF ORGANIZATIONS (73%); EUROPEAN UNION (73%); MANUFACTURING FACI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ITIES (68%); CONSUMPTION (64%); \par \par  PFIZER INC (90%); GLAXOSMITHKLINE PLC (90%); CIPLA LTD (57%); RANBAXY LABORATORIES LTD (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE NEWS; World\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 610 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 1, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Cheap drug plan founders The Globe and Mail (Canada) August 30, 2003 Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_256}{\*\bkmkstart DOC_ID_256_0}{\*\bkmkstart doc_id_118}{\*\bkmkend DOC_ID_256}{\*\bkmkend DOC_ID_256_0}{\*\bkmkend doc_id_118}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_118"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 118 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Globe and Mail (Canada)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  30, 2003 Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Cheap drug plan founders}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WARREN GILES, Bloomberg News\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 REPORT ON BUSINESS: INTERNATIONAL; Pg. B6\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 544 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  A U.S.-backed compromise meant to boost poor countries' access to inexpensive medicines threatened to unravel yesterday after the Philippines and as many as two dozen other nations put up last-minute obstacles.  \par  Philippine and other negotiators demanded "modifications" to a World Trade Organization agreement that would increase sales of generic drugs from countries such as India to the poorest nations in Africa and Latin America so that they could fight diseases such as AIDS and malaria. \par  "I'm very, very disappointed," WTO secretary-general Supachai Panitchpakdi said after negotiations broke off. Officials from the 146-nation WTO met late yesterday afternoon to try to resolve their differences, on the last day before they were scheduled to return to their individual capitals. \par  The impasse casts a shadow over broader WTO talks to give the global economy an $800-billion-a-year (U.S.) boost by lowering trade barriers on financial services and products from cars to chocolate. A deadlock over drugs may jeopardize progress on issues such as reducing rich nations' farm subsidies when trade mi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 isters meet next month in Cancun, Mexico. \par  The compromise was meant to limit the ability of companies in larger poor nations, including India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd., to profit on sales to the poorest nations, such as Zambia or Bolivia, of drugs patented by companies such as Pfizer Inc. The Philippines said it objected to this restriction. \par  Carlos Perez del Castillo, Uruguay's ambassador to the WTO and the chairman of the governing council, said he's still aiming for an accord before the Cancun gathering. \par  "My bet is that there will be [an agreement] either before or at Cancun," European Union Trade Commi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sioner Pascal Lamy told French radio Station Europe 1. \par  Observers said that the compromise that the United States worked out with India, Kenya, South Africa and Brazil this week represented a reversal for the Bush administration from December, when the United States was the sole holdout to an agreement. \par  "We're back to the December text," said James Love, director of the Washington-based Consumer Project on Technology, which has lobbied for lower drug prices. "A lot of developing countries think this is the best deal they're going to get." \par  Negotiators are scheduled to return to their capitals this weekend, before travelling to the Mexico meeting, which begins Sept. 10, WTO spokesman Keith Rockwell told reporters. \par  An agreement would clear the way for the poorest nations, such as Bolivia and Zambia, to buy cheap copies of medicine to fight health epidemics. Sub-Saharan Africa is home to almost 30 million of the 42 million pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple worldwide with AIDS or HIV. \par  Even as it held out in December, the Bush administration had pledged not to oppose at the WTO any use by poor nations of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement to treat medical emergencies and says it wants a deal that both helps the poor and protects the investments of the pharmaceutical companies. \par  American drug makers including Pfizer and Merck & Co. Inc. had feared that any loosening of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules could be interpreted to allow nations such as Brazil to override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on medicines for non- infectious di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 eases such as asthma or cancer, and flood European and U.S. markets with cheap generics. \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTERNATIONAL ECONOMIC ORGANIZATIONS (92%); TRADE DEVELOPMENT (90%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERNATIONAL TRADE (90%); AGRICULTURAL TRADE (90%); DEVELOPING COUNTRIES (90%); DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EASES & DISORDERS (89%); COMMERCE DEPARTMENTS (89%); AIDS & HIV (89%); PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); PHARMACEUTICALS INDUSTRY (78%); GENERIC DRUGS (78%); INTERN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL TRADE LAW (77%); MALARIA (76%); EPIDEMICS (76%); GENERIC PRODUCTS (76%); GLO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ALIZATION (75%); TRADE DISPUTES (75%); DRUG PRICES (73%); BANKING & FINANCE (72%); TRE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIES & AGREEMENTS (72%); EUROPEAN UNION (71%); INTELLECTUAL PROPERTY LAW (70%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (70%); LOBBYING (68%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRINGEMENT (65%); GOVERNMENT GRANTS & SUBS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DIES (57%); AGRICULTURAL SUBSIDIES (52%) trade; policy; drugs\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (84%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION (94%) World Trade Organization\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (84%); PFEB (BRU) (84%); PFE (NYSE) (84%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (84%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (84%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (84%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (84%); SIC2834 PHARMACEUTICAL PREPARATIONS (84%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (84%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PASCAL LAMY (56%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (95%); INDIA (94%); MEXICO (94%); PHILIPPINES (93%); AFRICA (93%); LATIN AMERICA (92%); ZAMBIA (92%); URUGUAY (79%); KENYA (79%); BRAZIL (79%); SUB SAHARAN AFRICA (79%); EUROPEAN UNION MEMBER STATES (77%) United States; Third World\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 16, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Illustration\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The Globe and Mail, a division of CTVglobemedia Publishing Inc.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore August 29, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_257}{\*\bkmkstart DOC_ID_257_0}{\*\bkmkstart doc_id_119}{\*\bkmkend DOC_ID_257}{\*\bkmkend DOC_ID_257_0}{\*\bkmkend doc_id_119}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_119"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100310039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 119 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Business Times Singapore\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Proposed WTO deal set to bring hope to poorer nations;\par It calls for relaxing }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  provisions, issuing of licences to producers in poorer nations}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  29, 2003 Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par Ravi Kanth\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PREPARATIONS are set for a final and long delayed humanitarian deal at the World Trade Organization to allow poor countries to relax }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  provisions on latest medicines and issue licences to generic producers in India and Brazil to supply them at affordable prices.\par 'We are hoping to have a deal by the end of the day,' said the architect of the proposed deal, Singapore A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bassador to the WTO Vanu Gopala Menon.\par Ensuring poorer states unable to manufacture medicines can import cheap generic drugs when they need to is seen as vital to beating major killers such as Aids and malaria. But it also means setting aside }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws protecting multinational firms. \par Agreement is crucial for the success of the WTO's current Doha Round of free trade talks, which is due to be discussed at a major summit in the Mexican city of Cancun next month.\par Over the last five months, Mr Menon, who now heads the WTO's Intellectual Property Council, quietly worked behind the scenes to resolve the differences between the key players such as the US, the European Union, India, Brazil, and South Africa for implementing the Doha Agreement on trade-related intellectual property rights (TRIPS) and Public Health.\par WTO members are expected to endorse the statement that Mr Menon had prepared to bring the US on the board.\par The leading US pharmaceutical companies, particularly Pfizer, were unhappy with the proposed agreement and forced their government to block the deal last year on the ground that it would be abused by generic producers like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and Ranbaxy in India to produce cheap copies of Viagra and other profit-making drugs.\par Except for the US, the entire WTO membership had approved a draft deal last year to implement the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plex 'paragraph six' mechanism requiring countries lacking manufacturing facilities to transfer their compuls}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ry licences to generic producers in India and Brazil for supply of affordable medicines.\par Faced with severe public criticism and the outbreak of Sars (severe acute respiratory syndrome) and A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thrax, the Bush administration was forced to give up its strident opposition to this agreement.\par The final three-page chairman's statement that Mr Menon issued late on Wednesday evening to members lists the 'the good faith' intentions for members to follow during the implementation of the 'paragraph six' mechanism. It would ensure that the proposed Doha agreement on TRIPS and Public Health is not pursued for 'industrial or commercial policy objectives'.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par  INTERNATIONAL ECONOMIC ORGANIZATIONS (91%); PHARMACEUTICALS INDUSTRY (90%); P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TENTS (90%); TRADE DEVELOPMENT (90%); PHARMACEUTICAL PREPARATION MFG (90%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (90%); INTELLECTUAL PROPERTY (90%); INTERNATIONAL TRADE (90%); RESPIRATORY DISEASE (78%); TRADE TREATIES & AGREEMENTS (78%); TALKS & MEETINGS (78%); INTERGOVERNMENTAL TALKS (78%); PATENT LAW (78%); FREE TRADE TREATIES & AGREEMENTS (78%); PUBLIC POLICY (78%); GENERIC DRUGS (78%); LICENSES & PERMITS (77%); MALARIA (77%); MANUFACTURING FACILITIES (76%); MULTINATIONAL CORPORATIONS (73%); G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC PRODUCTS (72%); APPROVALS (71%); EUROPEAN UNION (68%); SARS (61%); \par \par  PFIZER INC (58%); CIPLA LTD (58%); RANBAXY LABORATORIES LTD (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THE NEWS; World\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 416 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 August 28, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Singapore Press Holdings Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Mixed View of a Pact for Generic Drugs   The New York Times August 29, 2003 Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_258}{\*\bkmkstart DOC_ID_258_0}{\*\bkmkstart doc_id_120}{\*\bkmkend DOC_ID_258}{\*\bkmkend DOC_ID_258_0}{\*\bkmkend doc_id_120}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_120"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 120 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  29, 2003 Friday  \par  Late Edition - Final \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Mixed View of a Pact for Generic Drugs }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  By TONY SMITH; Saritha Rai and Nicole Itano contributed to this article. \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section C; Column 3; Business/Financial Desk; Pg. 3\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 990 words\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 DATELINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SAO PAULO, Brazil, Aug. 28  \par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The prospect of a trade agreement that would help give poor countries access to cheap generic drugs was criticized today by activists but welcomed as progress by some health officials in developing countries.\par      "This is a step forward for the third world," said Alexandre Grangeiro, head of Brazil's AIDS treatment program. "Those countries with the most severe health problems don't have conditions to produce their own generic drugs like we do." \par  The deal, endorsed by a major committee of the World Trade Organization in Geneva though not yet fina}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ized by the group as a whole, aims to balance the commercial interests of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -holding pharmaceutical companies with the needs of developing countries to provide affordable medicines to their impoverished populations. \par Brazil's AIDS program provides 135,000 patients with a life-saving "cocktail" of antiretroviral drugs free of charge, something it can do because the country makes its own generic versions of some drugs in the coc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tail and uses the threat of local production to force multinational producers to lower their prices on others. The program has halved the number of people dying from the disease since 1996. \par But Brazil and the handful of other developing countries, like China, India and South Korea, that can produce generic drugs have been blocked by World Trade Organization intellectual property rights rules from expor}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing them. That has left most poor countries dependent on expensive patented drugs to fight the world's dea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 liest diseases. The deal announced late tonight in Geneva is meant to change that.\par Under the agreement, a country needing to import a drug would be able to ask the government of a country that produces a generic version of it to authorize one of its manufacturers to export it without needing the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder's permission. The requests would have to be made "in good faith" and "for no commercial gain," and the generic drugs would have to be packaged and labeled distinctively to prevent the importing countries from re-exporting them at a profit. \par Although the agreement is not limited to specific drugs and specific diseases, as the United States had once demanded, it does exclude several rich countries from importing the generic drugs, and it restricts some poorer nations' use of the imported drugs to cases of national emergency. \par Representatives of many nongovernment health organizations working in the developing world were highly critical of the deal, saying it made too many concessions to Western drug companies and set too many co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ditions for poor nations.\par Celine Charveriat, head of advocacy at Oxfam, called the deal "largely cosmetic" and said it "will not make a significant difference to the millions of sick people who die unnecessarily in the third world every year." \par Others said that while the deal might seem to offer new opportunities on paper, few countries that produce generic drugs would likely be willing to risk the wrath of the United States by repeatedly breaking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to help their neighbors. \par "It involves an awful lot of red tape," said Ellen 't Hoen, a spokeswoman for Doctors Without Borders in Paris. "The statement doesn't say it's not possible to import generics -- it says it's possible. But the list of conditions attached is almost as long" as the trade group's entire agreement on intellectual property rights, she said.\par Nevertheless, Mr. Grangeiro said the deal vindicated Brazil's continuing fight to promote access to medicines for all countries. He predicted that it would help him bargain to lower the price of three drugs that Brazil must still import to make its anti-AIDS cocktail: Lopinavir from Abbott Laboratories, Efavirenz from Merck, and Nelfinavir from Roche. \par "Now we have legitimacy if we want to import from somewhere else," like India, he said. \par India's pharmaceutical industry, which has also challenged American and European companies over }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , reacted cautiously. \par Dr. Yusuf K. Hamied, the chairman of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a Bombay laboratory that caused a stir in 2001 by offering an inexpensive cocktail of generic AIDS drugs to humanitarian organizations in Africa, said the deal's "no co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mercial gain" clause should be replaced with a call for fair and reasonable pricing, especially since the drugs are generally distributed through health agencies and charitable groups, not sold at retail. \par "If the patients get the drug for free ultimately, where does the question of 'commercial pricing' come in?" he asked in a telephone interview. "And who is to determine commercial gain?" \par He said some multinational drug companies were guilty of "obscene pricing" -- for example, charging as much as $12,000 for a course of AIDS drugs that he said his company could match with generic equivalents for $300. \par "India, Brazil, Korea and China -- we all could do quite a bit in manufacturing drugs for national-emergency diseases in the third world," Dr. Hameid said. \par In South Africa, another country with a well-established local generic-drug industry, AIDS activists said they were worried that the Geneva deal could restrict exports to impoverished countries in the region, like Swaz}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 land and Lesotho, which have alarmingly high AIDS infection rates.\par This month, Aspen Pharmacare introduced a generic version of Stavudine, an antiretroviral drug, the first to be produced in Africa. It has asked South African authorities for permission to produce six more AIDS drugs, and says it hopes eventually to offer antiretroviral cocktails for less than $1 a day. The }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders of the seven drugs in question have said that Aspen can sell them only in sub-Saharan Africa. \par "Because we've already started, we've already negotiated, we've already started making generics, and we've already started building capacity, it's not a big step for us," Linda Philip, Aspen's chief operating officer, said of the Geneva deal. "But for countries that don't have manufacturing capacity, it's a big step for them."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (96%); DEVELOPING COUNTRIES (94%); GENERIC PRODUCTS (92%); INTERNATIONAL TRADE LAW (90%); TRADE TREATIES & AGREEMENTS (90%); PHARMACEUTICALS INDUSTRY (90%); INTELLECTUAL PROPERTY LAW (90%); INTERNATIONAL ECONOMIC ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (90%); AIDS & HIV TREATMENT (90%); LICENSING AGREEMENTS (90%); DISEASES & DISO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DERS (89%); IMPORT TRADE (89%); INTERNATIONAL TRADE (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); EXPORT TRADE (89%); ANTIVIRALS (78%); HEALTH DEPARTMENTS (78%); AIDS & HIV (78%); EMERGING MARKETS (78%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); TREATIES & AGREEMENTS (78%); POOR POPULATION (78%); INTELLECTUAL PROPERTY (78%); PHARMACEUTICAL PREPARATION MFG (74%); PRICE CHANGES (73%); RELIEF ORGANIZATIONS (70%); PRICE CUTTING (67%) MEDICINE AND HEALTH;  DRUGS (PHARMACEUTICALS);  INTERNATIONAL TRADE AND WORLD MARKET;  G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NERIC AND BRAND NAME PRODUCTS;  PRICES (FARES, FEES AND RATES);  THIRD WORLD AND DEVELOPING COUNTRIES \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION (84%) WORLD TRADE ORGANIZATION \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SMITH, TONY \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SAO PAULO, BRAZIL (79%); MUMBAI, INDIA (55%) BRAZIL (95%); SWITZERLAND (90%); INDIA (79%); CHINA (79%); UNITED STATES (79%); AFRICA (79%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 August 29, 2003  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photo: A scientist at }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  a Bombay laboratory that caused a stir in 2001 by offering inexpe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sive AIDS drugs to humanitarian groups in Africa. (Photo by Associated Press) \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Last-minute deal on cheap drugs: Late deal on cheap drugs The Guardian (London) August 28, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_259}{\*\bkmkstart DOC_ID_259_0}{\*\bkmkstart doc_id_121}{\*\bkmkend DOC_ID_259}{\*\bkmkend DOC_ID_259_0}{\*\bkmkend doc_id_121}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_121"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 121 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  28, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Last-minute deal on cheap drugs: Late deal on cheap drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Charlotte Denny and Sarah Boseley\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Home Pages, Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 757 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  An eleventh-hour deal to provide cut-price drugs for the world's poorest people was being finalised in Gen}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 va last night in an effort to save next month's trade summit in Cancun, Mexico, from collapse.\par  After being delayed for nine months by intense lobbying from US pharmaceutical companies, the agreement between key developing countries and Washington is meant to open the door for poor countries to import copies of life-saving drugs without running foul of global }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  laws.\par  But fears expressed by US pharmaceutical companies, led by Pfizer, that relaxing the rules will open wes}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ern markets to a flood of copycat drugs, have forced poor countries to accept strict safeguards against smuggling.\par  The deal represents a climbdown for Washington, which has single-handedly blocked agreement at the World Trade Organisation's Geneva headquarters since December, demanding that the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  override be restricted to the poorest countries and for a limited list of diseases. \par  Agreement was secured after the US agreed instead to accept assurances from developing countries that they would not bend the rules for "commercial objectives".\par  Diplomats said a deal on drugs was the bare minimum needed to prevent the trade ministers' Cancun mee}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing turning into a rerun of the WTO's disastrous Seattle meeting, which ended in chaos after African cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries walked out. Even now, heated disagreements over agriculture and whether the liberalisation of trade should be extended into new areas are clouding last-minute preparations for next month's meeting.\par  Washington was under intense pressure to deliver a package on drugs for poor countries after concessions were promised at the WTO meeting in Doha, Qatar, in November 2001, as a way of getting the sceptical d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 veloping world on board.\par  The details were supposed to have been hammered out in Geneva by the end of last year, but the White House vetoed the proposed deal after heavy lobbying from US drug companies.\par  Aid agencies said America's intransigence had forced the developing world to accept a flawed agreement with significant hurdles for countries hoping to import cheap drugs from abroad.\par  Oxfam said last night that the draft agreement had left the world's poorest states dependent upon other countries standing up to the intense pressure from the US pharmaceutical industry. "This deal has been w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tered down so much that it isn't really anything to cheer about," said Oxfam's Michael Bailey.\par  Under current trade rules any country can override }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in its home market and authorise production of the generic equivalent - as the US threatened to do during the anthrax scare in 2001 to force down the price of treatment. But global trade rules prevent generic manufacturers from exporting to countries that do not have a domestic drug industry.\par  Under the deal, exporting countries would have to issue a compulsory licence overriding foreign }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , something the agencies fear they may be reluctant to do.\par  Ellen t'Hoen, of the volunteer doctors' organisation Medecins sans Frontieres, said the deal was disastrous. She said: "It poses so many hurdles and hoops to jump through that we are really worried it may not work at all.\par  "By continually demanding more restrictions, the US seems to be pushing for a watertight system so that no generic drugs ever get through to the patients in developing countries who desperately need them.\par  "(This) will, over time, lead to the complete drying up of availability of generic sources and will inevitably lead to increased drug prices."\par  The undertaking that the Doha get-out clause, allowing the overriding of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , should not be used for commercial advantage meant that generics companies such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India, which undercut the multin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tionals to offer Aids drugs for less than Dollars 300 (pounds 190) a year and forced the big companies to bring down their prices, would have no incentive to produce cheap copies.\par  "The drugs that we have access to now that are affordable are produced by commercial entities," Ms t'Hoen said. "We need more industrial activity and greater competition in the market. That is the mechanism which is being killed."\par  She blamed pressure from the US for "a text that is blatantly ridiculous", but also the EU for failing to join the closed discussions. "After all the rhetoric of (Pascal) Lamy (its chief trade negotiator), he is completely a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sent from these talks," she said.\par  Notebook, page 22\par  Gordon Brown, page 25\par  guardian.co.uk/aids\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFIZER INC (90%);   WORLD TRADE ORGANIZATION  (83%); WORLD TRADE ORGANIZ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (83%); WORLD TRADE ORGANIZATION (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PFZ (LSE) (90%); PFE (NYSE) (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (90%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (90%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (90%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (90%); SIC2834 PHARMACEUTICAL PREPARATIONS (90%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (95%); MEXICO (93%); QATAR (92%); SWITZERLAND (91%); AFRICA (79%);   WASHINGTON, USA (79%);   SEATTLE, WA, USA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (95%); MEXICO (93%); QATAR (92%); SWITZERLAND (91%); AFRICA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRADE DEVELOPMENT (91%); PHARMACEUTICALS INDUSTRY (90%); DEVELOPING COUNTRIES (90%); INTERNATIONAL TRADE (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); EMERGING MARKETS (89%); EXPORT TRADE (89%); PHARMACEUTICAL PREPARATION MFG (89%); AGRICULTURAL TRADE (89%); GENERIC DRUGS (89%); INTERNATIONAL TRADE LAW (89%); IMPORT TRADE (89%); LOBB}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 Y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (89%); RELIEF ORGANIZATIONS (88%); GENERIC PRODUCTS (78%); POVERTY & HOMELES}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NESS (78%); TALKS & MEETINGS (77%); GLOBALIZATION (76%); INTERNATIONAL ECONOMIC O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GANIZATIONS (76%); VETO (75%); SMUGGLING (73%); COMMERCE DEPARTMENTS (72%); INTE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 L}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LECTUAL PROPERTY LAW (71%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (70%); ANTHRAX (67%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 August 28, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Americans seeking pledges on drug rules The Toronto Star August 26, 2003 Tuesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_260}{\*\bkmkstart DOC_ID_260_0}{\*\bkmkstart doc_id_122}{\*\bkmkend DOC_ID_260}{\*\bkmkend DOC_ID_260_0}{\*\bkmkend doc_id_122}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_122"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 122 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Toronto Star\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  26, 2003 Tuesday Ontario Edition\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Americans seeking pledges on drug rules}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Warren Giles, Bloomberg News\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BUSINESS; Pg. D02\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 238 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The United States is pressing poor countries to accept a new condition before agreeing to let them bypass drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  to import copies of medical treatments for AIDS, malaria and other diseases, according to aid agencies including Oxfam.\par In December, the United States was the only member of the World Trade Organization to block an accord to ease the supply of essential medicines to poor countries. \par Washington says a pact may enable generic drug makers, such as India's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd., to sidestep }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  held by U.S. companies including Pfizer Inc. and Merck & Co. on other drugs, such as those used to treat obesity or hair loss.\par The administration of U.S. President George W. Bush is trying to secure guarantees from countries including Brazil, Kenya, South Africa and India that they won't apply the new agreement except for "humanitarian use" to fight AIDS, tuberculosis and malaria, according to Oxfam, Doctors Without Borders and the Third World Network. Treatments for illnesses such as cancer may be excluded.\par "The U.S. seems to be pushing for a watertight system so that no generic drugs ever get through to the p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tients in developing countries who desperately need them," Ellen 't Hoen, a spokesperson for Paris-based Doctors Without Borders, said in an e-mail. "We are really worried it may not work at all."\par Dave Hamill, a spokesperson for the U.S. mission to the WTO in Geneva, declined comment.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); RELIEF ORGANIZATIONS (91%); AIDS & HIV TREATMENT (90%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); DISEASES & DISORDERS (90%); PHA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MACEUTICAL PREPARATION MFG (90%); AIDS & HIV (90%); MEDICAL CHARITIES (90%); GENERIC DRUGS (90%); DEVELOPING COUNTRIES (90%); MALARIA (90%); CANCER (78%); INTERNATIONAL ASSISTANCE (77%); PHYSICIANS & SURGEONS (75%); TUBERCULOSIS (73%); US PRESIDENTS (73%); BARIATRICS (73%); INTERNATIONAL ECONOMIC ORGANIZATIONS (73%); OBESITY (72%); HAIR LOSS (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MRK (PAR) (91%); MRK (NYSE) (91%); PFZ (LSE) (91%); PFE (NYSE) (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (83%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (91%); SIC2834 PHARMACEUTICAL PREPARATIONS (91%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOSTIC) MANUFACTURING (91%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (91%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (91%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (91%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANIZATION  (84%); WORLD TRADE ORGANIZATION (84%); DOCTORS WITHOUT BORDERS  (83%); DOCTORS WITHOUT BORDERS (83%); THIRD WORLD NE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORK  (56%); THIRD WORLD NETWORK (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED STATES (98%); INDIA (92%); KENYA (79%); BRAZIL (79%); SWITZERLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENEVA, SWITZERLAND (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MERCK & CO INC (91%); PFIZER INC (91%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (83%);   WORLD TRADE ORGAN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ZATION  (84%); WORLD TRADE ORGANIZATION (84%); DOCTORS WITHOUT BORDERS  (83%); DO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TORS WITHOUT BORDERS (83%); THIRD WORLD NETWORK  (56%); THIRD WORLD NETWORK (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 August 26, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Toronto Star Newspapers, Ltd.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Future looks healthy for India's copycat drugs industry The Times (London) August 16, 2003, Saturday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_261}{\*\bkmkstart DOC_ID_261_0}{\*\bkmkstart doc_id_123}{\*\bkmkend DOC_ID_261}{\*\bkmkend DOC_ID_261_0}{\*\bkmkend doc_id_123}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_123"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 123 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Times (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 August}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  16, 2003, Saturday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  Future looks healthy for India's copycat drugs industry}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Carl Mortished\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business; 46\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1308 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Carl Mortished uncovers a new force in the global pharmaceutical business\par  A FRANTIC Christmas race to a late-night pharmacy in South London was my introduction to Indian drug companies. I handed over a prescription written for an unhappy two-year-old and was given a bottle of ant}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 biotic syrup.\par  I looked at the label suspiciously. Would this cure my son's ear infection (and the Bank Holiday misery of an entire family plus grandparents)? Who or what, I asked, is Ranbaxy?\par  The pharmacist, a Sikh, replied: "It is an Indian drug company." And then, anticipating my response, said: "Don't worry. We sell a lot of it." \par  The syrup went down a treat and I swallowed my prejudice. But the Christmas earache also brought to my attention a business success story that is not well understood outside the pharmaceutical arena. Within little more than two decades, a clutch of pill-makers, branch plants inherited from Western drug companies, have been transformed by Indian scientists into a multibillion-pound generic drug industry.\par  Their star is ascendant. The share price of Ranbaxy Laboratories has risen by more than 50 per cent since the beginning of the year, valuing the company, which is quoted on New York's Nasdaq exchange, at some Pounds 2 billion. Within the past two months, the stock price of Dr Reddy's Labs, a leading competitor of Ranbaxy, has risen 40 per cent, making the Hyderabad firm a billion-pound enterprise.\par  The Bombay share market is notoriously volatile but there is reason for excitement about Indian pharmace}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ticals. The industry was built on copycat products, some would say rip-offs, of branded drugs developed by the world leaders, firms whose names you know well: Pfizer, GlaxoSmithKline and Roche. Firms you know less well, such as }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  another Indian company based in Bombay, became highly accomplished at making knock-off versions of famous brands. Erecto is }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  version of Viagra and Nuzac is its version of Prozac, sold in India at a tiny fraction of the US price.\par  The drug multinationals ranted and raged at the impudence of the Indian upstarts, accusing them, not u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 reasonably, of stealing intellectual property. Recently, the war of words has been muted. The big guns of Indian pharma have changed tack and are launching legal challenges to US }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Dr Reddy's made a small fortune with a six-month exclusive right to sell generic Prozac as the product came off }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par  Meanwhile Ranbaxy secured an exclusive on Ceftin, a GlaxoSmithKline antibiotic.\par  Bigger legal changes are on the way, both in India and in the US, which will cause upheaval in the worl}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 wide drug industry. India is to bring its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law into line with the West, outlawing copycats. At the same time America is making it easier for generic drug-makers to challenge US }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 .\par  The new Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law could consign smaller, weaker drug-makers to bankruptcy and oblivion. But for the successful firms, the US craving for cheaper drugs, combined with greater }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  leniency, opens a wealth of opportunity and there is excitement among some Indian manufacturers.\par  "This is a big opportunity for Indian companies," Ajay Pira-mal, managing director of Nicholas Piramal, a Bombay drug manufacturer, says. "Until a few years ago a US consumer would not accept a product made in India."\par  He rationalises the lack of Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  protection as a tool needed to build up a manufacturing base. "We needed time for the industry to develop. People could not afford imported drugs. Indian companies could produce products at a hundredth of the cost."\par  Poor Indian }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law made it possible. But it was the skills of Indian scientists and the entrepreneurial flair of men such as Anji Reddy that made it happen. In 1984, the farmer's son founded Dr Reddy's Labs with a $ 120,000 bank loan and set about making generic versions of branded prescription drugs. Today his family's quarter share of the company is worth half a billion pounds.\par  Indian science and engineering graduates fled to America in the 1970s and 1980s, but in the past decade the brain drain has become more of a two-way shuttle.\par  Returnees from the US West Coast have created software empires in the southern cities of Bangalore and Hyderabad. The same phenomenon is occurring in the pharmaceutical sector.\par  Lars Walan is in charge of AstraZeneca's Indian venture, a Pounds 25 million investment in a research facil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ty in Bangalore. He predicts a bright future for the best Indian firms. "The Ranbaxys and the Reddy's are e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tremely good at producing high-quality generic products. I see some of the Indian companies in the same situation as Japanese pharmaceutical companies were two decades ago."\par  Contract manufacturing -making the basic molecules of branded drugs for multinationals -is a growing bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ness in India. The US Food and Drug Administration regularly inspects and approves Indian factories. But for AstraZeneca India offers scope for more than just cheap manufacturing. According to Walan, clinical r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 search is a major opportunity for India. A new drug might cost a firm such as AstraZeneca as much as $ 800 million to bring to market and between 70 per cent and 80 per cent of the cost is the clinical work, testing the drug on real patients.\par  "In India, there is hospital care that is on a par with London or New York. The quality of physicians and nurses is outstanding. And you can do it at a fraction of the cost," he says.\par  There is also the lure of disease. Killer infections, such as typhoid, tuberculosis or bubonic plague are not uncommon in India, providing researchers with a supply of ready patients.\par  Piramal points to another facet of Indian public health: "In the developed world, most patient-volunteers have taken a lot of medication. Their bodies are infused with medicines and it makes it difficult to conduct trials. In India, modern medicine has not reached as many people and the sheer number of people provides more potential patients."\par  A change in regulation and improvements in healthcare have made it possible to do new clinical trials in I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dia. Fears that drug companies would exploit Indian patients have been allayed. Piramal says that standards are equal to those in the West.\par  But the larger challenge for Indian drug companies is discovery research. The sheer scale of the financial advantage of the multinationals is intimidating.\par  "Pfizer spends more on research than the value of our domestic market," Piramal says.\par  That represents some $ 4 billion in sales, divided between almost 20,000 Indian companies, most unlikely to survive the new }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law. For the few that can compete, supplying America with generic drugs is the route to profit, investment and, they hope, their own branded discoveries. Piramal reckons that the latter prize is probably a decade away.\par  But the pressure for discovery is even greater on the multinationals. The pipeline of new drugs is looking thin. With competition from generic manufacturers, the stock prices of Pfizer and GSK are knocked from pi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lar to post by news of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  litigation. Drug companies are under huge pressure to get more products out of their labs at a faster pace and that means cutting the billion-dollar price of success.\par  With its new intellectual property law, India might offer a solution. AstraZeneca is employing 100 Indian sc}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 entists in Bangalore, seeking new tuber-culosis treatments. Many are returning expatriates who earned their doctorates at Harvard or Stanford and their spurs in the research labs of multinationals. In cash terms, they might earn a fifth or even a tenth of a US salary but they are attracted by the opportunity to work in Indian labs equipped to Californian standards. "They can live and work in their own culture and that is very i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 portant to them," Walan says.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LONDON, ENGLAND, UK (68%); HYDERABAD, INDIA (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASIA (91%); INDIA (91%); EUROPE (68%);   LONDON, ENGLAND, UK (68%); HYDER}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BAD, INDIA (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ASIA (91%); INDIA (91%); EUROPE (68%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (90%); PRESCRIPTION DRUGS (90%); ANTIINFECTIVES (89%); GENERIC DRUGS (89%); PHARMACEUTICAL PREPARATION MFG (89%); CHEMICAL INDU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRY (89%); PHARMACEUTICAL & MEDICINE MFG (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (74%); GENERIC PRODUCTS (71%); INTELLECTUAL PROPERTY (69%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 August 16, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li480\ri480\widctlpar\wrapdefault\faauto\rin480\lin480\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Times Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bush in Africa: The diplomacy: SPECIAL REPORT by Jo Revill in Gaborone: How the Aids battle can be won: In Botswana, where a third of the population has the condition, one pioneering clinic has shown it is not too late for a ravaged continent to fight back and survive the epidemic The Observer July 6, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_262}{\*\bkmkstart DOC_ID_262_0}{\*\bkmkstart doc_id_124}{\*\bkmkend DOC_ID_262}{\*\bkmkend DOC_ID_262_0}{\*\bkmkend doc_id_124}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_124"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 124 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Observer\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 July}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  6, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Bush in Africa: The diplomacy: SPECIAL REPORT by Jo Revill in Gab}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 rone: How the Aids battle can be won: In Botswana, where a third of the population has the condition, one pioneering clinic has shown it is not too late for a ravaged continent to fight back and survive the epidemic}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Jo Revill\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Observer News Pages, Pg. 21\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1244 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  PATIENTS start queuing at 6am outside the two steel portable buildings of the Princess Marina Hospital in Gaborone, some standing, others supporting themselves on a stick or a child's arm. The queue looks bleak but is actually testimony to a remarkable success story in Botswana which suggests it may not be too late for Africa to start fighting back against its ferocious Aids epidemic.\par  Inside the buildings, reminiscent of a rather overcrowded NHS clinic, doctors are giving patients blood tests. If their CD4 cell count is lower than 200, which denotes a weakened immune system, they will receive the antiretroviral (ARV) drugs needed to stay alive. For some it is too late but others get better, and return to work.\par  President Bush is expected to visit the hospital when he makes a whistlestop trip to Botswana this week as part of his five-nation African tour. He will be told the doctors have treated more than 6,000 patients with the drugs, and plan to open up new clinics. For Bush, who has pledged Dollars 15 billion over five years for Aids treatment and prevention, this is the kind of project he needs to see to know such initiatives are worthwhile. \par  There are 120,000 people eligible for these drugs in Botswana, a southern African country where an est}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mated 36 per cent of the population has the disease. Aids arrived in the early Nineties, but very few will put themselves forward for diagnosis, knowing friends and family may shun them. Life expectancy for a Bo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 swanan, which was due to reach 72 by 2010, will have flipped back to 27.\par  Dr Ndwapi Ndwapi left his job in America to come back to his native land and help run what is now the bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 est Aids clinic in the world, seeing 120 patients a day. 'The first came here thinking they were going to be given a death sentence. Now with the drugs, we have a new beginning,' he said, squeezing between patients as they queued in the corridors.\par  It is not an easy career choice. 'I try not to get too tied up in the daily suffering - but it is tough. I'm aware I could do more, and I feel frustrated. Still, before there were ARVs, it was hopeless, you just helped people to die as comfortably as possible. Many, many lives have been changed with this treatment,' he said.\par  This project, the first full attempt to prevent and treat Aids ever undertaken in Africa, is known as the African Comprehensive HIV/Aids Partnerships, (Achap). It involves the government working with the Bill Gates Foundation, and pharmaceutical firm Merck, each putting in Dollars 50 million into a five-year-initiative. The drugs are being bought by the government at cost price from the pharmaceutical companies, and one of the medications is being given free by Merck. The total package of care per patient costs Dollars 1,000 a year.\par  SOME SEE this kind of joint partnership as the most realistic way forward; one is Professor Brian Gazzard, Aids physician at the Chelsea and Westminster Hospital in London, who comes here every six months to oversee the training of staff.\par  'HIV is rooted in poverty and ignorance and poor infrastructure,' he said. There is no GP system in Botsw}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 na, where 30,000 traditional healers have to be persuaded the new drugs do work.\par  'In some ways, Africa is caught in this time warp. It is so far behind the West in being able to provide basic healthcare. But I am optimistic because if you can treat 10,000 patients really well in Botswana you can say to the rest of the world, "For Christ's sake, this can work."'\par  But there remains great uncertainty over how the rest of Africa will find the money for such projects. The drugs companies are fighting a battle for their right to keep }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on HIV drugs, preventing others from copying them, as part of global trade negotiations. It has left companies like GlaxoSmith Kline facing accus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions of denying the poorest nations life-saving drugs.\par  There is also cynicism over their new found philanthropy. In Botswana, Merck and Bristol Myers Squibb are putting in Dollars 200m over five years for medical pro jects. But is their beneficence any more than an e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pensive attempt to win good publicity, against a backdrop of protests about drug pricing? The companies insist they want to help, and are well placed to do so, but only if they are able to work with governments to set up a proper health infrastructure - hospitals, clinics, trained staff - to deliver the drugs safely.\par  On the other side of the continent, Tanzania has Dollars 6 a year to spend on each resident's healthcare and has not even talked to the pharmaceutical giants about drugs. Instead, it hopes the Bill Gates Found}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion or the UN Global Fund might come up with some money.\par  As part of a trip funded by the International Federation of Pharmaceutical Manufacturers Associations, The Observer was taken to see various projects around the country, where compa nies and health officials were working together to cure river blindness and elephantitis. Important projects, but small beer compared with the financial and organisational challenges presented by the two biggest killers, malaria and Aids.\par  In stark contrast to Botswana, Tanzania has no access to antiretroviral drugs until someone is wealthy enough to pay Dollars 60 a month for them through a private pharmacy. The drugs companies argue they cannot come in unless the government negotiates with them, and the government says it cannot afford them.\par  ONE COUPLE are managing to bring in Aids drugs, in order to save the lives of their own staff. Doctors Richard and Carolyn Collins came out to Tanzania two years ago to work for the Teule Hospital in Muheza. They found hospital staff were dying of Aids at the rate of one a month. With the help of friends in Britain, they started a charity providing enough money to enable them to pay for imported generic HIV drugs which have saved 16 lives so far. But there is no money to pay for treatment for partners of staff, or for children.\par  The generic drugs from the Indian company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  cost Dollars 30 a month, half the price of patented med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines. 'Thank goodness for the generics, because otherwise we would have nothing,' said Carolyn Collins.\par  She laughs at the idea that they might get financial aid from the West. 'For it to work, we would need to give them the drugs for free, because there's nothing these people can afford. People in high places say, "Why are you bothering, because these people are going to die anyway?" But back home, we give people with brain tumours another nine months of life with treatment. It's about the value you place on life.'\par  Nowhere is that value more apparent than in the orphanage in Otse, back in Botswana, where 50 children sit down to a meal of chicken stew.\par  There is a sense of hope and purpose here at the Dula Sentle Trust, as the children, from five to 17, are taught ways of coping with the loss of their parents, and given skills to survive. The girls are taught how to say no to a boy who wants sex, but in a charming way, using funny songs.\par  Its founder, Gill Fonteyn, said: 'At the moment we have 50 kids. Within five years, that's likely to be over 200 orphans. At the moment, everyone has someone they can go home to at night, even if it's a distant relative. But soon there will be a few with no adult to look after them.'\par  Richard and Karilyn Collins, who import generic Aids drugs to Tanzania's Teule hospital.\par  www.observer.co.uk/worldview\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MERCK & CO INC (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MRK (PAR) (84%); MRK (NYSE) (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DISEASES & DISORDERS (90%); EPIDEMICS (90%); AIDS & HIV TREATMENT (89%); PHARMACEUTICALS INDUSTRY (89%); AIDS & HIV (89%); PHARMACEUTICAL PREPARATION MFG (85%); PREVENTION & WELLNESS (79%); LIFE EXPECTANCY (79%); HEALTH CARE COSTS (78%); ANTIVIRALS (75%); PHYSICIANS & SURGEONS (74%); CLINICS & OUTPATIENT SERVICES (73%); FOUNDATIONS (71%); NATIONAL HEALTH INSURANCE (71%); POPULATION & DEMOGRAPHICS (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 July 7, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAPER\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 South Africa;Generic Medicines Market May Double Africa News June 25, 2003 Wednesday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_263}{\*\bkmkstart DOC_ID_263_0}{\*\bkmkstart doc_id_125}{\*\bkmkend DOC_ID_263}{\*\bkmkend DOC_ID_263_0}{\*\bkmkend doc_id_125}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_125"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 125 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  25, 2003 Wednesday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 South Africa;\par Generic Medicines Market May Double}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Business Day\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 328 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 A NEW law to promote the substitution of generic medicines for their more expensive off-}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  brand name equivalents could almost double the size of the private sector generic medicine market in SA, according to a senior executive of SA's second largest generic medicine manufacturer, Adco.\par As the industry embarks on a nationwide drive to publicise the benefits of generic medicines, Adco marketing manager Francois Hoffmann said that generics now accounted for just 19% of the R12bn private sector pharmaceutical market. The newly implemented Medicines and Related Substances Control Amendment Act should boost the generic share of pharmaceutical spend in the private sector to 35% within the next 18 months, he said. \par The act came into effect on May 2, and stipulates that pharmacists must offer patients a generic substitute for brand name medicines where one exists. "That alone will ensure that more generic medicines will be used," said Hoffman. The new law presented growth opportunities for local generic drug manufacturers and new entrants.\par "At the moment our generic business is growing at 26%, which we hope to increase to 28-30%," said Hof}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 f}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 mann.\par Adco is the generic wing of SA's largest pharmaceutical company, Adcock Ingram, which is owned by Tiger Brands. The market leader on the generics front is Aspen Pharmacare, which is the largest supplier of gene}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ic medicines to the state and SA's only listed generic drug company. Other players include }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 -Medpro, Ranbaxy, and Rolab.\par Hoffmann said SA lagged far behind European and North American countries when it came to the use of g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nerics, citing Germany, where generics had a market share of more than 70% and the UK, where three-quarters of all prescriptions were written for generic medicines.\par He attributed comparatively low SA use of generic medicines to mistrust by doctors, pharmacists and co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sumers, who historically regarded generics as inferior because they were cheaper.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC DRUGS (95%); GENERIC PRODUCTS (91%); PHARMACEUTICALS INDUSTRY (91%); PHARMACEUTICAL PREPARATION MFG (90%); BRANDING (90%); PHARMACISTS (89%); MARKET SHARE (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 APN (JSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (57%); RANBAXY (NSE) (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (54%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FRANCOIS HOFFMANN (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GERMANY (79%); UNITED KINGDOM (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 25, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Drug Maker's Vow to Donate Cancer Medicine Falls Short   The New York Times June 5, 2003 Thursday Correction Appended \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_264}{\*\bkmkstart DOC_ID_264_0}{\*\bkmkstart doc_id_126}{\*\bkmkend DOC_ID_264}{\*\bkmkend DOC_ID_264_0}{\*\bkmkend doc_id_126}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_126"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 126 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The New York Times\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 June}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2003 Thursday \par Correction Appended  \par  Late Edition - Final\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Drug Maker's Vow to Donate Cancer Medicine Falls Short }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964   By STEPHANIE STROM and MATT FLEISCHER-BLACK; Saritha Rai in Bangalore, India, co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tributed to this report. \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Section A; Column 1; Business/Financial Desk; Pg. 1\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 3007 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 When Novartis, one of the world's largest pharmaceutical companies, set out to give away a revolutionary cancer drug to people around the world who could not otherwise afford it, the company promised that no p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tient who needed the medicine would go without it.\par      It was an incredibly ambitious pledge. Often, drug companies donate in bulk to public health systems to combat epidemic diseases like AIDS or malaria. Novartis, however, set out to build a system that would evaluate the health and finances of individual cancer patients scattered aroundthe globe. Those who qual}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fied would get Glivec, a capsule that combats certain types of leukemia and stomach tumors, at no cost. E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 perts estimate that as many as 600,000 patients -- most of them in poor countries -- could benefit. \par  Two years later, 2,000 patients in the United States have gotten free Glivec, which costs an average of $27,000 a year. But elsewhere, doctors and patients say, the effort is off to a fitful start -- one that has e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 posed Novartis to criticism that its charity is a stalking horse for its commercial goal of building Glivec sales to $1 billion annually.  \par For example, in India -- a country that holds huge promise for Western drug makers -- Novartis began its d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nations of Glivec with a warning that it would halt the program if the government let local companies eat into its profits by selling generic versions of the drug. \par Hundreds of Indian cancer patients got Glivec free, and commercial sales soared, as well. But after India cleared generic Glivec for sale, Novartis made good on its threat last month, saying it would leave it to Indian companies to meet the needs of the indigent.\par The Glivec donations are a study in both the promise and the perils of corporate philanthropy. Across a wide span of industries, a growing number of companies are giving away products and services, entwining doing good with doing business.\par Drug makers, their images battered by criticism of high drug prices, have become some of the world's bi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 g}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gest corporate philanthropists. NeedyMeds, an online service that provides information about donation pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 grams, lists 213 of them in the United States alone, giving away 1,030 drugs that treat everything from AIDS to hay fever. \par With Glivec, Novartis has stumbled in reaching the neediest people. Its international patient assistance pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gram -- run by a tiny nonprofit group that Novartis selected after established charities turned down the job -- has gotten the drug to just over 1,500 patients outside the United States. In the 49 poorest countries, where Novartis estimates that 9,500 patients could be helped by Glivec, the program has reached 11 people, a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cording to the latest count. \par In wealthier countries like South Korea, Hong Kong and New Zealand, Novartis, meanwhile, has encouraged patients who have received free drugs to become advocates, pressing public health systems to pay high prices for the drug. One company document declared that drug donations -- along with media campaigns and legal tactics -- were part of a concerted plan to win reimbursement for Glivec.\par "The glorified term 'patient assistance program' is nothing but a marketing strategy," said Dr. Arun Bal, a medical ethicist in Bombay.\par Novartis acknowledged encouraging patients to campaign for access to Glivec. A spokeswoman said that the internal document was probably genuine, though officials could not recall creating it. But the company denies that its program has commercial aims. It is not intended "to obtain or lobby for treatment reimburs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment," said Gloria Stone, a Novartis spokeswoman. \par Beneficiaries care little about the company's motives. The family of Vasamvada Shukla, a 52-year-old wo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 an in Bombay, had almost bankrupted itself trying to pay for Glivec, selling land it had owned for generations for the $2,769 monthly cost. Then Mrs. Shukla was accepted for the free program. "We went to the temple to pray and give thanks," said her daughter Prachi.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par The Partnership\par How Novartis Found The Max Foundation\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Glivec is a miracle drug for the new century, the first in a class of medications that fight cancer cells without being toxic to healthy cells. Clinical trials showed that it restored healthy blood counts in 9 of 10 patients with chronic myelogenous leukemia, or C.M.L., one of the four main types of the disease. Recent studies have shown Glivec to be effective against other diseases, as well.\par To get the drug to needy patients in the United States (where it is called Gleevec), Novartis selected Do}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 umedics, a fast-growing company with 110 employees.\par Finding someone to handle the effort in the rest of the world proved more troublesome. \par Paula Boultbee, global director for brand management of Glivec, said that Novartis was looking for an orga}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ization that had experience with cancer patients, particularly those with leukemia, and had run an intern}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional drug donation program. An administrator would have to be on top of customs, tax and shipping rules, transportation conditions and the structure of health care systems in scores of countries.\par Novartis said it ran the idea past organizations it had worked with before, like Doctors Without Borders and the International Red Cross, but found no takers. Among the issues, cost loomed large: budget projections submitted by some prospective partners were twice Novartis's own estimates.\par "The vast majority recommended that we not do such a program," said Dr. David R. Epstein, president of Novartis Oncology, the unit dedicated to cancer treatments.\par So Novartis officials jumped to respond in March 2001 when the Max Foundation, an obscure Seattle-area charity that helped cancer patients in Latin America, sent the company an e-mail message asking for a don}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of cyclosporine, an immunosuppressant, for a patient in Honduras. \par A few days later, Ms. Boultbee, the Glivec brand manager, left a message for Max's founder, Pedro Rivarola, asking him to fly to New Jersey to discuss plans for Glivec. \par They met for the first time on April 2. A month later, the Food and Drug Administration formally approved Glivec. And in July, Dr. Epstein sent a memo to company executives around the world proudly announcing that Novartis was establishing a drug donation program aimed at ensuring that "no CML patient will be d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nied treatment with Glivec for financial reasons." \par He described the effort as "the most generous and far-reaching access program ever developed for a brea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 through cancer therapy," adding that the intent was to help the company "achieve its therapeutic and bus}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ness goals" for the drug. \par A slide presentation prepared by Novartis a month earlier was more explicit in outlining the path to meeting the latter objective. "Max Patient Advocacy Work," it said, would be directed at "payers," "physicians," "p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tients," "media," "legal pressure" and "community involvement," all with a single aim: "OK Reimbursement." \par With financing of $1 million a year from Novartis, the Max Foundation rented an office, hired an administr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tive staff and began building a computer system that could handle the program, called the Glivec Internatio}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 al Patient Assistance Program, or Gipap. According to Dr. Epstein's memo, Novartis granted the foundation "sole and final responsibility for approving each single patient's eligibility" for the program.\par The assignment was an astounding leap for an organization that reported revenue of just over $20,000 the year before. The foundation was a mom-and-pop operation, established to honor the memory of Mr. Riv}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 rola's son Maximiliano, who died in 1991 of the leukemia that Glivec combats. Ms. Stone, the Novartis spokeswoman, said "they were one of the only foundations dedicated specifically to helping C.M.L. patients, and therefore they understood both the scientific aspects of the disease and the desperation of patients seeking a treatment or cure." \par It did not take long, however, for many patients and their advocates and doctors to question Novartis's choice -- and for a program intended to sow good will instead to breed conflict. \par By January 2002, objections from around the globe began appearing in online discussion groups dedicated to C.M.L. Patients complained that eligibility requirements were out of step with the way doctors were pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 scribing the drugs. Some patients were getting the drug and others were not, for reasons not easily di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cerned. \par "A C.M.L. friend of ours in Singapore who had applied for Gipap got 37 percent worth of Glivec free," Anjana Rai Chaudhuri, a chemist in Singapore whose husband has leukemia, wrote on a Yahoo bulletin board. "He has to pay for 63 percent himself. There is no 'free' Glivec as we have been led to believe."\par In part, the frustrations stemmed from the inconsistency of medical standards from nation to nation. Novartis requires patients' treatments to match local drug regulators' guidelines for Glivec. While the United States has approved Glivec as a first-line treatment, many countries recommend it only after other drugs have failed.\par Yet the reports of Glivec's success have led doctors to prescribe it for their patients anyway. A result is that patients who qualify for assistance on financial grounds -- often because they have bankrupted themselves buying the drug -- are rejected because they have not first taken an older drug, interferon. And "many of them can't afford that either," said Robert W. Neill Jr., a North Carolina real estate developer who administers an Internet list for leukemia patients.\par Yet for some patients, the rules are bent. Sourabh Ghosh, an Indian student studying in Switzerland who is a volunteer for the Max Foundation, said he had been receiving Glivec since last June, even though he has never taken interferon. Rakesh Nagpal, a 41-year-old father of twins in New Delhi who makes $4,800 a year, said he was also getting the drug without having first taken interferon. \par Such inconsistencies abound. Fatima Ouassini, a patient in Tangiers, Morocco, waited seven months for a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 knowledgment of her application, said her son, Khalid Hmam. Mr. Hmam, who runs an electronics repair business, e-mailed, faxed and finally called the foundation. He said that he was told by Patricia Garcia-Gonzalez, who runs the program and is married to Mr. Rivarola, that there was nothing it could do, because Glivec had not been approved in Morocco.\par But when he sought help from Life Raft, a support group for patients with the tumors his mother has, he was able to get Glivec directly from Novartis. \par Ms. Garcia-Gonzalez said that the foundation had met patients' needs while running the program on lines dictated by Novartis. \par "We have done an outstanding job managing the program, and more than 1,000 patients are benefiting from it," she said. "I believe we should be judged for what we do and not for what is still to be done."\par Novartis is satisfied with the Glivec program, Dr. Epstein said. "Considering how much there was to learn when we set it up, it's done remarkably well," he said.\par While Novartis alienated some patients with the fitful start of Gipap, another, larger group became vocal a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 vocates for the company's interests after receiving Glivec free.\par Under a special program, these 7,500 patients got Glivec as Novartis undertook clinical trials, country by country, to win regulatory approvals. But once Glivec is approved, the company stops supplying it under the special program; patients must then seek Glivec through private or government insurance and other conve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tional channels. \par But instead of becoming angry at Novartis, patients have protested to governments and have helped win vi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tories for the company.\par In South Korea, for example, the Ministry of Health and Welfare initially set the price of a Glivec capsule at $15, lower than what Novartis wanted. The company refused to sell the drug at that price, and as the two sides bickered, patients held demonstrations. Novartis encouraged them, promising to reimburse patients for a portion of their co-payments. In January, the government and Novartis agreed to a price of almost $18 a capsule, a 20 percent increase over the government's original offer.\par Under terms of the national health plan, that means patients will pay $243 to $486 a month for the drug, d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pending on their dosage, keeping it out of reach for many, according to Hee Seob Nam, a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  lawyer turned patient advocate in Seoul. When patients protested the new price outside Novartis's office in Febr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ary, 13 were arrested and one protester was injured so badly he had to be taken to the hospital. \par In March 2002, as Novartis was having a similar wrangle with Hong Kong authorities over Glivec's price, it sent a letter to the 53 patients in clinical trials there, telling them that the trials were ending and their free drugs would be cut off in July 2002, according to a patient who received the letter. \par Another patient in Hong Kong said that Novartis hired the public relations firm Ruder Finn to help patients get their stories of financial distress into the newspapers. Patients lobbied through the summer and fall, and in December, the government went along with Novartis's price. \par When Novartis told 30 patients in New Zealand a year ago that their free Glivec supplies were about to end, Wayne McNee, the head of Pharmac, the country's drug purchasing agency, issued a press release bran}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing the move "a marketing exercise to increase pressure on getting Pharmac to fund the drug."\par He has not changed his opinion, though the agency agreed in October to purchase Glivec. "There was no doubt that by threatening to remove the medicine, it put pressure on the funding decision," Mr. McNee said in a telephone interview.\par Novartis sees no reason to shy from mobilizing patients in such disputes. "Patients play a key role, and they're going to continue to play a key role," said Dr. Epstein of Novartis Oncology. "I think it's the wave of the future, and it's a good thing. It helps drug manufacturers get closer to the people we're doing this work for."\par Nowhere has Novartis been more active in giving away Glivec than in India. About 44 percent of the Max Foundation program's beneficiaries live there. But while the company's generosity is applauded, its motives have been questioned.\par Novartis started the program in India with a warning. "They had told us all in the beginning that they will stop the program if somebody launches a generic version in India," said Dr. P. P. Bapsy, an oncologist at the Kidwai Memorial Institute of Oncology, the leading cancer hospital in Bangalore.\par To some doctors in India, the warning underscored the pragmatic aims of the company's philanthropy. The giveaway was a means, they contend, to establish a commercial beachhead in India's brutally competitive drug business. If Novartis somehow managed to ward off generic versions of Glivec, India could be a huge market for the drug and a bellwether for other emerging markets. \par After all, India's middle class is growing, and private insurers like Cigna and others have begun selling insu}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ance more widely there, hoping ultimately to cover 100 million to 300 million Indians, according to a report by McKinsey & Company. Moreover, starting in 2005, global trading rules will require India to honor drug co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  So brand-name drug manufacturers like Novartis have hopes of wresting away a bigger share of the Indian market, where 76 percent of sales are controlled by local companies.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par A Key Market\par Generic Competitor Starts Sales in India\par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The market for Glivec certainly seemed promising. Profits at Novartis's Indian unit in the quarter ended Sept. 30 were 48 percent higher than a year earlier, thanks in large part, the company said, to Glivec sales. \par But those results are unlikely to be replicated. On Jan. 26, Natco Pharmaceutical, a generic drug maker based in Hyderabad, began selling generic Glivec under the name Veenat. A month's supply costs $377, versus $2,769 for Glivec.\par Mente Subba Rao, a Natco spokesman, said that the months-long process of winning government approval for Veenat, while swift by American standards, seemed unusually long and tedious. "We are guessing that Novartis attempted to pressure the drug controller," he said, referring to India's top drug regulator. \par That suspicion was echoed in an interview with Dr. Yusuf K. Hamied, the chairman of a Natco competitor, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  which is planning its own generic version of Glivec.\par Asked if generic licenses had been delayed because of pressure from Novartis, Ashwini Kumar, the drug controller of India, said, "No comment." In response to the same question, Ms. Stone said in an e-mail me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 sage that Novartis had provided information on the manufacture of Glivec to the drug controller's office. \par With Veenat's approval, Novartis made good on its threat, announcing that as of May 1 it would accept no more applications for the Glivec giveaway program in India. Since a generic version is available, the comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ny said on its Web site, generic manufacturers should "shoulder some of the responsibility" of supplying the drug. It also chided the Indian government for failing to respect international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents.}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par "Within Novartis's capabilities," the company said, patients in the Max Foundation program will continue to get the drug.\par Novartis offered to turn over its donation program's apparatus to Indian manufacturers, but Natco, at least, did not wait for the offer to try its hand at mixing commerce and charity. With an eye on rivals like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  it already had established a giveaway program for Veenat in conjunction with the Cancer Patients Aid Associ}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion, which had sought the same role in Novartis's program.\par Ms. Garcia-Gonzalez, meanwhile, has asked Natco to take over the Max Foundation program in India.\par Chowdary V. Nannapaneni, Natco's chairman, said the company had agreed in principle to give three-month supplies of Veenat to 200 patients screened by the foundation.\par Natco, Mr. Nannapaneni said, does not want poor patients to suffer on its account. "We are not as big as Novartis," he said, "but we are eager to help needy Indian patients in the best way we can."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 URL: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 http://www.nytimes.com \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICAL PREPARATION MFG (93%); CANCER (93%); PHARMACEUTICALS I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DUSTRY (92%); CANCER DRUGS (91%); DISEASES & DISORDERS (90%); GENERIC PRODUCTS (90%); DRUG PRICES (89%); PHILANTHROPY (89%); CHARITIES (89%); CORPORATE GIVING (89%); FOUNDATIONS (87%); AIDS & HIV (78%); GENERIC DRUGS (78%); SALES FIGURES (78%); LEUKEMIA (78%); MALARIA (76%); NONPROFIT ORGANIZATIONS (76%); EPIDEMICS (76%); PHYSICIANS & SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEONS (72%); RETAIL MERCHANDISE MANAGEMENT (61%); HAY FEVER (50%) CANCER;  DRUGS (PHARMACEUTICALS);  GLIVEC (DRUG);  PHILANTHROPY;  MARKETING AND MERCHANDISING;  SALES;  PRICES (FARES, FEES AND RATES);  GENERIC AND BRAND NAME PRODUCTS \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOVARTIS AG (92%); NOVARTIS GROUPE FRANCE SA (91%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NOVARTIS AG; MAX FOUNDATION \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NVS (NYSE) (92%); NOVN (SWX) (92%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS339115 OPHTHALMIC GOODS MANUFACTURING (92%); NAICS325412 PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MANUFACTURING (92%); SIC3851 OPHTHALMIC GOODS (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (91%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (91%)  SIC2834 PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATIONS; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STROM, STEPHANIE; FLEISCHER-BLACK, MATT \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NEW DELHI, INDIA (70%) INDIA (93%); UNITED STATES (93%); MOROCCO (74%) I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DIA;  SOUTH KOREA;  HONG KONG;  NEW ZEALAND; \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 5, 2003  \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 June 10, 2003\par \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CORRECTION:}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  A front-page article on Thursday about an effort by Novartis to distribute the cancer drug Glivec to poor patients around the world used a title erroneously for David R. Epstein, president of the co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany's oncology unit. He is not a physician.\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Photos: A slide from a Novartis presentationshows how the company planned to use a free ca}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cer medicine program to help get eventual reimbursement for the medication.; Getting a miracle drug to treat cancer depends on where a patient lives. In Morocco, Fatima Ouassini, left, with her son Khalid Hmam, wai}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed for seven months before she was finally able to get Glivec directly from Novartis. In New Delhi, Rakesh Nagpal, below, was able to get it more quickly. (Amit Bhargava for The New York Times); (Abdelhak Se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 na/Agence France-Press for The New York Times)(pg. C7)      \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The New York Times Company\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIME TO PUT DRUG GIANTS ON TRIAL The Scotsman May 19, 2003, Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_265}{\*\bkmkstart DOC_ID_265_0}{\*\bkmkstart doc_id_127}{\*\bkmkend DOC_ID_265}{\*\bkmkend DOC_ID_265_0}{\*\bkmkend doc_id_127}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_127"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 127 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Scotsman\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  19, 2003, Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 TIME TO PUT DRUG GIANTS ON TRIAL}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Margaret Cook\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pg. 12\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1543 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  SOME years ago, I looked after a patient, a young man in his teens with the serious blood disorder thala}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 saemia, who begged me to use him as a guinea pig. He had read of a new tablet called L1 which was being tested, and wanted to try it even if it made him trial fodder.\par  Kept alive by regular blood transfusions, he also needed medication to leech surplus iron from his tissues. The only treatment then available was desferal, which had to be injected over 12 hours several times a week; painful, inconvenient and cumbersome.\par  I was not in a position to put him in a trial, and in any case, dangers for volunteers are often greater than benefits, so advised him to wait till L1 passed safety and other hurdles. \par  Now L1 - the trade name for which is Ferriprox - has reached the markets in Europe, where it has been l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 censed in 24 countries, including the UK. The story of how Apotex, the manufacturing company, has intr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duced it here - described in detail by Channel 4 documentary Dying for Drugs - makes uncomfortable rea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing.\par  Much of the research was carried out in a children's hospital in Toronto, Canada, and was supervised by Dr Nancy Olivieri, a world expert in thalassaemia. After initial euphoria, some of her data showed a few patients deteriorating. Then, more worryingly, there emerged some evidence of rapid liver damage.\par  On voicing these concerns to Apotex, Dr Olivieri claims that the trial, and her leadership of it, were abruptly terminated, her concerns labelled "misinterpretations" and her work rubbished.\par  When other colleagues waded in to support her, they were reportedly also treated to intimidating tactics, even poison pen letters.\par  This scarifying battle, which almost ruined Dr Olivieri's professional life, is now in the public arena, and the European Commission is currently being charged in court with premature licensing. The jury is still out. Meanwhile, children keep taking the tablets.\par  Dr Olivieri received letters from hundreds of research doctors bearing witness to thuggish techniques, even intrusions into personal lives by private investigators hired by drug companies.\par  Many will no doubt have preferred to give in for the sake of a quiet life and a swift backhander, lacking Dr Olivieri's courage. Editors of the American Journal of Medicine and the Lancet also admit to pressures - of a more gentlemanly kind - to change results.\par  Where huge profits are at stake, it seems global companies behave as if they are beyond the rules - or else they bind other heavyweight interest groups to change or bend those rules.\par  One of these groups, I fear, is doctors. Their sins may be individually tiny, and often are of omission rather than commission, but collectively, they have a huge impact.\par  The side effects of drugs, until recently, were not shared with patients at all and the public is still amazingly ignorant. Even now, potential problems are soft-pedalled, described in emollient terms.\par  Monitoring is so ineffectual as to be culpably neglectful. All doctors have a duty to report problems to the Committee on Safety of Medicines using a yellow card system, even on suspicion. But few perform this vo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 untary duty. It seems unscientific, anecdotal, ineffective - if our discretionary points systems were based on the number of reports we made, you would see a stratospheric response.\par  Yet the recent Panorama television programme on Seroxat, an antidepressant, revealed to the experts just how this should be done. Here is a riveting programme, to which thousands responded, and immediately patterns can be recognised.\par  The repeated description of nightmares, often about blood, suicides - attempted and achieved - emotional turmoil, personality changes and violence cannot be ignored. Similarly, the terrifying electric-shock sens}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions in the head on withdrawal was beamed in from many sources.\par  Of course, doctors don't recognise problem-patterns when they come singly. In these days of sophisticated IT, it is not beyond the imagination to collect data straight from patients, who are far more motivated to report than their doctors.\par  Certainly, the manufacturing company is not motivated to draw attention to side effects. "My heart goes out to anybody...," gushed the oily GlaxoSmithKline captive doctor, dripping with insincerity and contorted with body language.\par  And serious questions should be asked about claims that early clinical trials by GlaxoSmithKline showed a ten-times greater risk of suicide on Seroxat than on placebo.\par  Equally penetrating queries should be directed at how, in the UK, a review committee of the Medical Co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 trols Agency to investigate Seroxat had to be disbanded because half its members were share-holders of GlaxoSmithKline. The name of the Medical Controls Agency was changed; but the government should jett}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 son the entire organisation and recreate a new, motivated, independent and listening organisation.\par  The Chancellor, Gordon Brown, clings to the Keynesian tenet that a nation's economy depends most strat}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gically on its business investments. Thus are governments worldwide at the beck and call of big business, of which, globally, pharmaceuticals top the chart.\par  Donald Rumsfeld, the United States defence secretary, is a former Pharma chief executive. When countries signed up to a World Trade Organisation ruling to protect poor countries in getting access to cheap generic drugs (especially for AIDS and infectious diseases), Mr Rumsfeld, loyal to his tribal trade roots, disagreed. The agreement was killed by the US veto.\par  Under world trade rules, a company has exclusive rights to the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  of a new drug for 20 years. Thus the price is set by the company, and governments can do little to interfere. Glivec, a genuinely innovative new drug for chronic myeloid leukaemia, is blisteringly costly, yet the price of $ 19 a tablet is not justified by the research costs.\par  Some third world countries have created a strong generic drug sector, notably India, where active ingred}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ents of much-needed medications (for AIDS and cancer, for instance), can be put together at a fraction of the patented cost.\par  Dr Hamied, of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian pharmaceutical company, talks of humanitarian values which can be reco}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ciled with business. "Do you want reasonable profits or do you want obscene profits?" he asks. When you see the plight of sick people in poor countries, the threshold for obscenity is at rock bottom.\par  In Korea, the minister of health delivered to his government an application for a compulsory licence to sid}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 track the high cost of Glivec. Korean patient volunteers had helped develop the drug but could not afford it thereafter. The minister was warned by the US secretary for trade not to meddle with drug prices. Continuing to campaign, he was sacked.\par  It seems his government had been threatened with crippling trade sanctions by the US and Europe unless he was silenced. The US has likewise threatened Thailand with tariffs on wood and jewel exports (30 per cent of their US trade) if they persist in making generic drugs.\par  Now, World Trade Organisation rules mean that cheap generics will soon no longer see the light of day, even in India. Money and markets rule OK. Yet there are regulations which in western countries are not so easily evaded, such as those controlling research and human rights.\par  Ever since Nuremberg, the principle of voluntary, informed consent by individuals has been paramount, and the details of any proposed trial must be scrutinised by a watchdog ethical committee.\par  From a business viewpoint, this is inconvenient; it interferes with access to test subjects and speed of the process to the summation of, hopefully, billion dollar returns.\par  Increasingly, pharmaceutical companies have found ways to bypass these formalities by taking trials to ina}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ticulate third world countries from where events tend to go unreported in the West.\par  It is claimed that Pfizer did this in Kano, Nigeria, during a meningitis outbreak, using their new, untested a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tibiotic Trovafloxacin. Children used in this life-and-death natural disaster were malnourished and not suit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ble subjects for oral treatment. Since then, the drug has not been approved because of a poor safety profile.\par  Pfizer's own child specialist objected vociferously to the trial organisation and was sacked.\par  Yet the Nigerians' voice has been heard, and the Kano story will be tested in court, if the lawyers involved have a measure of compassion and can detach themselves from deference to might instead of right.\par  Now I do not want to put anyone off taking essential medications. However, it is time for patient empowe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment.\par  If you need treatment, it is far better to be taking something that has stood the test of time and long exper}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ence, something which has long passed its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  time, and is no longer the vehicle of massive profits.\par  Do not be seduced into thinking the newest is the brightest and best. Know about side-effects, and insist on your doctor reporting any new ones, even - or especially - if they seem bizarre. Lobby your MP about trade sanctions with third world countries. And don't buy shares in pharmaceutical companies.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ONTARIO, CANADA (75%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TORONTO, ON, CANADA (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLOBAL COS LLC (62%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NORTH AMERICA (51%); CANADA (51%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (90%); EUROPEAN UNION MEMBER STATES (76%); CANADA (75%); UNITED KINGDOM (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BLOOD DISORDERS (90%); ANEMIA (90%); ADOLESCENTS (90%); INVESTIGATIONS (87%); BLOOD TRANSFUSIONS (78%); DRUG INTERACTIONS & SIDE EFFECTS (77%); PHARMACE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TICALS INDUSTRY (76%); WITNESSES (76%); CHILDREN'S HOSPITALS (73%); LIVER DISEASE (73%); MULTINATIONAL CORPORATIONS (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 19, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PAPER\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The Scotsman Publications Ltd.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Uganda;3 Firms to Supply Cheap Aids Drugs Africa News May 8, 2003 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_266}{\*\bkmkstart DOC_ID_266_0}{\*\bkmkstart doc_id_128}{\*\bkmkend DOC_ID_266}{\*\bkmkend DOC_ID_266_0}{\*\bkmkend doc_id_128}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_128"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 128 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  8, 2003 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Uganda;\par 3 Firms to Supply Cheap Aids Drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Monitor\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 363 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The National Drug Authority has licensed three Indian companies to supply cheap Aids drugs, lawmakers heard yesterday.\par The head of drug registration at the National Drug Authority Francis Otim told a seminar organised for me}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 bers of the committee on Legal and Parliamentary Affairs that Ranbaxy Laboratories Ltd, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd and Hefero Drugs Ltd have been licensed, while five others are being appraised.\par Unfortunately, he said, a proposed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law could bar Uganda from importing the cheap generic drugs from the Indian companies. \par "That is what we are fighting," Mr Otim said. "If government passes this law the way it is, it will exclude Uganda from using these cheap drugs."\par The seminar, held at the International Conference Centre in Kampala, was organised by Uganda Access to Essential Medicines Coalition to discuss the proposed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  law now before the Law Reform Commission.\par The United States Agency for International Development (USAID) is funding the exercise.\par The revelation followed fears from some of the MPs that if the law is not enacted, cheap but ineffective drugs could find their way here.\par "NDA does not in any way allow poor quality drugs to come into the market," Mr Otim said. "The companies we allow into the country do research. They are approved by the Medicine Control Authority of the UK and even the World Trade Organisation. So their quality is not any different from that of the companies in deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oped countries."\par Ms Winnie Masiko (Rukungiri) said that government should instead provide incentives such as tax exem}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tions on packaging materials for local pharmaceuticals to manufacture drugs.\par "Many of these drugs, I hear are made from simple raw materials like plants," she said.\par The MPs also wondered why government is in such a hurry to enact the law yet WTO allows poor countries up to 2016 to enact it.\par "I get worried; most of our people use generic drugs," Ms Jane Alisemera (Bundibugyo) said. "If we are going to pass a law allowing the manufacturer to charge expensively, I look at a situation where our people can not even get an Aspirin. When we pass the law, it may make some of these drugs inaccessible."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (90%); GENERIC DRUGS (90%); LEGISLATORS (90%); INTELLE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TUAL PROPERTY LAW (78%); PHARMACEUTICALS INDUSTRY (78%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (78%); CONFE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENCES & CONVENTIONS (78%); INTERNATIONAL ECONOMIC ORGANIZATIONS (77%); LEGISLATION (76%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (76%); TRADE DEVELOPMENT (76%); INTERNATIONAL ASSISTANCE (74%); I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TERNATIONAL TRADE (74%); APPROVALS (73%); LICENSES & PERMITS (73%); GENERIC PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UCTS (73%); TAX LAW (73%); PHARMACEUTICALS PRODUCT DEVELOPMENT (73%); INTERNATIO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AL ECONOMIC DEVELOPMENT (68%); PACKAGING MATERIALS (64%); TAX INCENTIVES (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (84%); RANBAXY (NSE) (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (84%); SIC2834 PHARMACEUTICAL PREPARATIONS (84%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (72%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FRANCIS OTIM (87%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 US AGENCY FOR INTERNATIONAL DEVELOPMENT (83%); WORLD TRADE ORGA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IZATION  (54%); WORLD TRADE ORGANIZATION (54%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UGANDA (95%); UNITED KINGDOM (79%); UNITED STATES (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 CITY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 KAMPALA, UGANDA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HEFERO DRUGS LTD (73%); INDIAN COS (73%); INTERNATIONAL DEVELOPMENT CO (68%); RANBAXY LABORATORIES LTD (68%);  NATIONAL DRUG AUTHORITY (90%); WORLD TRADE ORGANISATION (68%); AGENCY FOR INTERNATIONAL DEVELOPMENT (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 8, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PanAfrica;Aids: Even With Discounts from Drug Firms, Generics Remain Far Cheaper Africa News May 5, 2003 Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_267}{\*\bkmkstart DOC_ID_267_0}{\*\bkmkstart doc_id_129}{\*\bkmkend DOC_ID_267}{\*\bkmkend DOC_ID_267_0}{\*\bkmkend doc_id_129}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_129"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100320039000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 129 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Africa News\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 May}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  5, 2003 Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 PanAfrica;\par Aids: Even With Discounts from Drug Firms, Generics Remain Far Cheaper}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The East African\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1233 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SEAN FLYNN, senior attorney at the Consumer Project on Technology (CPTech), a non-profit organisation in Washington DC that focuses on the impact of intellectual property protection on consumer interests, spoke to GICHINGA NDIRANGU on compulsory licensing in relation to the HIV/Aids pandemic\par What is the problem you are addressing?\par It is the lack of access to medicines needed to treat Aids. About 95 per cent of people who have HIV/Aids live in the developing world. Africa accounts for over 70 per cent of the world's Aids deaths and Aids is the leading cause of deaths in Africa. \par Since 1996, there have been antiretroviral (ARV) medicines that can cut Aids deaths by up to 70 per cent and allow people with Aids to live relatively normal lives. There are about 30 million people with Aids in Africa and between four and five million Africans need immediate access to ARV treatment or they will soon die. Yet, only 30,000-50,000 people in Africa have access to this treatment, including only about 7,000 in Kenya and 10,000 people in Uganda. We want to help increase the accessibility of treatment.\par How do you plan to do that?\par For there to be treatment, affordable medication must be available as well as effective health systems, sele}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion of medicines through registration procedures and funding. CPTech's work focuses on expanding access to affordable medicines by attacking }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  barriers that prevent low-cost/high-quality drugs from reaching African markets. We are helping citizen groups and government officials understand the flexibilities they have under national and international law to force }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holders to allow competition in the supply of life-saving products, thereby bringing the prices of the products down. Of course, to get the drugs to people who need them, the other barriers - health systems, drug registration and funding - need to be addressed.\par How can a government force a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder to allow competition?\par We are educating African decision makers on compulsory licensing. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are sets of rights granted by the government to an inventor to use and profit from an invention. Since the first international agreement regar}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the late 1800s, governments have always retained the right to allow others to use the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  without permission from the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder if the holder fails to serve the needs of the market on reasonable terms.\par The act of allowing another to use a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  without permission of the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder is called "non-voluntary use" or a "compulsory licence."\par The latest international agreement, the World Trade Organisation Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS), authorises governments to use compulsory licences for government use, to meet public emergencies or circumstances of extreme urgency (including health crises), as a remedy to anticompetitive practices or for any other public purpose, as long as certain procedures are followed.\par The Ministerial Conference of the WTO in Doha (2001) instructed states to interpret the TRIPS agreement "in a manner supportive of WTO members' right to protect public health and, in particular, to promote access to medicines for all." Specifically, the Conference agreed that "each member has the right to grant compulsory licences and the freedom to determine the grounds upon which such licences are granted."\par Has competition affected the price of Aids drugs?\par In the past few years, several countries have allowed the manufacture of generic ARVs with the result that prices dropped. In 1998, multinational companies were charging about $12,000 per year for the cheapest ARV treatment - a combination of d4T+3TC+nevirapine. In 2000, Brazil began offering this triple drug ther}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 py for $2,767 annually after allowing local suppliers to make or import the medicines. By March 2001, Indian drug manufacturer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was offering a generic treatment for $350 and the brand name version had dropped to $727. Today, suppliers offer the treatment for as low as $200 per year.\par Are there other benefits of competition for the supply of medicines?\par Competition has multiple benefits. One of the most dramatic in the supply of ARV medicines has been the ability to compete to provide the most innovative product for developing countries.\par For example, none of the brand name companies provides a d4T+3TC+nevirapine treatment in a single pill because the drugs are patented by different companies and they do not work together. But several generic firms now provide these treatments in a single pill, allowing increased ease of administration.\par Having one company provide each drug has also caused shortages of supplies because when the supplier runs out of a product there are no alternatives, as has happened several times recently in Kenya.\par Another benefit may be the possibility that local production could begin to capture a share of the market, providing positive feedback effects in terms of employment and technology transfer.\par There is an argument that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  cannot be a problem in Africa because most ARVs are not patented in most countries in Africa?\par It is true that not all ARV drugs are patented Africa. The multinational pharmaceutical companies use this information to argue that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are not a problem. But when one looks at which drugs are patented in Afr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ca, one finds that the drugs that are the cheapest to produce and the most effective to administer are widely patented.\par For example, a drug called Indinivir is only patented in two African countries. But it is very expensive to pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 duce and is not appropriate for many patients in Africa because you must consume at least two litres of w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ter each day (more in hot areas) to prevent kidney stones. The least expensive, easy to administer and most effective treatments are (AZT or d4T)+3TC+nevirapine. One or more of these drugs or combinations are p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tented in 37 African countries.\par When should countries grant compulsory licences?\par To maximise the ability of competition in the supply of medicines to drive down prices and foster innovation, compulsory licences of right (a licence for any supplier to compete that can meet regulatory approval r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 quirements) should be granted whenever the number of people who need access to the medicines signif}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cantly exceeds those with access; or the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  holder has not implemented an automatic licensing pr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 gramme for all qualified suppliers on reasonable terms (international standard of two per cent to five 5 per cent royalties on annual sales) or if the major barrier to access is price. These drugs have been available in the West since 1996. The time to act is now.\par Are discounts and donations by the brand companies not solving the problem?\par No. Even with the most recent discounts by GlaxoSmithKline last week, the generic price for ARVs remains far cheaper than those of the brand name companies. The drug company discounts do not reach the private sector where perhaps a majority of people receive treatment now, and where more could receive treatment if prices were low enough. In addition, the prices will not fall further unless competition is allowed.\par Finally, the other benefits of competition - incentives to innovate, an increase in the number of suppliers to avert shortages and an allowance of local production - will not occur through discounts and donations.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GENERIC PRODUCTS (90%); HEALTH CARE ACCESS (90%); AIDS & HIV TREATMENT (90%); PHARMACEUTICALS INDUSTRY (90%); AIDS & HIV (90%); PHARMACEUTICAL PREPARATION MFG (89%); INTELLECTUAL PROPERTY LAW (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); NONPROFIT ORGANIZATIONS (89%); LICENSING AGREEMENTS (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LAW (78%); ANTIVIRALS (76%); DEATHS & DEATH RATES (76%); INTERNATIONAL ECONOMIC ORGANIZATIONS (74%); EPIDEMICS (72%); RESTRAINT OF TRADE (72%); INFECTIOUS DISEASE (72%); TRADE TREATIES & AGREEMENTS (71%); INTERN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONAL TRADE LAW (68%); TREATIES & AGREEMENTS (65%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANISATION (66%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (94%); UNITED STATES (92%); KENYA (79%); UGANDA (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 STATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DISTRICT OF COLUMBIA, USA (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD TRADE ORGANISATION (66%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 May 13, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 AllAfrica, Inc.\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LAST NIGHT'S TELEVISION: ENOUGH TO MAKE YOU FEEL SICK;DYING FOR DRUGS C4 The Independent (London) April 28, 2003, Monday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_268}{\*\bkmkstart DOC_ID_268_0}{\*\bkmkstart doc_id_130}{\*\bkmkend DOC_ID_268}{\*\bkmkend DOC_ID_268_0}{\*\bkmkend doc_id_130}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_130"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 130 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Independent (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 April}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  28, 2003, Monday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 LAST NIGHT'S TELEVISION: ENOUGH TO MAKE YOU FEEL SICK;\par  DYING FOR DRUGS C4}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THOMAS SUTCLIFFE\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 FEATURES; Pg. 21\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 690 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  It's an odd world in which the makers of medicine jostle with arms traders at the top of the moral pariah league, but it is, unfortunately, the one we live in. This has something to do with the reflex suspicion against any form of global capitalism - a reflex which isn't always trustworthy - but it has much more to do with the way that big pharmaceutical companies behave. They are among the most profitable and powerful busines}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es in the world - capable of coercing foreign governments into disregarding the interests of their own citizens, of bullying scientists into silence when research results look as if they might affect the share price, and of treating the world's poor as little more than human lab rats.\par  Dying for Drugs, a film by Michael Simkin and Brian Woods, offered examples of all three in their detailed account of "Big Pharma". It was, by several long-haul jet flights, the most powerful documentary I've seen this year or last - a film which had an almost pharmaceutical effect, steadily increasing the viewer's blood pressure and sense of moral outrage. \par  The film began and ended with two suffering children - a cheap and dangerous polemical weapon, but one which was ultimately justified by the film's content. The first was a young Nigerian boy, Anas (below), who now suffers from damage to his knee joint, an injury his doctor believes is connected to his participation in a drug trial for a meningitis treatment. Pfizer, who were conducting the trial, insist that the parents of all those involved in the trial gave their informed consent, but they can produce no written records to back up this claim, and the parents themselves insist they were never told that the drug was on trial, or that it had known side effects (including damage to joints). A senior Pfizer executive who protested on ethical grounds about the trial was subsequently sacked and the matter is currently before the courts.\par  The second child was Jairo, a young Honduran boy dying of Aids. Jairo needed a Pfizer drug called Diflucan to treat the oral thrush that was preventing him from eating, but his aunt and an uncle couldn't afford to buy it at the $ 27 a capsule Pfizer charge. Across the border in Guatamala, where it was legal to sell a generic copy of the drug, it cost a fraction of that price - but getting hold of it meant Hondurans had to break the law. The big pharmaceutical companies are now using every means at their disposal to close down the generic drugs companies and protect their }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  against cheaper competitors. In South Korea, the programme filmed leukaemia patients dependent on corporate whim for their continued existence - as "a gesture" Nova}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tis supplied them with free drugs, but it steadfastly refused to alter the market-place price so that it matched those of generic drug suppliers.\par  There were some hard questions that weren't asked here. It would have been nice, for example, to know whether }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian generic drugs manufacturer which was held up as a model of ethical capitalism, had spent any of its more modest profits on research and development. The argument that successful drugs have to bear the R&D costs of all the ones that don't get to market is grotesquely abused by the big pharm}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ceutical companies, but it isn't simply inadmissible.\par  But Dying for Drugs unquestionably made its case - that corporate greed condemns many of the world's poor to ill-health and early death. If you want an example of the kind of Potemkin village that big business erects to hide those ugly facts, visit the Pfizer website, where the company boasts that: "We dedicate ou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 selves to humanity's quest for longer, healthier, happier lives", and grandstands its initiative to distribute free Diflucan in Africa (an initiative it has undertaken only after overwhelming public pressure). The website doesn't mention the gross overpricing of Diflucan in Honduras, and it naturally doesn't mention Jairo - who eventually died on the way to hospital in the film's deeply painful final sequence. I don't suppose Pfizer will mind too much. He was never going to be a big spender anyway.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DISEASES & DISORDERS (90%); ARMS TRADE (90%); PHARMACEUTICALS INDUSTRY (90%); CHEMICAL INDUSTRY (90%); PHARMACEUTICAL & MEDICINE MFG (90%); PHARMACEUTICAL PREPARATION MFG (90%); GENERIC DRUGS (78%); ETHICS (78%); PRESCRIPTION DRUGS (78%); PHARMACEUTICAL PRODUCT DEVELOPMENT (76%); CANCER (76%); RESEARCH (75%); CLINICAL TRIALS (73%); LEUKEMIA (73%); AIDS & HIV (70%); IMMUNE SYSTEM DISORDERS (70%); GENERIC PRODUCTS (69%); HUMAN SUBJECTS (66%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 April 28, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Independent Print Ltd\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Lundbeck setback to protection of Cipramil Chemist & Druggist February 22, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_269}{\*\bkmkstart DOC_ID_269_0}{\*\bkmkstart doc_id_131}{\*\bkmkend DOC_ID_269}{\*\bkmkend DOC_ID_269_0}{\*\bkmkend doc_id_131}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_131"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 131 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Chemist & Druggist\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  22, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Lundbeck setback to protection of Cipramil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Pg. 24\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 220 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Danish pharmaceutical company Lundbeck has suffered a setback in its efforts to protect its branded pro}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 uct Cipramil (citalopram) from generic competition.\par  Its offer of 300 million Danish Crowns (around pounds 30 million) to Indian company Matrix for it to disco}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tinue the production of its active pharmaceutical ingredient (API) has been rejected, according to The Times Of India last week. \par  Currently, Matrix is one of only two companies supplying citalopram into Europe. It is made using a process that is claimed not to infringe UK and European }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  granted to Lundbeck at the end of 2000. The other supplier is also an Indian company, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Ltd.\par  Matrix currently supplies Lagap in the UK and several other Novartis subsidiaries in Europe. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plied Neolab in the UK since October 2002.\par  The first major hearing on Matrix/Lagap infringement issues was scheduled for mid February but has now been put back to October 3. Lagap is still supplying product in the UK.\par  Neolab stopped selling its product in December 2002, giving an undertaking not to re-enter the market until a judgement had been made on the validity of the Lundbeck }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . Neolab "strongly asserts" its }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  su}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 plied product does not infringe Lundbeck's UK }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , but no date has been fixed for a trial.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Lundbeck; Matrix; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Lagap; Neolab  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (93%); NOVARTIS AG (58%); Lundbeck; Matrix; }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla;}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Lagap; Neolab }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (93%); NOVARTIS AG (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS339115 OPHTHALMIC GOODS MANUFACTURING (58%); NAICS325412 PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MANUFACTURING (58%); SIC3851 OPHTHALMIC GOODS  (58%); SIC2834 PHARMACEUTICAL PREPARATIONS  (58%);  NAICS339115 OPHTHALMIC GOODS MANUFACTURING (58%); NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC3851 OP}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 H}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 THALMIC GOODS  (58%); SIC2834 PHARMACEUTICAL PREPARATIONS  (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DK Denmark, EC; IN India, Asia; GB United Kingdom, EC  UNITED KINGDOM (91%); DENMARK (90%); EUROPE (70%); DK Denmark, EC; IN India, Asia; GB United Kingdom, EC UNITED KINGDOM (91%); DENMARK (90%); EUROPE (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DK Denmark, EC; IN India, Asia; GB United Kingdom, EC  UNITED KINGDOM (91%); DE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MARK (90%); EUROPE (70%); DK Denmark, EC; IN India, Asia; GB United Kingdom, EC UNITED KIN}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DOM (91%); DENMARK (90%); EUROPE (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  & copyright; (2834) Pharmaceutical Preparations  PHARMACEUTICALS INDUSTRY (90%); PHARMACEUTICAL PREPARATION MFG (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRINGEMENT (75%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  & copyright; (2834) Pharmaceutical Preparations PHARMACEUT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CALS INDUSTRY (90%); PHARMACEUTICAL PREPARATION MFG (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (90%); GENERIC DRUGS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  INFRINGEMENT (75%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JOHN MAJOR (53%);  JOHN MAJOR (53%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 24, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 English\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUB-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Magazine\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 CMP Information Ltd\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Saving grace: Yusuf Hamied Generic drugs boss: He says he could save millions from death if the western giants would waive their patent rights and more governments would buy his drugs The Guardian (London) February 18, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_270}{\*\bkmkstart DOC_ID_270_0}{\*\bkmkstart doc_id_132}{\*\bkmkend DOC_ID_270}{\*\bkmkend DOC_ID_270_0}{\*\bkmkend doc_id_132}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_132"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330032000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 132 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Saving grace: Yusuf Hamied Generic drugs boss: He says he could save millions from death if the western giants would waive their }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\cf18\insrsid2900964 patent}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964  rights and more governments would buy his drugs}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Special Supplement, Pg. 8\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1353 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  The drug barons consider him a pirate and a thief. Yusuf Hamied, a Cambridge-educated multi-millionaire who lives for the summer months in what used to be Lady Shirley Porter's London apartment, believes he is doing Ghandi's bidding. He manufactures perfect copies of many of the world's best and most important medicines and sells them at a snip. Dr Hamied and his family are certainly very rich but many poor people owe him their health, without which they would be destitute indeed.\par  The question of Dr Hamied's motivation is absorbing but at the end of the day irrelevant. What matters is that he exists. He single-handedly broke the cartel of the big drug companies by offering to supply Aids drugs at less than a tenth of their prices. That audacious offer at a big European Commission meeting on Aids in September 2000 ("you could hear the breath being sucked out of the room" said Bill Haddad, former New York Post investigative journalist turned US generics boss) made everything possible. The assumption that Aids drugs were not for the poor - that they could not afford them and therefore that there was no point even thinking about ways to get people treated - was blown out of the water. \par  Now, in the post-Hamied era, the genie will not go back in the bottle. The big drug companies have been forced to drop their prices for these new and powerful drugs and offer them to a market they had no interest in developing - the impoverished African states where a whole generation of parents, teachers and workers are dying.\par  Dr Hamied's prices are still lower - his Bombay-based company, }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , offers a three-drug cocktail for around Dollars 304 per year which used to sell for around Dollars 12,000 and would now cost Dollars 727 from the brand-name companies. And yet his sales are few in countries where the need is desperate. Fewer than 50,000 people are being treated out of nearly 30 million infected with the lethal HIV virus in Africa, and - although Malawi is buying them - most of those are not getting }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  drugs.\par  Part of the reason is money - Dollars 304 is still impossible in countries with a per capita income of under Dollars 200 a year. But another part of it is a fight-back by the US and Europe-based big-name pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal industry, which has long wanted to wipe the buccaneering generics companies off the face of the planet. Their long-term strategy to do that, through a World Trade Organisation agreement called Trips (trade rela}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed intellectual property rights) - which will sign up every nation to protect }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on new drugs for 20 years - is now in jeopardy because of the Aids crisis and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  affordable medicines.\par  The drug giants have dropped their prices and argue that there is no need for generic piracy. But many of those who are concerned about the damage being wreaked on the economies of poor nations by a single virus have come to believe that it is not safe for the world to rely on voluntary price reductions by generous drug barons for desperately needed medicines to keep poor people alive and nations stable.\par  Campaigners in the US and Europe, as well as governments in developing countries, now see generics - or the threat of them - as the only way to get affordable medicines for all sorts of diseases that afflict the pop}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lation of poor countries and damage their economies. Just over a year ago, they secured an exemption clause to Trips, called the Doha Declaration, which allows developing countries to ignore }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and buy generics in a health crisis. Now the fight is on to decide in which countries and for which diseases poor pe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ple should be allowed cheap medicines - the US government, which champions the industry, wants to rule out such illnesses as asthma, diabetes and cancer and restrict the concession to the very poorest nations.\par  The crucial issue is whether the generics companies of India, Brazil and Thailand will be allowed to export to countries that cannot make their own cheap copies after the Trips }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules bite in 2005. Unless they can, new drugs invented for Aids or other diseases will be untouchable and unaffordable in Africa for 20 years.\par  }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  was set up as an Indian solution to India's health problems by Dr Hamied's father in 1935 when war stopped medicines arriving from Europe. Its website features a picture of Ghandi expressing his delight at visiting "this Indian enterprise". In 1972, India passed a law which permitted medicines to be copied even if they were under international }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 , as long as the process was not the same. There are now hundreds of generic companies in India - many of them tiny. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  is one of the biggest, with a market capitalisation, said Dr Hamied, of about Dollars 1.4bn. "I don't want to make money on Aids drugs," he says. "I make enough money on other things. On this particular issue, can't we all pool our resources? I make 800 drugs. If I don't make money on six, why should I worry?"\par  Dr Hamied runs a free cancer hospital in India. There are reasons to believe in his altruism. "I'm not going to take it with me, so I have to leave it here," he says. But there's no doubt he stands to win all ways round. His public stand has given }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  excellent publicity. The World Health Organisation has endorsed the quality of his generic Aids drugs and approved his factories. And the fight over the Trips agreement could bring him a lot more business not only from the poorest countries but - and this is why the research-based companies are fighting so hard - also the massive developing markets of China and South America.\par  Dr Hamied, though, is frustrated. He is disappointed with the governments of Aids-hit nations, who are not placing orders for his drugs. "It is a joke," he says. "I should have the demand. Demand creates the incentive to produce, but with only 50,000 in the whole of Africa, where is the demand?"\par  If demand grew as fast as the spread of the virus, he could not keep pace. He would like to see countries set up their own generics factories, and he has offered to show them how to produce Aids drugs for free. The Global Fund should put up the money, he says. None of that is happening. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  sells a three-drug cocktail in one pill, called Triomune, to be taken twice a day, which makes treatment much easier in poor countries. Malawi buys it for the couple of thousand patients who can afford to pay Dollars 28 a month, but its Dollars 196m from the Global Fund will only buy treatment for 50,000 more.\par  Dr Hamied will shortly launch the world's first once-a-day, three-drug treatment, called Odivir. It's clearly well suited to poor countries and it will be affordable, he says, but there's no reason to suppose it will be taken up where his other drugs have not been. "India has four million cases and I'm breaking my head to make my government take a more active role," he says. "I offered totally free nevirapine (to prevent babies being i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fected by their mothers at birth) and nobody takes it. It is up to the various governments to avail (themselves) of the opportunities offered. What has really saddened me is, firstly, the governments and, sec ondly, I have been totally disillusioned by the UN who talk, talk, talk and do nothing at all."\par  What, apart from lack of money in the poorest, is stopping the governments biting }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  hand off? The research-based pharmaceutical industry would say the political will is not there. But }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have been an issue. In Ghana, for instance, says Dr Hamied, it was GlaxoSmithKline that challenged the decision to import generic versions of drugs which were under }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  there.\par  But there are countries where Aids drugs are not patented. According to Bill Haddad, who has voluntarily taken up }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  cause in the US, "the governments are too scared of the US government to buy generics". The US trade representative bats for the giant pharmaceutical companies. Whatever the WTO trade rules say about allowing countries to buy generics in a health crisis, he suggests, there are those who would rather not risk the wrath and possible sanctions of the US.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (82%);   EUROPEAN COMMISSION  (56%); EUROPEAN COMMISSION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPEAN COMMISSION  (56%); EUROPEAN COMMISSION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (82%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (82%); SIC2834 PHARMACEUTICAL PREPARATIONS (82%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (92%); AFRICA (92%); UNITED STATES (79%); MALAWI (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 EUROPE (92%); AFRICA (92%); UNITED STATES (79%); MALAWI (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (90%); WEALTHY PEOPLE (90%); INTELLECTUAL PRO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ERTY LAW (90%); GENERIC DRUGS (90%); AIDS & HIV TREATMENT (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 P}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 TENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (83%); PHARMACEUTICALS ASSOCIATIONS (78%); CONTROLLED SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STANCES CRIME (78%); AIDS & HIV (78%); INTELLECTUAL PROPERTY (78%); TRADE DEVELO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 P}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (73%); TALKS & MEETINGS (73%); GENERIC PRODUCTS (73%); INVESTIGATIONS (72%); CA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TELS (69%); TREATIES & AGREEMENTS (50%); VIRUSES (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 18, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Saving grace: Harvey Bale Jnr Drug firms' federation: The 20-year monopoly on new drugs is essential in generating profits to pay for research. Aids is a government problem, he says, not an industry one The Guardian (London) February 18, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_271}{\*\bkmkstart DOC_ID_271_0}{\*\bkmkstart doc_id_133}{\*\bkmkend DOC_ID_271}{\*\bkmkend DOC_ID_271_0}{\*\bkmkend doc_id_133}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_133"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330033000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 133 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Saving grace: Harvey Bale Jnr Drug firms' federation: The 20-year m}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 o}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 nopoly on new drugs is essential in generating profits to pay for r}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 search. Aids is a government problem, he says, not an industry one}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Special Supplement, Pg. 8\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 1329 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  In Geneva, that odd hybrid lakeside city where altruism and money rub shoulders, sits one of the most po}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 w}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 erful figures in one of the most powerful industries in the world. Harvey Bale Jnr heads the trade body for the multinational drug giants, the International Federation of Pharmaceutical Manufacturers Associations. The man from IFPMA fights their corner, defends their interests and gives not an inch to the clamour from acti}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ists who think the drug barons should tear up the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on their expensive drugs in the interests of the sickest and poorest people on the planet.\par  He's junior only in respect of his father. Dr Bale - not a medical doctor, but an economics PhD - has a lif}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 time of conference table tussle, of steamrollering the opposition and midnight deals in corridors already b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 hind him. He was in government for 13 years, in the office of the US Trade Representative, pushing for poo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 er countries to demolish barriers and to trade with the US on its own terms.\par  His mission today is the defence of drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  - the 20-year monopoly that a com pany enjoys on a new medicine. It means the company can set the price high and hold it there for two decades while, argues Dr Bale, recouping the astronomical costs of research and development, which he controversially claims are as high as Dollars 800m for each new drug that ends up on a pharmacy shelf. \par  That sort of equation leaves Grace in Malawi with no turning off the road to a lingering death. Patented Aids drugs in the UK cost up to pounds 10,000 a year. Companies under pressure from outraged activists from Cape Town to California have dropped their prices for individual African countries (although they are still at least double those of the generics companies) and yet still less than 50,000 people out of 29.4 million infec}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ed with HIV are on the life-preserving medicines. That just goes to show that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are not the problem, argues Dr Bale.\par  And the drug companies need their huge profits. "In about 1960, the average cost of a new drug would be about Dollars 1m to Dollars 2m," he says. "Today it is approaching Dollars 1bn or a billion Euros. The reason for that is that in the 50s and 60s the research was basically for antibiotics. Some people say to me that fin}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 d}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing those things was like shooting ducks in a pond. The bacteria were sitting there and the companies were trying to find materials and methods to stop them duplicating. Today we're trying to deal with cancer, heart disease, Aids and schizophrenia. This is not simple chemistry."\par  Then there are the expensive hoops the companies have to jump through to get a medicine licensed - ever more testing to ensure it is safe. Dr Bale pulls a quotation out of his capacious memory. "It was Abraham Lincoln in 1859 who said that the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has added the fuel of interest to the spark of genius. In today's world, you need the fuel." Dr Bale would have us believe that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are good for everybody, rewarding innovation in rich and poor countries alike. Last September, the independent Commission on Intellectual Property Rights, set up by development secretary Clare Short, disagreed. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  are bad for poor cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries, it said. They keep prices high and the only winners are the rich. It's not a report the IFPMA enjoyed. "I've got a tremendous amount of respect for Clare Short," Dr Bale begins. "Where I fault her is in letting the organisation of the CIPR not fully reflect developing country interests." Only those developing countries wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out a }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system were on it, he says.\par  He accepts that the poor of Africa and Asia cannot afford brand-name drugs. But they cannot afford the cheap copycat generics made in India either. "For people with no income or little income, price is a barrier. I mean I can't afford certainly a car of my dreams, you know, which might be a Jaguar XJE or something like that." It's maybe not the best of jokes. He adds quickly: "If it's a life-saving drug that's quite different."\par  He has more arguments. Most countries in Africa don't have }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on Aids drugs, because they were never filed. They were never filed, campaigners counter, because there was never the slightest possibility that anybody could afford them. Where they were registered by GlaxoSmithKline and Boehringer Ingelheim, it was in countries like South Africa and Kenya, which had rich people alongside the poor. And the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that exist on certain drugs make three-drug combinations very expensive.\par  But, says Bale, what about the other killer diseases? TB, malaria, polio and measles are killing thousands of people, yet the medicines to cure them are mostly out of }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and cheap. If the world had wanted to cure the sick, it could have done so many years ago, he is saying - why pick on us over Aids?\par  Dr Bale's bete noir is the generics industry - the companies based in India, Thailand, Brazil and other cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries without as yet any }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  system - which makes a living from copying brand-name drugs and selling them at cut-prices. To the disgust of the drug giants, who consider them thieves and pirates, the Aids pa}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 demic has won them respectability. The World Health Organisation has listed generic Aids drugs made by the Indian company }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  as safe, high quality and acceptable. An agreement during World Trade Organis}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion negotiations at Doha in November 2001 said that poor countries could waive }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and import cheap generics in a health crisis.\par  Dr Bale becomes as heated as a seasoned negotiator gets. "I mean, carpe diem, fine. If we had a cure for Aids, I would say to the generics make my day - go for it. If you want to steal it, I'll try to stop you and all that, but OK. But we don't have a cure for Aids, we don't have a vaccine for Aids. All we have is the most impe}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 fect instruments for HIV/Aids yet everybody is acting as though this is the end of the line on research - as if this is the best that there's ever going to be - let's just waive the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ."\par  So whose fault is it that Grace must die? "The biggest problem we have today is state failure, not market failure. I'm sorry, but look at the government in sub-Saharan Africa, which spends four billion Euros on new submarines and refuses to buy Aids drugs." He means South Africa, which has controversially dragged its feet. "They have allowed the Aids problem to become so large that it would totally wipe out their defence budget, and then some - a defence budget which is being spent on weapons to defend against an enemy, though who it is I can't think." There were governments doing well, like Uganda, Botswana, Senegal and Cote d'Ivoire, and to those, the drugs industry was selling Aids medicines, discounted to a price, activists would say, that still only a fraction of the populations can afford.\par  The pharmaceutical industry stands accused of neglecting to look for cures for diseases of the poorest countries in the world - devastating diseases, which kill and maim parents and children. The enormous crisis over Aids has brought that neglect into focus for the first time. Does Dr Bale think the industry has a moral obligation to do more for Grace and African women like her?\par  "Yes we do," he says shortly, "but the stimulus needs to come from outside, from the governments. Here's where the WHO can play a very constructive role."\par  But he issues a coded warning to campaigners to back off. "If industry feels threatened in certain areas over a long period of time, then the only thing that can happen is simply to drop back on their commitment in those areas, because you know here in the UK and in America we have cancer patients who are demanding a cure and these are companies that are based in the UK and the United States and there is a certain oblig}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion there too. So how do you divide your loyalties? These are patients who are willing to put up money - you see it on the streets in collections at Christmas time. The companies can't walk away from that."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS ASSOCI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (58%); OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 INTERNATIONAL FEDERATION OF PHARMACEUTICAL MANUFACTURERS ASS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 O}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CIATIONS (58%); OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SWITZERLAND (90%); MALAWI (79%); AFRICA (79%); UNITED STATES (79%); UNITED KINGDOM (79%); SOUTH AFRICA (76%);   CALIFORNIA, USA (79%);   CAPE TOWN, SOUTH AFRICA (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SWITZERLAND (90%); MALAWI (79%); AFRICA (79%); UNITED STATES (79%); UNITED KINGDOM (79%); SOUTH AFRICA (76%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); PHARMACEUTICALS ASSOCIATIONS (90%); PHARMACEUTICAL PREPARATION MFG (90%); BUSINESS & PROFESSIONAL ASSOCIATIONS (90%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (89%); RESEARCH & DEVELOPMENT (78%); CO}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 M}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PANY PROFITS (78%); POOR POPULATION (78%); AIDS & HIV TREATMENT (77%); DISEASES & DI}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ORDERS (77%); SCHIZOPHRENIA (77%); TRADE DEVELOPMENT (77%); ANTIBIOTICS (77%); AIDS & HIV (77%); CANCER (77%); INTELLECTUAL PROPERTY LAW (76%); EURO (73%); CONTROLLED SU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 B}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 STANCES CRIME (72%); PHYSICIANS & SURGEONS (70%); MENTAL ILLNESS (70%); BACTERIA (67%); GENERIC PRODUCTS (66%); HEART DISEASE (62%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MICHAEL MCMAHON  (50%); MICHAEL MCMAHON (50%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 18, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Saving Grace: The 12 essential Aids drugs: The World Health Organisation list The Guardian (London) February 18, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_272}{\*\bkmkstart DOC_ID_272_0}{\*\bkmkstart doc_id_134}{\*\bkmkend DOC_ID_272}{\*\bkmkend DOC_ID_272_0}{\*\bkmkend doc_id_134}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_134"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330034000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 134 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Saving Grace: The 12 essential Aids drugs: The World Health Organis}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 tion list}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Special Supplement, Pg. 9\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 825 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Nucleoside reverse transcriptase inhibitors such as AZT. These slow down production of the reverse tra}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 scriptase enzyme that HIV needs to turn RNA into DNA\par  Abacavir\par  UK price: pounds 2901.75/Dollars 4635.50. Africa price: pounds 631.45/Dollars 985.50\par  Trade name Ziagen\par  Made by Gsk Adult dosage 300mg twice a day, capsule form.\par  Stavudine (d4T)\par  UK price: pounds 922.80/Dollars 1514.10 Africa price pounds 33.37/Dollars 54.75\par  Trade name Zerit\par  Made by Bristol-Myers Squib Adult Dosage 40mg twice a day for those over 60kg and 30mg for those who weigh less. \par  Zidovudine(AZT OR ZDV)\par  UK price: pounds 3485.75/Dollars 5475Africa price: pounds 281.05/Dollars 438\par  Trade name Retrovir\par  Made by Gsk and }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Adult dosage 300-600mg per day\par  Didanosine (ddI)\par  UK price: pounds 1338.33/Dollars 2195.88 Africa price: pounds 189.09/Dollars 310.25\par  Trade name Videx (videx\par  EC is the one-a-day form) Made by Bristol-Myers Squibb Adult dosage Based on body weight 25, 50, 100, 150mg doses. Didanosine and stavudine in combination are sold for Dollars 1 a day in Africa by BMS.\par  Lamivudine (3TC)\par  UK price: pounds 1989.25/Dollars 3175.50 Africa price: pounds 149.65/Dollars 237.25\par  Trade name Epivir or 3TC\par  Made by Gsk Adult dosage 150mg twice daily.\par  Protease inhibitors work on an enzyme which breaks down protein. HIV uses protease to reproduce itself when the viral DNA reaches the nucleus of a host cell\par  Indinavir\par  UK price: pounds 2469.44/Dollars 4048.00 Africa price: pounds 366.03/Dollars 600.00\par  Trade name Crixivan\par  Made by Merck & co Dosage 800mg every 8 hours.\par  Saquinavir\par  UK price: pounds 3808.41/Dollars 6093.45\par  Africa price: (Invirase) pounds 1079.00/Dollars 1726.40\par  Trade name Fortovase or Invirase. Made by Hoffman-La Roche Adult dosage Eight 200mg capsules twice a day or six\par  200mg capsules three times a day. Roche has very recently discounted Invirase in Africa.\par  Ritonavir\par  UK price: pounds 4528.68/Dollars 7425.76 Africa price: pounds 304.77/Dollars 500.00\par  Trade name Norvir\par  Made by Abbott Laboratories Adult dosage 600mg twice a day (WHO recommend that this drug is used in combination with indinavir, lopinavir and saquinavir as a booster and not in its own right).\par  Nelfinavir\par  UK price: pounds 3535.07/Dollars 5708.08\par  Africa price: pounds 496.08/Dollars 801.00\par  Trade name Viracept\par  Made by Roche Adult dosage Three 250mg, three times a day.Roche recently discounted these drugs for Africa, down from over Dollars 3000 per year.\par  Lopinavir+ RitonavirUK price: pounds 3987.72/Dollars 6538.45 Africa price: Dollars 304.77/Dollars 500.00\par  Trade name Kaletra\par  Made by Abbot laboratories Adult dosage (Adults) Three pills twice a day with food.\par  Non-nucleoside reverse transcriptase inhibitors also block production of transcriptase but they bind the cells reverse transcriptase in a slightly different way. This group of drugs began to be approved in the late 1990s\par  Efavirenz\par  UK price: pounds 2689.08/Dollars 4342.06 Africa price: pounds 216.71/Dollars 346.75\par  Trade name Sustiva but\par  Stocrin in Africa Made by Bristol Myers Squibbin UK but Merck under licence in Africa Dosage 600mg once a day.\par  Nevirapine\par  UK Price: pounds 2016.00/Dollars 3399.61\par  Africa Price: pounds 271.35/Dollars 438.00\par  Trade name Viramune\par  Made by Boehringer Ingelheim/ Roxanne laboratories (aidsmeds.com) Adult dosage 200mg per day for two weeks, then 400mg per day. Is offered free for one-off treatment of mothers about to give birth to prevent transmission of HIV to the baby.\par  Combination Drugs\par  These pills, which mix some or all of the types above, are sold at low prices by generics companies and have made treatment far simpler in poor countries. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  prevent the big firms from combining their own drugs with those of others\par  Duovir-N\par  Not available in the UK\par  Africa price: pounds 258.96/Dollars 418.00\par  Contains Lamivudine,\par  Zidovudine, Nevirapine Made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Adult dosage One tablet, twice a day.Must only be started if the p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tient has been on nevirapine alone for at least two weeks without problems.\par  Triomune\par  Not available in the UK.\par  Africa Price pounds 188.34/Dollars 304.00\par  Contains Stavudine,\par  Zidovudine, Nevirapine Made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  Adult dosageOne tablet twice a day.\par  Combivir\par  UK Price pounds 4110.96/Dollars 6637.97\par  Africa Price pounds 384.42/Dollars 620.50\par  Contains Lamivudine, Zidovudine\par  Made by GSK\par  Adult dosage One tablet, twice a day. Should be taken with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor.\par  Trizivir\par  UK Price pounds 6960.00/Dollars 11,487.29\par  Africa Price pounds 974.76/Dollars 1602.00\par  Contains Lamivudine,\par  Zidovudine, Abacavir\par  Made by GSK\par  Adult dosage One tablet, twice daily\par  'All prices are per patient per year, and may not always be exact because of currency variations, taxes etc.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROCHE HOLDING AG (85%); MERCK & CO INC (84%); ABBOTT LABORATORIES (81%); BRISTOL-MYERS SQUIBB CO (74%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (56%); HOFFMANN-LA ROCHE INC (52%);   WORLD HEALTH ORGANIZATION  (84%); WORLD HEALTH ORGANIZATION (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD HEALTH ORGANIZATION  (84%); WORLD HEALTH ORGANIZATION (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ROG (SWX) (85%); MRK (PAR) (84%); MRK (NYSE) (84%); ABT (SWX) (81%); ABT (NYSE) (81%); ABT (LSE) (81%); ABL (FRA) (81%); BMY (NYSE) (74%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325413 IN-VITRO DIAGNOSTIC SUBSTANCE MANUFACTURING (85%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (85%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (84%); SIC2834 PHARMACEUTICAL PREPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TIONS (84%); NAICS339113 SURGICAL APPLIANCE & SUPPLIES MANUFACTURING (81%); N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ICS339112 SURGICAL & MEDICAL INSTRUMENT MANUFACTURING (81%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTURING (81%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (96%); UNITED KINGDOM (90%);   LONDON, ENGLAND (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (96%); UNITED KINGDOM (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV TREATMENT (92%); ANTIVIRALS (91%); PHARMACEUTICALS INDUSTRY (90%); AIDS & HIV (90%); ENZYME INHIBITORS (90%); ENZYMES (90%); PHARMACEUTICAL PREPARATION MFG (89%); DNA (89%); PUBLIC HEALTH ADMINISTRATION (86%); PROTEIN BASED DRUGS (78%); AMINO ACIDS PEPTIDES & PROTEINS (78%); HEALTH DEPARTMENTS (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 BRISTOL-MYERS SQUIBB ADULT (92%); ROCHE ADULT (71%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 18, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Saving grace: Jean Pierre Garnier Head of Glaxo: He will drop the prices of his drugs to the poorest countries, as long as GSK does not make a loss. If they are still unaffordable, the UN should pay The Guardian (London) February 18, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_273}{\*\bkmkstart DOC_ID_273_0}{\*\bkmkstart doc_id_135}{\*\bkmkend DOC_ID_273}{\*\bkmkend DOC_ID_273_0}{\*\bkmkend doc_id_135}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_135"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330035000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 135 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Saving grace: Jean Pierre Garnier Head of Glaxo: He will drop the prices of his drugs to the poorest countries, as long as GSK does not make a loss. If they are still unaffordable, the UN should pay}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Special Supplement, Pg. 10\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 2546 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  It was tough enough negotiating the security guards at the gates of the glass fortress in west London that is the global headquarters of GlaxoSmithKline, even though they had names and the car registration number. But then came the encounter with the receptionist at her computer.\par  "Step two paces back please and look up at the camera." High above her back, in the wall of the vast glass atrium of Glaxo SmithKline's pounds 150m headquarters in Brentford, was a small, dark, round hole. She pressed the return key, gave a polite smile of dismissal, and within moments a thick plastic visitor's pass suspended on a chain, with integral photo, slid across the desk.\par  It was more than mere thousands of land miles from Malawi. This was wealth and the fear of losing it b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 yond the imaginings of Lilongwe's citizens. The 12th floor of GSK's huge boardroom has vast windows loo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 k}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing out as far as the Post Office tower in central London. To the south, you can follow the flightpath as one jet pursues another to land at Heathrow. After September 11, GSK's employees used to watch in fear that their glass tower would be the target for a copycat UK attack. \par  It takes a big man to run the second largest pharmaceutical company in the world - one of the richest and most powerful commercial entities on the planet. Jean Pierre Garnier, who years ago lost some of his French identity, if not his accent, to the ubiquitous American initialising and became universally known in the pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 maceutical world as JP, doesn't wear a tie. Why would he?\par  Within his own parameters - within the affluent world order of wealth, power and influence - JP is not only a big man but a good man. Some call him a humanitarian. He has been awarded the Legion d'Honneur by the French government. He has indisputably taken GSK several rungs higher on the ladder of altruism than any other drug company. But at the end of the day, he says, he runs a for-profit company. And if people are still dying of Aids in Africa, it is because their governments are ineffective or do not care. It is not to do with the greed or indifference of the pharmaceutical companies.\par  He agrees that drug prices must come down, but not at a loss to his company. JP's vision is clear. He is wil}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to supply not just antiretrovirals but other medicines poor countries need for epidemics, such as malaria, at cost, he says. In the case of Combivir, GSK's dual combination Aids drug, he sells at Dollars 1.70 a day. For a Malawian woman like Grace on wages of 50 cents a day, it might as well be the price of a flight on Concorde. But he knows that.\par  His answer is twofold: order from GSK in bulk, perhaps for the whole of sub-Saharan Africa, and the price will drop and, secondly, persuade the rich countries to support the Global Fund so that poor countries will have the money to buy GSK's drugs.\par  It's win-win for Glaxo. It need do nothing that is incompatible with the capitalist ideology of the marketplace or would upset the shareholders, even if it may seem ironic - to those who were baying for JP's blood over the recent offer from the GSK board to boost his pay to pounds 20m - that he should be asking effectively for government subsidies. (Garnier, for the record, says he was 11th out of 12 drug company CEOs and he did not ask for the pay rise - the board offered it and later withdrew it because of the scale of the protest from British shareholder groups.)\par  But the reality in distant Africa where people live on less than Dollars 1 a day is that GSK's drugs are far more expensive than the cheap versions made by generics companies like }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . And in South Africa, where Glaxo has }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  that keep }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  out and sells only to the private sector because the government says Aids drugs are too expensive, the prices are higher still. Combivir costs Dollars 2.50 a day instead of Dollars 1.70 - which is Dollars 927 a year, instead of Dollars 620. The difference for individual men and women tr}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ing to raise the money for the drugs themselves can mean life or death.\par  So why, ask campaigning organisations like Medecins sans Frontieres and Oxfam, should the Global Fund's hard-won and limited money be spent on Glaxo? }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in India sells a copy of Combivir called Duovir for Do}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lars 292. Glaxo's three-drug combination Trizivir costs Dollars 1,602 in Africa, but Malawi is buying }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  three-in-one pill, Triomune, for Dollars 304 a year. The World Health Organisation has endorsed the quality of many generic Aids drugs. The Global Fund has now said it will require countries receiving its grants to buy the cheapest.\par  JP waves it all away as an irrelevance. }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  only has the capacity to produce small quantities of the drugs, he says. With the very low manufacturing overheads in India, they offer cheap prices for thousands of tablets that would have to soar if they needed to produce millions. The overheads for producing Combivir in GSK's Kent factory, on the other hand, go down as the bulk goes up.\par  "I'll take on any generic company in the world on Combivir pricing on large quantities," he says, "because I think we are very efficient producers and because we don't take any profit, while the generic companies do. I am confident that we are going to be the lower cost producer but that's going to be far more visible when we deal with large quantities, so it is a bit of a Catch 22 here. Give me a big order and I'll be able to cut my pri}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 c}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 es even further."\par  Then why not slash them now, to encourage African governments to buy? "The only problem with making a loss is that, to be fair, we are a for-profit organisation," he says. "You could say commercially that it is astute to do this, but we don't want to play games. We just want to say look - we are not for profit - we are commi}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ted to that. This is a lot to do for a multinational company. To take that model as a business model is not without risks."\par  But while GSK is keeping its books in order, there are 29.4 million mostly very poor people set to die of Aids in sub-Saharan Africa and drug company profits, at 18.5% in 2001, are the highest of any industry on the planet. JP acknowledges that there is an image difficulty.\par  "I think the public has much higher expectations of multinational companies than they did 10 years ago or 15 years ago," he says. "I think they have lost their confidence in the ability of the governments and the large international institutions to solve the world's problems. I think that they feel that now that the multinationals have become so powerful, frankly they should take on those problems and they should contribute more to the communities and the like and rebalance a little bit the equation with employees, shareholders, commun}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ties - and I totally agree with this.\par  "I think fundamentally the public needs to be reassured that multinational companies and globalisation are not bad - quite the reverse. We have the power to do an awful lot of good but we have to use it. We have to use it."\par  He is mostly talking about old-fashioned philanthropy - about Glaxo's very creditable Dollars 1bn programme to eradicate lymphatic filiariasis and Merck's campaign to stamp out river blindness. Aids is a much bigger and more complex problem, with political, social and economic dimensions. The industry as a whole has shown few signs yet of leading the charge where governments hang back.\par  Where is the transparent global policy, for instance, to ensure that all the badly-needed Aids drugs are sold at the lowest possible prices? Others are less eager to discount than GSK. For ten months, the Swiss co}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 pany Roche ignored pleas from the doctors at Medecins sans Frontieres to cut the price of nelfinavir, a WHO approved drug that is much easier to use and take than Merck's cheaper equivalent indinavir. Last Friday the company finally announced a price cut for the poorest countries from Dollars 3,100 a year to around Dollars 900.\par  "While our policy has significantly reduced prices and removed }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  issues as barriers to HIV therapy, it would be wrong to suggest that we can solve the problem through these steps alone," said William M. Burns, head of Roche Pharma. "Affordability is only one of many barriers to care in developing countries."\par  MSF, though pleased at the result, is unimpressed. "The long struggle to reduce the price of this Roche drug is proof of the limitations of a fully voluntary system," says Daniel Berman. "For new drugs, there needs to be an internationally-supported enforceable system that reduces prices to affordable levels in developing cou}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tries."\par  These sorts of cuts will not make the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  issue go away. Campaigners like Oxfam and MSF say only competition from the generic companies can force prices down further. They must be allowed to export whatever drugs are needed to all developing countries - south America and Asia as well as Africa.\par  The drug giants, whose interests are invariably represented at world trade talks by the US, Switzerland and Germany, where much of Big Pharma is based, will concede that Africa can set aside certain }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  in the interests of public health. But they insist there can be no exemption for middle income countries like Brazil, India and China, which currently make and export most of the generics. And they also insist that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  can be waived only for Aids and certain tropical diseases. The matter should have been sorted at the World Trade Organisation by the end of last year. The battle is still raging.\par  Garnier, like all the drug company bosses, sees the generic pirates as a threat to the future of Big Pharma, stealing their ideas and their profits. He gets heated. "Why is there a disagreement here?" he asks. "The di}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 agreement is because there is an economic war going on. This is a great opportunity for the Indian and Br}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 zilian generic companies to conquer the world. If they could just get rid of our }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  then the whole deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oping world would open up to them.\par  "So this is an economic war. There are a couple of pirate companies who want to undermine the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  sy}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tem and they have found the best horse of Troy - whatever it's called in English - to come in against the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 p}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 tent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . This is the first time there is a genuine risk that intellectual property would disappear in the developing world. I'm saying in the poorest countries of the world - and there is a list prepared by WHO - they should be able to disregard }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 . That's what I'm for, in all the diseases that constitute healthcare crises for those countries. So it's HIV, and malaria and TB and infectious diseases and so forth.\par  "What I don't agree is that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  would be disregarded in China, in India, and so forth and those comp}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 nies would be able to prosper by pirating our discoveries made in Europe and the US and therefore we'd be shut out of 80% of the world population. That is not fair. If the }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  go away in those countries it's the end of the pharmaceutical industry as we know it."\par  The wide list of diseases now up for discussion proves the generic pirates are up to no good. "This is the proof of the pudding. They say no - we want asthma, we want diabetes. I mean excuse me - what has it got to do with helping Malawi with HIV?"\par  So should children in Malawi die of asthma? "I don't care. Malawi can violate my }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  on asthma. I don't have a problem with Malawi. I have a problem with Brazil and China - and Chile and Argentina and ever}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 y}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 thing. It isn't fair. It isn't fair to people who have discovered those drugs."\par  Garnier says he cares deeply about neglected diseases and is proud of GSK's record. It is developing la}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dap (a new malaria drug), investigating leishmaniasis and hunting for an Aids vaccine. "I think it's a treme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 n}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 dous contradiction for me and for our scientists to have a disease sitting there and say this one we can't go after because there's no profit in it. We can't have that. If we see a scientific opportunity that happens to a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 p}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ply to a not for profit, we'll go after it. It's just that we've got to be street smart about the funding. We can't use our shareholders' money excessively so let's use the public money. There's plenty of money in the world to fund those initiatives and we've never been turned down. I talk to Bill Gates all the time - I knock on his door all the time for funding and I get it," he says.\par  Should it work that way? Ellen t'Hoen of MSF has doubts. "If you put money in, you will get your drugs, but whether it is the most effective way to have it done by Glaxo is the question," she says. She cites the pha}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 r}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 maceutical industry claim that it costs Dollars 800m to develop a new drug. The Global TB Alliance, devoted to fostering new TB drugs, puts it at around Dollars 40m, up to Dollars 115m if you cost in the failures and at most Dollars 240m including the initial discovery (which often comes out of a state-funded university) as well as the development.\par  But Glaxo is doing more for neglected diseases than most drug companies. Garnier also believes Glaxo has behaved well over Aids. "I think that the people who know give us kudos. We broke the camel's back. Wit}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 out GSK we would still be arguing about how to price Aids drugs in Africa and we wouldn't have 40-50,000 patients being treated. Now you could say 50,000 is not that many but it's a lot better than zero. And reme}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 m}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ber, we started on the wrong foot. I inherited the problem two years ago (when he became chief executive of the merged company). Two years ago was the time we were suing the South African government."\par  The court case in March 2001 was a public relations disaster. There was uproar over the attempt by 39 drug companies to block legislation by the South African government to allow it to import cheap medicines at a time when millions were dying of Aids.\par  "The South African government was using this as an excuse not to treat their population," says JP. "Once the lawsuit was over South Africa did not look too good because they turned round and told the Aids patients 'We are still not going to do anything'. So it proved the industry wasn't exactly the guilty party, was it?"\par  But although he believes the companies were in the right, he concedes that the case - which was in fact about all kinds of medicines and not just antiretrovirals - should not have been brought because of the Aids pandemic. "That's why I was convinced on the first day I inherited this problem we had to get out of the case and I negotiated with the South African government with the help of Kofi Annan and we started on a better foot.\par  "It's tough. We can do a lot more and we will, but everything comes progressively. We still have to balance running a business and discovering drugs, but I think we have made tremendous progress. I think we're a model for philanthropy. In the words of a very famous person in Washington, GSK is a company with a soul. I love it. I love it. When I heard that I knew I was on the right track."\par  Maybe, in time, that track will lead to Grace's humble wooden door in Lilongwe. Whether she will still be there - listening to her radio, laughing with her neighbours and walking in the cool early hours of the morning to the Central Market to open up the shoe shop - is another matter entirely.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (92%);   UNITED NATIONS  (84%); UNITED NATIONS (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 UNITED NATIONS  (84%); UNITED NATIONS (84%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (92%); GSK (LSE) (92%); BIOC (EGX) (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (92%); SIC2834 PHARMACEUTICAL PREPARATIONS (92%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MALAWI (92%); UNITED STATES (79%); AFRICA (79%); UNITED KINGDOM (79%);   LONDON, ENGLAND (93%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MALAWI (92%); UNITED STATES (79%); AFRICA (79%); UNITED KINGDOM (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (91%); PHARMACEUTICAL PREPARATION MFG (89%); DRUG PRICES (89%); AIRPORTS (78%); WEALTHY PEOPLE (73%); AFFLUENT MARKET (73%); WA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 G}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ES & SALARIES (71%); AIDS & HIV (69%); AIDS & HIV TREATMENT (66%); ANTIVIRALS (66%); MALA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IA (65%); PRICE CUTTING (64%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 JEAN-PIERRE GARNIER (77%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 18, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Leading article: Saving Grace: Defeating Aids needs a global approach The Guardian (London) February 18, 2003 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_274}{\*\bkmkstart DOC_ID_274_0}{\*\bkmkstart doc_id_136}{\*\bkmkend DOC_ID_274}{\*\bkmkend DOC_ID_274_0}{\*\bkmkend doc_id_136}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_136"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330036000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 136 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Guardian (London)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  18, 2003\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Leading article: Saving Grace: Defeating Aids needs a global approach}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Guardian Leader Pages, Pg. 19\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 716 words\par \par  \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  There is another war to fight, but few appear ready to pick up weapons for the cause. Ranged against some of the poorest people in the world is a determined killer which is slowly claiming millions - and the list of its potential victims is getting longer. Aids is a disease that is turning back the clock in many countries. Nations which should be seeing life expectancy going up, instead witness lives cut short. In others more teachers are dying each week than can be trained. The shadow cast on Africa has seen more than 2 million people die in the last year. Three of the world's largest countries, India, China and Russia, are on the edge of outbreaks that, if not tackled, will dwarf the scale of the current crisis, which already affects 40 million people. There are many roots, but where there is destruction there should now be salvation. \par  With the Guardian today is a supplement, Saving Grace, which poses the question: why can the poor not get the drugs to live with Aids when the rich can? The Grace in the headline is Grace Matnanga, a 30-year-old shoeseller with HIV. She has already lost her husband and child to the disease but cannot afford the Do}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lars 28 a month for pills to treat her condition. There are no easy answers. Poor nations often have too small a health budget. Developing countries do not have enough doctors and nurses. Diseases are shaped by h}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 man behaviour and many politicians have not said loudly enough that prevention would be more effective than cure. But, running through the debate, is an argument which pits the rich world against the poor and asks for sacrifice from the drugs industry to save lives. Asking pharmaceutical companies to forgo profits is a request that until recently dared not speak its name. High prices, said the firms, are needed to develop new drugs.\par  This argument faltered, partly because the price of medicines matters in the war against want, but mostly because it was the wealthy world which saw new treatments appear. Though under pressure from domestic lobbying, the pharmaceutical industry remained reluctant to cater for customers without the income to pay for drugs costing millions of dollars to develop. This became increasingly untenable as profits rose in London and New York and bodies fell in sub-Saharan Africa. Competition from copycat drug producers such as the Indian chemical firm }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  has also helped to lower prices. GlaxoSmithKline's HIV drug treatment used to cost Dollars 12,000 a year. It is now priced at Dollars 727, still more than double }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  alternative, World Health Organisation-approved, remedy. Even this exceeds current per capita health spending in low income countries, which average Dollars 23 a year. So aid from rich countries will be required to buy medicines to cope with epidemics that threaten to overwhelm nation states.\par  It is encouraging that money is forthcoming, especially from George Bush, who last month pledged Dollars 15bn over the next five years. It is less inspiring to see this cash bypass UN attempts to fight Aids, thereby undermining it. Even worse is Mr Bush's sabotaging of global trade talks. These were designed to allow poor countries to import cheap drugs in the event of epidemics. This was to be a significant victory for the deve}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 oping world, acknowledging that }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  rules created for today's rich nations should not apply to countries whose income is only that of early 19th-century Britain. Yet this has not happened. Firms which lavished the US Republican party with Dollars 63m worth of donations have Mr Bush fighting their corner, not the poor's, in trade negotiations. Aids is not the only illness that can be alleviated by access to cheap medicines. Re}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 s}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 piratory tract diseases such as bronchitis affect the elderly in the developed world but end the lives of 1.5 million children in the developing world before their fifth birthdays. Yet continuing protection for pharmaceut}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cal firms will stop cheaper generic treatments emerging, and deny drugs to the poor that are available to the rich. Unlike Aids, many diseases have cures, and the moral imperative to do something is greater. The sol}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion for salvation is not unattainable, but it will be made harder unless both the US and the global responses get more generous.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (57%); GLAXOSMITHKLINE PLC (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (57%); GSK (NYSE) (55%); GSK (LSE) (55%); BIOC (EGX) (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (57%); SIC2834 PHARMACEUTICAL PREPARATIONS (57%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (92%); INDIA (79%); CHINA (79%); SUB SAHARAN AFRICA (79%); UNITED STATES (72%); RUSSIAN FEDERATION (56%);   NEW YORK, USA (72%);   NEW YORK, NY, USA (72%); LONDON, ENGLAND (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (92%); INDIA (79%); CHINA (79%); SUB SAHARAN AFRICA (79%); UNITED STATES (72%); RUSSIAN FEDERATION (56%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 DISEASES & DISORDERS (90%); POOR POPULATION (90%); PHARMACEUTICALS INDU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRY (89%); AIDS & HIV (89%); POVERTY & HOMELESSNESS (89%); PHARMACEUTICAL PREPAR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TION MFG (87%); LIFE EXPECTANCY (77%); BUDGETS (77%); EPIDEMICS (77%); AIDS & HIV TREA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 T}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MENT (73%); WAR & CONFLICT (73%); ANTIVIRALS (72%); HEALTH DEPARTMENTS (72%); DRUG DESIGN & DISCOVERY (72%); DRUG PRICES (72%); HEALTH CARE COSTS (72%); NURSES & NUR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 S}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (72%); TEACHING & TEACHERS (71%); DEVELOPING COUNTRIES (71%); PUBLIC HEALTH A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 D}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MINISTRATION (70%); LOBBYING (70%); PHYSICIANS & SURGEONS (66%); CHEMICALS (60%); CHEMICALS MFG (60%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE BUSH (72%); GRACE MATNANGA (70%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 February 18, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Guardian Newspapers Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Glaxo hit over on-line stand, AIDS; Ad campaign, false advertising suit land as drug maker announces 11% profit rise The Globe and Mail (Canada) February 13, 2003 Thursday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_275}{\*\bkmkstart DOC_ID_275_0}{\*\bkmkstart doc_id_137}{\*\bkmkend DOC_ID_275}{\*\bkmkend DOC_ID_275_0}{\*\bkmkend doc_id_137}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_137"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330037000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 137 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 The Globe and Mail (Canada)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 February}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  13, 2003 Thursday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Glaxo hit over on-line stand, AIDS; \par Ad campaign, false advertising suit land as drug maker announces 11% profit rise}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 BYLINE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 LEONARD ZEHR, BIOTECHNOLOGY REPORTER, With files from Reuters\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 REPORT ON BUSINESS: INTERNATIONAL; Pg. B11\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 620 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  A coalition of 10 health care and business groups in Canada and the United States has fired the first salvo in a campaign against }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GlaxoSmithKline PLC's}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  plan to stop supplying on-line pharmacies in Canada that sell drugs to U.S. consumers. \par  A full-page ad in The New York Times, featuring a seething elderly woman, says "Glaxo is taking away your right to affordable prescription drugs."  \par  It coincided with the company's announcement yesterday that its 2002 sales rose 7 per cent to $31.8-billion (U.S.), while profit climbed 11 per cent to $6.9-billion. \par  Meanwhile, the AIDS Healthcare Foundation, the largest AIDS group in the United States and a member of the coalition, has filed a false advertising lawsuit against Europe's biggest drug maker, citing false claims by Glaxo about its AIDS drug prices and policies. \par  In a statement, the foundation rejected claims by Glaxo that its makes "no profit" and sells AIDS drugs "at cost" to developing countries. \par  Foundation president Michael Weinstein said Glaxo's prices are far higher than those of Indian generics manufacturer }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  and the government of Thailand. \par  "In developing countries, Glaxo's so-called preferential prices are also up to double that charged by Bristol-Myers Squibb, Merck and Pfizer," he added. \par  Glaxo did not return calls for comment. \par  Andy Troszok, vice-president of the Canadian International Pharmacy Association, another member of the coalition, said yesterday's newspaper ad will soon appear in other major media outlets in the United States. \par  "This is our immediate response to Glaxo," he said, adding that plans for a lawsuit and possible action by the Competition Tribunal in Ottawa are longer-term strategies. \par  Provincial controls on drug costs and an exchange rate that favours the U.S. dollar has made Canadian on-line pharmacies a mecca for about one million Americans, especially seniors on limited incomes, giving them access to Canadian drugs at about half the comparable cost in the United States. \par  Estimates put the annual Internet trade at $600-million, with much of the industry based in Manitoba. \par  Glaxo began blacklisting Internet pharmacies last month, citing concerns about the safety of products e}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 x}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ported from Canada as the sector expands. \par  "All drug makers will follow [Glaxo's] lead and eventually strip seniors of their well-established right to access affordable drugs from alternative sources," the coalition's ad warns. \par  It urges Americans to lobby their House and Senate members, complain to Glaxo's consumer hot line, seek medical advice about switching to competing medicines, sell shareholdings in Glaxo and boycott such pop}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 lar over-the-counter products as Tums, Nicorette, Poligrip and Contac. \par  Separately, the No. 2 drug maker worldwide met analysts' expectations for profit and sales in 2002. Bo}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 l}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stered by strong sales of asthma drug Advair, Glaxo said 2002 earnings rose to $6.9-billion, or $2.35 per American depository share, from $6.3-billion, or $2.08 a share a year earlier. \par  Sales climbed to $31.8-billion last year from $29.5-billion. \par  Fourth-quarter results, however, were hurt by the arrival of a generic competitor to Glaxo's second-largest product, the antibiotic Augmentin. \par  In addition to inroads made by generic Augmentin, Glaxo faces threats of knockoffs on seven of its med}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 i}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 cines in the United States, including top-selling antidepressant Paxil, Imitrex for migraine and herpes trea}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 t}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ment Valtrex. \par  The Federal District Court of the Northern District of Illinois is now hearing Glaxo's }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patent}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  infringement case against Toronto-based Apotex Inc. for its generic version of Paxil. A decision is expected next month. \par  Glaxo shares dropped 44 cents to $35.86 on the New York Stock Exchange yesterday.\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 PHARMACEUTICALS INDUSTRY (92%); MARKETING & ADVERTISING (92%); PHARM}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CEUTICAL PREPARATION MFG (92%); RETAIL PHARMACEUTICALS (91%); AIDS & HIV (91%); FALSE OR MISLEADING ADVERTISING (90%); BUSINESS TORTS (90%); PRESCRIPTION DRUGS (90%); AIDS & HIV TREATMENT (90%); PHARMACIES & DRUG STORES (89%); DRUG PRICES (89%); HEALTH CARE (89%); PHARMACIES (89%); SALES FIGURES (89%); EXPORT TRADE (87%); LOBBYING (78%); MARKETING CAMPAIGNS (78%); HEALTH CARE COSTS (78%); BUSINESS FORECASTS (77%); ANT}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 VIRALS (77%); BOYCOTTS (77%); NEWSPAPER ADVERTISING (77%); GENERIC DRUGS (77%); PR}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 E}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 SCRIPTION DRUG POLICY (77%); RESTRAINT OF TRADE (77%); GENERIC PRODUCTS (77%); SE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 N}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 IOR CITIZENS (76%); COMPANY PROFITS (75%); LEGISLATIVE BODIES (73%); LITIGATION (73%); PRODUCT SAFETY (72%); DEVELOPING COUNTRIES (72%); INDUSTRY ANALYSTS (68%); ELE}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 C}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TRONIC COMMERCE (65%); EXCHANGE RATES (62%); CURRENCIES (62%); ASTHMA (50%) trade; exports; prescription drugs; electronic commerce; finance; financial statements\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GLAXOSMITHKLINE PLC (96%); PFIZER INC (90%); BRISTOL-MYERS SQUIBB CO (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GlaxoSmithKline PLC\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GSK (NYSE) (96%); GSK (LSE) (96%); BIOC (EGX) (96%); PFZ (LSE) (90%); PFEB (BRU) (90%); PFE (NYSE) (90%); BMY (NYSE) (58%); }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (55%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (96%); SIC2834 PHARMACEUTICAL PREPARATIONS (96%); NAICS325411 MEDICINAL & BOTANICAL MANUFACTU}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 R}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ING (90%); NAICS325414 BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING (90%); SIC2836 BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES (90%); SIC2833 MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (90%)\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 GEOGRAPHIC: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MANITOBA, CANADA (73%) CANADA (99%); UNITED STATES (96%); NORTH AMERICA (92%); EUROPE (79%); THAILAND (70%) Canada; United States\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 September 14, 2006\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PUBLICATION-TYPE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Newspaper\par \par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 The Globe and Mail, a division of CTVglobemedia Publishing Inc.\par All Rights Reserved\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \page \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\qr \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Page \chpgn \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Bush in backflip with AIDS approach Hobart Mercury (Australia) January 31, 2003, Friday \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 {\*\bkmkstart DOC_ID_276}{\*\bkmkstart DOC_ID_276_0}{\*\bkmkstart doc_id_138}{\*\bkmkend DOC_ID_276}{\*\bkmkend DOC_ID_276_0}{\*\bkmkend doc_id_138}\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 HYPERLINK \\l"cite_id_138"}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid9710937 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000c00000063006900740065005f00690064005f003100330038000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\ul\cf2\insrsid2900964 Return to List}}}\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\hyphpar0\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 138 of 138 DOCUMENTS\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Hobart Mercury (Australia)\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }\pard \ltrpar\qc \li1200\ri1200\widctlpar\wrapdefault\faauto\rin1200\lin1200\itap0 {\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 January}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  31, 2003, Friday\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1\afs28 \ltrch\fcs0 \b\f1\fs28\insrsid2900964 Bush in backflip with AIDS approach}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SOURCE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AP\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SECTION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 WORLD; Pg. 18\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LENGTH: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 358 words\par \par }\pard \ltrpar\ql \li0\ri0\sb120\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  PRESIDENT George W. Bush's $15 billion commitment to AIDS relief in Africa will include condom distrib}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 u}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 tion and generic AIDS drugs, administration officials said yesterday, bucking two of his political bases -- a}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 b}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 stinence-advocating conservatives and brand-name pharmaceutical giants.\par  Generic AIDS drugs made by }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 Cipla,}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  an Indian company, would be among those recommended to the 14 nations getting the help, said Anthony Fauci, a senior National Institutes of Health official.\par  In November, Bush administration negotiators urged the World Trade Organisation to confine generic drugs to domestic markets and ban their export. Western companies holding AIDS drug }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 patents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  have been major contributors to Bush's Republican party. \par  Fauci said condom distribution would be part of the prevention component -- as would abstinence education.\par  Christian conservatives, pillars of Bush's support, believe distributing condoms promotes promiscuity, and preach abstinence.\par  Fauci said the 12 points of prevention included stopping mother-child transmission, media campaigns and making sure blood used in transfusions was safe.\par  "It's not about [Bush] . . . trying to get the African American vote," said Jendayi Frazer, the top Africa adviser on the White House's National Security Council.\par  "It derives from his sense of the need to preserve human dignity."\par  In his State of the Union speech, Bush asked Congress to budget $10 billion in new money and $5 billion in already allocated assistance over five years to provide AIDS drugs to two million Africans, help prevent se}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 v}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 en million new infections, and care for those infected with the virus and AIDS orphans.\par  Groups promoting AIDS relief were generally pleased -- even stunned -- by the proposal.\par  "Inspiring and clearly heartfelt," said Sandra Thurman, the Clinton administration's top AIDS official who now heads the International AIDS trust.\par  Salih Booker, of Africa Action, said he was concerned the plan would help just 13 nations in Africa -- the 14th is Haiti.\par  "Why leave out Malawi and Zimbabwe?" he asked. "It can't be successful because borders are porous."\par }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 SUBJECT: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AIDS & HIV (96%); AIDS & HIV TREATMENT (92%); GENERIC DRUGS (92%); CONSERV}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 A}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 TISM (90%); PHARMACEUTICALS INDUSTRY (90%); ANTIVIRALS (90%); US PRESIDENTS (90%); AIDS & HIV POLICY (90%); CHRISTIANS & CHRISTIANITY (84%); SEX EDUCATION (78%); US FEDERAL GOVERNMENT (78%); HEALTH DEPARTMENTS (78%); PRESCRIPTION DRUGS (78%); US REPUBL}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 I}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 CAN PARTY (78%); POLITICAL PARTIES (77%); EXPORT TRADE (76%); TRADE DEVELOPMENT (75%); INTERNATIONAL TRADE (75%); ORPHANS (73%); PHARMACEUTICALS }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 PATENTS}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (73%); NATIONAL SECURITY (71%); PUBLIC HEALTH ADMINISTRATION (71%); PHARMACEUTICAL PREPARATION MFG (57%); BLOOD TRANSFUSIONS (53%); AFRICAN AMERICANS (52%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COMPANY: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  LTD (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 ORGANIZATION: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NATIONAL INSTITUTES OF HEALTH  (57%); WORLD TRADE ORGANIZATION  (57%); WORLD TRADE ORGANIZATION (57%); NATIONAL INSTITUTES OF HEALTH (57%); NATIONAL SEC}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964\hres1\chhres0 U}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 RITY COUNCIL  (55%); NATIONAL SECURITY COUNCIL (55%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 TICKER: }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\cf18\insrsid2900964 CIPLA}{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964  (NSE) (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 INDUSTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 NAICS325412 PHARMACEUTICAL PREPARATION MANUFACTURING (58%); SIC2834 PHARMACEUTICAL PREPARATIONS (58%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 PERSON: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 GEORGE W BUSH (90%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 COUNTRY: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 AFRICA (95%); UNITED STATES (94%); MALAWI (79%); HAITI (79%); ZIMBABWE (79%); \par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LOAD-DATE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 January 30, 2003\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 LANGUAGE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 ENGLISH\par \par }{\rtlch\fcs1 \ab\af1 \ltrch\fcs0 \b\f1\insrsid2900964 JOURNAL-CODE: }{\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 MER\par \par }\pard \ltrpar\qc \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 Copyright 2003 Nationwide News Pty Limited\par \sect }\sectd \ltrsect\sbknone\linex0\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0\afs24 \ltrch\fcs0 \fs24\insrsid2900964 \par }}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1033 \ltrch\fcs0 \f6\fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \f1\insrsid2900964 \par }{\*\themedata 504b0304140006000800000021009be8704ffc0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb6ac3301045f785fe83d0b6d872ba28a5d8cea28f5d1f8bf40306796c8bd823214d42f2f71d3b2e941202856e04d2ccbdf7cca85c1fc641ed3126e7a9d2abbcd00ac9fac65157e9cfcd4b76af5562a006064f58e92326bdaeafafcacd316052a2a654e99e393c18936c8f23a4dc0724a9b43e8ec0728d9d0960b7d0a1b92d8a3b633d3112673c79e8ba7cc2167603abe7833c9f4844aed5e3a96f8aaa348430380b2ca066aa9ab3ba8843ba20dc53f38b2e5bc87251cee6a97721dd2c09efb29ae81a541f10f90d46e1302c43e2cff31548468bf965e633d1be6d9dc5c6dbdd28ebc867e3c5ec4f00abff89fece34f3dfd65f000000ffff0300504b030414000600080000002100a5d6a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4fc7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b63095120f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f7468656d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b4757e8d3f729e245eb2b260a0238fd010000ffff0300504b030414000600080000002100215aa28421070000db1d0000160000007468656d652f7468656d652f7468656d65312e786d6cec594f6f1b4514bf23f11d467b2fb113274da23a55ecd80db469a3d82dea71bc3bf64e33bbb39a1927f10db547242444411ca8c48d03022ab51297f269024550a47e05deccecae77e271939400153487d63bfb7b6fdefbbd3ff367af5c3d4a183a2042529e3683fa7bb5009134e4114d47cde076bf7b69354052e134c28ca7a4194c880cae6ebcfbce15bcae62921004f2a95cc7cd20562a5b5f5890210c63f91ecf480aef865c2458c1a3182d44021f82de842d2cd66a2b0b09a66980529c80da5bc3210d09ea6b95c146a1bcc3e03155520f844cf4b46ae248186cb45fd70839916d26d00166cd00e689f8619f1ca900312c15bc680635f3172c6c5c59c0ebb9105373642b725df397cbe502d1fea299538c06e5a4f56e63edf256a9df00989ac5753a9d76a75eea33001c86e0a9b5a5aab3d15dadb70a9d1590fd39abbb5d5bae355c7c45ffd28ccd6bad566b792db7c52a3520fbb331835fadad3436171dbc0159fcf20cbed1da6cb7571cbc0159fcca0cbe7b796da5e1e20d286634dd9f41eb8076bbb9f61232e46cdb0b5f05f86a2d874f51900d6576e929863c55f3722dc1f7b8e8024003195634456a9291210e218bdb98d181a07a02bc4e70e58d1d0ae5cc909e0bc950d04c35830f320c1531d5f7f2d9772f9f3d41c7f79f1edffff1f8c183e3fb3f58458ed4364e4755a917df7cfac7a38fd0ef4fbe7ef1f0733f5e56f1bf7cfff1cf3f7de60742f94ccd79fec5e35f9f3e7efee527bf7dfbd003df14785085f7694224ba490ed11e4fc031c38a6b391988f349f4634cab129be948e214eb593cfa3b2a76d0372798610fae455c06ef08681f3ee0b5f13dc7e05e2cc62a8fb7e3d9f53871803b9cb316175e16aeebb92a34f7c7e9c83fb91857717b181ff8e66ee3d4896f679c41dfa43e95ed983866ee329c2a3c22295148bfe3fb8478f8ba4ba9c3eb0e0d05977ca8d05d8a5a987a29e9d381934d53a16d9a405c263e0321de0e373b77508b339fd75be4c045425560e631be4f9843e3353c5638f1a9ece3845509bf8155ec33b237116115d7910a223d228ca34e44a4f4c9dc12e06f25e8d7a175f8c3bec326898b148aeefb74dec09c57915b7cbf1de324f3617b348dabd8f7e53ea42846bb5cf9e03bdcad10fd0c71c0e9dc70dfa1c409f7e9dde0361d39264d1344bf190b4f2caf11eee46f6fc286989856034ddde9d5094d5fd5b813e8dbb9e317d7b8a1553effea91c7ee37b5656f0209be9ad93ed1a8e7e14eb6e73617117df3bbf3161ea7bb040a6276897adb9cdf36e7e03fdf9ce7d5f3c5b7e469178606adb74c76a36db6ddc9dc5df79032d65313466e48b3f196b0f6445d18d472e6c449ca535816c34f5dc93081831b096c6490e0ea43aae25e8c33d8b4d703ad642473d52389322ee1b06886bdba351e36feca1e3597f521c4760e89d50e8fecf0921e2ece1aa51a63d5c81c688b8996b482b34eb67439570abebdce64756dd49967ab1bd34c5374662b5dd6149b4339505eba0683259bb0a941b015029657e0ccafa786c30e6624d2bcdb1815613151f87b42947b6d1d8971446c889ce10a9b7513bb228566fcd3eed91c391f9b256b40dae94698b4989f3f6724b950302519044f56134babb5c55274d80cd69617970314e2ac190ce1980b3f930c8226f53610b311dc15854ad8ac3db5164d914e3d5ef367551d6e2ee6148c53c699906a0bcbd8c6d0bcca43c5523d93b57f71b9a193ed621cf03493b359b1b40a29f2af5901a176434b864312aa6ab02b239a3bfb9877423e5644f4e2e8100dd858ec61083f70aafd89a884db0a53d0fa01aed634dbe695db5bf34e53bdd032383b8e5916e3bc5beaab99a2e22cdcf493d206f354310f7cf3da6e9c3bbf2bbae22fca956a1affcf5cd1cb015c1e2c453a0221dcec0a8c74a534032e54cca10b65310dbb02d67dd33b205be07a165e03f970bf6cfe17e440ff6f6bceea30650d6740b547474850584e542c08d985b664b2ef1465f57ce9b12a59aec86454c55c9959b307e480b0beee812bba070728865437dd246f03067732ffdce7bc820623bd47a9d69bd3c9caa5d3d6c03fbd71b1c50c4e9dd84be8fc2df82f4d2c57f7e9ea67e58d78b146561dd12fa6bba4465115cee2b7b6964ff59a269c6501aeacb5b663cd78bcb85c1807519cf51806cbfd4c06574048ff03eb1f1521b31f2bf482dae77bd05b117c7bb0fc21c8ea4bbaab4106e906697f0d60df63076d32695596da7ce7a3592b16eb0bdea896f39e205b5b7696789f93ec7213e54ee7d4e245929d33ec706dc7e6520d913d59a230342cce212630e62b57f543141fdc83406fc195ff98d94f533283275307d9ae30d935e0d124ffc9a45d706dd6e9338c46b2748f0c118d8e8af347c9842d21fb79a4d8221bb416d389560a2ef90e0dae608ed7a276b52c85174f172e25ccccd0b24b617397e653001fc7f2c6ad8f7680b74dd67aad8bab608aa57f85b23318efa7cc7bf2392b65f6a0f8ca40bd0665eae8d594e54c0179b389079f370586a357cff45f58746ca69b94ddf8130000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4350d363f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d262452282e3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe514173d9850528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d00140006000800000021009be8704ffc0000001c0200001300000000000000000000000000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b000000000000000000000000002d0100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c00000000000000000000000000160200007468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d0014000600080000002100215aa28421070000db1d00001600000000000000000000000000d30200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b0100002700000000000000000000000000280a00007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d010000230b00000000}{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d61696e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}{\*\latentstyles\lsdstimax276\lsdlockeddef0\lsdsemihiddendef1\lsdunhideuseddef1\lsdqformatdef0\lsdprioritydef99{\lsdlockedexcept \lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority0 \lsdlocked0 Normal;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority9 \lsdlocked0 heading 1;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 2;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 3;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 4;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 5;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 6;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 7;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 8;\lsdqformat1 \lsdpriority9 \lsdlocked0 heading 9;\lsdpriority39 \lsdlocked0 toc 1;\lsdpriority39 \lsdlocked0 toc 2;\lsdpriority39 \lsdlocked0 toc 3;\lsdpriority39 \lsdlocked0 toc 4;\lsdpriority39 \lsdlocked0 toc 5;\lsdpriority39 \lsdlocked0 toc 6;\lsdpriority39 \lsdlocked0 toc 7;\lsdpriority39 \lsdlocked0 toc 8;\lsdpriority39 \lsdlocked0 toc 9;\lsdqformat1 \lsdpriority35 \lsdlocked0 caption;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority10 \lsdlocked0 Title;\lsdpriority1 \lsdlocked0 Default Paragraph Font;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority11 \lsdlocked0 Subtitle;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority22 \lsdlocked0 Strong;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority20 \lsdlocked0 Emphasis;\lsdsemihidden0 \lsdunhideused0 \lsdpriority59 \lsdlocked0 Table Grid;\lsdunhideused0 \lsdlocked0 Placeholder Text;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdunhideused0 \lsdlocked0 Revision;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdsemihidden0 \lsdunhideused0 \lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority62 \lsdlocked0 Light Grid Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdsemihidden0 \lsdunhideused0 \lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdpriority37 \lsdlocked0 Bibliography;\lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;}}{\*\datastore 010001000200000008000000556e6b6e6f776e00000000000000000000060000d0cf11e0a1b11ae1000000000000000000000000000000003e000300feff090006000000000000000000000001000000010000000000000000100000feffffff00000000feffffff0000000000000000fffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffdfffffffeffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffffff5200000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000002000500ffffffffffffffffffffffff0c6ad98892f1d411a65f0040963251e50000000000000000000000008beac5fadfeace01feffffff00000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000ffffffffffffffffffffffff0000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000100010000000000}}